0001383395-24-000034.txt : 20240515 0001383395-24-000034.hdr.sgml : 20240515 20240515124034 ACCESSION NUMBER: 0001383395-24-000034 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 154 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SEQUANS COMMUNICATIONS CENTRAL INDEX KEY: 0001383395 STANDARD INDUSTRIAL CLASSIFICATION: SEMICONDUCTORS & RELATED DEVICES [3674] ORGANIZATION NAME: 04 Manufacturing IRS NUMBER: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-35135 FILM NUMBER: 24948747 BUSINESS ADDRESS: STREET 1: 15-55 BLVD CHARLES DE GAULLE STREET 2: LES PORTES DE LA DEFENSE CITY: COLOMBES STATE: I0 ZIP: 92700 BUSINESS PHONE: 33170721600 MAIL ADDRESS: STREET 1: 15-55 BLVD CHARLES DE GAULLE STREET 2: LES PORTES DE LA DEFENSE CITY: COLOMBES STATE: I0 ZIP: 92700 20-F 1 sqns-20231231.htm 20-F SEQUANS COMMUNICATIONS 2023 sqns-20231231
false00013833952022FYP1YP1YP5Y356101215222P10YP2YP2YP3YP4Y0.5405405P3YP4YP3YP3YP10YP7Y1.503.501.503.501.503.50606260626062222101010xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesiso4217:EURxbrli:sharesxbrli:puresqns:uSD_to_EURsqns:uSD_to_GBPsqns:uSD_to_SGDsqns:uSD_to_NISsqns:segmentsqns:categoryiso4217:EURsqns:projectsqns:instalmentsqns:borrowingsqns:employeesqns:bank00013833952023-01-012023-12-310001383395dei:BusinessContactMember2023-01-012023-12-310001383395sqns:AmericanDepositarySharesMember2023-01-012023-12-3100013833952023-12-310001383395ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2023-01-012023-12-310001383395us-gaap:ProductMember2021-01-012021-12-310001383395us-gaap:ProductMember2022-01-012022-12-310001383395us-gaap:ProductMember2023-01-012023-12-310001383395sqns:OtherRevenueMember2021-01-012021-12-310001383395sqns:OtherRevenueMember2022-01-012022-12-310001383395sqns:OtherRevenueMember2023-01-012023-12-3100013833952021-01-012021-12-3100013833952022-01-012022-12-3100013833952021-12-3100013833952022-12-310001383395sqns:ConvertibleBorrowingsIssuedMember2021-12-310001383395sqns:ConvertibleBorrowingsIssuedMember2022-12-310001383395sqns:ConvertibleBorrowingsIssuedMember2023-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2021-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2022-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2023-12-310001383395ifrs-full:IssuedCapitalMember2020-12-310001383395ifrs-full:SharePremiumMember2020-12-310001383395ifrs-full:OtherReservesMember2020-12-310001383395ifrs-full:RetainedEarningsMember2020-12-310001383395ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001383395sqns:AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember2020-12-3100013833952020-12-310001383395ifrs-full:RetainedEarningsMember2021-01-012021-12-310001383395ifrs-full:PreviouslyStatedMembersqns:AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-12-310001383395ifrs-full:PreviouslyStatedMember2021-01-012021-12-310001383395ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-12-310001383395sqns:AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-12-310001383395ifrs-full:IssuedCapitalMember2021-01-012021-12-310001383395ifrs-full:SharePremiumMember2021-01-012021-12-310001383395ifrs-full:IssuedCapitalMember2021-04-092021-04-090001383395ifrs-full:SharePremiumMember2021-04-092021-04-090001383395ifrs-full:OtherReservesMember2021-01-012021-12-310001383395ifrs-full:IssuedCapitalMember2021-12-310001383395ifrs-full:SharePremiumMember2021-12-310001383395ifrs-full:OtherReservesMember2021-12-310001383395ifrs-full:RetainedEarningsMember2021-12-310001383395ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-12-310001383395sqns:AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember2021-12-310001383395ifrs-full:RetainedEarningsMember2022-01-012022-12-310001383395ifrs-full:PreviouslyStatedMembersqns:AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember2022-01-012022-12-310001383395ifrs-full:PreviouslyStatedMember2022-01-012022-12-310001383395ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-01-012022-12-310001383395sqns:AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember2022-01-012022-12-310001383395ifrs-full:IssuedCapitalMember2022-01-012022-12-310001383395ifrs-full:SharePremiumMember2022-01-012022-12-310001383395ifrs-full:IssuedCapitalMember2022-01-012022-01-310001383395ifrs-full:SharePremiumMember2022-01-012022-01-3100013833952022-01-012022-01-310001383395ifrs-full:IssuedCapitalMember2022-03-112022-03-110001383395ifrs-full:SharePremiumMember2022-03-112022-03-110001383395ifrs-full:OtherReservesMember2022-03-112022-03-1100013833952022-03-112022-03-110001383395ifrs-full:OtherReservesMember2022-01-012022-12-310001383395ifrs-full:IssuedCapitalMember2022-12-310001383395ifrs-full:SharePremiumMember2022-12-310001383395ifrs-full:OtherReservesMember2022-12-310001383395ifrs-full:RetainedEarningsMember2022-12-310001383395ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-12-310001383395sqns:AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember2022-12-310001383395ifrs-full:RetainedEarningsMember2023-01-012023-12-310001383395sqns:AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember2023-01-012023-12-310001383395ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-01-012023-12-310001383395ifrs-full:IssuedCapitalMember2023-01-012023-12-310001383395ifrs-full:SharePremiumMember2023-01-012023-12-310001383395ifrs-full:IssuedCapitalMember2023-04-122023-04-120001383395ifrs-full:SharePremiumMember2023-04-122023-04-1200013833952023-04-122023-04-120001383395ifrs-full:IssuedCapitalMember2023-09-262023-09-260001383395ifrs-full:SharePremiumMember2023-09-262023-09-2600013833952023-09-262023-09-260001383395ifrs-full:OtherReservesMember2023-01-012023-12-310001383395ifrs-full:IssuedCapitalMember2023-12-310001383395ifrs-full:SharePremiumMember2023-12-310001383395ifrs-full:OtherReservesMember2023-12-310001383395ifrs-full:RetainedEarningsMember2023-12-310001383395ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001383395sqns:AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember2023-12-310001383395sqns:SequansCommunicationsLtd.Member2023-01-012023-12-310001383395sqns:SequansCommunicationsInc.Member2023-01-012023-12-310001383395sqns:SequansCommunicationsLtd.Pte.Member2023-01-012023-12-310001383395sqns:SequansCommunicationsIsrael2009Ltd.Member2023-01-012023-12-310001383395sqns:SequansCommunicationsFinlandOyMember2023-01-012023-12-310001383395sqns:SequansCommunicationsSASMember2023-01-012023-12-310001383395ifrs-full:NotLaterThanOneYearMember2022-12-310001383395ifrs-full:LaterThanOneYearMember2022-12-310001383395ifrs-full:NotLaterThanOneYearMember2021-12-310001383395ifrs-full:LaterThanOneYearMember2021-12-310001383395ifrs-full:ComputerEquipmentMember2023-01-012023-12-310001383395sqns:FurnitureAndOfficeEquipmentMember2023-01-012023-12-310001383395ifrs-full:LicencesAndFranchisesMember2023-01-012023-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:TopOfRangeMember2023-01-012023-12-310001383395ifrs-full:MachineryMemberifrs-full:BottomOfRangeMember2022-01-012022-12-310001383395ifrs-full:MachineryMemberifrs-full:TopOfRangeMember2022-01-012022-12-310001383395sqns:BuildingsAndLeaseholdImprovementsMember2022-01-012022-12-310001383395country:CN2021-01-012021-12-310001383395country:CN2022-01-012022-12-310001383395country:CN2023-01-012023-12-310001383395country:TW2021-01-012021-12-310001383395country:TW2022-01-012022-12-310001383395country:TW2023-01-012023-12-310001383395country:KR2021-01-012021-12-310001383395country:KR2022-01-012022-12-310001383395country:KR2023-01-012023-12-310001383395srt:AsiaPacificMember2021-01-012021-12-310001383395srt:AsiaPacificMember2022-01-012022-12-310001383395srt:AsiaPacificMember2023-01-012023-12-310001383395srt:AsiaMember2021-01-012021-12-310001383395srt:AsiaMember2022-01-012022-12-310001383395srt:AsiaMember2023-01-012023-12-310001383395country:DE2021-01-012021-12-310001383395country:DE2022-01-012022-12-310001383395country:DE2023-01-012023-12-310001383395country:US2021-01-012021-12-310001383395country:US2022-01-012022-12-310001383395country:US2023-01-012023-12-310001383395sqns:EuropeMiddleEastAndAfricaMember2021-01-012021-12-310001383395sqns:EuropeMiddleEastAndAfricaMember2022-01-012022-12-310001383395sqns:EuropeMiddleEastAndAfricaMember2023-01-012023-12-310001383395sqns:RevenueRiskMembersqns:InternationalMember2023-01-012023-12-310001383395sqns:RevenueRiskMembersqns:InternationalMember2022-01-012022-12-310001383395sqns:RevenueRiskMembersqns:InternationalMember2021-01-012021-12-310001383395sqns:TechnologyBroadbandMember2021-01-012021-12-310001383395sqns:TechnologyBroadbandMember2022-01-012022-12-310001383395sqns:TechnologyBroadbandMember2023-01-012023-12-310001383395sqns:TechnologyIOTMember2021-01-012021-12-310001383395sqns:TechnologyIOTMember2022-01-012022-12-310001383395sqns:TechnologyIOTMember2023-01-012023-12-310001383395sqns:LicenseFeeMember2021-01-012021-12-310001383395sqns:LicenseFeeMember2022-01-012022-12-310001383395sqns:LicenseFeeMember2023-01-012023-12-310001383395sqns:DevelopmentAndOtherServicesMember2021-01-012021-12-310001383395sqns:DevelopmentAndOtherServicesMember2022-01-012022-12-310001383395sqns:DevelopmentAndOtherServicesMember2023-01-012023-12-310001383395sqns:LoansAndFinanceLeasesRelatedToConvertibleDebtsIssuedAndGovernmentLoansGrantedMember2023-01-012023-12-310001383395sqns:LoansAndFinanceLeasesRelatedToConvertibleDebtsIssuedAndGovernmentLoansGrantedMember2022-01-012022-12-310001383395sqns:LoansAndFinanceLeasesRelatedToConvertibleDebtsIssuedAndGovernmentLoansGrantedMember2021-01-012021-12-310001383395sqns:CostOfSales1Member2021-01-012021-12-310001383395sqns:CostOfSales1Member2022-01-012022-12-310001383395sqns:CostOfSales1Member2023-01-012023-12-310001383395sqns:OperatingExpenseNettingMember2021-01-012021-12-310001383395sqns:OperatingExpenseNettingMember2022-01-012022-12-310001383395sqns:OperatingExpenseNettingMember2023-01-012023-12-310001383395ifrs-full:WarrantsMember2021-01-012021-12-310001383395ifrs-full:WarrantsMember2022-01-012022-12-310001383395ifrs-full:WarrantsMember2023-01-012023-12-310001383395sqns:ResearchTaxCredit2023Member2023-12-310001383395sqns:ResearchTaxCredit2022Member2022-12-310001383395sqns:ResearchTaxCredit2021Member2021-12-310001383395sqns:ResearchTaxCredit2020Member2020-12-3100013833952024-01-012024-12-310001383395sqns:GovernmentLoansMember2021-12-310001383395sqns:GovernmentLoansMember2022-12-310001383395sqns:GovernmentLoansMember2023-12-310001383395sqns:GovernmentLoansMember2021-01-012021-12-310001383395sqns:GovernmentLoansMember2022-01-012022-12-310001383395sqns:GovernmentLoansMember2023-01-012023-12-310001383395sqns:FixedAssetsMember2021-12-310001383395sqns:FixedAssetsMember2022-12-310001383395sqns:FixedAssetsMember2023-12-310001383395sqns:FixedAssetsMember2021-01-012021-12-310001383395sqns:FixedAssetsMember2022-01-012022-12-310001383395sqns:FixedAssetsMember2023-01-012023-12-310001383395ifrs-full:CashFlowHedgesMember2021-12-310001383395ifrs-full:CashFlowHedgesMember2022-12-310001383395ifrs-full:CashFlowHedgesMember2023-12-310001383395ifrs-full:CashFlowHedgesMember2021-01-012021-12-310001383395ifrs-full:CashFlowHedgesMember2022-01-012022-12-310001383395ifrs-full:CashFlowHedgesMember2023-01-012023-12-310001383395sqns:RemeasurementOfNonMonetaryAccountsMember2021-12-310001383395sqns:RemeasurementOfNonMonetaryAccountsMember2022-12-310001383395sqns:RemeasurementOfNonMonetaryAccountsMember2023-12-310001383395sqns:RemeasurementOfNonMonetaryAccountsMember2021-01-012021-12-310001383395sqns:RemeasurementOfNonMonetaryAccountsMember2022-01-012022-12-310001383395sqns:RemeasurementOfNonMonetaryAccountsMember2023-01-012023-12-310001383395sqns:ConvertibleDebtAndVentureDebtLiabilityMember2021-12-310001383395sqns:ConvertibleDebtAndVentureDebtLiabilityMember2022-12-310001383395sqns:ConvertibleDebtAndVentureDebtLiabilityMember2023-12-310001383395sqns:ConvertibleDebtAndVentureDebtLiabilityMember2021-01-012021-12-310001383395sqns:ConvertibleDebtAndVentureDebtLiabilityMember2022-01-012022-12-310001383395sqns:ConvertibleDebtAndVentureDebtLiabilityMember2023-01-012023-12-310001383395sqns:OtherProvisionsAndAccrualsMember2021-12-310001383395sqns:OtherProvisionsAndAccrualsMember2022-12-310001383395sqns:OtherProvisionsAndAccrualsMember2023-12-310001383395sqns:OtherProvisionsAndAccrualsMember2021-01-012021-12-310001383395sqns:OtherProvisionsAndAccrualsMember2022-01-012022-12-310001383395sqns:OtherProvisionsAndAccrualsMember2023-01-012023-12-310001383395srt:SubsidiariesMember2021-12-310001383395srt:SubsidiariesMember2022-12-310001383395srt:SubsidiariesMember2023-12-310001383395srt:SubsidiariesMember2021-01-012021-12-310001383395srt:SubsidiariesMember2022-01-012022-12-310001383395srt:SubsidiariesMember2023-01-012023-12-310001383395ifrs-full:UnusedTaxLossesMember2021-12-310001383395ifrs-full:UnusedTaxLossesMember2022-12-310001383395ifrs-full:UnusedTaxLossesMember2023-12-310001383395ifrs-full:UnusedTaxLossesMember2021-01-012021-12-310001383395ifrs-full:UnusedTaxLossesMember2022-01-012022-12-310001383395ifrs-full:UnusedTaxLossesMember2023-01-012023-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2020-12-310001383395ifrs-full:GrossCarryingAmountMembersqns:PlantAndEquipmentMember2020-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2020-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:GrossCarryingAmountMember2020-12-310001383395ifrs-full:GrossCarryingAmountMember2020-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001383395ifrs-full:GrossCarryingAmountMembersqns:PlantAndEquipmentMember2021-01-012021-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001383395ifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2021-12-310001383395ifrs-full:GrossCarryingAmountMembersqns:PlantAndEquipmentMember2021-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2021-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:GrossCarryingAmountMember2021-12-310001383395ifrs-full:GrossCarryingAmountMember2021-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2022-01-012022-12-310001383395ifrs-full:GrossCarryingAmountMembersqns:PlantAndEquipmentMember2022-01-012022-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2022-01-012022-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:GrossCarryingAmountMember2022-01-012022-12-310001383395ifrs-full:GrossCarryingAmountMember2022-01-012022-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2022-12-310001383395ifrs-full:GrossCarryingAmountMembersqns:PlantAndEquipmentMember2022-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2022-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:GrossCarryingAmountMember2022-12-310001383395ifrs-full:GrossCarryingAmountMember2022-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2023-01-012023-12-310001383395ifrs-full:GrossCarryingAmountMembersqns:PlantAndEquipmentMember2023-01-012023-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2023-01-012023-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:GrossCarryingAmountMember2023-01-012023-12-310001383395ifrs-full:GrossCarryingAmountMember2023-01-012023-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2023-12-310001383395ifrs-full:GrossCarryingAmountMembersqns:PlantAndEquipmentMember2023-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2023-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:GrossCarryingAmountMember2023-12-310001383395ifrs-full:GrossCarryingAmountMember2023-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersqns:PlantAndEquipmentMember2020-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersqns:PlantAndEquipmentMember2021-01-012021-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersqns:PlantAndEquipmentMember2021-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersqns:PlantAndEquipmentMember2022-01-012022-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersqns:PlantAndEquipmentMember2022-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-01-012023-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersqns:PlantAndEquipmentMember2023-01-012023-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-01-012023-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-01-012023-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-01-012023-12-310001383395ifrs-full:LeaseholdImprovementsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersqns:PlantAndEquipmentMember2023-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-12-310001383395ifrs-full:RightofuseAssetsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-12-310001383395ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-12-310001383395ifrs-full:LeaseholdImprovementsMember2020-12-310001383395sqns:PlantAndEquipmentMember2020-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMember2020-12-310001383395ifrs-full:RightofuseAssetsMember2020-12-310001383395ifrs-full:LeaseholdImprovementsMember2021-12-310001383395sqns:PlantAndEquipmentMember2021-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMember2021-12-310001383395ifrs-full:RightofuseAssetsMember2021-12-310001383395ifrs-full:LeaseholdImprovementsMember2022-12-310001383395sqns:PlantAndEquipmentMember2022-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMember2022-12-310001383395ifrs-full:RightofuseAssetsMember2022-12-310001383395ifrs-full:LeaseholdImprovementsMember2023-12-310001383395sqns:PlantAndEquipmentMember2023-12-310001383395sqns:InformationTechnologyAndOfficeEquipmentMember2023-12-310001383395ifrs-full:RightofuseAssetsMember2023-12-310001383395sqns:RealEstateRightofuseAssetsMember2023-12-310001383395sqns:RealEstateRightofuseAssetsMember2022-12-310001383395sqns:RealEstateRightofuseAssetsMember2021-12-310001383395sqns:ITandOfficeEquipmentRightofuseAssetsMember2023-12-310001383395sqns:ITandOfficeEquipmentRightofuseAssetsMember2022-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:GrossCarryingAmountMember2020-12-310001383395us-gaap:LicenseMemberifrs-full:GrossCarryingAmountMember2020-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001383395us-gaap:LicenseMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:GrossCarryingAmountMember2021-12-310001383395us-gaap:LicenseMemberifrs-full:GrossCarryingAmountMember2021-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:GrossCarryingAmountMember2022-01-012022-12-310001383395us-gaap:LicenseMemberifrs-full:GrossCarryingAmountMember2022-01-012022-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:GrossCarryingAmountMember2022-12-310001383395us-gaap:LicenseMemberifrs-full:GrossCarryingAmountMember2022-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:GrossCarryingAmountMember2023-01-012023-12-310001383395us-gaap:LicenseMemberifrs-full:GrossCarryingAmountMember2023-01-012023-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:GrossCarryingAmountMember2023-12-310001383395us-gaap:LicenseMemberifrs-full:GrossCarryingAmountMember2023-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001383395us-gaap:LicenseMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-12-310001383395us-gaap:LicenseMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001383395us-gaap:LicenseMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-12-310001383395us-gaap:LicenseMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-12-310001383395us-gaap:LicenseMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-01-012023-12-310001383395us-gaap:LicenseMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-01-012023-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-12-310001383395us-gaap:LicenseMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMember2020-12-310001383395us-gaap:LicenseMember2020-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMember2021-12-310001383395us-gaap:LicenseMember2021-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMember2022-12-310001383395us-gaap:LicenseMember2022-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMember2023-12-310001383395us-gaap:LicenseMember2023-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMembersqns:DevelopmentOfThe5GMember2023-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMembersqns:DevelopmentOfThe5GMember2022-12-310001383395ifrs-full:CapitalisedDevelopmentExpenditureMembersqns:DevelopmentOfThe5GMember2021-12-310001383395sqns:InventoryAdjustmentsMember2021-12-310001383395sqns:InventoryAdjustmentsMember2022-12-310001383395sqns:InventoryAdjustmentsMember2023-12-310001383395sqns:LeadTimesIncreasedCOVID19AndOtherSupplyChainConstraintsMembersqns:InventoryAdjustmentsMember2022-12-310001383395sqns:LeadTimesIncreasedCOVID19AndOtherSupplyChainConstraintsMember2023-01-012023-12-310001383395sqns:LeadTimesIncreasedCOVID19AndOtherSupplyChainConstraintsMembersqns:InventoryAdjustmentsMember2023-12-310001383395sqns:ProvisionToServeExpectedDemandForCustomersAndProjectsMembersqns:InventoryAdjustmentsMember2023-12-310001383395ifrs-full:TradeReceivablesMember2020-12-310001383395ifrs-full:TradeReceivablesMember2021-12-310001383395ifrs-full:TradeReceivablesMember2022-12-310001383395ifrs-full:TradeReceivablesMember2021-01-012021-12-310001383395ifrs-full:TradeReceivablesMember2022-01-012022-12-310001383395ifrs-full:TradeReceivablesMember2023-01-012023-12-310001383395ifrs-full:TradeReceivablesMember2023-12-310001383395ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsNeitherPastDueNorImpairedMember2021-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMemberifrs-full:CurrentMemberifrs-full:TradeReceivablesMember2021-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMemberifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMemberifrs-full:TradeReceivablesMember2021-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMembersqns:LaterThanTwoMonthsAndNotLaterThanFourMonthsMemberifrs-full:TradeReceivablesMember2021-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMemberifrs-full:LaterThanFourMonthsMemberifrs-full:TradeReceivablesMember2021-12-310001383395ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsNeitherPastDueNorImpairedMember2022-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMemberifrs-full:CurrentMemberifrs-full:TradeReceivablesMember2022-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMemberifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMemberifrs-full:TradeReceivablesMember2022-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMembersqns:LaterThanTwoMonthsAndNotLaterThanFourMonthsMemberifrs-full:TradeReceivablesMember2022-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMemberifrs-full:LaterThanFourMonthsMemberifrs-full:TradeReceivablesMember2022-12-310001383395ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsNeitherPastDueNorImpairedMember2023-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMemberifrs-full:CurrentMemberifrs-full:TradeReceivablesMember2023-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMemberifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMemberifrs-full:TradeReceivablesMember2023-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMembersqns:LaterThanTwoMonthsAndNotLaterThanFourMonthsMemberifrs-full:TradeReceivablesMember2023-12-310001383395ifrs-full:FinancialAssetsPastDueButNotImpairedMemberifrs-full:LaterThanFourMonthsMemberifrs-full:TradeReceivablesMember2023-12-310001383395currency:USD2021-12-310001383395currency:USD2022-12-310001383395currency:USD2023-12-310001383395currency:EUR2021-12-310001383395currency:EUR2022-12-310001383395currency:EUR2023-12-310001383395currency:GBP2021-12-310001383395currency:GBP2022-12-310001383395currency:GBP2023-12-310001383395currency:SGD2021-12-310001383395currency:SGD2022-12-310001383395currency:SGD2023-12-310001383395currency:ILS2021-12-310001383395currency:ILS2022-12-310001383395currency:ILS2023-12-310001383395currency:CNY2021-12-310001383395currency:CNY2022-12-310001383395currency:CNY2023-12-310001383395sqns:OtherCurrenciesMember2021-12-310001383395sqns:OtherCurrenciesMember2022-12-310001383395sqns:OtherCurrenciesMember2023-12-310001383395ifrs-full:IssuedCapitalMember2022-06-242022-06-240001383395ifrs-full:SharePremiumMember2022-06-242022-06-240001383395ifrs-full:RetainedEarningsMember2022-06-242022-06-240001383395ifrs-full:SharePremiumMember2023-06-272023-06-270001383395ifrs-full:RetainedEarningsMember2023-06-272023-06-270001383395ifrs-full:OrdinarySharesMember2023-09-260001383395ifrs-full:OrdinarySharesMember2023-04-120001383395ifrs-full:IssuedCapitalMember2022-01-112022-01-1100013833952022-01-112022-01-110001383395ifrs-full:SharePremiumMember2022-01-112022-01-1100013833952021-04-092021-04-090001383395sqns:ConvertibleNotes2016And20191Member2021-02-120001383395ifrs-full:IssuedCapitalMember2021-01-132021-02-120001383395ifrs-full:SharePremiumMember2021-01-132021-02-120001383395sqns:ConsultantsMembersqns:Warrant1Member2023-01-012023-12-310001383395sqns:ConsultantsMembersqns:Warrant1Member2021-01-012021-12-310001383395sqns:ConsultantsMembersqns:Warrant1Member2022-01-012022-12-310001383395sqns:CostOfRevenueMember2021-01-012021-12-310001383395sqns:CostOfRevenueMember2022-01-012022-12-310001383395sqns:CostOfRevenueMember2023-01-012023-12-310001383395sqns:ResearchAndDevelopmentMember2021-01-012021-12-310001383395sqns:ResearchAndDevelopmentMember2022-01-012022-12-310001383395sqns:ResearchAndDevelopmentMember2023-01-012023-12-310001383395sqns:SalesAndMarketingMember2021-01-012021-12-310001383395sqns:SalesAndMarketingMember2022-01-012022-12-310001383395sqns:SalesAndMarketingMember2023-01-012023-12-310001383395sqns:GeneralAndAdministrativeMember2021-01-012021-12-310001383395sqns:GeneralAndAdministrativeMember2022-01-012022-12-310001383395sqns:GeneralAndAdministrativeMember2023-01-012023-12-310001383395sqns:FoundersWarrantsAndStockOptionsMember2023-01-012023-12-310001383395sqns:FoundersWarrantsAndStockOptionsMembersqns:ShareBasedCompensationAwardTrancheOne1Member2023-01-012023-12-310001383395sqns:ShareBasedCompensationAwardTrancheTwo1Membersqns:FoundersWarrantsAndStockOptionsMember2023-01-012023-12-310001383395sqns:RestrictedStock1Member2023-01-012023-12-310001383395sqns:ShareBasedCompensationAwardTrancheOne1Membersqns:RestrictedStock1Member2023-01-012023-12-310001383395sqns:RestrictedStock1Membersqns:ShareBasedCompensationAwardTrancheThree1Member2023-01-012023-12-310001383395sqns:RestrictedStock1Membersqns:ShareBasedCompensationAwardTrancheFourMember2023-01-012023-12-310001383395sqns:SharebasedCompensationAwardTrancheFiveMembersqns:RestrictedStock1Member2023-01-012023-12-310001383395sqns:ConsultantsMembersqns:ShareBasedCompensationAwardTrancheOne1Membersqns:Warrant1Member2023-01-012023-12-310001383395sqns:ShareBasedCompensationAwardTrancheTwo1Membersqns:ConsultantsMembersqns:Warrant1Member2023-01-012023-12-310001383395sqns:ConsultantsMembersqns:Warrant1Membersqns:ShareBasedCompensationAwardTrancheThree1Member2023-01-012023-12-310001383395sqns:ConsultantsMembersqns:Warrant1Member2021-12-310001383395sqns:ConsultantsMembersqns:Warrant1Member2022-12-310001383395sqns:ConsultantsMembersqns:Warrant1Member2023-12-310001383395sqns:RestrictedShareAwardsRSAMember2020-12-310001383395sqns:RestrictedShareAwardsRSAMember2021-12-310001383395sqns:RestrictedShareAwardsRSAMember2022-12-310001383395sqns:RestrictedShareAwardsRSAMember2021-01-012021-12-310001383395sqns:RestrictedShareAwardsRSAMember2022-01-012022-12-310001383395sqns:RestrictedShareAwardsRSAMember2023-01-012023-12-310001383395sqns:RestrictedShareAwardsRSAMember2023-12-310001383395ifrs-full:BottomOfRangeMember2023-01-012023-12-310001383395ifrs-full:TopOfRangeMember2023-01-012023-12-310001383395ifrs-full:BottomOfRangeMember2022-01-012022-12-310001383395ifrs-full:TopOfRangeMember2022-01-012022-12-310001383395ifrs-full:BottomOfRangeMember2021-01-012021-12-310001383395ifrs-full:TopOfRangeMember2021-01-012021-12-310001383395srt:MinimumMember2022-01-012022-12-310001383395srt:MaximumMember2022-01-012022-12-310001383395sqns:ConvertibleBorrowingsEmbeddedDerivativeMember2021-12-310001383395sqns:ConvertibleBorrowingsEmbeddedDerivativeMember2022-12-310001383395sqns:ConvertibleBorrowingsEmbeddedDerivativeMember2023-12-310001383395sqns:FinanceLeaseLiabilitiesMember2021-12-310001383395sqns:FinanceLeaseLiabilitiesMember2022-12-310001383395sqns:FinanceLeaseLiabilitiesMember2023-12-310001383395sqns:BorrowingsExcludingGovernmentLoansAndResearchProjectFinancingMember2021-12-310001383395sqns:BorrowingsExcludingGovernmentLoansAndResearchProjectFinancingMember2022-12-310001383395sqns:BorrowingsExcludingGovernmentLoansAndResearchProjectFinancingMember2023-12-310001383395sqns:ConvertibleBorrowingsIssuedApril2015Member2015-04-140001383395sqns:ConvertibleBorrowingsIssuedApril2015Member2018-09-270001383395sqns:ConvertibleBorrowingsIssuedSeptember2018Member2018-09-270001383395sqns:ConvertibleBorrowingsIssuedSeptember2018Member2018-09-272018-09-270001383395sqns:ConvertibleBorrowingsIssuedApril2016Member2016-04-270001383395sqns:ConvertibleBorrowingsIssuedApril2016Member2017-10-300001383395sqns:ConvertibleBorrowingsIssuedApril2016Member2018-09-270001383395sqns:ConvertibleNotes20191Member2019-05-070001383395sqns:ConvertibleNotes20192Member2019-08-160001383395sqns:ConvertibleNotes2016Member2020-02-100001383395sqns:ConvertibleNotes2016Member2020-02-110001383395sqns:ConvertibleNotesAmendedOptionOneMember2020-03-200001383395sqns:ConvertibleNotesAmendedOptionTwoMember2020-03-200001383395sqns:ConvertibleNotesAmendedOptionThreeMember2020-03-200001383395sqns:ConvertibleNotes2015Member2021-02-120001383395sqns:ConvertibleNotes2015Member2021-01-132021-02-120001383395ifrs-full:OtherReservesMembersqns:ConvertibleNotes2015Member2023-01-012023-12-310001383395sqns:ConvertibleNotes2021LynrockLakeNoteMember2021-04-090001383395sqns:ConvertibleNotes2021LynrockLakeNoteMemberifrs-full:MarketApproachMember2021-04-140001383395sqns:ConvertibleNotes2021LynrockLakeNoteMember2021-04-092021-04-090001383395sqns:ConvertibleNotes2015And2018NokomisMember2021-04-140001383395sqns:ConvertibleNotes2015NokomisMember2021-04-142021-04-140001383395sqns:ConvertibleNotes2018NokomisMember2021-04-142021-04-140001383395sqns:ConvertibleNotes2015And2018NokomisMember2023-01-012023-12-310001383395ifrs-full:WarrantsMembersqns:ConvertibleBorrowingsIssuedSeptember2018Member2022-08-150001383395sqns:AmericanDepositarySharesMembersqns:ConvertibleBorrowingsIssuedSeptember2018Member2022-08-150001383395ifrs-full:WarrantsMembersqns:ConvertibleBorrowingsIssuedSeptember2018Member2022-08-152022-08-150001383395sqns:AmericanDepositarySharesMembersqns:ConvertibleBorrowingsIssuedSeptember2018Member2022-08-152022-08-150001383395sqns:ConvertibleNotes2015And2018NokomisMember2022-08-150001383395sqns:ConvertibleNotes20192Member2022-08-150001383395sqns:ConvertibleNotes20192Memberifrs-full:MarketApproachMember2022-08-150001383395sqns:ConvertibleNotes20192Member2022-08-1400013833952022-08-150001383395ifrs-full:OtherReservesMembersqns:ConvertibleNotes2016And20191Member2022-08-152022-08-150001383395ifrs-full:WarrantsMembersqns:ConvertibleBorrowingsIssuedSeptember2018Member2023-08-150001383395sqns:AmericanDepositarySharesMembersqns:ConvertibleBorrowingsIssuedSeptember2018Member2023-08-1500013833952023-08-152023-08-150001383395ifrs-full:WarrantsMembersqns:ConvertibleBorrowingsIssuedSeptember2018Member2023-08-152023-08-150001383395sqns:AmericanDepositarySharesMembersqns:ConvertibleBorrowingsIssuedSeptember2018Member2023-08-152023-08-150001383395sqns:ConvertibleNotes2015And2018NokomisMember2023-08-150001383395sqns:ConvertibleNotes20192Member2023-08-140001383395sqns:ConvertibleNotes20192Memberifrs-full:MarketApproachMember2023-08-150001383395sqns:ConvertibleNotes20192Member2023-08-1500013833952023-08-150001383395sqns:ConvertibleNotes20192Memberifrs-full:OtherReservesMember2023-08-152023-08-150001383395sqns:ConvertibleNotes20192Member2023-12-310001383395sqns:ConvertibleNotes2021LynrockLakeNoteMember2023-12-310001383395sqns:ConvertibleBorrowingsIssuedApril2015Member2015-04-142015-04-140001383395sqns:UnsecuredRelatedPartyLoanMembersqns:SecurityPurchaseAgreementMember2023-11-080001383395sqns:SecurityPurchaseAgreementMembersqns:OrdinarySharesAndADSMember2023-11-080001383395sqns:SecurityPurchaseAgreementMemberifrs-full:OrdinarySharesMember2023-11-080001383395sqns:SecurityPurchaseAgreementMember2023-11-082023-11-080001383395sqns:UnsecuredRelatedPartyLoanMembersqns:SecondSecurityPurchaseAgreementMember2023-12-270001383395sqns:UnsecuredRelatedPartyLoanMember2023-01-012023-12-310001383395ifrs-full:FactoringOfReceivablesMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2014-06-012014-06-300001383395sqns:ServiceSalesMemberifrs-full:FactoringOfReceivablesMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2017-07-310001383395sqns:LondonInterbankOfferedRateLIBOR1Membersqns:InterestBearingReceivablesFinancingLineOfCreditMember2017-07-010001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2017-07-010001383395ifrs-full:FactoringOfReceivablesMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2022-01-012022-12-310001383395sqns:InterestBearingReceivablesFinancingResearchTaxCreditMember2021-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:InterestBearingReceivablesFinancingResearchTaxCreditMember2021-12-310001383395sqns:InterestBearingReceivablesFinancingResearchTaxCreditMemberifrs-full:LaterThanFiveYearsMember2021-12-310001383395sqns:InterestBearingReceivablesFinancingResearchTaxCreditMember2021-02-280001383395sqns:InterestBearingReceivablesFinancingResearchTaxCreditMember2022-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:InterestBearingReceivablesFinancingResearchTaxCreditMember2022-12-310001383395sqns:InterestBearingReceivablesFinancingResearchTaxCreditMemberifrs-full:LaterThanFiveYearsMember2022-12-310001383395sqns:InterestBearingReceivablesFinancingResearchTaxCreditMember2022-03-310001383395sqns:InterestBearingReceivablesFinancingResearchTaxCreditMember2023-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:InterestBearingReceivablesFinancingResearchTaxCreditMember2023-12-310001383395sqns:InterestBearingReceivablesFinancingResearchTaxCreditMemberifrs-full:LaterThanFiveYearsMember2023-12-310001383395sqns:IFRS16Member2023-12-310001383395sqns:RealEstateRightofuseAssetsMember2020-12-310001383395sqns:ITandOfficeEquipmentRightofuseAssetsMember2020-12-310001383395sqns:RealEstateRightofuseAssetsMember2021-01-012021-12-310001383395sqns:ITandOfficeEquipmentRightofuseAssetsMember2021-01-012021-12-310001383395sqns:RealEstateRightofuseAssetsMember2021-12-310001383395sqns:ITandOfficeEquipmentRightofuseAssetsMember2021-12-310001383395sqns:RealEstateRightofuseAssetsMember2022-01-012022-12-310001383395sqns:ITandOfficeEquipmentRightofuseAssetsMember2022-01-012022-12-310001383395sqns:RealEstateRightofuseAssetsMember2022-12-310001383395sqns:ITandOfficeEquipmentRightofuseAssetsMember2022-12-310001383395sqns:RealEstateRightofuseAssetsMember2023-01-012023-12-310001383395sqns:ITandOfficeEquipmentRightofuseAssetsMember2023-01-012023-12-310001383395sqns:RealEstateRightofuseAssetsMember2023-12-310001383395sqns:ITandOfficeEquipmentRightofuseAssetsMember2023-12-3100013833952020-01-010001383395sqns:LongTermResearchProjectOctober2014Member2014-10-012014-10-310001383395sqns:LongTermResearchProjectOctober2014Member2020-10-012020-12-310001383395sqns:LongTermResearchProjectOctober2014Member2021-01-012021-12-310001383395sqns:LongTermResearchProjectOctober2014Membersqns:ResearchProjectFinancingMember2020-12-310001383395sqns:ResearchProjectFinancingGovernmentGrantMembersqns:LongTermResearchProjectOctober2014Member2020-12-310001383395sqns:LongTermResearchProjectOctober2014Membersqns:ResearchProjectFinancingForgivableLoanMember2020-12-310001383395sqns:LongTermResearchProjectOctober2014Member2016-12-012016-12-310001383395sqns:LongTermResearchProjectOctober2014Membersqns:ResearchProjectFinancingForgivableLoanMember2021-01-012021-12-310001383395sqns:LongTermResearchProjectOctober2014Membersqns:ResearchProjectFinancingForgivableLoanMember2023-01-012023-12-310001383395sqns:LongTermResearchProjectOctober2014Membersqns:ResearchProjectFinancingForgivableLoanMember2022-01-012022-12-310001383395sqns:LongTermResearchProjectOctober2014Memberifrs-full:FixedInterestRateMember2023-12-310001383395sqns:LongTermResearchProjectOctober2014Membersqns:RoyaltyAgreementTerms1Member2021-01-012021-12-310001383395sqns:LongTermResearchProjectOctober2014Membersqns:RoyaltyAgreementTerms1Member2014-10-012014-10-310001383395sqns:ResearchProjectFinancingMembersqns:LongTermResearchProjectJanuary2016Member2016-01-310001383395sqns:ResearchProjectFinancingGovernmentGrantMembersqns:LongTermResearchProjectJanuary2016Member2016-01-310001383395sqns:LongTermResearchProjectJanuary2016Membersqns:ResearchProjectFinancingForgivableLoanMember2016-01-310001383395sqns:LongTermResearchProjectJanuary2016Member2016-01-012016-01-310001383395sqns:LongTermResearchProjectJanuary2016Membersqns:ResearchProjectFinancingForgivableLoanMemberifrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember2020-02-012020-02-290001383395ifrs-full:FixedInterestRateMembersqns:LongTermResearchProjectJanuary2016Member2016-01-310001383395sqns:LongTermResearchProjectJanuary2016Membersqns:GovernmentGrantAdvancesAndLoansMember2022-02-012022-02-280001383395sqns:ResearchProjectFinancingMembersqns:LongTermResearchProjectJanuary2016Member2022-12-300001383395sqns:ResearchProjectFinancingGovernmentGrantMembersqns:LongTermResearchProjectJanuary2016Member2022-12-300001383395sqns:ResearchProjectFinancingGovernmentGrantMember2023-01-012023-12-310001383395sqns:ResearchProjectFinancingForgivableLoanMember2023-01-012023-12-310001383395sqns:ResearchProjectFinancingGovernmentGrantMembersqns:FirstInstallmentMember2023-01-012023-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:BottomOfRangeMember2023-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:TopOfRangeMember2023-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:BottomOfRangeMember2021-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:TopOfRangeMember2021-12-310001383395sqns:GovernmentLoansMember2015-09-012015-09-300001383395sqns:GovernmentLoansMember2015-09-300001383395sqns:GovernmentLoans5.24PercentLoanMember2015-09-300001383395sqns:GovernmentLoansInterestFreeLoanMember2015-09-300001383395sqns:GovernmentLoanCovid19SupportPlanMember2020-04-300001383395sqns:GovernmentLoanCovid19SupportPlanMember2020-04-302020-04-300001383395sqns:GovernmentLoanCovid19SupportPlanMember2023-12-310001383395ifrs-full:PreviouslyStatedMembersqns:ProvisionsForEmployeeBenefitsNettingMember2020-12-310001383395ifrs-full:MiscellaneousOtherProvisionsMemberifrs-full:PreviouslyStatedMember2020-12-310001383395ifrs-full:PreviouslyStatedMember2020-12-310001383395sqns:ProvisionsForEmployeeBenefitsNettingMember2021-01-012021-12-310001383395ifrs-full:MiscellaneousOtherProvisionsMember2021-01-012021-12-310001383395sqns:ProvisionsForEmployeeBenefitsNettingMember2021-12-310001383395ifrs-full:MiscellaneousOtherProvisionsMember2021-12-310001383395sqns:ProvisionsForEmployeeBenefitsNettingMember2022-01-012022-12-310001383395ifrs-full:MiscellaneousOtherProvisionsMember2022-01-012022-12-310001383395sqns:ProvisionsForEmployeeBenefitsNettingMember2022-12-310001383395ifrs-full:MiscellaneousOtherProvisionsMember2022-12-310001383395sqns:ProvisionsForEmployeeBenefitsNettingMember2023-01-012023-12-310001383395ifrs-full:MiscellaneousOtherProvisionsMember2023-01-012023-12-310001383395sqns:ProvisionsForEmployeeBenefitsNettingMember2023-12-310001383395ifrs-full:MiscellaneousOtherProvisionsMember2023-12-310001383395ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMembercountry:FR2023-01-012023-12-310001383395ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMembercountry:FR2022-01-012022-12-310001383395ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMembercountry:FR2021-01-012021-12-310001383395ifrs-full:BottomOfRangeMember2021-12-310001383395ifrs-full:TopOfRangeMember2021-12-310001383395ifrs-full:BottomOfRangeMember2022-12-310001383395ifrs-full:TopOfRangeMember2022-12-310001383395ifrs-full:BottomOfRangeMember2023-12-310001383395ifrs-full:TopOfRangeMember2023-12-310001383395sqns:DirectorsVicePresidentsAndManagersMember2021-12-310001383395sqns:DirectorsVicePresidentsAndManagersMember2022-12-310001383395sqns:DirectorsVicePresidentsAndManagersMember2023-12-310001383395sqns:OtherEmployeesMember2021-12-310001383395sqns:OtherEmployeesMember2022-12-310001383395sqns:OtherEmployeesMember2023-12-310001383395sqns:ExecutiveTeamMember2021-12-310001383395sqns:ExecutiveTeamMember2022-12-310001383395sqns:ExecutiveTeamMember2023-12-310001383395sqns:A5GNewProductDevelopmentMember2021-12-310001383395sqns:A5GNewProductDevelopmentMember2022-01-012022-12-310001383395sqns:A5GNewProductDevelopmentMember2022-12-310001383395sqns:A5GNewProductDevelopmentMember2023-01-012023-12-310001383395sqns:A5GNewProductDevelopmentTeamOfEngineersMember2023-12-310001383395sqns:A5GNewProductDevelopmentTeamOfEngineersMember2022-12-310001383395sqns:A5GNewProductDevelopmentTeamOfEngineersMember2021-12-310001383395sqns:DevelopmentServicesAgreementsMember2021-12-310001383395sqns:DevelopmentServicesAgreementsMember2022-12-310001383395sqns:DevelopmentServicesAgreementsMember2023-12-310001383395sqns:A5GNewProductDevelopmentMember2021-01-012021-12-3100013833952019-10-240001383395us-gaap:LicenseMember2023-01-012023-12-310001383395sqns:StrategicPartnerMembersqns:DevelopmentServicesMember2021-01-012021-12-310001383395sqns:StrategicPartnerMembersqns:DevelopmentServicesMember2023-01-012023-12-310001383395sqns:StrategicPartnerMembersqns:DevelopmentServicesMember2022-01-012022-12-310001383395sqns:StrategicPartnerMember2023-01-012023-12-310001383395sqns:StrategicPartnerMembersqns:DevelopmentServicesMember2023-12-310001383395sqns:StrategicPartnerMembersqns:DevelopmentServicesMember2022-12-310001383395sqns:StrategicPartnerMembersqns:DevelopmentServicesMember2021-12-310001383395sqns:DevelopmentServicesMembersqns:StrategicPartnerAmendmentContractMember2022-01-012022-12-310001383395sqns:DevelopmentServicesMembersqns:StrategicPartnerAmendmentContractMember2022-02-012022-02-280001383395sqns:StrategicPartnerAmendmentContractMember2023-01-012023-12-310001383395sqns:StrategicPartnerAmendmentContractMember2022-01-012022-12-310001383395sqns:StrategicPartnerAmendmentContractMember2021-01-012021-12-310001383395sqns:DevelopmentServicesMembersqns:StrategicPartnerAmendmentContractMember2023-12-310001383395sqns:DevelopmentServicesMembersqns:StrategicPartnerAmendmentContractMember2022-12-310001383395sqns:StrategicPartnerSecondAmendmentContractMembersqns:DevelopmentServicesMember2023-01-012023-12-310001383395sqns:StrategicPartnerSecondAmendmentContractMemberus-gaap:LicenseMember2023-01-012023-12-310001383395sqns:StrategicPartnerSecondAmendmentContractMember2023-01-012023-12-310001383395sqns:StrategicPartnerSecondAmendmentContractMembersqns:DevelopmentServicesMember2023-12-310001383395sqns:StrategicPartnerSecondAmendmentContractMembersqns:DevelopmentServicesMember2022-12-310001383395sqns:StrategicPartnerSecondAmendmentContractMembersqns:DevelopmentServicesMember2021-12-310001383395sqns:DevelopmentServicesMembersqns:StrategicPartnerSecondAmendmentContract5GChipsetChinaMember2022-08-012022-08-010001383395us-gaap:LicenseMembersqns:StrategicPartnerSecondAmendmentContract5GChipsetChinaMember2023-01-012023-12-310001383395us-gaap:LicenseMembersqns:StrategicPartnerSecondAmendmentContract5GChipsetChinaMember2022-01-012022-12-310001383395sqns:DevelopmentServicesMembersqns:StrategicPartnerSecondAmendmentContract5GChipsetChinaMember2023-12-310001383395sqns:TradeAndOtherReceivablesMemberifrs-full:TradeReceivablesMember2021-12-310001383395sqns:TradeAndOtherReceivablesMemberifrs-full:TradeReceivablesMember2022-12-310001383395sqns:TradeAndOtherReceivablesMemberifrs-full:TradeReceivablesMember2023-12-310001383395sqns:LoansAndOtherReceivablesMembersqns:Deposits1Member2021-12-310001383395sqns:LoansAndOtherReceivablesMembersqns:Deposits1Member2022-12-310001383395sqns:LoansAndOtherReceivablesMembersqns:Deposits1Member2023-12-310001383395sqns:LongTermInvestmentsMembersqns:AvailableForSaleSecuritiesMember2021-12-310001383395sqns:LongTermInvestmentsMembersqns:AvailableForSaleSecuritiesMember2022-12-310001383395sqns:LongTermInvestmentsMembersqns:AvailableForSaleSecuritiesMember2023-12-310001383395ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMembersqns:DerivativeAssetsMember2021-12-310001383395ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMembersqns:DerivativeAssetsMember2022-12-310001383395ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMembersqns:DerivativeAssetsMember2023-12-310001383395sqns:CashCashEquivalentsAndShortTermInvestmentsMembersqns:CashCashEquivalentsAndShortTermInvestmentsMember2021-12-310001383395sqns:CashCashEquivalentsAndShortTermInvestmentsMembersqns:CashCashEquivalentsAndShortTermInvestmentsMember2022-12-310001383395sqns:CashCashEquivalentsAndShortTermInvestmentsMember2023-12-310001383395sqns:CashCashEquivalentsAndShortTermInvestmentsMember2021-12-310001383395sqns:CashCashEquivalentsAndShortTermInvestmentsMember2022-12-310001383395ifrs-full:LeaseLiabilitiesMember2021-12-310001383395ifrs-full:LeaseLiabilitiesMember2022-12-310001383395ifrs-full:LeaseLiabilitiesMember2023-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMembersqns:InterestBearingLoansAndBorrowingsMember2021-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMembersqns:InterestBearingLoansAndBorrowingsMember2022-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMembersqns:InterestBearingLoansAndBorrowingsMember2023-12-310001383395sqns:ConvertibleBorrowingsIssuedMembersqns:InterestBearingLoansAndBorrowingsMember2021-12-310001383395sqns:ConvertibleBorrowingsIssuedMembersqns:InterestBearingLoansAndBorrowingsMember2022-12-310001383395sqns:ConvertibleBorrowingsIssuedMembersqns:InterestBearingLoansAndBorrowingsMember2023-12-310001383395sqns:VentureDebtMembersqns:InterestBearingLoansAndBorrowingsMember2021-12-310001383395sqns:VentureDebtMembersqns:InterestBearingLoansAndBorrowingsMember2022-12-310001383395sqns:VentureDebtMembersqns:InterestBearingLoansAndBorrowingsMember2023-12-310001383395sqns:GovernmentLoansMembersqns:InterestBearingLoansAndBorrowingsMember2021-12-310001383395sqns:GovernmentLoansMembersqns:InterestBearingLoansAndBorrowingsMember2022-12-310001383395sqns:GovernmentLoansMembersqns:InterestBearingLoansAndBorrowingsMember2023-12-310001383395sqns:ResearchProjectFinancingMembersqns:InterestBearingLoansAndBorrowingsMember2021-12-310001383395sqns:ResearchProjectFinancingMembersqns:InterestBearingLoansAndBorrowingsMember2022-12-310001383395sqns:ResearchProjectFinancingMembersqns:InterestBearingLoansAndBorrowingsMember2023-12-310001383395sqns:TradeAndOtherPayablesMembersqns:TradeAndOtherPayablesMember2021-12-310001383395sqns:TradeAndOtherPayablesMembersqns:TradeAndOtherPayablesMember2022-12-310001383395sqns:TradeAndOtherPayablesMembersqns:TradeAndOtherPayablesMember2023-12-310001383395sqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMembersqns:DerivativeAssetsMember2021-12-310001383395sqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMembersqns:DerivativeAssetsMember2022-12-310001383395sqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMembersqns:DerivativeAssetsMember2023-12-310001383395ifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMember2021-12-310001383395ifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMemberifrs-full:Level1OfFairValueHierarchyMember2021-12-310001383395ifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMemberifrs-full:Level2OfFairValueHierarchyMember2021-12-310001383395ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMember2021-12-310001383395sqns:DerivativeLiabilitiesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2021-12-310001383395sqns:DerivativeLiabilitiesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:Level1OfFairValueHierarchyMember2021-12-310001383395sqns:DerivativeLiabilitiesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:Level2OfFairValueHierarchyMember2021-12-310001383395sqns:DerivativeLiabilitiesMemberifrs-full:Level3OfFairValueHierarchyMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2021-12-310001383395ifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMember2022-12-310001383395ifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMemberifrs-full:Level1OfFairValueHierarchyMember2022-12-310001383395ifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMemberifrs-full:Level2OfFairValueHierarchyMember2022-12-310001383395ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMember2022-12-310001383395sqns:DerivativeAssetsMembersqns:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2022-12-310001383395ifrs-full:Level2OfFairValueHierarchyMembersqns:DerivativeAssetsMember2022-12-310001383395sqns:DerivativeLiabilitiesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2022-12-310001383395sqns:DerivativeLiabilitiesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:Level2OfFairValueHierarchyMember2022-12-310001383395ifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMember2023-12-310001383395ifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMemberifrs-full:Level1OfFairValueHierarchyMember2023-12-310001383395ifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMemberifrs-full:Level2OfFairValueHierarchyMember2023-12-310001383395ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:FinancialAssetsAvailableforsaleCategoryMembersqns:LongTermInvestmentsMember2023-12-310001383395sqns:DerivativeAssetsMembersqns:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2023-12-310001383395ifrs-full:Level2OfFairValueHierarchyMembersqns:DerivativeAssetsMember2023-12-310001383395sqns:DerivativeLiabilitiesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:Level2OfFairValueHierarchyMember2023-12-310001383395sqns:DerivativeLiabilitiesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:Level1OfFairValueHierarchyMember2023-12-310001383395sqns:DerivativeLiabilitiesMemberifrs-full:Level3OfFairValueHierarchyMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2023-12-310001383395ifrs-full:CashFlowHedgesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:ForwardContractMember2021-12-310001383395ifrs-full:CashFlowHedgesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:OptionContractMember2021-12-310001383395ifrs-full:CashFlowHedgesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2021-12-310001383395ifrs-full:CashFlowHedgesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:ForwardContractMember2022-12-310001383395ifrs-full:CashFlowHedgesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:OptionContractMember2022-12-310001383395ifrs-full:CashFlowHedgesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2022-12-310001383395ifrs-full:CashFlowHedgesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:ForwardContractMember2023-12-310001383395ifrs-full:CashFlowHedgesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrs-full:OptionContractMember2023-12-310001383395ifrs-full:CashFlowHedgesMembersqns:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2023-12-310001383395sqns:CurrenciesOtherThanUSDollarMember2023-12-310001383395sqns:CurrenciesOtherThanUSDollarMember2022-12-310001383395sqns:CurrenciesOtherThanUSDollarMember2021-12-310001383395ifrs-full:CurrencyRiskMembercurrency:USD2023-01-012023-12-310001383395ifrs-full:CurrencyRiskMembercurrency:EUR2023-01-012023-12-310001383395ifrs-full:CurrencyRiskMember2023-01-012023-12-310001383395sqns:CustomerAMemberifrs-full:CreditRiskMembercountry:CN2023-01-012023-12-310001383395sqns:CustomerAMemberifrs-full:CreditRiskMembercountry:CN2022-01-012022-12-310001383395sqns:CustomerAMemberifrs-full:CreditRiskMembercountry:CN2021-01-012021-12-310001383395sqns:CustomerAMemberifrs-full:CreditRiskMembercountry:CN2023-12-310001383395sqns:CustomerAMemberifrs-full:CreditRiskMembercountry:CN2022-12-310001383395sqns:CustomerAMemberifrs-full:CreditRiskMembercountry:CN2021-12-310001383395country:DEifrs-full:CreditRiskMembersqns:CustomerBMember2023-01-012023-12-310001383395country:DEifrs-full:CreditRiskMembersqns:CustomerBMember2022-01-012022-12-310001383395country:DEifrs-full:CreditRiskMembersqns:CustomerBMember2021-01-012021-12-310001383395country:DEifrs-full:CreditRiskMembersqns:CustomerBMember2023-12-310001383395country:DEifrs-full:CreditRiskMembersqns:CustomerBMember2022-12-310001383395country:DEifrs-full:CreditRiskMembersqns:CustomerBMember2021-12-310001383395sqns:CustomerCMemberifrs-full:CreditRiskMembercountry:US2023-01-012023-12-310001383395sqns:CustomerCMemberifrs-full:CreditRiskMembercountry:US2022-01-012022-12-310001383395sqns:CustomerCMemberifrs-full:CreditRiskMembercountry:US2021-01-012021-12-310001383395sqns:CustomerCMemberifrs-full:CreditRiskMembercountry:US2023-12-310001383395sqns:CustomerCMemberifrs-full:CreditRiskMembercountry:US2022-12-310001383395sqns:CustomerCMemberifrs-full:CreditRiskMembercountry:US2021-12-310001383395country:JPifrs-full:CreditRiskMembersqns:CustomerDMember2023-01-012023-12-310001383395country:JPifrs-full:CreditRiskMembersqns:CustomerDMember2022-01-012022-12-310001383395country:JPifrs-full:CreditRiskMembersqns:CustomerDMember2021-01-012021-12-310001383395country:JPifrs-full:CreditRiskMembersqns:CustomerDMember2023-12-310001383395country:JPifrs-full:CreditRiskMembersqns:CustomerDMember2022-12-310001383395country:JPifrs-full:CreditRiskMembersqns:CustomerDMember2021-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerEMembercountry:TW2023-01-012023-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerEMembercountry:TW2022-01-012022-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerEMembercountry:TW2021-01-012021-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerEMembercountry:TW2023-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerEMembercountry:TW2022-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerEMembercountry:TW2021-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerFMembercountry:CN2023-01-012023-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerFMembercountry:CN2022-01-012022-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerFMembercountry:CN2021-01-012021-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerFMembercountry:CN2023-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerFMembercountry:CN2022-12-310001383395ifrs-full:CreditRiskMembersqns:CustomerFMembercountry:CN2021-12-310001383395ifrs-full:CreditRiskMember2023-01-012023-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMember2021-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2021-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2021-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2021-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2021-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMember2021-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2021-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2021-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2021-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2021-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanFiveYearsMember2021-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2021-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:GovernmentLoansMemberifrs-full:LiquidityRiskMember2021-12-310001383395sqns:GovernmentLoansMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2021-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2021-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2021-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2021-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMember2021-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMember2021-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMember2021-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersqns:ConvertibleBorrowingsIssuedMember2021-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMembersqns:ConvertibleBorrowingsIssuedMember2021-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersqns:ConvertibleBorrowingsIssuedMember2021-12-310001383395ifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMemberifrs-full:LaterThanFiveYearsMember2021-12-310001383395ifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMember2021-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMember2021-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2021-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2021-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2021-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2021-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMember2021-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMember2021-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2021-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2021-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2021-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2021-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMember2021-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMember2021-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMember2021-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersqns:OtherFinancialLiabilitiesMember2021-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMembersqns:OtherFinancialLiabilitiesMember2021-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersqns:OtherFinancialLiabilitiesMember2021-12-310001383395ifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMemberifrs-full:LaterThanFiveYearsMember2021-12-310001383395ifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMember2021-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMember2021-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2021-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2021-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2021-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2021-12-310001383395ifrs-full:LiquidityRiskMember2021-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMember2022-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2022-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2022-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2022-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2022-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMember2022-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2022-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2022-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2022-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2022-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanFiveYearsMember2022-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2022-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:GovernmentLoansMemberifrs-full:LiquidityRiskMember2022-12-310001383395sqns:GovernmentLoansMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2022-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2022-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2022-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2022-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMember2022-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMember2022-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMember2022-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersqns:ConvertibleBorrowingsIssuedMember2022-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMembersqns:ConvertibleBorrowingsIssuedMember2022-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersqns:ConvertibleBorrowingsIssuedMember2022-12-310001383395ifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMemberifrs-full:LaterThanFiveYearsMember2022-12-310001383395ifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMember2022-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMember2022-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2022-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2022-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2022-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2022-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMember2022-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMember2022-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2022-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2022-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2022-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2022-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMember2022-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMember2022-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMember2022-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersqns:OtherFinancialLiabilitiesMember2022-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMembersqns:OtherFinancialLiabilitiesMember2022-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersqns:OtherFinancialLiabilitiesMember2022-12-310001383395ifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMemberifrs-full:LaterThanFiveYearsMember2022-12-310001383395ifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMember2022-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMember2022-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2022-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2022-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2022-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2022-12-310001383395ifrs-full:LiquidityRiskMember2022-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMember2023-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2023-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2023-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2023-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2023-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2023-12-310001383395sqns:ResearchProjectFinancingMemberifrs-full:LiquidityRiskMember2023-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2023-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMemberifrs-full:LaterThanFiveYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2023-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:GovernmentLoansMemberifrs-full:LiquidityRiskMember2023-12-310001383395sqns:GovernmentLoansMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2023-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2023-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2023-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2023-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2023-12-310001383395sqns:GovernmentLoansMemberifrs-full:LiquidityRiskMember2023-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMember2023-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMember2023-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersqns:ConvertibleBorrowingsIssuedMember2023-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMembersqns:ConvertibleBorrowingsIssuedMember2023-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersqns:ConvertibleBorrowingsIssuedMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMemberifrs-full:LaterThanFiveYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:ConvertibleBorrowingsIssuedMember2023-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMembersqns:UnsecuredRelatedPartyLoanMember2023-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMembersqns:UnsecuredRelatedPartyLoanMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:UnsecuredRelatedPartyLoanMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:UnsecuredRelatedPartyLoanMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:UnsecuredRelatedPartyLoanMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:UnsecuredRelatedPartyLoanMemberifrs-full:LaterThanFiveYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:UnsecuredRelatedPartyLoanMember2023-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMember2023-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2023-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2023-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2023-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2023-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2023-12-310001383395ifrs-full:LeaseLiabilitiesMemberifrs-full:LiquidityRiskMember2023-12-310001383395ifrs-full:NotLaterThanOneYearMembersqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMember2023-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2023-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2023-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2023-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2023-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2023-12-310001383395sqns:TradeAndOtherPayablesMemberifrs-full:LiquidityRiskMember2023-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMember2023-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMember2023-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersqns:OtherFinancialLiabilitiesMember2023-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMembersqns:OtherFinancialLiabilitiesMember2023-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersqns:OtherFinancialLiabilitiesMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMemberifrs-full:LaterThanFiveYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMembersqns:OtherFinancialLiabilitiesMember2023-12-310001383395ifrs-full:NotLaterThanOneYearMemberifrs-full:LiquidityRiskMember2023-12-310001383395ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberifrs-full:LiquidityRiskMember2023-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMemberifrs-full:LaterThanFiveYearsMember2023-12-310001383395ifrs-full:LiquidityRiskMember2023-12-310001383395sqns:GovernmentGrantAdvancesAndLoansMember2020-12-310001383395sqns:GovernmentGrantAdvancesAndLoansMember2021-01-012021-12-310001383395ifrs-full:PreviouslyStatedMembersqns:GovernmentGrantAdvancesAndLoansMember2021-12-310001383395sqns:ConvertibleDebtAndAccruedInterestMember2020-12-310001383395sqns:ConvertibleDebtAndAccruedInterestMember2021-01-012021-12-310001383395ifrs-full:PreviouslyStatedMembersqns:ConvertibleDebtAndAccruedInterestMember2021-12-310001383395sqns:VentureDebtMember2020-12-310001383395sqns:VentureDebtMember2021-01-012021-12-310001383395ifrs-full:PreviouslyStatedMembersqns:VentureDebtMember2021-12-310001383395sqns:LeaseContractsMember2020-12-310001383395sqns:LeaseContractsMember2021-01-012021-12-310001383395sqns:LeaseContractsMember2021-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2020-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2021-01-012021-12-310001383395ifrs-full:PreviouslyStatedMembersqns:InterestBearingReceivablesFinancingLineOfCreditMember2021-12-310001383395ifrs-full:PreviouslyStatedMember2021-12-310001383395sqns:GovernmentGrantAdvancesAndLoansMember2021-12-310001383395sqns:GovernmentGrantAdvancesAndLoansMember2022-01-012022-12-310001383395sqns:GovernmentGrantAdvancesAndLoansMember2022-12-310001383395sqns:ConvertibleDebtAndAccruedInterestMember2021-12-310001383395sqns:ConvertibleDebtAndAccruedInterestMember2022-01-012022-12-310001383395sqns:ConvertibleDebtAndAccruedInterestMember2022-12-310001383395sqns:LeaseContractsMember2022-01-012022-12-310001383395sqns:LeaseContractsMember2022-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2021-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2022-01-012022-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2022-12-310001383395sqns:GovernmentGrantAdvancesAndLoansMember2023-01-012023-12-310001383395sqns:GovernmentGrantAdvancesAndLoansMember2023-12-310001383395sqns:ConvertibleDebtAndAccruedInterestMember2023-01-012023-12-310001383395sqns:ConvertibleDebtAndAccruedInterestMember2023-12-310001383395sqns:UnsecuredRelatedPartyLoanMember2022-12-310001383395sqns:UnsecuredRelatedPartyLoanMember2023-01-012023-12-310001383395sqns:UnsecuredRelatedPartyLoanMember2023-12-310001383395sqns:LeaseContractsMember2023-01-012023-12-310001383395sqns:LeaseContractsMember2023-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2023-01-012023-12-310001383395sqns:InterestBearingReceivablesFinancingLineOfCreditMember2023-12-310001383395ifrs-full:FinancialGuaranteeContractsMember2023-01-012023-12-310001383395ifrs-full:FinancialGuaranteeContractsMember2023-12-310001383395ifrs-full:FinancialGuaranteeContractsMember2022-12-310001383395ifrs-full:FinancialGuaranteeContractsMember2021-12-310001383395sqns:PurchaseCommitment1Member2023-12-310001383395sqns:B.RileyAssetManagementLLCAndLynrockLakeMember2023-01-012023-12-310001383395sqns:AmericanDepositarySharesMembersqns:A272CapitalFundLPMember2023-04-122023-04-120001383395sqns:AmericanDepositarySharesMembersqns:LynrockLakeMember2023-04-122023-04-120001383395sqns:AmericanDepositarySharesMembersqns:A272CapitalFundLPMember2023-09-262023-09-260001383395sqns:LynrockLakeMember2022-01-012022-12-310001383395sqns:AmericanDepositarySharesMembersqns:A272CapitalFundLPMember2022-03-112022-03-110001383395sqns:LynrockLakeMember2021-01-012021-12-310001383395sqns:AffiliatedEntity1Membersqns:ConvertibleBorrowingsIssuedApril2015Member2015-04-300001383395sqns:AffiliatedEntity1Membersqns:ConvertibleBorrowingsIssuedApril2016Member2016-04-300001383395sqns:AffiliatedEntity1Membersqns:ConvertibleBorrowingsIssuedApril2015Member2022-09-300001383395sqns:AffiliatedEntity1Membersqns:ConvertibleNotes20191Member2019-05-310001383395sqns:ConvertibleNotes20192Membersqns:AffiliatedEntity1Member2019-08-310001383395sqns:AffiliatedEntity1Membersqns:ConvertibleBorrowingsIssuedApril2015Member2023-12-310001383395sqns:ABLEFranceMemberifrs-full:KeyManagementPersonnelOfEntityOrParentMember2021-01-012021-12-310001383395sqns:RenesasElectronicsCorporationMember2023-01-012023-12-310001383395sqns:RenesasElectronicsCorporationMember2022-01-012022-12-310001383395ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2023-12-3100013833952023-07-250001383395ifrs-full:OtherRelatedPartiesMember2023-01-012023-12-310001383395ifrs-full:WarrantsMembersqns:BoardOfDirectorsMember2021-06-252021-06-250001383395ifrs-full:WarrantsMembersqns:BoardOfDirectorsMember2022-06-242022-06-240001383395ifrs-full:WarrantsMembersqns:BoardOfDirectorsMember2023-06-272023-06-270001383395ifrs-full:WarrantsMembersqns:BoardOfDirectorsMember2023-12-310001383395ifrs-full:WarrantsMembersqns:BoardOfDirectorsMember2021-12-310001383395ifrs-full:WarrantsMembersqns:BoardOfDirectorsMember2022-12-310001383395ifrs-full:WarrantsMembersqns:BoardOfDirectorsMember2023-01-012023-12-310001383395ifrs-full:WarrantsMembersqns:BoardOfDirectorsMember2022-01-012022-12-310001383395ifrs-full:WarrantsMembersqns:BoardOfDirectorsMember2021-01-012021-12-3100013833952023-02-072023-02-070001383395sqns:GrantingOfSharesMembersqns:RestrictedSharesMember2024-03-052024-03-050001383395sqns:France20234GERedCapProjectMemberifrs-full:LoanCommitmentsMemberifrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember2024-03-270001383395sqns:UnsecuredPromissoryNoteMemberifrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember2024-04-220001383395sqns:GrantingOfSharesMembersqns:RestrictedSharesMember2024-04-302024-04-300001383395sqns:AmericanDepositarySharesMembersqns:GrantingOfSharesMembersqns:RestrictedSharesMember2024-04-302024-04-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
     ¨
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
     þ
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
     ¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
OR
    ¨
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report                     
Commission file number 001-35135
SEQUANS COMMUNICATIONS S.A.
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
French Republic
(Jurisdiction of incorporation or organization)
15-55 Boulevard Charles de Gaulle
92700 Colombes, France
(Address of principal executive offices)
Georges Karam
Chairman and Chief Executive Officer
Sequans Communications S.A.
15-55 Boulevard Charles de Gaulle
92700 Colombes, France
Telephone: +33 1 70 72 16 00
Facsimile: +33 1 70 72 16 09
(Name, telephone, e-mail and/or facsimile number and address of company contact person)
Securities registered or to be registered pursuant to Section 12(b) of the Act.



Title of each classSymbolName of each exchange on which registered
American Depositary Shares, each representing four ordinary shares, nominal value €0.01 per shareSQNSNew York Stock Exchange
Ordinary shares, nominal value €0.01 per share
New York Stock Exchange*
 
*Not for trading, but only in connection with the registration of American Depositary Shares.
Securities registered or to be registered pursuant to Section 12(g) of the Act.
Not Applicable
(Title of Class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.
Not Applicable
(Title of Class)
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

Ordinary shares, nominal value €0.01 per share: 246,262,004 as of December 31, 2023
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    ¨  Yes   þ  No
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.    Yes  ¨    No  þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  þ    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  þ    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated file, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, and "emerging growth company" in Rule 12b-2 of the Exchange Act.:
Large accelerated filer  ¨                 Accelerated filer  þ                
                Non-accelerated filer  ¨        Emerging growth company  ¨
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨
The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.     Yes  þ No  ¨

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ¨




Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨
Indicate by check mark which basis for accounting the registrant has used to prepare the financing statements included in this filing:
U.S. GAAP  ¨
International Financial Reporting Standards as issued
by the International Accounting Standards Board  þ
Other  ¨
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.  ¨ Item 17  ¨ Item 18
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨     No  þ



SEQUANS COMMUNICATIONS S.A.
________________________________________________
 FORM 20-F
ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
_________________________________________________
TABLE OF CONTENTS
Item 1.
Item 2.
Item 3.
Item 4.
Item 4A.
Item 5.
Item 6.
Item 7.
Item 8.
Item 9.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Item 15.
Item 16A.
Item 16B.
Item 16C.
Item 16D.
Item 16E.
Item 16F.
Item 16G.
Item 16H.
Item 16I.
Item 16J.
Item 16K.
Item 17.
Item 18.
Item 19.
 
i


INTRODUCTION
Unless otherwise indicated, “Sequans Communications S.A.”, “Sequans Communications”, “the Company”, “we”, “us” and “our” refer to Sequans Communications S.A. and its consolidated subsidiaries.
In this annual report, references to the “euro” or “€” are to the euro currency of the European Union and references to “U.S. dollars” or “$” are to United States dollars.
Reference to “the Shares” are references to Sequans Communications’ Ordinary Shares, nominal value €0.01 per share, and references to “the ADSs” are to Sequans Communications’ American Depositary Shares (each representing four Ordinary Shares), which are evidenced by American Depositary Receipts (ADRs).

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This annual report contains projections and forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on our management’s beliefs and assumptions and on information currently available to our management. All statements other than present and historical facts and conditions contained in this annual report on Form 20-F, including statements regarding our future results of operations and financial positions, business strategy, financing plans, including our ability to issue additional equity or debt to finance our continued operations, our ability to enter into new strategic agreements, the exploration of strategic options, expectations for Massive IoT sales, the impact of inventory in our customers' supply chain on customer demand, our ability to convert our pipeline to revenue, our ability to maintain the NYSE listing of our ADS, and our objectives for future operations, are forward looking statements. These statements are only predictions and reflect our current beliefs and expectations with respect to future events and are based on assumptions and subject to risk and uncertainties and subject to change at any time. We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Actual events or results may differ materially from those contained in the projections or forward-looking statements. Some of the factors that could cause actual results to differ materially from the forward-looking statements contained herein include, without limitation:

our ability to enter into a strategic transaction or secure financing necessary to continue to operate our business;
the contraction or lack of growth of markets in which we compete and in which our products are sold;
unexpected increases in our expenses resulting from inflationary pressures and rising interest rates, including manufacturing and operating expenses and interest expense;
our inability to adjust spending quickly enough to offset any unexpected revenue shortfall;
delays or cancellations in spending by our customers;
unexpected average selling price reductions;
the significant fluctuation to which our quarterly revenue and operating results are subject due to cyclicality in the wireless communications industry and transitions to new process technologies;
our inability to anticipate the future market demands and future needs of our customers;
our inability to achieve new design wins or for design wins to result in shipments of our products at levels and in the timeframes we currently expect;
our inability to enter into and execute on strategic alliances;
our ability to meet performance milestones under strategic license agreements;
the impact of component shortages, suppliers’ lack of production capacity, natural disasters or pandemics on our sourcing operations and supply chain;
the impact of the Ukraine-Russia conflict on our independent contractors located in Ukraine and the Israeli-Hamas conflict on our employees located in Israel;
our ability to raise debt and equity financing; and
other factors detailed in documents we file from time to time with the Securities and Exchange Commission.

In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” as well as similar expressions. Forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks, uncertainties and other important factors. We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. We cannot assure you that our plans, intentions or expectations
1


will be achieved. Our actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained in this prospectus supplement as described in “Item 3.D—Risk Factors”, “Item 4—Information on the Company” and “Item 5—Operating and Financial Review and Prospects”. Given these risks, uncertainties and other important factors, you should not place undue reliance on these forward-looking statements. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this annual report. Also, these forward-looking statements represent our estimates and assumptions only as of the date such forward-looking statements are made. Except as required by law, we assume no obligation to update any forward-looking statements publicly, whether as a result of new information, future events or otherwise.
2


PART I
Item 1. Identity of Directors, Senior Management and Advisers
Not applicable.
Item 2. Offer Statistics and Expected Timetable
Not applicable.
Item 3. Key Information
A. Selected Financial Data
[Reserved]

B. Capitalization and Indebtedness
Not applicable.

C. Reasons for the Offer and Use of Proceeds
Not applicable.

D. Risk Factors
Our business faces significant risks. You should carefully consider all of the information set forth in this annual report and in our other filings with the United States Securities and Exchange Commission (“SEC”), including the following risk factors which we face, and which are faced by our industry. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this report and our other SEC filings. See “Special Note Regarding Forward-Looking Statements” on page 1.
Risk Factor Summary
Risks Related to Our Business and Industry
We need to enter into a strategic transaction or raise significant equity or debt financing in the near term to continue to operate our business.
We have a history of losses and may not achieve or sustain profitability in the future.
Our industry is subject to rapid technological change.
If we are unable to effectively manage our business through periods of economic or market slow-down and any subsequent future growth, we may not be able to execute our business plan.
If we fail to successfully develop, commercialize, produce and sell our module product line, our business, revenue and operating results may be harmed.
We depend on a small number of customers for a significant portion of our revenue.
Our customers may cancel their orders, change production quantities or delay production, and if we fail to forecast demand for our products accurately, we may incur product shortages, delays in product shipments or excess or insufficient product inventory, which could harm our business.
If customers do not design our semiconductor solutions into their product offerings, our business would be harmed.
If we are unable to compete effectively, we may not increase or maintain our revenue or market share.
If we experience material changes to the competitive structure of our industry, we may not increase or sustain our revenue or market share.
Our business may be impacted by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties beyond our control, including the Russian-Ukraine and the Israeli-Hamas conflicts.
3


We have significant ongoing capital requirements.
The average selling prices of our semiconductor solutions have historically decreased over time.
The semiconductor and communications industries have historically experienced significant fluctuations with prolonged downturns.
The complexity of our semiconductor solutions could result in unforeseen delays or expenses from undetected defects or design errors in hardware or software.
We are subject to risks inherent in our international operations.
We depend on the commercial deployment of 4G LTE narrow band variants and 5G communications equipment, products and services to grow our business.
Rapidly changing standards could make our semiconductor solutions obsolete.
Changes in current laws or regulations or the imposition of new laws or regulations could impede the sale of our products or otherwise harm our business.
Fluctuations in foreign exchange rates may harm our financial results.
Our global operations are subject to risks for which we may not be adequately insured.
Risks Related to the Manufacture of Our Products
Global supply chain constrains may negatively impact our business.
Certain natural disasters may negatively impact our business.
We depend on one independent foundry to manufacture our semiconductor wafers and do not have a long-term agreement with such foundry.
If our foundry vendor does not achieve satisfactory yields or quality, our reputation and customer relationships could be harmed.
We depend on one technology partner to provide components for and to manufacture the Monarch SiP.
Any increase in the manufacturing cost of our products would reduce our gross margins and operating profit.
We outsource our assembly, testing, warehousing and shipping operations to third parties.
We may experience difficulties in transitioning to new wafer fabrication process technologies or in achieving higher levels of design integration.
Risks Related to Intellectual Property Rights
We or our customers may be required to obtain licenses for certain so-called “standard essential patents” in order to comply with applicable standards.
We may not be able to obtain, or may choose not to obtain, sufficient intellectual property rights to provide us with meaningful protection or commercial advantage.
Assertions by third parties of infringement by us or our customers of their intellectual property rights could result in significant costs and cause our operating results to suffer.
Any potential dispute involving our patents or other intellectual property could also include our industry partners and customers, which could trigger our indemnification obligations to them and result in substantial expense to us.
Our failure to comply with obligations under open source licenses could require us to release our source code to the public or cease distribution of our products.
Risks Related to Our Internal Control Over Financial Reporting
We are required to document and test our internal control procedures and to provide a report by management on internal control over financial reporting.
Risks Related to Ownership of Our Shares and ADSs
We are not in compliance with the Continued Listing Criteria of the New York Stock Exchange (NYSE), and our failure to regain compliance may result in the delisting of our ADSs.
Fluctuations in our operating results on a quarterly or annual basis and difficulty predicting our quarterly operating results could cause the market price of the ADSs to decline.
If securities or industry analysts cease to publish research reports about us or our industry, or if they adversely change their recommendations regarding the ADSs.
If we raise additional capital in the future, your ownership in us could be diluted.
We have no present intention to pay dividends on our ordinary shares in the foreseeable future.
You may not be able to exercise your right to vote the ordinary shares underlying your ADSs.
As a foreign private issuer, we are exempt from certain rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company, which may limit the information available to holders of the ADSs.
4


As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from NYSE corporate governance listing standards.
U.S. holders of the ADSs may suffer adverse tax consequences if we are characterized as a Passive Foreign Investment Company.
We may be subject to legal actions that could distract our management and increase costs.
You may be unable to recover in civil proceedings for U.S. securities laws violations.
ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement.
The rights of shareholders in companies subject to French corporate law differ in material respects from the rights of shareholders of corporations incorporated in the United States.
Our by-laws and French corporate law contain provisions that may delay or discourage a takeover attempt.
The exercise or conversion of outstanding stock options, founders' warrants, restricted shares, warrants and convertible notes into ordinary shares will dilute the percentage ownership of our other shareholders.

Risks Relating to Our Indebtedness
Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the notes.
We may be unable to raise the funds necessary to repurchase our convertible notes for cash following a change of control, or to pay any cash amounts due upon conversion, and our other indebtedness may limit our ability to repurchase the convertible notes or pay cash upon its conversion.
Provisions in the notes could delay or prevent an otherwise beneficial takeover of us.

General Risks
The loss of any of our key personnel could seriously harm our business.
Adverse outcomes in tax disputes could subject us to tax assessments and potential penalties.
Our business and operations could suffer in the event of security breaches.
Changes in International Financial Reporting Standards (“IFRS”) could adversely affect our financial results and may require significant changes to our internal accounting systems and processes.
In preparing our financial statements we make certain assumptions, judgments and estimates that affect amounts reported in our consolidated financial statements, which, if not accurate, may significantly impact our financial results.

Risks Related to Our Business and Industry
We need to enter into a strategic transaction or raise significant equity or debt financing in the near term. If we fail to do so, we may be unable to continue to operate our business and may need to seek a court ordered restructuring.
We entered into a Memorandum of Understanding (“MoU”) in August 2023 to be acquired by Renesas Electronics Corporation (“Renesas”). We incurred a significant amount of debt to operate our business during the pending tender offer, and our business suffered due, in part, to uncertainty raised by the pending acquisition. Renesas terminated the MoU in February 2024 due to the receipt of an adverse Japanese tax ruling. The termination of the MoU has created significant liquidity concerns and raised substantial doubt about our ability to continue to operate absent a new strategic transaction or financing in the near term. We were not able to pay our outstanding notes due in April 2024 and will not be able to pay the outstanding notes due in May 2024, but have negotiated standstill agreements with our major lenders until April 26, 2024. The agreements may be further extended subject to certain milestones being met; the request for the extension of the agreements is in process as of this date, however there can be no assurance of the length of the extension, if any.
We are in discussions with several parties regarding potential strategic transactions, but we may not be able to enter into a definitive agreement in sufficient time. Even if we are able to enter into a definitive agreement, there is no certainty that a transaction will ultimately close or that we will be able to raise bridge financing and extend the standstill for our major lenders to continue to operate our business until the transaction closes. If we are not able to enter into a strategic transaction for the sale of the company or a major licensing transaction in the near term and raise substantial new equity or debt financing, we may not be able to continue to operate our business and may need to seek a court ordered restructuring. Any restructuring would likely have a significant impact on the value of our ordinary shares and ADSs.
We have a history of losses and we may not achieve or sustain profitability in the future, on a quarterly or annual basis.
We were established in 2003 and began operations in 2004, and have incurred losses on an annual basis since inception. We experienced net losses of $9.0 million and $41.0 million in 2022 and 2023, respectively. At December 31, 2023, our
5


accumulated deficit was $93.4 million. If we are able to address our immediate liquidity needs, we still expect to continue to incur significant expense related to the development of our 5G products and expansion of our business. Additionally, we may encounter unforeseen difficulties, complications, product delays and other unknown factors that require additional expense. As a result of these expenditures, we will have to generate and sustain substantially increased revenue to achieve profitability. If we do not, we may not be able to achieve or maintain profitability, and we may continue to incur significant losses in the future.
These facts and conditions raise substantial doubt about our ability to continue as a going concern, and our independent registered public accounting firm has included an explanatory paragraph regarding going concern qualification in its audit report. The failure to raise additional equity may have a material adverse effect on our business, results of operations and financial position, and may adversely affect our ability to continue as a going concern. If we do not become consistently profitable, our accumulated deficit will grow larger and our cash balances will decline further, and we will require further financings to continue operations. Any such financings may not be accessible on acceptable terms, if at all. If we are unable to
to stabilize our losses and raise new financing, we could be required to significantly downsize or discontinue our business or
seek a court ordered restructuring.
Our industry is subject to rapid technological change that could result in decreased demand for our products and those of our customers, or result in new specifications or requirements for our products, each of which could negatively affect our revenues, margins and operating results.
The markets in which we and our customers compete or plan to compete are characterized by rapidly changing technologies and industry standards and technological obsolescence, including the evolving trends in IoT and the emergence of 5G. Our ability to compete successfully depends on our ability to design, develop, manufacture, assemble, test, market and support new products and enhancements on a timely and cost-effective basis. A fundamental shift in technologies in any of our target markets could harm our competitive position within these markets. In addition, such shifts can cause a significant decrease in our revenues and adversely affect our operating results. Our failure to anticipate these shifts, to develop new technologies or to react to changes in existing technologies could materially delay our development of new products, which could result in product obsolescence, decreased revenue and a loss of design wins. The development of new technologies and products generally requires substantial investment before they are commercially viable. We intend to continue to make substantial investments in developing new technologies and products, including our 5G products, and it is possible that our development efforts will not be successful and that our new technologies and products will not be accepted by customers or result in meaningful revenue. If the semiconductor solutions we develop fail to meet market or customer requirements or expectations, or do not achieve market acceptance, our operating results and competitive position would suffer.
Our success and the success of our new products will depend on accurate forecasts of future technological developments, customer and consumer requirements and long-term market demand, as well as on a variety of specific implementation factors, including:
accurate prediction of the size and growth of the 4G and 5G markets;
accurate prediction of changes in device manufacturer requirements, technology, industry standards or consumer expectations, demands and preferences;
accurate prediction of the growth of the Internet of Things markets and 5G networks;
timely and efficient completion of process design and transfer to manufacturing, assembly and testing, and securing sufficient manufacturing capacity to allow us to continue to timely and cost-effectively deliver products to our customers;
market acceptance, adequate consumer demand and commercial production of the products in which our semiconductor solutions are incorporated;
the quality, performance, functionality and reliability of our products as compared to competing products and technologies; and
effective marketing, sales and customer service.
The markets for our semiconductor solutions are characterized by frequent introduction of next generation and new products with new features and functionalities, short product life cycles in the case of consumer products and significant price competition. If we or our customers are unable to manage product transitions in a timely and cost-effective manner, our business and results of operations would suffer. In addition, frequent technology changes and introduction of next generation products may result in inventory obsolescence, which could reduce our gross margins and harm our operating performance. If we fail to timely introduce new products that meet the demands of our customers or our target markets, or if we fail to penetrate new markets, our revenue will decrease, and our financial condition would suffer.
6


If we are unable to effectively manage our business through periods of economic or market slow-down and any subsequent future growth, we may not be able to execute our business plan and our operating results could suffer.
Our future operating results depend to a large extent on our ability to successfully manage our business through periods of economic or market slow-down, and periods of subsequent expansion and growth. To manage our growth successfully, we believe we must, among other things, effectively:
recruit, hire, train and manage additional qualified engineers for our research and development activities, especially in the positions of design engineering, product and test engineering, and applications engineering;
add additional sales personnel and expand sales offices;
add additional finance and information systems personnel;
implement and improve our administrative, financial and operational systems, procedures and controls; and
enhance our information technology support for enterprise resource planning and design engineering by adapting and expanding our systems and tool capabilities, and properly training new hires as to their use.
Furthermore, to remain competitive and manage future expansion and growth, we must carry out extensive research and development, which requires significant capital investment. New competitors, technological advances in the semiconductor industry or by competitors, our entry into new markets, or other competitive factors may require us to invest significantly greater resources than we anticipate. If we are required to invest significantly greater resources than anticipated without a corresponding increase in revenue, our operating results could decline. Additionally, our periodic research and development expenses may be independent of our level of revenue, which could negatively impact our financial results. Finally, there can be no guarantee that our research and development investments will result in products that create additional revenue.
During periods of economic or market slow-down, we must also effectively manage our expenses to preserve our ability to carry out such research and development. We are likely to incur product and market development costs earlier than some of the anticipated benefits, and the return on these investments, if any, may be lower, may develop more slowly than we expect, or may not materialize at all, which could harm our operating results. Since 2020, we have dedicated a large portion of our operating expenses to our development of 5G products, which we do not expect will result in significant product revenues before late 2025.
If we are unable to manage our business during both periods of economic or market slow-down and periods of growth effectively, we may not be able to take advantage of market opportunities or develop new products, and we may fail to satisfy customer requirements, maintain product quality, execute our business plan or respond to competitive pressures, any of which could harm our operating results.
If we fail to successfully develop, commercialize, produce and sell our module product line, our business, revenue and operating results may be harmed.
Our modules incorporate many components in addition to our chipsets. We may lack the purchasing power to acquire at competitive prices certain components required to produce modules, and we do not expect to be able to command selling prices for those modules that allow us to maintain traditional semiconductor-only margins for the full module. Currently, and in the coming year at least, modules could represent a large portion of our revenue mix, which would negatively impact our overall gross margin. Certain large customers may decide to buy the modules directly from the manufacturers who purchase our chipsets, rather than us, in order to reduce their costs. This may result in a reduction of our revenue and gross profit, but an improvement of overall gross margin percentage, compared to the case where we sell the modules ourselves.
Module components may be sourced from numerous different suppliers. Some of these components have been and may periodically be in short supply or be subject to long lead times, which could affect our ability to meet customer demand for our modules, therefore delaying our revenue. In addition, we rely on various contract manufacturers to produce our modules. If these manufacturers encounter any issues with production capacity, quality or reliability of their products, it could adversely affect our revenue and our reputation in the market. If our ability to expand our product platform is significantly delayed or if we are unable to leverage our module as expected, our business and financial condition could be materially and adversely affected.
If customers request from us, and we agree to provide, a wide variety of module variants or stock-keeping units, or SKUs, to support different operators or different end-applications, our expenses associated with developing, sourcing and certifying our module products would increase. In addition, managing supply and demand across multiple SKUs may increase the possibility that we will under-or over-forecast a given SKU, resulting in either delayed revenue or excess inventory.
7


Participating in the module business could create a perception among our customers that we are competing with them if they are also in the module business, which could impair our chipset business prospects with such customers. The module can be considered an end product with full 4G LTE functionality; therefore, there is market pressure for us to sell our modules with standard essential IP indemnification from manufacturers of products not normally incorporating a communication function. We intend to seek license agreements for the module in order to offer standard indemnification to our manufacturing partners, but there can be no assurance that we will be successful in obtaining licenses for standard essential IP on acceptable terms.
We depend on a small number of customers for a significant portion of our revenue. If we fail to retain or expand customer relationships, our business could be harmed.
A significant amount of our total revenue is attributable to a small number of customers, and we anticipate that this will continue to be the case for the foreseeable future. These customers may decide not to purchase our semiconductor solutions and services at all, to purchase fewer semiconductor solutions and services than they did in the past or to alter the terms on which they purchase our products and services. In addition, to the extent that any customer represents a disproportionately high percentage of our accounts receivable, our exposure to that customer is further increased should they be unable or choose not to pay such accounts receivable on a timely basis or at all.
Our top ten customers accounted for 92%, 95% and 92% of our total revenue in 2021, 2022 and 2023 respectively; four customers each accounted for more than 10% of our total revenue in 2021 and 2022, and two customers each accounted for more than 10% of our total revenue in 2023. The following table summarizes customers representing a significant portion of total revenue:
Customer% of total revenues for the year ended December 31,% of our trade receivable at
December 31,
 2021202220232023
A— %33 %56 %40 %
B13 %11 %16 %— %
CLess than 10%24 %Less than 10%— %
D23 %14 %— %— %
E23 %Less than 10%Less than 10%— %
F14 %Less than 10%Less than 10%11 %
We expect that some of these customers, particularly those above 10% during 2023, could each continue to represent at least 10% of our revenue in 2024 given the long product design and life cycles in our markets and the nature of long-term service contracts. The loss of any significant customer, a significant reduction in sales we make to them in general or during any period, or any issues with collection of receivables from customers would harm our financial condition and results of operations. Furthermore, we must obtain orders from new customers on an ongoing basis to increase our revenue and grow our business. If we fail to expand our customer relationships, our business could be harmed.
Consolidation among our customers could also lead to increased customer bargaining power, or reduced customer spending. Further, new business may be delayed if a key customer uses its leverage to push for terms that are worse for us and we nonetheless continue to negotiate for better terms, in which case revenue in any particular quarter or year may fail to meet expectations. Also, the loss of any of these customers or the failure to secure new contracts with these customers could further increase our reliance on our remaining customers. Further, if any of our key customers default, declare bankruptcy or otherwise delay or fail to pay amounts owed, or we otherwise have a dispute with any of these customers, our results of operations would be negatively affected in the short term and possibly the long term. These customers may seek to renegotiate pre-existing contractual commitments due to adverse changes in their own businesses or, in some cases, take advantage of contractual provisions that permit the suspension of contracted work for some period if their business experiences a financial hardship, which would harm our operating results. To the extent our customers experience liquidity constraints, we may incur bad debt expense, which may have a significant impact on its results of operations. Major customers may also seek pricing, payment, intellectual property-related, or other commercial terms that are less favorable to us, which may have a negative impact on our business, cash flow, revenue and gross margins. In addition, these events could cause significant fluctuations in results of operations because our expenses are fixed in the short term and it takes us a long time to replace customers or reassign resources.
8


Our customers may cancel their orders, change production quantities or delay production, and if we fail to forecast demand for our products accurately, we may incur product shortages, delays in product shipments or excess or insufficient product inventory, which could harm our business.
We do not have firm, long-term purchase commitments from our customers. Substantially all of our sales are made on a purchase order basis, and in most cases, our customers are not contractually committed to buy any quantity of products from us beyond firm purchase orders. Additionally, customers may cancel, change or delay purchase orders already in place under certain conditions. Because production lead times often exceed the amount of time required to fulfill orders, we often must manufacture in advance of orders, relying on an imperfect demand forecast to project volumes and product mix. Our ability to accurately forecast demand can be harmed by a number of factors, including inaccurate forecasting by our customers, changes in market conditions, changes in our product order mix and demand for our customers’ products. Even after an order is received, our customers may cancel these orders or request a decrease in production quantities if certain lead times are respected. Any such cancellation or decrease subjects us to a number of risks, most notably, that our projected sales will not materialize on schedule or at all, leading to unanticipated revenue shortfalls and excess or obsolete inventory, which we may be unable to sell to other customers. Alternatively, if we are unable to project customer requirements accurately, we may not manufacture enough semiconductor solutions, which could lead to delays in product shipments and lost sales opportunities in the near term, as well as force our customers to identify alternative sources, which could affect our ongoing relationships with these customers. We have in the past had customers significantly increase their requested production quantities with little or no advance notice. If we do not fulfill customer demands in a timely manner, our customers may cancel their orders, and we may be subject to customer claims for cost of replacement. Underestimating or overestimating demand would lead to insufficient, excess or obsolete inventory and could harm our operating results, cash flow and financial condition, as well as our relationships with our customers and our reputation in the marketplace.
If customers do not design our semiconductor solutions into their product offerings, or if our customers’ product offerings are not commercially successful, our revenue and our business would be harmed.
We sell our semiconductor solutions directly to OEMs who include them in their products, and to ODMs who include them in their products that they supply to OEMs. As a result, we rely on OEMs to design our semiconductor solutions into the products they sell. Because our semiconductor solutions are generally a critical component of our customers’ products, they are typically incorporated into our customers’ products at the design stage, and the design cycle typically takes at least 12 months and frequently much more to complete before generating sales of our products. Without these design wins, our revenue and our business would be significantly harmed. We often incur significant expenditures on the development of a new semiconductor solution without any assurance that an OEM will select our semiconductor solution for design into its own product. Because the types of semiconductor solutions we sell are a critical aspect of an OEM’s product, once an OEM designs a competitor’s semiconductor into its product offering, it becomes significantly more difficult for us to sell our semiconductor solutions to that customer for a particular product offering as changing suppliers involves significant cost, time, effort and risk for the customer. Further, if we are unable to develop new products in a timely manner for inclusion in such products, or if major defects or errors that might significantly impair performance or standards compliance are found in our products after inclusion by an OEM, OEMs will be unlikely to include our semiconductor solutions into their products and our reputation in the market and future prospects would be harmed.
Furthermore, even if an OEM designs one of our semiconductor solutions into its product offering, we cannot be assured that its product will be commercially successful and that we will receive any revenue from that OEM. This risk is heightened because some of our customers, particularly in the massive Internet of Things markets, do not have significant experience designing products utilizing 4G technology. If our customers’ products incorporating our semiconductor solutions fail to meet the demands of their customers or otherwise fail to achieve market acceptance, our revenue and business would be harmed.
If we are unable to compete effectively, we may not increase or maintain our revenue or market share, which would harm our business.
We may not be able to compete successfully against current or potential competitors. If we do not compete successfully, our revenue and market share may decline. We face or expect to face competition from established semiconductor companies such as Altair Semiconductor (a Sony Corporation subsidiary), HiSilicon Technologies (a Huawei subsidiary), Mediatek, Nordic Semiconductor, Qualcomm Incorporated, RDA, Samsung Electronics Co. Ltd. and Unisoc (formerly Spreadtrum Communications), as well as smaller actors in the market such as GCT Semiconductor. Many of our competitors have longer operating histories, significantly greater resources and name recognition, and a larger base of existing customers than us. The significant resources of these larger competitors may allow them to respond more quickly than us to new or emerging
9


technologies or changes in customer requirements or to bring new products to market in a more timely manner than us. For example, some competitors may have greater access or rights to complementary technologies, including GNSS (GPS), Bluetooth, sensors, graphic processing, etc., and we may need to develop or acquire complementary technologies or partner with others to bring to market solutions that integrate enhanced functionalities. We expect to pursue such transactions or partnerships if appropriate opportunities arise. However, we may not be able to identify suitable transactions or partners in the future, or if we do identify such transactions or partners, we may not be able to complete them on commercially acceptable terms, or at all. In addition, these competitors may have greater credibility with our existing and potential customers. Many of these competitors are located in Asia or have a significant presence and operating history in Asia and, as a result, may be in a better position than we are to work with manufacturers and customers located in Asia. Many of our competitors have been doing business with customers for a longer period of time and have well-established relationships, which may provide them with advantages, including access to information regarding future trends and requirements that may not be available to us. In addition, some of our competitors may provide incentives to customers or offer bundled solutions with complementary products, which could be attractive to some customers, or adopt more aggressive pricing policies, which may make it difficult for us to gain or maintain market share.
Our ability to compete effectively will depend on a number of factors, including:
our ability to anticipate market and technology trends and successfully develop products that meet market needs;
our ability to deliver products in large volume on a timely basis at competitive prices;
our success in identifying and penetrating new markets, applications and customers;
our ability to accurately understand the price points and performance metrics of competing products in the market;
our products’ performance and cost-effectiveness relative to those of our competitors;
our ability to develop and maintain relationships with key customers, wireless carriers, OEMs and ODMs;
our ability to secure sufficient high-quality supply for our products;
our ability to conform to industry standards while developing new and proprietary technologies to offer products and features previously not available in the 4G and 5G markets;
our ability to develop or acquire complementary technologies or to partner with others to bring to market products with enhanced functionalities; and
our ability to recruit design and application engineers with expertise in wireless broadband communications technologies and sales and marketing personnel.
Our current or future competitors may establish cooperative relationships among themselves or with third parties. In addition, there has been consolidation within our industry over the past several years, notably the acquisition of smaller competitors by larger competitors with significantly greater resources than ours. These events may result in the emergence of new competitors with greater resources and scale than ours that could acquire significant market share, which could result in a decline of our revenue and market share. Our ability to maintain our revenue and market share will depend on our ability to compete effectively despite material changes in industry structure. If we are unable to do so, we may not increase or sustain our revenue or market share, which would harm our business. In addition, actual or speculated consolidation among competitors, or the acquisition by, or of, our partners and/or resellers by competitors can increase the competitive pressures faced by us as customers may delay spending decisions or not purchase our products at all. Consolidation could also delay spending or require us to reduce the prices of our products to compete, which could also adversely affect our business.
Our business may be impacted by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties beyond our control, including the Russian-Ukraine and Israeli-Hamas conflicts.
War, terrorism, geopolitical uncertainties and other business interruptions could cause damage to, disrupt or cancel sales of our products and services on a global or regional basis, which could have a material adverse effect on our business or vendors with which we do business. Such events could also make it difficult or impossible for us to deliver products and services to our customers, or to advance our product development efforts. In addition, territorial invasions can lead to cybersecurity attacks on technology companies, such as ours, located far outside of the conflict zone. In the event of prolonged business interruptions due to geopolitical events, we could incur significant losses, require substantial recovery time and experience significant expenditures in order to resume our business operations.
We have certain key engineering competencies performed by a team of 42 engineers in Israel, and we outsource some application software development and testing activities to a Kyiv, Ukraine-based dedicated team of 50 software engineers from a global US-based independent third-party provider of engineering services. If the ongoing Russian-Ukraine or the Israeli-Hamas conflicts intensify, or if Ukraine experiences further political instability, the engineers in Ukraine or Israel may be unable to work for a sustained period of time, which could adversely impact our research and development operations. We have developed contingency plans if these engineers are unable to continue working on their projects for us for a sustained period of
10


time, but if our contingency plans are not effective, or sanctions are imposed that prevent us from conducting business in Ukraine or Israel, we could suffer delays in product introduction or delays in resolution of customer software bugs, which could have a negative impact on our revenues.
We do not and cannot know if the current uncertainties in these geopolitical areas, which are unfolding in real-time, may escalate and result in broad economic and security conditions, which could result in material implications for our business. In addition, our insurance policies typically contain a war exclusion of some description and we do not know how our insurers are likely to respond in the event of a loss alleged to have been caused by geopolitical uncertainties.
We have significant ongoing capital requirements that could have a material effect on our business and financial condition if we are unable to generate sufficient cash from operations.
Our business requires significant capital investment to carry out extensive research and development in order to remain competitive. At the same time, demand for our products is highly variable and there have been downturns. If our cash on hand, net proceeds from financing activities and cash generated from operations are not sufficient to fund our operations and capital requirements, we may be required to limit our growth, or enter into financing arrangements at unfavorable terms, any of which could harm our business and financial condition.
Additionally, we anticipate that strategic alliances and partnerships will be an important source of revenue and possible financing for us going forward. If we are unable to develop alliances with or otherwise attract investment from strategic partners, or if strategic partners are not willing to enter into transactions with us on favorable terms, our business and financial condition could be harmed.
The average selling prices of our semiconductor solutions have historically decreased over time and will likely do so in the future, which could harm our gross profits and financial results.
Average selling prices of our semiconductor solutions have historically decreased over time, although such decreases have been reduced or eliminated during the inflationary period in 2022 and 2023, and we expect such declines to continue to occur in the future. Our gross profits and financial results will suffer if we are unable to offset reductions in our average selling prices by reducing our costs, developing new or enhanced semiconductor solutions on a timely basis with higher selling prices or gross profits, or increasing our sales volumes. Even if we are successful in reducing our costs or improving sales volumes, such improvements may not be sufficient to offset declines in average selling prices in the future. Additionally, because we do not operate our own manufacturing, assembly or testing facilities, we may not be able to reduce our costs and our costs may even increase, either of which would reduce our margins. In the past, we have reduced the prices of our semiconductor solutions in line with, and at times in advance of, competitive pricing pressures, new product introductions by us or our competitors and other factors. We expect that we will have to do so again in the future.
The semiconductor and communications industries have historically experienced significant fluctuations with prolonged downturns, which could impact our operating results, financial condition and cash flows.
The semiconductor industry has historically been cyclical, experiencing significant downturns in customer demand. Because a significant portion of our expenses is fixed in the near term or is incurred in advance of anticipated sales, we may not be able to decrease our expenses rapidly enough to offset any unanticipated shortfall in revenue. If this situation occurs, it could harm our operating results, cash flow and financial condition. Furthermore, the semiconductor industry has periodically experienced periods of increased demand and production constraints, including recent supply chain challenges. When this occurs, we may not be able to obtain sufficient quantities of our semiconductor solutions to meet the increased demand, resulting in lost sales, loss of market share and harm to our customer relationships. We may also have difficulty in obtaining sufficient assembly and testing resources from our subcontract manufacturers. Any factor adversely affecting the semiconductor industry in general, or the particular segments of the industry that we target, may harm our ability to generate revenue and could negatively impact our operating results.
The communications industry has experienced pronounced downturns, and these cycles may continue in the future. A future decline in global economic conditions and increasing inflationary pressure could have adverse, wide-ranging effects on demand for our semiconductor solutions and for the products of our customers, particularly wireless communications equipment manufacturers or other participants in the wireless industry, such as wireless carriers. Recent increases in inflation and interest rates and economic recessions that harm the global economy and capital markets also harm our customers and our end consumers. Specifically, the continued deployment of new 5G networks requires significant capital expenditures and wireless carriers may choose not to undertake network expansion efforts during an economic downturn or time of other
11


economic uncertainty. Our customers’ ability to purchase or pay for our semiconductor solutions and services, obtain financing and upgrade wireless networks could be harmed, and networking equipment providers may slow their research and development activities, cancel or delay new product development, reduce their inventories and take a cautious approach to acquiring our products, which would have a significant negative impact on our business. If such economic situations were to continue or worsen, our operating results, cash flow and financial condition could be harmed. In the future, any of these trends may also cause our operating results to fluctuate significantly from year to year.
The complexity of our semiconductor solutions could result in unforeseen delays or expenses from undetected defects or design errors in hardware or software, which could reduce the market acceptance for our semiconductor solutions, damage our reputation with current or prospective customers and increase our costs.
Highly complex semiconductor solutions such as ours can contain defects and design errors, which, if significant, could impair performance or prevent compliance with industry standards. We have not in the past, but may in the future, experience such significant defects or design errors. In addition, our semiconductor solutions must be certified by individual wireless carriers that such solutions function properly on the carrier’s network before our solutions can be designed into a particular product. If any of our semiconductor solutions have reliability, quality or compatibility problems from defects or design errors, we may not be able to successfully correct these problems in a timely manner, or at all. Furthermore, we may experience production delays and increased costs correcting such problems. Issues in the carrier certification process, which varies among carriers, may also create delays. Consequently, and because our semiconductor solutions are a critical component of our customers’ products, our reputation may be irreparably damaged, and customers may be reluctant to buy our semiconductor solutions, which could harm our ability to retain existing customers and attract new customers and harm our financial results. In addition, these defects or design errors or delays in the carrier certification process could interrupt or delay sales to our customers. If any of these problems are not found until after we have commenced commercial production of a new semiconductor solution, we may be required to incur additional development costs and product recalls, repairs or replacement costs. Furthermore, we provide warranties on our products ranging from one to two years, and thus may be obligated to refund sales with respect to products containing defects, errors or bugs. These problems may also result in claims against us by our customers or others, all of which could damage our reputation and increase our costs.
We are subject to risks inherent in our international operations.
Our international revenues account for a substantial majority of our total revenues. As a result, we must provide significant service and support globally. We intend to maintain or expand our international operations and expect to incur costs doing so. We cannot assure you that we will be able to recover our investments in international markets. Our results of operations could be adversely affected by a variety of factors, including:
the longer payment cycles associated with many foreign customers;
the typically longer periods from placement of orders to revenue recognition in certain international and emerging markets;
currency fluctuations;
the difficulties in interpreting or enforcing our agreements and collecting receivables through many foreign countries’ legal systems;
unstable regional political and economic conditions or changes in restrictions on trade among countries;
changes in the political, regulatory, safety or economic conditions in a country or region;
the imposition by governments of additional taxes, tariffs, global economic sanctions programs or other restrictions on foreign trade, including U.S. and Chinese tariffs and trade restrictions;
any inability to comply with export or import laws and requirements or any violation of sanctions regulations, which may result in enforcement actions, civil or criminal penalties and restrictions on exports;
any increase in the cost of trade compliance functions to comply with changes to regulatory requirements; and
the possibility that it may be more difficult to protect our intellectual property in foreign countries.
In addition, our global operations are subject to numerous U.S. and foreign laws and regulations, including those related to anti-corruption, tax, corporate governance, imports and exports, financial and other disclosures, privacy and labor relations. These laws and regulations are complex and may have differing or conflicting legal standards, making compliance difficult and costly. In addition, there is uncertainty regarding how proposed, contemplated or future changes to these complex laws and regulations could affect our business. We may incur substantial expense in complying with the new obligations to be imposed by these laws and regulations, and we may be required to make significant changes in our business operations, all of which may adversely affect our revenues and our business overall. If we violate these laws and regulations we could be subject to fines, penalties or criminal sanctions, and may be prohibited from conducting business in one or more countries. Although we have
12


implemented policies and procedures to help ensure compliance with these laws and regulations, there can be no assurance that our employees, contractors, agents or partners will not violate such laws and regulations. Any violation individually or in the aggregate could have a material adverse effect on our operations and financial condition.
We depend on the commercial deployment of 4G LTE narrow band variants and 5G communications equipment, products and services to grow our business, and our business may be harmed if wireless carriers delay in the adoption of Cat M, Cat NB and 5G standards, or if they deploy technologies that are not supported by our solutions.
We depend upon the continued commercial deployment of 4G and 5G wireless communications equipment, products and services based on our technology. Deployment of new networks by wireless carriers requires significant capital expenditures, well in advance of any revenue from such networks. If the rate of deployment of new networks by wireless carriers is slower than we expect, this will reduce the sales of our products and could cause OEMs and ODMs to hold excess inventory. This would harm our revenues and our financial results.
The worldwide commercial deployment and adoption of the narrow band LTE variants, Cat M and Cat NB, are expected to expand further the markets for Internet of Things devices. If deployments of the Cat M or Cat NB standards are delayed or if competing standards for Internet of Things devices become favored by wireless carriers, we may not be able to successfully increase sales of our Cat M and Cat NB products, which would harm our revenues and our financial results.
Rapidly changing standards could make our semiconductor solutions obsolete, which would cause our operating results to suffer.
We design our semiconductor solutions to conform to standards set by industry standards bodies such as the Institute of Electrical and Electronics Engineers, Inc. (IEEE), the 3rd Generation Partnership Project (3GPP) and Open Mobile Alliance (OMA). We also depend on industry groups such as the Global Certification Forum (GCF) and the PTS Type Certification Review Board (PTCRB) to help certify and maintain certification of our semiconductor solutions. If our customers adopt new or competing industry standards that are not compatible with our semiconductor solutions, if industry groups fail to adopt standards compatible with our semiconductor solutions or if our customers are requiring chip certifications that we did not design our products for, our existing semiconductor solutions would become less desirable to our customers and our sales would suffer. The emergence of markets for our products is affected by a variety of factors beyond our control. In particular, our semiconductor solutions are designed to conform to current specific industry standards. Competing standards may emerge that are preferred by our customers, which could also reduce our sales and require us to make significant expenditures to develop new semiconductor solutions. For example, in the Internet of Things markets, we could face indirect competition from companies using alternative technologies such as LoRa Wireless RF technology, a long range, low power consumption and data transmission protocol for Internet of Things devices. Wireless carriers started deploying 5G technology, the next phase of mobile telecommunications standards, beginning in 2020. If we are unable to successfully develop or commercialize products for the 5G standard, our semiconductor solutions could become obsolete, which would cause our sales and financial results to suffer. Governments and foreign regulators may adopt standards that are incompatible with our semiconductor solutions, favor alternative technologies or adopt stringent regulations that would impair or make commercially unviable the deployment of our semiconductor solutions. In addition, existing standards may be challenged as infringing upon the intellectual property rights of other companies or may become obsolete.
Changes in current laws or regulations or the imposition of new laws or regulations could impede the sale of our products or otherwise harm our business.
Wireless networks can only operate in the spectrum allowed by regulators and in accordance with rules governing how that spectrum can be used. Regulators in various countries have broad jurisdiction over the allocation of spectrum for wireless networks, and we therefore rely on these regulators to provide sufficient spectrum and usage rules. For example, countries such as China, India, Japan or Korea heavily regulate all aspects of their wireless communication industries, and may restrict spectrum allocation or usage. If further restrictions were to be imposed over the frequency bands where our semiconductor solutions are designed to operate, we may have difficulty selling our products in those regions. In addition, some of our semiconductor solutions operate in the 2.5 and 3.5 gigahertz, or GHz, bands, which in some countries are also used by government and commercial services such as military and commercial aviation. European and United States regulators have traditionally protected government uses of the 2.5 and 3.5 GHz bands by setting power limits and indoor and outdoor designation, and by requiring that wireless local area networking devices not interfere with other users of the band such as government and civilian satellite services. Changes in current laws or regulations or the imposition of new laws and regulations
13


in the markets in which we operate regarding the allocation and usage of the 2.5 and 3.5 GHz band, may harm the sale of our products and our business, financial condition and results of operations.
Fluctuations in foreign exchange rates may harm our financial results.
Our functional currency is the U.S. dollar. Substantially all of our sales are denominated in U.S. dollars and the payment terms of all of our significant supply chain vendors are also denominated in U.S. dollars. We incur operating expenses and hold assets and liabilities denominated in currencies other than the U.S. dollar, principally the euro, and to a lesser extent the British pound sterling and the New Israeli shekel. As a result, our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, in particular the U.S. dollar to euro exchange rate. As we grow our operations, our exposure to foreign currency risk could become more significant. If there had been a 10% increase or decrease in the exchange rate of the U.S. dollar to the euro, as measured using the Company's 2023 weighted average exchange rate of one euro = $1.0816, we estimate the impact, in absolute terms, on operating expenses and on financial liabilities for the year ended December 31, 2023 would have been $4.2 million.
Our exposure to foreign currency risk may change over time as business practices evolve and economic conditions change.
We from time to time enter into foreign currency hedging contracts primarily to reduce the impact of variations in the U.S. dollar to euro exchange rate on our operating expenses denominated in euros. However, hedging at best reduces volatility and helps to lock in a target rate for the following six to twelve months but cannot eliminate the fundamental exposure and may not be effective.
Our global operations are subject to risks for which we may not be adequately insured.
Our global operations are subject to many risks including errors and omissions, infrastructure disruptions, such as large-scale outages or interruptions of service from utilities or telecommunications providers, supply chain interruptions, third-party liabilities and fires or natural disasters. In addition, we have been in the past, and may in the future be, subject to securities litigation. No assurance can be given that we will not incur losses beyond the limits or outside the scope of coverage of our insurance policies. From time-to-time, various types of insurance may not be available on commercially acceptable terms or, in some cases, at all. We cannot assure you that in the future we will be able to maintain existing insurance coverage or that premiums will not increase substantially. We maintain limited insurance coverage and in some cases no coverage for cyber security incidents, natural disasters and sudden and accidental environmental damages as these types of insurance are sometimes not available or available only at a prohibitive cost. Accordingly, we may be subject to an uninsured or under-insured loss in such situations.
Risks Related to the Manufacture of Our Products
Global supply chain shortages.
Any disruptions to our supply chain, significant increase in component costs, or shortages of critical components, could decrease our sales, earnings, and liquidity or otherwise adversely affect our business and result in increased costs. For example, in 2021 and 2022, we experienced significant supply constraints for PCB and other standard components, including crystals and flash, and our supply of silicon wafers from Taiwan Semiconductor Manufacturing Company Limited, or TSMC, were placed on allocation. The allocation of wafers have impacted our ability to fulfill customer orders in the past, and we may not get sufficient allocation to meet demand in the future. Such a disruption could occur as a result of any number of events, including, but not limited to: an extended closure of or any slowdown at our suppliers' plants or shipping delays due to efforts to limit the spread of COVID-19, market shortages due to the surge in demand from other purchasers for critical components, increases in prices, the imposition of regulations, quotas or embargoes or tariffs on components or our products themselves, labor stoppages, transportation delays or failures affecting the supply chain and shipment of materials and finished goods, third-party interference in the integrity of the products sourced through the supply chain, cyberattacks, the unavailability of raw materials, severe weather conditions, adverse effects of climate change, natural disasters, geopolitical developments, war or terrorism and disruptions in utilities and other services. In addition, the development, licensing, or acquisition of new products in the future may increase the complexity of supply chain management. Failure to effectively manage the supply of components and products would adversely affect our business.
In response to supply chain disruptions, we purchased our entire allocation of wafers from TSMC, our wafer supplier, in 2022 to ensure adequate supply over the year and to avoid expected further price increases on wafers. This action resulted in
14


increased inventory at the end of 2022 and 2023. Apart from the increase in inventory, the mitigation actions have not resulted in any known trends or uncertainties or new material risks, but there is no assurance we will be able to procure sufficient wafers in the future.
Certain natural disasters, such as fires, coastal flooding, large earthquakes, volcanic eruptions or pandemics, may negatively impact our business. Any disruption to the operations of our foundry and assembly and testing subcontractors or our supply chain could cause significant delays in the production or shipment of our products.
If fires, coastal flooding, a large earthquake, volcanic eruption, new pandemic or other natural disaster were to directly damage, destroy or disrupt our partners’ manufacturing facilities or the facilities of our testing, assembly and manufacturing contractors or our component suppliers, it could disrupt our operations, delay new production and shipments of existing inventory, or result in costly repairs, replacements, the need to find alternative suppliers or other costs, all of which would negatively impact our business. For example, a fire at Asahi Kasei Microsystem’s semiconductor factory in Japan in October 2020 completely shut down production of its TCXO crystal oscillator products, which account for approximately half of the worldwide industry production of these products and are a primary component in our products. Unimicron, a major supplier of PCB and substrates for packaging, also had a factory fire in October 2020 which has constrained the supply of these components and increased lead times, as well as increasing pricing across. If similar events occur in the future and we are unable to qualify additional suppliers prior to exhausting our current inventory or are unable to source alternative components in sufficient quantity, we could experience significant delays in the production or shipment of our semiconductor solutions or experience significant increases in our supply chain costs until we are able to shift our supply to an alternative vendor. These events and their consequences could negatively impact our results of operations and cash flows, both during and after the period of operational difficulties, and could harm our reputation.
We depend on one independent foundry to manufacture our semiconductor wafers and do not have a long-term agreement with such foundry, and loss of this foundry or our failure to obtain sufficient foundry capacity would significantly delay our ability to ship our products, cause us to lose revenue and market share and damage our customer relationships.
Access to foundry capacity is critical to our business because we are a fabless semiconductor company. We depend on a sole independent foundry, TSMC in Taiwan, to manufacture our semiconductor wafers. Because we outsource our manufacturing to a single foundry, we face several significant risks, including:
constraints in or unavailability of manufacturing capacity;
limited control over delivery schedules, quality assurance and control, manufacturing yields and production costs; and
the unavailability of, or potential delays in obtaining access to, key process technologies.
If we do not accurately forecast our capacity needs, TSMC may not have available capacity to meet our immediate needs, or we may be required to pay higher costs to fulfill those needs, either of which could harm our business, results of operations or financial condition.
The ability of TSMC to provide us with semiconductor wafers is limited at any given time by their available capacity, and we do not have a guaranteed level of manufacturing capacity. We do not have any agreement with TSMC and place our orders on a purchase order basis. As a result, if TSMC raises its prices due to inflationary pressures or is not able to satisfy our required capacity for any reason, including natural or other disasters or as a result of factory shutdowns, allocates capacity to larger customers or to different sectors of the semiconductor industry, experiences labor issues or shortages or delays in shipment of semiconductor equipment or materials used in the manufacture of our semiconductors, or if our business relationship with TSMC deteriorates, we may not be able to obtain the required capacity and would have to seek alternative foundries, which may not be available on commercially reasonable terms, in a timely manner, or at all. If demand in 2024 increases, our ability to meet all our customer demand could be limited, with a corresponding negative impact on revenues.
Locating and qualifying a new foundry would require a significant amount of time, which would result in a delay in production of our products, and cost, as new production masks would be required. In addition, using foundries with which we have no established relationship could expose us to unfavorable pricing and terms, delays in developing and qualifying new products, unsatisfactory quality or insufficient capacity allocation. We place our orders on the basis of our customers’ purchase orders and sales forecasts; however, foundries can allocate capacity to the production of other companies’ products and reduce deliveries to us on short notice. Many of the customers of TSMC, or foundries that we may use in the future, are larger than we are, or have long-term agreements with such foundries, and as a result, those customers may receive preferential treatment from the foundries in terms of price, capacity allocation and payment terms. Any delay in qualifying a new foundry or production issues with any new foundry would result in lost sales and could damage our relationship with existing and future customers as well as our reputation in the market.
15


If our foundry vendor does not achieve satisfactory yields or quality, our reputation and customer relationships could be harmed.
The fabrication of semiconductor solutions such as ours is a complex and technically demanding process. Minor deviations in the manufacturing process can cause substantial decreases in yields, and in some cases, cause production to be suspended. TSMC, or foundries that we may use in the future, could, from time to time, experience manufacturing defects and reduced manufacturing yields. Changes in manufacturing processes or the inadvertent use of defective or contaminated materials by our foundry vendor could result in lower than anticipated manufacturing yields or unacceptable performance. Many of these problems are difficult to detect at an early stage of the manufacturing process and may be time consuming and expensive to correct. Poor yields from our foundry vendor, or defects, integration issues or other performance problems in our semiconductor solutions could cause us significant customer relations and business reputation problems, harm our financial results and result in financial or other damages to our customers. In addition, because we have a sole supplier of wafers, these risks are magnified because we do not have an alternative source to purchase from should these risks materialize. If TSMC fails to provide satisfactory products to us, we would be required to identify and qualify other sources, which could take a significant amount of time and would result in lost sales. In addition, we indemnify our customers for losses resulting from defects in our products, which costs could be substantial. A product liability or other indemnification claim brought against us, even if unsuccessful, would likely be time-consuming and costly to defend.
We depend on one technology partner to provide components for and to manufacture the Monarch SiP. If this partner declares end of life of any of its components included in the Monarch SiP, or decides to no longer produce the Monarch SiP, this would cause us to lose revenue and market share and damage our customer relationships.
The Monarch SiP includes radio components from and is assembled by Skyworks Solutions, Inc. ("Skyworks"). The Monarch SiP is commercialized by both Skyworks and us, under each company's own part number. If Skyworks decides to cease manufacturing any of the components incorporated in the Monarch SiP, or decides to cease manufacturing the Monarch SiP, we do not have an alternative solution for producing this product and would be unable to ship. This would cause us to lose revenue and market share and could damage our customer relationships.
Any increase in the manufacturing cost of our products would reduce our gross margins and operating profit.
The semiconductor business is characterized by ongoing competitive pricing pressure from customers and competitors. Accordingly, any increase in the cost of our products, whether by adverse purchase price or manufacturing cost variances, inflationary pressures, or due to other factors, will reduce our gross margins and operating profit. For example, in 2021 and 2022 due to the global supply chain disruption stemming from the Covid-19 pandemic, certain of our suppliers increased prices significantly. In most cases, we were able to pass on a corresponding price increase to our customers, but this may not always be the case in the future. We do not have long-term supply agreements with our manufacturing, testing or assembly suppliers, although with large suppliers we typically negotiate pricing on an annual basis. With other suppliers we typically negotiate on a purchase order by purchase order basis. We may not be able to obtain price reductions, or anticipate or prevent future price increases from our suppliers. Because we have a sole supplier of wafers and limited sources of testing and assembly for both chipsets and modules, we may not be able to negotiate favorable pricing terms from our suppliers. These and other related factors could impair our ability to control our costs and could harm our operating results.
We outsource our assembly, testing, warehousing and shipping operations to third parties, and if these parties fail to produce and deliver our products in a timely manner and in accordance with our specifications, our reputation, customer relationships and operating results could suffer.
We rely on third parties for the assembly, testing, warehousing and shipping of our products. We currently rely on Siliconware Precision Industries Limited, or SPIL; ASE ChungLi, or ASCL; and other third-party assembly and test subcontractors for assembly and testing chipsets. We rely on Universal Scientific Industrial (Shanghai) Ltd., or USI, and Asiatelco Technologies Co., or Asiatelco, for manufacturing of our modules. We further rely on a single company for logistics and storage. We depend on these parties to supply us with material of a requested quantity in a timely manner that meets our standards for yield, cost and manufacturing quality. We are unable to maintain the same level of oversight and control of these outsourced operations as we would if we were to conduct them internally.
The services provided by these vendors could be subject to disruption for a variety of reasons, including natural disasters, such as earthquakes, labor disputes, power outages, or if our relationship with a vendor is damaged. If we experience problems at a particular location, we would be required to transfer the impacted services to a backup vendor, which could be costly and
16


require a significant amount of time. During such a transition, we would be required to meet customer demand from our then-existing inventory, as well as any partially finished goods that can be modified to the required product specifications, which may not be possible or cost effective. Further, we do not have any long-term agreements with most of these vendors. If one or more of these vendors terminates its relationship with us, allocates capacity to other customers or if we encounter any problems with our supply chain, it could harm our ability to ship our products to our customers on time and in the quantity required, which in turn could cause an unanticipated decline in our sales and possibly damage our customer relationships.
We may experience difficulties in transitioning to new wafer fabrication process technologies or in achieving higher levels of design integration, which may result in reduced manufacturing yields, delays in product deliveries and increased costs.
To remain competitive, we expect to continue to transition our semiconductor products to increasingly smaller geometries and to achieve higher levels of design integration. These ongoing efforts require us from time to time to modify the manufacturing processes for our semiconductor solutions and to redesign some solutions, which in turn may result in delays in product deliveries. We periodically evaluate the benefits of migrating to new process technologies to reduce cost and improve performance. We may face difficulties, delays and increased expenses as we transition our products to new processes. We depend on our relationship with TSMC and our testing and assembly subcontractors to transition to new processes successfully. We cannot assure you that TSMC or our testing and assembly subcontractors will be able to effectively manage the transition or that we will be able to maintain our relationship with TSMC or our testing and assembly vendors or develop relationships with new foundries and vendors if necessary. If TSMC, any of our subcontractors or we experience significant delays in transitioning to smaller geometries or fail to efficiently implement transitions, we could experience reduced manufacturing yields, or delays in product deliveries and increased costs, all of which could harm our relationships with our customers, our margins and our operating results. As new processes become more prevalent, we expect to continue to integrate greater levels of functionality, as well as end-customer and third-party intellectual property, into our products. However, we may not be able to achieve higher levels of design integration or deliver new integrated products on a timely or cost-effective basis.
Risks Related to Intellectual Property Rights
We or our customers may be required to obtain licenses for certain so-called “standard essential patents” in order to comply with applicable standards, which could require us to pay additional royalties on certain of our products. If we or our customers are unable to obtain such licenses, our business, results of operations, financial condition and prospects would be harmed.
We or our customers may be required to obtain licenses for third-party intellectual property. In particular, we may be required to obtain licenses to certain third-party patents, so-called “standard essential patents,” that claim features or functions that are incorporated into applicable industry standards and that we are required to provide in order to comply with the standard. If we need to license any third-party intellectual property, standard essential patents or other technology, we could be required to pay royalties on certain of our products. In addition, while the industry standards bodies and antitrust laws in certain countries may require participating companies to license their standard essential patents on fair, reasonable, and nondiscriminatory terms, there can be no assurances that we will be able to obtain such licenses on commercially reasonable terms or at all. Although we have implemented a dedicated standard essential patents licensing-in reference policy, our inability to obtain required third-party intellectual property licenses on commercially reasonable terms or at all could harm our business, results of operations, financial condition or prospects. If our customers are required to obtain such licenses, there can be no assurances that their businesses will not be adversely affected. In addition, if our competitors have significant numbers of essential patents and/or patent license rights, they could be at an advantage in negotiating with our customers or potential customers, which could influence our ability to win new business or could result in downward pressure on our average selling prices.
Though we rely to a significant extent on proprietary intellectual property, we may not be able to obtain, or may choose not to obtain, sufficient intellectual property rights to provide us with meaningful protection or commercial advantage.
We depend significantly on intellectual property rights to protect our products and proprietary technologies against misappropriation by others. We generally rely on the patent, trademark, copyright and trade secret laws in Europe, the United States and certain other countries in which we operate or in which our products are produced or sold, as well as licenses and nondisclosure and confidentiality agreements, to protect our intellectual property rights.
We may have difficulty obtaining patents and other intellectual property rights, and the patents and other intellectual property rights we have and obtain may be insufficient to provide us with meaningful protection or commercial advantage. We
17


currently do not apply for patent protection in all the countries in which we operate. Instead we select and focus on key countries for each patent family. In addition, the protection offered by patents and other intellectual property rights may be inadequate or weakened for reasons or circumstances that are out of our control. For instance, we may not be able to obtain patent protection or secure other intellectual property rights in all the countries in which we have filed patent applications or in which we operate, and under the laws of such countries, patents and other intellectual property rights may be or become unavailable or limited in scope.
We may not be able to adequately protect or enforce our intellectual property against improper use by our competitors or others and our efforts to do so may be costly to us, which may harm our business, financial condition and results of operations.
Our patents and patent applications, or those of our licensors, could face challenges, such as interference proceedings, opposition proceedings, nullification proceedings and re-examination proceedings. Any such challenge, if successful, could result in the invalidation or narrowing of the scope of any such patents and patent applications. Any such challenges, regardless of their success, would also likely be time-consuming and expensive to defend and resolve, and would divert management time and attention. Further, our unpatented proprietary processes, software, designs and trade secrets may be vulnerable to disclosure or misappropriation by employees, contractors and other persons. While we generally enter into confidentiality agreements with such persons to protect our intellectual property, we cannot assure you that our confidentiality agreements will not be breached, that they will provide meaningful protection for our proprietary technology and trade secrets, or that adequate remedies will be available in the event they are used or disclosed without our authorization. Also, intellectual property rights are difficult to enforce in the People’s Republic of China, or PRC, and certain other countries, particularly in Asia, where the application and enforcement of the laws governing such rights may not have reached the same level as compared to other jurisdictions where we operate, such as Europe and the United States. Consequently, because we operate in these countries and all of our manufacturing, testing and assembly takes place in PRC, Taiwan, South Korea and Singapore, we may be subject to an increased risk that unauthorized parties may attempt to copy or otherwise use our intellectual property or the intellectual property of our suppliers or other parties with whom we engage or have licenses.
There can be no assurance that we will be able to protect our intellectual property rights, that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that we will have adequate legal recourse in the event that we seek legal or judicial enforcement of our intellectual property rights. Any inability on our part to adequately protect or enforce our intellectual property may harm our business, financial condition and results of operations. We may in the future initiate claims or litigation against third parties for infringement of our intellectual property rights to protect these rights, or to determine the scope and validity of our proprietary rights or the proprietary rights of competitors. These claims could result in costly litigation and the diversion of our technical and management personnel, and we may not prevail in making these claims.
Assertions by third parties of infringement by us or our customers of their intellectual property rights could result in significant costs and cause our operating results to suffer.
The markets in which we compete are characterized by rapidly changing products and technologies, and there is intense competition to establish intellectual property protection and proprietary rights to these new products and the related technologies. The semiconductor and wireless communications industries, in particular, are characterized by vigorous protection and pursuit of intellectual property rights and positions, which has resulted in protracted and expensive litigation for many companies.
We may be unaware of the intellectual property rights of others that may cover some of our technology, products and services. In addition, third parties may claim that we or our customers are infringing or contributing to the infringement of their intellectual property rights.
We have in the past received, and as a public company operating in a highly competitive marketplace, we expect that in the future we will receive, communications and offers from various industry participants and others alleging that we have infringed or have misappropriated their patents, trade secrets or other intellectual property rights and/or inviting us to license their technology and intellectual property. For example, in August 2022, we were sued in three lawsuits by Bell Semiconductor, LLC, accusing us of infringing certain U.S. patents that we license from another party. The case was settled in 2023, and in this instance, all costs were covered under our indemnification rights from the licensor. However, that may not be the case in future instances. Any lawsuits resulting from such allegations of infringement or invitations to license, including suits challenging 4G or 5G standards, could subject us to significant liability for damages and/or challenge our activities. Any potential intellectual property litigation also could force us to do one or more of the following:
stop selling products or using technology that contain the allegedly infringing intellectual property;
abandon the opportunity to license our technology to others or to collect royalty payments;
18


incur significant legal expenses;
pay substantial damages to the party whose intellectual property rights we may be found to be infringing;
redesign those products that contain the allegedly infringing intellectual property; or
attempt to obtain a license to the relevant intellectual property from third parties, which may not be available on reasonable terms or at all.
Our customers could also become the target of litigation relating to the patents and other intellectual property rights of others. This could, in turn, trigger an obligation for us to provide technical support and/or indemnify such customers. These obligations could result in substantial expenses, including the payment by us of costs and damages relating to claims of intellectual property infringement. In addition to the time and expense required for us to provide support or indemnification to our customers, any such litigation could disrupt the businesses of our customers, which in turn could hurt our relationships with our customers and cause the sale of our products to decrease. We cannot assure you that claims for indemnification will not be made or that if made, such claims would not materially harm our business, operating results or financial conditions.
Any potential dispute involving our patents or other intellectual property could also include our industry partners and customers, which could trigger our indemnification obligations to them and result in substantial expense to us.
In any potential dispute involving our patents or other intellectual property, our licensees could also become the target of litigation, and certain customers have received notices of written offers from our competitors and others claiming to have patent rights in certain technology and inviting our customers to license this technology. Because we indemnify our licensees and customers for intellectual property claims made against them for products incorporating our technology, any litigation could trigger technical support and indemnification obligations in some of our license agreements, which could result in substantial payments and expenses by us. In addition to the time and expense required for us to supply support or indemnification to our licensees and customers, any such litigation could severely disrupt or shut down the business of our customers, which in turn could hurt our relations with our customers and cause the sale of our proprietary technologies and products to decrease.
Our failure to comply with obligations under open source licenses could require us to release our source code to the public or cease distribution of our products, which could harm our business, financial condition and results of operations.
Some of the software used with our products, as well as that of some of our customers, may be derived from so-called “open source” software that is generally made available to the public by its authors and/or other third parties. Such open source software is often made available to us under licenses, such as the GNU General Public License, which impose certain obligations on us in the event we were to make available derivative works of the open source software. These obligations may require us to make source code for the derivative works available to the public, and/or license such derivative works under a particular type of license, rather than the licenses we customarily use to protect our intellectual property. In addition, there is little or no legal precedent for interpreting the terms of certain of these open source licenses, including the determination of which works are subject to the terms of such licenses. While we believe we have complied with our obligations under the various applicable licenses for open source software, in the event the copyright holder of any open source software were to successfully establish in court that we had not complied with the terms of a license for a particular work, we could be required to release the source code of that work to the public and/or stop distribution of that work.

Risks Related to Our Internal Control Over Financial Reporting
Pursuant to the Sarbanes-Oxley Act of 2002, we are required to document and test our internal control procedures and to provide a report by management on internal control over financial reporting, including management’s assessment of the effectiveness of such control.
In the past, we identified deficiencies in our internal control over financial reporting that constituted a material weakness in our internal control over financial reporting. Although we were able to remedy the material weaknesses and no new material weaknesses have been identified since 2020, we have a small finance team with limited resources, and we can give no assurances that other material weaknesses will not arise in the future. Failure to comply with Section 404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. Deficiencies, including any material weakness, in our internal control over financial reporting that may occur in the future could result in misstatements of our results of operations, restatements of our financial statements, a decline in our stock price, suspension or delisting of our ADSs from the New York Stock Exchange, or otherwise materially adversely affect our business, reputation, results of operations and financial condition.
19


Risks Related to Ownership of Our Shares and ADSs
We are not in compliance with the Continued Listing Criteria of the New York Stock Exchange (NYSE), and our failure to regain compliance may result in the delisting of our ADSs.
On April 9, 2024, the New York Stock Exchange (the “NYSE”) notified us that we are no longer in compliance with the minimum market capitalization and minimum share price requirements of the NYSE Listed Company Manual because (i) we had an average global market capitalization over a consecutive 30 trading-day period below $50,000,000 and, at the same time, stockholders’ equity less than $50,000,000, and (ii) because the average closing price of the Company’s ADSs was less than $1.00 over a consecutive 30 trading-day period.
We have until October 9,2024 to regain compliance with the minimum share price requirement. We can regain compliance during the six-month cure period if on the last trading day of any calendar month during the period or on the last trading day of the period, our ADSs have a closing share price of at least $1.00 per share and an average closing share price of at least $1.00 per share over the previous 30 consecutive day trading period. If we are unable to regain compliance, the NYSE will initiate procedures to suspend and delist the ADSs.
We have until July 8, 2024 to submit a business plan advising the NYSE of the definitive action(s) we have taken, or are taking, that would bring us into compliance with continued listing standards by October 9, 2025. The NYSE will review the plan and determine whether we have made a reasonable demonstration of an ability to conform to the relevant standards in the 18-month period. If the NYSE accepts the plan, our ADSs will continue to be listed and traded on the NYSE during the 18-month period, subject to our compliance with the other continued listing standards of the NYSE and continued periodic review by the NYSE of our progress with respect to our plan.
There can be no assurance that we can cure the deficiencies. If our ADSs are delisted and we are not able to list our ADSs on another national securities exchange, we expect our securities would be quoted on an over-the-counter market. If this were to occur, our stockholders could face significant material adverse consequences, including limited availability of market quotations for our ADSs and reduced liquidity for the trading of our securities. In addition, we could experience a decreased ability to issue additional securities and obtain additional financing in the future. There can be no assurance that an active trading market for our ADSs will develop or be sustained
Fluctuations in our operating results on a quarterly or annual basis and difficulty predicting our quarterly operating results could cause the market price of the ADSs to decline.
Our revenue and operating results have fluctuated significantly from period to period in the past and will do so in the future. As a result, you should not rely on period-to-period comparisons of our operating results as an indication of our future performance. In future periods, our revenue and results of operations may be below the expectations of analysts and investors, which could cause the market price of the ADSs to decline.
Factors that may cause our operating results to fluctuate include but are not limited to:

reductions in orders or cancellations by our customers;
changes in customer mix, the mix of products and services sold and the mix of geographies in which our products and services are sold;
reduced visibility into our customers’ spending plans and associated revenue;
current and potential customer, partner and supplier consolidation and concentration;
changes in the size, growth or growth prospects of the LTE and IoT markets;
changes in the competitive dynamics of our market, including new entrants or pricing pressures, and our ability to compete in the LTE and IoT markets;
timing and success of commercial deployments of and upgrades to 4G wireless networks and the next generation 5G wireless networks;
timely availability, at a reasonable cost, of adequate manufacturing capacity with the sole foundry that manufactures our products;
our ability to successfully define, design and release new products in a timely manner that meet our customers’ needs;
timing and growth rate of revenues from the LTE and IoT markets;
changes in manufacturing costs, including wafer, test and assembly costs, mask costs and manufacturing yields;
the timing of product announcements by competitors or us;
costs associated with litigation, especially related to intellectual property and securities class actions;
20


costs associated with any violation of the U.S. Foreign Corrupt Practices Act, the United Kingdom Bribery Act, or other similar foreign laws;
the effects of a widespread outbreak of contagious disease;
changing economic and political conditions at a global or local level;
the impact of rising inflation and interest rates on consumer demand for electronic products;
how well we execute on our strategy and operating plans and the impact of changes in our business model that could result in significant restructuring changes; and
our ability to achieve targeted cost reductions.
Moreover, sales of our semiconductor solutions fluctuate from period to period due to cyclicality in the semiconductor industry and the short product life cycles and wide fluctuations in product supply and demand characteristic of this industry. We expect these cyclical conditions to continue. Due to our limited operating history, we have yet to experience an established pattern of seasonality. However, business activities in Asia generally slowdown in the first quarter of each year during the lunar new year period, which could harm our sales and results of operations during the period. Our expense levels are relatively fixed in the short-term and are based, in part, on our future revenue projections. If revenue levels are below our expectations, we may experience declines in margins and profitability or incur a loss from our operations. As a result, our quarterly operating results are difficult to predict, even in the near term, which may result in our revenue and results of operations being below the expectations of analysts and investors, and which could cause the market price of the ADSs to decline.
If securities or industry analysts cease to publish research reports about us or our industry, or if they adversely change their recommendations regarding the ADSs, the market price for the ADSs and trading volume could decline.
The trading market for the ADSs is influenced by research reports that industry or securities analysts publish about us or our industry. If one or more analysts who cover us downgrade the ADSs, the market price for the ADSs would likely decline. If one or more of these analysts ceases coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for the ADSs to decline.
If we raise additional capital in the future, your ownership in us could be diluted.
Any issuance of equity we may undertake in the future to raise additional capital could cause the price of the ADSs to decline, or require us to issue shares or ADSs at a price that is lower than that paid by holders of our shares or ADSs in the past, which would result in those newly issued shares or ADSs being dilutive. If we obtain funds through a credit facility or through the issuance of debt or preferred securities, these securities would likely have rights that are senior to your rights as an ADS holder, which could impair the value of the ADSs.
We have no present intention to pay dividends on our ordinary shares in the foreseeable future and, consequently, your only opportunity to achieve a return on your investment during that time is if the price of the ADSs appreciates.
We have no present intention to pay dividends on our ordinary shares in the foreseeable future. Any recommendation by our board of directors to pay dividends will depend on many factors, including our financial condition, results of operations, legal requirements and other factors. Accordingly, if the price of the ADSs falls in the foreseeable future, you will incur a loss on your investment, without the likelihood that this loss will be offset in part or at all by potential future cash dividends. In addition, even if we were to pay a dividend on our ordinary shares, French law may prohibit paying such dividends to holders of the ADSs or the tax implications of such payments may significantly diminish what you receive.
You may not be able to exercise your right to vote the ordinary shares underlying your ADSs.
Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the provisions of the deposit agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will, as soon as practicable thereafter, fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (i) the notice of the meeting or solicitation of consent or proxy sent by us and (ii) a statement as to the manner in which instructions may be given by the holders.
You may instruct the depositary of your ADSs to vote the ordinary shares underlying your ADSs. Otherwise, you will not be able to exercise your right to vote, unless you withdraw the ordinary shares underlying the ADSs you hold. However, you may not know about the meeting far enough in advance to withdraw those ordinary shares. If we ask for your instructions, the
21


depositary, upon timely notice from us, will notify you of the upcoming vote and arrange to deliver our voting materials to you. We cannot guarantee you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your ordinary shares or to withdraw your ordinary share so that you can vote them yourself. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions, or for the manner of carrying out voting instructions. This means that you may not be able to exercise your right to vote, and there may be nothing you can do if the ordinary shares underlying your ADSs are not voted as you requested.
As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company, our ordinary shares are not listed, and we do not intend to list our shares, on any market in France, our home country. This may limit the information available to holders of the ADSs.
We are a “foreign private issuer”, as defined in the SEC’s rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable to public companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section 14 of the Exchange Act. In addition, our officers and directors are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we have and expect to continue to submit quarterly interim consolidated financial data to the SEC under cover of the SEC’s Form 6-K, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies, and are not required to file quarterly reports on Form 10-Q or current reports on Form 8-K under the Exchange Act. Furthermore, our ordinary shares are not listed, and we do not currently intend to list our ordinary shares on any market in France, our home country. As a result, we are not subject to the reporting and other requirements of listed companies in France. For instance, we are not required to publish quarterly or semi-annual financial statements. Accordingly, there is less publicly available information concerning our company than there would be if we were a U.S. public company.
As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from NYSE corporate governance listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with NYSE corporate governance listing standards.
As a foreign private issuer listed on the NYSE, we are subject to NYSE corporate governance listing standards. However, NYSE rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in France, which is our home country, may differ significantly from NYSE corporate governance listing standards. For example, neither the corporate laws of France nor our by-laws require a majority of our directors to be independent, and we could include non-independent directors as members of our compensation committee and nominating committee, and our independent directors would not necessarily hold regularly scheduled meetings at which only independent directors are present. Currently, we intend to comply with the NYSE corporate governance listing standards to the extent possible under French law. However, if we choose to change such practice to follow home country practice in the future, our shareholders may be afforded less protection than they otherwise would under NYSE corporate governance listing standards applicable to U.S. domestic issuers.
U.S. holders of the ADSs may suffer adverse tax consequences if we are characterized as a Passive Foreign Investment Company.
Generally, if for any taxable year 75% or more of our gross income is passive income, or at least 50% of our assets are held for the production of, or produce, passive income, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. To determine if at least 50% of our assets are held for the production of, or produce, passive income, we may use the market capitalization method for certain periods. Under the market capitalization method, the total asset value of a company would be considered to equal the fair market value of its outstanding shares plus outstanding indebtedness on a relevant testing date. Because the market price of the ADSs has fluctuated substantially and is likely to fluctuate in the future, and the market price may affect the determination of whether we will be considered a PFIC, there can be no assurance that we will not be considered a PFIC for any taxable year. While we do not believe we were a PFIC for 2023, there is no assurance that we will not be a PFIC in 2024 or later years. If we are characterized as a PFIC, U.S. holders of the ADSs may suffer adverse tax consequences, including having gains realized on the sale of the ADSs treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable to dividends received on the ADSs by individuals who are U.S. holders, having interest charges apply to distributions by us and the proceeds of ADS sales and additional reporting requirements. We do not expect to provide to U.S. holders, the information needed to report income and gain pursuant
22


to a “qualified electing fund” election, which election would alleviate some of the adverse tax consequences of PFIC status, and we make no undertaking to provide such information in the event that we are a PFIC. See “Item 10.E—Taxation—Material United States Federal Income Tax Consequences.
We have been and in the future may be subject to legal actions that could distract our management and increase costs, which may adversely affect our financial condition or our reputation.

We have been subject to securities class action lawsuits alleging violations of the U.S. federal securities laws by us and certain of our officers. The costs of the ultimate resolution of these lawsuits did not exceed our insurance coverage after our deductible. However, the premium for our directors and officers insurance increased significantly with a higher retention and reduced coverage. An unfavorable outcome in any future lawsuit or proceeding could have an adverse impact on our business, financial condition and results of operations. Further, if our stock price is volatile, we may become involved in further litigation. Any current or future litigation, regardless of its merits, could result in substantial costs and a diversion of our management’s attention and resources that are needed to successfully run our business.
You may be unable to recover in civil proceedings for U.S. securities laws violations.
We are a corporation organized under the laws of France. The majority of our directors are citizens and residents of countries other than the United States, and the majority of our assets are located outside of the United States. Accordingly, it may be difficult for investors to obtain jurisdiction over us or our directors in courts in the United States and enforce against us or them judgments obtained against us or them. In addition, we cannot assure you that civil liabilities predicated upon the federal securities laws of the United States will be enforceable in France.
ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.
The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws.
If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.
If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and / or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action. Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. No condition or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.
The rights of shareholders in companies subject to French corporate law differ in material respects from the rights of shareholders of corporations incorporated in the United States.
We are a French company with limited liability. Our corporate affairs are governed by our by-laws and by the laws governing companies incorporated in France. The rights of shareholders and the responsibilities of members of our board of
23


directors are in many ways different from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. For example, in the performance of its duties, our board of directors is required by French law to consider the interests of our company, its shareholders, its employees and other stakeholders, rather than solely our shareholders and/or creditors. It is possible that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder.
Our by-laws and French corporate law contain provisions that may delay or discourage a takeover attempt.
Provisions contained in our by-laws and the corporate laws of France, the country in which we are incorporated, could make it more difficult for a third party to acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of our by-laws impose various procedural and other requirements, which could make it more difficult for shareholders to effect certain corporate actions. These provisions include the following:
our shares are in registered form only, and we must be notified of any transfer of our shares in order for such transfer to be validly registered;
our by-laws provide for directors to be elected for three-year terms, and we intend to elect one third of the directors every year;
our shareholders may grant our board of directors, broad authorizations to increase our share capital;
our board of directors has the right to appoint directors to fill a vacancy created by the resignation, death or removal of a director, subject to the approval by the shareholders of such appointment at the next shareholders’ meeting, which prevents shareholders from having the sole right to fill vacancies on our board of directors;
our board of directors can only be convened by its chairman except when no board meeting has been held for more than two consecutive months;
our board of directors' meetings can only be regularly held if at least half of the directors attend either physically or by way of secured telecommunications;
approval of at least a majority of the shares entitled to vote at an ordinary shareholders’ general meeting is required to remove directors with or without cause;
advance notice is required for nominations for election to the board of directors or for proposing matters that can be acted upon at a shareholders’ meeting; and
the sections of the by-laws relating to the number of directors and election and removal of a director from office may only be modified by a resolution adopted by 66 2/3% of our shareholders present or represented at the meeting.
The exercise or conversion of outstanding stock options, restricted shares, warrants and convertible notes into ordinary shares will dilute the percentage ownership of our other shareholders and the sale of such shares may adversely affect the market price of the ADSs.
As of May 7, 2024, there were outstanding stock options, warrants, and unvested restricted shares representing an aggregate of approximately 28.4 million of our ordinary shares (representing approximately 7.1 million ADSs), and more restricted shares, options and warrants will likely be granted in the future to our officers, directors and employees. We also have outstanding issuances of convertible notes issued in 2019 (the " 2019 Notes") and in April 2021 (the "2021 Notes"). The 2019 Notes may be converted into 2.2 million ADSs at a conversion price of $4.12 per ADS, subject to adjustment if the maturity is further extended. The 2021 Notes may be converted into 6.2 million ADSs at term at a conversion price of $7.66 per ADS, subject to adjustment if the maturity is further extended. In September 2018, August 2022 and August 2023, we issued warrants to purchase 0.5 million, 0.2 million and 0.3 million ADSs with exercise prices of $6.80 per ADS, $4.12 per ADS and $3.23 per ADS, respectively, to the holder of the 2019 Notes. In October 2018, we issued warrants to purchase 0.2 million ADSs with an exercise price of $5.36 per ADS to a venture debt lender. In February 2019, we issued warrants to purchase 2.3 million ADSs with an exercise price of €0.08 per ADS to a strategic investor. We may issue additional warrants or convertible notes in connection with acquisitions, borrowing arrangement or other strategic or financial transactions. The exercise of outstanding stock options, warrants, or convertible notes, and the vesting of restricted shares, will dilute the percentage ownership of our other shareholders. The exercise of these options, warrants and convertible notes and the vesting of restricted shares, with the subsequent sale of the underlying ordinary shares could cause a decline in the market price of the ADSs.
Risks Relating to Our Indebtedness
Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the notes.
24


As of December 31, 2023, we had approximately $80.7 million of consolidated indebtedness, of which $52.3 million ($55.0 million due at maturity in April 2024) is currently in default but subject to standstill agreements. On April 9, 2024, we secured standstill agreements from our three main debt holders. The agreements granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met; the request for the extension of the agreements is in process as of this date, however there can be no assurance of the length of the extension, if any. We may also incur additional indebtedness to meet future financing needs.

Our indebtedness has significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:
increasing our vulnerability to adverse economic and industry conditions;
limiting our ability to obtain additional financing;
requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness if we do not make interest payments in kind, which will reduce the amount of cash available for other purposes;
limiting our flexibility to plan for, or react to, changes in our business;
diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of our outstanding convertible notes; and
placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.
We are currently in default on $55.0 million of notes. Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under our indebtedness, and our cash needs may increase in the future.
We are currently in default under $55.0 million of our notes. We have obtained standstill agreements from our three major noteholders that restricts them from enforcing their rights until April 26, 2024. The agreements granted may be further extended subject to certain milestones being met; the request for the extension of the agreements is in process as of this date, however there can be no assurance of the length of the extension, if any. We may be unable to raise the funds necessary to repay our notes upon the expiration of the standstill or to repurchase our convertible notes for cash if we enter into a strategic transaction that results in a change of control. If we cannot obtain further standstills or extend the maturity of the notes in default, we may be forced to seek a court ordered restructuring or liquidation.

If not cured, the defaults under the notes could also lead to a default under agreements governing our other indebtedness and agreements, which may result in that other indebtedness becoming immediately payable in full or counterparties having the right to terminate our agreements.
Provisions in the 2021 Notes could delay or prevent an otherwise beneficial takeover of us.
Certain provisions in the 2021 Notes could make a third party attempt to acquire us more difficult or expensive. For example, if a takeover constitutes a change of control, then the noteholder will have the right to require us to repurchase the 2021 Notes for cash. In this case, and in other cases, our obligations under the 2021 Notes could increase the cost of acquiring us or otherwise discourage a third party from acquiring us, including in a transaction that holders of our ordinary shares, or the ADSs represented thereby, may view as favorable.
General Risks
The loss of any of our key personnel could seriously harm our business, and our failure to attract or retain specialized technical, management or sales and marketing employees could impair our ability to grow our business.
We believe our future success will depend in large part upon our ability to attract, retain and motivate highly skilled management, engineering and sales and marketing personnel. The loss of any key employees or the inability to attract, retain or motivate qualified personnel, including engineers and sales and marketing personnel, could delay the development and introduction of and harm our ability to sell our semiconductor solutions. We believe that our future success is dependent on the contributions of Georges Karam, our co-founder and chief executive officer. The loss of the services of Dr. Karam, other executive officers or certain other key personnel could materially harm our business, financial condition and results of operations. For example, if any of these individuals were to leave unexpectedly, we could face substantial difficulty in hiring qualified successors, and could experience a loss in productivity during the search for any such successor and while any successor is integrated into our business and operations.
25


Our key technical and engineering personnel represent a significant asset and serve as the source of our technological and product innovations. We plan to recruit additional design and application engineers with expertise in wireless broadband communications technologies. We may not be successful in attracting, retaining and motivating sufficient technical and engineering personnel to support our anticipated growth. In addition, to expand our customer base and increase sales to existing customers, we will need to hire additional qualified sales personnel. The competition for qualified marketing, sales, technical and engineering personnel in our industry is very intense. If we are unable to hire, train and retain qualified marketing, sales, technical and engineering personnel in a timely manner, our ability to grow our business will be impaired. In addition, if we are unable to retain our existing sales personnel, our ability to maintain or grow our current level of revenue will be harmed.
Adverse outcomes in tax disputes could subject us to tax assessments and potential penalties.
From time to time, we are subject to tax audits that could result in tax assessments and potential penalties, particularly with respect to claimed research tax credits due to the judgment involved in determining which projects meet the tax code’s criteria for innovation and fundamental research. For example, in January 2022, we received notification from the French tax authorities that our tax declarations for the years ended December 31, 2019 and 2020 would be reviewed. In December 2022, we received notification of an adjustment related to employment taxes on employees in foreign offices totaling €80,000 ($82,000) for the year ended December 31, 2019. After we contested the finding, the adjustment was reduced to €38,000 ($39,000), which we recorded as an expense in 2022. In December 2023, the tax audit was finalized and did not result in any further tax expense. Our actual costs for any disputes in the future may be materially different from the provisions recorded if we are not successful in our appeal of any assessment, which could have a material adverse effect on our business.
Our business and operations could suffer in the event of security breaches.
Attempts by others to gain unauthorized access to our information technology systems are becoming more sophisticated. These attempts, which might be related to industrial or other espionage, include covertly introducing malware to our computers and networks and impersonating authorized users, among others. Hackers may also develop and deploy viruses, worms and other malicious software programs that attack or otherwise exploit security vulnerabilities in our systems or products. Attacks may create system disruptions, cause shutdowns or result in the corruption of our engineering data, which could result in delays in product development or software updates and harm our business. Additionally, the theft, unauthorized use or publication of our intellectual property and/or confidential business information could harm our competitive position, reduce the value of our investment in research and development and other strategic initiatives or otherwise adversely affect our business. To the extent that any security breach results in inappropriate disclosure of our customers’ or business partners’ confidential information, we may incur liability as a result. We could also suffer monetary and other losses, including reputational harm, which costs we may not be able to recover. We seek to detect and investigate all security incidents and to prevent their recurrence, but in some cases, we might be unaware of an incident or its magnitude and effects. While we have identified some incidents involving attempts at unauthorized access, we are not aware of any that have succeeded. We expect to continue to devote resources to the security of our information technology systems.
Changes in International Financial Reporting Standards (“IFRS”) could adversely affect our financial results and may require significant changes to our internal accounting systems and processes.
We prepare our consolidated financial statements in conformity with IFRS. These principles are subject to interpretation by the International Accounting Standard Board and various bodies formed to interpret and create appropriate accounting principles and guidance. The IFRS periodically issues new accounting standards on a variety of topics. For information regarding new accounting standards, please refer to Note 2.2 of Notes to Consolidated Financial Statements under the heading “Changes in accounting policy and disclosures.” These and other such standards generally result in different accounting principles, which may significantly impact our reported results or could result in variability of our financial results.
In preparing our financial statements we make certain assumptions, judgments and estimates that affect amounts reported in our consolidated financial statements, which, if not accurate, may significantly impact our financial results.
In preparing our financial statements, we make assumptions, judgments and estimates for a number of items. These assumptions, judgments and estimates are drawn from historical experience and various other factors that we believe are reasonable under the circumstances as of the date of the consolidated financial statements. Actual results could differ materially from our estimates, and such differences could significantly impact our financial results.
26



Item 4. Information on the Company

A.History and Development of the Company
Our History
Sequans Communications S.A. was incorporated as a société anonyme under the laws of the French Republic on October 7, 2003, for a period of 99 years. We are registered at the Nanterre Commerce and Companies Register under the number 450 249 677. Our principal executive offices are located at 15-55 boulevard Charles de Gaulle, 92700 Colombes, France, and our telephone number is +33 1 70 72 16 00. Our agent for service of process in the U.S. is GKL Corporate/Search, Inc., One Capitol Mall, Suite 660, Sacramento, California 95814.
The SEC maintains an Internet site at http:// www.sec.gov that contains reports, proxy and information statements, and other information that we file electronically with the SEC. Our website is www.sequans.com. The information on, or that can be accessed through, our website is not part of this annual report.
We entered into a Memorandum of Understanding (“MoU”) in August 2023 to be acquired by Renesas Electronics Corporation. Renesas terminated the MoU in February 2024 due to the receipt of an adverse Japanese tax ruling.
As of the date of this annual report, there has been no indication of any public takeover offers by third parties in respect of our ADSs or ordinary shares or by the Company in respect of other companies’ shares.
Principal Capital Expenditures
Our capital expenditures including purchase of intangible assets and capitalized development costs for the years ended December 31, 2021, 2022 and 2023 amounted to $28.9 million, $22.7 million and $29.6 million, respectively. They primarily consisted of purchases related to 5G product development as well as capitalized development costs. We anticipate our capital expenditures in the year ended December 31, 2024 to be primarily for ongoing 5G product development. We anticipate our capital expenditure in 2024 to be financed from our cash on hand plus financing from strategic alliances, R&D project financing, issuance of debt and/or equity. Should we decide to broaden our product range by acquiring or developing complementary technologies, we would need additional capital expenditures in order to support development of multi-mode or multi-feature products.

B.Business Overview
We are a fabless designer, developer and supplier of cellular semiconductor solutions for the massive and broadband Internet of Things (IoT) markets. We offer a comprehensive set of 5G/4G chips and modules fully optimized for non-smartphone devices. Massive IoT refers to applications with lower data transmission needs but where the technology must be extremely optimized in power consumption and cost to enable massive deployment. It covers applications such as smart mobility and logistics, smart utility meters, smart cities, e-health and wellness, and smart homes to name few. On the other side, for broadband IoT applications, the technology is optimized to provide to homes, enterprises and industrial sites the highest possible throughput and the lowest latency. While this requirement is similar to what we can see in a smartphone, our solutions focus on providing better trade-off in cost and performance optimized for broadband IoT devices such as enterprise routers and home gateways. Our product portfolio is composed of chips, or integrated circuits (IC) of baseband processors and radio frequency (RF) transceivers, as well as machine-to-machine (M2M) modules that incorporate these chips along with radio front end subsystem, and rich software that includes advanced modem and signal processing code as well as protocol stack and higher-layer applications. Our goal is to deliver an advanced set of features with technology optimized to address the IoT requirements: power, cost and size for massive IoT, and throughput, cost and latency for broadband and critical IoT. And for both, to deliver high reliability with advanced security algorithms at a competitive price.
As operators are expanding the 4G networks coverage and deploying 5G, the massive, broadband and critical IoT markets are frequently served with single-mode 4G LTE, or LTE-only, devices and with 5G devices that can fallback to 4G LTE. The completion of 3GPP Release 13/14 in 2016 ratified two new LTE categories targeting low power, low data-use machine-type communications to serve the massive IoT market. LTE-M (also known as LTE Cat M) and NB-IoT (also known as Cat NB) enable dramatically better power efficiency, reduced module costs and better coverage for massive IoT devices compared to high-speed LTE (targeting broadband speed). With the evolution in 3GPP release 15 of the standard moving to 5G, compatibility with 4G becomes a requirement. We believe we will be able to deliver dual mode (5G and 4G) products
27


leveraging all our past 4G development efforts and reinforcing our position in both the massive IoT and broadband and critical IoT spaces.
With our solutions we address the rapidly-growing 5G/4G massive IoT market with the NB-IoT and LTE-M technologies, which continue to be rolled out around the world. For 5G/4G massive IoT applications, Sequans provides a comprehensive product portfolio based on its flagship Monarch, Monarch 2 dual mode LTE-M/NB IoT, and Calliope and Calliope 2 Cat 1 and Cat 1 bis chip platforms, featuring industry-leading low power consumption, a large set of integrated functionalities, and global deployment capability.
We also address the broadband IoT market, mainly consisting of wide-area use cases that require higher throughput, lower latency and larger data volumes than massive IoT, as well as wide-area and local-area use cases with requirements for extremely low latency and ultra-high reliability. For 5G/4G broadband IoT applications, Sequans is offering products based on its Cassiopeia 4G Cat 4/Cat 6 platforms and is developing a high-end Taurus 5G/4G chip platform, both optimized for low-cost residential, enterprise, and industrial applications.
Note that many vertical applications, such as satellite, avionic, public safety and military are interested to leverage the cellular 5G/4G 3GPP standard to serve their markets. Using our 5G/4G platforms developed originally for the cellular IoT market segments described above, we address this market by offering software services to do the required modifications on such platforms in order to offer optimized solutions for these vertical applications.
Our product portfolio allows us to target the IoT market segments described above, with purpose-built, price/performance-optimized chipset solutions. This includes chips and modules that have the advantage to accelerate the time-to-market in some market segments.
Our 4G LTE solutions are currently or have been in commercial deployments in the United States, Canada, Italy, France, Germany, United Kingdom, Nordic countries, Eastern Europe, the Middle East, Indonesia, Malaysia, Philippines, Vietnam, Japan, China, Taiwan, South Korea, India, Australia, Brazil and elsewhere.
Our 4G LTE solutions have been incorporated into devices sold by many leading OEMs and ODMs, including in the Verizon Wireless Ellipsis Jetpack MHS900L portable router, the Telit Cinterion IoT (formerly Thales Gemalto) ELS31 LTE Cat 1 and EMS31 Cat M industrial M2M modules, the Renesas LTE Cat M RYZ024A and RYZ014A modules, the AT&T WNC Cat M IMS2 module and in a variety of devices and modules produced by Abeeway, AsiaTEL, Casa Systems, Connected Holdings, Daatrics, FlorLink, Foxconn, Gemtek, Geotab, Invoxia, Itron, Lockheed Martin, Multitech, Next Meters, Pebblebee, Polymer Logistics, Positioning Universal Inc, Quidel, Samea, Sercomm, SG Wireless, Tozed, Trackimo, Ubiik, Wistron NeWeb, Withings, and others.
Industry Background
Evolution of Wireless Networks
The use of wireless communications devices has increased dramatically in the past decade, and mobile phones and wireless data services have become an integral part of day-to-day communication. This has created demand for 4G and 5G broadband technology that can serve mobile devices such as smartphone but also that can serve all other non-handset devices such as routers and gateways that we refer to as broadband IoT devices. On top of this, the price point, size and low power consumption of the more recent 4G LTE variants, Cat 1, Cat 1bis, LTE-M and NB-IoT, are expected to facilitate a proliferation of massive IoT devices, such as those using our solutions for cellular connectivity, and further driving wireless data traffic and volumes of cellular devices.
The first version of the 3GPP LTE specification, Release 8, defined four User Equipment (UE) categories, or performance levels. UE Category 1 provides peak downlink speeds of 10 Mbps, and uplink of 5 Mbps. UE Category 2 provides 50 Mbps downlink and 25 Mbps uplink, while Categories 3 and 4 deliver 100 Mbps and 150 Mbps downlink, respectively, each with a peak uplink speed of 50 Mbps. In subsequent releases of the 3GPP LTE specifications, Releases 10 and later-called LTE-Advanced, additional improvements in features and performance were specified. The initial versions of LTE-Advanced can provide as much as 300 Mbps of downlink speed (3GPP Release 10 UE Category 6), with subsequent versions providing downlink speeds of up to 600 Mbps and peak uplink speeds of up to 100 Mbps (3GPP Release 12 User Equipment Category 12). Several UE Categories (16 and above, introduced as part of 3GPP Release 12 and 13) have specified speeds up to or exceeding one gigabit per second (Gbps). These higher speed categories involve aggregating multiple carriers, applying higher-order multiple input multiple output (MIMO) antenna technology, and more advanced modulation techniques. The highest LTE categories as defined in 3GPP Release 15 and used in practice, allow in downlink (among the 26 defined LTE downlink categories) up to 2Gbps (Category 20), and in uplink (among the 26 defined LTE uplink categories) up to 315Mbps (Category 20).
28


In 2016, the first operators began deploying network equipment using the variants of LTE optimized for massive IoT (LTE-M and NB-IoT). Operating in licensed spectrum, low power wide area networks can provide low cost, yet secure, connectivity to battery-powered devices in both rural and urban locations. Following successful pilots involving a wide variety of use cases, LTE-M and NB-IoTconnectivity has now been deployed across North America, Japan, most of the rest of the Asia-Pacific region and in many European countries. According to Global Mobile Supplier Association, 128 Cat NB-IoT and 60 LTE-M commercial network launches were already made around the world by September 2023.
In 2016 as well, major works were going on at 3GPP to add 5G to the cellular landscape through the introduction of New Radio (NR) which makes its entrance in Release 15. This is done through new waveforms and operation in a whole new set of bands. Some bands are referred to as sub-6GHz, or FR1 (frequency range 1), and span from 600MHz up to 7125MHz. The other bands are referred to as millimeter wave (mmwave), or FR2 (frequency range 2), and span today from 24GHz to 40GHz. Future expansions of those ranges may be considered. 3GPP Release 16 completes the initial specifications initiated in Release 15, and 5G continues evolving through the latest 3GPP Release 17. The 3GPP work on Release 17 closed in 2022 and Release 18 is now in process and expected to close by June 2024.
With respect to 5G, according to a report from the Global Mobile Supplier Association issued in January 2024, 302 operators in 113 countries/territories have launched commercial 5G services and 582 operators in 173 countries/territories have been investing in 5G, including trials, acquisition of licenses, planning, network deployment and launches.
The initial 5G device ecosystem was mostly made of smartphones as these can be launched before the operator achieves full deployment of their 5G network. We are now beginning to see devices to address fixed wireless access, including CPE, portable routers; and we expect that future devices will include mobile computing, and industrial applications. 5G generally has been described as targeting three main segments: enhanced mobile broadband (eMBB), massive machine type communications (mMTC), and ultra-reliable low latency communications (URLLC). The latter has been specifically addressed as part of 3GPP Release 16. This can be illustrated in the figure below with some application examples.
a5gfeaturestriangle.jpg
Wireless carriers are seeking to quickly transition existing wireless data services to more efficient 4G and 5G networks, which require less capital expenditure for a given amount of data throughput. At the same time, potential average revenue per account, or ARPA, can be increased by providing value-added mobile broadband services and solutions that are better enabled by the speed and performance of 4G and 5G networks.
Carriers in developing regions are increasingly embracing 4G wireless technology as a cost-effective and easier-to-deploy alternative to wireline networks for delivering broadband capability to subscribers. 4G wireless technology is being deployed in many of these developing regions to increase access to broadband services. This trend is expected to continue, especially as the higher 4G UE category implementations approach or even exceed gigabit per second performance levels. 5G deployment is becoming the natural next step in those regions when the technology matures and reaches mass market.
In addition to deployment driven by the wireless carriers, 4G and 5G technologies are considered for private networks applications leveraging unlicensed or semi-licensed frequency bands. Specifically, as the 3.5GHz CBRS band is currently
29


underused in the U.S., the Federal Communications Commission has opened 150 MHz in this band for access to licensed users with a Priority Access License and to registered users with General Authorized Access. The spectrum is also shared by incumbents who retain the right to use the band. CBRS enables 4G and 5G deployments in this band. Our broadband products have been supporting 3.5GHz devices worldwide for a decade, and we launched low-cost Cat 4 and Cat 6 modules that are cost-optimized for CBRS broadband IoT. These bands are also available in Europe, the Middle East and South Asia and are also considered for 5G deployment.

IoT Network Evolution
While increasing demand for mobile and fixed broadband connectivity is driving 4G and 5G technologies along a performance vector, the IoT market is pushing wireless technology along a different vector. Many machine-to-machine (M2M) and other low-power IoT applications are moving to LTE connectivity for its expected longevity, and because the technology is being optimized for reduced power consumption, improved coverage and lower cost. Many M2M connections are of the “set it and forget it” variety, and are expected to remain operational for ten or more years, sometimes powered by a battery. The overall surge in the number of mobile and M2M connections and the traffic they produce, coupled with the relative scarcity of available wireless spectrum, has prompted a number of operators, including AT&T in the United States and others in South Korea and Japan, to shut down their aging 2G networks so they can re-farm the spectrum for use with 4G LTE technology. This trend is also expanding in European countries and in Australia, with leading operators such as Vodafone and EE announcing their roadmaps to shut down 2G and 3G. As a result, many traditional M2M devices have evolved and replaced 2G by 4G LTE technology, using either Cat 4 (150 Mbps), or more generally Cat 1 (10 Mbps) category and/or LTE-M and NB-IoT (see illustration below).
Realizing the demand for low-throughput IoT applications, the industry introduced new variants of 4G LTE which are optimized for low power consumption and reduced complexity, rather than high speed, in order to address the needs of machine-to-machine and other connected objects in the IoT, i.e., the massive IoT. More specifically, 3GPP has defined LTE-based standards for Machine-Type Communications (MTC), introducing narrower bandwidths, reduced complexity, reduced throughput, improved coverage and reduced power modes to the LTE standard. These MTC features began to be introduced in 3GPP Release 12, with further additions and optimizations in Releases 13, 14, 15 and 16. The optimizations are summarized in the graphic below.
mtcoptimizations.jpg
3GPP Release 13, completed in mid-2016, introduced Cat M, also called LTE Category M1 or LTE-M, featuring 1.4 MHz bandwidth and peak speeds under 1 Mbps; and it also introduced a narrowband IoT (NB-IoT) category, also called Category NB1 or Cat NB, with 200 kHz bandwidth and peak speeds under 200 kbps. The 3GPP Release 14 completed in June 2017 added a higher data rate and multicast support, improved positioning and enhanced voice and mobility for Cat M. For Cat NB, Release 14 added positioning, exclusive chip identification, multicast and low power class (14Bdm). These categories provide excellent power efficiency, enabling years-long battery life for the devices they connect. They also provide superior network coverage and reduced module costs compared to their predecessor technologies, including traditional LTE, 2G and 3G. These technologies are compatible with existing LTE networks, generally via a software upgrade to the network infrastructure already deployed, and they can operate on the same spectrum already deployed by LTE operators. This combination of attributes is expected to drive significant demand for these technologies in M2M and other massive IoT applications. The graphic below depicts how various LTE categories might map to a range of IoT applications.
30


applicationsegmentation.jpg
The narrowband UE categories NB-IoT and LTE-M address most of the applications of the massive IoT market. Nevertheless, they do not replace the need for lower 4G LTE categories, like Cat 1 to address the higher category of the massive IoT devices where higher throughput and high-quality voice are required. Specifically, some applications in the wearable and hearable markets may require Cat 1 to support audio streaming and voice command and calls - features that cannot be served with narrowband LTE (LTE-M and NB-IoT). A new UE category, derived from Cat 1, has been introduced in Release 12 and fully completed in terms of requirements in Release 14: Category 1bis. This Category is very similar to Cat 1, but with a single receive chain, allows for chipsets and modules that can be designed at lower cost while keeping data rates of 10 Mbps in downlink and 5 Mbps in uplink: both LTE-M and NB-IoT categories have also been designed with a single receive chain, notably to help reducing the cellular LPWA module cost.
4G and 5G Wireless Networks
4G architecture represented a fundamental technological change from 3G and 2G in the design of wireless communication networks. 4G is now evolving in the framework of 5G.
4G, which employs concepts such as packet switching and internet protocol, or IP, improves the scalability and performance of data networks. Packet switching technology makes more efficient use of network capacity for data communication by transmitting data in packets over multiple shared connections as compared to a dedicated connection. OFDMA (a digital modulation and access technique) and MIMO have emerged as key technologies that increase efficient use of spectrum, signal reliability, throughput and range in 4G networks compared to 2G and 3G networks.
The throughput and range extension capabilities of OFDMA and MIMO technologies also enable infrastructure installations to cover a larger service area and provide increased network capacity, thereby reducing capital expenditures for wireless carriers.
4G LTE has become the dominant technology for 4G wireless broadband access. The GSA counted 824 commercial LTE networks (up from 817 one year earlier) around the world as of January 2024.
The rapid pace of deployment of LTE networks worldwide implies that in some regions, operators already have or are preparing to achieve LTE coverage at parity or better compared to their 2G or 3G coverage footprint. As of October 2023, ABI Research projected that the single-mode LTE IoT (Cat 1, LTE-M/NB-IoT) device market will grow at a CAGR of 18% between 2023 and 2028 to reach annual IoT device shipments of 593 million units in 2028.
5G further expands the principles of 4G, bringing two main values: higher throughput, and lower latency. This opens new opportunities for applications, ranging from gaming, to medical monitoring, and autonomous vehicles. MIMO techniques have been extended compared to 4G, and aggregated bandwidth is coming at a much larger scale. While 4G is mostly using aggregated bandwidth of 20, 40, or, in some rare cases 100MHz, 5G makes use of aggregated bandwidth up to 800MHz. The combination of powerful MIMO schemes and very large bandwidth allows for much higher throughput, in the range of several Gbps. Regulatory aspects have facilitated such a transition; spectrum is known to be a scarce resource. Beyond the re-farming of legacy spectrum (in the sub-6GHz range), new spectrum has been allocated in both this sub-6GHZ, and in the millimeter wave space (24GHz and above). Additionally, 5G was built so as to allow a smooth transition from 4G networks, with two main modes of operations: 5G Standalone (SA) for pure 5G operation and Non Standalone (NSA) for coexistence with 4G. This
31


specifically allows legacy devices already deployed to be smoothly integrated in a brand new 5G network. Some mechanisms, like Dynamic Spectrum Sharing (DSS), have been introduced so as to duplex - over time - 4G operation and 5G operation.
The figure below provides a simplified perspective on the evolution of wireless technologies providing ever-increasing performance:
a3gpprelease.jpg
Thanks to the technical evolutions behind 5G New Radio (NR), allowing for high peak data rate, high spectrum efficiency, mobility, and low latency, and hence enabling eMBB and URLLC, 5G is also growing the capability of the IoT space with dedicated evolutions for massive machine type evolutions, through constant additional features over LTE-M and NB-IoT.
Starting in Release 17 with its Reduced Capability (RedCap) category of devices, 5G NR is also trying to address, through NR, the “lower” data rates below 300Mbps, providing an NR solution to replace the legacy LTE Cat 6 and Cat 4. This approach is being pursued as part of 3GPP Release 18 with an evolution of RedCap (eRedCap) that provides capability for an optimized solution addressing the capabilities of an LTE Cat 1 solution today.
Challenges Faced By 4G/5G Wireless Semiconductor Providers
Suppliers of 4G and 5G semiconductor solutions face significant challenges:
Execution Challenges. The rapid evolution of wireless protocols, such as 4G LTE, 4G LTE Advanced and 5G NR, requires sustained product development excellence and ongoing collaboration with carriers to meet market technology needs. Subscriber demand and carriers’ push to increase revenues by providing new and higher performance devices have driven OEM and ODM product life cycles to become shorter and require semiconductor solution providers to adhere to quick time-to-market schedules while providing fast and efficient transition from design-in to volume production. Typical design cycles range from six months for consumer electronics devices up to two years or more for industrial or automotive applications. In addition, wireless carriers require semiconductor solutions to undergo extensive certification qualification and interoperability testing prior to mass production.
Technology Challenges. In order to increase throughput with minimal cost, wireless carriers require more efficient use of spectrum through the implementation of complex signal processing algorithms, such as OFDMA with always higher modulation schemes, advanced MIMO, carrier aggregation and millimeter wave support, that require a significant amount of system-level and software expertise in addition to IC design knowledge. In addition, OEM and ODM customers’ desire for continuous improvements in power efficiency, reduced form factor and lower cost require rapid design cycles employing increasingly advanced silicon processes, improved RF transceiver performance and integration of additional features.
Semiconductor Supply Constraints. Periodically, worldwide component shortages have created significant obstacles to on-time production and have resulted in cost increases and/or increases in lead times for components. As an example, supply of silicon wafers from our single-source supplier was put on allocation in 2021 and in 2022. The situation required us in some cases to qualify new sources of supply. In other cases, we, as well as some of our customers, purchased more inventory than required in the short-term, in order to ensure adequate supply over the following quarters. In 2022, as supply constraints lessened, many companies in the supply chain found themselves with excess inventory, resulting in lower purchasing as inventories were worked down.
32


Our Competitive Strengths
We believe the following competitive strengths enable us to address the challenges faced by 4G and 5G wireless semiconductor providers:
A strong track record of execution in 4G, that we are leveraging for 5G. We believe we are well positioned in the 4G LTE market, with more than 70 end customers having already launched or in the development phase of products using Sequans LTE chipsets, and in particular, we are a recognized innovator and leader in LTE for IoT chipsets. We have released many generations of 4G/5G chips from WiMax to LTE that have been deployed in a variety of devices including smartphones, USB dongles, tablets, mobile routers, broadband access CPEs, in-car telematics devices, smart meters, eHealth/well-being applications, and other industrial and consumer IoT devices. In the past three years, we have accomplished the following milestones:
in December 2021, Monarch 2 becomes first Common Criteria EAL5+ certified cellular platform;
announced in December 2021, availability of GNSS positioning technology on Monarch 2 platform;
in December 2021, introduced Cat 1bis modules based on second-generation Cat 1 chip, Calliope 2;
in August 2022, executed a multi-year, strategic 5G licensing agreement in excess of $50 million;
introduced in November 2022, jointly with Skyworks Solutions, Inc., a SiP (system-in-package) solution combining Sequans’ Monarch 2 modem with Skyworks’ radio front-end solution, creating the world’s smallest LTE-M/NB-IoT connectivity platform in a single package;
in April 2023, introduced in collaboration with Anterix, the Cassiopeia CA410 LTE Cat 4 multi-band module for public and private networks in North America; and
in May 2023, introduced the Taurus 5G NR, the world's first chipset specifically optimized fro 5G Broadband IoT devices..
Understanding of wireless system-level architecture and expertise in signal processing. We have an end-to-end understanding of wireless system-level architectures and networks based on our team’s experience in a broad range of wireless technologies. This enables us to serve as a trusted advisor to wireless carriers, OEMs and infrastructure vendors to optimize the performance of their 4G and 5G devices and networks. For example, our solutions offer improved standby-mode battery life in wireless devices as a result of our in-depth understanding of the interactions between the device and the network and of our implementation of advanced power-saving techniques in our solutions. We have implemented a proprietary technique called Dynamic Power Management in our Monarch chip that assures the longest possible battery life for IoT devices by dynamically adapting the chip’s deep-sleep implementation to the traffic patterns of various IoT use cases. We have also implemented another proprietary technique called eco-Paging that allows very low power consumption while maintaining a good level of reachability for the IoT device. We also leveraged our signal processing know-how to embed new functionalities such as GNSS. Security, which is at the heart of the IoT devices, has also been strengthened in our Monarch 2, embedding a Common Criteria EAL5+ secure enclave. We also invest into enabling our customers to benefit from an integrated development environment on our Monarch 2 platform.
High performance solutions for 4G and 5G applications. Our solutions offer high performance for use in a wide array of wireless devices. The key performance characteristics of our solutions include:
high throughput with peak downlink data transfer rates of 150 Mbps and 300 Mbps in our 4G LTE and LTE-Advanced solutions, which is now evolving to up to 2 Gbps in our 5G Taurus chipset product portfolio with support of 5G NR with fallback to high-category 4G LTE;
high power efficiency in both active and idle modes using our patented idle mode optimization algorithms that improve standby time and help maximize device battery life;
support for LTE-Advanced features, including carrier aggregation, a capability of creating a single virtual wide channel from two or more different narrower channels, resulting in higher throughput;
integration of complete on-chip support for Voice over LTE (VoLTE), including support for high-definition voice using wideband codecs;
support for LTE-Advanced technology band 48 for CBRS solutions available through two of our LTE modules;
support of integrated secure element function and iSIM for better end-to-end security and built-in MNO/MVNO data plans;
integrated RF and Baseband functions in single die optimizing power consumption and reducing solution cost and size;
development and integration of specific high doppler tolerant algorithms to allow for in-plane connectivity, and efficient LTE-to-satellite communication schemes for breakthrough in mobility and connectivity for satellite services;
33


development of Cat 1bis technology to address the cost and power consumption barriers that we believe have inhibited widespread use of 4G in wearables and consumer applications, as well as traditional IoT voice-oriented applications such as alarm systems;
support of outdoor location services with embedded GNSS functionality, allowing an efficient cost structure of our customers, while enabling very low power applications requiring positioning; and
support of an embedded applications environment.
Highly optimized 4G and 5G solutions. We have successfully produced and ramped into commercial production multiple generations of 4G system-on-chip, or SoC, semiconductor solutions. We delivered the first cellular technology (Cat 1 and LTE-M) for massive IoT, and we began delivering the second generation dual mode LTE-M/NB-IoT for this segment in 2021. We expect to ramp up in 2024 our Cat 1bis platform, the second generation Cat 1 solution. This experience has resulted in what we believe to be one of the industry’s most efficient implementations, providing high performance at low cost and low power consumption. Some of our solutions have integrated the baseband processor and the RF transceiver into a single die, resulting in extremely high integration, small footprint and low cost. We developed and launched our second-generation Cat M chipset, the Monarch 2 that provides major improvement in power and cost with new advanced features. Furthermore, our comprehensive software solutions help our customers get to market quickly with an optimized, mature and field proven solution. Our highly optimized solutions offer key advantages for both ourselves and our end customers:
Lower overall system cost for our end customers, coupled with higher functionality and smaller form factor. Our ability to integrate digital and RF functions into a single device also allows us to maintain higher product margins as we believe device manufacturers are willing to pay a premium for our integrated 4G solutions, while also enabling us to reduce our manufacturing costs for wafer fabrication, assembly and testing.
The implementation of advanced “known good die” and wafer-level chip-scale packaging (WLCSP) technology, which reduces chip cost and design footprint, enables the creation of very small and cost-effective LTE modules.
Simplified product design for device manufacturers, as our solutions incorporate all key components required for a 4G device in a single die or package. We believe these advantages enable our products to be incorporated into leading edge devices that offer a high-quality user experience, as well as accelerate our end customers’ time-to-market.
Proprietary embedded protocol software that has been exhaustively tested with major base station vendors’ equipment to ensure reliable performance in the field. We also offer host software that facilitates rapid development of high performance device drivers, connection managers and other key application-layer software functionality.
Provide lowest power consumption with 1µA PSM and eco-Paging™ for optimized Extended Discontinuous Reception (eDRX), a feature that allows IoT devices to remain inactive for longer periods.
Optimized dual-mode Cat M/NB-IoT operation.
VoLTE support for integrated voice.
GNSS positioning.
Common Criteria EAL5+ certified cellular platform.
Long-term relationships with wireless carriers. We have developed close relationships with wireless carriers around the world, helping them to test their new networks and specific features of those networks. We believe these relationships are critical to being able to certify our products quickly and to help our customers to certify and deploy their products efficiently.
Our Strategy
Our goal is to be a leading provider of next-generation wireless semiconductors for broadband, critical and massive IoT by providing best-in-class solutions that enable mass-market adoption of 4G and 5G technologies worldwide. Key elements of our strategy include:

Identifying and optimally serving 4G and 5G market segments. As cellular operators continue to build out their 4G LTE and 5G NR networks and re-farm their 2G and 3G spectrum to support demand for data capacity, we expect to see significant growth in the demand for 4G LTE-only, 5G and 5G with 4G fallback devices. In our estimation, this demand is expected to come from three areas:
1)Massive IoT devices: massive IoT refers to the universe of connected objects that together result in very large number of connections, small data volumes, low-cost devices and stringent requirements on energy consumption. While a large number of IoT connections are expected to use WiFi, Bluetooth or some other local-area or personal-area networking technology, there are many applications for wide-area connectivity which can be
34


addressed by cellular networks. Applications for cellular connectivity include smart utility meters, security, asset tracking, mobile/remote healthcare, industrial automation and monitoring, retail, smart cities, consumer wearables, agriculture and environmental monitoring, and more. This trend toward the use of 4G LTE in the massive IoT market began with the arrival of cost- and power-optimized Category 1 LTE solutions in 2015, and is accelerating with the arrival of machine type communications (MTC)-optimized 3GPP Release 13/14/15 LTE solutions, which define Cat M and Cat NB user equipment categories. In 2021, we also observed a slower than expected adoption of NB-IoT in several regions, notably in Japan (which appears to be abandoning NB-IoT networks), in Europe (developing LTE-M on top of NB-IoT), and even in China (where some applications are progressively turning to higher data rate Cat 1bis vs. lower data rate NB-IoT). On the other hand, LTE-M has been steadily growing, and new generation Cat 1 and Cat 1bis have been on the rise. Our massive IoT product family is composed of our world-first Calliope Cat 1 LTE chipset platform, announced in January 2015, certified and shipping in commercial products. Monarch, the world’s first Cat M/NB chip, was announced in February 2016, certified in 2017 and is shipping in devices for Verizon, AT&T, as well as carriers in Japan, Europe, Australia, and Canada. Monarch 2, the 5G-ready Cat M/NB evolution of our Monarch flagship platform, is now contributing to our massive IoT offering with additional benefits in terms of cost, power saving, and integrated features such as an application development environment, GNSS, and iUICC. The introduction of Calliope 2, our Cat1bis chip, should enable us to gain market share in wearable and consumer application as well to support existing IoT applications, such as smart home and smart metering, that require higher bandwidth than Cat M.
2)Broadband IoT devices: broadband IoT adopts the capabilities of Mobile Broadband connectivity for IoT by providing much higher data rates and lower latencies than for massive IoT, while optimizing the technology for non-smartphone devices. Mobile routers, also called mobile hotspots, provide convenient, on-the-go Internet access via WiFi for users in homes, offices, hotel rooms, vehicles and outdoor locations. Fixed-location (non-mobile) routers (also sometimes generically called broadband wireless CPE, or customer premise equipment) provide broadband Internet access for residential and industrial applications. Critical IoT refers to Ultra-Reliable Low- Latency Communications (URLLC) introduced by the 3GPP standard in the scope of the 5G and that we plan to support in our Taurus platform. Here the promise is to reduce latency as an important feature for both residential and industrial applications, such as gaming and robotic. Solutions based on our Cassiopeia LTE-Advanced platform (including our CBRS modules), and our 5G Taurus platform are optimized to address these types of devices.

Accelerating our, and our customers’, time to market and reducing our customers’ development costs. By packaging our LTE semiconductor solutions in a complete, turnkey module form factor and certifying them with key wireless carriers, we have been catalyzing the market for cellular devices, speed time to market for customers wishing to incorporate connectivity in their devices and reduce the cost and complexity for our customers. In 2021, we announced our new generation Calliope 2 and related modules for Cat 1 devices, which is expected to move into mass production in 2024. Moving forward, we are improving our customer time-to-market by integrating features that allow customers to forego using additional external components such as a SIM Card (with our iUICC feature), a microcontroller (with our on-platform development environment), and a GNSS component (with our GNSS functionality on our modules). Furthermore, we facilitate cellular technology adoption with all documentation easily available on our customer portal, and further service enablers for our partners (for device management or connectivity services).

Leveraging our multiple generations of 4G chip design experience to become a leader in advanced 4G and 5G technology and cost efficiency. The cost and power efficiency achieved from our many generations of 4G modem design has enabled us to deliver our family of products at attractive price points, enabling LTE connectivity to be embedded in a wide range of cost-sensitive IoT applications in both consumer and machine-to-machine applications. The most recent members of our massive IoT family are the 4G/5G chips, Monarch 2, and Calliope 2, with increasing level of integration and features.

Partnering with other leading technology companies to complement our technology offerings. We regularly collaborate with ecosystem partners who provide complementary technology or strengthen our capabilities to address customer needs and competitive pressure. In 2020, we engaged a collaboration with Renesas across our entire product portfolio that will enable Renesas to sell M2M modules based on Sequans chipsets in combination with their own semiconductor offerings. We believe these collaborations will allow us to address the mass market in an effective way and acquire customers which were not yet cellular connected but were integrating Bluetooth and WiFi connectivity. We are also partnering with MVNOs to enable new potential customers using multi-region coverage. We have signed worldwide distribution contracts with Avnet, Digi-Key, Mouser Electronics and Richardson RFPD. This will facilitate access to our technology through the distributors’ wide go-to-market presence.

35


Our Solutions
We have developed a portfolio of 4G and now 5G semiconductor solutions to address a variety of applications and market segments. We offer baseband solutions used to encode and decode data based on 4G and 5G protocols that serve as the core wireless processing platform for a cellular device; RF transceivers used to transmit and receive wireless transmissions; and highly integrated SoC solutions that combine these and other functions into a single die or package. Some of our SoC solutions integrate the baseband and RF transceiver functions, in some cases with an applications processor and memory. This advanced integration reduces the size, cost, design complexity and power consumption of cellular solution. We offer a family of LTE modules that vastly simplify the task of embedding LTE connectivity for device makers lacking cellular experience. This helps us expanding our options in adjusting our business model on case-by-case basis.
All of our baseband, SoC products and modules are provided with comprehensive software, including relevant source code and tools, to enable manufacturers to easily integrate our solutions into their devices in a wide variety of environments. In addition, we provide our customers with design support, in the form of reference designs that specify recommended methods for interconnecting our chips to surrounding devices, such as host processors, memory and RF front-end components as well as tools to integrate with products from major automatic test equipment vendors.
Our primary chipset products during the last three financial years are summarized in the table below. For each baseband chipset, we have a number of modules available as well.
Platform Name
Chipset ID
Family
Description
Broadband IoTMassive IoTKey Features
Monarch
SQN3330
LTE Release 13/14
SoC
*LTE UE Category M1 and NB1 supported; Baseband, RF transceiver, memory and power management integrated in a single package; power optimized for IoT applications requiring lower throughput.
Modules based on this chipset: GM01Q
Monarch 2
SQN3430
LTE Release 14/15 dual-mode LTE-M/NB-IoT
SoC
*
Highly integrated chip with extremely low power consumption, supporting power class 3 (23 dBm) and lower (20, 14 dBm), with an integrated MCU with Sensor-Hub Mode Secure element & iUICC, EAL5+ security government grade.
 Modules based on this chipset: GM02S, GM02SP
MonarchSiP
SQN66430
SKY66430
LTE Release 13/14 SiP
*
Ultra-compact complete LTE System in Package; integrated baseband, RF, pSRAM, power management, front-end and passives.
Designed in collaboration with Skyworks.

Monarch 2 SiP SQN66431
SKY66431
LTE Release 14/15 dual-mode LTE M/NB-IoT
SiP
*
Second generation of Ultra-compact complete LTE System in Package; integrated baseband, RF, pSRAM, power management, front-end and passives; eco-Paging™ for optimized eDRX; power class options 20 and 23dBm; integrated MCU, Secure element & iUICC, EAL5+ security grade, GNSS support.
Designed in collaboration with Skyworks

Calliope
SQN3223
LTE Release 9/10
BB
*
10Mbps CAT 1 peak throughput, USB and HS UART interfaces, integrated processor, cost- and power-optimized for IoT and M2M applications requiring lower throughput.
Modules based on this chipset: US130Q, VZ120Q

36


Colibri / Calliope
SQN3241
LTE
RF
**
Supports 700-900MHz and 1.8-2.7GHz, up to 20 MHz bandwidth. WLCSP.
Modules based on this chipset: VZ22Q/US30Q/EU40Q
Calliope 2
SQN3520
LTE Release 14/15 SoC*
Cat 1bis SoC, A-CPU, Audio, secure enclave, iUICC (40nm) technology. Baseband, RF, power management and memory integrated in one chip platform. Significant improvement in power consumption. Integrated secure enclave with EAL5 level of security.
Module family based on this chipset: GC02S1
Cassiopeia
SQN3220/ SQN3220sc
LTE-Advanced Release 10 BB*
LTE Cat 4 / Cat 6 with carrier aggregation up to 20 + 20 MHz
Modules based on this chipset: CB410 / CB610

Cassiopeia
SQN3240/SQN3242/SQN3244
LTE RF*
Supports FDD and TDD 700 MHz - 2.7 GHz, up to 20 MHz bandwidth
Modules based on this chipset: CB410L/CB610L
Taurus
SQN5006

5G NR Release 17
SA and NSA
Baseband SoC
*2 Gbps 5G NR broadband speed
Frequency range: 600-7126 MHz (FR1)
SA, NSA and CA for global deployment, LTE fallback
Dual-core Application Processor for smart edge application High speed interface (including ethernet)
Abbreviations used in this table: BB = baseband processor, nm = nanometer, dBm = decibels; iUICC = integrated Universal Integrated Circuit Card; MCU = micro controller unit; PMIC = power management IC; RF = radio frequency transceiver, SDRAM = Synchronous Dynamic Random Access Memory, SiP = system in package, SoC = system-on-chip, VoLTE = Voice over LTE.
Competition
The wireless semiconductor business is very competitive. We believe that our competitive strengths will enable us to compete favorably in the 4G and 5G markets. The following are the primary elements on which companies in our industry compete:
functionality, form factor and cost;
product performance, as measured by network throughput, signal reach, latency and power consumption;
software maturity and carrier certification coverage;
track record of providing high-volume deployments in the industry; and
systems knowledge helping customers to optimize their products.
We face competition from established semiconductor companies such as Huawei HiSilicon, Mediatek, Qualcomm Incorporated, Samsung Electronics Co. Ltd., Sony Corporation, ASR Micro and Unisoc, as well as smaller actors in the market such as GCT Semiconductor and Nordic Semiconductor.
The larger competitors have longer operating histories, significantly greater resources and name recognition, and a larger base of existing customers than us. In addition, some of them may provide incentives to customers or offer bundled solutions with complementary products, which could be attractive to some customers, or adopt more aggressive pricing policies to offset what we believe are the performance and cost advantages of our solutions.
Business Development, Sales, and Marketing
Our business development efforts are focused on developing relationships with wireless carriers to identify the market opportunities in general. Often with broadband IoT business, the carriers have their own product to launch, in this case our sales
37


efforts are focused on determining which OEMs and ODMs are most likely to win in the various carrier product opportunities and securing design wins. With massive IoT, the carriers are often a partner providing the data plan service and our customers are major OEMs or ODMs addressing the various applications of massive IoT, e.g., metering, asset tracking, alarms etc. In this case, we engage with the end customers directly or via our module partners, technology partner or distributors to develop relationships and promote our solutions. We work closely with key players across the wireless industry to understand their requirements and enable them to certify and deploy cellular solutions in high volume.
Our business development team is organized regionally and by wireless carrier. In addition to identifying new business opportunities based on the wireless carriers' product launch plan, the business development team also works to understand the wireless carriers’ future technological requirements, so that we can incorporate appropriate features in our product roadmap. We have a business development team of both dedicated employees and outside contractors.
Our sales force is organized regionally to provide account management and customer support functions as close to customer physical locations as practical. As of December 31, 2023, we had a direct sales force serving our OEM and ODM customers in the Asia-Pacific region, including Taiwan, China, and Japan; Europe; the Middle East and North America. In the United States, Brazil and Israel, we have supplemented our direct sales team with sales representatives who help with sales enablement, lead generation, customer communications and customer support functions. We have continued to reinforce our go-to-market capabilities by expanding our new distributor channels implementation, including the four worldwide agreements with Avnet, Digi-Key, Mouser Electronics and Richardson RFPD. These agreements encompass lead generation and support as well as fulfillment. To further the reach of our sales channels, we are collaborating with microcontroller vendors like Renesas, Microchip and NXP, to develop IoT design kits that provide us the scale of these large corporations and also help their existing end customers easily integrate our products while keeping their software legacy intact. They are useful to address the massive IoT market as the numbers of applications and potential customers are very large.
Our sales force works closely with a team of technical support personnel. This team assists customers in solving technical challenges during the design, manufacturing implementation and certification phases of a customer’s product life cycle. The information obtained from customer support is then communicated back to the direct product development teams to be considered in future software releases or hardware development. This high-touch approach allows us to facilitate the successful certification and acceptance by the wireless carriers of our customers’ products, which speeds time-to-market for our customers and reinforces our role as a trusted advisor to our customers.
Our sales cycles typically take 12 months or more to complete and our solutions are generally incorporated into our customers’ products at the design stage. Prior to an end customer’s selection and purchase of our solutions, our sales force and technical support engineers provide our end customers with technical assistance in the use of our solutions in their products. Once our solution is designed into a customer’s product offering, it becomes more difficult for a competitor to sell its semiconductor solutions to that end customer for that particular product offering given the significant cost, time, effort and risk involved in changing suppliers. In addition, once we win a particular design with an end customer, we believe our ability to penetrate other product families at that end customer increases significantly.
Our marketing strategy is focused on enabling broad adoption of 4G and 5G solutions and communicating our technology advantages to the marketplace. This includes building awareness of and preference for our technology at wireless carriers who generate demand for 4G- and/or 5G-enabled devices. By working to understand carrier services strategies, device roadmaps and technical requirements, we believe we are better positioned to drive our roadmap to meet these needs, to influence their choice of technology suppliers, and to identify manufacturers in the wireless industry who are best prepared to serve the needs of the wireless carrier. Our technical and business relationships with AT&T, ChungHwa Telecom CHT, Deutsche Telekom, KDDI, NTT DoCoMo, Orange, Softbank, Spark Networks, T-Mobile, Telefonica, Telenor, Telstra, Verizon Wireless, Vodafone and other operators have allowed us to anticipate requirements and develop solutions tailored for their respective networks, which helped us secure several design wins and launch multiple products. Our Monarch and Monarch 2 chipsets and module offerings have been certified by AT&T, T-Mobile, Verizon, Sprint, NTT DoCoMo, Softbank, KDDI, Telstra, LG U+, Deutsche Telekom, Telus, Orange, Vodafone, CHT, Firstnet, Spark Networks — as well as certified with most global and regional industry and regulatory bodies (GCF, PTCRB, FCC, IC/ISED, ACMA, UKCA, RED, NCC, JATE, TELEC). In addition to these carrier relationships, Sequans has expanded its customer designs in 2022 and 2023 with names such as FlorLink, Geotab, Infrafon, Invoxia, Itron, Next Meters, Ubiik, WiThings. We also announced, and subsequently expanded to include the entire Sequans product line, our partnership with Renesas, in addition to partnerships on massive IoT solutions with NXP and Microchip for integrating our solutions with these microprocessors giving us access to their IoT customers.
Our marketing team is also responsible for product management, strategic planning, product roadmap creation, OEM, ODM and wireless carrier business development and corporate communications. All of these functions are aimed at strengthening the competitiveness of our solutions in response to evolving industry needs and competitive activities, and at articulating the value proposition of our technology throughout the 4G and 5G wireless industry. Our business development, sales and marketing organizations work closely together to ensure that evolving industry requirements are reflected in our
38


product plans, and that customers have early access to our roadmaps and can communicate the value of our technology to the wireless carriers. This end-to-end value chain management approach is designed to grow and preserve our market share in the segments we serve.
As of December 31, 2023, we had 45 employees and five outside contractors in our business development, sales, customer support and marketing teams.
Customers
We maintain relationships with 4G and 5G wireless carriers and with OEMs and ODMs who supply devices to those carriers and their end users. We do not typically sell directly to wireless carriers, except from time to time in the context of selling services to enable new technologies or markets being developed by the carrier. Our sales are conducted on a purchase order basis with OEMs, ODMs, contract manufacturers, system integrators, or distributors (who provide certain customer communications, fulfillment and customer support functions).
Our top ten customers accounted for 92%, 95% and 92% of our total revenue in 2021, 2022 and 2023, respectively. Our strategic partner based in China accounted for 33% of our revenue in 2022 and 56% in 2023. A distributor serving multiple end customers in China and Taiwan, accounted for 23% in 2021 and less than 10% of our revenue in 2022 and 2023. Our oldest strategic partner, a Fortune Global 500 company, represented 23%, 14% and less than 10% of our revenue in 2021, 2022 and 2023, respectively. Another strategic partner accounted for 13%, 11% and 16% of our revenue in 2021, 2022 and 2023, respectively. The following is a list of our top ten customers (names given when we have permission), in alphabetical order, based on total revenue during 2023:
•    Anterix
 
•    Asiatelco
 
•    Geotab
 
•    Next Century Meters
 
•    Renesas Electronics
•    RFPD
 
•   Telit Cinterion Deutschland GmbH
 
•   Verizon Wireless
 
•   WiThings
 
•   Strategic partner (China)
Manufacturing
We operate a fabless business model and use third-party foundries and assembly and test contractors to manufacture, assemble and test our semiconductor solutions.
Our sole foundry vendor is TSMC, and we use their commercially available mature standard 65nm and 40nm, standard RF, mixed-signal and digital CMOS foundry processes to enable us to produce our products more cost-effectively. We use well-known outsourced semiconductor assembly and test (OSAT) suppliers such as Advanced Semiconductor Engineering ChungLi (ASECL), STATS ChipPAC Limited and Silicon Precision Industries Limited (SPIL) for most of our chipset assembly and testing. We use Asiatel Technologies Co., Foxconn (Hon Hai Precision Industry Co., Ltd.) and BYD Electronic International Co Ltd. for manufacturing of our modules.
We generally manufacture to our internal sales forecasts and fill orders as received. We do not have manufacturing agreements with our foundry or with our testing and packaging or module vendors, other than agreements with Asiatel, Foxconn and BYD, and we place our orders with our foundry and other vendors on a purchase order basis. See “Risk Factors—Risks Related to Our Business and Industry”.
We strive for continuous improvement in manufacturing processes to deliver year-on-year improvement in output, cost and product quality. We closely monitor the overall production cycle from wafer to finished goods through statistical analysis of the manufacturing data. We also run routine reliability monitoring programs to ensure long term product reliability. This enables us to operate certain test processes on demand to reduce the time-to-market for our products and to help ensure their performance, quality measures, including customer feedback and reliability.
Our quality management system is based upon the requirements of ISO 9001. We are ISO 9001 (2015) certified, and all of our major suppliers and subcontractors are required to have quality management systems certified to ISO 9000 and ISO 14000 levels, as well as appropriate environmental control, corporate social responsibility and sustainability programs.
We also comply with RoHS and REACH requirements. We perform regular routine supplier audits to ensure that our suppliers meet the required quality standards.

39


Intellectual Property
We rely on a combination of intellectual property rights, or IPR, including patents, trade secrets, copyrights and trademarks, and contractual protections, to protect our core technology and intellectual property. At December 31, 2023, we had 53 issued and allowed United States patents, 18 European patents, and 8 pending United States patents. The first of our issued and allowed patents is not expected to expire until 2025.
In addition to our own intellectual property, we have also entered into a number of licensing arrangements pursuant to which we license third-party technologies and intellectual property. In particular, we have entered into such arrangements for certain technologies embedded in our semiconductor, hardware and software designs. These are typically non-exclusive contracts provided under royalty-accruing or paid-up licenses. These licenses are generally perpetual or automatically renewed for so long as we continue to pay any royalty that may be due and in the absence of any uncured material breach of the agreement. Certain licenses for technology used for development of a particular product are for a set term, generally at least two years, with a renewal option, and can be easily replaced with other currently available technology in subsequent product developments. In the event that such licenses are not renewed, they nevertheless continue with regard to products distributed in the field. Except for our licenses to the so called “essential patents” described below, we do not believe our business is dependent to any significant degree on any individual third-party license.
In the past, we have entered into licensing arrangements with respect to so called “essential patents” that claim features or functions that are incorporated into applicable industry standards and that we are required to provide in order to comply with the standard. We may be required to enter into such licensing arrangements in the future in order to comply with applicable industry standards, in particular with respect to the sales of our module products, which have full 4G or 5G functionality. We believe that general practice in the industry is that essential patent holders’ licensing policy is to license only to licensees selling a full 4G or 5G product, not to component vendors.
In 2015, we entered into an agreement to license the patent portfolio of Gemalto S.A., including at least one patent which may be considered essential for the LTE standard.
Facilities
Our principal executive offices are located in Colombes, France, consisting of approximately 21,625 square feet under a lease that expires in May 2029, but which may be terminated in May 2026. This facility accommodates our principal research and development, product marketing, and finance and administrative activities.
We have a 7,843 square-foot facility in Winnersh Triangle, England, which accommodates a research and development center under a lease expiring in October 2025. We have a 4,884 square-foot facility in Ramat Gan, Israel, which houses a research and development center, under a lease that expires in December 2024, with the option to renew. We have a 1,600 square foot office in Singapore under a lease expiring in February 2025. We have a 2,318 square-foot facility in Burnsville, Minnesota for engineering personnel under a lease that expires in January 2025. We have a 645 square-foot facility in Salo, Finland under a lease that expires in November 2024. We rent additional office space in Taipei, Taiwan; Shanghai and Shenzhen, China; Seoul, South Korea and in Bedminster, New Jersey under short-term lease agreements, and in Sophia-Antipolis, France under long-term lease agreements.
We do not own any real property. We believe that our leased facilities are adequate to meet our current needs and that additional facilities will be available on suitable, commercially reasonable terms to accommodate any future needs.
C.
Organizational Structure
The Company is the ultimate parent of the group comprised of the Sequans Communications S.A. and its subsidiaries at December 31, 2023:
NameCountry of
incorporation
Year of
incorporation
% equity
interest
Sequans Communications Ltd.United Kingdom2005100
Sequans Communications Inc.United States2008100
Sequans Communications Ltd. Pte.Singapore2008100
Sequans Communications Israel (2009) Ltd.Israel2009100
Sequans Communications Finland OyFinland2020100
Sequans Communications SAS (inactive)France2023100
        
40


D.
Property, Plants and Equipment
For a discussion of property, plants and equipment, see “Item 4.B—Business Overview—Facilities.”

Item 4A. Unresolved Staff Comments
Not applicable.

Item 5. Operating and Financial Review and Prospects

Summary
We are a fabless designer, developer and supplier of semiconductor solutions for broadband, critical “Internet of Things” (IoT) and massive IoT applications. Our solutions incorporate baseband processor and radio frequency, or RF, transceiver integrated circuits, or ICs, along with a front end subsystem and our proprietary signal processing techniques, algorithms and software stacks. Our high performance ICs deliver high throughput, low power consumption and high reliability in a small form factor and at a competitive price.
We shipped 1.5 million semiconductor units during 2023, compared to 3.4 million units during 2022,and 3.8 million units during 2021. Our total revenue was $33.6 million in 2023, $60.6 million in 2022 and $50.9 million in 2021.
We currently have more than 70 end customers worldwide, consisting primarily of OEMs and ODMs for modules, telematics devices, tracking devices, security devices, CPE, home routers, mobile routers, embedded devices and other data devices. We derive a significant portion of our revenue from a small number of end customers, and we anticipate that we will continue to do so for the foreseeable future. We do not have long-term purchase agreements with any of our end customers, and substantially all of our sales are made on a purchase order basis. We expect that the percentage of revenue derived from each end customer may vary significantly due to the order patterns of our end customers, the timing of new product releases by our end customers, and consumer demand for the products of our end customers. Customers representing more than 10% of total revenue in any of the years 2021, 2022 or 2023 and their locations are as follows:
CustomerCustomer Location% of total revenue for the year ended
December 31,
 202120222023
AChina—%33%56%
BJapan13%11%16%
CGermanyLess than 10%24%Less than 10%
DAmerica23%14%—%
ETaiwan23%Less than 10%Less than 10%
FChina14%Less than 10%Less than 10%
Our Consolidated Financial Statements for 2021, 2022 and 2023, have been prepared in accordance with IFRS as issued by the IASB.

Recent Developments
On August 4, 2023, we entered into a Memorandum of Understanding (the “MoU”) with Renesas Electronics Corporation, a Japanese corporation (“Renesas”). The MoU provided, among other things, that Renesas and the Company engage in a series of transactions pursuant to which, among other transactions, Renesas would seek to acquire (through an affiliate) all of the issued and outstanding ordinary shares for $0.7575 per ordinary share and $3.03 per ADS.
On September 26, 2023, we entered into a Securities Purchase Agreement with 272 Capital Master Fund, LTD, a fund affiliated with Wes Cummins, a director of the Company, to issue an aggregate of 2,120,141 American Depositary Shares at a price of $2.83 per ADS for a total capital increase of $5,999,999. The private placement closed on September 29, 2023, and we used proceeds of the private placement to partially fund operations.
41


On November 8, 2023, we entered into a Security Purchase Agreement (the “Purchase Agreement”) with Renesas Electronics America Inc., (“Renesas America”) a wholly owned subsidiary of Renesas, providing for the issuance of an unsecured subordinated note in an aggregate principal amount of $6 million. The transaction closed on November 8, 2023. On December 27, 2023, we entered into a second Security Purchase Agreement with Renesas America providing for the issuance of an additional unsecured subordinated note in an aggregate principal amount of $3 million. The transaction closed on December 27, 2023. On February 12, 2024, we entered into a third Security Purchase Agreement with Renesas America providing for the issuance of an additional unsecured subordinated note in an aggregate principal amount of $9 million. The transaction closed on February 12, 2024.

On February 22, 2024, Renesas notified us that Renesas was terminating the MoU due its receipt of an adverse Japanese tax ruling on February 15, 2024 from the National Tax Agency of Japan. We incurred a significant amount of debt to operate our business during the pending tender offer, and our business suffered due, in part, to uncertainty raised by the pending acquisition. The termination of the MoU has created significant liquidity concerns and raised substantial doubt about our ability to continue to operate absent a new strategic transaction or financing in the near term. We were not able to pay our outstanding convertible notes due in April 2024. On April 9, 2024, we secured standstill agreements from our three main debt holders. The agreements granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met; the request for the extension of the agreements is in process as of this date, however there can be no assurance of the length of the extension, if any. The goal is to provide sufficient time for the Company to effectively negotiate and finalize a new strategic transaction, thereby securing a long-term solution that aligns with the interests of all stakeholders.
On April 22, 2024, we issued an Unsecured Promissory Note with a principal amount of $5,000,000 to 272 Capital Master Fund, Ltd. The transaction closed on April 24, 2024. The Note bears paid-in kind interest at a rate of 12.0% per annum, compounded annually, with a guaranteed return of 40.0%. The Note matures on the earlier of April 22, 2025, or one day prior to the earliest maturity date of the Company’s existing convertible debt held by Lynrock Lake and Nokomis and subordinated notes held by Renesas. The Note contains customary covenants and is subject to customary events of default.
We are in discussions with several parties regarding potential strategic transactions, but we may not be able to enter into a definitive agreement in sufficient time. Even if we are able to enter into a definitive agreement, there is no certainty that a transaction will ultimately close or that we will be able to raise bridge financing and extend the standstill for our major lenders to continue to operate our business until the transaction closes.
If we are not able to enter into a strategic transaction for the sale of the company or a major licensing transaction in the near term and raise substantial new equity or debt financing, we may not be able to continue to operate our business and may need to seek a court ordered restructuring.

A.
Operating Results
Revenue
Our total revenue consists of product revenue and other revenue. Revenue from contracts with customers is recognized when control of the goods or services is transferred to the customer at an amount that reflects the fair value of the consideration to which the Company is entitled, excluding sales taxes or duties.
The Company applies a five-step approach in determining the amount and timing of revenue to be recognized: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when the performance obligation is satisfied.
When a contract includes multiple promised goods and services, the Company evaluates each component to determine whether they represent separate performance obligations and determines the appropriate allocation of the contract consideration to each identified performance obligation based on estimated relative stand-alone selling prices.
Product Revenue
We derive the large majority of our revenue from the sale of semiconductor solutions and modules for 4G wireless broadband and narrowband applications, and we currently expect to continue to do so for the foreseeable future. Our solutions are sold both directly to our end customers and indirectly through distributors.
42


Our sales cycles typically take 12 months or more to complete, and our solutions are generally incorporated into our end customers’ products at the design stage. Prior to an end customer’s selection and purchase of our solutions, our sales force and applications engineers provide our end customers with technical assistance in the use of our solutions in their products. Once our solution is designed into an end customer’s product offering, it becomes more difficult for a competitor to sell its semiconductor solutions to that end customer for that particular product offering given the significant cost, time, effort and risk involved in changing suppliers. In addition, once we win a particular design with an end customer, we believe our ability to penetrate other product families at that end customer increases significantly.
Our product revenue is also affected by changes in the unit volume and average selling prices, or ASPs, of our semiconductor solutions. The ASP of the module is much higher than the ASP of our semiconductor solutions as many other components are added in order to provide a complete 4G- LTE solution. Our products are typically characterized by a life cycle that begins with higher ASPs and lower volumes as our new products use more advanced designs or technology and are usually incorporated into new devices that consumers adopt over a period of time. This is followed by broader market adoption with higher volumes and ASPs that are lower than initial levels, due to the maturity of the technology, greater availability of competing products or less demand as our end customers’ products reach the end of their life cycle.
The proportion of our product revenue that is generated from the sale of various products, also referred to as product mix, affects our overall ASP, product revenue and profitability. Given the varying ASPs of our solutions, any material change in our product mix may affect our gross margins and operating results from period to period. We expect to continue to broaden our product portfolio by introducing new solutions.
License and Services Revenue
License and services revenue consists of the sale of licenses to use our technology solutions and revenue from associated annual software maintenance and support services, as well as revenue from technical support services and development services. Development services include advanced technology development services for technology partners and software development and integration services for customers, and wireless operators.
We license the right to use our solutions, including embedded software that enables our end customers to customize our solutions for use in their products. The license generally is perpetual and covers unlimited product designs by the end customer. We expect that we will continue to sign new license agreements as we begin working with new customers, but the amount may vary significantly from year to year.
Development services agreements typically call for a number of milestones to be delivered over several quarters, with revenue generally recognized on the percentage of completion method as the contract progresses. The amount of development services can vary over time depending on the timing of when new contracts are won and the length of the contract period.
License and services revenue decreased in 2023 due to a peak in licensing revenue recognized in 2022 following execution of a large 5G license with a Chinese strategic partner. This contract resulted in an increase in license and service revenue compared to 2021.
We expect license and services revenue to continue to be a significant part of the total revenue mix in the short term as we complete delivery on existing contracts and as we enter into similar smaller new agreements.
Cost of Revenue
Our cost of revenue includes cost of product revenue and cost of services and license revenue.
A significant portion of our cost of semiconductor product revenue consists of the cost of wafers manufactured by third-party foundries and costs associated with assembly and test services. Cost of product revenue is impacted by manufacturing variances such as cost and yield for wafer, assembly and test operations and package cost. To a lesser extent, cost of product revenue includes expenses relating to depreciation of production mask sets, the cost of shipping and logistics, royalties, personnel costs, including share-based compensation expense, valuation provisions for excess inventory and warranty costs.
For our module products, the cost of product revenue includes not only the cost of the semiconductor solution but also other components such as power amplifiers and filters, as well as greater packaging costs.
Early in the life cycle of our products, we typically experience lower yields and higher associated costs. Over the life cycle of a particular product, our experience has been that the cost of product revenue has typically declined as volumes increase and test operations mature, while ASPs generally decline.
43


We use third-party foundry, assembly and test subcontractors, which are primarily located in Asia, to manufacture, package and test our semiconductor solutions. We purchase processed wafers from our fabrication supplier, currently TSMC. We also rely on third-party assembly and test subcontractors to assemble, package and test our products, and on third-party logistics specialists for logistics and storage. We generally do not have long-term agreements with our suppliers. Our obligations with our vendors for manufacturing, assembly and testing are generally negotiated on a purchase order basis.
As most of the costs related to services and license revenue are incurred as part of our normal research and development efforts, we allocate to cost of services and license revenue only the incremental costs related to service contract obligations and specific direct costs related to providing maintenance and technical support and generating development services revenue.
Gross Profit
Our gross profit is affected by a variety of factors, including our product and revenue mix, the ASPs of our products, the volumes sold, the purchase price of fabricated wafers, assembly and test service costs and royalties, provision for inventory valuation charges, and changes in wafer, assembly and test yields. We expect our gross profit will fluctuate over time depending upon competitive pricing pressures, the timing of the introduction of new products, product and revenue mix, volume pricing, variances in manufacturing costs and the level of royalty payments to third parties possessing intellectual property necessary for our products.
Operating Expenses
Research and Development
We engage in substantial research and development efforts to develop new products and integrate additional capabilities into our core products. Research and development expense consists primarily of personnel costs, including share-based compensation, for our engineers engaged in design and development of our products and technologies. These expenses also include the depreciation cost of intellectual property licensed from others for use in our products and depreciation of capitalized internal development costs, and directly expensed product development costs, which include external engineering services, cost of development software and hardware tools, cost of fabrication of mask sets for prototype products, external laboratory costs for certification procedures, equipment depreciation and facilities expenses.
We expect research and development expense (net of the effects of research tax credits, increased government grants and increased capitalization) to increase slightly in 2024 as we continue our 5G development effort.
Under IFRS, research and development expense is required to be capitalized if certain criteria are met and then amortized over the life of the product. In 2021, we started capitalizing costs for the 5G product and continued capitalizing certification costs and costs for the LTE Category NB (Monarch 2/ N) and for the LTE Category 1 (Calliope 2) for a total amount of $18.3 million (net of research tax credit for $1.6 million); in 2022, we continued capitalizing costs for the 5G product, certification costs and costs for the LTE Category 1 (Calliope 2) for a total amount of $13.8 million (net of research tax credit for $1.9 million), and in 2023 we continued capitalizing costs for the 5G product, certification costs and costs for the LTE Category 1 (Calliope 2) for a total amount of $22.3 million (net of research tax credit for $2.1 million). We expect that we will continue to capitalize 5G development costs going forward if the relevant accounting criteria continue to be met.
Research and Development Incentives
In France and the United Kingdom, we receive certain tax incentives based on the qualifying research and development expense incurred in those jurisdictions. When the incentive is available only as a reduction of taxes owed, such incentive is accounted for as a reduction of tax expense; otherwise, it is accounted for as a government grant with the benefit recorded as a reduction of research and development expense. We expect to be able to continue to qualify for such tax incentives in these jurisdictions in future periods. We expect the tax incentives, which are based on a percentage of qualifying research and development expense, to remain fairly stable in the short term. For 2023, we recorded a net amount of approximately $5.4 million in tax incentives compared with $4.6 million in 2022, and $6.3 million in 2021.
In France, we also receive incentives in the form of grants from agencies of the French government and the European Union, based on qualifying research and development expense incurred pursuant to collaborative programs carried out with other companies and universities. These incentives are recorded as a reduction of research and development expense and are recognized when there is a reasonable assurance that the grant will be received, and all relevant conditions will be complied with. For 2023, we recorded approximately $1.8 million in grants compared with approximately $4.9 million in 2022 and $3.6 million in 2021
44


In 2019, we received the final $2.1 million payment of grants and debt financing related to a large research project funded by the French government, called FELIN. The total value of the project funding for the Company was €7.0 million ($9.0 million). Of the €7.0 million, €3.0 million was in the form of a grant and €4.0 million was in the form of interest-bearing debt to be repaid beginning in 2019 and through 2024. The Company made principal and interest payments on the FELIN debt of €675,000 ($804,000) in 2021, €540,000 ($571,000) in 2022 and €870,000 ($939,000) in 2023.
In 2020, we received the final $0.4 million payment of grants and debt financing related to another large research project funded by the French government, called LTE4PMR. The total value of the project funding for the Company was €2.1 million ($2.3 million using the exchange rate at the grant date) to be received over four years. Of the €2.1 million, €0.7 million was in the form of a grant and €1.4 million was in the form of interest-bearing debt that was to be repaid beginning in 2020 and through 2024. In late 2020, the Company determined that the LTE variant financed by this project would not be commercially viable and requested that the debt be forgiven. In 2021, the government agreed to forgive 85% of the debt, which was recorded as a $241,000 grant, reducing research and development expense as a one-time event in April 2021.
In 2021, a new financing called CRIIoT to finance 5G developments was received with a total value of €5,615,000 ($6,793,000 using exchange rate at the grant date) in the form of a grant. The funding is paid in three installments: €1,404,000 ($1,670,000 using exchange rate at the funding date) after the signature of the contract, received in April 2021; €2,808,000 ($2,966,000 using exchange rate at the funding date) received in July 2022 based on achievement of milestones and the remaining amount of €1,403,000 ($1,550,000 using exchange rate as of December 31, 2023) after final claims have been approved, which is expected to occur in 2024.
In March 2024, we were awarded a new financing called eRedCap to support our low-power 5G developments with a total value of €10,888,000 ($11,771,000 using the exchange rate at the grant date), of which €7,451,000 is in the form of a grant and €3,437,000 in the form of interest-bearing debt that is to be repaid beginning in 2028 and through 2031.
With the benefit of the large eRedCap grant to begin being recognized in the second quarter of 2024, we expect that the amounts we recognize from such grants overall should increase in 2024.
Sales and Marketing
Sales and marketing expense consists primarily of personnel costs, including sales commissions, and share-based compensation for our business development, sales, customer support and marketing personnel, commissions paid to independent sales agents, marketing fees paid to industrial partners, the costs of advertising and participation in trade shows. We expect the size of our business development, sales and marketing organization, and sales and marketing expense, to remain fairly stable in 2024 after having increased during 2023.
General and Administrative
General and administrative expense consists primarily of personnel costs and share-based compensation for our finance, human resources, purchasing, quality and administrative personnel; professional services costs related to recruiting, accounting, tax and legal services; bad debt expense, investor relations costs; insurance; and depreciation. Information technology and facilities expenses are accounted for as overhead and allocated across all departments of the Company based on a pro rata basis. Legal expenses were unusually high in 2023 due to the tender offer from Renesas, which was terminated in February 2024. Absent any similar transaction in 2024, we expect general and administrative expense to decrease in 2024.
Interest Income (Expense), Net
Interest income consists of interest earned on cash and cash equivalent balances. We have historically invested our cash primarily in commercial bank accounts, short term deposits and money market funds.
Interest expense relates to our convertible debt issued in 2019 and 2021; lease contracts; an upfront payment received in October 2019; a French government debt financing received in May 2020; our government debt put in place in 2015; our accounts receivable financing facility put in place in 2014 and tax credit receivable financing put in place in 2021, 2022 and 2023; research project loans received from 2014 to 2019; and unsecured loans received from Renesas in November and December 2023.
Convertible Debt Amendments
In August 2022, the Company exercised its option to extend the term of the convertible notes issued in August 2019 by one year to August 2023 in exchange for an increase of the interest rate from 7.0% to 9.5% per annum effective August 15,
45


2022 and the issuance of 594,680 warrants (148,670 ADSs) at an exercise price of $1.03 per warrant ($4.12 per ADS). The conversion price of the debt was not changed as the existing conversion price was less than 120% of 20-day VWAP. The exercise of the option resulted in the extinguishment of the existing note and issuance of a new note for accounting purposes. The change in the liability component before and after the amendment was recorded as financial gain for an amount of $476,000.
In August 2023, the Company exercised its option to extend the term of the convertible notes issued in August 2019 to April 2024 in exchange for an increase of the interest rate from 9.5% per annum to 13.5% per annum effective August 15, 2023 and the issuance of 1,244,820 warrants (311,205 ADSs) at an exercise price of $0.8082 per warrant ($3.23 per ADS). The conversion price of the debt was decreased from $1.03 per share ($4.12 per ADS) to $0.8082 per share ($3.23 per ADS). The exercise of the option resulted in the extinguishment of the existing note and issuance of a new note for accounting purposes. The change in the liability component before and after the amendment was recorded as financial gain for an amount of $247,000.
With the extension of the maturity of the 2021 Note from Lynrock Lake due to the standstill agreement put in place, the PIK rate of interest increased from 6% to 8% beginning April 10, 2024.
Change in Fair Value of Convertible Debt Embedded Derivative
In January and February 2021, Nokomis converted portions of the convertible note issued in 2015 with a total principal value of $7,750,000 plus accrued interest and conversion bonus of $4,536,438, into a total of 7,227,308 ordinary shares. The recalculated fair value of the embedded derivatives related to the note at the conversion dates was $6,534,000, and the change of the fair value amounted to a loss of $3,269,000.
On April 9, 2021, the Company entered into a convertible note agreement with Lynrock Lake Master Fund LP in the principal amount of $40.0 million. The convertible note matures in April 2024 and is convertible, at the holder’s option, into the Company’s shares at a conversion rate of $1.915 per share (representing $7.66 per ADS), subject to a 9.9% ownership limit for Lynrock Lake. The convertible debt pays interest annually at an interest rate of 5.0625% for cash payments or 6% for payment in kind accruals. Sequans retains an option to call the convertible debt under certain circumstances after 12 months, either in full or in part. If a change of control occurs at any time prior to the payment of the note in full, Lynrock Lake Master Fund LP shall have the right, in its sole discretion, to convert or to require Sequans to redeem all of the outstanding principal amount (including accrued interest and unpaid interest).
The note was accounted for as compound financial instruments with two components: (i) a liability component reflecting the Company’s contractual obligation to pay interest and redeem the bonds in cash; and (ii) an embedded derivative, which reflects the value of the conversion option.
The initial fair value of the notes was split between these two components.
The fair value of the liability component on the issuance date of the Lynrock Lake convertible debt represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. On April 9, 2021, the initial fair value of the embedded derivative of the Lynrcok Lake notes was calculated to be $12,713,000. The change in fair value is remeasured and recorded as financial income or loss at each statement of financial position date. At December 31, 2023, the recalculated fair value of the convertible debt instruments was nil ($1,956,000 and $7,003,000 at December 31, 2022 and 2021, respectively), and the gain in change of the fair value of $1,956,000 for the year ended December 31, 2023 (gains of $5,047,000 and $5,710,000 for the years ended December 31, 2022 and 2021) was recorded in the Consolidated Statement of Operations.
On April 14, 2021, the Company repaid the remaining principal amount of the existing convertible debts that were due on April 14 (convertible notes issued in April 2015 and in September 2018) with accrued paid-in-kind interest of 7%. $6,378,104 was repaid for the April 2015 convertible note ($4,250,000 in principal and $2,128,000 as accrued interest) and $5,346,699 ($4,500,000 in principal and $847,000 as accrued interest) for the September 2018 convertible note. The recalculated fair value of the embedded derivatives at the repayment date was $4,645,000 and was recorded as financial income in the Consolidated Statement of Operations and the change of the fair value amounted to a loss of $934,000.
On August 16, 2022, the accounting for the exercise of the option to extend the term of the convertible note issued in August 2019 resulted in an embedded derivative. The initial fair value of the embedded derivative of the note was calculated to be $1,920,000, including the fair value of the warrants to be granted at the extension date for an amount of $195,000. After the issuance of the warrants (recorded in Other Capital reserves in shareholders' equity), the fair value of the embedded derivative of the note was $1,725,000.
46


On August 16, 2023, the accounting for the exercise of the option to extend the term of the convertible note issued in August 2019 resulted in an embedded derivative. The initial fair value of the embedded derivative of the note was calculated to be $215,000, including the fair value of the warrants to be granted at the extension date for an amount of $82,000. After the issuance of the warrants (recorded in Other Capital reserves in shareholders' equity), the fair value of the embedded derivative of the note was $133,000. At December 31, 2023, the recalculated fair value of the convertible debt was $3,000 ($1,247,000 and $3,078,000 at December 31, 2022 and 2021) and the gain in change of the fair value of $1,244,000 for the year ended December 31, 2023 (gains of $1,831,000 and $2,341,000 for the years ended December 31, 2022 and 2021), were recorded in the Consolidated Statement of Operations.
Foreign Exchange Gain (Loss), Net
Foreign exchange gain (loss) represents exchange gains and losses on our exposures to non-U.S. dollar denominated transactions, primarily associated with the changes in exchange rates between the U.S. dollar and the euro, and re-measurement of foreign currency balances at reporting date. As a result of our international operations, we are subject to risks associated with foreign currency fluctuations. Almost all of our revenues are in U.S. dollars and a portion of our expenses are also in U.S. dollars. However, a significant portion of our personnel costs is in euros and some long-term items on our statement of financial position are also denominated in euros. We use hedging instruments in order to reduce volatility in operating expenses related to exchange rate fluctuations. We classify foreign exchange gains and losses related to hedges of euro-based operating expenses as operating expenses.
Income Tax Expense (Benefit)
We are subject to income taxes in France, the United States and numerous other jurisdictions. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. As a result, we recognize tax liabilities based on estimates of whether additional taxes will be due. These tax liabilities are recognized when we believe that certain positions may not be fully sustained upon review by tax authorities, notwithstanding our belief that our tax return positions are supportable. Our effective tax rates differ from the statutory rate primarily due to any valuation allowance, the tax impact of local taxes, international operations, research and development tax credits, tax audit settlements, non-deductible compensation, and transfer pricing adjustments. In respect of our subsidiaries outside of France, we operate on a “cost plus” basis.
In the years ended December 31, 2022 and 2023, a withholding tax was retained from a license fee invoiced in China. This withholding was only recoverable in the year of the invoicing. As the Company was in a tax loss position in both years, the amounts of $2,250,000 in 2022 and $1,875,000 in 2023, were not recoverable and were recorded in Income tax expense.
In France, we have significant net deferred tax assets resulting from net operating loss carry forwards, tax credit carry forwards and deductible temporary differences that reduce our taxable income. Our ability to realize our deferred tax assets depends on our ability to generate sufficient taxable income within the carry back or carry forward periods provided for in the tax law for each applicable tax jurisdiction. Following the issuance of convertible debt and debt with warrants attached, we have deferred tax liabilities resulting from the bifurcation of the conversion feature and warrants from the debts. The deferred tax liabilities have allowed us to recognize deferred tax assets, subject to certain limitations on their use under French tax law. In the years ended December 31, 2021, 2022 and 2023, deferred tax liabilities of $121,000, $139,000 and $(9,000), respectively, were recognized through income tax expense on our Consolidated Statement of Operations. Over time, as we generate taxable income, we expect our tax rate to increase significantly.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations is based on our Consolidated Financial Statements contained elsewhere in this annual report, which are prepared in accordance with IFRS as described in Note 2 to our Consolidated Financial Statements.
Some of the accounting methods and policies used in preparing our Consolidated Financial Statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the circumstances concerned. The actual value of our assets, liabilities and shareholders’ equity and of our earnings could differ from the value derived from these estimates if conditions changed and these changes had an impact on the assumptions adopted. We believe that the most significant management judgments and assumptions in the preparation of our financial statements are described below.

47


Revenue Recognition
Arrangements with customers are considered contracts if all the following criteria are met: (a) parties have approved the contract and are committed to perform their respective obligations; (b) each party’s rights regarding the goods or services to be transferred can be identified; (c) payment terms related to the goods or services to be transferred can be identified; (d) the contract has commercial substance and (e) collectability of substantially all of the consideration is probable.
Revenue is recognized when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. We follow a five-step model to: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the separate performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.
Our contracts with customers often include promises to transfer multiple products and/or services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Judgment is also required to determine the stand-alone selling price (“SSP") for each distinct performance obligation. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, we determine the SSP using information that may include market conditions and other observable inputs.
If the consideration in a contract includes a variable amount, we use our judgment to estimate the amount of consideration to which we will be entitled in exchange for transferring the goods or services to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in comparison to the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved.
We sometimes receive advance payments from customers for the provision of development services. We determine if there is a significant financing component for these contracts considering the length of time between the customers’ payment and the transfer of control of the goods and services. When a significant financing component has been identified, the transaction price for these contracts is discounted, using the rate that we estimate would be reflected in a separate financing transaction at contract inception.
We recognize revenue when we satisfy the performance obligation by transferring the control over a product to the customer. Judgment is required to assess the pattern of transfer of control, in particular with regards to products’ sales to distributors and the rendering of services. Where we render services to the customers, they usually correspond to performance obligations which are satisfied over time, which are accounted for using the percentage-of-completion method, electing an input method of estimated costs as a measure of performance completed.
We rely on estimates around the total estimated costs to complete the contract (“Estimated Costs at Completion”). Total Estimated Costs at Completion include direct labor, material and subcontracting costs. Due to the nature of the efforts required to be performed to meet the underlying performance obligation, determining Estimated Costs at Completion is subject to many variables. Management quarterly reviews the progress and performance of open contracts in order to determine the best estimate of Estimated Costs at Completion. As part of this process, management reviews information including, but not limited to, any outstanding key contract matters, progress towards completion, the project schedule, identified risks and opportunities, and the related changes in estimates of costs. The risks and opportunities include management’s judgment about the ability and cost to achieve the project schedule, technical requirements, and other contract obligations.
Trade Receivables
We maintain an allowance for doubtful accounts for potential estimated losses resulting from our customers’ inability to make required payments. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take into account the risk of payment default throughout the lifetime of the receivables. Based on an analysis of historical credit losses, we have not applied any expected credit losses to our outstanding receivables as of the reporting date beyond specific provisions for doubtful accounts. If we receive information that the financial condition of our customers has deteriorated, resulting in an impairment of their ability to make payments, or there are indicators that amounts receivable will become uncollectible, additional allowances could be required. We record an allowance for any specific account we consider as doubtful based on the particular circumstances of the account. The carrying amount of the receivable is thus reduced through the use of an allowance account, and the amount of the charge is recognized in the Consolidated Statement of Operations. Subsequent recoveries, if any, of amounts previously provided for are credited against the same line in the Consolidated Statement of Operations. When a trade accounts receivable is uncollectible, it is written-off against the allowance account for trade accounts receivable.
48


Inventories
Inventories consist primarily of the cost of semiconductors, including wafer fabrication, assembly, testing and packaging; components; and modules purchased from subcontractors. We write down the carrying value of our inventories to the lower of cost (determined using the moving average method) or net realizable value (estimated market value less estimated costs of completion and the estimated costs necessary to make the sale). We write down the carrying value of our inventory for estimated amounts related to lower of cost or net realizable value, obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated net realizable value. The estimated net realizable value of the inventory is based on historical usage and assumptions about future demand, future product purchase commitments, estimated manufacturing yield levels and market conditions on a product-by-product basis. Once established, inventory reserves are not reversed until the related inventory has been sold or scrapped. Actual demand may differ from forecasted demand and these differences may have a material effect on recorded inventory values and cost of revenue.
When we consider future demand for a product, there are a number of factors that we take into consideration, including purchase orders and forecasts from customers, which in normal market conditions give us visibility for the next three months and some view on the following three months, our own internal projections based on customer inputs and new business opportunities, and estimates of market potential based on reports from industry analysts. The time horizon considered for future demand varies depending on the nature of the product, meaning we consider if the product is newly-introduced or approaching end-of-life, if the product is in finished good form or in component form, and if the product is incorporated in a large or small number of different end-user products from few or many customers.
We evaluate the realizability of our inventory at each balance sheet date. In doing so, we consider, among other things, demand indicated by our customers, overall market potential based on input from operators and analysts, and the remaining estimated commercial life of our products.
At December 31, 2021, 2022 and 2023, we had provisions for slow-moving LTE inventory totaling $1.3 million, $1.9 million and $2.9 million, respectively.
Share-Based Compensation
We have various share-based compensation plans for employees. The expense recorded in our statement of operations for equity awards under these plans is affected by changes in valuation assumptions. For example, the fair value of stock options is estimated by using the binomial model on the date of grant based on certain assumptions, including, among others, expected volatility, the expected option term and the expected dividend payout rate.
For the years ended December 31, 2021 and 2022, the assumption for expected volatility was based on the Company’s historical volatility since the initial public offering in 2011. For the year ended December 31, 2023, the 6-year volatility of the Company was used.
We recognize compensation expense only for the portion of share options that are expected to vest. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from our estimates.
For 2021, 2022 and 2023, we recorded employee share-based compensation expense of $5.1 million, $5.5 million and $7.1 million, respectively. Share-based compensation expense related to non-employees was not material for 2021, 2022 and 2023.
Fair Value of Financial Instruments
The Company determined that the fair values of cash, trade receivables and trade payables approximate their carrying amounts largely due to the short-term maturities of these instruments.
Where no active market exists, the Company establishes fair value by using a valuation technique determined to be the most appropriate in the circumstances.
Regarding compound debt instruments, the fair value of the debt component was determined at the date of issuance using a valuation model that requires judgment, including estimating the change in value of the Company at different dates and market yields applicable to the Company’s straight debt (without the conversion option(s)). The assumptions used in calculating the value of the conversion option(s), the expected volatility of the Company’s underlying stock price which has experienced fluctuations, and the market discount rate, represent the Company’s best estimates based on management’s judgment and subjective future expectations. The fair value of the debt component was supported by work performed by an independent valuation specialist engaged by the Company.

49


Deferred Tax Assets and Liabilities
Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. Management makes assumptions, judgments and estimates to determine our deferred tax assets and liabilities, including whether deferred tax assets are likely to be realized.
Research and Development Costs
Costs incurred internally in research and development activities are charged to expense until technological feasibility and commercial viability has been established for the project. Once technological feasibility and commercial viability are established, development costs are capitalized until the product is available for general release to customers. Judgment is required in determining when technological feasibility and commercial viability of a product is established. We have determined that technological feasibility for our software products is reached after all high-risk development issues have been resolved. Generally, this occurs when the preliminary design review has been completed.

50


Results of Operations
The following tables set forth a summary of our consolidated results of operations for the periods indicated. This information should be read together with our Consolidated Financial Statements and related notes included elsewhere in this annual report. The results of operations in any period are not necessarily indicative of the results that may be expected for any future period.
Comparison of Years Ended December 31, 2022 and 2023
 Year ended December 31,Change
 20222023%
 (in thousands) 
Revenue:
Product revenue$22,974 $8,060 (65)%
License and services revenue37,577 25,556 (32)
Total revenue60,551 33,616 (44)
Cost of revenue17,671 9,476 (46)
Gross profit42,880 24,140 (44)
Operating expenses:
Research and development26,610 26,124 (2)
Sales and marketing10,027 11,861 18 
General and administrative10,082 15,993 59 
Total operating expenses46,719 53,978 16 
Operating income (loss)(3,839)(29,838)677 
Financial income (expense):
Interest income (expense), net(10,857)(11,233)
Impact of debt reimbursement— — 
Convertible debt amendments476 247 (48)
Change in the fair value of convertible debt derivative6,878 3,200 (53)
Foreign exchange gain (loss)1,082 (692)(164)
Profit (Loss) before income taxes(6,260)(38,316)
Income tax expense (benefit)2,748 2,674 (3)
Profit (Loss)$(9,008)$(40,990)

51


The following table sets forth a summary of our statements of operations as a percentage of total revenue:
 Year ended
December 31,
 20222023
 (% of total revenue)
Revenue:
Product revenue38 24 
License and services revenue62 76 
Total revenue100 100 
Cost of revenue29 28 
Gross profit71 72 
Operating expenses:
Research and development44 78 
Sales and marketing17 35 
General and administrative17 48 
Total operating expenses78 161 
Operating income (loss)(7)(89)
Financial income (expense):
Interest income (expense), net(18)(33)
Impact of debt reimbursement— — 
Convertible debt amendments
Change in the fair value of convertible debt derivative11 10 
Foreign exchange gain (loss)(2)
Profit (Loss) before income taxes(11)(113)
Income tax expense (benefit)
Profit (Loss)(16)(121)
Revenue
Product Revenue
Product revenue decreased 65% from $23.0 million in 2022 to $8.1 million in 2023. The decrease was mainly due to various delays by our customers in the launch of their products and to lower purchasing by existing customer products due to excess inventory throughout the supply chain from overstocking during the previous years' supply shortages. In 2022 and 2023, massive IoT product revenue accounted for approximately 96% and 97%, respectively, of total product revenue, and broadband product revenue accounted for approximately 4% and 3%, respectively, of total product revenue.
Total massive IoT product revenue decreased 64% from $22.0 million in 2022 to $7.8 million in 2023 due to the decline in our first-generation Cat 1 product revenue, related to one large customer's inventory rationalization that carried over from 2022. The Cat 1 business is in various applications, such as electrical meters in Japan, vending machines, security and asset tracking. Cat M product category revenue decreased around 30%, due to customer delays in the move to production for several large design wins.
Total broadband product revenue decreased 76% from $1.0 million in 2022 to $0.2 million in 2023. Broadband revenue is expected to accelerate in the future with the launch of our 5G Taurus platform in late 2025.
In 2023, we shipped approximately 1.5 million units of 4G products compared to 3.4 million units in 2022. We expect revenue growth in the second half of 2024, supported by a strong ramp-up of the second generation Cat 1 Calliope 2 business.

52


License and Services Revenue
License and services revenue decreased 32% from $37.6 million in 2022 to $25.6 million in 2023. Revenue related to large 5G licensing deals signed in 2020, 2021 and 2022 declined sequentially, as expected, due to the payment structure of the most recent 5G strategic agreements. Development services revenue decreased 62% from $6.1 million in 2022 to $2.3 million in 2023. License revenue decreased 26% from $31.0 million in 2022 to $23.0 million in 2023, and maintenance revenue decreased 51% from $0.4 million in 2022 to $0.2 million in 2023. License and maintenance revenues can vary quite significantly from one period to another.
Sales to external customers disclosed below are based on the geographical location of the customers to which the Company invoices. The following table sets forth the Company’s total revenue by region for the periods indicated.
 Year ended December 31,
 20222023
 
Asia:
  China (including Hong-Kong)$24,018 $21,702 
  Taiwan1,066 29 
  Korea 30 
  Rest of Asia2,202 62 
      Total Asia27,294 21,823 
Germany15,525 1,001 
United States of America16,749 8,666 
Rest of world983 2,126 
Total revenue$60,551 $33,616 
We categorize our total revenue based on technology.
Year ended December 31,
20222023
Broadband$36,181 $21,842 
Massive IoT24,370 11,774 
Total revenue$60,551 $33,616 
Additionally, we categorize our total revenue based on product and service revenue including license revenue and development and other services.
Year ended December 31,
20222023
Product $22,974 $8,060 
License31,005 22,997 
Development and other services6,572 2,559 
Total revenue$60,551 $33,616 

Cost of Revenue
Cost of product revenue decreased 51% from $15.5 million in 2022 to $7.6 million in 2023 mainly due to the decrease in shipments of modules, partially offset by an increase in the provision for slow-moving inventory . Cost of services and license revenue decreased 13% from $2.2 million in 2022 to $1.9 million in 2023.

Gross Profit
Gross profit decreased 44% from $42.9 million in 2022 to $24.1 million in 2023, and gross margin percentage increased from 70.8% in 2022 to 71.8% in 2023. Product gross margin percentage decreased from 32.7% in 2022 to 6.2% in 2023 due to
53


the lower volume of product sales, while fixed costs remained approximately the same, and an increase in the provision for slow-moving inventory. License and services revenue gross margin decreased from 94.1% in 2022 to 92.5% in 2023 due to the higher proportion of license revenue in the mix in 2023.

Research and Development
Research and development expense decreased 2% from $26.6 million in 2022 to $26.1 million in 2023 reflecting increases in research incentives and capitalization of development costs, partially offset by the provision for impairment of the value of the initial mask for our 5G product, an increase in headcount costs and the impact on expenses in euros of an unfavorable foreign exchange rate between euros and US dollars.
Research and development incentives decreased from $9.5 million in 2022 to $7.2 million in 2023. In the year ended December 31, 2023, we continued capitalizing 5G development and Calliope 2 costs and other development costs related mainly to operator certifications. The total amount of capitalized costs was $22.3 million, net of research tax credit of $2.1 million in 2023 compared to $13.8 million, net of research tax credit of $1.9 million in 2022. In each of the years ended December 31, 2023 and 2022, the amount of the amortization of these capitalized costs was $2.6 million.
Research and development costs associated with product development (including normal customer support which generates product improvements) are recorded in operating expense. In some cases, we have negotiated agreements with customers and partners whereby we provide certain development services beyond our normal practices or planned product roadmap. Amounts received from these agreements are recorded in services and license revenue. Direct costs, including both internal resources and out-of-pocket expenses, that we incur as a result of the commitments in the agreements are recorded in cost of services and license revenue, rather than in research and development expense. Other research and development costs related to the projects covered by the agreements, but which we would have incurred without the existence of such agreements, are recorded in research and development expense.
There were 330 employees and independent contractors in research and development at December 31, 2023 compared to 274 at December 31, 2022.

Sales and Marketing
Sales and marketing expense increased 18% from $10.0 million in 2022 to $11.9 million in 2023. The increase primarily reflects higher average headcount and stock-based compensation expenses which represented more than $1.7 million of the increase. There were 50 employees and independent contractors in sales and marketing at December 31, 2023 compared to 47 employees at December 31, 2022.

General and Administrative
General and administrative expense increased 59% at $16.0 million in 2023 compared to $10.1 million in 2022. Stock-based compensation increased $1.1 million in 2023, legal fees and other expenses increased primarily due to approximately $3.5 million in fees related to the Renesas tender offer, and in addition expenses in euros were impacted by a unfavorable foreign exchange rate between euros and US dollars. There were 25 employees in general and administrative functions at December 31, 2023 compared to 23 employees at December 31, 2022.
Interest Income (Expense), Net
Net interest expense increased to $11.4 million in 2023 compared to $10.9 million in 2022. The increase in interest expense in 2023 reflected the increase in the interest rate on an existing convertible note and interest on unsecured note signed in November 2023. Interest expense in 2022 included $1.0 million related to the financing component of the upfront payment of the non-exclusive license and development services agreement signed in October 2019. Interest income was insignificant in both years.

Convertible debt amendment
On August 15, 2023, the Company exercised its second option to extend the maturity of the convertible note issued in April 2019 to April 16, 2024. Following the option exercise, the change in the liability component before and after the extension and the fair value of the warrants granted, which resulted in a gain on extinguishment of $247,000 was recorded as "Convertible debt amendments" in the Consolidated Statements of Operations. On August 15, 2022, the Company exercised its first option to extend the maturity to August 16, 2023 resulting in a gain on extinguishment of $476,000

54


Change in fair value of convertible debt embedded derivative
At December 31, 2023, the recalculated fair value of the remaining convertible debt issued in August 2019 was $3,000, and the change of the fair value of $1,244,000 in 2023 was recorded as a gain in the Consolidated Statement of Operations. At December 31, 2022, the recalculated fair value of this convertible debt was $1,247,000, and the change of the fair value of 1,831,000 in 2022 was recorded in the Consolidated Statement of Operations.
At December 31, 2023, the recalculated fair value of the convertible debt issued on April 9, 2021 was null, and the change of the fair value of $1,956,000 in 2022 was recorded as a gain in the Consolidated Statement of Operations. At December 31, 2022, the recalculated fair value of the convertible debt was $1,956,000, and the change of the fair value of $5,047,000 in 2022 was recorded as a gain in the Consolidated Statement of Operations.
Foreign Exchange Gain (Loss), Net
We had a net foreign exchange loss of $0.7 million in 2023 compared to a net foreign exchange gain of $1.1 million in 2022 primarily due to movements in the U.S. dollar versus the euro, particularly in the revaluation of euro-denominated net debt on the balance sheet.
Income Tax Expense (Benefit)
In 2023, we recorded current tax expense of $2.7 million arising from taxable income incurred at certain subsidiaries and a withholding tax of $1,875,000 retained from a license fee invoiced in China. This withholding was only recoverable the year of the invoicing. As we were in a loss position in France in 2023, we were not able to recover the withholding credit. Deferred tax income recorded in 2023 amounted to $9,000 and related to origination and reversal of timing differences. In 2022, we recorded current tax expense of $2.6 million arising from taxable income incurred at certain subsidiaries, a withholding tax of $2,250,000 retained from a license fee invoiced in China.and a deferred tax expense amounting to $139,000, related to origination and reversal of timing differences.

55


Comparison of Years Ended December 31, 2021 and 2022


 Year ended December 31,Change
 20212022%
 (in thousands) 
Revenue:
Product revenue$30,410 $22,974 (24)%
License and services revenue20,469 37,577 84 
Total revenue50,879 60,551 19 
Cost of revenue23,690 17,671 (25)
Gross profit27,189 42,880 58 
Operating expenses:
Research and development26,414 26,610 
Sales and marketing9,049 10,027 11 
General and administrative10,045 10,082 — 
Total operating expenses45,508 46,719 
Operating income (loss)(18,319)(3,839)(79)
Financial income (expense):
Interest income (expense), net(11,282)(10,857)(4)
Impact of debt reimbursement5,177 — 
Convertible debt amendments— 476 100 
Change in the fair value of convertible debt derivative3,848 6,878 (100)
Foreign exchange gain (loss)938 1,082 (100)
Profit (Loss) before income taxes(19,638)(6,260)
Income tax expense (benefit)625 2,748 340 
Profit (Loss)$(20,263)$(9,008)

56


The following table sets forth a summary of our statements of operations as a percentage of total revenue:
 Year ended
December 31,
 20212022
 (% of total revenue)
Revenue:
Product revenue60 38 
License and services revenue40 62 
Total revenue100 100 
Cost of revenue47 29 
Gross profit53 71 
Operating expenses:
Research and development52 44 
Sales and marketing18 17 
General and administrative20 17 
Total operating expenses90 78 
Operating income (loss)(37)(7)
Financial income (expense):
Interest income (expense), net(22)(18)
Impact of debt reimbursement10 — 
Convertible debt amendments— 
Change in the fair value of convertible debt derivative11 
Foreign exchange gain (loss)
Profit (Loss) before income taxes(39)(11)
Income tax expense (benefit)
Profit (Loss)(40)(16)
Revenue
Product Revenue
Product revenue decreased 24% from $30.4 million in 2021 to $23.0 million in 2022. The decrease was mainly due to various delays by our customers in the launch of their products and to supply challenges impacting their legacy products, which caused them to prioritize fixing shortages in the existing products and reduce the priority of new projects with us. In 2021 and 2022, massive IoT product revenue for approximately 82% and 96%, respectively, of total product revenue, and broadband product revenue accounted for approximately 18% and 4%, respectively, of total product revenue.
Total massive IoT product revenue decreased 12% from $25.0 million in 2021 to $22.0 million in 2022 due to the expected decline in our first-generation Cat 1 product revenue, mostly due to higher-than-normal revenue in 2021 from this product line, as one large customer built over six months of inventory to avoid a potential supply shortage. The Cat 1 Calliope 2 business is in various applications, such as electrical meters in Japan, vending machines, security and asset tracking. Cat M product category revenue increase around 26%, driven by the success of second-generation of Monarch products.
Total broadband product revenue decreased 82% from $5.4 million in 2021 to $1.0 million in 2022. The broadband business declined due to the end of life of the product sold to Verizon in April 2021 for its JetPack Ellipsis, the portable router that included a Sequans modem, to facilitate at home schooling during the COVID-19 pandemic. The expected growth in the broadband CBRS business did not occur in 2022. Our CBRS customers are building devices to serve private networks for factories, utilities, campuses, stadiums, and transportation hubs such as airports and train stations. The broadband revenue is expected to accelerate in the future with the launch of our 5G Taurus platform.
In 2022, we shipped approximately 3.4 million units of 4G products compared to 3.8 million units in 2021. We expect revenue growth in 2023, supported by strong ramp-up of Cat M products for massive IoT and the launch of Cat 1 Calliope 2.

57


License and Services Revenue
License and services revenue increased 84% from $20.5 million in 2021 to $37.6 million in 2022, mainly due to revenue related to large 5G licensing deals signed in 2020, 2021 and 2022. Development services revenue increased 95% from $3.2 million in 2021 to $6.1 million in 2022. License revenue increased 82% from $17.1 million in 2021 to $31.0 million in 2022, and maintenance revenue increased 75% from $0.2 million in 2021 to $0.4 million in 2022. License and maintenance revenues can vary quite significantly from one period to another.
Sales to external customers disclosed below are based on the geographical location of the customers to which the Company invoices. The following table sets forth the Company’s total revenue by region for the periods indicated.
 Year ended December 31,
 20212022
 
Asia:
  Taiwan$14,668 $1,066 
  Korea 1,090 
  China (including Hong-Kong)3,509 24,018 
  Rest of Asia898 2,202 
      Total Asia20,165 27,294 
Germany4,990 15,525 
United States of America22,565 16,749 
Rest of world3,159 983 
Total revenue$50,879 $60,551 
We categorize our total revenue based on technology.
Year ended December 31,
20212022
Broadband IoT$23,699 $36,181 
Massive IoT27,180 24,370 
Total revenue$50,879 $60,551 
Additionally, we categorize our total revenue based on product and service revenue including license revenue and development and other services.
Year ended December 31,
20212022
Product $30,410 $22,974 
License17,073 31,005 
Development and other services3,396 6,572 
Total revenue$50,879 $60,551 

Cost of Revenue
Cost of product revenue decreased 30% from $22.0 million in 2021 to $15.5 million in 2022 mainly due to the decrease in shipments of modules. Cost of services and license revenue increased 28% from $1.7 million in 2021 to $2.2 million in 2022.

Gross Profit
Gross profit increased 58% from $27.2 million in 2021 to $42.9 million in 2022, and gross margin percentage increased from 53.4% in 2021 to 70.8% in 2022. Product gross margin percentage increased from 27.7% in 2021 to 32.7% in 2022 due to
58


a higher proportion of higher-margin chipsets in the revenue mix in 2022. License and services revenue gross margin increased from 91.6% in 2021 to 94.1% in 2022 due to the higher proportion of license revenue in the mix in 2022.

Research and Development
Research and development expense increased 1% from $26.4 million in 2021 to $26.6 million in 2022 reflecting a decrease of expenses in euros impacted by a favorable foreign exchange rate between euros and US dollars and increases in research incentives and capitalization of development costs, offset by a net benefit in 2021 of $1.2 million from a one-time research and development grant and other one-time items.
Research and development incentives decreased from $9.9 million in 2021 to $9.5 million in 2022. In the year ended December 31, 2021, we started capitalizing 5G development costs. We also capitalized other development costs related mainly to operator certifications. The total amount of capitalized costs was $13.8 million, net of research tax credit of $1.9 million in 2022 compared to $18.3 million, net of research tax credit of $1.6 million in 2021. In the year ended December 31, 2022, the amount of the amortization of these capitalized costs was $2.4 million compared to $2.5 million in 2021.
Research and development costs associated with product development (including normal customer support which generates product improvements) are recorded in operating expense. In some cases, we have negotiated agreements with customers and partners whereby we provide certain development services beyond our normal practices or planned product roadmap. Amounts received from these agreements are recorded in services and license revenue. Direct costs, including both internal resources and out-of-pocket expenses, that we incur as a result of the commitments in the agreements are recorded in cost of services and license revenue, rather than in research and development expense. Other research and development costs related to the projects covered by the agreements, but which we would have incurred without the existence of such agreements, are recorded in research and development expense.
There were 274 employees and independent contractors in research and development at December 31, 2022 compared to 273 at December 31, 2021.

Sales and Marketing
Sales and marketing expense increased 11% from $9.0 million in 2021 to $10.0 million in 2022. The increase primarily reflects higher average headcount and stock-based compensation expenses which represented more than $0.7 million of the increase. There were 47 employees and independent contractors in sales and marketing at December 31, 2022 compared to 46 employees at December 31, 2021.

General and Administrative
General and administrative expense remained flat at $10.1 million in 2022 compared to $10.0 million in 2021. Stock-based compensation increased in 2022 and legal fees increased due to the new 5G strategic contract signed during the year, offset by expenses in euros impacted by a favorable foreign exchange rate between euros and US dollars. There were 23 employees in general and administrative functions at December 31, 2022 and 2021.
Interest Income (Expense), Net
Net interest expense decreased to $10.9 million in 2022 compared to $11.3 million in 2021. The decrease in interest expense in 2022 reflected the conversion in 2021 of portions of convertible debt issued in December 2019, January 2021 and February 2021; and the repayment of the venture debt and of convertible debt in April 2021; partially offset by the full year of interest expense of the new convertible debt issued in April 2021 and the increase in the interest rate on the existing convertible note. Interest expense included $1.0 million related to the financing component of the upfront payment of the non-exclusive license and development services agreement signed in October 2019 compared to $2.2 million in 2021. Interest income was insignificant in both years.
Impact of debt repayment
On April 14, 2021, the Company repaid the remaining amount of the Nokomis Notes that were due on April 14, 2021, which were issued in April 2015 and in September 2018). The recalculated fair value of the embedded derivatives at the
59


repayment date was $4,645,000 and was recorded as financial income in the Consolidated Statement of Operations and the change of the fair value amounted to a loss of $934,000.
On April 15, 2021, following the issuance of new convertible debt and a private placement, the Company used a portion of the proceeds to prepay in full all amounts due to Harbert. The prepayment in full was considered a debt renegotiation. The positive impact of $532,000 was recognized as financial income in the Consolidated Statement of Operations.
There was no debt repayment in 2022.

Convertible debt amendment
On August 15, 2022, the convertible note issued in August 2019 arrived at maturity and the Company exercised its first option to extend the maturity to August 16, 2023. Following the option exercise, the change in the liability component before and after the extension and the fair value of the warrants granted, which resulted in a gain on extinguishment of $476,000 was recorded as "Convertible debt amendments" in the Consolidated Statements of Operations.

Change in fair value of convertible debt embedded derivative
At December 31, 2022, the recalculated fair value of the remaining convertible debt issued in August 2019 was $1,247,000, and the change of the fair value of $1,831,000 in 2022 was recorded as a gain in the Consolidated Statement of Operations. At December 31, 2021, the recalculated fair value of this convertible debt was $3,078,000, and the change of the fair value of 1,862,000 in 2021 was recorded in the Consolidated Statement of Operations.
At December 31, 2022, the recalculated fair value of the convertible debt issued on April 9, 2021 was $1,956,000, and the change of the fair value of $5,047,000 in 2022 was recorded as a gain in the Consolidated Statement of Operations. At December 31, 2021, the recalculated fair value of the convertible debt was $7,003,000, and the change of the fair value of $5,710,000 in 2021 was recorded as a gain in the Consolidated Statement of Operations.
Foreign Exchange Gain (Loss), Net
We had a net foreign exchange gain of $1.1 million in 2022 compared to a net foreign exchange gain of $0.9 million in 2021 primarily due to movements in the U.S. dollar versus the euro, particularly in the revaluation of euro-denominated net debt on the balance sheet.
Income Tax Expense (Benefit)
In 2022, we recorded current tax expense of $2.6 million arising from taxable income incurred at certain subsidiaries and a withholding tax of $2,250,000 retained from a license fee invoiced in China. This withholding was only recoverable the year of the invoicing. As we were in a loss position in France in 2022, we were not able to recover the withholding credit. Deferred tax expense recorded in 2022 amounted to $139,000 and related to origination and reversal of timing differences. In 2021, we recorded current tax expense of $504,000 arising from taxable income incurred at certain subsidiaries, and a deferred tax expense amounting to $121,000, related to origination and reversal of timing differences.

B.Liquidity and Capital Resources
Sources of Liquidity
Our cash and cash equivalents and short-term investments were $5.7 million at December 31, 2023.
Since inception, we have financed our operations primarily through proceeds from the issues of our shares, convertible notes and venture debt, which totaled $73.1 million from 2004 to the end of 2010; from $59.1 million in net proceeds from our initial public offering on the New York Stock Exchange in April 2011 and from $178.3 million in net proceeds from our follow-on public offerings and private placements in 2013, 2016, 2017, 2018, 2020, 2021, 2022 and 2023.
In June 2014, we entered into a factoring agreement with a French financial institution whereby a line of credit was made available equal to 80-90% of the face value of accounts receivable from qualifying customers. We transfer to the finance company all invoices issued to qualifying customers and the customers are instructed to settle the invoices directly with the finance company. In May 2020, we entered into an agreement to finance the 2020 research tax credit receivable as it is earned over the year, which was renewed for the 2021, 2022 and 2023 research tax credits. At December 31, 2023, $9.5 million had been drawn on the lines of credit from these agreements and recorded as a current borrowing.
60


In October 2014, Bpifrance, a financial agency of the French government, provided funding to the Company in the context of a long-term research project, estimated to be completed over a three-year period. The total funding was €7.0 million ($9.0 million), a portion in the form of a grant (€3.0 million or $3.8 million) and a portion in the form of a loan (€4.0 million or $5.2 million). The funding was paid in installments after milestones defined in the contract, the last of which was received in 2019. The advance will be repaid from March 31, 2019 to December 31, 2024 of which €870,000 ($939,000) in principal and interests was paid in 2023, and bears interests at a 1.53% fixed contractual rate.
In April 2015, we completed the sale of a $12 million convertible note to Nokomis Capital, L.L.C. (Nokomis) in a private placement transaction. In addition, we issued warrants to purchase 450,000 ADSs to the holder of this note in connection with the September 2018 amendment with an exercise price of $6.80 per ADS. In January and February 2021, Nokomis converted portions of the note issued with a total principal value of $7,750,000, and the balance was repaid at term in April 2021.
In September 2015, the Company received two loans from the financial agency of the French government for a total amount of €2 million ($2.2 million). One loan of €1 million bears interest at 5.24% per year, paid quarterly; the second loan of €1 million is interest-free. The interest-free loan has been revalued using the 5.24% interest rate payable on the other loan. Both loans have seven-year terms with the principal being amortized on a quarterly basis beginning in September 2017. At December 31, 2023, both loans were fully reimbursed.
In January 2016, Bpifrance provided funding to the Company for a new long-term research project, estimated to be completed over a 27-month period. The total of the funding amounts to €2.1 million ($2.3 million) comprising a portion in the form of a grant (€0.7 million or $0.7 million) and a portion in the form of a forgivable loan (€1.4 million or $1.6 million). The funding was paid in four installments, with the last being received in 2020. The forgivable loan advance was to be repaid, except if the project is a commercial failure, from July 1, 2020 to July 1, 2024. In late 2020, the Company determined that there was not enough market interest for the radio frequency of the product development funded by this grant, and abandoned the project. A request for forgiveness of the debt was made and in April 2021 and Bpifrance forgave a large portion of the advance. The unforgiven portion of €213,000 ($241,000) was reimbursed in the February 2022.
On September 27, 2018, the Company sold a convertible note in the principal amount of $4.5 million to Nokomis in a private placement transaction. The convertible note had the same terms as the convertible note issued in 2015.
On October 26, 2018, the Company entered into a bond issuance agreement with Harbert European Specialty Lending Company II S.a.r.l (the “Harbert”) whereby Harbert agreed to loan to the Company €12 million ($13.8 million). Also, on October 26, 2018, the Company issued to Harbert, for a total subscription price of $1.00, warrants to acquire 204,179 ADSs at an exercise price of $5.36 per ADS. Such warrants are exercisable at any time and expire October 26, 2028. The loan was repaid in April 2021.
On February 18, 2019, a new strategic investor subscribed for warrants for a total subscription price of approximately $8.4 million in support of accelerating Sequans’ 5G product roadmap. Upon the closing of this transaction, the Company issued to the investor warrants to purchase 2,348,247 ADSs. The warrants are exercisable upon 61 days’ notice to Sequans at an exercise price of €0.02 per share (€0.08 per ADS). The warrants expire 15 years from the issuance date.
On August 16, 2019, the Company entered into a convertible note agreement with Nokomis in the principal amount of 5.0 million. The convertible note was to mature in August 2022, bore interest at a rate of 7% per year, paid in kind annually on August 16th and is convertible, at the holder’s option, into the company’s ADSs at a conversion rate of $4.12 per ADS.
In March 2020, the convertible notes issued in April 2015, September 2018 and August 2019 were amended to grant the Company three options to extend the term of each note, except for the August 2019 note which has two options to extend. Each option gives the Company the right to extend the term of such note by one year and consequently reset the conversion price to a 20% premium above the 20-day volume weighted average price (VWAP) if it is lower than the existing conversion price. On the first option exercise, the payment-in-kind interest (PIK) will stay at 7% but the holder will be granted a warrant for 10% of the value of the note with a three-year term, at an exercise price of 20% premium above 20-day VWAP. On the second option exercise, the PIK will be adjusted to 9.5%, the previous warrants granted on the first option exercise will be extended by one year and the holder will be granted an additional warrant for 15% of the value of the note with a three-year term, at an exercise price of 20% premium above 20-day VWAP. On the third option exercise, the PIK will be adjusted to 13.5%, and the holder will be granted an additional warrant for 20% of the value of the note with a three-year term, at an exercise price of 20% premium above 20-day VWAP. In consideration for entering into the amendments, the warrants that Nokomis owns that were scheduled to expire April 2021 were extended to April 2024 upon the signing of the note amendments.
On April 2, 2020, the Company entered into a Shareholder Loan Agreement with Bpifrance Participations, providing for an unsecured shareholder loan in an aggregate principal amount of $2.2 million. The loan accrued interest at 4.0% per annum. On May 15, 2020, the Company completed a private placement of 428,869 ADSs (1,715,476 ordinary shares) to Bpifrance
61


Participations at a price of $5.15 per ADS, which equaled the offering price to the public of ADSs sold in the underwritten public offering that closed on May 14, 2020.
On April 30, 2020, the Company finalized €5 million of French government debt financing that was received in May 2020 as part of the French COVID-19 economic support plan. The French loan is unsecured and can, at Sequans’ option, be repaid in full in one year plus 1.75% interest or, with one to four months’ notice before April 30, 2021, be repaid over the following five years. In March 2021, the Company exercised the option to repay over an additional five years (from August 2022 to May 2026, only interest will be paid from August 2021 to May 2022). €938,000 ($1,020,000) in principal and interests was reimbursed in 2023 (€736,000 ($742,000) in 2022).
On January 13, 2021, January 17, 2021 and February 12, 2021, Nokomis Capital, L.L.C, converted portions of the convertible note issued in 2015 with a total principal value of $7,750,000 plus accrued interest and conversion bonus of $4,536,438, into a total of 7,227,308 ordinary shares.
On March 5, 2021, the Company executed an agreement with Bpifrance that provides funding to the Company in the context of a long-term research project named CRIIOT, estimated to be completed over a 33-month period. The total value of the project is €5,615,000 ($6,890,000) in the form of a grant. The funding will be paid in three installments: €1,404,000 ($1,670,000) after the signature of the contract, received in March 2021; €2,808,000 ($2,966,000) received in July 2022 based on achievement of milestones and the remaining amount of €1,403,000 ($1,550,000) at the end of the contract which is expected to occur in 2024.
On April 9, 2021, the Company entered into a convertible note agreement with Lynrock Lake Master Fund LP in the principal amount of $40.0 million. The convertible note matures in April 2024 and is convertible, at the holder’s option, into the company’s shares at a conversion rate of $1.915 per share (representing $7.66 per ADS), subject to a 9.9% ownership limit for Lynrock Lake. The convertible debt pays interest annually at an interest rate of 5.0625% for cash payments or 6% for payment in kind accruals. Sequans retains an option to call the convertible debt under certain circumstances after 12 months, either in full or in part. If a change of control occurs at any time prior to the payment of the note in full, Lynrock Lake Master Fund LP shall have the right, in its sole discretion, to require Sequans to convert or redeem all of the outstanding principal amount (including accrued interest and unpaid interest).
On April 14, 2021, the Company repaid the remaining amount of the Nokomis Notes that were due on April 14 (Nokomis Notes issued in April 2015 and in September 2018) with accrued paid-in-kind interest of 7%. $6,378,104 was repaid for the April 2015 convertible note ($4,250,000 in principal and $2,128,000 as accrued interest) and $5,346,699 ($4,500,000 in principal and $847,000 as accrued interest) for the September 2018 convertible note.
On January 11, 2022, the Company issued and sold 7,899,020 ordinary shares in the form of 1,974,755 American Depositary Shares (ADSs) in a private placement to Renesas Electronics Corporation at a price of $4.70 per ADS, for total gross proceeds of $9.3 million.
On March 10, 2022, the Company increased its capital in connection with a public offering by issuing 6,666,667 ordinary shares at a price of $0.75 per share ($3.0 per ADS). On March 28, 2022, the underwriters exercised their option to purchase an additional 4,000,000 ordinary shares (represented by 1,000,000 ADS) at the public offering price, settled on April 1, 2022. The total gross proceeds from the offering, including from the exercise of the over-allotment option, amount to $23.0 million.
On August 15, 2022, the Company exercised its option to extend the term of the remaining Nokomis Note outstanding, that issued in August 2019. This convertible note now matures in August 2023, bears interest at a rate of 9.5% per year, paid in kind annually on August 16th and is convertible, at the holder’s option, into the company’s ADSs at a conversion rate of $4.12 per ADS. In connection with the extension of the debt, the Company issued to Nokomis warrants to acquire 594,680 ordinary shares (148,670 ADS) at an exercise price of $4.12 per ADS.
On April 12, 2023, the Company increased its capital in connection with a private offering to 272 Capital Master Fund Ltd, Lynrock Lake Master Fund LP and several other institutional investors by issuing 38,834,952 ordinary shares at $0.515 per ordinary share (or $2.06 per ADS). The total gross proceeds from the offering amounted to $20.0 million.
On August 4, 2023, the Company entered into a Memorandum of Understanding (the “MoU”) with Renesas Electronics Corporation, a Japanese corporation (“Renesas”). The MoU provided, among other things, that Renesas and the Company engage in a series of transactions pursuant to which, among other transactions, Renesas would seek to acquire (through an affiliate) all of the issued and outstanding ordinary shares for $0.7575 per ordinary share and $3.03 per ADS.
On August 15, 2023, the Company exercised its second option to extend the term of the remaining Nokomis Note outstanding, that issued in August 2019. This convertible note maturity was extended to April 2024, bears interest at a rate of 13.5% per year, paid in kind, and is convertible, at the holder’s option, into the company’s ADSs at a conversion rate of $3.23
62


per ADS. In connection with the extension of the debt, the Company issued to Nokomis warrants to acquire 244,820 warrants (311,205 ADSs) at an exercise price of $3.2328 per ADS.
On September 26, 2023, the Company entered into a Securities Purchase Agreement with 272 Capital Master Fund, LTD, a fund affiliated with Wes Cummins, a director of the Company, to issue an aggregate of 2,120,141 American Depositary Shares at a price of $2.83 per ADS for a total capital increase of $5,999,999. The private placement closed on September 29, 2023, and we used proceeds of the private placement to partially fund operations.
On November 8, 2023, the Company entered into a Security Purchase Agreement (the “Purchase Agreement”) with Renesas Electronics America Inc., (“Renesas America”) a wholly owned subsidiary of Renesas, providing for the issuance of an unsecured subordinated note in an aggregate principal amount of $6 million. The transaction closed on November 8, 2023. On December 27, 2023, we entered into a second Security Purchase Agreement with Renesas America providing for the issuance of an additional unsecured subordinated note in an aggregate principal amount of $3 million. The transaction closed on December 27, 2023. On February 12, 2024, we entered into a third Security Purchase Agreement with Renesas America providing for the issuance of an additional unsecured subordinated note in an aggregate principal amount of $9 million. The transaction closed on February 12, 2024.
On February 22, 2024, Renesas notified us that Renesas was terminating the MoU due its receipt of an adverse Japanese tax ruling on February 15, 2024 from the National Tax Agency of Japan. We incurred a significant amount of debt to operate our business during the pending tender offer, and our business suffered due, in part, to uncertainty raised by the pending acquisition. The termination of the MoU has created significant liquidity concerns and raised substantial doubt about our ability to continue to operate absent a new strategic transaction or financing in the near term. We were not able to pay our outstanding convertible notes due on April 9, 2024. On April 9, 2024, we secured standstill agreements from our three main debt holders. The agreements granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met; the request for the extension of the agreements is in process as of this date, however there can be no assurance of the length of the extension, if any. The goal is to provide sufficient time for the Company to effectively negotiate and finalize a new strategic transaction, thereby securing a long-term solution that aligns with the interests of all stakeholders.
On April 22, 2024, we issued an Unsecured Promissory Note with a principal amount of $5,000,000 to 272 Capital Master Fund, Ltd. The transaction closed on April 24, 2024. The Note bears paid-in kind interest at a rate of 12.0% per annum, compounded annually, with a guaranteed return of 40.0%. The Note matures on the earlier of April 22, 2025, or one day prior to the earliest extended maturity date of the Company’s existing convertible debt held by Lynrock Lake and Nokomis and subordinated notes held by Renesas. The Note contains customary covenants and is subject to customary events of default.
We are in discussions with several parties regarding potential strategic transactions, but we may not be able to enter into a definitive agreement in sufficient time. Even if we are able to enter into a definitive agreement, there is no certainty that a transaction will ultimately close or that we will be able to raise bridge financing and extend the standstill for our major lenders to continue to operate our business until the transaction closes.
If we are not able to enter into a strategic transaction for the sale of the company or a major licensing transaction in the near term and raise substantial new equity or debt financing, we may not be able to continue to operate our business and may need to seek a court ordered restructuring.
Cash Flows
The following table summarizes our cash flows for the periods indicated:
 
 Year ended December 31,
 202120222023
 (in thousands)
Net cash used in operating activities$(8,505)$(1,839)$(7,261)
Net cash used in investing activities$(19,666)$(26,047)$(24,437)
Net cash from financing activities$25,428 $28,715 $31,736 
Net increase (decrease) in cash and cash equivalents$(2,743)$829 $38 
Cash Flows from Operating Activities
Net cash used in operating activities during 2023 was $7.3 million, reflecting a net loss (before income tax) of $38.3 million, increases in research tax credit receivable of $3.3 million and in trade payables and other liabilities of $7.3 million, and decreases, contract liabilities of $0.2 million and in government grant advances of $1.1 million, offset by decreases in inventories of $3.1 million and in trade receivables and other receivables of $0.1 million. In addition, there were several non-
63


cash charges, including depreciation and amortization of $11.9 million, interest expense of $11.2 million, change in the fair value of convertible debt embedded derivative of $3.2 million, and share-based compensation expense of $7.1 million during the period. There was a non-cash benefit of $0.2 million related to convertible debt amendment.
Net cash used in operating activities during 2022 was $1.8 million, reflecting a net loss (before income tax) of $6.3 million, increases in inventories of $3.0 million and in research tax credit receivable of $1.6 million and decreases in trade payables and other liabilities of $7.0 million, contract liabilities of $6.2 million and in government grant advances of $2.5 million, offset by decreases in trade receivables and other receivables of $6.7 million. In addition, there were several non-cash charges, including depreciation and amortization of $12.0 million, interest expense of $10.9 million, change in the fair value of convertible debt embedded derivative of $6.9 million, and share-based compensation expense of $5.5 million during the period. There was a non-cash benefit of $0.5 million related to convertible debt amendment.
Net cash from in operating activities during 2021 was $8.5 million, reflecting a net loss (before income tax) of $19.6 million, increases in inventories of $0.2 million and in research tax credit receivable of $3.7 million and decreases in contract liabilities of $6.8 million and in government grant advances of $1.4 million, offset by increases in trade payables and other liabilities of $4.7 million, and decreases in trade receivables and other receivables of $1.4 million. In addition, there were several non-cash charges, including depreciation and amortization of $10.6 million, interest expense of $11.3 million, change in the fair value of convertible debt embedded derivative of $3.8 million, and share-based compensation expense of $5.1 million during the period. There was a non-cash benefit of $5.2 million related to debt repayment.
Cash Used in Investing Activities
Cash used in investing activities during 2023, 2022 and 2021, consisted primarily of purchases of property and equipment and intangible assets of $5.5 million, $7.2 million and $9.5 million, respectively, of capitalized development expenditures of $24.1 million, $15.5 million and $19.4 million, respectively, and the purchase for short-term deposits of $5.0 million in 2023 and $10.9 million in 2021 (sale of $5.0 million in 2022). In 2021, 2022 and 2023, the purchase of intangible assets included licenses purchased for the 5G product development.
Cash Flows from Financing Activities
Net cash provided by financing activities was $31.7 million in 2023, reflecting $25.5 million in net proceeds from our follow-on private placements of equity in April and September 2023, net proceeds from loans of $9.0 million, $0.5 million in proceeds of research project financings and $1.5 million in net proceeds drawn on interest-bearing receivables financing, offset by $1.1 million repayment of a government loan, $1.3 million payment of lease liabilities, $0.9 million repayment of research project financing and a $1.4 million payment of interest.
Net cash provided by financing activities was $28.7 million in 2022, reflecting $30.1 million in net proceeds from our follow-on public offering in March 2022 and $3.0 million in net proceeds drawn on interest-bearing receivables financing, offset by $1.0 million repayment of government loan, $1.2 million payment of lease liabilities, $0.8 million repayment of research project financing and a $1.5 million payment of interest.
Net cash provided by financing activities was $25.4 million in 2021, reflecting $49.5 million in net proceeds from the issuance of convertible debt and equity in April 2021 and $21,000 in net proceeds drawn on interest-bearing receivables financing, offset by an $8.8 million repayment of the convertible debt, $7.9 million repayment of the venture debt, $0.5 million repayment of government loan, $1.1 million payment of lease liabilities, $0.8 million repayment of research project financing and a $5.3 million payment of interest (including $3.0 million related to the repayment of convertible debt).
Operating and Investing Requirements
We expect our cash operating expenses will be slightly higher than in 2023 as we continue the development of our new 5G chipset targeting broadband IoT applications. We expect that investments in tangible and intangible assets are likely to be higher than in 2023 as we capitalize internally developed R&D related to the 5G product at a higher rate. We will incur expenses to meet our commitments to our customers under various purchase orders and contracts. The Company believes that it will be required to obtain additional financing to meet cash flow needs in order to fund operations until 4G product revenues ramp and is targeting the execution of new strategic agreements, such as licensing or a sale of assets, as the preferred mechanism to meet cash needs, as well as debt financing to bridge to the execution of such strategic agreements.
64


The Company’s internal cash forecast, which is built from sales forecasts by product and by customer, assumes higher product revenues, a slight increase in the operating cost structure, ongoing and new government funding of research programs and new strategic or financial funding activities. The Company seeks to obtain additional funding through one or more possible license agreements or sales of assets; or from financing from institutional or strategic investors, from the capital markets, or a combination of the above. However, the Company cannot guarantee if or when any such transactions will occur or whether they will be on satisfactory terms. Furthermore, geopolitical uncertainties, including the Russian-Ukraine and the Israeli-Hamas conflicts, could have a negative impact on sales of our products or make it difficult to produce and deliver products to our customers. The effects of the hostilities in Ukraine and Israel/Gaza also could negatively impact the ability of the Company to raise funds to meet its financial needs in the next twelve months and beyond. While the Company has taken and will continue to take actions to obtain new funding, the above factors raise substantial doubt about the Company’s ability to continue as a going concern as there is no assurance that the Company will be successful in satisfying its future cash needs.
If our available cash balances are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or more debt securities or enter into a credit facility, which may contain restrictive covenants. The sale of equity and convertible debt securities may result in dilution to our shareholders and those securities may have rights senior to those of the ADSs. If we raise additional funds through the issue of convertible debt securities, these securities could contain covenants that would restrict our operations.
Our estimates of the period of time through which our financial resources will be adequate to support our operations and the costs to support research and development and our sales and marketing activities are forward-looking statements and involve risks and uncertainties, and actual results could vary materially and negatively as a result of a number of factors, including the factors discussed in “Item 3.D—Risk Factors”. We have based our estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.
Our short and long-term capital requirements will depend on many factors, including the following:
our ability to generate cash from operations or to minimize the cash used in operations;
our ability to control our costs;
the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, or participating in litigation-related activities;
the impact of supply chain disruptions on our business;
the impact of the hostilities in Ukraine and in Israel/Gaza; and
the acquisition of products and technologies.
From time to time, we have entered into foreign currency hedging contracts primarily to reduce the impact of variations in the U.S. dollar to euro exchange rate on our operating expenses denominated in euros. (See Note 20.2 for more information on our hedging arrangements.)

C.
Research and Development, Patents and Licenses, etc.
We engage in substantial research and development efforts to develop new products and integrate additional capabilities into our core products. Our research and development team of 330 employees and independent contractors, at December 31, 2023, includes experienced semiconductor designers, software developers and test engineers. Key areas of expertise include wireless systems architecture, SoC architecture, digital and RF IC design, digital signal processing, embedded real-time and application software design, cellular protocol stack development, hardware and software integration, quality assurance test development and scripting and field testing. Our team has significant experience in the principal cellular wireless domains and other wireless communication technologies. Approximately 71% of our employee engineers have more than 10 years of experience in their specific domain, and 67% of our engineers hold masters degrees.
The ability to successfully integrate and mass-produce digital and/or RF functionality in advanced process technology with acceptable yields is a significant industry challenge. Due to the robustness of our silicon design and verification methodologies, we have demonstrated competency in repeatedly achieving production-capable products with the first version of our chip, reducing time to market and avoiding costs associated with additional design revisions. Our products in mass production use 65nm and 40nm silicon geometries (RF and baseband), and we are designing with denser process geometries for our 5G products.
We design our products with careful attention to quality, flexibility, cost-and power-efficiency requirements. Our 4G modem architecture, which has been refined through multiple generations of integrated circuit designs, is designed to optimize hardware and software partitioning to provide more flexibility and better cost without compromising performance. As a result,
65


we achieve equivalent or higher throughput and lower power consumption in a smaller die size than other single-mode 4G chip competitors.
Since February 2009, we have been certified as ISO 9001 compliant, an international standard set by the International Organization for Standardization, or ISO, that sets forth requirements for an organization’s quality management system. We believe this certification gives our customers confidence in our quality control procedures. We also participate in a number of organizations and standards bodies, including the 3rd Generation Partnership Project (3GPP), Open Mobile Alliance (OMA), the PTS Type Certification Review Board (PTCRB) the Global Certification Forum (GCF), the GSMA, European Telecommunications Standards Institute (ETSI) and CTIA—The Wireless Association.
We participate in multiple European Union and French collaborative projects for advanced studies to benefit from cutting edge innovations from industry and academic partners in areas spanning from signal processing to end-to-end solutions. Recent activities focus on the defining of IoT for industrial needs, in line with the evolution of 5G.
At December 31, 2023, we had 53 patents issued.
Our research and development expense was $26.4 million for 2021, $26.6 million for 2022 and $26.1 million for 2023.

D.Trend Information
Other than these items, or as disclosed elsewhere in this annual report, including in “Item 5. A. Operating Results” and in "Item 3. D. Risk Factors", we are not aware of any trends, uncertainties, demands, commitments or events that are reasonable likely to have a material adverse effect on our net revenues, income, profitability, liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial condition.

E.Critical Accounting Estimates
See footnote 2.4 to the Consolidated Financial Statements.

Item 6. Directors, Senior Management and Employees

A.Directors and Senior Management
Executive Officers and Directors
The following table sets forth information about our executive officers and directors as the date of this annual report.
66


NameAgePosition(s)
Executive Officers
Dr. Georges Karam62 Chairman of the Board and Chief Executive Officer
Deborah Choate60 Chief Financial Officer
Louis Chuang43 Executive Vice President - Massive IoT Business
Bertrand Debray59 Executive Vice President - Broadband IoT Business
Danny Kedar52 Chief Operating Officer
Olivier Pauzet49 Executive Vice President, Marketing and Strategy
Nikhil Taluja52 Executive Vice President Worldwide Sales
Directors
Wesley Cummins46 Director
Yves Maitre61 Director
Maria Marced69 Director
Richard Nottenburg70 Director
Hubert de Pesquidoux56 Director
Dominique Pitteloud62 Director
Zvi Slonimsky74 Director
Executive Officers
Dr. Georges Karam has served as our chairman of the board and chief executive officer since the company was founded in 2003. Before founding Sequans, Dr. Karam was vice president of cable access at Juniper Networks, running the cable engineering and marketing departments and managing the cable sales launch in the Europe, Middle East and Africa region. He joined Juniper Networks when the company acquired Pacific Broadband Communications (PBC), where he was vice president of engineering and general manager for Europe. Dr. Karam has served in a variety of senior management positions at Alcatel, SAGEM and Philips. He is a senior member of IEEE, has authored numerous technical and scientific papers and holds several patents in digital communications. Dr. Karam holds a PhD in signal processing and communication theory from Ecole Nationale Supérieure des Télécommunications, Paris.
Deborah Choate has served as our chief financial officer since July 2007. Prior to joining Sequans, she was chief financial officer at Esmertec AG from September 2005 to June 2007 and at Wavecom SA, from August 1998 to August 2004, and as vice president of finance at Platinum Equity from October 2004 to September 2005. Earlier in her career, she was an audit partner with Ernst & Young. Ms. Choate has over 35 years of experience in management, finance and accounting, including over 20 years working with technology companies, in particular communications hardware, software and services. Ms Choate holds a BS in business administration from the University of California at Berkeley.
Louis Chuang has served as executive vice president for the massive IoT business unit since April 2022; from May 2021 until March 2022, Mr. Chuang served as Sequans' general manager for Asia-Pacific. Prior to joining Sequans, Mr. Chuang was senior director of sales and marketing for the broadband wireless access business unit of Gemtek, a wireless solutions provider, where he held various positions within the wireless WAN and telecom products devisions since 2003. Mr. Chuang holds an MS in communication and microwave engineering from Yuan Ze University in Taiwan.
Bertrand Debray has served as our executive vice president for the broadband IoT business unit since October 2020; from July 2013 until September 2020, Mr. Debray served as our chief operating officer and prior to that as vice president, engineering since the company was founded in 2003. Before joining Sequans, Mr. Debray was director of hardware and ASIC development in the cable product division at Juniper Networks. He joined Juniper Networks after the company acquired Pacific Broadband Communications, where he played the same role and was significantly involved in developing the cable product and team. Mr. Debray has held technical and management positions at Alcatel. He has over 20 years’ experience in large project development covering all access technologies, including wireless, satellite and cable. Mr. Debray holds a MSE from Ecole Nationale Supérieure des Télécommunications, Paris.
Danny Kedar has served as our chief operating officer since November 2020. Prior to that Mr. Kedar served as vice president of the IoT business unit from February 2016 to November 2020. Mr. Kedar returned to Sequans in June 2015 after three years as CEO of Stylls, an internet start-up offering a photo book creation and sharing application. From 2009 to 2012,
67


Mr. Kedar was one of the lead product managers instrumental in the development of Sequans’ first LTE products. Prior to this, Mr. Kedar was CEO of Dorfour, a company developing technology for LTE modems. Earlier in his career, Mr. Kedar held positions including design engineer and marketing manager at companies including Agere Systems and Texas Instruments. Danny holds an engineering degree from Technion, Israel’s leading engineering school, and an MBA from Lehigh University, Pennsylvania, USA.
Olivier Pauzet has served as our executive vice president, marketing and strategy, since June 2023. Prior to that Mr. Pauzet was vice president of product and IoT solutions at Sierra Wireless (a Semtech company). From 2017 to 2020, he was vice president and general of the IoT Solutions business line at Sierra Wireless. Prior to that, he led the global business development, marketing, and strategic team of Sierra Wireless in the IoT sector. Earlier in his career, Mr. Pauzet was based in Asia, managing sales, businesses, and strategic programs at Wavecom. Mr. Pauzet holds a MBA from INSEAD and a Master of Science in Engineering from Centrale Supélec.
Nikhil Taluja has served as our executive vice president of worldwide sales since September 2016. From July 2013 until August 2016, Mr. Taluja was vice president of sales at SK hynix, a leading supplier of DRAM and Flash memory solutions, where he led the sales organization for the Americas. From March 2012 until July 2013, Mr. Taluja led the Americas’ sales and marketing organizations at ST-Ericsson, the former multinational supplier of wireless semiconductor products, including LTE solutions. From November 2007 until March 2012, Mr. Taluja held various other sales and marketing position at ST-Ericsson. Mr. Taluja has more than 20 years of sales, product marketing and business development experience, including having worked for Texas Instruments and TranSwitch, specifically in the areas of wireless and wireline communications and has co-authored three patents in the field of near field communications (NFC). Mr. Taluja holds an M.S. in electrical engineering and a BS in computer engineering and mathematics from Kansas State University.
Directors
Wesley Cummins has served as a director since June 2018. Mr. Cummins has served as a member of the Board of Directors of Applied Digital Corporation from 2007 until 2020 and from March 11, 2021 through present. During that time Mr. Cummins also served in various executive officer positions and he is currently serving as Applied Digital Corporation's chairman of the Board and chief executive office. Mr. Cummins is the president of B. Riley Asset Management, a position he has held since B. Riley Financial acquired his firm 272 Capital L.P. in August 2021. Prior to founding 272 Capital, Mr. Cummins was an analyst with Nokomis Capital, LLC, an investment advisory firm and a debtholder of the Company, from 2013 to February 2020. Mr. Cummins is also a board member of Vishay Precision Group and of CalAmp. He previously served on the board of Telenav, Inc., a connected car company. Mr. Cummins holds a B.S.B.A. from Washington University in St. Louis, Missouri.
Yves Maitre has served as a director since June 2014. Mr. Maitre has served as the CEO of Able France, a consulting firm, since July 2022. From October 2019 until September 2020, Mr. Maitre was Chief Executive Officer of HTC Corporation. Until September 2019, Mr. Maitre served as Executive VP for Connected Objects and Partnerships at Orange Corporate where he was responsible for managing Orange’s relationships with global device makers as well as partnering with ecosystem players from chipset upwards to internet companies. Prior to joining Orange, Mr. Maitre spent six years working for the consumer electronics company Thomson. He was President of Key MRO America, a subsidiary of Thomson United States and whilst living in Singapore he worked for Thomson Asia as Director of Manufacturing Supply Chain and Product Management. Before Thomson, Mr. Maitre spent five years as the COO of Quante-Pouyet, a subsidiary of 3M, making connectors for the telecoms business. He is also a board member of Orange China and several midsize / start-up companies. Mr. Maitre is an Engineering graduate in Nuclear Physics from Polytech Grenoble (France).
Maria Marced has served as a director since June 2023. Ms. Marced has served as president of TSMC Europe since 2007, where she is responsible for driving the development and strategy of TSMC’s business in Europe. Before joining TSMC, Marced was senior vice president of sales and marketing at NXP/Philips Semiconductors from 2003 until 2006, where she also served as GM of Philips’ Connected Multimedia Solutions Business Unit, overseeing Philips’ semiconductor solutions for connected consumer applications. Earlier, Marced spent more than 19 years at Intel, rising to the position of vice president and GM for Intel’s Europe, Middle East and Africa region. Marced serves as chairwoman of the Global Semiconductor Alliance (GSA) EMEA leadership council, an organization dedicated to the advancement of the worldwide semiconductor industry. Ms. Marced holds a masters degree in telecommunications engineering from Politechnique Madrid (Spain).
Richard Nottenburg has served as a director since June 2016. He has served as Executive Chairman of NxBeam Inc., a private company, since February 2022, and an investor in various early-stage technology companies. Previously, Dr. Nottenburg served as president, chief executive officer, and member of the board of directors of Sonus Networks, Inc. from
68


2008 through 2010. From 2004 until 2008, Dr. Nottenburg was an officer with Motorola, Inc., ultimately serving as its executive vice president, chief strategy officer and chief technology officer. He served on the boards of Aeroflex Corporation from 2010 until 2014, PMC Sierra, where he was a member of the audit committee, from 2011 until 2016 and Violin Memory where he served as Chairman from 2014 until 2017. Dr. Nottenburg is currently a member of the board of directors of Verint Systems Inc., where he is chairman of the compensation committee; Cognyte Ltd., where he is chairman of the compensation committee, and Applied Digital Inc., where he is chairman of the compensation committee and a member of the audit committee. He previously served on the boards of directors of PMC-Sierra Inc., Aeroflex Holding Corp., Anaren, Inc., Comverse Technology, Inc. and Violin Memory, Inc. Dr. Nottenburg has a BSEE in Electrical Engineering from New York University, an MSEE in Electrical Engineering from Colorado State University and a PhD in Electrical Engineering from Ecole Polytechnique Federal Lausanne.
Hubert de Pesquidoux has served as a director since March 2011. Mr. de Pesquidoux has served as an Executive Partner at Siris Capital, a private equity firm focused on making control investments in data/telecom, technology and technology-enabled business service companies in North America, since October 2012. From 1991 until December 2009, Mr. de Pesquidoux held various positions at the telecommunications company Alcatel-Lucent SA (and its predecessor, Alcatel S.A. and its affiliates), where he most recently served as Chief Financial Officer from November 2007 until December 2008 and as President of the Enterprise business from November 2006 until December 2008. Mr. de Pesquidoux was also previously a member of the Alcatel Executive Committee and held various executive positions including President and Chief Executive Officer of Alcatel North America, Chief Executive Officer of Alcatel Canada (formerly NewbridgeNetworks) and Chief Financial Officer of Alcatel USA. Mr. de Pesquidoux currently serves as a director and audit committee chair of Criteo S.A., as executive chairman of Mavenir Systems, Inc. and is a member of the board of Tarana Wireless. Mr. de Pesquidoux holds a Master in Law from University of Nancy II, a Master in Economics and Finance from Institut d’Etudes Politiques de Paris, a DESS in International Affairs from University of Paris Dauphine and was a laureate in the “Concours Général de Droit”.
Dominique Pitteloud has served as a director since January 2005. Mr. Pitteloud is a co-founder and has served as managing partner at Climb Ventures in Geneva since 2020. He was managing partner with Ginko Ventures from 2015 to 2020, partner with Endeavour Vision from 2007 to 2015, and principal at Vision Capital from 2001 to 2007. Mr. Pitteloud is also an advisor to ASSIA, a provider of DSL management solutions and serves or has served as a director of number of private companies. Prior to becoming a venture capitalist, Mr. Pitteloud was vice president of marketing at 8×8, a Silicon Valley semiconductor and telecommunication company, which he joined in 1999 as part of the acquisition of Odisei, a VoIP start-up from Sophia Antipolis, France. At Odisei, Mr. Pitteloud led the development of the company’s business and financing activities. Prior to Odisei, Mr. Pitteloud held various engineering and management positions at Logitech, including Vice President of the scanner and video camera business units. Mr. Pitteloud received a BS in electrical engineering and telecommunications from the School of Business and Engineering in Vaud, Switzerland and an MBA from Santa Clara University.
Zvi Slonimsky has served as a director since November 2006. Since 2005, Mr. Slonimsky has been chairman of the board of several Israeli high tech companies, currently including several private companies as well as Awear, Maradin and Surf, and previously Alvarion, Extricom, Pentalum and Teledata. He served as CEO of Alvarion Ltd. from 2001 to October 2005, following Alvarion’s establishment via merger of BreezeCOM and Floware in August 2001. Prior to the merger, Mr. Slonimsky was CEO of BreezeCom. Before that, he served as president and CEO of MTS Ltd. and was general manager of DSP Group, Israel. Earlier in his career, he held senior positions at several Israeli telecom companies, including C.Mer and Tadiran. Mr. Slonimsky holds a BSEE and a MSEE from the Technion Israel Institute for Technology and an MBA from Tel-Aviv University.

B.Compensation
Compensation of Executive Officers and Directors
The compensation policies applicable to our executive officers and directors are designed to promote the Company’s performance and competitiveness in the mid and long term and to be aligned with shareholders’ interests, while being competitive in order to attract and retain qualified executive officers and directors.
Director compensation elements are submitted to the approval of the shareholders annually.
The compensation policy applicable to executive officers is determined by the board of directors on the basis of recommendations made by the compensation committee and is reviewed annually. The compensation committee comprises exclusively independent directors.
69


All executive officers are compensated by a combination of fixed salary, bonus based of performance on quarterly or annual objectives and long-term incentives in the form of grants of restricted free shares vesting over four years.
On October 23, 2023, the Company adopted its Compensation Recovery Policy which specifies when we will seek recovery of performance based bonuses awarded or paid based on financial metrics that were subsequently restated.
The aggregate compensation paid and benefits in kind granted by us to our executive officers and directors, including share-based compensation, for the year ended December 31, 2023 was $7.0 million. For the year ended December 31, 2023, we estimate that approximately $23,000 of the amounts set aside or accrued to provide pension, retirement or similar benefits to our employees was attributable to our executive officers.
Our non-employee directors are entitled to the following annual compensation as an annual retainer:
 
Attendance fees$20,000 
Attendance fees for lead independent director$20,000 
Attendance fees for board committee chairperson
       Audit committee$12,000 
Compensation committee$9,000 
Nominating and corporate governance committee$5,000 
Attendance fees for board committee members
Audit committee$6,000 
Compensation committee$4,500 
Nominating and corporate governance committee$2,500 
In addition, our non-employee directors, are also entitled to the following equity awards as an annual retainer:
Annual award for continuing board members(1)(2)
Warrants to purchase 45,000 ADSs
(1)The annual equity award for continuing board members has an exercise price equal to the fair market value of the ADSs on the date of grant and will fully vest on the anniversary of the date of grant of the award, subject to the non-employee director’s continued service to us through the vesting date.
(2)All such awards will become fully vested upon a change of control.

Employment Agreements with Executive Officers
We have entered into a managing director agreement with Georges Karam, our chairman and chief executive officer, which contains provisions regarding salary and bonus, severance payment and benefits.
In accordance with French law, our chief executive officer (“directeur général” or “managing director”) cannot be an employee in connection with the performance of his duties in such capacity. The managing director agreement entered into with Dr. Karam does not constitute and does not contain the compulsory provisions under French law to be construed as, an employment agreement. Therefore, Dr. Karam does not benefit from the status of employee nor from any benefit that French laws and regulations grant to employees, including unemployment benefits. The managing director agreement only sets forth the terms and conditions, including compensation, under which Dr. Karam performs his duties as chief executive officer.
Fixed compensation: Dr. Karam benefits from a fixed annual gross compensation of €400,000 as of November 1, 2022, increased from €350,000 which had been unchanged since December 2016. Dr. Karam's fixed compensation is determined by taking into account the level and complexity of his responsibilities, his experience in similar positions and market practices for comparable companies.
Variable compensation: Dr. Karam’s annual variable compensation can represent between 0% and 100% of Dr. Karam’s annual fixed compensation. The amount of variable compensation is based on the achievement of pre-determined performance conditions defined by the board of directors based on recommendations issued by the compensation committee. The performance conditions are a combination of financial and strategic targets. The board of directors in its meeting of January 25, 2024, approved a bonus of €320,000 for the year ended December 31, 2023, compared with €358,333 for the year ended December 31, 2022 and €276,500 for the year ended December 31, 2021.
70


On July 25, 2023, the board of directors approved a special transaction bonus to Dr. Karam in the amount of €1,000,000 conditional upon the closing the proposed acquisition of the Company by Renesas. The transaction bonus was never paid due of the termination of the proposed transaction by Renesas in February 2024. In addition, on August 15, 2023, the board of directors approved the payment by the Company of legal fees incurred by Dr. Karam in the connection with the negotiation with Renesas of the conditions of his retention as Chief Executive Officer of the Company upon change of control. A total amount of $50,401 in such legal fees were paid during 2023.
Long-term variable compensation – restricted free shares: While not an obligation of his employment agreement, each year Dr. Karam is granted restricted free shares. Dr. Karam is granted restricted free shares from the same plans used for all employees, and is subject to all the same terms and conditions. Detail of Dr. Karam's restricted free shares is described in Item 6.B.
Benefits in kind: Dr. Karam, as he is not entitled to normal French legal employee unemployment benefits, we have subscribed to private unemployment insurance on his behalf and increase Dr. Karam's compensation to cover the income taxes associated with this benefit (total cost of €14,909 in 2023; €14,099 in 2022; €14,901 in 2021). He is however eligible for the French defined contribution pension plan, which also applies to all of our French employees.
Directors’ compensation: Dr. Karam does not receive any compensation for the directorship duties that he performs for the Company or any of our subsidiaries.
Commitments given by our Company to Dr. Karam in relation to the termination or change of his executive corporate officer duties: If Dr. Karam is terminated without cause, he is entitled to a lump sum severance payment equal to eighteen months of his gross annual base remuneration and 150% of bonus, plus vesting of the ordinary shares that would have been vested during the twelve months following the end of his term. In case the dismissal would occur during the three months before or the twelve months following a change of control, he would be entitled to all the unvested share awards at the date of dismissal.
His employment contract also included a non-compete clause applicable for one year as from the termination date and applicable only to competing businesses in France. However, the Company had the option to waive this non-compete clause subject to the waiver being notified to him within 15 days after the notification of termination.
We have entered into standard employment agreements with each of our other executive officers. There are no arrangements or understanding between us and any of our other executive officers providing for benefits upon termination of their employment, other than as described in our chief executive officer's employment agreement and other than as required by applicable law.
Equity Plans
We have issued to our employees and certain consultants, stock options, founders' warrants and warrants to purchase our ordinary shares, and restricted share awards. Due to French corporate law and tax considerations, we have issued such equity awards under four types of equity plans, collectively referred to in this discussion as our equity plans. Our equity plans provide for the issue of restricted free shares or stock options to employees pursuant to our Stock Option and Restricted Share Award Plans; warrants to our business partners, including certain consultants and advisors, who have long-term relationships with us and advise us on a regular basis, pursuant to our BSA Subscription Plans; and prior to our initial public offering in the United States in April 2011, founders' warrants to employees in France, pursuant to our BCE Subscription Plans.
Under French law, the creation of each of these equity plans and the issuance of the underlying shares must be approved at the shareholders’ general meeting. The shareholders may delegate to our board of directors the authority to finalize the form of the plans and to grant the securities within a period that cannot exceed 18 months for restricted share awards, founders' warrants and warrants, and 38 months for stock options. The shareholders have nevertheless historically delegated the authority to our board to grant these securities within a period that cannot exceed 12 months. Once approved by the shareholders’ general meeting, these equity plans cannot be extended either in duration or in size. We have therefore implemented new equity plans each year and expect to continue to do so.
From 2004 through May 7, 2024, our shareholders have approved and authorized the issuance of an aggregate of 57,961,256 shares (14,490,314 ADSs) under our equity plans. At May 7, 2024, there were outstanding stock options and warrants to purchase a total of 1,741,987 of our ADSs issued under our equity plans at a weighted average exercise price of $4.96, of which 1,288,750 were held by our directors and executive officers at a weighted average exercise price of $4.83 per ADS. Of these outstanding stock options and warrants, at May 7, 2024, options and warrants to purchase 1,426,987 ADSs were vested and exercisable, of which 1,288,750 in the form of ADS were held by our directors and executive officers. At May 7,
71


there were unvested restricted share awards outstanding representing 5,325,411,ADSs, of which 2,887,690 were held by our directors and executive officers. As of May 7, 2024, there were 719,095 restricted shares in the form of ADSs (507,026 held by our directors and executive officers) had vested but were not yet freely transferable under the restrictions of the plans.
The stock options and warrants granted under each of our equity plans were granted on substantially the same terms. In general, vesting of the stock options occurs over four years, with 25% vesting after an initial 12 months and the remaining 75% vesting monthly over the remaining 36 months or twelve quarters, or may be immediate when linked to employee performance. Restricted shares also generally vest over four years with either 25% vesting after an initial 12 months or 50% vesting after the initial 24 months, and the remainder vesting over the remaining 12 or 8 quarters, respectively. In addition, restricted shares cannot be sold during the first 24 months after the grant date. In general, vesting of warrants may be either on a monthly basis over a two-year period, 100% after a one-year period or may be immediate. The stock options and warrants generally expire ten years after the date of grant if not exercised earlier. In general, when a stock option or restricted shareholder’s employment service with us, or a warrant holder’s service with us, terminates for any reason, his or her stock options or restricted shares or warrants, as the case may be, will no longer continue to vest following termination. The holder may exercise any vested stock options or warrants for a period of 30-90 days. In the event of death, the holder’s heirs or beneficiaries shall have a period of six months to exercise such stock options or warrants. In the event that a third party acquires a 100% interest in us, an employee holder of stock options and restricted shares who is subsequently dismissed has the right to exercise all of his or her options or warrants within 30 days, notwithstanding the current vesting schedule, and all unvested restricted shares shall vest immediately, conditional upon such dismissal being at least one year from grant date and subject to the same requirement to hold the restricted shares until two years from the grant date. In the event of a change of control, as defined in the warrant equity plans subject to vesting, warrants that are not yet exercisable will become exercisable for 30 days following the effective date of the change of control.
The exercise price of the stock options or warrants is set at the fair market value of the shares on the effective date of grant as determined by our board of directors, typically the closing price of the ADSs on the effective date.
In the event of certain changes in our share capital structure, such as a consolidation or share split or dividend, appropriate adjustments will be made to the numbers of shares and exercise prices under outstanding stock options, founders' warrants and warrants.
The following table provides information regarding the options to purchase our ordinary shares and restricted shares held by each of our directors and officers who beneficially own greater than one percent of our ordinary shares or ADS or have options to purchase more than one percent of our ordinary shares or ADS as of May 7, 2024:
Restricted Shares (1)(2)Options (2)
Name (Title)Number UnvestedNumber Vested, Trading RestrictedGrant Date Fair ValueNumberExercise
Price
Expiration Date
Dr. Georges Karam, Chairman and Chief Executive Officer168,750$1.35170,000$1.58July 22, 2024
437,500$1.08130,000$1.25Dec. 11, 2024
125,024$1.0398,000$1.94Apr. 21, 2025
421,848328,104$0.91170,000$1.55July 20, 2025
1,750,0001,050,000$0.92100,000$1.97Dec. 14, 2025
825,000375,000$0.90
4,000,000$0.18
(1) The restricted shares also vest over four years with 25% vesting after an initial 12 months and the remainder vesting over the remaining 36 months. The restricted shares cannot be sold during the first 24 months after the grant date.
(2) The numbers in the table represent the number of underlying ordinary shares. To obtain the number of ADS, it is necessary to divide by four. To obtain the exercise price per ADS or the grant date fair value per ADS, it is necessary to multiply by four.
All ADS and per ADS amounts reflect the current ADS to ordinary share ratio of one ADS representing four ordinary shares.

72


C.Board Practices
In accordance with French law governing a société anonyme, our business is overseen by our board of directors and by our chairman. The board of directors has appointed Dr. Karam as our chairman, who also serves as our chief executive officer. Subject to the prior authorization of the board of directors for certain decisions as required under French law, the chief executive officer has full authority to manage our affairs.
Our board of directors is responsible for, among other things, presenting our accounts to our shareholders for their approval and convening shareholder meetings. The board of directors also reviews and monitors our economic, financial and technical strategies. The directors are elected by the shareholders at an ordinary general meeting. Under French law, a director may be an individual or a corporation and the board of directors must be composed at all times of a minimum of three members.
Within the limits set out by the corporate purposes (objet social) of our company and the powers expressly granted by law to the shareholders’ general meeting, the board of directors may deliberate upon our operations and make any decisions in accordance with our business. However, a director must abstain from voting on matters in which the director has an interest. The board of directors can only deliberate if at least half of the directors attend the meeting in the manners provided for in our by-laws. Decisions of the board of directors are taken by the majority of the directors present or represented. Under French law, our directors and chief executive officer may not, under any circumstances, borrow money from us or obtain an extension of credit or obtain a surety from us.
Our board of directors currently consists of eight directors, which is the maximum permitted under our by-laws. Our board of directors has determined that each of Messrs. Cummins, Maitre, Nottenburg, de Pesquidoux, Pitteloud, and Slonimsky and Ms. Marced qualify as independent under the applicable rules and regulations of the SEC and the NYSE.
The sections of the by-laws relating to the number of directors, election and removal of a director from office may be modified only by a resolution adopted by 66 2/3% of our shareholders present or represented. A director’s term expires at the end of the ordinary shareholders’ general meeting convened to vote upon the accounts of the then-preceding fiscal year and is held in the year during which the term of such director comes to an end unless such director’s term expires earlier in the event of a resignation or removal. The following table sets forth the names of the directors of our company, the dates of their initial appointment as directors and the expiration dates of their current term.
NameCurrent
position
Year of
appointment
Term
expiration
year
Georges KaramChairman20032024
Wesley CumminsDirector20182024
Yves MaitreDirector20142026
Maria MarcedDirector20232026
Richard NottenburgDirector20162025
Hubert de PesquidouxDirector20112026
Dominique PitteloudDirector20052025
Zvi SlonimskyDirector20062024
Each director is elected for a three-year term by a vote of the majority of the shareholders present or represented. Under French law, a director who is an individual cannot serve on more than five boards of directors or supervisory boards in corporations (société anonyme) registered in France; directorships in companies controlled by us, as defined in article L.233-16 of the French Commercial Code, are not taken into account.
Directors may resign at any time and their position as members of the board of directors may be revoked at any time by a majority vote of the shareholders present or represented at a shareholders’ general meeting, excluding abstentions. The number of directors who are over 70 years old may not exceed one third of the total number of directors and the chairman of our board must not be over 65 years old. A director does not need to be a French national, and there is no limitation on the number of terms that a director may serve. In case of removal without cause, directors may be entitled to damages.
Vacancies on our board of directors, including vacancies resulting from there being fewer than the maximum number of directors permitted by our by-laws, provided there are at least three directors remaining, may be filled by a vote of a simple majority of the directors then in office. The appointment must then be ratified by the next shareholders’ general meeting. Directors chosen or appointed to fill a vacancy shall be elected by the board for the remaining duration of the current term of
73


the replaced director. In the event the board would be composed of less than three directors as a result of a vacancy, meetings of the board of directors shall no longer be permitted to be held except to immediately convene a shareholders’ general meeting to elect one or several new directors so there are at least three directors serving on the board of directors, in accordance with French law.
Under French law, employees may be elected to serve as a director. However, such employee-director must perform actual functions separate from his/her role as director in order to retain the benefit of his/her employment agreement. The number of directors who are our employees cannot exceed one third of the directors then in office. No director can enter into an employment agreement with us after his/her election to the board of directors.
French law requires that companies having at least 50 employees for a period of 12 consecutive months have a Comité Social et Economique, or Workers’ Council, composed of representatives elected from among the personnel. Our Workers’ Council was formed in 2007. Two of these representatives are entitled to attend all meetings of the board of directors and the shareholders, but they do not have any voting rights.
Directors are required to comply with applicable law and with our by-laws. Our directors may be jointly and severally liable for actions that they take that are contrary to our interests. Directors are jointly and severally liable for collective decisions. However, each director may avoid liability by proving that he or she acted diligently and with caution, in particular by not approving the decision at issue or even by resigning in the event of certain critical situations. In certain critical situations, in order to avoid liability for decisions made by the board, a director must resign from his or her office. Directors may be individually liable for actions fully attributable to them in connection with a specific mission assigned to them by the board of directors. As a director, the chairman of the board is liable under the same conditions. The chief executive officer may be liable with respect to third parties if he commits a fault that is severable from his duties and which is only attributable to him.
Directors’ Service Contracts
In March 2021, we entered into a consulting agreement with Yves Maitre. See “Item 7.B—Related Party Transactions—Agreements with Executive Officers and Directors—Director Compensation and Agreements”. Except for this consulting agreement and directors compensation, there are no other arrangements or understandings between us and any of our non-employee directors providing for benefits upon termination of their employment or service as directors of our company, other than as required by applicable law.
Board Leadership Structure
We believe that the interests of our shareholders are best served by maintaining our Board of Directors’ flexibility in determining the board leadership structure that is best suited to the needs of the Company at any particular time. Mr. Yves Maitre currently serves as lead independent director. The defined role of the lead independent director is designed to ensure a strong, independent and active Board of Directors. As set forth in the Board Internal Charter, the lead independent director has clearly delineated and comprehensive duties. These duties included:
Presiding at all meetings of the board at which the chairman is not present, including executive sessions of the independent directors.
Calling meetings of the independent directors.
Serving as liaison between the independent directors and the chairman and chief executive officer.
Collecting feedback from the board members in order to help the chairman finalize the meeting agendas.
Based on feedback from the other board members, recommending to the chairman that a special board of directors meeting be called focused on a specific agenda.
If a shareholder requests to talk with an independent director and not to the chairman and/or the chief executive officer, representing the board of directors for such communication in coordination with the chairman.
Board Committees
Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee.
Audit Committee
Our audit committee consists of Hubert de Pesquidoux, Richard Nottenburg and Dominique Pitteloud, with Mr. de Pesquidoux serving as chairperson. Our audit committee oversees our corporate accounting and financial reporting process and
74


internal controls over financial reporting. Our audit committee evaluates the independent registered public accounting firm’s qualifications, independence and performance; recommends to the shareholders with respect to the identity and compensation of the independent registered public accounting firm; approves the retention of the independent registered public accounting firm to perform any proposed permissible non-audit services; reviews our Consolidated Financial Statements; reviews our critical accounting policies and estimates and internal controls over financial reporting; discusses with management and the independent registered public accounting firm the results of the annual audit and the reviews of our quarterly Consolidated Financial Statements; and reviews the scope and results of internal audits and evaluates the performance of the internal auditor. Our board of directors has determined that each of our audit committee members meets the requirements for independence and financial literacy under the applicable rules and regulations of the SEC and the NYSE. Our board of directors has determined that Mr. de Pesquidoux is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication under the applicable rules and regulations of the NYSE. The audit committee operates under a written charter that satisfies the applicable rules of the SEC and the NYSE.
Compensation Committee
Our compensation committee consists of Zvi Slonimsky, Richard Nottenburg and Dominique Pitteloud, with Mr. Slonimsky serving as chairperson. Our compensation committee reviews and recommends policies relating to the compensation and benefits of our officers and employees, which includes reviewing and approving corporate goals and objectives relevant to compensation of our chief executive officer and other senior officers, evaluating the performance of these officers in light of those goals and objectives and setting compensation of these officers based on such evaluations. The compensation committee also recommends to the board of directors the issue of stock options and other awards. Our board of directors has determined that each member our compensation committee meets the requirements for independence under the applicable rules and regulations of the SEC and the NYSE. The compensation committee operates under a written charter.
Nominating and Corporate Governance Committee
Our nominating and corporate governance committee consists of Yves Maitre, Maria Marced and Zvi Slonimsky, with Mr. Maitre serving as chairperson. The nominating and corporate governance committee is responsible for making recommendations regarding candidates for directorships and the size and composition of our board. In making such recommendations, the nominating and corporate governance committee considers the skills and experience of the directors or nominees in the context of the needs of our board of directors as well as the directors’ or nominees’ diversity of skills and experience in areas that are relevant to our business and activities. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate governance guidelines and reporting and making recommendations concerning governance matters. Our board of directors has determined that each member of our nominating and corporate governance committee meets the requirements for independence under the applicable rules and regulations of the NYSE. The nominating and corporate governance committee operates under a written charter.

D.Employees
At December 31, 2023, we had 264 full-time employees, of whom 140 were located in France, 43 were in Israel, 34 were in the United Kingdom, 22 were in the United States, 11 were in Taiwan, 5 were in Singapore, 7 were in China, and there was one employee in each of Finland and Hong Kong. Management considers labor relations to be good. We also have independent contractors and consultants. At December 31, 2023, we had 48 dedicated engineers from Global Logic in Ukraine for software development and testing, and also had 98 independent contractors primarily in research and development but also in business development and finance in France, Finland, Germany,India, Israel, Poland, Serbia, the United Kingdom, the United States, China and Japan.
At each date shown, we had the following employees, broken out by department and geography:
75


 At December 31,
 202120222023
Department:
Research and development189 183 190 
Sales and marketing36 44 45 
General and administration18 23 24 
Operations785
Total250 258 264 
Geography:
Europe, Middle East, Africa210 211 218 
Asia222724
Americas18 20 22 
Total250 258 264 


E.Share Ownership
For information regarding the share ownership of our directors and executive officers, please refer to “Item 6.B.—Compensation—Equity Plans” and “Item 7.A—Major Shareholders.

F.Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation
S’share Ownership

Not applicable.

Item 7. Major Shareholders and Related Party Transactions

A.Major Shareholders
The following table sets forth information with respect to the beneficial ownership of our shares as of May 7, 2024 :
each person, or group of affiliated persons, known by us to own beneficially more than 5% of our outstanding ADSs or ordinary shares;
each of our executive officers;
each of our directors; and
all of our executive officers and directors as a group.
Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting or investment power with respect to those securities, and include shares subject to options that are exercisable within 60 days after the date of this annual report. Such shares are also deemed outstanding for purposes of computing the percentage ownership of the person holding the option, but not the percentage ownership of any other person.
For the purpose of calculating the percentage of shares beneficially owned by any shareholder, this table lists applicable percentage ownership based on 247,755,548 ordinary shares (the equivalent of 61,938,887 ADSs) outstanding as of May 7, 2024.
Unless otherwise indicated below, to our knowledge, all persons named in the table have sole voting and investment power with respect to their shares. To our knowledge, none of the shareholders in this table is a broker-dealer or is affiliated with a broker-dealer.
Unless otherwise indicated in the footnotes to the table, the address of each individual listed in the table is c/o Sequans Communications S.A., 15-55 boulevard Charles de Gaulle, 92700 Colombes, France.
76


 Ordinary Shares
Beneficially  Owned
ADSs Beneficially Owned
 NumberNumberPercent
5% Shareholders
B. Riley Asset Management LLC(1)
45,013,764 11,253,441 18.2 %
Lynrock Lake Master Fund LP (2)
34,711,652 8,677,913 14.0 %
Divisar Partners QP, L.P.(3)
18,905,516 4,726,379 7.6 %
Bpifrance Participations(4)
13,200,072 3,300,018 5.3 %
Executive Officers and Directors
Dr. Georges Karam(5)
6,256,907 1,687,138 2.7 %
Deborah Choate(6)
858,252 214,563 *
Louis Chuang(7)
112,520 28,130 *
Wesley Cummins(8)
45,575,764 11,393,941 18.4 %
Bertrand Debray(9)
1,648,292 412,073 *
Danny Kedar(10)
552,520 138,130 *
Yves Maitre(11)
823,360 205,840 *
Maria Marced(12)
180,000 45,000 *
Richard Nottenburg(13)
634,500 158,624 *
Olivier Pauzet— — *
Hubert de Pesquidoux(14)
674,400 168,600 *
Dominique Pitteloud(15)
728,000 182,000 *
Zvi Slonimsky(16)
752,388 188,097 *
Nikhil Taluja(17)
639,256 159,814 *
All executive officers and directors as a group (14 persons)(18)
59,115,404 14,981,950 23.3 %
 * Represents beneficial ownership of less than 1%.

(1)Based on a Schedule 13D/A filed with the SEC on October 27, 2023. B. Riley Asset Management LLC (“BRAM”) is the investment manager for certain funds and accounts (the "BRAM Funds and Accounts") and Mr. Cummins is the President of BRAM. BRAM and Mr. Cummins share voting and dispositive rights over the ADSs. The principal business address of BRAM is 3811 Turtle Creek Boulevard, Suite 2100, Dallas, TX 75219.
(2)Based on a Schedule 13F filed with the SEC on February 14, 2024. The amount reported includes 34,711,652 ordinary shares represented by 8,677,913 ADSs. In addition, Lynrock Lake Master Fund LP ("Lynrock Lake Master") directly held convertible notes of the Company that are not presently convertible into ADSs due to a 9.99% beneficial ownership limitation. Lynrock Lake LP (the "Investment Manager") is the investment manager of Lynrock Lake Master, and pursuant to an investment management agreement, the Investment Manager has been delegated full voting and investment power over securities of the Company held by Lynrock Lake Master. Cynthia Paul, the Chief Investment Officer of the Investment Manager and Sole Member of Lynrock Lake Partners LLC, the general partner of the Investment Manager, may be deemed to exercise voting and investment power over securities of the Issuer held by Lynrock Lake Master. The address of Lynrock Lake is 12 International Drive, Suite 130, Rye Brook NY 10573.
(3)Based on a Schedule 13G/A filed with the SEC on February 14, 2024. Includes 18,905,516 ordinary shares (represented by 4,726,379 ADSs) beneficially owned by Divisar Capital Management, LLC, which is the general partner of Divisar Partners QP, L.P.. Included in this amount are 17,605,068 ordinary shares (represented by 4,401,267 ADSs) held by Divisar Partners QP, L.P. Mr. Steven Baughman, as CEO of Divisar Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares held by Divisar Partners QP, L.P. The principal business address for Divisar Partners QP, L.P. is 275 Sacramento Street, 8th Floor, San Francisco, CA. Mr. Steven Baughman, as CEO of Divisar Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares held by Divisar Partners QP, L.P. The principal business address for Divisar Partners QP, L.P. is 275 Sacramento Street, 8th Floor, San Francisco, CA 94111.
(4)Based on a Schedule 13D/A filed with the SEC on August 29, 2023. Bpifrance Participations S.A., or Bpifrance Participations. Bpifrance Participations is a wholly-owned subsidiary of Bpifrance S.A., a French credit institution ("Bpifrance"). Caisse de Dépôts, or CDC, and EPIC Bpifrance, a French public institution of industrial and
77


commercial nature (“EPIC”) each hold 49.2% of the share capital of Bpifrance and jointly control Bpifrance. None of Bpifrance, CDC or EPIC holds any shares directly. Bpifrance may be deemed to be the beneficial owner of 13,200,072 shares, indirectly through its ownership of Bpifrance Participation. CDC and EPIC may be deemed to be the beneficial owner of 13,200,072 shares, indirectly through their joint ownership and control of Bpifrance. The principal address for CDC is 56, rue de Lille, 75007 Paris, France. The principal address for Bpifrance Participations, Bpifrance and EPIC is 27-31, avenue du Général Leclerc, 94710 Maisons-Alfort Cedex, France.
(5)Includes 877,376 ordinary shares subject to options that are exercisable and restricted shares that vest within 60 days of May 7, 2024.
(6)Includes 185,500 ordinary shares subject to options that are exercisable and restricted shares that vest within 60 days of May 7, 2024.
(7)Includes no restricted shares that vest within 60 days of May 7, 2024.
(8)Includes 562,000 ordinary shares subject to warrants that are exercisable within 60 days of May 7, 2024 and 44,201,364 ordinary shares (represented by 11,050,341ADSs) owned by BRAM Funds and Accounts.
(9)Includes 209,500 ordinary shares subject to options that are exercisable and restricted shares that vest within 60 days of May 7, 2024.
(10)Includes 131,252 ordinary shares subject to options that are exercisable and restricted shares that vest within 60 days of May 7, 2024.
(11)Includes 647,000 ordinary shares subject to warrants that are exercisable within 60 days of May 7, 2024.
(12)Includes 180,000 ordinary shares subject to warrants that are exercisable within 60 days of May 7,, 2024.
(13)Includes 632,000 ordinary shares subject to warrants that are exercisable within 60 days of May 7,, 2024.
(14)Includes 632,000 ordinary shares subject to warrants that are exercisable within 60 days of May 7, 2024.
(15)Includes 632,000 ordinary shares subject to warrants that are exercisable within 60 days of May 7, 2024.
(16)Includes 632,000 ordinary shares subject to warrants that are exercisable within 60 days of May 7, 2024.
(17)Includes 208,752 ordinary shares subject to options that are exercisable and restricted shares that vest within 60 days of May 7, 2024.
(18)Includes 5,529380 ordinary shares subject to options and warrants that are exercisable and restricted shares that vest within 60 days of May 7, 2024.
None of our principal shareholders have voting rights different than our other shareholders.
At May 7, 2024, there were 61,855,829 of our ADSs outstanding, representing 247,423,716 of our ordinary shares or 99.9% of our 247,755,548 total outstanding ordinary shares. At such date, there were 309 holders of record registered with the Bank of New York Mellon, depositary of our ADSs.

B.Related Party Transactions
Since January 1, 2023, we have engaged in the following transactions with our directors and executive officers, holders of more than 5% of our voting securities and affiliates of our directors, executive officers and 5% shareholders.
Under French law, agreements entered into directly or indirectly between us and either one of our officers or one of our shareholders owning more than 10% of our shares, or any company controlling one of our shareholders owning more than 10% of our shares, are subject to the prior approval of the board of directors and must be ratified by our ordinary shareholders’ general meetings on the basis of a specific report issued by our statutory auditors on such agreements. Our managing director agreement with Georges Karam has been submitted to the prior approval of the board of directors and has been or will be submitted to our shareholders at each annual shareholders’ general meeting.
Agreements with Major Shareholders
Bpifrance
In October 2014, Bpifrance, the financial agency of the French government, provided funding to the Company in the context of a long-term research project, to be completed over a 3-year period. In December 2016, Bpifrance and the Company signed an amendment to extend the period from three to four years. The total funding remained unchanged and amounted to €6,967,000 ($8,988,000) comprising a portion in the form of a grant (€2,957,000 or $3,815,000) and a portion in the form of a forgivable loan (€4,010,000 or $5,173,000). The forgivable loan advance will be repaid, as the project was not a commercial failure, from March 31, 2019 to December 31, 2024 of which €540,000 ($571,000) in paid in 2021, €870,000 ($939,000) in paid in 2022 and €870,000 ($939,000) in paid in 2023, and bears interest at a 1.53% fixed contractual rate. In the event of commercial success, defined as sales of the product developed under this program in excess of €350 million ($396 million)
78


during a period of three years, then the Company shall pay for three consecutive years after the date of the termination of the reimbursement a bonus to Bpifrance of 1% of annual revenues generated by products issued from the project. As of December 31, 2023, €1,440,000 ($1,591,000) remain outstanding on the forgivable loan advance.
In September 2015, the Company received two loans from the financial agency of the French government for a total amount of €2 million ($2.2 million). One loan of €1 million bears interest at 5.24% per year, paid quarterly; the second loan of €1 million is interest-free. The interest-free loan has been revalued using the 5.24% interest rate payable on the other loan. Both loans have seven-year terms with the principal being amortized on a quarterly basis beginning in September 2017. As of December 31, 2023, both loans had been totally reimbursed.
In January 2016, Bpifrance provided funding to the Company for a new long-term research project, estimated to be completed in early 2020. The total of the funding amounts to €2,095,000 ($2,288,000) comprising a portion in the form of a grant (€668,000 or $729,000) and a portion in the form of a forgivable loan (€1,427,000 or $1,558,000). The forgivable loan advance was to be repaid, except if the project is a commercial failure, from July 1, 2020 to July 1, 2024 and bore interest at a 1.17% fixed contractual rate. In late 2020, the Company determined that there was not enough market interest for the radio frequency of the product development funded by this grant and abandoned the project. A request for forgiveness of the debt was made and in April 2021 and Bpifrance forgave a large portion of the advance. The unforgiven portion of €213,000 ($241,000) was reimbursed in the February 2022.
On April 30, 2020, Bpifrance provided €5 million of debt financing as part of the French COVID-19 economic support plan. The French loan is unsecured and could, at Sequans’ option, be repaid in full in one year plus 1.75% interest or, with one to four months’ notice before April 30, 2021, be repaid over the following five years. In March 2021, the Company exercised the option to repay over five years with an additional deferral (from August 2022 to May 2026, only interest will be paid from August 2021 to May 2022). As of December 31, 2023, €3,438,000 ($3,798,000) remain outstanding on the debt financing.
Lynrock Lake Master Fund LP
In April 2021, we completed the sale of 1,818,181 ADSs in connection with a private placement with Lynrock Lake Master Fund LP for $10.0 million. In April 2021, the Company entered into a convertible note agreement with Lynrock Lake Master Fund LP in the principal amount of $40.0 million. The convertible note matures in April 2024 and is convertible, at the holder’s option, into the Company’s ADSs at a conversion price of $7.66 per ADS, subject to a 9.9% ownership limit for Lynrock Lake.
On April 3, 2023, we entered into a Securities Purchase Agreement with Lynrock Lake to issue to them 3,930,663 American Depositary Shares at a price of $2.06 per ADS for a capital increase of $8.1 million.
As of December 31, 2023, $40.0 million principal amount remains outstanding ($46.9 million including accrued interest on a contractual basis).
On April 9, 2024, we secured a standstill agreement from Lynrock Lake. The agreements granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met; the request for the extension of the agreements is in process as of this date, however there can be no assurance of the length of the extension, if any.
Renesas Electronics Corporation
In January 2022, we completed the sale of 1,974,755 ADSs to Renesas Electronics Corporation for $9.3 million in a private placement transaction. As part of the investment agreement, a representative of Renesas Electronics Corporation (Mr. Sailesh Chittipeddi) became a board observer in January 2022. Mr. Chittipeddi was elected as a board member by the shareholders at their June 2022 annual meeting. In 2020 and 2021, we signed license and services agreements with Renesas Electronics Corporation and Renesas Electronic America. In 2022, we signed amendments of the agreement with Renesas Electronics Corporation. In the year ended December 31, 2023, we recognized total revenue of $5.3 million from these agreements.
On November 8, 2023, in connection with contemplated acquisition of the Company by Renesas Electronics Corporation ("Renesas") that was in process at the time (subsequently terminated in February 2024), the Company entered into a Security Purchase Agreement with Renesas Electronics America ("Renesas America") whereby Renesas America agreed to the issuance of an unsecured subordinated note (the “Note”) in an aggregate principal amount of $6.0 million, at a stated rate of interest of 9.5% per annum. On December 27, 2023, the Company entered into a second Security Purchase Agreement with Renesas America whereby Renesas America agreed to the issuance of a Note in an aggregate principal amount of $3.0 million, at a stated rate of interest of 9.5% per annum.
79


On August 4, 2023, the Company entered into a Memorandum of Understanding (the “MoU”) with Renesas. The MoU provided, among other things, that Renesas and the Company engage in a series of transactions pursuant to which, among other transactions, Renesas would seek to acquire (through an affiliate) all of the issued and outstanding ordinary shares for $0.7575 per ordinary share and $3.03 per ADS.
On November 8, 2023, the Company entered into a Security Purchase Agreement (the “Purchase Agreement”) with Renesas Electronics America Inc., (“Renesas America”) a wholly owned subsidiary of Renesas, providing for the issuance of an unsecured subordinated note in an aggregate principal amount of $6 million. The transaction closed on November 8, 2023. On December 27, 2023, we entered into a second Security Purchase Agreement with Renesas America providing for the issuance of an additional unsecured subordinated note in an aggregate principal amount of $3 million. The transaction closed on December 27, 2023. On February 12, 2024, we entered into a third Security Purchase Agreement with Renesas America providing for the issuance of an additional unsecured subordinated note in an aggregate principal amount of $9 million. The transaction closed on February 12, 2024.
On February 22, 2024, Renesas notified us that Renesas was terminating the MoU due its receipt of an adverse Japanese tax ruling on February 15, 2024 from the National Tax Agency of Japan. Following the termination of the MoU, the maturity of the unsecured subordinated notes accelerated to May 22, 2024. On April 5, 2024, we secured a standstill agreement from Renesas. The agreement granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met; the request for the extension of the agreement is in process as of this date, however there can be no assurance of the length of the extension, if any.
In March 2024, Mr. Chittipeddi resigned from his role as member of our board of directors.
B. Riley Asset Management LLC
On April 3, 2023, we entered into a Securities Purchase Agreement with Boothbay Diversified Alpha Master Fund LP, Boothbay Absolute Return Strategies LP and 272 Capital Master Fund LP, funds affiliated with B. Riley Asset Management and Wes Cummins, a director of the Company, to issue an aggregate of 3,930,663 American Depositary Shares at a price of $2.06 per ADS for a total capital increase of $8.1 million.
On September 26, 2023, we entered into a Securities Purchase Agreement with 272 Capital Master Fund, LTD, a fund affiliated with B. Riley Asset Management LLC and Wes Cummins, a director of the Company, to issue to them 2,120,141 American Depositary Shares at a price of $2.83 per ADS for a total capital increase of $6.0 million.
On April 22, 2024, we issued an Unsecured Promissory Note with a principal amount of $5,000,000 to 272 Capital
Master Fund, Ltd. The transaction closed on April 24, 2024.
Agreements with Executive Officers and Directors
Employment and Compensation Agreement
We have entered into a managing director agreement with Georges Karam, our chairman and chief executive officer, which contains provisions regarding salary and bonus, severance payment and benefits. See “Item 6.B—Compensation—Employment Agreements with Executive Officers”.
Director Compensation and Agreements
The non-employee members of our board of directors and directors who are permitted to receive remuneration by their employers, receive compensation based on our director compensation policy. A description of the cash compensation and equity awards that non-employee members of our board of directors will be entitled to receive is described under “Item 6. B—Compensation—Compensation of Executive Officers and Directors”.
Restricted Shares, Stock Options, and Warrants
Since our inception, we have granted restricted shares, stock options and warrants to purchase our shares to certain of our executive officers and to our non-employee directors and directors who are permitted by their employers to receive warrants. For more information about our option and warrant plans see “Item 6. B—Compensation—Equity Plans”.
C.Interests of Experts and Counsel
Not applicable.
80



Item 8. Financial Information

A.Consolidated Statements and Other Financial Information
Consolidated Financial Statements
We have appended our consolidated financial statements at the end of this annual report, starting at page F-1, as part of this annual report.
Legal Proceedings
The Company was sued in three lawsuits in the United States District Court for the district of Minnesota by a company called Bell Semiconductor, LLC (“Bell”), accusing the Company of infringing certain U.S. Patents by the Company's use of certain design tools. In Bell Semiconductor, LLC v. Sequans Communications, SA et al, Case No. 0-22-cv-02106 (DMN), filed August 26, 2022, Bell accused the Company of infringing U.S. Patent Nos. 7,149,989 and 7, 260,803. In Bell Semiconductor, LLC v. Sequans Communications, SA et al, Case No. 0-22-cv-02344 (DMN), filed September 23, 2022, Bell accused the Company of infringing U.S. Patent Nos. 6,436,807 and 7,007,259. In Bell Semiconductor, LLC v. Sequans Communications, SA et al, Case No. 0-22-cv-02660 (DMN), filed October 21, 2022, Bell accused the Company of infringing U.S. Patent Nos. 7,231,626 and 7,396,760. The Company filed motions to dismiss in each case. In August 2023, Bell entered into a settlement agreement with supplier of the design tools that Bell asserts infringe the Patents and the three lawsuits against the Company were dismissed. The supplier of the design tools indemnified the Company for all the costs to defend and/or settle the lawsuits. the lawsuits were dismissed in August 2023.
Except as set forth above, we are not a party to any material legal proceedings.
Dividend Policy
We have never declared or paid any cash dividends on our ordinary shares. We do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future and intend to retain all available funds and any future earnings for use in the operation and expansion of our business.
Subject to the requirements of French law and our by-laws, dividends may only be distributed from our statutory retained earnings. See “Item 10. B—Memorandum and Articles of Association” for further details on the limitations on our ability to declare and pay dividends. Dividend distributions, if any, will be made in euros and converted into U.S. dollars with respect to the ADSs, as provided in the deposit agreement.
B.Significant Changes
No significant changes have occurred since December 31, 2023, except as otherwise disclosed in this annual report.

Item 9. The Offer and Listing

A.Listing Details
Our ADSs have been listed on the New York Stock Exchange under the symbol “SQNS” since April 15, 2011. Prior to that date, there was no public trading market for ADSs or our ordinary shares.
  
B.Plan of Distribution
Not applicable.
 
C.Markets
Our ADS have been listed on the New York Stock Exchange under the symbol “SQNS” since April 15, 2011.
 
D.Selling Shareholders
Not applicable.
81


 
E.Dilution
Not applicable.
 
F.Expenses of the Issue
Not applicable.
Item 10. Additional Information

A.Share Capital
Not applicable.
B.Memorandum and Articles of Association
The information set forth in our Registration Statement on Form F-3 (File No. 333-250122), filed with the SEC on November 16, 2020, under the heading “Description of Share Capital” is incorporated herein by reference.
C.Material Contracts
With the exception of the material agreements described in “Item 7.B Related Party Transactions—Agreements with Major Shareholders”, all contracts concluded by the Company during the two years preceding the date of this annual report were entered into in the ordinary course of business.
D.Exchange Controls
Under current French foreign exchange control regulations there are no limitations on the amount of cash payments that we may remit to residents of foreign countries. Laws and regulations concerning foreign exchange controls do, however, require that all payments or transfers of funds made by a French resident to a non-resident be handled by an accredited intermediary. All registered banks and substantially all credit institutions in France are accredited intermediaries.
E.Taxation
Material United States Federal Income Tax Consequences
The following is a description of the material United States federal income tax consequences of the acquisition, ownership and disposition of the ADSs. This description addresses only the United States federal income tax consequences to holders that are purchasers of the ADSs and hold such ADSs as capital assets (generally property held for investment). This description does not address tax considerations applicable to holders that may be subject to special tax rules, including:
financial institutions or insurance companies;
real estate investment trusts, regulated investment companies or grantor trusts;
dealers or traders in securities or currencies;
tax-exempt entities;
certain former citizens or former long-term residents of the United States;
persons that received the ADSs as compensation for the performance of services;
persons that will hold the ADSs as part of a “hedging” or “conversion” transaction or as a position in a “straddle” for United States federal income tax purposes;
holders that will hold the ADSs through a partnership or other pass-through entity;
U.S. Holders, as defined below, whose “functional currency” is not the United States dollar; or
holders that own, directly, indirectly or through attribution, 10.0% or more of the voting power or value of our shares.
Moreover, this description does not address the United States federal estate and gift or alternative minimum tax, or foreign, state or local tax, consequences of the acquisition, ownership and disposition of the ADSs.
This description is based on the United States Internal Revenue Code of 1986, as amended, or the “Code”, existing, proposed and temporary United States Treasury Regulations and judicial and administrative interpretations thereof, in each case
82


as in effect and available on the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax consequences described below.
For purposes of this description, a “U.S. Holder” is a beneficial owner of the ADSs that, for United States federal income tax purposes, is:
a citizen or resident of the United States;
a corporation or other entity treated as a corporation for United States federal income tax purposes, created or organized in or under the laws of the United States or any state thereof, including the District of Columbia;
an estate the income of which is subject to United States federal income taxation regardless of its source; or
a trust if such trust has validly elected to be treated as a United States person for United States federal income tax purposes or if (1) a court within the United States is able to exercise primary supervision over its administration and (2) one or more United States persons have the authority to control all of the substantial decisions of such trust.
A “Non-U.S. Holder” is a beneficial owner of the ADSs that is neither a U.S. Holder nor a partnership, or other entity or arrangement treated as a partnership, for United States federal income tax purposes.
If a partnership or any other entity or arrangement treated as a partnership for United States federal income tax purposes holds the ADSs, the tax treatment of a partner in such partnership will depend on the status of the partner and the activities of the partnership. Such a partner or partnership is encouraged to consult its tax advisor as to its tax consequences.
You are encouraged to consult your tax advisor with respect to United States federal, state, local and foreign tax consequences of acquiring, owning and disposing of the ADSs.
For United States federal income tax purposes, you will be treated as the owner of our ordinary shares represented by your ADSs. Exchanges of ordinary shares for ADSs, and ADSs for ordinary shares, will not be subject to United States federal income tax.
Distributions with Respect to ADSs
If you are a U.S. Holder, for United States federal income tax purposes, the gross amount of any distribution made to you with respect to your ADSs (other than certain distributions, if any, of the ADSs distributed pro rata to all our shareholders), before reduction for any French taxes withheld therefrom, will be includible in your income as dividend income to the extent such distribution is paid out of our current or accumulated earnings and profits as determined under United States federal income tax principles. Subject to the discussion below under “Passive Foreign Investment Company Considerations”, non-corporate U.S. Holders may qualify for the lower rates of taxation with respect to dividends on ADSs applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than one year), provided that certain conditions are met, including certain holding period requirements and the absence of certain risk reduction transactions. However, such dividends will not be eligible for the dividends received deduction generally allowed to corporate U.S. Holders. Subject to the discussion below under “Passive Foreign Investment Company Considerations”, to the extent, if any, that the amount of any distribution by us exceeds our current and accumulated earnings and profits as determined under United States federal income tax principles, such excess amount will be treated first as a tax-free return of your adjusted tax basis in your ADSs and thereafter as capital gain. We do not expect to maintain calculations of our earnings and profits under United States federal income tax principles and, therefore, if you are a U.S. Holder you should expect that the entire amount of any distribution generally will be reported as dividend income to you.
Dividends, if any, paid to U.S. Holders in euros or currency other than the U.S. dollar (“Other Foreign Currency”) will be includible in income in a U.S. dollar amount based on the prevailing spot market exchange rate in effect on the date of actual or constructive receipt, whether or not converted into U.S. dollars at that time. Assuming dividends received in euros (or Other Foreign Currency) are converted into U.S. dollars on the day they are received, the U.S. Holder will not be required to recognize foreign currency gain or loss in respect of the dividend income. If, however, the payment is not converted at that time, a U.S. Holder will have a tax basis in euros (or Other Foreign Currency) equal to the U.S. dollar amount of the dividend included in income, which will be used to measure gain or loss from subsequent changes in exchange rates. Any gain or loss that a U.S. Holder recognizes on a subsequent conversion of euros (or Other Foreign Currency) into U.S. dollars (or on other disposition) will be U.S. source ordinary income or loss. U.S. Holders should consult their own tax advisors regarding the tax consequences to them if the dividends are paid in euros (or Other Foreign Currency).
Subject to certain conditions and limitations, French tax withheld on dividends may be deducted from your taxable income or credited against your United States federal income tax liability. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends, if any, that we distribute will
83


constitute “passive category income”, or, in the case of certain U.S. Holders, “general category income”. A foreign tax credit for foreign taxes imposed on distributions may be denied if you do not satisfy certain minimum holding period requirements or if you engage in certain risk reduction transactions. If you are a U.S. Holder, dividends, if any, paid to you with respect to your ADSs will be treated as foreign source income, which may be relevant in calculating your foreign tax credit limitation. The rules relating to the determination of the foreign tax credit are complex, and you are encouraged to consult your tax advisor to determine whether and to what extent you will be entitled to this credit.
Subject to the discussion below under “Backup Withholding Tax and Information Reporting Requirements”, if you are a Non-U.S. Holder, you should not be subject to United States federal income or withholding tax on dividends received by you on your ADSs unless such income is effectively connected with your conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base).
Sale, Exchange or Other Disposition of ADSs
Subject to the discussion below under “Passive Foreign Investment Company Considerations”, if you are a U.S. Holder, you will recognize capital gain or loss on the sale, exchange or other disposition of your ADSs equal to the difference between the amount realized on such sale, exchange or other disposition and your adjusted tax basis in your ADSs. If you are a non-corporate U.S. Holder, capital gain from the sale, exchange or other disposition of ADSs will be eligible for the preferential rate of taxation applicable to long-term capital gains if your holding period for such ADSs exceeds one year (i.e., such gain is long-term capital gain). Gain or loss, if any, recognized by a U.S. Holder will be treated as U.S. source gain or loss, as the case may be, for foreign tax credit limitation purposes. The deductibility of capital losses for United States federal income tax purposes is subject to limitations.
Subject to the discussion below under “Backup Withholding Tax and Information Reporting Requirements”, if you are a Non-U.S. Holder, you will not be subject to United States federal income or withholding tax on any gain realized on the sale or exchange of your ADSs unless:
such gain is effectively connected with your conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base); or
you are an individual and have been present in the United States for 183 days or more in the taxable year of such sale or exchange and certain other conditions are met.
Passive Foreign Investment Company Considerations
A non-U.S. corporation will be classified as a “passive foreign investment company”, or a PFIC, for United States federal income tax purposes for any taxable year in which, after applying certain look-through rules, either
at least 75% of its gross income is “passive income”; or
at least 50% of the average value of its gross assets is attributable to assets that produce “passive income” or are held for the production of passive income.
Passive income for this purpose includes dividends, interest, royalties, rents, gains from commodities and securities transactions and the excess of gains over losses from the disposition of assets which produce passive income, including amounts derived by reason of the investment of funds raised in offerings of the ADSs. If a non-U.S. corporation owns at least 25% by value of the stock of another corporation, the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation and as receiving directly its proportionate share of the other corporation’s income.
Based on the character of our gross income and the average value of our passive assets relative to the gross value of our assets for the taxable year ended December 31, 2023, we do not believe we were a PFIC for 2023. Because PFIC status is determined annually based on our income, assets and activities for the entire taxable year, it is not possible to determine whether we will be characterized as a PFIC for 2024 or any other future year until after the close of that year. While we intend to manage our business so as to avoid PFIC status to the extent consistent with our other business goals, we cannot predict whether our business plans will allow us to avoid PFIC status. In addition, because the market price of the ADSs has fluctuated and is likely to fluctuate in the future and because that market price may affect the determination of whether we are a PFIC, there can be no assurance that we will not be a PFIC for any taxable year.
If we are a PFIC for a given year, and you are a U.S. Holder, then unless you make one of the elections described below, a special tax regime will apply to both (a) any “excess distribution” by us to you for the year (defined as your ratable portion of distributions in the year which are greater than 125% of the average annual distribution received by you in the shorter of the
84


three preceding years or your holding period for the ADSs) and (b) any gain realized on the sale or other disposition (including a pledge) of the ADSs. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if (i) the excess distribution or gain had been realized ratably over your holding period, (ii) the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. Holder’s regular ordinary income rate for the current year and would not be subject to the interest charge discussed below), and (iii) the interest charge applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, the tax liability for amounts allocated to years prior to the year of disposition or “excess distribution” cannot be offset by any net operating losses for such years, and dividend distributions made to you will not qualify for the lower rates of taxation applicable to long-term capital gains discussed above under “Distributions with Respect to ADSs.”
Certain elections are available to U.S. Holders of shares that may serve to alleviate some of the adverse tax consequences of PFIC status described above. One such election is a qualified electing fund, or a QEF, election, under which you would be required to include in income on a current basis your pro rata share of our ordinary earnings as ordinary income and your pro rata share of our net capital gains as capital gain. However, we do not expect to provide to U.S. Holders the information needed to report income and gain pursuant to a QEF election, and we make no undertaking to provide such information in the event that we are a PFIC.
Under an alternative tax regime, you may also avoid certain adverse tax consequences relating to PFIC status discussed above by making a mark-to-market election with respect to your ADSs, provided that the ADSs are “marketable.” The ADSs will be marketable if they are regularly traded on certain U.S. stock exchanges, including the NYSE, or on certain non-U.S. stock exchanges. For these purposes, the ADSs will be considered regularly traded during any calendar year during which they are traded, other than in negligible quantities, on at least 15 days during each calendar quarter. U.S. Holders should be aware, however, that if we are determined to be a PFIC, the interest charge regime described above could be applied to indirect distributions or gains deemed to be attributable to U.S. Holders in respect of any of our subsidiaries that also may be determined to be a PFIC, and the mark-to-market election would not be effective for such subsidiaries.
If you choose to make a mark-to-market election, you would recognize as ordinary income or loss each year in which we are a PFIC an amount equal to the difference as of the close of the taxable year between the fair market value of your ADSs and your adjusted tax basis in your ADSs. Losses would be allowed only to the extent of net mark-to-market gain previously included by you under the election for prior taxable years. If the mark-to-market election were made, then the PFIC rules described above relating to excess distributions and realized gains would not apply for periods covered by the election. If you do not make a mark-to-market election for the first taxable year in which we are a PFIC during your holding period of the ADSs, you would be subject to interest charges with respect to the inclusion of ordinary income attributable to each taxable year in which we were a PFIC during your holding period before the effective date of such election.
A U.S. Holder who is a direct or “indirect” holder of stock of a PFIC must file United States Internal Revenue Service Form 8621 in respect of such PFIC for a taxable year in the circumstances described in the United States Treasury Regulations. If we are a PFIC for a given taxable year, you are encouraged to consult your tax advisor concerning the availability and consequences of making any of the elections mentioned above, as well as concerning your annual filing requirements.
Medicare Tax
A United States person that is an individual or estate, or a trust that does not fall into a special class of trusts that is exempt from such tax, is subject to a 3.8% tax on net investment income in excess of certain amounts. In the case of an individual, the tax is imposed on the lesser of (1) the United States person’s “net investment income” for the relevant taxable year and (2) the excess of the United States person’s modified adjusted gross income for the taxable year over $250,000 (in the case of a taxpayer filing a joint return or a surviving spouse), $125,000 (in the case of a married taxpayer filing a separate return) or $200,000 (in any other case). In the case of an estate or trust, the tax is imposed on the lesser of (1) the entity’s “undistributed net investment income” for the taxable year and (2) the excess (if any) of the entity’s “adjusted gross income” over the dollar amount at which the highest tax bracket begins for such entity. A holder’s net investment income will include its gross dividend income and its net gains from the disposition of ADSs unless such dividends or net gains are derived in the ordinary course of the conduct of a trade or business (other than a trade or business that consists of certain passive or trading activities). If you are a United States person that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability of the Medicare tax to your income and gains in respect of your investment in the ADSs.

85


Information with Respect to Foreign Financial Assets
Individuals who own “specified foreign financial assets” with an aggregate value in excess of $50,000 are required to file an information report with respect to such assets with their tax returns. “Specified foreign financial assets” include any financial accounts maintained by foreign financial institutions, as well as any of the following, but only if they are not held in accounts maintained by financial institutions: (i) stocks and securities, including ADSs. issued by non-U.S. persons, (ii) financial instruments and contracts held for investment that have non-U.S. issuers or counterparties and (iii) interests in foreign entities. U.S. holders that are individuals are encouraged to consult their tax advisors regarding the application of this reporting requirement as it relates to their ownership of ADSs.
Backup Withholding Tax and Information Reporting Requirements
United States backup withholding tax and information reporting requirements apply to certain payments to certain non-corporate holders of stock. Information reporting will apply to payments of dividends on, and to proceeds from the sale or redemption of, the ADSs made within the United States, or by a United States payor or United States middleman, to a holder of the ADSs, other than an exempt recipient, including a corporation, a payee that is not a United States person that provides an appropriate certification and certain other persons. A payor will be required to withhold backup withholding tax from any payments of dividends on, or the proceeds from the sale or redemption of, ADSs within the United States, or by a United States payor or United States middleman, to a holder, other than an exempt recipient, if such holder fails to furnish its correct taxpayer identification number or otherwise fails to comply with, or establish an exemption from, such backup withholding tax requirements. Any amounts withheld under the backup withholding rules will be allowed as a refund or credit against the beneficial owner’s United States federal income tax liability, if any, provided that the required information is timely furnished to the IRS.
French Material Tax Consequences
The following is a description of the material French tax consequences of the acquisition, ownership and disposition of the ADSs by a U.S. Holder. This description is based on applicable tax laws, regulations and judicial decisions as of the date of this annual report, and, where applicable, the Convention between the United States of America and the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital, dated August 31, 1994, as amended from time to time (the “U.S. Treaty”).
This description is based in part upon the representation of the custodian and the assumption that each obligation in the Depositary Agreement with the depositary relating to your ADRs and any related agreement will be performed in accordance with their terms.
The following is a description of the principal tax effect on U.S. Holders for the purposes of French tax if, all of the following points apply:
the U.S. Holder owns, directly, indirectly or constructively, less than 10% of the Company capital and dividend rights;
the U.S. Holder is entitled to the benefits of the U.S. Treaty (including under the “limitation on benefits” article of the U.S. Treaty);
the U.S. Holder does not hold the ADSs through a permanent establishment or a fixed base in France;
the U.S. Holder is not multi-resident and is considered as a U.S. resident under the U.S. Treaty;
the U.S. Holder does not hold the ADSs through a non-U.S. based pass-through entity; and
the U.S. Holder does not receive dividend, capital gains or other payments on the ADSs on an account located in a Non-cooperative State as defined in Article 238-0 A of the French General Tax Code and as mentioned in a list published by the French tax authorities as amended from time to time (punitive tax measures targeting Non-cooperative States apply as from the beginning of the third month following the inclusion of a jurisdiction on the list).
A U.S. Holder to whom all the above requirements apply will be hereafter defined as a Qualifying U.S. Holder.
This description is relevant only to holders of ADSs who are Qualifying U.S. Holders.
For purposes of the U.S. Treaty Qualifying U.S. Holders of ADSs will be treated as the owners of Company’s ordinary shares represented by such ADSs.
Special rules apply to U.S. expatriates, trusts, insurance companies, pass-through entities and investors in such entities, tax-exempt organizations, financial institutions, persons subject to the alternative minimum tax and securities broker-dealers, among others. Those special rules are not discussed in this annual report and the below rules may not apply.
86


Holders of Company ADSs are encouraged to consult their own tax advisors as to the particular tax consequences to them of owning the ADSs, including their eligibility for benefits under the U.S. Treaty, the application and effect of state, local, foreign and other tax laws and possible changes in tax laws or in their interpretation.
Taxation of Dividends
Dividends paid by a French company to corporate non-French holders are subject to a withholding tax at a rate equal to the standard corporate income tax rate (i.e., 25% since 2022). Such withholding tax rates can be increased to 75% if the dividend is paid towards Non-cooperative States or territories (as mentioned above) irrespective of the tax residence of the beneficiary of the dividends. Such withholding tax rates may, however, be reduced or eliminated by application of a tax treaty with France.
Dividends paid by a French company to individual non-French holders are generally subject to a 12.8% withholding tax. Such withholding tax rate can be increased to 75% if the dividend is paid towards Non-cooperative States or territories (as mentioned above) irrespective of the tax residence of the beneficiary of the dividends. Such withholding tax rate may, however, be reduced or eliminated by application of a tax treaty with France.
Taxation of Capital Gains
A Qualifying U.S. Holder will not be subject to any French income or withholding tax on any capital gain realized upon the sale or exchange of ADSs of the Company.
Estate and Gift Taxes
Under the Convention between the United States of America and the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates, Inheritance and Gifts, dated November 24, 1978 (as amended from time to time), if a U.S. Holder transfers his or her shares by gift or by reason of the U.S. Holder’s death, that transfer will not be subject to French gift or inheritance tax unless the U.S. Holder is domiciled in France at the time of making the gift or at the time of his or her death or if the shares are held for use in the conduct of a business or profession through a permanent establishment or a fixed base in France.
Wealth Tax
As of January 1, 2018, the French wealth tax namely the Impôt de Solidarité sur la Fortune (“ISF”) is replaced by the Impôt sur la Fortune Immobilière (“IFI”). The IFI generally applies to real estate assets to the extent that their net value exceeds €1,300,000. Therefore, all other movable assets (tangible assets, shares, life insurance, cash, etc.) are excluded from the tax base, unless their underlying assets (direct or indirect) consist of real estate assets or rights. However, a general exclusion applies to real estate assets owned by companies pursuing a commercial, industrial, craft, agricultural or liberal activity when the taxpayer (together with the members of its tax household) holds directly or indirectly less than 10% of the share capital or the voting rights of the company. As a result, Qualifying U.S. Holders will not be subject to French IFI in respect of their shareholding in the Company.
F.Dividends and Paying Agents
Not applicable.
G.Statement by Experts
Not applicable.
H.Documents on Display
We are currently subject to the informational requirements of the Exchange Act applicable to foreign private issuers and fulfill the obligations of these requirements by filing reports with the Securities and Exchange Commission. As a foreign private issuer, we are exempt from the rules under the Exchange Act relating to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the Securities and Exchange Commission as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we intend to file with the Securities and Exchange Commission, within 120 days after the end of each subsequent fiscal year, an annual report on Form 20-F containing financial
87


statements which will be examined and reported on, with an opinion expressed, by an independent public accounting firm. We also intend to file with the Securities and Exchange Commission reports on Form 6-K containing unaudited financial information for the first three quarters of each fiscal year, within 60 days after the end of each quarter.

As a foreign private issuer, our officers and directors are not required to report insider transactions on Form 3s and Form 4s under Section 16 of the Securities Exchange Act of 1934.
The Securities and Exchange Commission maintains an Internet site that contains reports and other information regarding issuers that file electronically with the Securities and Exchange Commission. Our filings with the Securities and Exchange Commission are available to the public through this web site at http://www.sec.gov.
I.Subsidiary Information
Not applicable.

Item 11. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk
We had cash and cash equivalents and short-term investments totaling $4.8 million, $10.7 million and $5.7 million, at December 31, 2021, 2022 and 2023, respectively. Our cash and cash equivalents consist of cash in commercial bank accounts and investments in money market funds. Short-term investments are investments in deposits or money market funds with terms greater than 90 days but less than one year. The primary objectives of our investment activities are to preserve principal and provide liquidity without significantly increasing risk. Our cash and cash equivalents are held for working capital purposes. We do not enter into investments for trading or speculative purposes.
Our exposure to interest rate risk primarily relates to the interest income generated by excess cash invested in money market funds. Due to the short-term and highly liquid nature of our portfolio, a movement in interest rates of 100 basis points during 2023 would not have a material effect on interest income.
Foreign Currency Risk
We use the U.S. dollar as the functional currency of Sequans Communications S.A. Substantially all of our sales are denominated in U.S. dollars. Therefore, we have very limited foreign currency risk associated with our revenue. The payment terms of our significant supply chain vendors are also denominated in U.S. dollars. We incur operating expenses and hold assets and liabilities denominated in currencies other than the U.S. dollar, principally the euro. In addition, we have limited exposure to the British pound sterling, the New Israeli shekel, the Taiwan dollar, the Chinese yuan and the Japanese yen. As a result, our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, primarily the U.S. dollar to euro exchange rate. As we grow our operations, our exposure to foreign currency risk could become more significant. If there had been a 10% increase or decrease in the exchange rate of the U.S. dollar to the euro, based on the weighted average rate of exchange in our financial statements for the year ending December 31, 2023, we estimate the impact, in absolute terms, on operating expenses and on financial liabilities for 2023, would have been $4.2 million.

From time to time, we have entered into foreign currency hedging contracts primarily to reduce the impact of variations in the U.S. dollar to euro exchange rate on our operating expenses denominated in euros. Currently, we do not expect to enter into foreign currency exchange contracts for trading or speculative purposes.
Item 12. Description of Securities Other than Equity Securities
A.Debt Securities
Not applicable.
B.
Warrants and Rights
Not applicable.
88


C.Other Securities
Not applicable.
D.American Depositary Shares
The Bank of New York Mellon, as depositary, registers and delivers our ADSs. Each ADS represents four ordinary shares (or a right to receive four ordinary shares) deposited with the principal Paris office of Société Générale or any successor, as custodian for the depositary. Each ADS will also represent any other securities, cash or other property which may be held by the depositary in respect of the depositary facility. A copy of our Amended and Restated Deposit Agreement among us, the depositary, owners and holders of ADSs was filed with the SEC as an exhibit to our Form 6-K filed November 16, 2020.
Fees and Expenses
Pursuant to the terms of the deposit agreement, we will be paying all fees and expenses relating to the ADSs on behalf of the holders. However, in the future that arrangement may be changed, at our option, such that the holders will be required to pay the following fees:
Persons depositing or withdrawing ordinary shares or ADS holders must pay:  For:
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)  
•         Issue of ADSs, including issues resulting from a distribution of ordinary shares or rights or other property
 
•         Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates
$0.05 (or less) per ADS  •         Any cash distribution to ADS holders
A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the shares had been deposited for issue of ADSs  •         Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS holders
$0.05 (or less) per ADSs per calendar year  •         Depositary services
Registration or transfer fees  •         Transfer and registration of ordinary shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares
Expenses of the depositary  
•         Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)
 
•         converting foreign currency to U.S. dollars
Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes  •         As necessary
Any charges incurred by the depositary or its agents for servicing the deposited securities  •         As necessary
The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable
89


property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may generally refuse to provide for-fee services until its fees for those services are paid.
Holders of ADS are responsible for any taxes or other governmental charges payable on the holders’ ADSs or on the deposited securities represented by any of ADSs. The depositary may refuse to register any transfer of the holders’ ADSs or allow the holder to withdraw the deposited securities represented by the holders’ ADSs until such taxes or other charges are paid. It may apply payments owed to the holder or sell deposited securities represented by the holders’ ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.
90


PART II
Item 13. Defaults, Dividend Arrearages and Delinquencies
None.
Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds
Not applicable.
Item 15. Controls and Procedures
Disclosure Controls and Procedures

Our chief executive officer and chief financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of December 31, 2023, have concluded that, as of such date, our disclosure controls and procedures were effective and ensured that information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.
Management Annual Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over our financial reporting.
Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the Company’s principal executive and principal financial officers and effected by the Company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS and includes those policies and procedures that:
Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use of disposition of the Company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting, as of December 31, 2023. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013 Framework).
Based on our assessment, management believes that as of December 31, 2023 our internal control over financial reporting is effective based on these criteria.
The effectiveness of the Company’s internal control over financial reporting has been audited by Ernst & Young Audit, independent registered public accounting firm, as stated in their report on the Company’s internal control over financial reporting as of December 31, 2023, which is included herein.



91


Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Sequans Communications S.A.:

Opinion on Internal Control Over Financial Reporting
We have audited Sequans Communications S.A.’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Sequans Communications S.A. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statements of financial position of the Company as of December 31, 2021, 2022 and 2023, the related consolidated statements of operations, comprehensive income (loss), changes in equity (deficit) and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and our report dated May 15, 2024 expressed an unqualified opinion thereon that included an explanatory paragraph regarding the Company’s ability to continue as a going concern.

Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management Annual Report on Internal Control Over Financial Reporting.
Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


/s/ Ernst & Young Audit
Paris-La Défense, France
May 15, 2024
92



Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the period covered by this annual report that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.
Item 16A. Audit Committee Financial Expert
Our Board has determined that Mr. de Pesquidoux is an audit committee financial expert as defined by the Securities and Exchange Commission rules and has the requisite financial sophistication under the applicable rules and regulations of the New York Stock Exchange. Mr. de Pesquidoux is independent as such term is defined in Rule 10A-3(b)(1) under the Exchange Act and under the listing standards of the New York Stock Exchange.
Item 16B. Code of Ethics
We have adopted a Code of Ethics that applies to the Company’s chief executive officer, chief financial officer and other senior financial officers, including the Company’s principal accounting officer. We have posted this code on our corporate website at https://www.sequans.com/company/investor-relations/corporate-governance/.
Item 16C. Principal Accountant Fees and Services
Ernst & Young Audit has served as our independent registered public accounting firm for 2022 and 2023. Our accountants billed the following fees to us for professional services in each of those fiscal years:
20222023
 (euros in thousands)
Audit Fees582 555 
Audit-Related Fees— — 
Tax Fees  
All Other Fees  
Total582 555 
“Audit Fees” are the aggregate fees billed for the audit of our annual financial statements. This category also includes services that generally the independent accountant provides, such as consents, provision of comfort letters, and assistance with and review of documents filed with the SEC. “Audit-Related Fees” are the aggregate fees billed for assurance and related services that are reasonably related to the performance of the audit and are not reported under Audit Fees. These fees include mainly accounting consultations regarding the accounting treatment of matters that occur in the regular course of business, implications of new accounting pronouncements and other accounting issues that occur from time to time. There were no “Tax Fees” or “Other Fees” billed or paid during 2022 or 2023.
Our audit committee has adopted a pre-approval policy for the engagement of our independent accountant to perform certain audit and non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee pre-approves annually a catalog of specific audit and non-audit services in the categories of audit service, audit-related service and tax services that may be performed by our independent accountants.
Item 16D. Exemptions from the Listing Standards for Audit Committees
Not applicable.
Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers
Not applicable.
Item 16F. Change in Registrant’s Certifying Accountant
Not applicable.
93


Item 16G. Corporate Governance
As a foreign private issuer listed on the NYSE, we are subject to NYSE corporate governance listing standards. However, NYSE rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Currently, we rely on the NYSE Listed Company Manual with respect to our corporate governance to the extent possible under French law. The following are the significant ways in which our corporate governance practices differ from those required for U.S. companies listed on the NYSE.

Audit Committee—Our audit committee is responsible for organizing for selecting our statutory auditors and making a recommendation to our board of directors regarding their chose and terms of compensation. As required by French law, the actual appointment of the statutory auditors is made by our shareholders at a general meeting of the shareholders. According to the Audit Committee Charter, our audit committee has the authority to engage advisors and determine appropriate funding for payment of compensation to an independent auditor or other advisors necessary or appropriate to aid the committee in carrying out its responsibilities.
Executive Sessions/Communications with Independent Directors—French law does not require (and we do not currently provide) for our independent directors to meet regularly without management, nor does it require the independent directors to meet alone in executive session at least once a year. However, if our independent directors decide to do so, they may do so. In addition, French law does not require (and we do not currently provide) a method for interested parties to communication with our independent directors.
Equity Compensation Plans—Under French law, we must obtain shareholder approval at a general meeting of the shareholders in order to adopt an equity compensation plan. Generally, the shareholders then delegate to our board of directors the authority to decide on the specific terms of the granting of equity compensation, within the limits of the shareholders’ authorization.
Corporate Governance Guidelines—We have adopted a Board Internal Charter as required by French law that sets forth certain corporate governance practices of our board under French law. This Board Internal Charter does not cover all items required by the NYSE Listed Company Manual for U.S. companies listed on the NYSE.
Item 16H. Mine Safety Disclosure
Not applicable.
Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
Item 16J. Insider Trading Policy
The Company has adopted an insider trading policy governing the purchase, sale, and other dispositions of our securities by directors, officers, employees and other persons in a special relationship with the Company. A copy of our insider trading policy is included as an exhibit to this Annual Report.
Item 16K. Cybersecurity
Cybersecurity Risk Management and Strategy
We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Form 20-F, Part II, Item 16K(a). These risks include, among other things, operational risks; intellectual property theft; fraud; extortion; harm to employees or customers; violation of privacy or security laws and other litigation and legal risk; and reputational risks.
We also maintain an incident response plan to coordinate the activities we take to protect against, detect, respond to and remediate cybersecurity incidents, as such term is defined in Form 20-F, Part II, Item 16K(a), as well as to comply with potentially applicable legal obligations and mitigate brand and reputational damage.
We have implemented several cybersecurity processes, technologies, and controls to aid in our efforts to identify, assess, and manage material risks, as well as to test and improve our incident response plan. Our approach includes, among other things:
• conducting regular network and endpoint monitoring designed to identify threat risks on our information systems, as such term is defined in Form 20-F, Part II, Item 16K(a);
94


• performing RBAC (role based access control) to groups of employees by isolating assets of each group, applying minimal rights for each group and ensuring that assets are not accessible from public network but only via a VPN;
• using basic open source software to detect intrusions;
• implementing disaster recovery procedures and multiple site redundancy;
• introduction in 2023 of new tools, applications, policies and cyber procedures based on a transition to Microsoft 365 efor mails, files sharing and communication of essential assets and to Teams with Microsoft 365 Standard Security providing a baseline protection profile that protects against spam, phishing, and malware threats; and
• general policy and practice requiring employees, as well as third-parties who provide services on our behalf, to treat customer information and data with care.
These approaches vary in maturity across the business and we work to continually improve them.
Our process for identifying and assessing material risks from cybersecurity threats operates alongside our broader overall risk assessment process, covering all company risks. As part of this process appropriate disclosure personnel will collaborate with subject matter specialists, as necessary, to gather insights for identifying and assessing material cybersecurity threat risks, their severity, and potential mitigations.
As part of the above approach and processes, we regularly engage with auditors to help identify areas for continued focus, improvement and/or compliance.
In our risk factors, we describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. See our risk factor disclosures at Item 3D of this Annual Report on Form 20-F.
In the last three fiscal years, we have not experienced any material cybersecurity incidents and the expenses we have incurred from cybersecurity incidents were immaterial. This includes penalties and settlements of which there were none.
Cybersecurity Governance
Cybersecurity is an important part of our risk management processes and an area of increasing focus for the Company's board of directors (the “Board”) and management.
As part of our entire Board’s operational risk management responsibilities, the Board provides oversight of risks from cybersecurity threats. The Audit Committee has been designated with the responsibility to regularly review the Company’s processes and procedures around managing cybersecurity threat risks and cybersecurity incidents. At least semi-annually, the Audit Committee receives an overview from management of our cybersecurity threat risk management and strategy processes covering topics such as data security posture, results from third-party assessments, progress towards pre-determined risk-mitigation-related goals, our incident response plan, and cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks.
Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Director of Information Systems (DIS), who has over 34 years of work experience in various roles in computer science and enterprise/solution/software architecture.
Throughout his career, our DIS has served in pivotal roles in our and other companies, including as Chief Information Officer, overseeing strategic initiatives and driving technological advancements. Notably, he led the implementation of security solutions for a public university with over 75,000 students and 3,000 teachers, ensuring robust protection of sensitive data. His expertise spans enterprise and systems architecture, software engineering, database management, and end-user computing, aligning closely with the multifaceted demands of modern cybersecurity. He has navigated complex regulatory landscapes, ensuring compliance with industry standards and regulatory requirements. His academic background as a lecturer, reinforced by practical experience, includes a Bachelor of Science and Master of Science degrees in Engineering from the French École Nationale Supérieure d'Electrotechnique, d'Electronique, d'Informatique, d'Hydraulique et des Télécommunications (ENSEEIHT), providing a strong foundation for addressing the evolving challenges of information security and cybersecurity strategy.
These members of management are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above.


95


PART III
Item 17. Financial Statements
See pages F-1 through F-60 of this annual report.
Item 18. Financial Statements
Not applicable.
Item 19. Exhibits
Exhibit
Number
Description of Exhibit
By-laws (statuts) of Sequans Communications S.A. effective March 5, 2024 (English translation)
Deposit Agreement among Sequans Communications S.A., The Bank of New York Mellon and owners and holders of American Depositary Shares (incorporated by reference to Exhibit 4.1 to Sequans Communications S.A.’s Report on Form 6-K filed with the SEC on November 16, 2020)
Form of American Depositary Receipt (included in Exhibit 2.2)
Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 1934 (incorporated by reference to Exhibit 2.4 to Sequans Communications S.A.’s Annual Report on Form 20-F filed with the SEC on March 31, 2022)
Amendment to amended and restated Deposit Agreement among Sequans Communications S.A., The Bank of New York Mellon and owners and holders of American Depositary Shares (incorporated by reference to Exhibit B to the Form F-6 filed by Sequans Communications S.A. with the SEC on September 11, 2023).
Stock Option Subscription Plan—2013-1 (incorporated by reference to Exhibit 4.1(c) to Sequans Communications S.A.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2013, filed with the SEC on March 31, 2014)
Stock Option Subscription Plan—2014-1 (incorporated by reference to Exhibit 4.1(d) to Sequans Communications S.A.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2014, filed with the SEC on April 21, 2015)
Stock Option Subscription Plan—2015-1 (incorporated by reference to Exhibit 4.1(e) to Sequans Communications S.A.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2015, filed with the SEC on April 29, 2016)
Stock Option Subscription Plan—2016-1 (incorporated by reference to Exhibit 99.1 to Registration No. 333-214444, filed with the SEC on November 4, 2016)
Stock Option Subscription Plan—2017-1 (incorporated by reference to Exhibit 99.1 to Registration No. 333-219430, filed with the SEC on July 24, 2017)
Stock Option Subscription Plan—2018 (incorporated by reference to Exhibit 99.1 to Registration No. 333-226458, filed with the SEC on July 31, 2018)
Stock Option Subscription Plan 2019 (incorporated by reference to Exhibit 99.1 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-233473, filed with the SEC on August 27, 2019)
Stock Option Subscription Plan 2020 (incorporated by reference to Exhibit 99.1 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-239968, filed with the SEC on July 21, 2020
Stock Option Subscription Plan 2021 (incorporated by reference to Exhibit 99.1 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-259914, filed with the SEC on September 30, 2021
Stock Option Subscription Plan 2022 (incorporated by reference to Exhibit 99.1 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-266481, filed with the SEC on August 3, 2022
BSA 2013-1 (Warrants) Issuance Agreement (incorporated by reference to Exhibit 4.2(c) to Sequans Communications S.A.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2013, filed with the SEC on March 31, 2014)
BSA Subscription Plan—2014-1 (incorporated by reference to Exhibit 4.2(d) to Sequans Communications S.A.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2014, filed with the SEC on April 21, 2015)
BSA (Warrants) Issuance Agreement, dated June 26, 2014 (incorporated by reference to Exhibit 4.12 to Sequans Communications S.A.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2014, filed with the SEC on April 21, 2015)
BSA (Warrants) Issuance Agreement, dated June 29, 2015 (incorporated by reference to Exhibit 4.17 to Sequans Communications S.A.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2015, filed with the SEC on April 29, 2016)
96


Exhibit
Number
Description of Exhibit
BSA (Warrants) Subscription Plan 2016-1 (incorporated by reference to Exhibit 99.3 to Registration No. 333-214444, filed with the SEC on November 4, 2016)
BSA (Warrants) Subscription Plan 2016-2 (incorporated by reference to Exhibit 99.4 to Registration No. 333-214444, filed with the SEC on November 4, 2016)
BSA (Warrants) Issuance Agreement, dated June 28, 2016 (incorporated by reference to Exhibit 99.5 to Registration No. 333-214444, filed with the SEC on November 4, 2016)
BSA (Warrants) Subscription Plan 2017-1 (incorporated by reference to Exhibit 99.5 to Registration No. 333-219430)
BSA (Warrants) Subscription Plan 2017-2 (incorporated by reference to Exhibit 99.6 to Registration No. 333-219430, filed with the SEC on July 24, 2017)
BSA (Warrants) Issuance Agreement, dated June 30, 2017 (incorporated by reference to Exhibit 99.5 to Registration No. 333-219430, filed with the SEC on July 24, 2017)
BSA 2018-1 (Warrants) Issuance Agreement (incorporated by reference to Exhibit 99.4 to Registration No. 333-226458, filed with the SEC on July 31, 2018)
BSA 2018-2 (Warrants) Issuance Agreement (incorporated by reference to Exhibit 99.5 to Registration No. 333-226458, filed with the SEC on July 31, 2018)
BSA (Warrants) Issuance Agreement, dated June 29, 2018 (incorporated by reference to Exhibit 99.6 to Registration No. 333-226458, filed with the SEC on July 31, 2018)
BSA 2019-1 (Warrants) Issuance Agreement (incorporated by reference to Exhibit 99.4 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-233473, filed with the SEC on August 27, 2019)
BSA 2019-2 (Warrants) Issuance Agreement (incorporated by reference to Exhibit 99.5 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-233473, filed with the SEC on August 27, 2019)
BSA (Warrants) Issuance Agreement, dated July 1, 2019 (incorporated by reference to Exhibit 99.6 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-233473, filed with the SEC on August 27, 2019)
BSA 2020-1 (Warrants) Issuance Agreement (incorporated by reference to Exhibit 99.4 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-239968, filed with the SEC on July 21, 2020)
BSA 2020-2 (Warrants) Issuance Agreement (incorporated by reference to Exhibit 99.5 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-239968, filed with the SEC on July 21, 2020)
BSA (Warrants) Issuance Agreement, dated June 29, 2020 (incorporated by reference to Exhibit 99.6 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-239968, filed with the SEC on July 21, 2020)
Partner Warrants 2021-1 Issuance Agreement 2021 (incorporated by reference to Exhibit 99.4 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-259914, filed with the SEC on September 30, 2021
Partner Warrants 2021-2 Issuance Agreement 2021 (incorporated by reference to Exhibit 99.5 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-259914, filed with the SEC on September 30, 2021
Director Warrants Issuance Agreement, Dated June 25, 2021 (incorporated by reference to Exhibit 99.6 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-259914, filed with the SEC on September 30, 2021
Partner Warrants 2022-1 Issuance Agreement 2021 (incorporated by reference to Exhibit 99.4 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-266481, filed with the SEC on August 3, 2022)
Partner Warrants 2021-2 Issuance Agreement 2021 (incorporated by reference to Exhibit 99.5 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-266481, filed with the SEC on August 3, 20222
Director Warrants Issuance Agreement, Dated June 24, 2022 (incorporated by reference to Exhibit 99.6 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-266481, filed with the SEC on August 3, 2022)
Director Warrants Issuance Agreement, Dated June 27, 2023
97


Exhibit
Number
Description of Exhibit
Partner Warrants 2023-1 Issuance Agreement 2023
Restricted Share Award Plan 2019-1 (incorporated by reference to Exhibit 99.2 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-233473, filed with the SEC on August 27, 2019)
Restricted Share Award Plan 2019-2 (incorporated by reference to Exhibit 99.3 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-233473, filed with the SEC on August 27, 2019)
Restricted Share Award Plan 2020-1 (incorporated by reference to Exhibit 99.2 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-239968, filed with the SEC on July 21, 2020
Restricted Share Award Plan 2020-2 (incorporated by reference to Exhibit 99.3 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-239968, filed with the SEC on July 21, 2020
Restricted Share Award Plan 2021-1 (incorporated by reference to Exhibit 99.2 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-259914, filed with the SEC on September 30, 2021
Restricted Share Award Plan 2021-2 (incorporated by reference to Exhibit 99.3 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-259914, filed with the SEC on September 30, 2021
Restricted Share Award Plan 2022-1 (incorporated by reference to Exhibit 99.2 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-266481, filed with the SEC on August 3, 2022)
Restricted Share Award Plan 2022-2 (incorporated by reference to Exhibit 99.3 to Sequans Communications S.A.’s Registration Statement on Form S-8, File Number 333-266481, filed with the SEC on August 3, 2022)
Restricted Share Award Plan 2023-1
Loan Agreement by and between Bpifrance Financement and Sequans Communications S.A., dated September 14, 2015 (English translation) (incorporated by reference to Exhibit 4.15 to Sequans Communications S.A.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2015, filed with the SEC on April 29, 2016)
Interest-Free Innovation Loan Agreement by and between Bpifrance Financement and Sequans Communications S.A., dated August 17, 2015 (English translation) (incorporated by reference to Exhibit 4.16 to Sequans Communications S.A.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2015, filed with the SEC on April 29, 2016)
COVID-19 economic support loan agreement by and between Bpifrance Financement and Sequans Communications S.A. dated April 30, 2020 (English translation) (incorporated by reference to Exhibit 4.4(c) to Sequans Communications S.A.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2020, filed with the SEC on April 1, 2021
Warrant Agreement by and between Sequans Communications S.A. and Nokomis Capital Master Fund, LP, dated September 27, 2018 (incorporated by reference to Exhibit 4.4 to Sequans Communications S.A.’s Report on Form 6-K filed with the SEC on October 30, 2018)
Convertible Note Agreement by and between Sequans Communications S.A. and Nokomis Capital Master Fund, LP, dated August 16, 2019 (incorporated by reference to Exhibit 4.1 to Sequans Communications S.A.’s Report on Form 6-K filed with the SEC on August 21, 2019)
Convertible Promissory Note issued by Sequans Communications S.A. to Nokomis Capital Master Fund, LP on August 16, 2019 (incorporated by reference to Exhibit 4.2 to Sequans Communications S.A.’s Report on Form 6-K filed with the SEC on August 21, 2019)
Amendment No 1 to the Convertible Note Agreement dated August 16, 2019 by and between Sequans Communications S.A. and Nokomis Capital Master Fund, LP dated March 20, 2020 (incorporated by reference to Exhibit 4.5 to Sequans Communications S.A.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019, filed withe the SEC on March 30, 2020)
Amendment No 1 to the Warrant Agreement dated September 27, 2018 by and between Sequans Communications S.A. and Nokomis Capital Master Fund, LP dated March 20, 2020 (incorporated by reference to Exhibit 4.6 to Sequans Communications S.A.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019, filed with the SEC on March 30, 2020)
Warrant Agreement by and between Sequans Communications S.A. and Nokomis Capital Master Fund, LP, dated August 16, 2022 (incorporated by reference to Exhibit 4.5 to Sequans Communications S.A.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2022, filed with the SEC on March 31, 2023
Warrant Agreement by and between Sequans Communications S.A. and Nokomis Capital Master Fund, LP, dated August 16, 2023
Warrant Issue Agreement by and between Sequans Communications S.A. and Harbert European Growth Capital Fund II, SCSp (incorporated by reference to Exhibit 4.9 to Sequans Communications S.A.’s Report on Form 6-K filed with the SEC on October 30, 2018)
98


Exhibit
Number
Description of Exhibit
Consultancy Services Agreement between Sequans Communications S.A. and ABLE FRANCE dated March 1, 2021 (incorporated by reference to Exhibit 4.9 to Sequans Communications S.A.'s Annual report on Form 20-F for the fiscal year ended December 31, 2020, filed with the SEC on April 1, 2021)
Securities Purchase Agreement by and between Sequans Communications S.A. and Lynrock Lake Master Fund LP (incorporated by reference to Exhibit 4.1 to Sequans Communications S.A.'s Report on Form 6-K filed with the SEC on April 12, 2021)
Convertible Promissory Note issued by Sequans Communications S.A. to Lynrock Lake Master Fund LP (incorporated by reference to Exhibit 4.2 to Sequans Communications S.A.'s Report on Form 6-K filed with the SEC on April 12, 2021)
Memorandum of Understanding, dated August 4, 2023 by and between Sequans Communications S.A and Renesas Electronics Corporation (incorporated by reference to Exhibit 99.1 of the Form 6-K filed by Sequans Communications S.A with the SEC on August 7, 2023).
Amendment No. 1 to Memorandum of Understanding, dated September 2, 2023, by and between Sequans Communications S.A. and Renesas Electronics Corporation (incorporated by reference to Exhibit 99 (D)(2) of the Form SC 13E3 filed by Sequans Communications S.A with the SEC on September 11, 2023).
Amendment No. 2 to Memorandum of Understanding, dated December 4, 2023, by and between Sequans Communications S.A. and Renesas Electronics Corporation (incorporated by reference to Exhibit 99 (D)(14) of the Form SC TO-T/A filed by Sequans Communications S.A with the SEC on December 5, 2023).
Amendment No. 3 to Memorandum of Understanding, dated January 5, 2024, by and between Sequans Communications S.A. and Renesas Electronics Corporation (incorporated by reference to Exhibit 99 (D)(18) of the Form SC TO-T/A filed by Sequans Communications S.A with the SEC on January 5, 2024).
Security Purchase Agreement by and Sequans Communications S.A. and Renesas Electronics America Inc. (incorporated by reference to Exhibit 4.1 to Sequans Communications S.A.'s Report on Form 6-K/A filed with the SEC on November 13, 2023 )
Security Purchase Agreement by and Sequans Communications S.A. and Renesas Electronics America Inc. (incorporated by reference to Exhibit 4.1 to Sequans Communications S.A.'s Report on Form 6-K filed with the SEC on January 5, 2024)
Security Purchase Agreement by and Sequans Communications S.A. and Renesas Electronics America Inc. (incorporated by reference to Exhibit 4.1 to Sequans Communications S.A.'s Report on Form 6-K filed with the SEC on February 13, 2024)
Unsecured Promissory Note by and between Sequans Communications S.A. and 272 Capital Master Fund, Ltd (incorporated by reference to Exhibit 4.1 to Sequans Communications S.A.'s Report on Form 6-K filed with the SEC on April 25, 2024)
List of Subsidiaries
Corporate Insider Trading Policy
Certificate of Chief Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002
Certificate of Chief Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002
Certificate of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002
Certificate of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002
Consent of Ernst & Young Audit, independent registered public accounting firm
Compensation Recovery Policy

*Filed herewith.


99

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.
 
Sequans Communications S.A.
By: /s/ Dr. Georges Karam
Name: Dr. Georges Karam
Title: Chief Executive Officer and Chairman
Date: May 15, 2024

100

Sequans Communications S.A.
Index to the Consolidated Financial Statements
F-1


Report of Independent Registered Public Accounting Firm


To the Shareholders and the Board of Directors of Sequans Communications S.A.:

Opinion on the Financial Statements
We have audited the accompanying consolidated statements of financial position of Sequans Communications S.A. (the Company) as of December 31, 2021, 2022 and 2023, the related consolidated statements of operations, comprehensive income (loss), changes in equity (deficit) and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, 2022 and
2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated May 15, 2024 expressed an unqualified opinion thereon.

The Company's Ability to Continue as a Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2.1 to the consolidated financial statements, the Company has suffered recurring losses from operations, has a working capital deficiency, and has stated that substantial doubt exists about the Company’s ability to continue as a going concern. Management's evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 2.1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

F-2



Allocation of consideration and estimate of costs to complete for development services
Description of the MatterAs described in note 2.3 of the consolidated financial statements, the Company’s contracts may include promises to transfer multiple products and/or services to a customer. The Company evaluates each component to determine whether they represent separate performance obligations and determines the appropriate allocation of the transaction price to each identified performance obligation based on estimated stand-alone selling prices. Revenue from technical support and development services is generally recognized over time using the percentage-of-completion method using an input method of estimated costs as a measure of performance completed. Management estimates total costs to complete the contract which include direct labor, material and subcontracting costs which can be subject to many variables such as management’s judgment about the ability and cost to achieve the project schedule and the costs to complete the technical requirements. Management uses these variables to estimate the costs at completion of open contracts and determine the amount of revenue to be recognized.

Auditing the Company’s determination of allocation of consideration to each performance obligation was complex and involved subjective auditor judgment, because management exercises significant judgment in determining the estimated stand-alone selling prices for each distinct performance obligation for products and services that are not sold separately and for which market conditions or other inputs and assumptions are used. In addition, testing the Company’s evaluation of estimated costs at completion involved subjective auditor judgment, because it involved management’s assumptions of the amount of future direct labor, material and subcontracting costs that will be required to complete the contracts, which could have a material effect on the amount of revenue recognized to date.
How We Addressed the Matter in Our AuditWe obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management’s determination of the estimated costs at completion and the allocation of the transaction price to each identified performance obligation based on estimated stand-alone selling prices. For example, we tested controls over management’s determination and review over significant inputs, such as direct labor, material and subcontractor costs and the percentage of completion used in the cost estimates at completion to recognize revenue. In addition, we tested controls over management’s determination of the estimated relative stand-alone selling prices.

We read the executed contracts to understand the contractual terms and the distinct performance obligations identified by management. To test the calculation of the amount of consideration allocated to each performance obligation, we performed audit procedures that included, among others, evaluating the accuracy and the completeness of the underlying data used in the Company’s calculation of the ranges or amount of each standalone selling price. We evaluated the methodology used to determine the standalone selling price, including against the requirements of IFRS 15, by comparing such prices to historical sales made to the customer or to customers with similar contracts or external market data, if available.

We also evaluated and tested the estimated revenue and costs at completion for the contracts. In so doing, our procedures included assessing the progress towards completion by obtaining customer validation of the achievement of milestones, if applicable, and performing inquiries of key operations executives to evaluate progress to date and factors impacting the amount and cost of direct labor, material and subcontracting costs necessary to complete the contracts. We performed retrospective reviews of contract cost estimates and changes in estimates over time. We also compared direct labor, material and subcontract costs incurred by the Company subsequent to year-end to assess the consistency with the costs estimated as of year-end. We also assessed the accuracy and sufficiency of the disclosures.


F-3


Accounting for Lynrock and Nokomis convertible notes
Description of the MatterAs described in Note 14.1 to consolidated financial statements, the Company entered into a convertible note agreement in the principal amount of $40 million with Lynrock Lake Master Fund LP (“Lynrock convertible notes”). The Company also has convertible notes with Nokomis Capital, LLC (“Nokomis convertible notes”) The Lynrock convertible notes and Nokomis convertible notes (collectively “the convertible notes”) have been accounted for as compound financial instruments with a liability component and an embedded derivative whose fair values were $52.3 million and $3.0 thousand, respectively, at December 31, 2023. The embedded derivative is accounted for as a liability, with changes in fair value recorded as financial income or loss at each statement of financial position date.
Auditing the Company’s accounting for these convertible notes was complex due to the significant judgments required by management to analyze and develop the assumptions used to calculate the fair values of the liability and embedded derivative components, in particular, the expected volatility of the Company’s underlying stock price which has experienced fluctuations, and the market discount rate.
How We Addressed the Matter in Our AuditWe obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management’s development of the assumptions used in the determination of the fair value of liability and embedded derivative components, including management’s oversight of the work performed by the independent valuation specialist engaged by the Company.

Our audit procedures related to the determination of the fair value of the liability and embedded derivative components included, among others, assessing the valuation methodologies, including key assumptions made, such as expected volatility of the Company’s stock price and market discount rates, applied by the Company. We read the underlying convertible note agreements to understand the contractual terms and the provisions impacting the Company’s valuations. We assessed the completeness and accuracy of the underlying data supporting the assumptions and involved our valuation specialists to assist us in reviewing the valuation methodology and testing the volatility and discount rate assumptions included in the models. We performed sensitivity analyses of significant assumptions to evaluate the changes in fair value of the liability and embedded derivative components from changes in these assumptions. These evaluations included consideration of external market data regarding market discount rates and fluctuations of the Company's stock price. We also assessed the accuracy and sufficiency of the fair value disclosures.


/s/ Ernst & Young Audit

We have served as the Company’s auditor since 2008.

Paris-La Défense, France

May 15, 2024
F-4

Sequans Communications S.A.
Consolidated Statements of Operations
  Year ended December 31,
 Note202120222023
  (in thousands, except share, ADS and per share and ADS amounts)
Revenue:
Product revenue$30,410 $22,974 $8,060 
License and services revenue20,469 37,577 25,556 
Total revenue350,879 60,551 33,616 
Cost of revenue4.223,690 17,671 9,476 
Gross profit27,189 42,880 24,140 
Operating expenses:
Research and development4.426,414 26,610 26,124 
Sales and marketing9,049 10,027 11,861 
General and administrative10,045 10,082 15,993 
Total operating expenses4.245,508 46,719 53,978 
Operating income (loss)(18,319)(3,839)(29,838)
Financial income (expense):
Interest expense4.1(11,329)(10,925)(11,409)
Interest income4.147 68 176 
Impact of debt reimbursement14.15,177   
Convertible debt amendments14.1 476 247 
Change in fair value of convertible debt derivative
14.13,848 6,878 3,200 
Foreign exchange gain (loss), net4.1938 1,082 (692)
Loss before income taxes(19,638)(6,260)(38,316)
Income tax expense (benefit)5625 2,748 2,674 
Net loss$(20,263)$(9,008)$(40,990)
Attributable to:
Shareholders of the parent$(20,263)$(9,008)$(40,990)
Basic earnings (loss) per ordinary share6$(0.14)$(0.05)$(0.18)
Diluted earnings (loss) per ordinary share6$(0.14)$(0.05)$(0.18)
Weighted average number of shares used for computing:
Basic per ordinary share146,691,784 184,587,104 225,183,996 
Diluted per ordinary share146,691,784 184,587,104 225,183,996 
Basic earnings (loss) per ADS$(0.55)$(0.20)$(0.73)
Diluted earnings (loss) per ADS$(0.55)$(0.20)$(0.73)
Weighted average number of ADS used for computing:
Basic per ADS36,672,946 46,146,776 56,295,999 
Diluted per ADS36,672,946 46,146,776 56,295,999 

F-5


Sequans Communications S.A.
Consolidated Statements of Comprehensive Income (Loss)
 Year ended December 31,
 202120222023
 (in thousands)
Loss for the year$(20,263)$(9,008)$(40,990)
Other comprehensive income (loss)
Other comprehensive income (loss) to be reclassified to profit or loss in subsequent years :
Net gain (loss) on cash flow hedge(129)202 (76)
Exchange differences on translation of foreign operations157 (638)97 
Net other comprehensive income (loss) to be reclassified to profit or loss in subsequent years28 (436)21 
Other comprehensive income (loss) not to be reclassified to profit or loss in subsequent years :
Re-measurement gains (losses) on defined benefit plans(33)71 (46)
Net other comprehensive income (loss) not to be reclassified to profit or loss in subsequent years(33)71 (46)
Total other comprehensive income (loss)(5)(365)(25)
Total comprehensive loss$(20,268)$(9,373)$(41,015)
Attributable to:
Shareholders of the parent$(20,268)$(9,373)$(41,015)
Non-controlling interests   
The following notes form an integral part of the annual financial statements

F-6

Sequans Communications S.A.
Consolidated Statements of Financial Position
 At December 31,
 Note202120222023
 (in thousands)
ASSETS
Non-current assets:
Property, plant and equipment$8,010 $8,489 $6,815 
Intangible assets37,984 48,705 64,300 
Deposits and other receivables20.1 2,311 783 801 
Other non-current financial assets20.1 357 337 360 
Total non-current assets48,662 58,314 72,276 
Current assets:
Inventories6,433 9,387 6,335 
Trade receivables10 13,622 8,494 8,115 
Contract assets10 789 176 497 
Prepaid expenses2,108 1,399 1,422 
Other receivables7,252 5,799 4,958 
Research tax credit receivable4.4 5,863 4,515 9,864 
Short-term deposits11  5,000  
Cash and cash equivalents11 4,835 5,671 5,705 
Total current assets40,902 40,441 36,896 
Total assets$89,564 $98,755 $109,172 
EQUITY (DEFICIT) AND LIABILITIES
Equity (deficit):
Issued capital, euro 0.01 nominal value, 246,262,004 ordinary shares issued and outstanding at December 31, 2023 (193,426,478 at December 31, 2022 and 151,419,322 at December 31, 2021 with euro 0.02 nominal value)
12 $3,687 $2,306 $2,878 
Share premium12 298,389 2,418 14,568 
Other capital reserves13-1457,198 62,870 70,261 
Accumulated deficit(383,554)(65,099)(93,362)
Other components of equity(26)(391)(416)
Total equity (deficit)(24,306)2,104 (6,071)
Non-current liabilities:
Government grant advances and loans16 9,354 6,235 3,256 
Convertible debt14 36,373 43,455  
Convertible debt embedded derivative14 10,081 3,203  
Lease liabilities15 3,373 2,278 1,645 
Provisions17 2,137 2,196 2,222 
Trade payables19 964 1,788  
Deferred tax liabilities19 138 258 264 
Contract liabilities19 2,706 404  
Total non-current liabilities65,126 59,817 7,387 
Current liabilities:
Trade payables18 13,916 9,342 16,281 
Interest-bearing financing of receivables14 9,518 7,723 9,544 
Convertible debt14   52,278 
Convertible debt embedded derivative14   3 
Lease liabilities15 1,247 1,291 1,471 
Unsecured related party loan14   8,922 
Government grant advances and loans16 6,206 4,159 4,606 
Other current liabilities and provisions18 9,180 8,355 8,899 
Contract liabilities18 8,677 5,964 5,852 
Total current liabilities48,744 36,834 107,856 
Total equity and liabilities$89,564 $98,755 $109,172 

The following notes form an integral part of the annual financial statements
F-7

Sequans Communications S.A.
Consolidated Statements of Changes in Equity (Deficit)

 Attributable to the shareholders of the parent
 Ordinary sharesShare
premium
Other
capital
reserves
Accumulated
deficit
Cumulative
translation
adjustments
Accumulated other comprehensive income (loss)Total
equity
(deficit)
 SharesAmount
 (Note 12)(Note 12)(Note 12)(Notes 13 and14)    
 (in thousands, except share and per share amounts)
At January 1, 2021133,934,090 $3,269 $276,560 $46,677 $(363,291)$(219)$198 $(36,806)
Loss for the year(20,263)(20,263)
Re-measurement gains (losses) on defined benefit plans(33)(33)
Foreign currency translation157 157 
Net loss on cash flow hedge(129)(129)
Total comprehensive income (loss)(20,263)157 (162)(20,268)
Issue of shares in connection with the exercise of options and warrants, and vesting of restricted shares awards2,985,200 70 68 138 
Issue of shares in connection with a private placement with Lynrock on April 2021 (Note 12)7,272,724 173 9,827 10,000 
Conversion of convertible debts (Note 14.1)7,227,308 175 12,111 5,386 17,672 
Transaction costs(177)(177)
Share-based payments5,135 5,135 
At December 31, 2021151,419,322 $3,687 $298,389 $57,198 $(383,554)$(62)$36 $(24,306)
Loss for the year(9,008)(9,008)
Re-measurement gains (losses) on defined benefit plans71 71 
Foreign currency translation(638)(638)
Net gain on cash flow hedge202 202 
Total comprehensive income (loss)(9,008)(638)273 (9,373)
Issue of shares in connection with the exercise of options and warrants, and vesting of restricted shares awards3,441,468 48 (48) 
Issue of shares in connection with a private placement with Renesas on January 2022 (Note 12)7,899,020 179 9,102 9,281 
Issue of shares in connection with the public offering of March 2022 (Note 12)30,666,668 675 22,325 23,000 
Transaction costs(2,170)(2,170)
Change in nominal value(2,283)2,283  
Incorporation of losses(327,463)327,463  
Warrants issued to Nokomis in August 2022195 195 
Share-based payments5,477 5,477 
At December 31, 2022193,426,478 $2,306 $2,418 $62,870 $(65,099)$(700)$309 $2,104 
Loss for the year(40,990)(40,990)
Re-measurement gains (losses) on defined benefit plans(46)(46)
F-8

Sequans Communications S.A.
Consolidated Statements of Changes in Equity (Deficit)
Foreign currency translation97 97 
Net loss on cash flow hedge(76)(76)
Total comprehensive income (loss)(40,990)97 (122)(41,015)
Issue of shares in connection with the exercise of options and warrants, and vesting of restricted shares awards5,520,010 60 (60) 
Issue of shares in connection with a private placement on April 2023 (Note 12)38,834,952 42319,577 20,000 
Issue of shares in connection with a private placement on September 2023 (Note 12)8,480,564 895,911 6,000 
Transaction costs(551)(551)
Incorporation of losses(12,727)12,727  
Bridge loans from related party205 205 
Warrants issued to Nokomis in August 202282 82 
Share-based payments7,104 7,104 
At December 31, 2023246,262,004 $2,878 $14,568 $70,261 $(93,362)$(603)$187 $(6,071)


The following notes form an integral part of the annual financial statements
F-9

Sequans Communications S.A.
Consolidated Statements of Cash Flow
  Year ended December 31,
 Note202120222023
  (in thousands)
Operating activities:
Loss before income taxes$(19,638)$(6,260)$(38,316)
Non-cash adjustment to reconcile profit (loss) before tax to net cash used in operating activities:
Amortization and impairment of property, plant and equipment3,354 3,979 4,594 
Amortization and impairment of intangible assets7,199 8,036 7,348 
Share-based payment expense4.3 5,135 5,477 7,104 
Increase (Decrease) in provisions461 207 (97)
Interest expense, net11,285 10,857 11,233 
Change in the fair value of convertible debt embedded derivative14.1 (3,848)(6,878)(3,200)
Impact of debt reimbursement(5,177)  
Convertible debt amendments14.1  (476)(247)
Foreign exchange loss (gain)(1,034)(394)741 
Loss (gain) on disposal of property, plant and equipment48 24  
Bad debt expense10 65   
Working capital adjustments:
Decrease (Increase) in trade receivables and other receivables1,366 6,660 (41)
Decrease (Increase) in inventories(208)(2,954)3,052 
Decrease (Increase) in research tax credit receivable(3,682)(1,556)(3,204)
Increase (Decrease) in trade payables and other liabilities4,693 (6,970)7,252 
Increase (Decrease) in contract liabilities(6,791)(6,171)(199)
Increase (Decrease) in government grant advances (1)
(1,387)(2,456)(1,080)
Income tax paid(346)(2,964)(2,201)
Net cash flow used in operating activities$(8,505)$(1,839)$(7,261)
Investing activities:
Purchase of intangible assets and property, plant and equipment7-8$(9,544)$(7,169)$(5,457)
Capitalized development expenditures(19,375)(15,494)(24,115)
Sale (Purchase) of financial assets(1,694)1,548 (41)
Decrease (Increase) of short-term deposit10,900 (5,000)5,000 
Interest received47 68 176 
Net cash flow used in investments activities$(19,666)$(26,047)$(24,437)
Financing activities:
Public and private equity offering proceeds, net of transaction costs paid$9,852 $30,111 $25,450 
Proceeds from issue of warrants and exercise of stock options/warrants granted under share-based payment plans, net of transaction costs138   
Proceeds from (repayment of) interest-bearing receivables financing, net14.3 21 3,046 1,483 
Proceeds from interest-bearing research project financing16.2   545 
Proceeds from related party loans14.2   9,000 
Proceeds from convertible debt, net of transaction cost12-14.139,682   
Repayment of venture debt14.2 (7,869)  
Repayment of government loans16.3 (469)(958)(1,126)
Repayment of convertible debt and accrued interest14.1 (8,750)  
Repayment of interest-bearing research project financing16.2 (804)(812)(939)
Payment of lease liabilities(1,063)(1,205)(1,321)
Interest paid(5,310)(1,467)(1,356)
Net cash flows from financing activities$25,428 $28,715 $31,736 
Net increase (decrease) in cash and cash equivalents(2,743)829 38 
Net foreign exchange difference4 7 (4)
Cash and cash equivalents at January 17,574 4,835 5,671 
Cash and cash equivalents at period end11 $4,835 $5,671 $5,705 

The following notes form an integral part of the annual financial statements

F-10


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
1. Corporate information
Sequans Communications S.A. (“Sequans”) is organized as a limited liability company (“société anonyme”) incorporated and domiciled in the Republic of France, with its principal place of business at 15-55 boulevard Charles de Gaulle, 92700 Colombes, France. Sequans, together with its subsidiaries (the “Company”), is a fabless designer, developer and provider of cellular semiconductor chips and modules for massive and broadband Internet of Things (IoT) markets. The Company’s semiconductor solutions incorporate baseband processor and radio frequency transceiver integrated circuits along with its proprietary signal processing techniques, algorithms and software stacks. For 5G/4G massive IoT applications, the Company provides a comprehensive product portfolio based on its Monarch LTE-M/NB-IoT and Calliope Cat 1 chip platforms, featuring low power consumption, a large set of integrated functionalities, and a global deployment capability. For 5G/4G broadband and critical IoT applications, the Company offers a product portfolio based on its Cassiopeia Cat 4/Cat 6 and planned Taurus 5G chip platforms, optimized for low-cost residential, enterprise, and industrial applications.
2. Summary of significant accounting and reporting policies
2.1. Basis of preparation
The Consolidated Financial Statements are presented in U.S. dollars.
The Consolidated Financial Statements for the year ended December 31, 2023 have been prepared on a going concern assumption. During 2021, 2022 and 2023, we financed our operations primarily through proceeds from the issue of shares through public offerings and private placements (2021, $9.9 million; 2022, $30.1 million; 2023, $25.5 million), bridge loans ($9.0 million in 2023) and convertible notes (2021, $39.7 million). We experienced net losses of $20.3 million, $9.0 million and $41.0 million in 2021, 2022 and 2023, respectively. At December 31, 2023, our accumulated deficit was $93.4 million and we had negative working capital of $71.0 million. We expect to continue to incur significant expense related to the development of our 4G and 5G products and expansion of our business, including research and development and sales and administrative expenses. In addition, we will incur expense to meet our commitments to our customers under various purchase orders and contracts. The Company will be required to obtain additional financing, including through a combination of government research and development funding, strategic licensing and/or service agreements, or additional equity, debt offerings or bridge loans, to meet these cash flow needs.
The Company’s internal cash forecast which is built from sales forecasts by products and by customer, assumes a slightly increasing operating cost structure, ongoing and new government funding of research programs and ongoing and new strategic funding activities. The Company expects to be able to obtain additional funding through one or more possible license agreements, business partnerships or other similar arrangements; or from financing from institutional or strategic investors, from the capital markets, or a combination of the above. However, the Company cannot guarantee if or when any such transactions will occur or whether they will be on satisfactory terms. In addition, the Company's forecasts of cash proceeds from revenues could be adversely impacted if customers delay or reduce purchases.
The Company does not and cannot know if the current uncertainties in these geopolitical areas, which are unfolding in real-time, may escalate and result in broad economic and security conditions, which could result in material implications for the Company's business. In addition, the Company's insurance policies typically contain a war exclusion of some description and the Company does not know how its insurers are likely to respond in the event of a loss alleged to have been caused by geopolitical uncertainties.
While the Company has taken and will continue to take actions to obtain new funding, the above factors raise substantial doubt about the Company’s ability to continue as a going concern as there is no assurance that the Company will be successful in satisfying its future cash needs.
F-11


Statement of compliance
The Consolidated Financial Statements of the Company have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standard Board (“IASB”) and whose application is mandatory for the year ended December 31, 2023. Comparative figures are presented for December 31, 2021 and 2022.
The accounting policies are consistent with those of the same period of the previous financial year, except for the changes disclosed in Note 2.2 to the Consolidated Financial Statements.
The Consolidated Financial Statements of the Company as of and for the years ended December 31, 2021, 2022 and 2023 have been authorized for issue in accordance with a resolution of the board of directors on April 30, 2024.
Basis of consolidation
The Consolidated Financial Statements comprise the financial statements of Sequans Communications S.A., which is the ultimate parent of the group, and its subsidiaries as of and for the years ended December 31, 2023, 2022 and 2021:
NameCountry of
incorporation
Year of
incorporation
%
equity
interest
Sequans Communications Ltd.United Kingdom2005100 
Sequans Communications Inc.United States2008100 
Sequans Communications Ltd. Pte.Singapore2008100 
Sequans Communications Israel (2009) Ltd.Israel2009100 
Sequans Communications Finland OyFinland2020100 
Sequans Communications SASFrance2023100 
The financial statements of the subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. All intra-group balances, transactions, income and expenses and profits and losses resulting from intra-group transactions are eliminated in full. The subsidiaries have been fully consolidated from their date of incorporation.
2.2. Changes in accounting policy and disclosures
New and amended standards and interpretations
The accounting policies used in 2023 are consistent with those of the previous financial year, except for the following new and amended IFRS and IFRIC interpretations effective as of January 1, 2023:
Amendments to IAS 1: Classification of Liabilities as Current or Non-current: In January 2020, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The Company adopted the amendments effective for annual reporting periods beginning on or after January 1, 2022. Adoption of these amendments had no material impact on the Consolidated Financial Statements.
Amendments to IAS 1 and IFRS Practice Statement 2: Disclosure of Accounting Policies: In February 2021, the IASB issued amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements, in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their ‘significant’ accounting policies with a requirement to disclose their ‘material’ accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendments to IAS 1 are applicable for annual periods beginning on or after January 1 2023 with earlier application permitted. Since the amendments to the Practice Statement 2 provide non-mandatory guidance on the application of the definition of material to accounting policy information, an effective date for these amendments is not necessary. The amendments had no material impact on the Company.
F-12


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Amendments to IAS 8: Definition of Accounting Estimates: In February 2021, the IASB issued amendments to IAS 8, in which it introduces a definition of ‘accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, they clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 and apply to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. Earlier application is permitted as long as this fact is disclosed. The amendments had no material impact on the Company.
Amendments to IAS 12: Deferred Tax related to Assets and Liabilities arising from a Single Transaction: In May 2021, the Board issued amendments to IAS 12, which narrow the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments should be applied to transactions that occur on or after the beginning of the earliest comparative period presented. In addition, at the beginning of the earliest comparative period presented, a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability should also be recognized for all deductible and taxable temporary differences associated with leases and decommissioning obligations. The amendments had no material impact on the Company.
Standards issued but not yet effective
Standards and interpretations issued but not yet effective up to the date of issue of the Company’s Consolidated Financial Statements are listed below. The Company intends to adopt these standards when they become effective:
Amendments to IFRS 16: Lease Liability in a Sale and Leaseback. In September 2022, the IASB issued amendments to IFRS 16 to specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction, to ensure the seller-lessee does not recognize any amount of the gain or loss that relates to the right of use it retains. The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and must applied retrospectively to sale and leaseback transactions entered into after the date of initial application of IFRS 16. Earlier application is permitted and that fact must be disclosed.The amendments are not expected to have a material impact on the Company’s financial statements.

Amendments to IAS 1: Classification of Liabilities as Current or Non-current. In January 2020 and October 2022, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify:
What is meant by a right to defer settlement
That a right to defer must exist at the end of the reporting period
That classification is unaffected by the likelihood that an entity will exercise its deferral right
That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification
In addition, a requirement has been introduced to require disclosure when a liability arising from a loan agreement is classified as non-current and the entity’s right to defer settlement is contingent on compliance with future covenants within twelve months.
The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and must be applied retrospectively. The Company is currently assessing the impact the amendments will have on current practice and whether existing loan agreements may require renegotiation.

Supplier Finance Arrangements - Amendments to IAS 7 and IFRS 7. In May 2023, the IASB issued amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures to clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity’s liabilities, cash flows and exposure to liquidity risk. The amendments will be effective for annual reporting periods beginning on or after 1 January 2024. Early adoption is permitted, but will need to be disclosed. The amendments are not expected to have a material impact on the Company’s financial statements.

COVID-19
Management has considered what effect the COVID-19 pandemic has on the amounts recognized in the financial statements. Management has identified potential risks related to the impact on the production of the Company's products, on the Company's ability to source components required for production and on the demand for the Company's products by customers impacted by the pandemic. In the year ended December 31, 2021, the primary impacts on operations of the COVID-19 pandemic were increased product demand in the broadband IoT business, increases in certain costs related to a temporary shortage of components, and delays in growth in product revenues in the massive IoT business due to the limits
F-13


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
placed on production capacity driven by the component shortages. During 2022 and 2023, the Company did not identify any direct impact of the pandemic on its business. As of December 31, 2023, the Company has not identified any impact on its assets and liabilities.

Russian invasion in Ukraine
While the Company's key engineering competencies are performed in-house, primarily in France, the United Kingdom, Israel and the United States, the Company outsources some application software development and testing activities to an independent third-party provider of engineering services. The Company works with a dedicated team of 48 software engineers based in Kyiv, Ukraine. If the Russian invasion of Ukraine is protracted or if Ukraine experiences further political instability, these engineers may be unable to work for a sustained period of time, which could adversely impact the research and development operations. The Company has developed a contingency plan if the engineers in Kyiv are unable to continue working on their projects for us for a sustained period of time, but if the contingency plan is not effective or sanctions are imposed that prevent the Company from conducting business in Ukraine, the Company could suffer delays in product introduction or delays in resolution of customer software bugs, which could have a negative impact on its revenues. During 2022 and 2023, the Ukraine team was able to work effectively and the Company did not identify any direct impact from the situation on its business. As of December 31, 2023, the Company has not identified any impact on its assets and liabilities.

2.3. Material accounting policies
Functional currencies and translation of financial statements denominated in currencies other than the U.S. dollar
The Consolidated Financial Statements are presented in U.S. dollars, which is also the functional currency of Sequans Communications S.A. The Company uses the U.S. dollar as its functional currency due to the high percentage of revenues, cost of revenue, capital expenditures and operating costs, other than those related to headcount and overhead, which are denominated in U.S. dollars. Each subsidiary determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency.
As at the reporting date, the assets and liabilities of each subsidiary are translated into the presentation currency of the Company (the U.S. dollar) at the rate of exchange in effect at the Statement of Financial Position date and their Statement of Operations is translated at the weighted average exchange rate for the reporting period. The exchange differences arising on the translation are taken directly to a separate component of equity (“Cumulative translation adjustments”).
Foreign currency transactions
Foreign currency transactions are initially recognized by Sequans Communications S.A. and each of its subsidiaries at their respective functional currency rates prevailing at the date of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency spot rate of exchange in effect at the reporting date. All differences are taken to the Consolidated Statement of Operations within financial income or expense. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the initial transactions.
The table below sets forth, for the periods and dates indicated, the average and closing exchange rate for the U.S. dollar (USD) to the euro (EUR), the U.K. pound sterling (GBP), the Singapore dollar (SGD) and the New Israeli shekel (NIS):
USD/EURUSD/GBPUSD/SGDUSD/NIS
December 31, 2021
Average rate1.1835 1.3761 0.7444 0.3097 
Closing rate1.1326 1.3479 0.7413 0.3221 
December 31, 2022
Average rate1.0539 1.2372 0.7255 0.2980 
Closing rate1.0666 1.2026 0.7459 0.2840 
December 31, 2023
Average rate1.0816 1.2435 0.7447 0.2716 
Closing rate1.1050 1.2714 0.7573 0.2763 

F-14


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Earnings (loss) per ordinary share and per ADS
Basic earnings (loss) amounts per ordinary share and per ADS are computed using the weighted average number of shares outstanding during each period.
Diluted earnings per ordinary share and per ADS include the effects of dilutive options and warrants as if they had been exercised, unless the effect would be anti-dilutive.
Revenue recognition
The Company’s total revenue consists of product revenue and services and license revenue.
Revenue from contracts with customers is recognized when control of the goods or services is transferred to the customer at an amount that reflects the fair value of the consideration to which the Company is entitled, excluding sales taxes or duties.
The Company applies a five-step approach in determining the amount and timing of revenue to be recognized: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when the performance obligation is satisfied.
When a contract includes multiple promised goods and services, the Company evaluates each component to determine whether they represent separate performance obligations and determines the appropriate allocation of the contract consideration to each identified performance obligation based on estimated relative stand-alone selling prices.
If the consideration in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the goods or services to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved. Specifically, milestone payments in development services contracts represent variable consideration, the receipt of which is dependent upon the achievement of technical milestones.
The Company sometimes receives advance payments from customers for the provision of development services. The Company determines if there is a significant financing component for these contracts considering the length of time between the customers’ payment and the transfer of control of the goods and services. When a significant financing component has been identified, the transaction price for these contracts is discounted, using the rate that would be reflected in a separate financing transaction at contract inception. The Company applies the practical expedient for short-term advances received from customers. That is, the promised amount of consideration is not adjusted for the effects of a significant financing component if the period between the transfer of the promised good or service and the payment is one year or less.
Product revenue
Substantially all of the Company’s product revenue is derived from the sale of semiconductor solutions for 4G wireless applications.
Revenue from the sale of products is usually recognized at a point in time when the Company satisfies its performance obligation to the buyer, whether direct end customer, end customer's manufacturing partner or distributor. This occurs when there is no continuing managerial involvement to the degree usually associated with ownership nor effective control over the sale of products is retained, which is based on the specified Incoterms, but usually occurs on shipment of the goods. Sale of products to some distributors is recognized when the products are sold to the end-customer but these contracts are not significant. The Company is the principal in all product sales regardless of customer type. Products are not sold with a right of return but are covered by warranty. This is an assurance-type warranty. The Company does not accrue for a general warranty obligation as the Company has not historically incurred and does not expect material warranty costs. Although the products sold have embedded software, the Company believes that software is incidental to the products it sells.
License and services revenue
License and services revenue consists of revenues from the sale of licenses to use the Company’s technology solutions and any fees for the associated annual software maintenance and support services, as well as from the sale of technical support and development services. Development services include advanced technology development services for technology partners and software or product development and integration services for customers.
F-15


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Revenue from the sale of licenses is recognized at a point in time when the Company satisfies its performance obligation which occurs when the software has been delivered to the customer (assuming no other significant obligations exist), as licenses provide the right to use the software as it exists when made available to the customer.
Revenue from the sale of software maintenance and support services is recognized over the period of the maintenance (generally one year). When the first year of maintenance is included in the software license price, an amount generally equal to the negotiated rate for one year of maintenance is deducted from the value of the license and recognized as revenue over the period of maintenance as described above. The difference between license and maintenance services invoiced and the amount recognized in revenue is recorded as deferred revenue.
Revenue from technical support and development services is generally recognized over time using the percentage-of-completion method. For each service contract, the Company determines whether the pattern of transfer of control meets one of the criteria for revenue recognition over time: (a) the customer simultaneously receives and consumes the benefits provided by the entity's performance as the entity performs (b) the Company's performance creates or enhances an asset (for example, work in progress) that the customer controls as the asset is created or enhanced or (c) the Company's performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. Generally, the support and development contracts meet one or more of these criteria, based on the facts and circumstances both within the contract and the nature of the services provided. Typically, the customers consume the services as they are provided through ongoing technical support or through an iterative development process. Certain contracts also include terms which allow the customer to have control over the asset as it is created or provide Sequans the right to payment for all work performed to date.
Due to revenue recognition over time, contract assets are created for services provided that Sequans does not yet have the right to invoice. Contract liabilities are created when milestones are billed in advance of being earned.
When a contract does not meet one of the criteria above, revenue is recognized at a point in time, when there is evidence of transfer of control, which typically occurs upon achievement of certain or all contract milestones. Percentage-of-completion is calculated based on the input method using estimated costs as a measure of performance completed.
The costs associated with these arrangements are recognized as incurred. Revenue from development contracts where no related direct costs were identified amounted to $214,000 for the year ended December 31, 2023 ($236,000 in 2022 and no direct cost in 2021).
Contract assets
A contract asset is the right to consideration in exchange for goods or services transferred to the customer. As described above, when the Company performs by transferring goods or services before the customer pays consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional. Where the Company has an unconditional right to payment, these are included in unbilled revenue until billing occurs and classified as trade receivables.
We have elected to use the practical expedient not to adjust the promised amount of consideration for the effects of a significant financing component when the period between when we transfer the promised good or service to our customers and when we expect the customers to pay for that good or service is one year or less.
We also have elected to use the practical expedient not to disclose information about our remaining performance obligations for contracts that have an original expected duration of one year or less.
We do not have any costs that meet the criteria for costs to obtain a contract or cost to fulfill a contract.
As of December 31, 2023, the transaction price allocated to the unsatisfied or partially unsatisfied performance obligations was $88,000 and is expected to be recognized in the 2024.
As of December 31, 2022, the transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) was $1,643,000 for which $1,276,000 was expected to be recognized in the next year and $367,000 in the years after, excluding the amounts related to the development service contract entered into in October 2019, described under note 19.
As of December 31, 2021, the transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) was $4,273,000 for which $4,017,000 was expected to be recognized in the next year and $256,000 in the year after, excluding the amounts related to the development service contract entered into in October 2019, described under note 19.

F-16


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Contract liabilities
Contract liabilities represent amounts invoiced and/or cash received in advance related to services being performed. Contract liabilities include both upfront payments from license and development service agreements in excess of revenues recognized, as well as deferred revenue from advance payments for goods or maintenance services.
Revenue recognized in the current period from amounts included in deferred revenue at the beginning of the year was $190,000, $271,000 and $765,000 for 2023, 2022 and 2021, respectively (See Note 19 Other non-current liabilities and Note 18 trade payables and other current liabilities).
Cost of revenue
Cost of product revenue includes all direct and indirect costs incurred with the sale of products, including shipping and handling. Cost of services revenue includes direct costs incurred to support the obligations covered by development services contracts (mainly employees and subcontractors costs). Research and development costs associated with product development (including normal customer support which generates product improvement) are recorded in research and development expenses.

Research and development costs
Research costs are expensed as incurred. Development costs are recognized as an intangible asset if the Company can demonstrate:
the technical feasibility of completing the intangible asset so that it will be available for use or sale;
its intention to complete the asset and use or sell it;
its ability to use or sell the asset;
how the asset will generate future economic benefits;
the availability of adequate resources to complete the development and to use or sell the asset; and
the ability to measure reliably the expenditure during development.
Beginning in 2015, certain development costs incurred at the end of the product development cycle when the criteria for capitalization are met, became material as the Company began making its product available on more operator networks which require significant testing and qualification work in order to finalize the product for sale on that network. In 2021, the Company capitalized costs for the development of the chipsets for LTE NB-IoT (the Monarch 2). In 2021, 2022 and 2023, the Company also capitalized costs for the development for LTE Category 1 and the development of the 5G chipsets. The intangible assets are tested for impairment annually. (See Notes 4.4 and 8 to the Consolidated Financial Statements).
Research and development costs associated with product development (including normal customer support which generates product improvements) are recorded in operating expense. In some cases, the Company has negotiated agreements with customers and partners whereby the Company provides certain development services beyond its normal practices or planned product roadmap. Amounts received from these agreements are recorded in services revenue. Direct costs incurred by the Company as a result of the commitments in the agreements are recorded in cost of revenue. Other research and development costs related to the projects covered by the agreements, but which would have been incurred by the Company without the existence of such agreements are recorded in research and development expense.

Government grants, loans and research tax credits
The Company operates in certain jurisdictions which offer government grants or other incentives based on the qualifying research expense incurred or to be incurred in that jurisdiction. These incentives are recognized as the qualifying research expense is incurred if there is reasonable assurance that all related conditions will be complied with and the grant will be received. When the grant relates to an expense item, it is recognized as a reduction of the related expense over the period necessary to match the grant on a systematic basis to the costs that it is intended to compensate. Any cash received in advance of the expenses being incurred is recorded as a liability.
Some long-term research projects are also financed through low-interest forgivable loans. The present value of forgivable loans is calculated based on expected future payments discounted using the interest rate applied for standard loans with the same maturity. The difference between present value and amount received is accounted for as a grant.
F-17


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Where loans or similar assistance provided by governments or related institutions are interest-free, the present value is calculated based on expected future payments discounted using the interest rate applied for standard loans with the same maturity. The difference between present value and amount received is accounted for as a grant.
The Company also benefits from research incentives in the form of tax credits which are detailed in Note 4.4 to the Consolidated Financial Statements. When the incentive is available only as a reduction of taxes owed, such incentive is accounted for as a reduction of tax expense; otherwise, it is accounted for as a government grant with the benefit recorded as a reduction of research and development costs, whether capitalized or expensed.
Financial income and expense
Financial income and expense include:
interest expense related to accounts receivable financing, the debt component of convertible debt, bridge loans, government loans, lease contracts, upfront payments, financing components of customer contracts and a supplier payable with extended payment terms;
other expenses paid to financial institutions for financing operations;
foreign exchange gains and losses;
change in fair value of financial assets and liabilities
impact of convertible debt amendments; and
impact of convertible debt reimbursement.
The Company reflects foreign exchange gains and losses related to hedges (through derivatives) of euro-based operating expenses in operating expenses.
Taxation
Current income tax
Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date.
Current income tax relating to items recognized directly in equity is recognized in equity.
Deferred income tax
Deferred income tax is provided using the liability method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.
Deferred income tax liabilities are recognized for all taxable temporary differences, except with respect to taxable temporary differences associated with investments in subsidiaries where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.
Deferred income tax assets are recognized for all deductible temporary differences, carry forwards of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forwards of unused tax credits and unused tax losses can be utilized.
The carrying amount of deferred income tax assets is reviewed at the reporting date and adjusted to the extent that it is probable that sufficient future taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.
Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the statement of financial position date.
Deferred income tax relating to items recognized directly in equity is recognized in equity.
Deferred income tax assets and deferred income tax liabilities are offset if a legally enforceable right of offset exists.
F-18


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Value added tax
Revenue, expenses and assets are recognized net of the amount of value added tax except:
where the value added tax incurred on a purchase of assets or services is not recoverable from the tax authorities, in which case the value added tax is recognized as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
receivables and payables that are stated with the amount of value added tax included.
Value added tax recoverable consists of value added tax paid by the Company to vendors and suppliers located in the European Union, in the United Kingdom and in Israel, and recoverable from the tax authorities. Value added tax recoverable is collected on a monthly or quarterly basis.
Inventories
Inventories consist primarily of the cost of semiconductors, including wafer fabrication, assembly, testing and packaging; components; and modules purchased from subcontractors. Inventories are valued at the lower of cost (determined using the weighted average cost method) or net realizable value (estimated market value less estimated cost of completion and the estimated costs necessary to make the sale).
The Company writes down the carrying value of its inventories for estimated amounts related to the lower of cost or net realizable value, obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated net realizable value. The estimated net realizable value of the inventory is based on historical usage and assumptions about future demand, future product purchase commitments, estimated manufacturing yield levels and market conditions on a product-by-product basis. When the circumstances that previously caused inventories to be written down below cost no longer exist or when there is clear evidence of an increase in net realizable value because of changed economic circumstances, the amount of the write-down is reversed (i.e. the reversal is limited to the amount of the original write-down) so that the new carrying amount is the lower of the cost and the revised net realizable value.
Financial assets
Financial assets are classified, at initial recognition, as (1) measured at amortized cost, (2) fair value through other comprehensive income (OCI), or (3) fair value through profit or loss. The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and Sequans’ business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value.
Receivables
Trade receivables are measured at amortized cost. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take into account the risk of payment default throughout the lifetime of the receivables. Based on an analysis of historical credit losses, the Company has not applied any expected credit losses to its outstanding receivables as of the reporting date beyond specific provisions for doubtful accounts. The Company records an allowance for any specific account it considers as doubtful based on the particular circumstances of the account. The carrying amount of the receivable is thus reduced through the use of an allowance account, and the amount of the charge is recognized on the line “General and administrative expenses” in the Consolidated Statement of Operations. Subsequent recoveries, if any, of amounts previously provided for are credited against the same line in the Consolidated Statement of Operations. When a trade accounts receivable is uncollectible, it is written-off against the allowance account for trade accounts receivable.
Short-term investments
Short-term investments are financial instruments with an initial maturity of greater than 90 days, but less than one year, and are reported as current financial assets.
Deposits
Deposits are reported as non-current financial assets (loans and receivables) when their initial maturity is more than twelve months.

F-19


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Cash and cash equivalents
Cash and cash equivalents in the Consolidated Statements of Financial Position includes cash at banks, term deposits and money market funds, which correspond to highly liquid investments readily convertible to known amounts of cash and subject to an insignificant risk of change in value.
Property, plant and equipment
Property, plant and equipment is stated at cost less accumulated depreciation and any accumulated impairment loss. Depreciation is computed using the straight-line method over the estimated useful lives of each component. The Company presents right-of-use of lease contracts in property, plant and equipment and right of use assets are depreciated on a straight-line basis over the lease term. The useful lives most commonly used are the following:
Machinery and equipment  3 to 5 years
Building and leasehold improvements  Lesser of 6 years or the life of the lease
Computer equipment  3 years
Furniture and office equipment  5 years
Impairment tests are performed whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If any indication exists, the Company estimates the asset’s recoverable amount, which is the higher of the fair value less cost to sell and the value in use. Where the carrying amount exceeds that recoverable amount, the asset is considered impaired and it is written down to its recoverable amount.
Depreciation expense is recorded in cost of revenue or operating expenses, based on the function of the underlying assets.
Intangible assets
Intangible assets, which primarily consist of purchased licenses for development or production technology and tools, as well as standard-related patent licenses and development costs meeting the criteria for capitalization, are stated at cost less accumulated amortization and any accumulated impairment loss. Amortization is computed using the straight-line method over the estimated useful life of each component. Acquired licenses are amortized over their contractual life or five years in the case of perpetual licenses. Capitalized development costs are generally amortized over periods ranging from 3 to 5 years, representing the expected life of the related technology.
Useful lives are reviewed on a regular basis and changes in estimates, when relevant, are accounted for on a prospective basis. The amortization expense is recorded in cost of revenue or operating expenses, based on the function of the underlying assets.
Impairment tests are performed whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If any indication exists, the Company estimates the asset’s recoverable amount, which is the higher of the fair value less cost to sell and the value in use. Where the carrying amount exceeds that recoverable amount, the asset is considered impaired and it is written down to its recoverable amount.
Costs of equity transactions
Incremental costs directly attributable to the equity transaction are recorded as a deduction from equity.
Provisions
Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event for which it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in operating income (loss) net of any reimbursement.
Provisions include the provision for pensions and post-employment benefits. Pension funds in favor of employees are maintained in France, the United Kingdom, Singapore, the United States, Finland and Israel, and they comply with the respective legislation in each country and are financially independent of the Company. The pension funds are generally financed by employer and employee contributions and are accounted for as defined contribution plans with the employer contributions recognized as expense as incurred. There are no actuarial liabilities in connection with these plans.
F-20


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
French law also requires payment of a lump sum retirement indemnity to employees based on years of service and annual compensation at retirement. Benefits do not vest prior to retirement. This defined benefit plan is self-funded by the Company. It is calculated as the present value of estimated future benefits to be paid, applying the projected unit credit method whereby each period of service is seen as giving rise to an additional unit of benefit entitlement, each unit being measured separately to build up the final obligation. Following the application of IAS 19 as revised, actuarial gains and losses are recognized in equity. The discount rate is based on iBoxx Corporates AA. Since January 1, 2021, the Company has applied the IFRS IC decision on IAS 19 - Employee benefits which revised the methods for calculating commitments for defined benefit plans. In accordance with the adoption elected, Sequans has applied the full retrospective transition method.
Share-based payment transactions
Employees (including senior executives and members of the board of directors) and certain service providers of the Company receive remuneration in the form of share-based payment transactions, whereby they render services as consideration for equity instruments (“equity-settled transactions”).
The cost of equity-settled transactions is measured by reference to the fair value at the date on which they are granted. The exercise price is based on closing market price on the date of grant.
The cost of equity-settled transactions is recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the beneficiary becomes fully entitled to the award (the “vesting date”). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest which includes assumptions on the number of awards to be forfeited due to the employees’ failing to fulfill the service condition, and forfeitures following the non-completion of performance conditions. The Consolidated Statement of Operations charge or credit for a period represents the movement in cumulative expense recognized as at the beginning and end of that period.
Financial liabilities
Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.
All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings, net of directly attributable transaction costs.
Non derivative financial liabilities are subsequently measured at amortized cost whereas derivative liabilities not designated as hedging instruments are recognized at fair value through profit or loss.
Convertible debt
The Company evaluates at initial recognition of a convertible debt the different components and features of the hybrid instruments and determines whether these elements are equity instruments or embedded derivatives which require bifurcation. In subsequent periods, the liability component is accounted for using the effective interest method, based on the expected maturity of the debt. The equity component is not remeasured, while embedded derivatives unless closely related to the host instruments, are recorded at fair value through the Consolidated Statement of Operations.
As described in Note 14.1 to the Consolidated Financial Statements, the Company issued debt with an option to convert into shares of the Company in April 2015, April 2016, October 2017 and September 2018. The convertible notes were amended several times to extend term of the notes and reduce conversion rates.
On March 20, 2020, the convertible notes issued in April 2015, April 2016, September 2018, May 2019 and August 2019 were amended to grant the Company three options to extend the term of each note, except for the August 2019 notes which have two options. Each option will give the Company the right to extend the term of such note by one year and consequently reset the conversion price to a 20% premium above the 20-day volume weighted average price (VWAP) if it is lower than the existing conversion price. On the first option exercise, the payment-in-kind interest (PIK) will stay at 7% but the holder will be granted a warrant for 10% of the value of the note with a three-year term, at an exercise price of 20% premium above 20-day VWAP. On the second option exercise, the PIK will be adjusted to 9.5%, the previous warrants granted on the first option exercise will be extended by one year and the holder will be granted an additional warrant for 15% of the value of the note with a three year term, at an exercise price of 20% premium above 20-day VWAP. On the third option exercise, the PIK will be adjusted to 13.5%, and the holder will be granted an additional warrant for 20% of the value of the note with a three year term, at an
F-21


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
exercise price of 20% premium above 20-day VWAP. If at any time, the holder converts a note prior to the date of April 2022, it will receive an extra year’s worth of PIK so as to incentivize early conversion. In consideration for entering into the amendments, the warrants that noteholder owns that were scheduled to expire April 2021 were extended to April 2024 upon the signing of the note amendments.
From an accounting perspective, the amendment of the convertible notes resulted in the extinguishment of the existing notes and issuance of five new notes, accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the notes in cash; and
An embedded derivative, which reflects the Company's call options to extend the term of each note, the conversion option of Nokomis and in certain cases a repricing to decrease the conversion price.
The change in the liability component before and after the amendment was recorded in the Consolidated Statement of Operations in “Convertible debt amendments”.
The fair value of the liability component on the amendment date represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 26.3% as the market rate of interest in order to value the liability components.

The embedded derivatives of the notes were valued using the Geometric Brownian Motion framework relying on Monte-Carlo simulations. On March 20, 2020, the initial fair value of the embedded derivative of the notes was recorded in Other Capital reserves in shareholders' equity. The change in fair value is remeasured and recorded in the Consolidated Statement of Operations as financial income or loss at each statement of financial position date.

On April 9, 2021, the Company issued a note with options to convert into shares of the Company, limited to such conversion resulting in the noteholder owning more than 10% of the Company's outstanding shares. The Company retains an option to call the convertible debt under certain circumstances after 12 months, either in full or in part. If a change of control occurs at any time prior to the payment of the note in full, the noteholder shall have the right, in its sole discretion, to require Sequans to convert or redeem all of the outstanding principal amount (including accrued interest and unpaid interest).
As described in Note 14.1, the note was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the bonds in cash; and
An embedded derivative, which reflects the value of the conversion option.
The initial fair value of the notes was split between these two components.
The fair value of the liability component on the issuance date represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 20.89% as the market rate of interest in order to value the liability components of the note on issuance. The embedded derivative of the note was valued using the Geometric Brownian Motion framework relying on Monte-Carlo simulations. The change in fair value is remeasured and recorded as financial income or loss at each statement of financial position date.
On August 15, 2022, the Company elected to exercise the first option of the amendment signed on March 20, 2020 to extend the maturity of the convertible note issued in August 2019 to August 16, 2023. On August 15, 2023, the Company elected to exercise the second option of the amendment to extend the maturity of the convertible note to April 16, 2024. This resulted in the extinguishment of the existing note and issuance of a new note for accounting purposes. Therefore, the fair value of the debt just prior to amendment was estimated in order to record a gain on extinguishment in the Consolidated Statement of Operations in “Convertible debt amendments. The amended debt was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the notes in cash; and
An embedded derivative, which reflects the value of the conversion option.

F-22


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
In early April 2024, both note holders agreed to stay repayment of the notes until April 26, 2024. In late April, the Company began discussions to extend the standstill agreements, which are still in process as of April 30, 2024.
Short-term debt secured by accounts receivables
As described in Note 14.3 to the Consolidated Financial Statements, the Company has a factoring agreement with a French financial institution. The Company transfers to the finance company all invoices issued to qualifying customers, and the customers are instructed to settle the invoices directly with the finance company. Because there is recourse to the Company for amounts that are overdue, the Company retains all receivables on its Consolidated Statement of Financial Position until they are paid and any amounts drawn on the line of credit are reflected in short-term debt. The Company pays a commission on the face value of the accounts receivable submitted, which is recorded in General and Administration expense, and pays interest on any draw-down of the resulting line of credit.
In February 2021, the Company entered into an agreement to finance the 2021 research tax credit as it is earned over the year. The Company transfers to the finance company research tax credit receivable on a quarterly basis. Because there is recourse to the Company for amount not paid by the French tax administration, the Company retains all receivables on its Consolidated Statement of Financial Position until the French tax administration reimburses the finance company. Amounts drawn on the line of credit are reflected in short-term debt and commissions in the Consolidated Statement of Operations as financial expense. In March 2022, the Company entered into another agreement to finance the 2022 research tax credit, and in March 2023, the Company agreed to finance the 2023 research tax credit.
Lease contracts
Except for leases related to low-value assets and short-term lease, lease contracts, as defined under IFRS 16 "Leases", are recorded in the Statement of Consolidated Financial Position, through the recognition of:
an asset representing a right-of-use of the asset leased during the lease term of the contract; and
a liability related to the payment obligation.
At the commencement date of the lease, the Company recognizes a lease liability measured at the present value of the remaining lease payments to be made over the lease term, discounted using the Company’s incremental borrowing rate. The liability increases by the accrued interest resulting from the initial discounting of the lease liability and decreases by the payments made.
Right-of-use assets are depreciated on a straight-line basis over the lease term and tested for impairment when required.
Derivative financial instruments and hedge accounting
The Company uses financial instruments, including derivatives such as foreign currency forward and options contracts, to reduce the foreign exchange risk on cash flows from firm and highly probable commitments denominated in euros. The effective portion of the gain or loss on the hedging instrument is recognized directly as other comprehensive income (loss) in the cash flow hedge reserve, while any ineffective portion is immediately accounted for in financial results in the Consolidated Statement of Operations. Amounts recognized as other comprehensive income (loss) are transferred to the Consolidated Statement of Operations when the hedged transaction affects profit or loss. If the forecasted transaction is no longer expected to occur, the cumulative gain or loss previously recognized in equity is transferred to the Consolidated Statement of Operations.
All derivative financial instruments are recorded at fair value. Changes in fair value are recorded in current earnings or other comprehensive income (loss), depending on whether the derivative is designated as a hedge, its effectiveness as a hedge, and the type of hedge transaction. Any change in the fair value of the derivatives deemed ineffective as a hedge is immediately recognized in earnings.
Commitments
Commitments comprise primarily purchase commitments with third-party manufacturers for future deliveries of equipment and components, which are described in Note 21 to the Consolidated Financial Statements.

F-23


2.4. Significant accounting judgments, estimates and assumptions
In the process of applying the Company’s accounting policies, management must make judgments and estimates involving assumptions. These judgments and estimates can have a significant effect on the amounts recognized in the financial statements and the Company reviews them on an ongoing basis taking into consideration past experience and other relevant factors. The evolution of the judgments and assumptions underlying estimates could cause a material adjustment to the carrying amounts of assets and liabilities as recognized in the financial statements. The most significant management judgments and assumptions in the preparation of these financial statements are:
Revenue recognition
The Company’s policy for revenue recognition, in instances where multiple deliverables are sold contemporaneously to the same counterparty, is in accordance with IFRS 15 Revenue from contracts with customers. The application of IFRS 15 to contracts with customers requires management to make certain judgments, the most significant of which are outlined below. These judgments are based on an analysis of the facts and circumstances surrounding the transactions on a contract-by-contract basis.
Determination of performance obligations within a contract
The Company applies judgment in determining whether a promised good or service is a performance obligation under the terms of the contract and whether multiple promised goods or services should be accounted for separately or together as a bundle.
Allocation of contract consideration to distinct performance obligations based on their relative stand-alone selling prices
Typically, contracts state the value of individual promised goods and services directly. However, in instances where the fair value is not observable, management applies judgment in determining the relative stand-alone selling price for goods and services.
Estimation of percentage-of-completion based on the input method
For service contracts that are recognized over time based on the percentage-of-completion, the Company sets up an initial budget at contract inception and tracks the progress to completion based on time and costs incurred by the employees directly working on each project. Management reviews the progress and performance of open contracts in order to determine the best estimate of estimated costs at completion on a quarterly basis and updates the revenue recognized as necessary.
Trade receivables
The Company records an allowance for any specific account it considers as doubtful based on the particular circumstances of the account. Additional allowances could be required if the Company receives information that the financial condition of its customers has deteriorated, resulting in an impairment of their ability to make payments, or there are indicators that amounts receivable will become uncollectible.
Inventories
As disclosed in Note 2.3 to the Consolidated Financial Statements, the Company writes down the carrying value of its inventory to the lower of cost or net realizable value. The estimated net realizable value of the inventory is based on historical usage and assumptions about future demand, future product purchase commitments, estimated manufacturing yield levels and market conditions on a product-by-product basis. Actual demand may differ from the forecast established by the Company, which may materially impact recorded inventory values and cost of revenue.
Share-based compensation
As disclosed in Note 13 to the Consolidated Financial Statements, the Company has various share-based compensation plans for employees and non-employees that may be affected, as to the expense recorded in the Consolidated Statements of Operations, by changes in valuation assumptions. Fair value of stock options is estimated by using the binomial model on the date of grant based on certain assumptions, including, among others expected volatility, the expected option term, the risk-free interest rate and the expected dividend payout rate. The fair value of the Company’s shares underlying stock option grants equals the closing price on the New York Stock Exchange on the date of grant.


F-24


Fair value of financial instruments
Fair value corresponds to the quoted price for listed financial assets and liabilities. The Company determined that the fair values of cash, trade receivables and trade payables approximate their carrying amounts largely due to the short-term maturities of these instruments.
Where no active market exists, the Company establishes fair value by using a valuation technique determined to be the most appropriate in the circumstances.
Regarding compound debt instruments, the fair value of debt component was determined at the date of issuance using a valuation model that requires judgment, including estimating the change in value of the Company at different dates and market yields applicable to the Company’s straight debt (without the conversion option). The assumptions used in calculating the value of the conversion option, the expected volatility of the Company’s underlying stock price which has experienced fluctuations, and the market discount rate, represent the Company’s best estimates based on management’s judgment and subjective future expectations. The fair value of debt component were supported by work performed by an independent valuation specialist engaged by the Company.
Research and Development Costs
Costs incurred internally in research and development activities are charged to expense until technological feasibility has been established for the project. Once technological feasibility is established, development costs are capitalized until the product is available for general release to customers. Judgment is required in determining when technological feasibility of a product is established. We have determined that technological feasibility for our software products is reached after all high-risk development issues have been resolved. Generally, this occurs when the preliminary design review has been done.
Leases
The application of IFRS 16 “Leases” requires the Company to make assumptions and estimates in order to determine the value of the right-of-use assets and lease liabilities, which mainly relates to the determination of the Company’s incremental borrowing rate.

3. Segment information and Disaggregated Revenue Disclosures
The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. All information required to be disclosed under IFRS 8 Operating Segments is shown in the Consolidated Financial Statements and these associated Notes.
Sales to external customers disclosed below are based on the geographical location of the customers to which the Company invoices. The following table sets forth the Company’s total revenue by region for the periods indicated.
Year ended December 31,
202120222023
(in thousands)
Asia :
  China (including Hong-Kong)$3,509 $24,018 $21,702 
  Taiwan14,668 1,066 29 
  Korea1,090 8 30 
  Rest of Asia898 2,202 62 
     Total Asia20,165 27,294 21,823 
Germany4,990 15,525 1,001 
United States of America22,565 16,749 8,666 
Rest of world 3,159 983 2,126 
Total revenue$50,879 $60,551 $33,616 
Of our total revenue, 96.2% is attributable to international sales for the year ended December 31, 2023 (99.8% for 2022 and 99.6% for 2021).
F-25


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
The Company categorizes its total revenue based on technology.
Year ended December 31,
202120222023
(in thousands)
Broadband IoT$23,699 $36,181 $21,842 
Massive IoT27,180 24,370 11,774 
Total revenue$50,879 $60,551 $33,616 
Additionally, the Company categorize its total revenue based on product, license and services revenue.
Year ended December 31,
202120222023
(in thousands)
Product$30,410 $22,974 $8,060 
License17,073 31,005 22,997 
Development and other services3,396 6,572 2,559 
Total revenue$50,879 $60,551 $33,616 
License revenue includes, in particular, license fees from agreements signed with strategic partners. See Note 19 to these Consolidated Financial Statements.
The substantial majority of the Company’s non-current assets are held by the parent company, Sequans Communications S.A. and located in France. See Note 20.3 to these Consolidated Financial Statements for information about major customers.

4. Other income and expenses
4.1. Financial income and expenses
Financial income:
 Year ended December 31,
 202120222023
 (in thousands)
Income from short-term investments and term deposits and other finance revenue$47 $68 $177 
Impact of debt reimbursement (Notes 14.1 and 14.2)5,177   
Convertible debt amendments (Note 14.1) 476 247 
Change in fair value of convertible debt derivative (Note 14.1)
3,848 6,878 3,200 
Foreign exchange gain3,032 7,076 1,166 
Total financial income$12,104 $14,498 $4,790 
Financial expenses:
 Year ended December 31,
 202120222023
 (in thousands)
Interest on loans$7,462 $8,146 $9,584 
Interest on lease contracts (see Note 15)760 571 479 
Interest on financing component of long term development services agreement (see Notes 18 and 19)2,156 966 115 
Interest on supplier payable with extended payment terms173 222 286 
Other bank fees and financial charges778 1,020 946 
Foreign exchange loss2,094 5,994 1,858 
Total financial expenses$13,423 $16,919 $13,268 
F-26


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
For the year ended December 31, 2023, interest on loans included $9,566,000 related to convertible debt instruments issued in 2021 and 2019, the French government debt financing received in 2020 and bridge loans received in later 2023 (compared with $8,094,000 and $7,334,000 for the years ended December 31, 2022 and 2021, respectively which also included government loans granted in 2015 and convertible debt instruments issued in 2018, 2016 and 2015, and the venture debt issued in 2018 in the year ended December 31, 2021) (See Note 14.1 to the Consolidated Financial Statements).
The net foreign exchange loss of $692,000 for the year ended December 31, 2023 (2022: net foreign exchange gain of $1,082,000; 2021: net foreign exchange gain $938,000) arises primarily from euro-based monetary liabilities.
For the year ended December 31, 2023, a gain of $3,200,000 (2022 : gain of $6,878,000; 2021: gain of $3,848,000) was recognized, related to the change in fair value of the convertible debt embedded derivative (See Note 14.1 to the Consolidated Financial Statements).
For the year ended December 31, 2023, income of $247,000 (2022: gain of $476,000) was recognized related to the impact of the convertible debt amendment (see Note 14.1 to the Consolidated Financial Statements).
For the year ended December 31, 2021, a gain of $5,177,000 was recognized related to the impact of the convertible debts reimbursement (see Note 14.1 to the Consolidated Financial Statements) and of the prepayment in full of the venture debt (see Note 14.2 to the Consolidated Financial Statements).

4.2. Cost of revenue and operating expenses
The tables below present the cost of revenue and operating expenses by nature of expense:
  Year ended December 31,
 Note202120222023
  (in thousands)
Included in cost of revenue:
Cost of components$18,365 $13,102 $5,071 
Depreciation and impairment7517 428 395 
Amortization of intangible assets8162 148 118 
Wages and benefits2,306 2,497 2,059 
Share-based payment expense1358 160 131 
Assembly services, royalties and other2,282 1,336 1,702 
$23,690 $17,671 $9,476 
Year ended December 31,
 Note202120222023
  (in thousands)
Included in operating expenses (between gross profit and operating result):
Depreciation and impairment7$2,837 $3,551 $4,082 
Amortization of intangible assets87,037 7,888 7,346 
Wages and benefits36,684 33,195 36,014 
Share-based payment expense135,077 5,317 6,973 
Foreign exchange (gains) losses related to hedges of euro(73)207 (180)
Other, net(6,054)(3,439)(257)
$45,508 $46,719 $53,978 
F-27


4.3. Employee benefits expense
  Year ended December 31,
 Note202120222023
  (in thousands)
Wages and salaries$29,422 $27,115 $28,863 
Social security costs and other payroll taxes9,386 8,408 9,087 
Other benefits167 159 159 
Pension costs15 10 (36)
Share-based payment expenses135,135 5,477 7,104 
Total employee benefits expense$44,125 $41,169 $45,177 
The amount recognized as an expense for mandatory social tax contributions amounts to $1,465,000 for the year ended December 31, 2023 ($1,434,000 and $1,398,000 for the years ended December 31, 2021 and 2022, respectively).

4.4. Research and development expense and tax credit receivable
The research tax credit in France is deducted from corporate income taxes due; if taxes due are not sufficient to cover the full amount of the credit, the balance is received in cash three years later (one year later if the Company is below certain size criteria, which was the case for each of the years ended December 31, 2023, 2022 and 2021). Total research tax credit receivable as of December 31, 2023 is $9,714,000, ($5,006,000 relating to tax credits receivables for 2023, $4,460,000 for 2022, $137,000 for 2021 and $111,000 for 2020). Part of the amount was financed in 2023 and the remaining amount is expected to be recovered in 2024 and 2029 in cash (see Note 14.3 to the Consolidated Financial Statements).
The Company also has research tax credits available in the United Kingdom.
In the years ended December 31, 2021, 2022 and 2023, the Company capitalized costs related to the development of chipsets for 5G, and related to certification of various products. In the year ended December 31, 2021, the Company also capitalized costs related to the development of chipsets for LTE NB-IoT (Monarch N/Monarch 2).
The impact of the reduction of research and development expense due to government grants, research tax credit and development costs capitalized was as follows:
 Year ended December 31,
 202120222023
 (in thousands)
Research and development costs$52,200 $47,353 $53,018 
Research tax credit(6,328)(4,622)(5,374)
Government and other grants(3,621)(4,888)(1,834)
Development costs capitalized (*)(18,297)(13,808)(22,328)
Amortization of capitalized development costs2,460 2,575 2,642 
Total research and development expense$26,414 $26,610 $26,124 
(*) Reflecting reduction for research tax credits of $2,145,000, $1,924,000 and $1,587,000 for the years ended December 31, 2023, 2022 and 2021, respectively.
F-28



5. Income tax
The major components of income tax expense are:
 Year ended December 31,
 202120222023
 (in thousands)
Consolidated Statement of Operations
Current income tax expense$504 $2,609 $2,683 
Deferred income tax expense (benefit)121 139 (9)
Income tax expense (benefit)$625 $2,748 $2,674 
In the years ended December 31, 2023 and 2022, withholding taxes were retained from a license fee invoiced in China. This withholding was only recoverable the year of the invoicing. As the parent company was in a tax loss position, the amount of $1,875,000 in 2023 and $2,250,000 in 2022 was not recoverable and was recorded in Income tax expense.
A reconciliation of income taxes computed at the French statutory rate 25.00% for the years ended December 31, 2023 and 2022 (26.50% for the year ended December 31, 2021) to the income tax expense (benefit) is as follows:
 Year ended December 31,
 202120222023
 (in thousands)
Profit (loss) before income taxes$(19,638)$(6,260)$(38,316)
At France’s statutory income tax rate of 26.5% in 2021 and 25% in 2022 and in 2023(5,204)(1,565)(9,579)
Non-deductible share-based payment expense1,361 1,369 1,776 
Tax credits(1,677)(1,156)(1,344)
Impact of the extinguishment of the convertible debts after amendment— 119 62 
Impact of debt reimbursement1,372 — — 
Permanent differences and other168 503 (212)
Withholding tax 2,250 2,055 
Unrecognized benefit of tax losses carryforward4,605 1,228 9,916 
Income tax expense (income)$625 $2,748 $2,674 

Significant components of the Company’s deferred tax assets and liabilities are as follows:

F-29


Consolidated Statement of Financial PositionEquityConsolidated Statement of Operations
December 31,December 31,Year ended December 31,
202120222023202120222023202120222023
(in thousands)(in thousands)(in thousands)
Government loan(135)7 (127)   (277)142 (135)
Intangible assets(28)(133)(120)   21 (105)13 
Cash flow hedge(2)(3)2    (4)(1)5 
Remeasurement of non-monetary accounts(171)(487)(3)   (899)(316)485 
Convertible debts and venture debt - liability      (23)  
Other provisions and accruals (490)(495)(962)   (242)(4)(468)
From subsidiaries138 258 264    119 139 (9)
Deferred tax asset not recognized on losses (Loss available for offsetting against future taxable income)
826 1,111 1,210    1,426 284 100 
        Total$138 $258 $264  $ $ $121 $139 $(9)
The changes in deferred tax assets and liabilities were as follows:
202120222023
(in thousands)
At January 1st$19 $138 $258 
Tax expense (income) during the year recognized in Profit or Loss121 139 (9)
Tax expense (income) during the year recognized in equity   
Effect of foreign exchange(2)(19)15 
At December 31st$138 $258 $264 
As of December 31, 2023 the Company had accumulated tax losses which arose in France of $402,130,063 that are available for offset against future taxable profits of Sequans Communications S.A within a limit of one million euro per year, plus 50% of the profit exceeding this limit. Remaining unapplied losses would continue to be carried forward indefinitely.
Deferred tax assets were recognized in 2021, 2022 and 2023 only to the extent that deferred tax liabilities existed relating to the same taxable entity, which are expected to reverse in the same period as the asset or into which a tax loss may be carried forward.

6. Earnings (loss) per share
Basic earnings (loss) per share and American Deposit Shares (ADS) amounts are calculated by dividing net income (loss) for the year attributable to all shareholders of the Company by the weighted average number of all shares or ADS outstanding during the year.
Diluted earnings per share and ADS amounts are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of shares or ADS outstanding during the year plus the weighted average number of shares or ADS that would be issued on the exercise of all the dilutive stock options and warrants, and upon vesting of restricted stock awards as well as conversion of convertible debt. Dilution is defined as a reduction of earnings per share or ADS or an increase of loss per share or ADS. As the exercise of all outstanding stock options and warrants as well as vesting as restricted stock awards and conversion of convertible debt, would decrease loss per ordinary share or ADS, they are considered to be anti-dilutive and excluded from the calculation of loss per ordinary share or ADS.
Basic and diluted earnings (loss) per ADS presented below reflect the ADS ratio in which each ADS represents 4 ordinary shares.
F-30


The following reflects the income and share data used in the basic and diluted earnings (loss) per ordinary share and ADS computations:
 Year ended December 31,
 202120222023
 (in thousands, except share and per share data)
Profit (Loss)$(20,263)$(9,008)$(40,990)
Weighted average number of shares outstanding for basic EPS146,691,784 184,587,104 225,183,996 
Net effect of dilutive stock options   
Net effect of dilutive warrants   
Net effect of vesting of restricted stock   
Net effect of conversion of convertible notes   
Weighted average number of shares outstanding for diluted EPS146,691,784 184,587,104 225,183,996 
Basic earnings (loss) per share$(0.14)$(0.05)$(0.18)
Diluted earnings (loss) per share$(0.14)$(0.05)$(0.18)
ADS outstanding for basic and diluted earnings (loss) per ADS36,672,946 46,146,776 56,295,999 
Basic earnings (loss) per ADS$(0.55)$(0.20)$(0.73)
Diluted earnings (loss) per ADS$(0.55)$(0.20)$(0.73)

F-31


7. Property, plant and equipment
Property, plant and equipment include:
Leasehold
improvements
Plant and
equipment
IT and office
equipment
Right of useTotal
 (in thousands)
Cost:
At January 1, 2021$1,340 $27,435 $4,006 7,013 $39,794 
Additions16 1,842 373 437 2,668 
Disposals(20)(415)(3)(756)(1,194)
Reclassification94  (94)  
Exchange difference7 (20)60  47 
At December 31, 20211,437 28,842 4,342 6,694 41,315 
Additions15 3,891 222 458 4,586 
Disposals (175)(54)(73)(302)
Exchange difference(35)(178)(123) (336)
At December 31, 20221,417 32,380 4,387 7,079 45,263 
Additions75 1,812 220 767 2,874 
Disposals (2)(3)(414)(419)
Exchange difference10 107 16  133 
At December 31, 2023$1,502 $34,297 $4,620 $7,432 $47,851 
Depreciation and impairment:
At January 1, 20211,233 23,323 3,694 2,357 30,607 
Depreciation charge for the year45 1,869 181 1,259 3,354 
Reclassification19  (19)  
Disposals(12)(372)(3)(296)(683)
Exchange difference1 (15)41  27 
At December 31, 20211,286 24,805 3,894 3,320 33,305 
Depreciation charge for the year67 2,441 241 1,230 3,979 
Disposals (153)(52)(73)(278)
Exchange difference(20)(122)(90) (232)
At December 31, 20221,333 26,971 3,993 4,477 36,774 
Depreciation charge for the year41 2,421 198 1,223 3,883 
Impairment 711   711 
Disposals (2) (414)(416)
Exchange difference7 69 8  84 
At December 31, 2023$1,381 $30,170 $4,199 5,286 $41,036 
Net book value:
At January 1, 2021$107 $4,112 $312 4,656 $9,187 
At December 31, 2021151 4,037 448 3,374 8,010 
At December 31, 202284 5,409 394 2,602 8,489 
At December 31, 2023$121 $4,127 $421 2,146 $6,815 
Right-of-use assets as of December 31, 2023 relate to real-estate leases ($7,212,000, gross, $6,859,000, gross as of December 31, 2022 and $6,474,000, gross as of December 31, 2021) as well as IT and office equipment leases ($220,000, gross, $220,000, gross as of December 31, 2022 and 2021).
In the year ended December 31, 2023, the Company recognized an impairment loss of $707,000 related to a production equipment with the carrying amount is not recoverable.
F-32


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
8. Intangible assets
Intangible assets include:
 Capitalized development costsLicensesTotal
 (in thousands)
Cost:
At January 1, 2021$16,798 $29,391 $46,189 
Additions18,297 1,450 19,747 
Disposals   
Exchange difference 167 167 
At December 31, 202135,095 31,008 66,103 
Additions13,808 5,101 18,909 
Disposals (2,441)(2,441)
Exchange difference (234)(234)
At December 31, 202248,903 33,434 82,337 
Additions22,327 633 22,960 
Disposals (2,121)(2,121)
Exchange difference (7)(7)
At December 31, 2023$71,230 $31,939 $103,169 
Depreciation and impairment:
At January 1, 2021$3,250 $17,627 $20,877 
Amortization2,460 4,591 7,051 
Impairment 148 148 
Exchange difference 43 43 
At December 31, 20215,710 22,409 28,119 
Amortization2,575 5,458 8,033 
Impairment 3 3 
Disposals (2,441)(2,441)
Exchange difference (82)(82)
At December 31, 20228,285 25,347 33,632 
Amortization2,640 4,708 7,348 
Disposals (2,121)(2,121)
Exchange difference 10 10 
At December 31, 2023$10,925 $27,944 $38,869 
Net book value:
At January 1, 2021$13,548 $11,764 $25,312 
At December 31, 202129,385 8,599 37,984 
At December 31, 202240,618 8,087 48,705 
At December 31, 2023$60,305 $3,995 $64,300 
In the year ended December 31, 2021, the Company started capitalizing costs related to the development of the 5G. At December 31, 2023, capitalized development costs included $18.4 million related to the 5G ($25.5 million at December 31, 2022 and $14.2 million at December 31, 2021).
F-33



9. Inventories
 At December 31,
 202120222023
 (in thousands)
Components$2,683 $6,641 $4,706 
Finished goods5,091 4,599 4,559 
Total inventories at cost$7,774 $11,240 $9,265 
Provision for slow-moving or damaged components$225 $606 $1,065 
Provision for slow-moving or damaged finished goods1,116 1,247 1,865 
Total provision for slow-moving or damaged inventory$1,341 $1,853 $2,930 
Components, net$2,458 $6,035 $3,641 
Finished goods, at the lower of cost and net realizable value3,975 3,352 2,694 
Total net inventories$6,433 $9,387 $6,335 
The provisions for slow-moving or damaged inventory are related to units either damaged or in excess of the units needed to serve the expected demand for identified customers and projects. In the year ended December 31, 2022, the Company recorded expense related to certain components whose lead-times increased during the COVID-19 and other supply chain constraints, that ultimately were not used in production and expired. This represented $340,000 of the 2022 provision. In the year ended December 31, 2023, the Company recorded an additional expense of $126,000 and some components were physically scrapped resulting in a provision reversal of $104,000. At December 31, 2023 the provision related to those components represented $362,000. The remaining amount of $2,568,000 in depreciation is related to finished goods and components in excess of the units needed to serve the expected demand for identified customers and projects.

10. Trade receivables and contract assets
Trade receivables and contract assets are non-interest bearing. Trade receivables generally have 30-90 day payment terms.
 At December 31,
 202120222023
 (in thousands)
Trade receivables$16,876 $11,243 $10,803 
Contract assets789 176 497 
Provision for credit notes to be issued(465)(225)(164)
Provisions on trade receivables(2,789)(2,524)(2,524)
Net trade receivables$14,411 $8,670 $8,612 
In the years ended December 31, 2023, 2022 and 2021, the Company recorded credit notes primarily related to customer rebate programs and product returns. Such rebates are recorded as a reduction of revenue in the same period that the product is delivered.
The movements in the provision for impairment of receivables were as follows:
 December 31,
 202120222023
 (in thousands)
At January 1,$2,724 $2,789 $2,524 
Charge for the year65   
Utilized amounts (265) 
Unutilized amounts  — 
At year end$2,789 $2,524 $2,524 
F-34


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
In the year ended December 31, 2021, the Company recognized a provision for impairment of $65,000. In the years ended December 31, 2022 and 2023, no new trade receivables were impaired. Trade receivables impaired are related primarily to significantly aged receivables, which the Company no longer expects to collect although still subject to enforcement.
As at year end, the aging analysis of trade receivables and contract assets that were not impaired is as follows:
 TotalNeither past
due nor
Impaired
Past due but not impaired
   <30 days30-60 days60-120 days>120 days
 (in thousands)
At December 31, 2021$14,411 $13,587 $241 $ $ $583 
At December 31, 2022$8,670 $8,367 $209 $94 $ $ 
At December 31, 2023$8,612 $6,532 $1,919 $101 $4 $56 
Due to its historical experience, the Company does not assign credit risk rating grades to its trade receivables, but assesses credit risk at the customer level. Based on an analysis of historical credit losses, the Company has not applied any expected credit losses to its outstanding receivables as of the year end beyond specific provisions for doubtful accounts.

11. Cash, cash equivalents and short-term deposits
 At December 31,
 202120222023
 (in thousands)
Cash at banks$4,828 $5,664 $5,697 
Cash equivalents7 7 8 
Short-term deposits 5,000  
Cash, cash equivalents and deposits$4,835 $10,671 $5,705 
Cash at banks earns no interest. Cash equivalents in money market funds and short-term deposits are invested for short-term periods depending on the immediate cash requirements of the Company, and earn interest at market rates for short-term investments. The fair value of cash, cash equivalents and short-term deposits is equal to book value. Most of the cash, cash equivalents and short-term deposits is held in U.S. dollar and euros as follows:
 At December 31,
 202120222023
 (in thousands)
U.S. dollar denominated accounts$2,869 $9,720 $5,250 
Euro denominated accounts1,564 466 91 
GBP denominated accounts143 19 319 
SGP denominated accounts47 23 13 
NIS denominated accounts160 428 1 
RMB denominated accounts35 3 10 
Other currencies denominated accounts17 12 21 
Cash, cash equivalents and short-term deposits$4,835 $10,671 $5,705 
F-35


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)

12. Issued capital and reserves
The share capital of Sequans Communications S.A. is denominated in euros, as required by law in France. Any distributions to shareholders are denominated in euros. Amounts of capital and reserves presented in the Consolidated Statements of Financial Position in U.S. dollars have been translated using historical exchange rates.
On June 24, 2022, the Company reduced its share capital and premium by $2,283,000 and $325,180,000, respectively, reducing accumulated deficits by $327,463,000. The nominal value of shares has decreased from €0.02 to €0.01 after the transaction was completed.
On June 27 2023, the Company reduced its accumulated deficits by $12,727,000, reducing the share premium for the same amount. There was no impact on the nominal value.
Authorized capital, in number of shares
Authorized capital includes all shares issued as well as all potential shares which may be issued upon exercise of stock options, warrants, restricted share awards and conversion of convertible debt, or which the shareholders have otherwise authorized for specific capital increases. There is no impact on shareholders from the capital reduction as no shares have been cancelled or rights varied, and there is no change in the net asset position of the Company. At December 31, 2023, taking into account resolutions for capital increases approved by the shareholders in June 2023, authorized capital was 421,418,563 ordinary shares with a nominal value of €0.01 each (244,254,014 ordinary shares at December 31, 2021 with a nominal value of €0.02 and 361,639,977 ordinary shares at December 31, 2022, respectively with a nominal value of €0.01).
There is one category of authorized shares: ordinary shares. The ratio of ordinary shares per ADS is four shares represented by one ADS.
Shares issued and fully paid
 At December 31,
 202120222023
 SharesAmountSharesAmountSharesAmount
 (in thousands, except for share data)
Ordinary shares151,419,322 3,028 193,426,478 1,934 246,262,004 2,463 
Converted to U.S. dollars at historical exchange rates$3,687 $2,306 $2,878 
Other capital reserves
Other capital reserves include the accumulated share-based payment expense as of period end, the counterpart of which is in retained earnings (accumulated deficit) as the expense is reflected in profit and loss, as well as the fair value of the convertible debt embedded derivatives at the time of conversion rate was fixed in 2016, the change in fair value of the conversion options resulting from the 2017 and 2018 amendments, the value of the conversion option of the 2018 and 2019 convertibles, the value of warrants issued to the holder of the 2015 convertible note in connection with the September 2018 amendment, the value of warrants issued to the holder of the venture debt, the value of warrants issued to the holder of the 2019 convertible note in connection with the August 2022 and August 2023 amendments, the deferred tax impact related to the equity component of the convertible debts and venture debt, the initial fair value of the convertible debt embedded derivatives at the time the amendments were signed in 2020, the reversal of deferred tax liabilities on the equity component of the amended convertible debts and the value of the conversion option of the 2015, 2016 and 2019 convertibles debts.
Dividend rights
Dividends may be distributed from the statutory retained earnings and additional paid-in capital, subject to the requirements of French law and the by-laws of Sequans Communications S.A. There were no distributable retained earnings at December 31, 2021, 2022 or 2023. Dividend distributions by the Company, if any, will be made in euros.
Capital transactions
On September 26, 2023, the Company increased its capital in connection with a private offering with 272 Capital Master Fund Ltd by issuing 8,480,564 ordinary shares at $0.7075 per ordinary share (or $2.06 per ADS). The total gross proceeds from the offering amounted to $5,999,999. Accordingly, issued capital in the Consolidated Statement of Financial Position was increased by $89,046 recorded in share capital and by $5,910,953 in share premium. Costs directly attributable to the equity transaction amounting to approximately $0.1 million were deducted from the share premium.
F-36


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
On April 12, 2023, the Company increased its capital in connection with a private offering to 272 Capital Master Fund Ltd, Lynrock Lake Master Fund LP and several other institutional investors by issuing 38,834,952 ordinary shares at $0.515 per ordinary share (or $2.06 per ADS). The total gross proceeds from the offering amounted to $20,000,000. Accordingly, issued capital in the Consolidated Statement of Financial Position was increased by $423,301 recorded in share capital and by $19,576,699 in share premium. Costs directly attributable to the equity transaction amounting to approximately $0.4 million were deducted from the share premium.
On January 11, 2022, the Company increased its capital in connection with a private offering with a strategic partner, Renesas Electronics Corporation by issuing 7,899,020 ordinary shares at $1.175 per ordinary share (or $4.70 per ADS). The total gross proceeds from the offering amounted to $9,281,349. Accordingly, issued capital in the Consolidated Statement of Financial Position was increased by $178,802 recorded in share capital and by $9,102,547 in share premium. Costs directly attributable to the equity transaction amounting to approximately $0.1 million were deducted from the share premium.
On March 11, 2022, the Company increased its capital in connection with a public offering by issuing 30,666,668 ordinary shares (including 4,000,000 shares from the underwriters' over-allotment option) at $0.75 per ordinary share (or $3.00 per ADS). The total gross proceeds from the offering amounted to $23,000,001. Accordingly, issued capital in the Consolidated Statement of Financial Position was increased by $674,813 recorded in share capital and by $22,325,188 in share premium. Costs directly attributable to the equity transaction amounting to approximately $2.0 million were deducted from the share premium.
On April 9, 2021, the Company increased its capital in connection with a private placement with Lynrock Lake Master Fund LP by issuing 7,272,724 ordinary shares at $1.375 per ordinary share (or $5.50 per ADS). The total offering amounted to $9,999,996. Accordingly, issued capital in the Consolidated Statement of Financial Position was increased by $172,698 recorded in share capital and by $9,827,297 in share premium. Costs directly attributable to the equity transaction amounting to approximately $0.1 million were deducted from the share premium.
On January 13, 2021, January 17, 2021 and February 12, 2021, Nokomis Capital, L.L.C, converted portions of the convertible note issued in 2015 totaling a principal value of $7,750,000, plus accrued interest and conversion bonus of $4,536,438, into a total of 7,227,308 ordinary shares. $175,239 was recorded in share capital in the Consolidated Statement of Financial Position and $12,111,185 in share premium.
In the years ended December 31, 2021, 2022 and 2023, ordinary shares were issued upon exercise of options and warrants as described in Note 13 to the Consolidated Financial Statements.

13. Share-based payment plans
The expense recognized for employee and other services received during the year ended December 31, 2023 and arising from equity-settled share-based payment transactions was $7,104,000 (2021: $5,135,000; 2022: $5,477,000). Of this total, $111,000 in 2023 (2021: $76,000; 2022: $124,000), related to warrants plans for consultants considered equivalent to employees.
The breakdown is as follows:
Year ended December 31,
 202120222023
 (in thousands)
Cost of revenue$57 $159 $131 
Research and development$2,109 $1,758 $2,019 
Sales and marketing$970 $1,132 $1,397 
General and administrative$1,999 $2,428 $3,557 
Total$5,135 $5,477 $7,104 
Stock options, warrants and restricted share awards give the right to acquire ordinary shares. The exercise price for options and warrants is based on the closing market price on the effective date of grant. There is no exercise price for restricted share awards; the beneficiary receives title to the underlying ordinary shares with no cash payment at the end of the vesting period. In general, the contractual life of the stock options and warrants is ten years. There are no cash settlement alternatives, and the Company has not developed a practice of cash settlement.
There have been no cancellations or modifications to any of the plans during the years ended December 31, 2021, 2022 or 2023.
F-37


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
General employee stock option and restricted shares awards
All employees of the French parent company and its subsidiaries are entitled to a grant of stock options or restricted shares awards.
In general, vesting of the stock options occurs over four years, with 25% vesting after the first anniversary of grant and the remaining 75% vesting monthly over the remaining 36 months. Restricted shares awards (RSA) vest over four years, with either 25% vesting after the 1-year anniversary of the grant and the remaining 75% of the grant vesting quarterly over the remaining 3 years, or with 50% vesting after the 2-year anniversary of the grant and the remaining 50% vesting quarterly over the remaining 2 years. From time to time, vesting of founders' warrants, stock options and restricted shares may be linked to employee performance with different vesting periods. Vested restricted shares may be sold only beginning two years after the effective date of grant.
All expenses related to these plans have been recorded in the Consolidated Statement of Operations in the same line items as the related employees’ cash-based compensation.
Warrant plans for board members and consultants
The Company awards warrants to members of the board of directors following approval by the shareholders and to a limited number of consultants who have long-term relationships with the Company. Vesting may be over a one-year, two-year, three-year or four-year period, or may be immediate, depending on the nature of the service contract. All expenses related to these plans have been recorded in the Consolidated Statements of Operations in the same line items as the related service provider’s cash-based compensation.
Movements in the periods presented
The following table illustrates the number of shares (ADS equivalents are not presented) and weighted average exercise prices (WAEP) of, and movements in, stock options and warrants during the period:
 December 31,
 202120222023
 NumberWAEPNumberWAEPNumberWAEP
Outstanding at January 1,5,687,367 $3.41 5,233,437 $1.73 5,868,521 $1.51 
Granted during the year1,076,000 $1.55 1,110,288 $0.70 1,500,000 $0.54 
Forfeited during the year(139,722)$1.85 (85,400)$1.78 (111,887)$1.70 
Exercised during the year(1)
(94,008)$1.47  $  $ 
Expired during the year(1,296,200)$8.35 (389,804)$2.05 (444,820)$1.89 
Outstanding at period end5,233,437 $1.73 5,868,521 $1.51 6,811,814 $1.27 
Of which, warrants for consultants equivalent to employees203,000 $1.79 487,288 $1.29 724,288 $1.05 
Exercisable at period end3,977,831 $1.79 4,685,828 $1.70 5,420,965 $1.44 
Of which, warrants for consultants equivalent to employees165,667 $1.72 228,595 $1.73 438,739 $1.28 
(1)The weighted average share estimated fair value at the dates of exercise of these options was $1.78 in 2021.

The following table illustrates the number of, and movements in, restricted shares awards (RSA) based on the number of ordinary shares (ADS equivalents are not presented) during the period:
December 31,
202120222023
Outstanding at January 1,9,525,135 10,379,481 16,752,551 
Granted during the year4,426,496 10,550,820 2,640,460 
Forfeited during the year(628,186)(736,282)(686,092)
Vested during the year(2,943,964)(3,441,468)(5,601,570)
Outstanding at period end10,379,481 16,752,551 13,105,349 
F-38


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Exercise prices are denominated in U.S. dollars. Euro-denominated exercise prices were converted to U.S. dollars at the historical exchange rate for purposes of presentation in this table.
The weighted average remaining contractual life of stock options and warrants outstanding as December 31, 2023 was 2.6 years (2022: 2.8 years; 2021: 3.0 years).
The range of exercise prices per share for stock options and warrants outstanding at December 31, 2023 was $0.54 - $3.31, $0.62 - $3.31 at December 31, 2022 and $0.89—$3.31 at December 2021.
The weighted average fair value of stock options and warrants granted during the year ended December 31, 2023 was $0.27 (2022: $0.34; 2021: $0.72). The weighted average fair value of the restricted shares awards granted during the year ended December 31, 2023 was $0.66 (2022: $0.91; 2021: $1.14). The fair value is measured at the grant date. The following table lists the inputs to the models used for determining the value of the grants made for the years ended December 31, 2021, 2022 and 2023:

 December 31,
 202120222023
Dividend yield (%)   
Expected volatility (%)59 57 59 
Risk–free interest rate (%) 
1.25 to 2.1
2.5
Assumed annual lapse rate of awards (%)
15 for all except 2 for warrants and a limited group of beneficiaries
20 for all except 2 for BSA and a limited group of beneficiaries20 for all except 2 for BSA and a limited group of beneficiaries
Sell price multiple (applied to exercise price)2 2 2 
Weighted average share price ($)1.22 0.89 0.86 
Model usedBinomialBinomialBinomial
For the years ended December 31, 2022 and 2021 the expected volatility assumption is based on the Company’s volatility since its initial public offering in 2011. For the year ended December 31, 2023, the 6-year volatility of the Company has been used.
Stock options and warrants can be exercised during a period after the vesting date until the plan terminates. In the pricing model, the assumption was made that plan participants will exercise before the end of the exercise period if the share price reaches a certain multiple of the exercise price.
If a sell-price multiple of 3 instead of 2 had been used (no impact on the restricted shares) and if the weighted average share price used in the pricing model had been decreased by 10%, share-based payment total compensation for stock options, warrants and restricted shares awards granted through December 31, 2023 would have decreased by approximately (7.51)% (2022: (9.40)%; 2021: (8.18)%).
The expected life of the stock options and warrants is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.
F-39


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
14. Interest-bearing loans and borrowings
At December 31,
Note202120222023
(in thousands)
Current
Convertible debt14.1   52,278 
Convertible debt embedded derivative14.1   3 
Unsecured related party loan14.2   8,922 
Interest-bearing receivables financing14.3 9,518 7,723 9,544 
Total current portion$9,518 $7,723 $70,747 
Non-current
Convertible debt14.1 $36,373 $43,455 $ 
Convertible debt embedded derivative14.1 10,081 3,203  
Total non-current portion$46,454 $46,658 $ 
As of December 31, 2023, the Company had no drawn or undrawn committed borrowing or overdraft facilities in place.

14.1. Convertible debt
On April 14, 2015, the Company entered into a convertible note agreement with Nokomis Capital, L.L.C., one of the Company’s shareholders, regarding the issuance and sale of a convertible note in the principal amount of $12 million (the “2015 note”), which note was convertible into the Company’s shares, nominal value €0.02 per share, at a conversion rate of 540.5405 shares for each $1,000 principal amount of the 2015 note, subject to certain adjustments, which equated to an initial conversion price of $1.85 per share. On October 30, 2017, the convertible note was amended to extend the term from April 14, 2018 to April 14, 2019. On September 27, 2018, the convertible note was further amended to extend the term by two years to April 14, 2021, and to decrease the conversion price from $1.85 to $1.70 per share. In addition, the Company issued to Nokomis, for a total subscription price of $1.00, warrants to acquire 1,800,000 shares at an exercise price of $1.70 per share. Such warrants are exercisable at any time and had an expiration date of April 14, 2021.
On April 27, 2016, the Company entered into a convertible note agreement with Nokomis Capital, L.L.C. and two other financial institutions (the “Holders”) regarding the issuance and sale of convertible notes in the aggregate principal amount of $7.16 million (the “2016 notes”), which are convertible into the Company’s shares. The initial conversion price of the 2016 notes was $2.7126 per share. On October 30, 2017, the convertible note agreement was amended to extend the term from April 27, 2019 to April 27, 2020. In addition, the conversion price was decreased from $2.71 to $2.25 per share.
On September 27, 2018, the Company entered into a convertible note agreement with Nokomis Capital, L.L.C. in the principal amount of $4.5 million (the "2018 notes") under which the convertible note matures in April 2021 and is subordinated to certain venture debt to be issued by the Company and is convertible, at the holder’s option, into the company’s shares at a conversion rate of $1.70 per share. On September 27, 2018, all of the convertible notes issued in 2015 and convertible notes with a principal amount of $6 million issued in 2016 were amended to allow the convertible notes to be subordinated to certain venture debt to be issued by the Company.
On October 26, 2018, the Company further amended the 2015 note, the 2016 note and the 2018 note with Nokomis to clarify the terms of the subordination of these convertible notes to the Company’s venture debt holder.
On May 7, 2019, the Company entered into a convertible note agreement with Nokomis Capital, L.L.C. in the principal amount of $3.0 million (the "2019-1 notes"). The convertible note matures in April 2021 and is convertible, at the holder’s option, into the Company’s shares at a conversion rate of $1.21 per share.
On August 16, 2019, the Company entered into a convertible note agreement with Nokomis Capital, L.L.C. in the principal amount of $5.0 million (the "2019-2 notes"). The convertible note matures in August 2022 and is convertible, at the holder’s option, into the Company’s shares at a conversion rate of $1.03 per share.
F-40


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Effective February 11, 2020, the Company amended the terms of the convertible note issued April 27, 2016 to Nokomis Capital, L.L.C., to extend the maturity of the note to April 14, 2021. In addition, the conversion price was reduced from $2.25 to $1.225 per ordinary share.
Effective March 20, 2020, the convertible notes issued in April 2015, April 2016, September 2018, May 2019 and August 2019 were amended to grant the Company three options to extend the term of each note, except for the August 2019 which has two options. Each option will give the Company the right to extend the term of such note by one year and consequently reset the conversion price to a 20% premium above the 20-day volume weighted average price (VWAP) if it is lower than the existing conversion price. On the first option exercise, the payment-in-kind interest (PIK) will stay at 7% but the holder will be granted a warrant for 10% of the value of the note with a three year term, at an exercise price of 20% premium above 20-day VWAP. On the second option exercise, the PIK will be adjusted to 9.5%, the previous warrants granted on the first option exercise will be extended by one year and the holder will be granted an additional warrant for 15% of the value of the note with a three year term, at an exercise price of 20% premium above 20-day VWAP. On the third option exercise, the PIK will be adjusted to 13.5%, and the holder will be granted an additional warrant for 20% of the value of the note with a three year term, at an exercise price of 20% premium above 20-day VWAP. If at any time, the holder converts a note prior to the date of August 2023, it will receive an extra year’s worth of PIK as a bonus so as to incentivize conversion. In consideration for entering into the amendments, the warrants that Nokomis owns that were scheduled to expire April 2021 were extended to April 2024 upon the signing of the note amendments.
The 2015, 2016, 2018 and 2019 notes (together, “the Nokomis Notes”) are unsecured obligations of the Company. The Nokomis Notes issued in 2015, 2016, 2018 and in May 2019 matured on April 14, 2021, and the 2019-2 Nokomis Note will mature on August 16, 2022, except if the Company exercises its option to extend the term of the notes as provided in the March 20, 2020 amendments. The Company has considered that the options to extend the terms will be exercised and therefore, has included the Nokomis Notes in non-current liabilities on the statement of financial position at December 31, 2020 and 2021. The Nokomis Notes are not redeemable prior to maturity. The accreted principal amounts of the Nokomis Notes are convertible at any time or times on or after the issuance dates until maturity, in whole or in part, subject to certain adjustments for significant corporate events, including certain dilutive issuances, dividends, stock splits and other similar events. Interest accrues on the unconverted portion of the Nokomis Notes at the rate of 7% per year (unless the above options are exercised), and is paid in kind annually on the anniversaries of the issuance of the Nokomis Notes. The Nokomis Notes also provide for customary events of default which, if any of them occurs, would permit or require the principal of and accrued interest on the Nokomis Notes to become or to be declared due and payable.
In the event of a recapitalization, reorganization, reclassification, consolidation, merger, sale of all or substantially all of the Company’s assets or other transaction, which in each case results in the Company’s shareholders receiving stock, securities or assets with respect to or in exchange for their ADSs or ordinary shares, the holders shall elect, at their option, either (a) to require the Company to repurchase for cash the entire accreted principal amount of the Nokomis Notes or (b) to convert the Nokomis Notes in their entirety.
The Nokomis Notes contain customary ongoing covenants of the Company. In addition, the Nokomis Notes provide that the Company will not grant a consensual security interest or pledge its personal property assets to a third-party lender (with certain limited exceptions) during the time that the notes are outstanding. Any amendment or waiver of the terms of the Notes requires the affirmative consent of the holders.
On January 13, 2021, January 17, 2021 and February 12, 2021, Nokomis Capital, L.L.C, converted portions of the convertible note issued in 2015 with a total principal value of $7,750,000 plus accrued interest and conversion bonus of $4,536,438, into a total of 7,227,308 ordinary shares. The recalculated fair value of the embedded derivatives related to the note at the conversion dates was $6,534,000 and the change of the fair value amounted to a loss of $3,269,000. The difference between the capital increase, the liability component and the fair value of the embedded option has been recorded in Other Capital Reserves in shareholders’ equity for an amount of $5,386,000.
On April 9, 2021, the Company entered into a convertible note agreement with Lynrock Lake Master Fund LP in the principal amount of $40.0 million (the "Lynrock Lake Note"). The Lynrock Lake Note matures in April 2024 and is convertible, at the holder’s option, into the Company’s shares at a conversion rate of $1.915 per share (representing $7.66 per ADS), subject to a 9.9% ownership limit for Lynrock Lake. The Lynrock Lake Note earns interest annually at an interest rate of 5.0625% for cash payments or 6% for payment in kind accruals. The Company retains an option to call the Lynrock Lake Note under certain circumstances after 12 months, either in full or in part. If a change of control occurs at any time prior to the payment of the note in full, Lynrock Lake Master Fund LP shall have the right, in its sole discretion, to require the Company to convert or redeem all of the outstanding principal amount (including accrued interest and unpaid interest). In the event that the note is not converted and the Company does not repay the amount due on the maturity date, the interest rate automatically increases to 8% beginning April 10, 2024.
F-41


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
The Lynrock Lake Note was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the bonds in cash; and
An embedded derivative, which reflects the value of the conversion option.
The initial fair value of the notes was split between these two components.
The fair value of the liability component on the issuance date represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 20.89% as the market rate of interest in order to value the liability components of the note on issuance. The embedded derivative of the Lynrock Lake Note was valued using the Geometric Brownian Motion framework relying on Monte-Carlo simulations. On April 9, 2021, the initial fair value of the embedded derivative of the notes was calculated to be $12,713,000 The change in fair value is remeasured and recorded as financial income or loss at each Statement of Financial Position date.
On April 14, 2021, the Company repaid the remaining amount of the Nokomis Notes that were due on April 14 (Nokomis Notes issued in April 2015 and in September 2018) with accrued paid-in-kind interest of 7%. $6,378,104 was repaid for the April 2015 convertible note ($4,250,000 in principal and $2,128,000 as accrued interest) and $5,346,699 ($4,500,000 in principal and $847,000 as accrued interest) for the September 2018 convertible note. The recalculated fair value of the embedded derivatives at the repayment date was $4,645,000 and was recorded as financial income in the Consolidated Statement of Operations and the change of the fair value amounted to a loss of $934,000.
On August 15, 2022, the Nokomis Note issued in August 2019 arrived at maturity and the Company elected to exercise the first option of the amendment signed on March 20, 2020, to extend the maturity to August 16, 2023 in exchange for the issuance of 594,680 warrants (148,670 ADSs) to Nokomis at an exercise price of $1.03 per warrant ($4.12 per ADS). The expiration date of these warrants is August 15, 2025. In accordance with Article II of the amendment, the interest rate on the note increased to 9.5% per annum effective August 15, 2022. Conversion price of the debt is unchanged. This resulted in the extinguishment of the existing note and issuance of a new note for accounting purposes. The amended debt was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the notes in cash; and
An embedded derivative, which reflects the value of the conversion option.
The value of the liability component at the extension date was $6,125,000. The fair value of the new liability component represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 23.2% as the market rate of interest in order to value the liability components for an amount of $5,454,000. The change in the liability component before and after the extension and the fair value of the warrants granted was recorded for a gain of $476,000 in the Consolidated Statement of Operations in “Convertible debt amendments. The fair value of the embedded derivative of the note was calculated at the extinguishment date and the change in fair value of $343,000 was recorded as financial expenses in the Consolidated Statement of Operations.
On August 15, 2023, the Nokomis Note issued in August 2019 arrived at maturity and the Company elected to exercise the second option of the amendment signed on March 20, 2020, to extend the maturity to August 16, 2024 in exchange for the issuance of 1,244,820 warrants (311,205 ADSs) to Nokomis at an exercise price of $0.8092 per warrant ($3.2328 per ADS). The expiration date of these warrants is August 15, 2026. In accordance with Article II of the amendment, the interest rate on the note increased to 13.5% per annum effective August 15, 2023. Conversion price of the debt is unchanged. This resulted in the extinguishment of the existing note and issuance of a new note for accounting purposes. The amended debt was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the notes in cash; and
An embedded derivative, which reflects the value of the conversion option.
On April 9, 2024, the Company secured standstill agreements from both convertible debt holders. The agreements granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met. In late April, the Company began discussions to extend the standstill agreements, which are still in process as of April 30, 2024.
F-42


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
The value of the liability component at the extension date was $6,707,000. The fair value of the new liability component represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 21.9% as the market rate of interest in order to value the liability components for an amount of $6,378,000. The change in the liability component before and after the extension and the fair value of the warrants granted was recorded for a gain of $247,000 in the Consolidated Statement of Operations in “Convertible debt amendments. The fair value of the embedded derivative of the note was calculated at the extinguishment date and the change in fair value of $421,000 was recorded as financial expenses in the Consolidated Statement of Operations.
At December 31, 2023, the recalculated fair value of the remaining Nokomis Note and the Lynrock Lake Note embedded derivatives was a total of $3,000 ($3,203,000 and $10,081,000 at December 31, 2022 and 2021 respectively) and the change of the fair value of $3,200,000 for the year ended December 31, 2023 ($6,878,000 and $3,848,000 for the years ended December 31, 2022 and 2021, respectively) was recorded in the Consolidated Statement of Operations.
The conversion rates of the convertible notes outstanding as of December 31, 2023, are as follows:
Conversion rate per shareConversion rate per ADS
2019-2 Nokomis Note$0.8082 $3.23 
2021 Lynrock Lake Note$1.915 $7.66 

14.2. Unsecured related party loan
On November 8, 2023, in connection with contemplated acquisition of the Company by Renesas Electronics Corporation ("Renesas") that was in process at the time (subsequently terminated in February 2024), the Company entered into a Security Purchase Agreement with Renesas Electronics America ("Renesas America") whereby Renesas America agreed to the issuance of an unsecured subordinated note (the “Note”) in an aggregate principal amount of $6.0 million, at a stated rate of interest of 9.5% per annum. The principal amount and any accrued interest on the Note is due on the earliest to occur of (i) the written demand by the holder of the Note for repayment after the successful consummation of the offer by Renesas Electronics Europe GmbH, incorporated as a limited liability company under the laws of Germany (Gesellschaft mit beschränkter Haftung—GmbH) and a direct wholly owned subsidiary of Renesas, to acquire all of the Company’s outstanding ordinary shares, nominal value €0.01 per share (“Ordinary Shares”), including Ordinary Shares represented by American Depositary Shares (“ADSs”) and Ordinary Shares issuable upon the exercise or conversion or exchange of any outstanding options, warrants, convertible securities, restricted share awards or rights to purchase, subscribe for, or be allocated Ordinary Shares of the Company, for $0.7575 per Ordinary Share and $3.03 per ADS (the “Tender Offer”), (ii) 90 days after the termination of the Tender Offer (other than by reason of successful completion thereof), (iii) 90 days after the termination of the Memorandum of Understanding (the "MoU), dated as of August 4, 2023, by and between Renesas and the Company, and (iv) the date a Company Termination Fee (as defined in the MoU) is payable under the MoU.
On December 27, 2023, the Company entered into a second Security Purchase Agreement with Renesas America whereby Renesas America agreed to the issuance of a Note in an aggregate principal amount of $3.0 million, at a stated rate of interest of 9.5% per annum.
Interest expense related to the Notes recorded during the year ended December 31, 2023 amounted to $127,000). No repayments of principal occurred during the year ended December 31, 2023.
On February 22, 2024, Renesas notified the Company that Renesas was terminating the MoU due its receipt of an adverse Japanese tax ruling on February 15, 2024 from the National Tax Agency of Japan.
On April 9, 2024, the Company secured a standstill agreements from Renesas. The agreement granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met. In late April, the Company began discussions to extend the standstill agreement, which are still in process as of April 30, 2024.

F-43


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
14.3. Interest-bearing financing of receivables
In June 2014, the Company entered into a factoring agreement with a French financial institution whereby a line of credit was made available equal to 90% of the face value of accounts receivable from product sales to qualifying customers, up to the amount covered by the Company's credit insurance per customer. In July 2017, the Company signed an amendment to the initial agreement to include limited financing of accounts receivable from service sales of $800,000. The Company transfers to the finance company all invoices issued to qualifying customers, and the customers are instructed to settle the invoices directly with the finance company. The Company pays a commission on the face value of the accounts receivable submitted and interest at SOFR 3 months USD +2% which represents approximately a rate of 1.81% on any draw-down of the resulting line of credit. In the event that the customer does not pay the invoice within 60 days of the due date, the receivable is excluded from the line of credit, and recovery becomes the Company’s responsibility. At December 31, 2023, $2,531,000 ($4,732,000 at December 31, 2022 and $5,651,000 at December 31, 2021) had been drawn on the line of credit and recorded as a current borrowing.
In February 2021, the Company entered into an agreement to finance the 2021 research tax credit receivable as it is earned over the year. At December 31, 2021, the amount financed was $3,867,000, recorded as current liabilities and does not include retention of $1,562,000, which was received in 2022 ($1,436,000) and in 2027 ($133,000). After the payment of the retention amount, the interest-bearing financing debt was netted with the research tax credit receivable. The effective interest rate of 6.20% includes expenses related to the financing.
In March 2022, the Company entered into a new agreement to finance the 2022 research tax credit as it is earned over the year. At December 31, 2022, the amount financed was $2,991,000, recorded as current liabilities and does not include retention of $1,249,000, which $360,000 was received in 2023, $780,000 in January 2024 and $109,000 is expected to be received in 2028. The effective interest rate of 5.33% includes expenses related to the financing.
In April 2023, the Company entered into a new agreement to finance the 2023 research tax credit as it is earned over the year. At December 31, 2023, the amount financed was $3,369,000, recorded as current liabilities and does not include retention of $1,531,000, which is expected to be received in 2024 ($1,409,000) and in 2029 ($122,000). The effective interest rate of 14.62% includes expenses related to the financing.
15. Lease liabilities
The Company recognized right-of-use of assets of $2,146,000 (included in property, plant and equipment in the Consolidated Statements of Financial Position). Identified lease contracts mainly relate to real-estate rental agreements and IT and office equipment leases. The lease liabilities were discounted at an incremental borrowing rate of 14.2%.
The table below presents the carrying amounts of right-of-use assets recognized and the movements during the period:
F-44


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Real-estateIT and office equipmentTotal
(In thousands)
As at January 1, 20214,184 472 4,656 
Additions437  437 
Disposals(210)(547)(757)
Depreciation expense(1,151)(108)(1,259)
Amortization disposals114 183 297 
As at December 31, 2021$3,374 $ $3,374 
Additions458  458 
Disposals(73) (73)
Depreciation expense(1,230) (1,230)
Amortization disposals73  73 
As at December 31, 2022$2,602 $ $2,602 
Additions767  767 
Disposals(414) (414)
Depreciation expense(1,223) (1,223)
Amortization disposals414  414 
As at December 31, 2023$2,146 $ $2,146 
The table below present the carrying amounts of lease liabilities and the movements during the period:
Lease liabilitiesCurrentNon-current
(In thousands)
As at January 1, 2021$5,776 $1,014 $4,762 
Additions437 
Disposals(993)
Interests expense760 
Foreign exchange loss (gain)(297)
Payments(1,063)
As at December 31, 2021$4,620 $1,247 $3,373 
Additions458 
Disposals(577)
Interests expense571 
Foreign exchange loss (gain)(298)
Payments(1,205)
As at December 31, 2022$3,569 $1,291 $2,278 
Additions767 
Disposals(414)
Interests expense479 
Foreign exchange loss (gain)36 
Payments(1,321)
As at December 31, 2023$3,116 $1,471 $1,645 
The rental charges relating to short-term and low value leases remained classified as operating expenses in the Consolidated Statements of Operations and amounted to $1,559,000 for the year ended December 31, 2023 ($1,248,000 and $1,411,000 for the years ended December 31, 2022 and 2021, respectively).
F-45


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)

16. Government grant advances and loans
  December 31,
 Note202120222023
  (in thousands)
Current
Government grant advances16.1$3,317 $968 $708 
Research project financing16.21,057 1,237 1,518 
Government loans16.21,832 1,954 1,727 
Accrued interest16.2  653 
Total current portion$6,206 $4,159 $4,606 
Non-current
Government grant advances16.1$2,048 $872 $328 
Research project financing16.22,248 1,567 259 
Government loans16.33,084 1,424 173 
Accrued interest16.21,974 2,372 2,496 
Total non-current portion$9,354 $6,235 $3,256 

Historically the Company has succeeded in obtaining partial financing of some its research and development projects in the form of government collaborative projects. In most cases, the financing is partly in the form of a grant, which is recorded as a reduction of research and development expense as the project progresses, and partly in the form of an interest-free or low-interest advance to be repaid after commercial launch of the financed product. When the Company is awarded a new project, the total amount of the financing is recorded as a receivable with a corresponding liability. The financing generally is paid partially upfront and then based on achievement of project milestones.
16.1. Government grant advances

In 2023, the Company was named as a participant in one new collaborative projects with combined funding of €428,000 ($436,000 using the exchange rate of the grant dates) which is expected to be released to the Consolidated Statement of Operations over the lives of the projects, estimated to be approximately three years.

In 2022, the Company was named as a participant in four new collaborative projects with combined funding of €1,376,000 ($1,364,000 using the exchange rate of the grant dates). Three of them are expected to be released to the Consolidated Statement of Operations over the lives of the projects, estimated to be approximately three years, one was fully released in the year ended December 31, 2022.

In 2021, the Company was named as a participant in two new collaborative projects with combined funding of €6,326,000 ($7,650,000 using the exchange rate of the grant dates) which is expected to be released to the Consolidated Statement of Operations over the lives of the projects, estimated to be approximately three years for both projects.

16.2. Research project financing

In October 2014, Bpifrance, one of the Company’s shareholders as well as the financial agency of the French government, provided funding to the Company in the context of a long-term research project, estimated to be completed over a 3-year period. In December 2016, Bpifrance and the Company signed an amendment to extend the period from three to four years. The total funding amounted to €6,967,000 ($8,988,000 using the exchange rate of the funding dates) with a portion in the form of a grant (€2,957,000 or $3,815,000) and a portion in the form of a forgivable loan (€4,010,000 or $5,173,000). The funding was paid in three installments, the last of which was received in 2019 for €992,000 ($1,126,000 using the exchange rate of the payment date). The grant was recognized as a reduction of research and development expense when corresponding expense was incurred. The forgivable loan advance will be repaid from March 31, 2019 to December 31, 2024 of which €870,000 ($939,000) using the exchange rate of the payment dates) in principal and interests was paid in 2023 (€540,000, or $571,000 in 2022; €675,000, or $804,000, in 2021), and bears interests at a 1.53% fixed contractual rate. The difference between the amount of grant received and the present value amounted to a reduction of $115,000 in the debt carrying value, with such difference
F-46


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
being amortized over the contract period. If the sales of the product developed under this program are in excess of €350 million ($396 million using the exchange rate as of December 31, 2021) during a period of three years, then the Company shall pay for three consecutive years after the date of the termination of the reimbursment a bonus to Bpifrance of 1% of annual revenues generated by products issued from the project (up to a maximum of €350,000,000 or $386,750,000 over a period of ten years). The Company doesn’t expect to perform any repayment to BPI.
In January 2016, Bpifrance provided funding to the Company for a new long-term research project, completed in early 2020. The total of the funding amounted to €2,095,000 ($2,288,000 using the exchange rate of the grant date) comprising a portion in the form of a grant (€668,000 or $729,000) and a portion in the form of a forgivable loan (€1,427,000 or $1,558,000). The funding was paid in four installments, the last of which was received in February 2020 for €365,000 ($405,000 using the exchange rate of the funding date). The grant was recognized as a reduction of research and development expense when corresponding expense was incurred. The forgivable loan advance was to be repaid, except if the project is a commercial failure, from July 1, 2020 to July 1, 2024 and bears interests at a 1.17% fixed contractual rate. The difference between the amount of grant received and the present value of future payments discounted using interest rate applied for standard loans with similar maturity amounted to a reduction of $30,000 in the debt carrying value, with such difference being amortized over the contract period. In late 2020, the Company determined that there was not enough market interest for the radio frequency of the product development funded by this grant, and abandoned the project. A request for forgiveness of the debt was made and, in April 2021, Bpifrance forgave a large portion of the advance, effectively transforming the forgiven advance to a grant and resulting in a one-time benefit of €1,214,000 ($1,442,111 using the exchange rate of the period), recorded as a reduction of Research and Development expenses. The unforgiven portion of €213,000 ($241,000) was reimbursed in February 2022.
In 2022, the Company received funding for one project of €309,000 ($316,000 using the exchange rate of the funding date) as a grant and €473,000 ($507,000 using the exchange rate of the funding date) as a reimbursable loan. The payment was received in March 2023.
In 2023, Bpifrance provided funding to the Company for a new long-term research project of €428,000 ($473,000 using the exchange rate at the closing date) as a grant and €142,000 ($157,000 using the exchange rate at the closing date) as a forgivable loan. The funding is paid in four installments. The first installment was received in March 2023 and amounted to €36,000 ($38,000 using the exchange rate of the funding date).
The accrued interest of $712,000 was recorded as of December 31, 2023 ($579,000 as of December 2022 and $563,000 as of December 31, 2021) at an estimated market rate in a range from 2.3% to 20.9%. The market rate of interest applied in 2021 ranged from 1.80% to 2.30%.

16.3. Government loans
In September 2015, the Company received two loans from Bpifrance for a total amount of €2,000,000 ($2,228,000 using the exchange rate of the grant date). One loan of €1,000,000 bears interest at 5.24% per year, paid quarterly; the second loan of €1,000,000 is interest-free. The interest-free loan has been revalued using the 5.24% interest rate payable on the other loan. Both loans have seven year terms with the principal being amortized on a quarterly basis beginning in June 2017 and March 2018. At December 31, 2023, both loans were fully reimbursed.
On April 30, 2020, the Company finalized €5 million of French government debt financing that was received in May 2020 as part of the French COVID-19 economic support plan. The French loan is unsecured. The original five years long repayment schedule agreed in May 2020 was then extended with only interest payable from August 2021 to May 2022. The repayments of principal started in August 2022 until May 2026. As of December 31, 2023, $1,727,000 has been classified as current and $2,610,000 as non-current.

F-47


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)

17. Provisions
Post-
employment
benefits
Other provisionsTotalCurrentNon current
 (in thousands)
At January 1, 2021$834 $809 $1,643 $89 $1,554 
Arising (released) during the year(28)850 822 — — 
Released (used) during the year (90)(90)— — 
Released (unused) during the year (238)(238)— — 
At December 31, 2021806 1,331 2,137  2,137 
Arising (released) during the year(101)428 327 — — 
Released (used) during the year   — — 
Released (unused) during the year (191)(191)— — 
At December 31, 2022705 1,568 2,273 77 2,196 
Arising (released) during the year107 257 364 — — 
Released (used) during the year(48)(76)(124)— — 
Released (unused) during the year (291)(291)— — 
At December 31, 2023$764 $1,458 $2,222 $ $2,222 
The provision for post-employment benefits is for the lump sum retirement indemnity required to be paid to French employees if they retire as a Company employee. The comprehensive income (loss) for 2023 includes $46,000 of actuarial loss (actuarial gain of $71,000 in 2022 and actuarial loss of $20,000 in 2021. One employee retired in 2023 and no employee retired in 2021 and 2022.
The main assumptions used in the calculation are the following:
202120222023
Discount rate0.98%3.75%3.20%
Salary increaseBetween 1.5% and 3.5%Between 1.5% and 3.5%Between 1.5% and 3.5%
Retirement age60-62 years60-62 years65-67 years
Turnover: depending on the seniorityDecrease by age from 2% for directors, Vice presidents and managers and from 10% for other employees. 0% for executive teamDecrease by age from 2% for directors, Vice presidents and managers and from 12% for other employees. 0% for executive teamDecrease by age from 2% for directors, Vice presidents and managers and from 20% for other employees. 0% for executive team
At December 31, 2021, 2022 and 2023, “Other provisions” include primarily estimated royalty payments assessed on sales of modules to holders of patents which may be deemed as essential under the requirements of the LTE standard. The royalty provision is based on management’s judgment, taking into consideration the published royalty rates, various legal decisions, articles, reports and industry discussions on the subject which were available, and is recorded in the cost of product revenue. The Company’s modules are considered as final products incorporating the full LTE function, and therefore may have royalties assessed on their sale; no royalties are accrued on the sales of chips as the full LTE functionality is not included in the chip and it is not current industry practice to license standard-essential patents at the component level.
F-48


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)

18. Trade payables, other current liabilities and current contract liabilities
 At December 31,
 202120222023
 (in thousands)
Trade payables$13,916 $9,342 $16,281 
Other current liabilities:
Employees and social debts7,987 7,497 7,383 
Provisions 77  
Others1,193 781 1,516 
Total other current liabilities$9,180 $8,355 $8,899 
Contract liabilities:
License and development services agreements (See Note 19)8,201 5,774 5,485 
Deferred revenue476 190 367 
$8,677 $5,964 $5,852 
As of December 31, 2021,trade payables included the current portion of a supplier debt related to acquisition of certain intangible assets of $244,000. In the year ended December 31, 2021, the Company contracted a new supplier debt related to the acquisition of certain intangible assets. As of December 31, 2021, $279,000 remained of this liability ($184,000 as the non-current portion). In the year ended December 31, 2022, the Company contracted a new supplier debt related to the acquisition of certain intangible assets. As of December 31, 2022, $3,350,000 remained of this liability ($786,000 as the non-current portion). As of December 31, 2023, $1,587,000 remained as current portion. In January 2020, the Company entered into an agreement with a technology company based in Israel to transfer a team of engineers to the Company for the purpose of accelerating 5G new product development. The remaining amount to be paid in June 2024 for this agreement is $1,430,000. This amount has been discounted and as of December 31, 2023, $1,288,000 is included in current trade payables ($1,002,000 and $780,000 as of December 31, 2022 and 2021, respectively), and the Company records interest expense associated with this amount each reporting period.
Terms and conditions of the above financial liabilities:
Trade payables are non-interest bearing and are generally settled on 30-day terms.
Other current liabilities, primarily accrued compensation and related social charges, are non-interest bearing.
Certain upfront payments received from strategic partners are deemed to include a financing component, and as such, bear interest.
Deferred revenue is primarily related to maintenance services. At December 31, 2021, 2022 and 2023, deferred revenue totaled $476,000 (recognized in 2022), $190,000 (recognized in 2023) and $367,000 (expected to be recognized during 2024), respectively.

19. Other non-current liabilities
 At December 31,
 202120222023
 (in thousands)
Trade payables$964 $1,788 $ 
Deferred tax liabilities138 258 264 
Contract liabilities:
  License and development services agreement2,706 404  
  Deferred revenue   
  Total contract liabilities 2,706 404  

F-49


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
At December 31, 2021 and 2022, trade payables included the non-current part of a supplier debt related to acquisition of certain intangible assets which is scheduled to be paid in 27 months.
At December 31, 2023, the Company recognized a net deferred tax liability of $264,000 ($258,000 and $138,000 at December 31, 2022 and 2021, respectively) related to origination and reversal of timing differences.
On October 24, 2019, the Company signed a multi-year, non-exclusive license and development services agreement with a strategic partner, a Fortune Global 500 company. The agreement provided for an upfront payment of $18 million, which was received in October 2019, and recorded as a contract liability upon receipt. The contract includes clauses that allow for termination in certain circumstances, or in some cases of a change in control of the Company, which could result in a refund of certain or all amounts received under the contract, depending on the circumstances. The Company determined that this agreement includes a financing component related to the upfront payment, whereas the deliverables under the contract were to be delivered over more than one year, which results in the recognition of interest expense over a portion of the term of the agreement. In the year ended December 31, 2023, no revenue was recognized as the strategic partner has suspended the project ($8,619,000 recognized in revenues in 2022 and $11,419,000 in 2021 as a result of development services performed), license revenue of $1,500,000 in the year end December 31, 2022 and interest expenses on the upfront payment of $810,000 in 2022 and $1,628,000 in 2021). There was no interest expenses in the year ended December 31, 2023. At December 31, 2022 and 2023, there was no net remaining contract liability presented on the Statement of Financial Position ($4,211,000 was presented at December 31, 2021, reflecting the expected net amount of revenue less interest expenses to be recognized in the year ended December 31, 2022).
In December 2020, the Company signed a 5G technology access and license agreement with another strategic partner for an amount of $4,500,000. The agreement provided for an upfront payment which was received in January 2021. The Company determined that this agreement includes a financing component related to the upfront payment, which will results in the recognition of interest expense over a portion of the term of the agreement. In the year ended December 31, 2023, the Company recognized revenues for an amount of $571,000 ($1,083,000 in 2022 and $3,008,000 in 2021) as a result of development services performed and interest expenses on the upfront payment of $14,000. At December 31, 2023, the net remaining contract liability of $245,000 was presented on the Statement of Financial Position as current contract liabilities (At December 31, 2022: $862,000 as current portion ;At December 31, 2021 : $1,853,000, $1,639,000 as current portion and $214,000 as non-current portion).
In December 2021, the Company signed two amendments with the second strategic partner to extend the 5G technology access and license agreement. The first amendment was signed to extend the agreement to a manufacturing license for the 5G chip for a total amount of $5,000,000 of which $3,000,000 in cash which was received in February 2022 and $2,000,000 in the form of investments in production and testing equipment that will then be made available to Sequans for its own use. In the year ended December 31, 2023, the Company recognized revenues for an amount of $296,000 ($2,983,000 in 2022 and $311,000 in 2021), as a result of development services performed and interest expenses on the upfront payment of $25,000. At December 31, 2023, no contract liability presented on the Statement of Financial Position remained ($271,000 net remaining contract liability presented as current contract liabilities and $1,189,000 at December 31, 2021).
The second amendment is related to a manufacturing license for Monarch 2 chips and NB-IoT in India, for a total amount of $4,500,000 which was received in February 2022. The Company determined that this amendment includes a financing component related to the upfront payment, which will results in the recognition of interest expense over a portion of the term of the agreement. In the year ended December 31, 2023, the Company recognized revenues for an amount of $2,536,000 as a result of development services performed ($1,507,000 in 2022: $800,000 as license fees and $707,000 as a result of development services performed) and no interest expenses on the upfront payment. At December 31, 2023, $8,000 contract liability presented on the Statement of Financial Position remained ($2,544,000 at December 31, 2022: $2,141,000 as current contract liabilities and $404,000 as non-current liabilities; $3,652,000 at December 31, 2021: $1,160,000 as current contract liabilities and $2,492,000 as non-current liabilities).
In August 2022, the Company signed a 5G license agreement with a strategic partner for an amount of up to $60,000,000, to be paid over three years, to manufacture and sell the 5G chipset in China and well as the right to create derivative products based on the licensed technology that may be sold in China if a minor derivative and worldwide if a major derivative. In the year ended December 31, 2023, the Company recognized license fee revenues for an amount of $18,750,000 ($20,000,000 in 2022). At December 31, 2023 and 2022, the net remaining contract liability of $2,500,000 was presented on the Statement of Financial Position as current contract liabilities.


F-50


Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)


20. Information about financial instruments

20.1. Financial assets and liabilities
 Carrying amountFair value
 December 31,December 31,
 202120222023202120222023
 (in thousands)
Financial assets:
Trade and other receivables
Trade receivables and contract assets$14,411 $8,670 $8,612 $14,411 $8,670 $8,612 
Deposits and other receivables
Deposits451 436 431 451 436 431 
Other financial assets
Long-term investments357 337 360 357 337 360 
Financial instruments at fair value through other comprehensive income
Cash flow hedges 142 74  142 74 
Cash, cash equivalents and short-term investments4,835 10,671 5,705 4,835 10,671 5,705 
Total financial assets$20,054 $20,256 $15,182 $20,054 $20,256 $15,182 
Total current$19,246 $19,483 $14,391 $19,246 $19,483 $14,391 
Total non-current$808 $773 $791 $808 $773 $791 
Financial liabilities:
Lease liability4,620 3,569 3,116 4,620 3,569 3,116 
Interest-bearing loans and borrowings:
Interest-bearing receivables financing9,518 7,723 9,544 9,518 7,723 9,544 
Convertible debt36,373 43,455 52,278 36,493 42,636 52,111 
Unsecured related party loan  8,922   8,922 
Government loans6,001 5,171 4,337 6,001 5,171 4,337 
Research project financing3,868 3,383 2,489 3,868 3,383 2,489 
Convertible debt embedded derivative10,081 3,203 3 10,081 3,203 3 
Trade and other payables (current and non current)14,880 11,130 16,281 14,880 11,130 16,281 
Financial instruments at fair value through other comprehensive income
Cash flow hedges50   50   
Total financial liabilities$85,391 $77,634 $96,970 $85,511 $76,815 $96,803 
Total current$27,631 $21,556 $92,484 $27,631 $21,556 $92,317 
Total non-current$57,760 $56,078 $4,486 $57,880 $55,259 $4,486 
The carrying values of current financial instruments (cash and cash equivalents, short-term investments, trade receivables and trade and other payables, and interest-bearing receivables financing) approximate their fair values, due to their short-term nature.
F-51

Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Long-term investments are primarily related to a bank guarantee secured by pledges of investments in money market funds issued in favor of the owners of leased office space to secure annual lease payments by the Company for its office space in Colombes.
Government loans received from the financial agency of the French government were recorded as financial instruments in compliance with IAS 20 Accounting for Government Grants and Disclosure of Government Assistance.
The use of different estimations, methodologies and assumptions could have a material effect on the estimated fair value amounts. The methodologies are as follows:
Cash, cash equivalents, short-term investments, accounts receivable, accounts payable, other receivable and accrued liabilities: due to the short-term nature of these balances, carrying amounts approximate fair value.
Long-term investments are composed of debt-based mutual funds with traded market prices. Their fair values amounted to $357,000, $337,000 and $360,000 at December 31, 2021, 2022 and 2023, respectively. The carrying amounts approximate fair value measured based on significant observable input (Level 2).
Foreign exchange forward and option contracts: the fair values of foreign exchange forward and option contracts were calculated using the market price that the Company would pay or receive to settle the related agreements, by reference to published exchange rates (Level 2).
At December 31, 2021 and 2022, fair value of the debt components of convertibles notes was calculated using the effective interest rate of the debt component of the convertible note issued in April 2021 and amounted to $36,493,000 and $42,636,000, respectively. At December 31, 2023, fair value of the debt components of convertibles notes was calculated using the effective interest rate of the unsecured related party loan issued in November 2023 and amounted to $52,111,000.
As described under Note 14.1, the fair value of the embedded derivative related to the convertible debt is recalculated at the end of each reporting period. The fair value measured is based on significant observable input (Level 3).
Interest-bearing receivable financing, government loans, research project financing and venture debt: carrying amounts approximate fair value.
Fair Value Hierarchy
The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:
Level 1: quoted (unadjusted) prices in active markets for identical assets or liabilities.
Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly.
Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

As at December 31, 2021, the Company held the following financial instruments carried at fair value on the statement of financial position:

Assets measured at fair value
At December 31,
 2021Level 1Level 2Level 3
 (in thousands)
Long-term investments$357  $357  




F-52

Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Liabilities measured at fair value
At December 31,
 2021Level 1Level 2Level 3
 (in thousands)
Convertible debt embedded derivative$10,081  $10,081  
Financial instruments at fair value through other comprehensive income:
Cash flow hedge50 50
As at December 31, 2022, the Company held the following financial instruments carried at fair value on the statement of financial position:
Assets measured at fair value
At December 31,
 2022Level 1Level 2Level 3
 (in thousands)
Long-term investments$337  $337  
Financial instruments at fair value through other comprehensive income:
Cash flow hedge142 142 
Liabilities measured at fair value
At December 31,
 2022Level 1Level 2Level 3
 (in thousands)
Convertible debt embedded derivative$3,203  $3,203  
As of December 31, 2023, the Company held the following financial instruments carried at fair value on the statement of financial position:
Assets measured at fair value
At December 31,
 2023Level 1Level 2Level 3
 (in thousands)
Long-term investments360  360  
Financial instruments at fair value through profit and loss:
Cash flow hedge74 — 74 — 
Liabilities measured at fair value
At December 31,
 2023Level 1Level 2Level 3
 (in thousands)
Convertible debt embedded derivative3  3  



20.2. Financial instruments at fair value
The Company uses financial instruments, including derivatives such as foreign currency forward and options contracts, to reduce the foreign exchange risk on cash flows from firm and highly probable commitments denominated in euros.
The following tables present fair values of foreign currency derivative financial instruments at December 31, 2023, 2022 and 2021.
F-53

Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
 At December 31, 2021
 Notional AmountFair value
 (in thousands)
Forward contracts (buy euros, sell U.S dollars)5,000 $(50)
Options (buy euros, sell U.S. dollars)  
Total5,000 $(50)
 At December 31, 2022
 Notional AmountFair value
 (in thousands)
Forward contracts (buy euros, sell U.S. dollars)3,000 $142 
Options (buy euros, sell U.S. dollars)  
Total3,000 $142 
At December 31, 2023
Notional AmountFair value
(in thousands)
Forward contracts (buy euros, sell U.S. dollars)2,000 $74 
Options (buy euros, sell U.S. dollars)  
Total2,000 $74 
The fair value of foreign currency related derivatives is included in the Consolidated Statement of Financial Position in "Other receivables" at December 31, 2022 and 2023 and in 'Other current liabilities" at December 31, 2021. The earnings impact of cash flow hedges relating to forecasted operating expense transactions is reported in operating expense. Realized and unrealized gains and losses on these instruments deemed effective for hedge accounting are deferred in accumulated other comprehensive income until the underlying transaction is recognized in earnings or the instruments are designated as hedges.
During the year ended December 31, 2023, the Company recorded a loss of $76,000 (gain of $202,000 and loss of $129,000 for the years ended December 31, 2022 and 2021, respectively) in other comprehensive income (loss) related to the effective portion of the change in fair value of its cash flow hedges. During the years ended December 31, 2021 and 2023, the amount reclassified from other comprehensive income to Consolidated Statement of Operations was gains of $53,000 and $139,000, respectively and loss of $143,000 during the year ended December 31, 2022.
There was no ineffective portion of hedging instruments in the years ended December 31, 2021, 2022 and 2023.
The derivatives have maturity dates of less than 12 months. Management believes counterparty risk on financial instruments is minimal since the Company deals with major banks and financial institutions.
At December 31, 2023, the Company holds $455,000 in currencies other than the U.S. dollar compared with $951,000 at December 31, 2022 and $1,966,000 at December 31, 2021 (See Note 11). The amount received from research tax credit in 2021, 2022 and 2023 denominated in euros. At December 31, 2023, the Company has loans denominated in euros for a principal amount of $12,957,000 ($10,817,000 and $13,525,000 at December 31, 2022 and 2021, respectively).

20.3. Financial risk management objectives and policies
The Company’s principal financial liabilities comprise trade payables (current and non-current), lease liabilities, interest-bearing receivables financing, government loans, convertible debt and unsecured related party loan. The Company has various financial assets such as trade receivables, deposits and cash and cash equivalents, which arise directly from its operations, as well as from capital increases.
The main risks arising from the Company’s financial instruments are foreign currency risk, credit risk, interest rate risk and cash flow liquidity risk. The Board of Directors reviews and agrees policies for managing each of these risks which are summarized below.
F-54

Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Foreign currency risk
The Company faces the following foreign currency exposures:
Operating activities, when revenues or expenses are denominated in different currencies from the functional currency of the entity carrying out these transactions.
Government loans are denominated in euros, and lease liabilities are denominated in different currencies while the functional currency of the entity carrying out these transactions is the U.S. dollar.
Non-derivative monetary financial instruments that are denominated and settled in a currency different from the functional currency of the entity which holds them.
Nearly 100% of total revenues and approximately 80% of total cost of sales are denominated in U.S. dollars. However, as a result of significant headcount and related costs from operations in France, which are denominated and settled in euros (the “structural costs”), the Company has transactional currency exposures which can be affected significantly by movements in the US dollar/euro exchange rates. Approximately 57% of operating expense is denominated in euros. (See Note 20.2 regarding hedging arrangements). If there were a 10% increase or decrease in exchange rate of the U.S. dollar to the euro, as measured using the Company's 2023 weighted average exchange rate of one euro = $1.0816, the Company estimates the impact, in absolute terms, on operating expenses and on financial liabilities for the year ended December 31, 2023 would have been approximately $4.2 million.
Credit risk
It is the Company’s policy that all customers who wish to trade on credit terms are subject to credit verification procedures and as such are considered to have low credit risk at initial recognition. The Company has subscribed to a credit insurance policy which provides assistance in determining credit limits and collection, in addition to some coverage of uncollectible amounts. In addition, receivable balances are monitored on an ongoing basis. There is a rebuttable presumption in IFRS 9 that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due. The Company considers that credit risk has not increased significantly on its outstanding not impaired trade receivables since initial recognition. The Company considers events of default based on the specific facts and circumstances relevant to the outstanding amount.
The following table summarizes customers representing a significant portion of the Company’s total revenue:
CustomerCustomer Location% of total revenues for the year ended December 31,Trade receivables at December 31,
  202320222021202320222021
AChina56 %33 % %3,411,000 3,375,000  
BJapan16 %11 %13 %18,000  7,736,000 
CGermanyLess than 10%24 %Less than 10% 3,585,000 3,652,000 
DAmerica %14 %23 %  1,800,000 
ETaiwanLess than 10%Less than 10%23 %26,000  545,000 
FChinaLess than 10%Less than 10%14 %945,000 169,500 203,000 
With respect to credit risk arising from the other financial assets, which comprise cash and cash equivalents, the Company’s exposure to credit risk arises from default of the counterparty, with a maximum exposure equal to the carrying amount of these instruments. Nearly all cash and cash equivalents are held in France at three large and international banks.
Vendor concentration risk
Access to foundry capacity is critical to the Company’s operations as a fabless semiconductor company. The Company depends on a sole independent foundry in Taiwan to manufacture its semiconductor wafers. The Company works with three vendors for manufacturing and testing chipsets and three vendors for assembling modules, but typically works with one dedicated vendor per product.


F-55

Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Liquidity risk
The Company monitors its risk of a shortage of funds using a cash flow planning tool. This tool considers the maturity of both its financial investments and financial assets (e.g. accounts receivables, other financial assets) and projected cash flows from operations.
The following table includes our contractual obligations, including interest, for existing financial liabilities as of the following dates:
Within 1
year
1 to 2
years
2 to 3
years
3 to 4
years
4 to 5
years
More
than 5
years
Total
 (in thousands)
At December 31, 2021
Research project financing$1,057 $1,042 $1,684 $ $ $ $3,783 
Interest-bearing receivables financing9,518      9,518 
Government loans1,240 1,573 1,483 1,452 714  6,462 
Convertible debt  54,623    54,623 
Lease liabilities1,238 1,043 965 1,052 322  4,620 
Trade payables13,916 171 1,477    15,564 
Other current liabilities9,180      9,180 
$36,149 $3,829 $60,232 $2,504 $1,036 $ $103,750 
At December 31, 2022
Research project financing$1,237 $1,683 $146 $221 $ $ $3,287 
Interest-bearing receivables financing7,723      7,723 
Government loans1,534 1,397 1,367 673   4,971 
Convertible debt (1)
 54,348     54,348 
Lease liabilities1,291 930 1,025 323   3,569 
Trade payables9,342 2,235     11,577 
Other current liabilities8,278      8,278 
$29,405 $60,593 $2,538 $1,217 $ $ $93,753 
At December 31, 2023
Research project financing$2,057 $113 $165 $207 $ $ $2,542 
Interest-bearing receivables financing9,544      9,544 
Government loans1,791 1,414 695    3,900 
Convertible debt52,278      52,278 
Unsecured related party loan8,922      8,922 
Lease liabilities1,471 1,102 387 61 70 25 3,116 
Trade payables16,281      16,281 
Other current liabilities8,899      8,899 
$101,243 $2,629 $1,247 $268 $70 $25 $105,482 
(1) Based on the existing contractual terms as of December 31, 2021 and 2022 and assuming the Company's options to extend maturity dates are exercised.
The Company’s liquidity risk for the next 12 months is described in note 2.1. The term of agreements with strategic partners which gave rise the contract liability recorded in the amount of $5,486,000, $6,178,000 and $10,907,000 as of December 31, 2023, 2022 and 2021, respectively, are described under note 19.
Capital management
The primary objective of the Company’s capital management is to continue to execute according to its business plans and budgets in order to achieve profitability and positive cash flow, and to maximize shareholder value.
F-56

Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
20.4. Changes in liabilities arising from financing activities, including government grants
(in thousands)January 1, 2021Cash flowsForeign exchange movementAccrued interest
Non-cash impact of amendment and conversion
Other(1)
December 31, 2021
Government grant advances and loans$15,070 592 (449)427  (80)$15,560 
Convertible debt$26,074 27,957  6,193 (16,008)(12,713)$36,373 
Venture debt$8,276 (8,743)180 819  (532)$ 
Lease liabilities$5,776 $(1,063)$(297)$760  $(556)$4,620 
Interest-bearing financing of receivables$14,228 21 (337,000)282,000  (4,676,000)$9,518 
Total$69,424 18,764 (903)8,481 (16,008)(18,557)$66,071 

(in thousands)January 1, 2022Cash flows
Foreign exchange movementAccrued interestNon-cash impact of amendment and conversion
Other(1)

December 31, 2022
Government grant advances and loans$15,560 406 (365)266  (5,473)$10,394 
Convertible debt$36,373   7,762 (671)(9)$43,455 
Lease liabilities$4,620 (1,205)(298)571  (119)$3,569 
Interest-bearing financing of receivables$9,518 3,046 (1)254  (5,094)$7,723 
Total$66,071 2,247 (664)8,853 (671)(10,695)$65,141 
(in thousands)January 1, 2023Cash flowsForeign exchange movementAccrued interestNon-cash impact of amendment and conversion
Other(1)
December 31, 2023
Government grant advances and loans$10,394 (466)182 225 (2,473)$7,862 
Convertible debt$43,455 9,152 (247)(82)$52,278 
Unsecured related party loan 9,000  127  (205)8,922 
Lease liabilities$3,569 (1,321)113 479  276 $3,116 
Interest-bearing financing of receivables$7,723 1,483 179 234  (191)$9,428 
Total$65,141 8,696 474 10,217 (247)(2,675)$81,606 
(1) In 2021, 2022 and 2023, Other includes additions in lease liabilities, which are non-cash. In 2021, Other includes the liability component and the fair value of the embedded option of the convertible debts converted during the year. In 2021, Other includes the impact of the forgiveness of the government grant advance and of the netting of the interest-bearing financing debt with the Research tax credit receivable.

F-57

Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
21. Commitments and contingencies
Contingencies
From time to time, the Company has been and may become involved in legal proceedings arising in the ordinary course of its business.
In 2022, the Company was sued in three lawsuits in the United States District Court for the district of Minnesota by a company called Bell Semiconductor, LLC (“Bell”), accusing the Company of infringing certain U.S. Patents by the Company's use of certain design tools. In Bell Semiconductor, LLC v. Sequans Communications, SA et al, Case No. 0-22-cv-02106 (DMN), filed August 26, 2022, Bell accused the Company of infringing U.S. Patent Nos. 7,149,989 and 7, 260,803. In Bell Semiconductor, LLC v. Sequans Communications, SA et al, Case No. 0-22-cv-02344 (DMN), filed September 23, 2022, Bell accused the Company of infringing U.S. Patent Nos. 6,436,807 and 7,007,259. In Bell Semiconductor, LLC v. Sequans Communications, SA et al, Case No. 0-22-cv-02660 (DMN), filed October 21, 2022, Bell accused the Company of infringing U.S. Patent Nos. 7,231,626 and 7,396,760. The Company filed motions to dismiss in each case. In August 2023, Bell entered into a settlement agreement with supplier of the design tools that Bell asserts infringe the Patents and the three lawsuits against the Company were dismissed. The supplier of the design tools indemnified the Company for all the costs to defend and/or settle the lawsuits. The lawsuits were dismissed in August 2023.
Management is not aware of any other legal proceedings that, if concluded unfavorably, would have a significant impact on the Company's financial position, operations or cash flows.
Bank guarantee
A bank guarantee was issued in favor of the owners of leased office space in France, in order to secure six months of lease payments, for an amount of $348,000 as of December 31, 2023 ($337,000 and $357,000 as of December 31, 2022 and 2021, respectively). This guarantee was secured by the pledge of certificates of deposit and mutual funds for 100% of the amount of the guarantee. The total value of investments secured to cover this bank guarantee was $360,000 at December 31, 2023 ($337,000 and $357,000 at December 31, 2022 and 2021).
Purchase commitments
As of December 31, 2023, the Company had $2.7 million of non-cancelable purchase commitments with its third-party manufacturer and suppliers for future deliveries of equipment and components, principally during 2024.
22. Related party disclosures
There is no single investor who has the ability to control the Board of Directors or the vote on shareholder resolutions.
As of December 31, 2023, B. Riley Asset Management LLC and Lynrock Lake owned 10% or more of the share capital of the Company. On April 12, 2023, 272 Capital Fund LP, an entity managed by B. Riley Asset Management LLC (“BRAM”) and affiliated with Wes Cummins, a director of the Company and the President of BRAM, purchased 1,310,221 ADSs in the offering. Lynrock Lake also purchased 3,930,663 ADSs. On September 26, 2023, 272 Capital Fund LP purchased 2,120,141 ADSs.
As of December 31, 2022, only B. Riley Asset Management LLC owned 10% or more of the share capital of the Company. On March 11, 2022, 272 Capital Fund LP, an entity managed by B. Riley Asset Management LLC (“BRAM”) and affiliated with Wes Cummins, a director of the Company and the President of BRAM, purchased 2,833,333 ADSs in the offering.
As of December 31, 2021, only Lynrock Lake owned 10% or more of the share capital of the Company. As of December 31, 2022, Lynrock Lake owned 9.8% of the share capital of the Company.
In April 2015, the Company completed the sale of a $12 million convertible note, in April 2016 the sale of a $6.0 million convertible note, in September 2018 the sale of a $4.5 million convertible note, in May 2019 the sale of a $3.0 million convertible note and in August 2019 the sale of a $5.0 million convertible note, all to an affiliate of Nokomis Capital, L.L.C., a beneficial owner of 9.9% of the share capital of the Company as of December 31, 2020. In 2017, the Company amended the terms of the notes issued in 2015 and 2016 and as part of the agreement, Wesley Cummins, a former (as of February 2020) representative of Nokomis Capital, L.L.C., became a board observer in November 2017, and on June 29, 2018, the shareholders approved Mr. Cummins' nomination to the board of directors. Since February 2020, Nokomis no longer has representation on the board of directors and as of December 31, 2022 has declared itself to be no longer an owner of any shares of the Company.
F-58

Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
Effective March 20, 2020, the convertible notes issued in April 2015, April 2016, September 2018, May 2019 and August 2019 were amended to grant the Company three options to extend the term of each note, except for the August 2019 which has two options (See Note 14.1).
In December 2020, January 2021 and February 2021, Nokomis converted the April 2015, April 2016 and May 2019 notes (see Note 14.1 Convertible debt). In August 2022, the Company elected to exercise the option to extend the maturity of the August 2019 note to August 2023. In August 2023, the Company elected to exercise the option to extend the maturity of the August 2019 note to April 2024. As of December 31, 2023, the principal amount and accrued interest of the convertible notes held by an affiliate of Nokomis Capital, L.L.C amounts to $6.9 million.
On April 9, 2021, the Company completed the sale of a $40.0 million convertible note with Lynrock Lake Master Fund LP. As of December 31, 2023, the principal amount and accrued interest of the convertible note amounts to $45.4 million.
On February 2, 2021, the board of director approved a consultancy services agreement with ABLE France, a company owned by Yves Maitre, member of the board of directors, for services in business development. The agreement was executed effective March 1, 2021. During the year ended December 31, 2021, $116,000 was paid to Mr. Maitre under the contract. No services were provided and payments were made in the years ended December 31, 2022 and 2023.
At the annual shareholders meeting on June 24, 2022, the shareholders approved the nomination of Dr. Sailesh Chittipeddi, Executive Vice President and Head of IoT and Infrastructure business unit of Renesas to the Board of Directors. As of December 31, 2023, Renesas Electronics Corporation owned 3.20% of the share capital of the Company (4.08% as of December 31, 2022).
On August 4, 2023,the Company entered into a Memorandum of Understanding with Renesas providing that Renesas and the Company engaged in a series of transactions pursuant to which Renesas would seek to acquire (through an affiliate) all of the issued and outstanding ordinary shares of the Company. On February 22, 2024, Renesas notified the Company that Renesas was terminating the Memorandum of Understanding due its receipt of an adverse Japanese tax ruling on February 15, 2024 from the National Tax Agency of Japan. Obtaining a favorable Japanese tax ruling had been one of the closing conditions for the transaction.
On March 19, 2024, Dr. Sailesh Chittipeddi resigned from the Company's Board of Directors.
No other transactions have been entered into with these or any other related parties in 2021, 2022 and 2023, other than normal compensation (including share based payment arrangements) for and reimbursement of expenses incurred in their roles as Directors or employees of the Company.
Compensation of key management personnel
 Year ended December 31,
 202120222023
 (in thousands)
Fixed and variable wages, social charges and benefits expensed in the year$2,837 $2,574 $2,689 
Share-based payment expense for the year2,478 2,903 4,144 
Board members fees to non-executive members210 199 199 
Total compensation expense for key management personnel$5,525 $5,676 $7,032 
Key management personnel comprises the chief executive officer and all executive vice presidents reporting directly to him.
The employment agreement with the chief executive officer calls for the payment of a termination indemnity of an amount equal to eighteen months of his gross annual base remuneration and 150% of bonus in the event of his dismissal without cause by the Board of Directors of the Company, as well as vesting of the ordinary shares that would have been vested during the twelve months following the end of his term. In case the dismissal would occur during the three months before or the twelve months following a change of control, he would be entitled to all the unvested share awards at the date of dismissal.
On July 25, 2023, the board of directors approved a special transaction bonus to Dr. Karam in the amount of €1,000,000 conditional upon the closing the proposed acquisition of the Company by Renesas. The transaction bonus was never paid due of the termination of the proposed transaction by Renesas in February 2024. In addition, on August 15, 2023, the board of directors approved the payment by the Company of legal fees incurred by Dr. Karam in the connection with the negotiation
F-59

Sequans Communications S.A.
Notes to the Consolidated Financial Statements—(Continued)
with Renesas of the conditions of his retention as Chief Executive Officer of the Company upon change of control. A total amount of $50,401 in such legal fees were paid during 2023.
For the year ended December 31, 2023, we estimate that approximately $23,000 of the amounts set aside or accrued to provide pension, retirement or similar benefits to our employees was attributable to our executive officers.
Directors’ interests in an employee share incentive plan
The Company granted warrants to certain members of the Board of Directors during the years ended December 31, 2021, 2022 and 2023:
- On June 25, 2021, the shareholders authorized the Board of Directors to grant to each of Messrs. de Pesquidoux, Maitre, Nottenburg, Pitteloud, Sharma, Slonimsky and Cummins warrants to purchase 140,000 ordinary shares. On June 29, 2021, the Board used this authorization to make such grants with an exercise price of $1.49 per ordinary share.
- On June 24, 2022, the shareholders authorized the Board of Directors to grant to each of Messrs. de Pesquidoux, Maitre, Nottenburg, Pitteloud, Slonimsky and Cummins warrants to purchase 140,000 ordinary shares. On June 24, 2022, the Board used this authorization to make such grants with an exercise price of $0.65 per ordinary share.
- On June 27, 2023, the shareholders authorized the Board of Directors to grant to Mrs Marced Martin and each of Messrs. de Pesquidoux, Maitre, Nottenburg, Pitteloud, Slonimsky and Cummins warrants to purchase 180,000 ordinary shares. On June 27, 2023, the Board used this authorization to make such grants with an exercise price of $0.54 per ordinary share.
The board members were required to subscribe to the warrants at a price of €0.00001 per warrant for the warrants granted in 2023 and €0.00000714 in 2021 and 2022.
Share-based payment expense incurred in connection with these transactions amounted to $292,000 in the year ended December 31, 2023 (2022: $495,000; 2021: $443,000).

23. Events after the reporting date
Subsequent events up to the date the consolidated financial statements were authorized for issue were as follows:
On February 22, 2024, Renesas notified us that Renesas was terminating the MoU due its receipt of an adverse Japanese tax ruling on February 15, 2024 from the National Tax Agency of Japan.
At the meeting of March 5, 2024, the Board of Directors granted to employees 10,060,288 restricted share awards, representing 2,515,072 ADS with vesting over four years.
On March 27, 2024, the Company received a commitment for financing of its 4G eRedCap project for a total of €10.9 million ($12.0 million at the closing period exchange rate) from the French government (operated for the state by Bpifrance) as part of the France 2030 initiative to support the development of technologies deemed to be strategically important to the national interest. An upfront payment of €2.7 million ($3.0 at the closing period exchange rate) was received in April; three milestone payments for the remaining amount are scheduled over the duration of the project.
On April 9, 2024, we secured standstill agreements from our three main debt holders. The agreements granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met. In late April, the Company began discussions to extend the standstill agreements, which are still in process as of April 30, 2024. The goal of the standstills is to provide sufficient time for the Company to effectively negotiate and finalize a new strategic transaction, thereby securing a long-term solution that aligns with the interests of all stakeholders.
On April 22, 2024, we issued an Unsecured Promissory Note with a principal amount of $5,000,000 to 272 Capital Master Fund, Ltd. The transaction closed on April 24, 2024. The Note bears paid-in kind interest at a rate of 12.0% per annum, compounded annually, with a guaranteed return of 40.0%. The Note matures on the earlier of April 22, 2025, or one day prior to the earliest extended maturity date of the Company’s existing convertible debt held by Lynrock Lake and Nokomis and subordinated notes held by Renesas. The Note contains customary covenants and is subject to customary events of default.
At the meeting of April 30, 2024, the Board of Directors granted to employees 147,776 restricted share awards, representing 36,944 ADS with vesting over four years.
F-60
EX-1.1 2 exhibit11-bylawsmarch52024.htm EX-1.1 BY LAW Document


logosequans2017.jpg


Société Anonyme
with a share capital of € 2,467,692.56
Registered office : 15-55 boulevard Charles de Gaulles - 92700 COLOMBES
Trade Register N° : 450 249 677 Nanterre









BY LAWS











As amended on March 5, 2024






























Article 1 - Legal Form

The company is a “société anonyme” (French corporation) governed by corporate law, subject to specific laws governing the company and to these by-laws.


Article 2 - Company name

The company’s name is:

« SEQUANS COMMUNICATIONS ».


Article 3 - Corporate purpose

The company’s corporate purpose, in France and abroad is:
The study, development and marketing of all products and/or services relating to radio fixed and/or optical-type communication networks systems;
Advising and training, by all means and technical media, relating to the aforementioned fields of operations;
The participation, directly or indirectly, in all transaction that may be related to any of the purposes defined above, through the creation of new companies or legal entities, the contribution, subscription, or purchase of securities or corporate rights, acquisition of interests, mergers, partnerships, or any other methods;
And, more generally, all industrial, commercial, and financial transactions, or transactions involving movable or fixed assets, that may be related directly or indirectly, in whole or in part, to any of the aforementioned corporate purposes, or to any similar or related purposes, or to any and all purposes that may enhance or develop the company’s business.


Article 4 - Registered office

The registered office is located at:

15-55 boulevard Charles de Gaulles - 92700 COLOMBES.

The board of directors is empowered to transfer the company’s registered office, within the applicable legal and regulatory provisions.


Article 5 -Term

The company was incorporated for a term of ninety-nine years starting the day of its registration with the trade and company register, except in the cases of extension or early dissolution.


Article 6 - Share capital

The share capital is set at the amount of two million four hundred sixty-seven thousand six hundred ninety-two euros and fifty-six cents (EUR 2,467,692.56).

It is divided into two hundred forty-six million seven hundred sixty-nine thousand two hundred fifty-six (246,769,256) shares of a par value of one Euro cent (EUR 0.01), fully paid up.

Article 7 - Changes to the capital
 
The share capital may be increased, decreased or amortized in accordance with applicable legal and regulatory provisions.





Article 8 - Subscription for shares

In the event of a share capital increase, shares subscribed for cash, when applied for, shall be paid up in the minimum proportion provided for by legal and regulatory provisions. Partly paid up shares shall be registered shares until fully paid up. Payment of the remainder shall be made in one or several installments pursuant to a decision by the board of directors, within a maximum time limit of five years as of the date of the final capital increase.

Subscribers will be informed of calls for funds by certified mail with acknowledgement of receipt within fifteen days at least before the date set for each payment. Payments shall be made either at the registered office, or at any other place designated for this purpose.

Should the shareholder fail to pay by the date set by the board of directors, any amounts due shall bear interest, ipso jure, at the legal rate of interest, as of the due date for payment, without prejudice to other statutory proceeding and penalties. In particular, the company may force the sale of the securities that have not been paid up.


Article 9 - Legal forms of the shares

Shares are in registered form and shall be registered in an individual share account as provided by legal and regulatory provisions.


Article 10 - Indivisibility of the shares

Shares shall be indivisible with respect to the company. Joint owners of indivisible shares shall be represented at shareholders’ general meetings by one of them or by a joint agent of their choice. Failing their agreement on the choice of an agent, such an agent is appointed by the courts of justice ruling in interim proceedings at the request of the co-owner who is in the greatest hardship.

The voting rights attached to the share shall belong to the beneficial-owner at ordinary shareholders’ meetings, and to the bare-owner at extraordinary shareholders’ general meetings.


Article 11 - Transfer and passing of the shares

Shares are freely negotiable.

They shall be transferred by means of a transfer order from account to account in accordance with the legal and regulatory provisions.

The shares can be leased out or lent with respect to the applicable legal and regulatory provisions.


Article 12 - Rights and obligations of the shares

Each share shall entitle its holder to a portion of the corporate profits and assets pro rata with respect to the amount of capital it represents.

Furthermore, each share shall entitle its holder to vote and be represented in the shareholders’ general meetings in accordance with legal rules and the provisions of these by-laws. Ownership of one share implies, ipso jure, adherence to the by-laws and the decisions of the shareholders’ general meeting.

Shareholders shall be liable for losses within the limits of their contributions to the company’s capital.

The heirs, creditors, legal beneficiaries and other representatives of a shareholder may not place liens on the property or securities of the company, nor request the division or the public sale, nor interfere in the administration



of the company. For the proper exercise of their right, they shall refer to the corporate records and to the decisions of the shareholders’ meetings.

At times when the ownership of several shares is necessary in order to exercise any right as in an exchange, grouping or allocation of shares, or as a consequence of a capital increase or decrease, merger or other corporate operation, the owner of isolated shares, or fewer shares than the required amount, may only exercise the particular right on condition that the shareholder personally takes the required steps to group or, if applicable, purchase or sell the number of requisite shares.


Article 13 - Organization and functioning of the board of directors

1 - Composition

The company is managed by a board of directors comprised of no more than 9 members, appointed by the shareholders’ meeting and that may be individuals or legal entities.

Directors that are legal entities shall designate a permanent legal representative when nominated. This legal representative will be subject to the same conditions and obligations and will be subject to the same civil and criminal liability as if he were director under his own name, without prejudice of the liability in solidum of the legal entity he represents. His mandate as director is for the same term as the mandate given to the legal entity he represents and must be renewed at each renewal of the legal entity’s mandate.

When the legal entity dismisses its representative, it must notify this dismissal to the company without delay, by certified mail and appoints, following the same procedure, a new permanent legal representative; the same rule applies in case of the death or resignation of the permanent legal representative.

2 - Term of office - renewal and rotation

The term of office for directors shall be three years, expiring at the end of the shareholders’ general meeting approving the accounts of the last fiscal years and held on the year of expiration of the mandate.

Directors can always be re-elected.

3 - Vacancy - Cooptation

In the event of vacancy, as a result of death or by resignation, of one or more seats of directors, the board of directors may, between two general meetings, make appointments on a provisional basis.

However, if the number of directors in function is less than the minimum required by legal and regulatory provisions, a general meeting will be convened with respect to applicable legal and regulatory provisions in order to complete the number of directors.

The provisional elections made by the board of directors will be subject to ratification by the next general meeting. In case of failure of ratification, the resolutions adopted and the acts accomplished by the board of directors will remain valid.

The director appointed as a replacement of another remains in the office only for the remaining time of his predecessor’s mandate.

4 - Remuneration

The shareholders’ meeting shall set the directors’ attendance fees. The board of directors, after express deliberation, shall be free to distribute this remuneration among the directors, subject to applicable legal and regulatory provisions.
 
Costs incurred by directors during their terms of office shall be reimbursed by the company against documentary evidence.





5 - Observers

The board of directors may appoint one or more observers chosen from among the shareholders, whether individuals or legal entities, or from outside their number.

Their terms of office shall be set by the board of directors, but shall not exceed two years and shall expire at the next general meeting approving the accounts of the last fiscal year and held on the year of expiration of the mandate. Observers can always be re-elected.

The board of directors may terminate their appointment at any time without cause nor indemnity.

In the event of an observer’s death, dismissal or surrender of office for any other reason, the board of directors may appoint a replacement for the remainder of said observer’s term office.

Observers are called to assist as observers at board of directors’ meetings and may be consulted by it or its chairman. They may not vote on the board of directors’ resolutions.


Article 14 - Chairman of the board of directors

The board of directors shall elect its chairman from among its members who are individuals. The chairman shall be elected for the entire duration of his office as director and may be re-elected.

The chairman of the board of directors is subject to the age limit set out by legal and regulatory provisions. If this limit is reached during office, the chairman of the board of directors shall be considered as having resigned from office at the end of the general meeting approving the accounts of the last fiscal year when the age limit was reached.

The board of directors determines the chairman’s remuneration.


Article 15 - Board meetings

1 - The board of directors shall convene as often as the company’s interest so require, pursuant to notice from the chairman.

The notice to convene must be given at least three days in advance by letter, telegram, telex or fax. It must contain the agenda. In the event of an emergency meeting, the notice may be given immediately and by any means, including orally.

The meeting shall take place at the company’s registered office or at any other place indicated in the notice to convene.

2 - The board may not validly deliberate unless a quorum of at least half of its members are present, or, as the case may be, deemed to be present as provided for under the internal charter of the board of directors set in accordance with applicable legal and regulatory provisions.

Any director may give, by letter, telegram, telex or fax, a proxy to one of his colleague in order to represent him at a meeting of the board of directors, but each director may only represent one of his colleagues.
Decisions will be taken by a majority of members present, deemed to be present, or represented. In the event of a tie vote, the chairman of the meeting shall cast the deciding vote.

3 - An attendance sheet shall be kept which must be signed by the directors at the board meeting and record, as the case may be, the participation of directors by means of videoconferencing or telecommunications.
 
4 - Board decisions shall be recorded in minutes drawn up in compliance with applicable legal provisions and signed by the chairman of the meeting and one director or, if the chairman of the meeting is unable to attend, by two directors. Copies or extracts of the minutes may be certified by the chairman of the board of directors, the chief



executive officer, the delegated managing director, the director temporarily delegated to the duties of chairman or the holder of a power of attorney duly authorized for this purpose.


Article 16 - Powers of the board of directors

The board of directors shall determine the strategy of the company’s activities and shall ensure its implementation. Subject to the powers expressly granted to the shareholders’ meetings, and within the scope of the company’s corporate purpose, the board shall take up all questions related to the management of the company and shall settle all related business through its deliberations.

The company shall be bound also by actions of the board of directors which do not fall within the corporate purpose, unless it proves that the third party knew such action was outside the limits of this purpose, or that the third party could not fail to be aware of this in view of the circumstances.

The board of directors carries out the controls and verifications it considers appropriate. All directors must receive all the necessary information in order to accomplish their task and may review all documents they consider useful.


Article 17 - Powers of the chairman of the board of directors

The chairman of the board of directors shall organize and direct the board’s work, which he shall report on to the general meeting. He shall ensure the proper functioning of the company’s governing bodies and shall ensure, in particular, that the directors are able to carry out their duties.

In case of a temporary unavailability or death of the chairman, the board of directors may delegate the powers of the chairman to a director. In case of a temporary unavailability, this delegation is granted for a limited duration and is renewable. In case of death, it is granted until the appointment of the new chairman.


Article 18 - General management

1 - Choice between two methods of conducting General Management

General management of the company shall be assumed under the responsibility of either the chairman of the board of directors or by another person appointed by the board and with the title of chief executive officer. The board of directors shall decide between these two methods of conducting general management, and shall duly inform the shareholders and third parties according to the applicable regulatory conditions.

When the general management of the company is assumed by the chairman of the board of directors, the provisions set forth above relating to the chief executive officer shall apply to him.

2 - Chief executive officer

The chief executive officer shall be nominated amongst the directors or from outside their number. The board of directors shall set his term of office and his remuneration. The chief executive officer is subject to the age limit set out by the applicable legal and regulatory provisions. If the age limit is reached during office, the chief executive officer shall be considered as having resigned from office at the next general meeting approving the accounts of the last fiscal year and held the year the limit was reached.
 
The chief executive officer may be dismissed at any time by the board of directors. If the dismissal is decided without fair grounds, it may give rise to damages, except if the chief executive officer is the chairman of the board of directors.

The chief executive officer shall be granted the widest powers to act in any manner on behalf of the company in all circumstances. He shall exercise his powers within the limits of the corporate purpose subject to the powers expressly attributed by legal and regulatory provisions to shareholders’ meetings and to the board of directors.




The chief executive officer shall represent the company in its relations with third parties. The company shall be bound also by actions of the chief executive officer which do not fall within the scope of the corporate purpose, unless its proves that the third party knew such action was outside of the limits of this purpose, or that the third party could not fail to be aware of this in view of the circumstances, it being specified that the mere publication of the by-laws does not constitute such proof.

The provisions of the by-laws or the resolutions of the board of directors limiting the powers of the chief executive officer are unenforceable against third parties.

3 - Deputy chief executive officer

Upon proposal of by the chief executive officer, the board of directors may appoint one or more individuals with the title of deputy chief executive officer and determine his remuneration in order to assist the chief executive officer.

The maximum number of deputy chief executives may not exceed five.

Deputy chief executives may be dismissed at any time by the board of directors upon proposal of the chief executive officer. If the dismissal is decided without fair grounds, it may give rise to damages.
If the chief executive officer ceases to exercise, or is prevented from carrying out his duties, the deputy chief executive officers shall, except when otherwise decided by the board of directors, remain in office and retain their duties until appointment of the new chief executive officer.

In agreement with the chief executive officer, the board of directors shall determine the scope and term of the powers granted to the deputy chief executive officers. With respect to third parties, the deputy chief executives shall have the same powers as the chief executive officer.

The age limit applicable to the chief executive officer also applies to the deputy chief executive officers.


Article 19 - Statutory auditors

The company’s account shall be audited by one or several statutory auditors appointed in accordance with legal and regulatory provisions and carrying out their duties in accordance therewith.


Article 20 - Shareholders’ meetings

1 - Shareholders’ meetings are convened and deliberate in accordance with legal and regulatory provisions and carry out their duties in accordance therewith.

Meetings are held at the company’s registered offices or at any other location indicated in the notice to convene.

2 - Any shareholder has the right to attend general meetings and to participate to the resolutions personally or through a proxy, by simple justification of his identity and no matter how many shares he owns as soon as the shares are paid up in accordance with applicable legal and regulatory provisions and that the shareholder justifies his shares are registered within the company’s books at least three days before the meeting.

Shareholders may only be represented by their spouse or another shareholder and for this purpose, the proxy must prove his mandate.

Shareholders may participate in general meetings by means of videoconferences or telecommunications in accordance with legal and regulatory requirements. The means of telecommunications authorized will be mentioned in the notice to convene.

3 - Shareholders’ general meeting shall be chaired by the chairman of the board of directors or, in his absence, by a director appointed for this purpose by the board of directors, failing which the shareholders’ general meeting itself shall elect its chairman.




4 - The minutes shall be prepared, and copies or excerpts of the deliberations shall be issued and certified as required by legal and regulatory provisions.


Article 21 - Financial year

The financial year is twelve months, beginning January 1 ending December 31 of each year.


Article 22 - Annual accounts - Allocation of results

The board of directors shall keep proper accounts of corporate activities and draw up annual and consolidated accounts, in accordance with applicable legal and regulatory provisions, regulations and standards.

The income statement, which summarizes the income and expenses for the financial year, shows, after deduction of amortization and provisions, the profit or loss for the year.

5% is set aside from the earnings for the financial year minus previous losses, if any, to fund the legal reserve. This withdrawal ceases to be mandatory when the reserve reaches one-tenth of the share capital and resumes when, for any reason, the legal reserve falls below the one tenth figure.

Distributable profits consist of the profits for the year, less prior losses, plus the amounts to be placed in reserves as required by legal and regulatory provisions or by the by-laws, plus retained earnings. The shareholders’ meeting may withdraw from these earnings any sum it deems appropriate to allocate any optional reserves or to carry forward to the next financial year.

Moreover the shareholders’ general meeting may decide to distribute sums taken from reserves at its disposal, expressly indicating the reserve items from which such withdrawals are made. Dividends shall however first be taken from the distributable earnings for the year.

Except in the case of a capital decrease, no distribution may be made to shareholders when shareholders’ equity is or would, as a result of such distribution, be less than the amount of capital plus reserves which legal and regulatory provisions or the by-laws prohibit from being distributed. The re-evaluation variance may not be distributed and may be incorporated, in whole or in part, into the capital.


Article 23 - Payment of dividends

The terms and conditions for the payment of the dividends approved by the shareholders’ general meeting are determined by the shareholders’ meeting, or in lieu, by the board of directors. However, cash dividends must be paid within a maximum of nine months after the close of the financial year, unless extended by court order.
 
The ordinary shareholders’ general meeting may grant each shareholder, for all or part of the dividends to be distributed, an option between payment of the dividends in cash or in shares, subject to legal requirements.

Interim dividends may be distributed before the approval of the financial statements for the year when the balance sheet established during or at the end of a financial year and certified by an auditor, shows that the company has made a profit since the close of the last financial year, after recognizing the necessary depreciation and provisions and after deducting prior losses, if any, and the sums to be allocated to reserves, as required by legal and regulatory provisions or the by-laws, and including any retaining earnings. The amount of such interim dividends may not exceed the amount of the profit so defined.

Dividends not claimed within five years after the payment date shall be deemed to expire.


Article 24 - Liquidation

Subject to the applicable legal provisions, the company shall be in liquidation from the time of its winding-up, however brought about. The general meeting of shareholders shall then decide on the method of liquidation and



appoint the liquidators. The legal entity of the company shall continue for the purposes of liquidation, until its definitive closure.


Article 25 - Disputes

All disputes which may arise during the company’s existence or its liquidation either between the shareholders and the company or among the shareholders themselves, concerning the business of the company or the interpretation or implementation of these by-laws will be submitted to the jurisdiction of the relevant courts located in the jurisdiction where the company’s registered office is located.
 





EX-4.2 3 exhibit42aa-partnerwarrant.htm EX-4.2 DIRECTOR WARRANTS ISSUANCE AGREEMENT Document



SEQUANS COMMUNICATIONS

Société anonyme au capital de 2 330 932,50 euros
Siège social : Les Portes de la Défense, 15-55 boulevard Charles de Gaulle - 92700 COLOMBES
RCS Nanterre 450 249 677


Partner Warrants Issuance Agreement 2023-1

______________________







(1) SEQUANS COMMUNICATIONS
(2) THE HOLDERS OF PARTNER WARRANTS 2023-1






























Summary


PREAMBLE : PRESENTATION OF THE ISSUANCE AGREEMENT


Title 1. SUBSCRIPTION AND FEATURES OF Partner Warrants 2023-1

Article 1. Holders of Partner Warrants 2023-1
Article 2. Grant and subscription of Partner Warrants 2023-1
Article 3. Features and period of validity of Partner Warrants 2023-1 – Vesting period -- Conditions of exercise
Article 4. Cessation of Holder's contractual relationship with Sequans Communications or one of its subsidiaries
Article 5. Setting of the Exercise Price for shares covered by the Partner Warrants 2023-1

Title 2. RIGHT OF EXERCISE – SUSPENSION – FORMALITIES – SHARES SUBSCRIBED

Article 6. Suspension of the rights to exercise the Partner Warrants 2023-1
Article 7. Conditions of exercise of Partner Warrants 2023-1
Article 8. Delivery and form of shares
Article 9. Rights and availability of shares

Title 3. REPRESENTATION OF HOLDERS - Protection – AMENDMENT OF THE ISSUANCE AGREEMENT

Article 10. Representation of Holders
Article 11. Protection of Holders – Rights of the Company
Article 12. Binding effect – Term – Jurisdiction































WHEREAS

In order to reward its business partners (consultants, advisers...) (hereinafter the "Beneficiaries"), Sequans Communications wishes to set up a system enabling them to share in its growth.

This Partner Warrants 2023-1 plan is a mechanism by which Sequans Communications offers the Beneficiaries the possibility of subscribing for warrants (hereafter referred to as "Partner Warrants 2023-1") at a set price; the exercise of each Partner Warrant 2023-1 allows the purchase of a new ordinary share during a certain period, at a price set on the date the Partner Warrants 2023-1 are issued, and that remains fixed during the entire period. In this way, the Beneficiaries participate in Sequans’ performance through the changes in share value, even before they become shareholders by exercising the Partner Warrants 2023-1 to purchase shares. This mechanism is governed, in particular, by the provisions set forth under article L.228-91 of the French Commercial Code.

In a decision taken on 27 June 2023, a combined general shareholders' meeting voted in favour of the principle of issuing Partner Warrants 2023-1, with a unitary warrant subscription price of 0.00002 Euro, which could give rise to the issuance of a maximum of 12,000,000 new ordinary shares with a unitary par value of EUR 0.01.

This combined general shareholders' meeting has defined the conditions of setting of the exercise price for the ordinary shares which would be issued upon exercise of each Partner Warrant 2023-1 and decided that this price would be equal to the closing price of the Sequans Communications share, as represented by American Depositary Shares (ADS), listed on the New York Stock Exchange (NYSE), on the date of the granting of said Partner Warrants 2023-1, adjusted to reflect the then current ratio of shares per ADS.

In addition, this decision delegated to the Board of Directors the authority to issue such Partner Warrants 2023-1, on one or more occasions, including the authority to determine the holders and the number of Partner Warrants 2023-1 to be issued and the exercise conditions. Furthermore, the Board of Directors was delegated the authority to increase share capital, subject to certain restrictions, by a maximum amount equal to the total number of Partner Warrants 2023-1 issued, to record the successive increases in share capital as a result of the exercise of the Partner Warrants 2023-1, and to carry out all formalities required as a result thereof.

Pursuant to the aforesaid delegation of power, the Board of Directors has defined, at a meeting held on 27 June 2023, the terms and conditions of the Partner Warrants 2023-1 (Warrants) Issuance Agreement (the “Issuance Agreement”) governing Partner Warrants 2023-1.


THE PARTIES AGREE AS FOLLOWS:


Title 1. SUBSCRIPTION AND FEATURES OF Partner Warrants 2023-1


Article 1. Holders of Partner Warrants 2023-1

The Holder is a physical person or legal entity having an effective contractual relationship – on the basis of a services contract duly signed - with Sequans Communications at the date an offer of subscription of Partner Warrants 2023-1 is made pursuant to this Issuance Agreement.

Holders are approved by the Company's Board of Directors.








Article 2. Grant and subscription of Partner Warrants 2023-1.

The Partner Warrants 2023-1 offered to the Holders shall be subscribed at the price of 0.00002 Euro per Partner Warrant 2023-1, price which shall be paid on subscription, either by means of a payment in cash or by way of a set-off with a debt owed by the Company to Holder.

The number of Partner Warrants 2023-1 granted to each Holder shall be indicated in an Individual Notification Letter sent to him/her by the Chairman or his delegate (including the Company’s on-line equity plan administrator); the subscription of such Partner Warrants 2023-1 shall be done no later than 7 days from the receipt of the aforesaid letter, by returning to the Company

(i) a copy of this Issuance Agreement,
(ii) a copy of the Individual Letter of Notification, and
(iii) the Partner Warrants subscription form duly signed

being specified that all such copies shall be duly executed by the Holder who acknowledges that the Individual Letter of Notification is part of these Issuance Agreement. Alternatively, the acknowledgement can be accomplished by responding to the electronic acknowledgement request from the Company’s on-line equity plan administrator.

Failure to comply with this major formality within the applicable period – except in the event of Force Majeure - shall render the Partner Warrants 2023-1 issued immediately and automatically null and void.


Article 3. Features and period of validity of Partner Warrants 2023-1 – Vesting period -- Conditions of exercise

Partner Warrants 2023-1 are valid for a period of 10 years as from the time they are granted by the Board of Directors, and provided they are subscribed for by the Holder.

Partner Warrants 2023-1 may only be exercised within the aforementioned maximum period of 10 years; any Partner Warrants 2023-1 not exercised by the expiry of such period shall automatically become null and void.

The Beneficiary acquires the right to exercise his/her Partner Warrants 2023-1 at the rate of 1/24th of the total grant amount per month for the 24 months following the effective grant date of such Partner Warrants 2023-1 (the “Vesting Period”).

Exercising a Partner Warrants 2023-1 entitles the Holder to purchase one new ordinary share with a par value of EUR 0.01 (hereafter a "Share") in consideration of the payment of the Exercise Price described in Article 5.

This number of shares cannot be modified during the Partner Warrants 2023-1 period of validity, except in the event of an adjustment in the Exercise Price - as defined under article 11 below - in accordance with the requirements provided by law.


Article 4. Cessation of Holder's contractual relationship with Sequans Communications or one of its subsidiaries - Exceptions

In the event of a termination, anticipated or not, of the Holder's services contract with Sequans Communications or one of its subsidiaries, regardless of the reason, said Holder shall lose any and all rights with regard to Partner Warrants 2023-1 not yet vested and exercisable on the date of the aforesaid termination.

However, the Holder retains the right to exercise Partner Warrants 2023-1 that are vested and that have not yet been exercised.

Notwithstanding the above and in the event of :

death of the Holder, his heirs or beneficiaries shall have a period of 6 months to exercise vested Partner Warrants 2023-1. After the expiry of this 6-month period hereinabove, said heirs or beneficiaries shall lose all rights with regard to unexercised Partner Warrants 2023-1,

2nd and 3rd category disability, within the meaning of article L.341-4 of the French Social Security Code - or an equivalent foreign social security regime - Holders may preserve their right to exercise their Partner Warrants 2023-1 which are vested and exercisable, but they will remain subject to the other conditions of this Plan.



Termination following an acquisition of Sequans Communications: in the event that a third party acquires a majority interest in Sequans Communications, the Partner Warrants awarded to a Holder whose contract with Sequans Communications is subsequently terminated within six months of the acquisition, other than for cause as defined in the contract, shall vest immediately upon the date of contract termination as a result of said termination, and shall have the right to exercise all of his/her Partner Warrants within a period of 30 days following the date of said termination, notwithstanding the schedule set out above for exercising his/her Partner Warrants.


Article 5. Setting of the Exercise Price for shares covered by the Partner Warrants 2023-1

The Exercise Price for Shares to be issued pursuant to an exercise of the Partner Warrants 2023-1 is set at the closing price of the Sequans Communications share, represented by ADS listed on the NYSE, adjusted to reflect the then current ratio of shares per ADS, on the effective grant date of such Partner Warrants 2023-1.

This price is mentioned in the Individual Notification Letter, price which may not be changed during the Partner Warrants 2023-1 period of validity, except in the event of adjustments in accordance with statutory and regulatory requirements.

The Exercise Price is set in USD per share; the counter value in Euros shall be determined on the exercise date of the Partner Warrants. The par value of each share is EUR 0.01.




Title 2. RIGHT OF EXERCISE – SUSPENSION – FORMALITIES – SHARES SUBSCRIBED


Article 6. Suspension of the rights to exercise Partner Warrants 2023-1

If necessary, the Board of Directors may suspend the right to exercise the Partner Warrants 2023-1. In particular, a suspension may be ordered whenever a transaction concerning Sequans Communications' share capital requires knowing in advance the exact number of shares that make up share capital or in the event that one of the financial transactions requiring an adjustment is carried out.

In such case, Sequans Communications shall inform the Beneficiaries of the Partner Warrants 2023-1, indicating the date of the suspension and the date on which the right to exercise Partner Warrants 2023-1 will be re-established. Such suspension may not exceed 3 months.

If the right to exercise a Partner Warrants 2023-1 expires during a period in which rights are suspended, the period for exercising the Partner Warrants 2023-1 shall be extended by the length of the suspension period.


Article 7. Conditions of exercise of Partner Warrants 2023-1

All requests for exercising Partner Warrants 2023-1, documented by the signature of an exercise certificate specific to this Partner Warrants 2023-1 Issuance Agreement, shall be sent to Sequans Communications, and shall be accompanied by a cheque made out to the Company's order in an amount corresponding to the number of Shares subscribed multiplied by the Exercise Price, considering that such shares must be fully paid up in cash at the time of exercise, except the case of settlement of the Exercise Price by way of a set-off with a debt.

If the Holder has been registered in the on-line equity management system established by the Company, exercise of Partner Warrants 2023-1 shall take place in accordance with the process manual provided to the Holder and/or available from the Company’s human resources department.

Failure to fully pay the Exercise Price renders the exercise null and void.





Article 8. Delivery and form of shares

Shares acquired by exercising Partner Warrants 2023-1 are registered in the books of Sequans Communications as registered shares.


Article 9. Rights and availability of shares

The Shares shall be subject to all provisions of the by-laws and shall enjoy all rights pertaining to ordinary shares as from the date the increase in share capital is completed.

However, since the Shares in the form of ADSs are listed for trading on the New York Stock Exchange and in order to avoid any insider trading risk, Holders shall comply with the Insider Trading Compliance Policy of the Company, available on the Company's intranet and website, and/or from the human resources department.



Title 3. REPRESENTATION OF HOLDERS – PROTECTION –
AMENDMENT OF THE ISSUANCE AGREEMENT


Article 10. Representation of Holders of Partner Warrants

Pursuant to the provisions of Article L. 228-103 of the French Commercial Code, the Holders of Partner Warrants 2023-1 are grouped into a body with legal personality protecting their joint interests (the "masse"). General meetings of Holders may meet at the registered office or in any other location of the department of the registered office or of bordering departments.

The masse will appoint one or more representatives of the body, if requested by the Board of Directors. The representative(s) of the masse will be governed by applicable legal and regulatory provisions. The representative of the masse will receive no remuneration for his duties.


Article 11. Protection of Holders – Rights of the Company

11.1 Holders will enjoy the protection reserved by law and regulations for holders of securities giving access to the capital. The Company will provide the Holders, or their representative, with the information set out by the law and regulations.

11.2 During the entire period of validity of the Partner Warrants 2023-1, the Company will have the option of changing its form or object, without obtaining prior authorisation from the Holders of Partner Warrants 2023-1. In addition, the Company shall be entitled to change the rules for distributing profits, write down its capital, or create preferred shares entailing such modification or writing down, subject to the prior authorisation to be delivered pursuant the terms of Article L. 228-103 of the French Commercial code and provided that the Company accordingly complies with applicable legal and/or regulatory provisions.

11.3 Subject to the powers expressly reserved by law for the general meeting of shareholders and, as the case may be, for the general meeting and for the representative of the body of Holders, the Board of directors will be empowered to take either of the measures relating to the protection and adjustment of the rights of Holders as provided for under paragraphs 1°, 2° or 3° of Article L. 228-99 of the French Commercial Code.




11.4 The Issuance Agreement and the conditions for the grant, subscription or exercise of equity securities determined at the time of the issuance may only be amended by the extraordinary general meeting of shareholders of the Company, with the authorisation of the Holders obtained under the conditions provided for by law, in particular by Article L. 228-103 of the French Commercial Code.


Article 12. Binding effect – Term – Jurisdiction

12.1 The Holders are automatically subject to this Issuance Agreement through the subscription of Partner Warrants 2023-1.

12.2 This Issuance Agreement becomes effective on the date of effective subscription of the Partner Warrants 2023-1 and ends on the first of the following dates: (a) the expiry date of the Partner Warrants 2023-1, (b) the date on which all the Partner Warrants 2023-1 have been exercised or forfeited. In addition, it will cease to be binding on each Partner Warrant 2023-1 Holder on the date on which such holder ceases to hold any Partner Warrants 2023-1.

12.3 This Issuance Agreement is subject to French law. Any dispute relating to this Issuance Agreement or relating to the application of the terms and conditions of the Partner Warrants 2023-1 will be referred to the relevant court of the district of the Cour d’appel (Court of Appeal) of the registered office of the Company.





SEQUANS COMMUNICATIONS ______________________________



____________________________ ______________________________

(the "Holder"")


(The Holder shall initialize each page, sign the last page and write down: "read and approved")





EX-4.2 4 exhibit42z-directorwarrant.htm EX-4.2 DIRECTOR WARRANTS ISSUANCE AGREEMENT Document


Director Warrants Issuance Agreement



Director Warrants Issuance Agreement



Dated June 27, 2023

(1) SEQUANS COMMUNICATIONS S.A. (the “Company”)

(2) THE HOLDER OF DIRECTOR WARRANTS

Summary





PREAMBLE: PRESENTATION OF THE ISSUANCE AGREEMENT


Title 1. SUBSCRIPTION AND FEATURES OF DIRECTOR WARRANTS

Article 1.     Holder of Director Warrants
Article 2.    Allotment and subscription of Director Warrants
Article 3.    Features and period of validity of Director Warrants – Conditions of exercise
Article 4.     Setting of the subscription price for shares covered by the Director Warrants
Article 5.     Termination of the mandate of non-executive Board Member of the Company -Exceptions

Title 2. RIGHT OF EXERCISE – SUSPENSION – FORMALITIES – SHARES SUBSCRIBED

Article 6. Suspension of the rights to exercise the Director Warrants
Article 7. Conditions of exercise of Director Warrants
Article 8. Delivery and form of shares
Article 9. Rights and availability of shares

Title 3. REPRESENTATION OF HOLDERS - Protection – AMENDMENT OF THE ISSUANCE AGREEMENT

Article 10. Representation of Holders
Article 11. Protection of Holders – Rights of the Company
Article 12. Binding effect – Amendment of the issuance agreement – Term – Jurisdiction






WHEREAS:

In a decision taken on June 27, 2023, a combined general shareholders' meeting (the "CGM") of the Company voted in favour of the issuance of a total number of 1,260,000 stock warrants (“Director Warrants”), at a subscription price of 0,00001 euro per Director Warrants (i.e. 1.80 euros for 180,000 Director Warrants), allocated as follows:

- Mr. Wesley Cummins     180,000 Director Warrants
- Mr. Yves Maître     180,000 Director Warrants
- Ms. Maria Marced Martin     180,000 Director Warrants
- Mr. Richard Nottenburg     180,000 Director Warrants
- Mr. Hubert de Pesquidoux     180,000 Director Warrants
- Mr. Dominique Pitteloud     180,000 Director Warrants
- Mr. Zvi Slonimsky     180,000 Director Warrants

Each Director Warrant subscribed gives the Holder the right to purchase one ordinary share of the Company at a fixed exercise price.

The CGM delegated to the Board of Directors the power (i) to record the exercise price equal to the closing market value on the issuance date of the Director Warrants, (ii) to ascertain the completion of the capital increase relating to the subscription of the Director Warrant, (iii) increase share capital by a maximum nominal amount of €12,600 with respect to 1,260,000 Director Warrants, and subsequently (iv) to record the successive increases in share capital as a result of the exercise of the Director Warrants, and to carry out all formalities required as a result thereof.

The Board of Directors, in their meeting of June [●], 2023, did record the exercise price and ascertain the increase of the share capital.

The CGM, having eliminated the preferred subscription right of shareholders to the Director Warrants, fully reserved subscription of these Director Warrants for the subscribers designated by the CGM.

The purpose of this Director Warrants issuance agreement (the “Issuance Agreement”) is to define the terms and conditions governing the Director Warrants issued to each Holder with a vesting period.

The parties AGREE AS FOLLOWS


Title 1. SUBSCRIPTION AND FEATURES OF Director Warrants

Article 1. Holder of Director Warrants

The Holder is a physical person being a non-executive member of the Company's Board of Directors, designated by the CGM.

The number of Director Warrants allocated to each Holder is 180,000, as provided in the recitals.




Article 2. Allotment and subscription of Director Warrants.

The Director Warrants proposed to the Holders shall be subscribed at the price of 0.00001 euro per Director Warrant (i.e. 1.80 euros for the 180,000 Director Warrants allotted to each Holder), price which shall be paid on subscription, either by mean of a payment in cash or by way of a set-off with a debt.

The number of Director Warrants allotted to Holder shall be indicated in an Individual Notification Letter sent to him/her by the Chairman; the subscription of such shall be done no later than 10 days from the receipt of the aforesaid letter, by returning to the Company

- the Director Warrants subscription form duly signed,
- as well as a copy of this Issuance Agreement attached to said letter, after the Holder has duly executed said copies.

Failure to comply with this major formality within the applicable period – except in the event of Force Majeure - shall render the Director Warrants issued immediately and automatically void.


Article 3. Features and period of validity of Director Warrants – Conditions of exercise

Provided they are subscribed for by the Holder, Director Warrants are granted for a period of 10 years as from June 27, 2023, date of their issuance by the CGM.

Director Warrants will vest on the first anniversary of their issuance, i.e. June 27, 2024, provided that the Holder still is a Director or is a member of the Strategic Advisory Board on that date (the “Vesting Period”), and must be exercised within the aforementioned maximum period of 10 years. For the sake of clarity, the Holder is entitled to exercise at any time and without restriction all or part of his/her fully vested Director Warrants as from June 27, 2024 until June 27, 2033 as documented in the Individual Notification Letter.

Exercising a Director Warrant entitles the Holder to subscribe for one ordinary share of the Company’s share capital.

This number of shares cannot be modified during the Director Warrants period of validity, except in the event of an adjustment in the subscription price and any other adjustments in accordance with applicable laws and regulations.

Any Director Warrant that is not exercised by the expiry of the aforementioned 10-year period shall be null and void.

Article 4. Setting of the exercise price for shares covered by the Director Warrants

The CGM decided that the exercise price for shares to be issued pursuant to an exercise of the Director Warrants shall be equal, based on the current share/ADS ratio, to 1/4th of the closing price on the New York Stock Exchange of a Company ADS on June 27, 2023.




This subscription price – with respect to this Director Warrants Issuance Agreement - is set in the amount of USD [●] per share (ADS); the counter value in Euros shall be determined on the exercise date of the Director Warrants. The par value of each share is EUR 0.01.

This price may not be changed during the Director Warrants period of validity, except in the event of adjustments in accordance with applicable laws and regulations.

Article 5. Termination of the mandate of non-executive Board member of the Company - Exceptions

5.1 In the event the Holder no longer holds his/her mandate as non-executive Board member of the Company on the first anniversary of issuance, the Holder shall lose any and all rights with regard to his/her Director Warrants which shall all become null and void, subject to clause 5.2.

5.2 In the event the Holder, whose mandate as non-executive Board member of the Company is terminated for whatever reason, is appointed member of the Strategic Advisory Board on or before the date of termination of the aforesaid mandate, all rights with regard to his/her Director Warrants shall remain in force as if the Holder was a Board member of the Company.

In the event the Holder no longer holds his/her position as member of the Strategic Advisory Board on the first anniversary of issuance, the Holder shall lose any and all rights with regard to his/her Director Warrants which shall become null and void.

5.3. Notwithstanding the provisions of article 5.1 and 5.2 above,

in the event of death of the Holder, all Director Warrants subscribed by the Holder and not yet exercisable would nevertheless become exercisable by his/her heirs or beneficiaries from the effective death date, notwithstanding the Vesting Period set forth under article 3 above, allowing said heirs or beneficiaries to exercise any and all remaining Director Warrants, provided that such exercise occurs within a period of 6 months following the aforesaid death.

should the Company be subject to an acquisition by a third party, all Director Warrants subscribed by the Holder and not yet exercisable would nevertheless become exercisable from the effective date of such change of control, notwithstanding the Vesting Period set forth under article 3 above, allowing said Holder to exercise any and all remaining Director Warrants, provided that such exercise occurs within a period of 90 days following the aforesaid acquisition.



Title 2. RIGHT OF EXERCISE – SUSPENSION – FORMALITIES – SHARES SUBSCRIBED

Article 6. Suspension of the rights to exercise Director Warrants

If necessary, the Board of Directors may suspend the right to exercise the Director Warrants. In particular, a suspension may be ordered whenever a transaction concerning the Company’s share capital requires knowing in advance the exact number of shares that make up share capital or in the event that one of the financial transactions requiring an adjustment is carried out.




In such case, the Company shall inform the Holders of the Director Warrants, indicating the date of the suspension and the date on which the right to exercise Director Warrants will be re-established. Such suspension may not exceed 3 months.

If the right to exercise a Director Warrant expires during a period in which rights are suspended, the period for exercising the Director Warrants shall be extended by 3 months.

Article 7. Conditions of exercise of Director Warrants

All requests for exercising Director Warrants, documented by the signature of the corresponding subscription certificate, shall be sent to the Company, and must be accompanied by a cheque or a money transfer made out to the Company's order in an amount corresponding to the number of shares subscribed. Alternatively, Director Warrants may be exercised via any on-line equity incentives system which may be put in place by the Company.

Shares subscribed must be, at the time of subscription, either fully paid up in cash or by way of a set-off with a debt. Failure to do so renders the subscription of shares null and void.

Article 8. Delivery and form of shares

Shares acquired by exercising Director Warrants are registered in the books of the Company as registered shares.

Article 9. Rights and availability of shares

The ordinary shares shall be subject to all provisions of the by-laws and shall enjoy all rights pertaining to shares of such class as from the date the increase in share capital is completed.

These shares shall be immediately transferable.


Title 3. REPRESENTATION OF HOLDERS – PROTECTION – AMENDMENT OF THE ISSUANCE AGREEMENT

Article 10. Representation of Holders of Director Warrants

Pursuant to the provisions of Article L. 228-103 of the French Commercial Code, the Holders of Director Warrants are grouped into a body with legal personality protecting their joint interests (the "Masse"). General meetings of Holders meet at the registered office or in any other location of the department of the registered office or of bordering departments.

The Masse will appoint one or more representatives of the body, at the request of the Board of Directors. The representative(s) of the Masse will be governed by applicable legal and regulatory provisions. The representative of the masse will receive no remuneration for his/her duties.





Article 11. Protection of Holders – Rights of the Company

11.1 Holders will enjoy the protection reserved by law and regulations for holders of securities giving access to the capital. The Company will provide the Holders, or their representative, with the information set out by the law and regulations.

11.2 During the entire period of validity of the Director Warrants, the Company will have the option of changing its form or object, without obtaining prior authorisation from the Holders of Director Warrants. In addition, the Company shall be entitled to change the rules for distributing profits, write down its capital, or create preferred shares entailing such modification or writing down, subject to the prior authorisation to be delivered pursuant the terms of Article L. 228-103 of the French Commercial code and provided that the Company accordingly take the measures necessary to maintain the rights of the Holders, in compliance with applicable legal and/or regulatory provisions.

11.3 Subject to the powers expressly reserved by law for the general meeting of shareholders and, as the case may be, for the general meeting and for the representative of the body of Holders, the Board of directors will be empowered to take any measure relating to the protection and adjustment of the rights of Holders as provided for by the law and regulations, in particular by Article L. 228-99 of the French Commercial Code.

11.4 The Issuance Agreement and the conditions for the subscription or allotment of equity securities determined at the time of the issuance may only be amended by the extraordinary general meeting of shareholders of the Company, with the authorisation of the Holders obtained under the conditions provided for by law, in particular by Article L. 228-103 of the French Commercial Code.


Article 12. Binding effect – Amendment of the issuance agreement – Term – Jurisdiction

12.1 The Holders are automatically subject to this Issuance Agreement, through this subscription or acquisition of Director Warrants.

12.2 This Issuance Agreement becomes effective on the date of effective subscription of the Director Warrants and ends on the first of the following dates: (a) the expiry date of the Director Warrants, (b) the date on which all the Director Warrants have been exercised or waived. In addition, it will cease to be binding on each Director Warrant Holder on the date on which such holder ceases to hold any Director Warrants.

12.3 This Issuance Agreement is subject to French law. Any dispute relating to this Issuance Agreement or relating to the application of the terms and conditions of the Director Warrants will be referred to the relevant court of the district of the Cour d’appel of the registered office of the Company.


SEQUANS COMMUNICATIONS _________________________


Mr/Ms.__________________________ ______________________________

(the "Holder"")
(The Holder shall initialize each page, sign the last page and write down: "read and approved")

EX-4.3 5 exhibit43i-restrictedshare.htm EX-4.3 REGISTRATION RIGHTS AGREEMENT Document

SEQUANS COMMUNICATIONS

Société anonyme au capital de 2 330 932,50 euros
Siège social : Les Portes de la Défense, 15-55 boulevard Charles de Gaulle - 92700 COLOMBES
RCS Nanterre 450 249 677




Regulations
______________________

Restricted Share Award Plan – 2023-1






- CONTENTS -




A.GENERAL PRINCIPLE OF RESTRICTED SHARE AWARDS

A.LEGAL FRAMEWORK OF THE PLAN

A.CHARACTERISTICS OF THE RESTRICTED SHARE AWARDS

A.CONDITIONS FOR THE RESTRICTED SHARE AWARDS AND BENEFICIARIES' RIGHTS

Vesting
Presence condition – Exceptions
Delivery of the Shares – Listing
Rights of the Shares after the Vesting Period – Holding Period
Adjustment
Reduction of Beneficiaries' rights in case of a capital decrease due to losses

A.TAX PROVISIONS

A.AMENDMENT OF THE PLAN



I – GENERAL PRINCIPLES OF RESTRICTED SHARE AWARDS

The purpose of this plan is to reward and retain employees and/or company executive officers (hereinafter the "Beneficiaries") of Sequans Communications (hereinafter "Sequans" or the "Company") and its subsidiaries within the meaning of Article L.233-3, 1° of the French Commercial code (hereinafter the "Subsidiaries") by enabling them to share in the growth of the Company.




A restricted share award plan allows the Beneficiaries to receive over time free ordinary shares of Sequans (hereinafter the "Award"), subject to certain temporary restrictions. i.e. the restricted shares (hereinafter referred to as the “Shares”).

The Award of the Shares is an offer reserved to the Beneficiaries restrictively designated by the Board of Directors and consequently does not represent an offer made to the public.

Beneficiaries are reminded that the change in the price of the Sequans’ shares and, consequently, the acquisition capital gain and the potential sale capital gain obtained through the sale of the Shares after the end of the Vesting Period, will depend on Sequans' performance and results, as well as overall industry and external economic factors.

Nothing in this Plan forms part of the employment contract of a Beneficiary. The rights and obligations arising from the employment relationship between the Beneficiary and the Company or its Subsidiaries are separate from, and are not affected by, this Plan. Participation in the Plan does not create any right to, or expectation of, continued employment.


II – LEGAL FRAMEWORK OF THE PLAN

This plan is governed by French legal and regulatory provisions in effect on the date hereof and namely by articles L.225-197-1 et seq. of the French Commercial Code.

Pursuant to these provisions, the Company's combined general shareholders' meeting held on 27 June 2023 adopted a resolution authorising the principle of the award of Shares, deciding that the maximum number of Shares which may be issued by virtue of this authorisation shall not exceed 12,000,000 new ordinary shares with a unitary par value of EUR 0.01.

This combined general shareholders' meeting has delegated to the Board of Directors the authority to allocate these Shares, on one or more occasions, including the authority to determine the Beneficiaries. No Share can be awarded to any employee who owns more than 10% of the share capital of the Company or who would own more than 10% of the share capital as a result of the Award.

Therefore and pursuant to the aforesaid grant of authority, at a meeting held on 27 June 2023, the Board of Directors decided the procedures applicable to Shares Awards and established the present Restricted Shares Award Plan 2023 (hereinafter the "Plan"), in conformity with the principles set by the combined general shareholders' meeting and aforesaid statutory provisions.


III – CHARACTERISTICS OF THE RESTRICTED SHARE AWARD

The list of the Plan's Beneficiaries is established and approved by the Company's Board of Directors as well as the decision to grant Shares. The Shares allocated to the Beneficiaries shall either be existing shares owned by the Company or new shares to be issued.

This Plan provides for the issuance of up to 12,000,000 Shares.

The effective date of the decision of Award taken by the Board of Directors (the “Grant Date”) shall mark the commencement of the Vesting Period.

Beneficiaries will be individually notified of the Award by the CEO acting through a delegation of the Board of Directors, directly or via notification by email from the Company’s external equity plan administrator (hereinafter the "Individual Letter of Notification").

Such Individual Letter of Notification is deemed to be an exhibit of this Plan and shall specify:

the number of Shares granted to the Beneficiary,
the term of the Vesting Period,
the manner of vesting over the Vesting Period, and
the right to accept or refuse the Award of Shares through a receipt confirmation form that must be returned to the Company.




Within a period of thirty (30) days following the receipt of the Individual Letter of Notification, the Beneficiary undertakes to return to the Company a copy of this Plan, a copy of the Individual Letter of Notification and the receipt confirmation form attached to said letter, being specified that all such copies shall be duly executed by the Beneficiary who acknowledges that the Individual Letter of Notification is part of this Plan. Alternatively, the Beneficiary may acknowledge the Notification and terms of the Plan via the on-line platform administered by the Company’s equity plan administrator.


IV – CONDITIONS FOR THE RESTRICTED SHARE AWARD AND BENEFICIARIES' RIGHTS

IV-1. Vesting

The Shares are effectively vested and acquired by the Beneficiaries over a period of four (4) years from the date of the Award by the Board of Directors (the "Vesting Period") provided that the Award conditions established by the Board of Directors in this Plan are observed on each Vesting Date as defined hereafter. Each Beneficiary is expressly informed that no Shares shall vest before the end of a minimum vesting period (the “Minimum Vesting Period”). The manner in which the Shares Vest over the Vesting Period shall be in accordance with either Option 1 or Option 2, depending on the tax jurisdiction applicable to the given Beneficiary :

Option 1 : if a Beneficiary is not resident in a jurisdiction where taxes on Shares are due when the Shares vest, the following vesting process shall apply:

- 25% of the Award shall be acquired (vest) on the one-year anniversary of the Award date;
- thereafter, an additional 1/12th of the remaining 75% of the Award shall be acquired (vest) on the corresponding day of each three month period thereafter (i.e. quarterly vesting), such that 100% of the Award has vested by the 4th anniversary of the Award date.

Option 2 : if a Beneficiary is resident in a jurisdiction where taxes on Shares are due when the Shares vest, the following vesting process shall apply:

- 50% of the Award shall be acquired (vest) on the two-year anniversary of the Award date;
- thereafter, an additional 1/8th of the remaining 50% of the Award shall be acquired (vest) on the corresponding day of each three month period thereafter (i.e. quarterly vesting), such that 100% of the Award has vested by the 4th anniversary of the Award date.

The Beneficiaries become owners of the Shares, with all related rights as described in section IV-4, only as the Shares are vested (hereinafter the "Vesting Date"), subject to the vesting conditions referred to above and the presence condition defined below under section IV-2 are met.

The application of Option 1 or Option 2 to each Beneficiary shall be determined by the Board on the Grant Date and shall not change regardless of any change in the Beneficiaries tax residence.

IV-2. Presence condition – Exceptions

The Award of Shares to Beneficiaries is strictly related to the Beneficiary’s status as an employee of Sequans or its Subsidiaries. The Vested Award of Shares is consequently reserved for any Beneficiary (employee) designated at the time of the initial Award, linked to Sequans or to a Subsidiary through an employment agreement still in effect on the Vesting Date.

In case of termination of the employment agreement of the Beneficiary, for any reason whatsoever, effective before the Vesting Date, the Beneficiary will lose any right to the related Shares.

Notwithstanding the above provisions, should the loss of the status as an employee during the Vesting Period be due to one of the following reasons, the granted Shares would be treated as follows:

Death: pursuant to the provisions of article L.225-197-3 of the French Commercial Code, the heirs (“héritiers”) of the Beneficiaries, may, if they so desire, request the Award of the Shares. Such request must be made within six (6) months of the date of death; after such time limit, the successors or beneficiaries of the Beneficiary will definitively lose the right to request the Award of Shares. All Shares shall vest immediately upon the aforesaid request, being specified that in such case the Acquisition Period and Holding Period (as referred to under section IV-1 below) shall not apply. The heirs of the Beneficiaries remain subject to the other conditions of this Plan, except the retention requirement described in IV-4.




2nd and 3rd category disability, within the meaning of article L.341-4 of the French Social Security Code: Upon the request of the Beneficiaries, all Shares shall vest immediately, being specified that in such case the Acquisition Period and Holding Period (as referred to under section IV-1 below) shall not apply. Beneficiaries will remain subject to the other conditions of this Plan, except the retention requirement described in IV-4.

Termination following an acquisition of Sequans Communications: in the event that a third party acquires a majority interest in Sequans Communications, the Restricted Shares awarded to a Beneficiary who is subsequently dismissed within six months of the acquisition, other than for misconduct or gross negligence, shall vest immediately upon the date of employment contract termination as a result of said dismissal, unless the contract termination date is less than one year from the Grant Date. In this latter case, all Restricted Shares shall then vest one year from the Grant Date. The retention requirement described in IV-4 remains in force.

IV-3. Delivery of Shares upon Vesting – Listing

At the Vesting Date and subject to the observance of the presence condition defined above, the Company shall transfer the number of granted Shares to the Beneficiary who shall thus become the owner of such Shares and a shareholder of the Company.

The Shares shall be registered in an account opened in the name of the Beneficiary, in the registers of Sequans Communications.

The new Shares issued for the purpose of the Plan will be subject to an application for admission for trading on the New York Stock Exchange, under the form of American Depositary Shares (ADS).

IV-4. Rights of the Shares after the Vesting Date – Holding Period

After the Vesting Date, the Shares shall entitle the Beneficiary, as of the Vesting Date, to all rights pertaining to ordinary shares comprising the share capital and shall be subject to all provisions of the by-laws.

Notwithstanding the foregoing, French law requires that the Shares be retained for a minimum period of two years from the Grant Date. Therefore, all Shares vested before the second anniversary date of the Award by the Board of Directors must be retained until the second anniversary date of the Award by the Board of Directors (the “Holding Period”). No Holding Period is required for Shares vested as from the second anniversary date of the Award by the Board of Directors. However, the shares may be subject to transfer or resale restrictions as required by applicable securities laws.

Furthermore, since these Shares, in the form of American Depositary Shares, are listed for trading on the New York Stock Exchange and in order to avoid any insider trading risk, Beneficiaries shall comply with the Insider Trading Compliance Program of the Company, available from the Human Resources department.

IV-5. Adjustment

Should the Company complete one of the financial transactions referred to under article L.225-181 of the French Commercial Code, no adjustment of the number of allocated Shares under this Plan shall be made, except if the general shareholders meeting voting the transaction decides otherwise.

IV-6. Reduction of Beneficiaries' rights in case of a capital decrease due to losses

In case of a capital decrease due to losses realized by a decrease either in the par value of Sequans shares or in the number thereof, the rights of the Beneficiaries shall be reduced accordingly as if the Beneficiaries had been shareholders prior to the date on which the capital decrease became final.


V – TAX PROVISIONS

This presentation of tax treatment is provided for informational purposes only. It corresponds to the French legislation in effect as of the date this plan was approved by the Board of Directors.

The Beneficiary shall be responsible for learning about any amendments to the applicable tax treatment and the Company shall have no liability whatsoever in this respect.




V-1. Tax provisions applicable to Beneficiaries who are resident in France from the date of the award up to the sale of the shares and submitted to the French Social Security

1. Gain realised at the time of acquisition (Vested Award)

The portion of the Vested Award, equal to the value of ordinary share at the Vesting Date, which does not exceed EUR 300,000, is subject to:
- individual income tax (impôt sur le revenu): progressive rate up to 45% after application of a 50% rebate on the Vested Award
- social contributions (prélèvements sociaux : CSG, CRDS...) : 17.2%, with 6.8% being deductible for income tax purposes to the extent of the ratio between the amount subject to individual income tax and the amount subject to social contributions (i.e. 50%)
- as the case may be, an exceptional contribution on high income (contribution exceptionnelle sur les hauts revenus): rate of 3% or 4% depending on the amount of income of the tax household

The portion of the Vested Award which exceeds EUR 300,000 is subject to:
- individual income tax (impôt sur le revenu): progressive rate up to 45% (without any rebate)
- social contributions (prélèvements sociaux : CSG, CRDS...) 9.7% (6.8% being deductible for income tax purposes)
- an employee specific contribution (contribution salariale spécifique): 10%
- as the case may be, an exceptional contribution on high income (contribution exceptionnelle sur les hauts revenus): rate of 3% or 4% depending on the amount of income of the tax household

Vested Award is taxable in the year during which the Shares are sold.

2. Gain realised at the time of disposal (Sale Gain)

The Sale Gain, which corresponds to the difference between the sale price of the ordinary share and the value of such share at the Vesting Date, is subject to:
- individual income tax (impôt sur le revenu): flat rate of 12.8%
- social contributions (prélèvements sociaux : CSG, CRDS...): 17.2%
- as the case may be, an exceptional contribution on high income (contribution exceptionnelle sur les hauts revenus): rate of 3% or 4% depending on the amount of income of the tax household

Sale Gain is taxable in the year during which the Shares are sold.

3. Wealth tax

The Impôt sur la Fortune Immobilière (“IFI”) generally applies to real estate assets to the extent that their net value exceeds EUR 1,300,000. Therefore, all other movable assets (tangible assets, shares, life insurance, cash, etc.) are excluded from the tax base, unless their underlying assets (direct or indirect) consist of real estate assets or rights.
The Beneficiaries should not be subject to French IFI in respect of their shareholding in the Company.


V-2. Tax provisions applicable to Beneficiaries who are not resident in France and not submitted to the French Social Security

Beneficiaries who are not resident in France are solely responsible for:

Determining the tax provisions applicable to gains resulting from (i) the acquisition of Shares and, (ii) the disposal of such shares;
Paying all taxes and contributions due as a result.

However, Beneficiaries domiciled abroad might be subject to a French withholding tax in respect of the Vested Award, to the extent of days worked in France over the vesting period.

Sequans Communications and its subsidiaries shall have no obligation to provide advice and/or assistance in this regard.





VI – AMENDMENT OF THIS PLAN

No amendment that could affect the rights of the Beneficiaries may be made to this Plan, without the authorization of the Beneficiaries voting by way of a formal meeting called for this purpose.

This Plan shall prevail in case of conflict of interpretation between the Individual Letter of Notification and the Plan itself.





Date : ______________




_________________________________________
(signature)

M. (name, surname) : _______________________
the "Beneficiary"


(The Beneficiary shall initialize each page, sign the last page and write down: "read and approved")


EX-4.5 6 exhibit45g-warrantagreemen.htm EX-4.5 WARRANT AGREEMENT WITH NOKOMIS Document

NEITHER THE WARRANTS NOR THE SHARES DELIVERABLE UPON EXERCISE OF THE WARRANTS (THE “WARRANT SHARES”) HAVE BEEN OR WILL BE REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL SELECTED BY THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO SEQUANS COMMUNICATIONS..

SEQUANS COMMUNICATIONS

WARRANT AGREEMENT

Nokomis Capital Master Fund, L.P.
P.O. Box 309
Ugland House
Grand Cayman,
KY1-1104,
Cayman Islands
hereinafter referred to as the “Beneficiary

On March 20, 2020, the Beneficiary and SEQUANS COMMUNICATIONS (the “Company”) entered into Amendment No. 1 to Convertible Promissory Note (the “Note”) pursuant to which the Note became due and payable on August 16, 2022 unless, prior to August 16, 2022, the Company elected to extend the maturity date to August 16, 2023 (the “Option”). On August 15, 2022, the Company exercised the Option. On August 15, 2023, pursuant to Section 3.1 of the Note, the Company elected to further extend the maturity date to April 16, 2024 (the “Second Option”).

On July 26, 2022, the board of directors of the Company, using the delegation of competence granted to it by the 15th resolution approved at the shareholders meeting of SEQUANS COMMUNICATIONS held on June 24, 2022, authorized the issuance of warrants to the Beneficiary in accordance with the Note (the “Warrants”).

On July 25, 2023, the board of directors approved the exercise of the Second Option, and on August 15, 2023, the Company exercised the Second Option. As a result, the Warrants have been issued on such date.

For the avoidance of doubt, the present document shall in no event be deemed as the certificate referred to in article R. 211-7 of the French Code monétaire et financier and shall only be deemed, for purposes of French law, to set forth the terms and conditions of the Warrants.





Date of Grant:August 15, 2023
Subscription Price of the Warrants:USD 0 (determined in accordance with article XII of the Note)
Maximum number of ordinary shares1,244,820 (determined in accordance with article XII of the Note)
(the “Warrant Shares”) to be subscribed upon exercise of the Warrants:
1,244,820 (i.e., 1 Warrant Share per Warrant)
Exercise price per Warrant Share:USD 0.8082 (determined in accordance with article XII of the Note)
Term/Expiration date of the Warrants:August 15, 2026

As of the Date of Grant, each ordinary share is exchangeable for 0.25 American Depositary Shares.

Article 1 - Validity of the Warrants

The Warrants will be validly issued as from the date of their subscription by the Beneficiary subject to the conditions precedent that the Beneficiary executes and returns to the Company the subscription form of the Warrants in the form attached as exhibit 1 hereto.

Article 2 - Exercise of the Warrants

2.1     Vesting period

The Warrants may be exercised at any time from their issue date until August 15, 2026.

Any Warrant not exercised on or before August 15, 2026 shall be automatically void.

2.2     Method of Exercise

The Warrants are exercisable by delivery of an exercise notice, in the form attached hereto under exhibit 2 (the “Exercise Notice”), comprising a Warrant Share subscription form (bulletin de souscription) which shall state the Beneficiary’s election to exercise all or parts of the Warrants and the number of Warrant Shares in respect of which the Warrants are being exercised. The Exercise Notice shall be signed by the Beneficiary and shall be delivered in person or by certified mail to the Company or its designated representative or by facsimile message to be immediately confirmed by certified mail to the Company. The Exercise Notice shall be accompanied by the payment of the aggregate exercise price (the “Exercise Price”) of all Warrant Shares being exercised. If the Exercise Price is paid by wire transfer, the Exercise Price will have to be paid on the Company’s bank account at the latest within 10 calendar days following the receipt by the Company of the Exercise Notice. The Warrants being exercised shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the proof of payment of such Exercise Price.



Upon exercise of the Warrants, the Warrant Shares issued to the Beneficiary shall be assimilated with all other ordinary shares of the Company (other than with respect to the obligation to transfer the Warrant Shares only in an “offshore transaction” as that term is defined in Regulation S under the Securities Act or otherwise in a transaction not requiring registration under the Securities Act) and shall be entitled to dividend for the fiscal year during which the Warrant Shares are subscribed and issued.

2.3     Payment of the Warrant Shares

Payment of the aggregate Exercise Price of the Warrant Shares being exercised shall be made, at the election of the Beneficiary, by:

(1) bank wire transfer; or
(2) set off against receivables in accordance with applicable French law; or
(3) any combination of the foregoing methods of payment.

Article 3 - Transfer of the Warrants

The Warrants shall not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities.

Article 4 - Other Terms of the Warrants

In the event of a reduction in the Company’s share capital resulting from losses and implemented through share cancellation, the Beneficiary’s rights regarding the number of shares to be issued upon exercise of its Warrants shall be reduced accordingly, as if the Beneficiary were a shareholder at the time of such reduction in share capital.

In the event of a reduction in the Company’s share capital resulting from losses and implemented through reduction of the Company’s shares par value, the subscription price for the shares issued upon exercise of the Warrants shall not change, and the issuance premium shall be increased in an amount corresponding to the aggregate amount of the reduction of the Company’s shares par value.

In the event of a reduction in the Company’s share capital not resulting from losses and implemented through reduction of the Company’s shares par value, the subscription price of the shares issued upon exercise of the Warrants shall be reduced accordingly.

In the event of a reduction in the Company’s share capital not resulting from losses and implemented through share cancellation, should the Beneficiary choose to exercise its Warrants, it shall be entitled to request the purchase by the Company of a quantum of shares (granted upon exercise of the Warrants) under the same conditions as those set in favor of then existing shareholders when such reduction in the Company’s share capital occurred.

In case of a rights issue, the Company will take one or several of the following decisions to preserve the rights of Warrants holders, in accordance with the provisions of article L. 228-99 of the French commercial code and applicable French and U.S. securities laws:




(1) permit any Warrant holder to exercise his Warrants immediately so that such holder may participate in the rights issue, which will not alter or limit the rights of the Beneficiary to exercise the Warrants under Section 2.1 of this Warrant Agreement; or

(2) take any measures which would allow the Beneficiary, should he decide to exercise the Warrants, to eventually be in the same position as other shareholders as if the Beneficiary were a shareholder at the time of such operations. Should the Beneficiary exercise its Warrants, the Company could thus allow the Beneficiary to subscribe a pro rata share of a new rights’ issue or be the beneficiary of free allocation of shares, or receive cash or goods under the same form, proportion, terms and conditions (except for use) as those set in favor of then existing shareholders when such operations occurred; or

(3) adjust the Warrants’ exercise price, conversion-into-shares ratio or other terms relating to subscription of the Company’s shares in order to take into account the new rights issue. In such case, any such adjustment shall be carried out in accordance with the method set forth in article R. 228-91 of French Commercial Code (Code de commerce), it being specified that the value of an existing shareholder’s right to participate, as well as the value of the share itself (including the right to participate in the rights issue), shall be determined by the board of directors of the Company. The board shall determine such value while taking into account, as the case may be, the subscription, exchange or sale price per share used during the last operation relating to the Company’s share capital (such as any share capital increase, contribution in kind, sale of shares) which occurred during a six (6)‑month period immediately preceding such board of directors’ meeting. In the event no such operation occurred over such period, the board shall take into account any other financial parameter which it finds relevant (and which relevancy shall then be confirmed by the Company’s statutory auditor).

The Company is authorized, without requesting the specific consent of the holder of the Warrants, to modify its corporate form and its corporate purpose.

The Company may amend the rules regarding profit allocation, amortize the share capital and create and issue preferred shares entailing any such modification or amortization without requesting the specific consent of the holder of the Warrants subject to complying with the provisions of Article L. 228-98 of the French Commercial Code.

Article 4 - Governing Law

This agreement is governed by the laws of the Republic of France.

Any claim or dispute arising under this agreement shall be subject to the exclusive jurisdiction of the court competent for the place of the registered office of the Company.

For: NOKOMIS CAPITAL MASTER FUND, L.P.
By:
Title:
For: SEQUANS COMMUNICATIONS
By: Georges KARAM
Title: Président-Directeur Général





EXHIBIT 1
SUBSCRIPTION FORM OF THE WARRANTS















































SEQUANS COMMUNICATIONS

French société anonyme with a share capital of EUR. 1,911,742.92
Registered office: 15-55 Boulevard Charles de Gaulle Les Portes de la Défense, 92700 Colombes


SUBSCRIPTION FORM

Amount and terms of the issuance of the warrant

On March 20, 2020, the undersigned and SEQUANS COMMUNICATIONS (the “Company”) entered into Amendment No. 1 to Convertible Promissory Note (the “Note”) pursuant to which the Note became due and payable on August 16, 2022 unless, prior to August 16, 2022, the Company elected to extend the maturity date to August 16, 2023 (the “Option”). On August 15, 2022, the Company exercised the Option. On August 15, 2023, pursuant to Section 3.1 of the Note, the Company elected to further extend the maturity date to April 16, 2024 (the “Second Option”).

As consideration for the exercise of the Second Option by the Company, the board of directors of the Company has decided to issue 1,244,820 warrants (the “Warrants”), giving the right to subscribe for a maximum number of 1,244,820 ordinary shares (the “Warrant Shares”), each of a nominal value of EUR. 0.01, at a fixed price of USD 0.8082 each (issue premium included), to be fully paid up in cash and/or by way of set off against receivables and the subscription of which has been reserved to the subscriber.

The issuance has been approved by the board of directors of Sequans Communications on July 25, 2023 pursuant to the authorization granted to it by the shareholders’ meeting of June 24, 2022.

The terms and conditions of the Warrants are described in the warrant agreement executed by the subscriber and Sequans Communications on August ___, 2023.

The exercise period is opened from August 15, 2023 to August 15, 2026 included.

—ooOoo—
The undersigned

Nokomis Capital Master Fund, L.P., a Cayman Island partnership, having its registered office at P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands,

acknowledging the terms and conditions of the Warrants, including:

that neither the Warrants nor the Warrant Shares have been, nor will be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the representations below;




and representing and warranting to Sequans Communications as follows:

that it is acquiring the Warrants for investment for its own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof, and that it has no present intention of selling, granting any participation in, or otherwise distributing the same;

that it does not have any contract, undertaking, agreement or arrangement with any person or entity to sell, transfer or grant participation to such person or entity or to any third person or entity with respect to any of the Warrants;

that it is an institutional “accredited investor” as defined in Regulation D, Rule 501(a) under the Securities Act, has such knowledge and experience in financial and business matters so that it is capable of evaluating the merits and risks of its investment in Sequans Communications and it understands and acknowledges that an investment in Sequans Communications is highly speculative and involves substantial risks. It can bear the economic risk of its investment and is able, without impairing its financial condition, to hold the Warrants and the Warrant Shares for an indefinite period of time and to suffer a complete loss of its investment;

that it has had an opportunity to ask questions of, and receive answers from, the officers of Sequans Communications concerning this Warrant Agreement, as well as its business, management and financial affairs, which questions were answered to its satisfaction;

that it believes that it has received all the information it considers necessary or appropriate for deciding whether to receive Warrants. It acknowledges that any future plans and forward looking statements expressed by Sequans Communications are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the future plans and forward looking statements will not materialize or will vary significantly from actual results. It also acknowledges that it is relying solely on its own counsel and not on any statements or representations of Sequans Communications, or any agent or adviser of Sequans Communications for legal advice with respect to the subscription of the Warrants;

that the Warrants are being acquired by it in reliance on a private placement exemption from the registration requirements of the Securities Act and the Warrant Shares are and will be “restricted securities” within the meaning of Rule 144(a)(3) under the Securities Act and that the exemption from registration provided under Rule 144 may not be available for resales by it of the Warrant Shares. Therefore, it further agrees that if it wishes to dispose of or exchange any of the Warrant Shares, it will not transfer any of the Warrant Shares, directly or indirectly, unless such transfer is a transaction that is deemed to occur outside of the United States under Regulation S under the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements, of the Securities Act. The Company may require, as a condition of allowing any transfer, that the holder or transferee of the Warrant Shares, as the case may be, provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be



reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Warrant Shares under the Securities Act;

hereby subscribes the Warrants.

Made in Dallas, TX, USA
On August _____, 2023
In two (2) copies

________________________________
For Nokomis Capital Master Fund, L.P.*
By:
Title:


___________
* the signature shall be preceded by the following handwritten sentence: “Approval for formal and irrevocable subscription of 1,244,820 (one million two-hundred-forty-four-thousand eight-hundred-twenty) Warrants”
































EXHIBIT 2

EXERCISE NOTICE OF THE WARRANTS
(Share Subscription Form)

SEQUANS COMMUNICATIONS
15-55 Boulevard Charles de Gaulle Les Portes de la Défense,
92700 Colombes
France
[—], 202__
Attention: Deborah Choate

Nokomis Capital Master Fund, L.P., a Cayman Island partnership, having its registered office at P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands, holder of 1,244,820 Warrants, each giving right to subscribe for one ordinary share (each a “Warrant Share”) of Sequans Communications (the “Company”) issued pursuant to the resolution of the board of directors of Sequans Communications held on July 25, 2023,

having examined the terms and conditions of the Warrants, including:

that neither the Warrants nor the Warrant Shares have been, nor will be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) by reason of a specific exemption from the registration provisions of the Securities Act and therefore the Warrants and the Warrant Shares are and will be “restricted securities” within the meaning of Rule 144(a)(3) under the Securities Act;

that the exemption from registration provided under Rule 144 may not be available for resales by it of the Warrant Shares;

therefore, it agrees that the Warrant Shares may only be transferred, directly or indirectly, in a transaction that is deemed to occur outside of the United States under Regulation S under the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act; it agrees that the Company may require, as a condition of allowing any transfer, that the holder or transferee of the Warrant Shares, as the case may be, provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Warrant Shares under the Securities Act and that these restrictions have been noted in Sequans Communications’ share registry held by its registrar;

hereby

exercises [______________] Warrants
and



subscribes consequently for [___________] Warrant Shares of Sequans Communications, each of a nominal value of EUR. 0.01, for a subscription price per share of USD 0.8082 share premium included,

pays, for this subscription, the total amount of USD [_______], corresponding to the aggregate of the nominal value and the share premium of the above Warrant Shares,

by wire transfer to Sequans Communications’ bank account opened at [—], Bank Code: [—], Desk Code: [—], Account: [—], Cle RIB: [—], IBAN International Bank Account Number [—].

Made in [—]
On [—], 202___
In two copies

________________________________
For Nokomis Capital Master Fund, L.P.*
By:
Title:
___________
* Signature preceded by: “Approval for formal and irrevocable subscription of [__________] ordinary shares” (number of shares to be mentioned in both figures and letters.)


EX-8.1 7 exhibit81-listofsubsidiari.htm EX-8.1 LIST OF SUBSIDIARIES FY2022 Document


Exhibit 8.1
LIST OF SUBSIDIARIES
 
Name of Subsidiary Jurisdiction
Sequans Communications Ltd. United Kingdom
Sequans Communications Inc. California (United States)
Sequans Communications Ltd. Pte. Singapore
Sequans Communications (Israel) Ltd. Israel
Sequans Communications Finland OyFinland
Sequans Communications SAS (Inactive)France


EX-11.1 8 exhibit111-insidertradingc.htm EX-11.1 INSIDER TRADING POLICY Document



Insider Trading Compliance Program:

Statement of Policies on Trading in Securities


To all Employees, Officers and Directors of Sequans Communications S.A.

Ladies and Gentlemen:

Attached is a copy of Sequans Communications’ Insider Trading Compliance Program Statement of Policies on Trading in Securities. These policies apply to all employees, officers, and directors of Sequans Communications.

As you will see from the attached Statement of Policies, the consequences of improper dealings in securities are devastating, both for the individual and for Sequans Communications. Please take a few minutes right now to read the Statement of Policies and then sign and return the attached copy of this letter to Sequans Communications’ Director of Human Resources, Sophie Jobert (sophie@sequans.com).

If you have any questions about the Statement of Policies or your personal situation, you are encouraged to call me. I can be reached at +33 1 70 72 16 04 or deborah@sequans.com.
Sincerely,

Deborah Choate
Chief Financial Officer

























ACKNOWLEDGMENT

I acknowledge that I have read and understand and agree to comply with the Sequans Communications Statement of Policies on Trading in Securities, a copy of which was distributed with this letter.



Date:___________________________
Signature:_______________________
Name:__________________________
(Please print)






































SEQUANS COMMUNICATIONS S.A.

Insider Trading Compliance Program:

Statement of Policies on Trading in Securities

Sequans Communications S.A. has adopted several policies on trading in securities of Sequans Communications S.A as well as the securities of publicly traded companies with whom we have a business relationship. These policies apply equally to directors and employees of Sequans Communications S.A. and of any additional companies at such time as they are owned by Sequans Communications S.A. (all of which are referred to collectively for convenience as “Sequans Communications” or the “Company”). Please read this document carefully.

Policy Statement No. 1:
(“Insider Trading”)
No member of the Board of Directors, officer, consultant, contractor or employee of Sequans Communications, and no member of the immediate family or household of any such person or any entity affiliated with such person, who has any material non-public information relating to the Company or to any publicly-traded companies with whom the Company does business, may, directly or indirectly, buy or sell securities of the Company or such other companies, pass the information to others for use in trading in securities of the Company or such other companies, or otherwise attempt to take advantage of the information.
Policy Statement No. 2:
(“Window Period”)
Members of the Board of Directors, officers, consultants, contractors and employees of Sequans Communications and any affiliated entity of such person may engage in transactions in Sequans Communications securities only during designated “window” periods unless (1) the transactions are made pursuant to an approved Rule 10b(5)-1 trading plan (a “Trading Plan”) or (2) the sales or dispositions are made in connection with the payment of the exercise price of any option or satisfaction of any tax obligation, withholding obligation or any other required deduction that arises in connection with any equity award granted by the Company. The “window” periods will generally open at the end of the second full trading day following the release of the Company’s quarterly and annual financial results, and close on the earlier of (i) the 10th calendar day of the third month of the Company’s quarter, or (ii) such other date as Sequans Communications shall specify.



Policy Statement No. 3:
(“Pre-clearance”)
Members of the Board of Directors, officers, and certain designated employees (see Appendix A) of Sequans Communications may only engage in trades in the Company’s securities, even during the window periods, after obtaining prior clearance from the Chief Financial Officer or Chief Executive Officer, unless the trades are made pursuant to a pre-approved Trading Plan.

The Chief Executive Officer and Chief Financial Officer may not pre-clear their own stock trades.

Note: Members of the Board of Directors and officers, in addition, are subject to certain volume and other restrictions under Rule 144 of U.S. securities laws. At the time of sale, the director or officer will have to file a Form 144; this is generally handled by the broker making the sale.
Policy Statement No. 4: (“10b5-1 Trading Plans”)Members of the Board of Directors, officers, consultants, contractors and employees of Sequans Communications may engage in stock sales in Sequans Communications securities pursuant to a pre-approved Trading Plan
Policy Statement No. 5:
(“Speculative Transactions”)
No member of the Board of Directors, officer or employee of Sequans Communications or any entity affiliated with such person may, directly or indirectly, engage in any speculative transactions involving the Company’s securities, including short sales, trading in exchange listed options or hedging transactions that insulate the person from the full risks and rewards of ownership of securities of the Company. The Company also prohibits those persons from holding its securities in margin accounts or pledging them as collateral for loans absent prior approval of certain pledges. The Company also strongly discourages short-term trading in the Company’s securities

Questions and Answers About Insider Trading, Window Periods and Pre-clearance

1.What are the consequences for violating the policy?

Although the Company may impose sanctions and discipline, up to and including termination, for failing to comply with these policies, U.S. securities laws provide far more draconian penalties. For individuals who trade on inside information, or tip information to others, the following penalties may apply:

A jail term of up to twenty years;



A civil penalty of up to three times the profit gained or loss avoided; and
A criminal fine (no matter how small the profit) of up to $5 million.

While the authorities generally concentrate their efforts on the individuals who trade, or who tip information to others who trade, U.S. securities laws also impose potential liability on companies and “controlling persons” if they fail to take reasonable steps to prevent insider trading by company personnel. This can include civil penalties of up to the greater of $1 million or three times the profit gained or loss avoided, as well as a criminal penalty of up to $25 million.

2. Why do we need a written policy?

American Depositary Shares (“ADSs”) representing the Company’s ordinary shares trade on the New York Stock Exchange in the U.S. Both the U.S. Securities and Exchange Commission (the “SEC”) and the U.S. Congress are very concerned about maintaining the fairness and integrity of the U.S. securities markets. The securities laws are continually reviewed and amended to prevent people from taking unfair advantage of non-public information and to increase the punishment for those who do. These laws require companies that are publicly traded in the U.S. to have clear policies on insider trading. In addition, Sequans Communications takes seriously its goal of upholding very high standards of ethics and conduct. We wish to avoid even the appearance of improper conduct on the part of anyone employed by, or associated with, the Company. We have worked hard to establish a reputation for integrity and ethical conduct and cannot afford to have it damaged. Needless to say, a violation of law, or even an SEC investigation that does not result in prosecution, can tarnish a person’s reputation and irreparably damage a career.

3. What is “material information”?

Material information is any information that a reasonable investor would consider important in deciding to buy, hold or sell securities. Any information that could reasonably be expected to affect the price of the securities, whether positive or negative, should be considered material. It can be information about the Company or about a company with which we do business. Common examples of material information are:

Projections of future earnings or losses or other earnings guidance
Earnings that are inconsistent with the consensus expectations of the investment community
A pending or proposed merger, acquisition or tender offer or an acquisition or disposition of significant assets
A change in management
Major events regarding the Company’s securities, including a potential stock split or proposed offering of equity or debt securities
New marketing or business announcements of a significant nature
Development of a significant new product or service
The gain or loss of a significant customer or business partner
A change in auditors or notification that the auditor’s reports may no longer be relied upon
Severe financial liquidity problems
Pending or threatened significant litigation, or the resolution of such litigation



A significant change in the Company’s pricing or cost structure

There is no bright-line standard for assessing materiality; rather materiality is based on an assessment of all the facts and circumstances, and it is often evaluated by enforcement authorities with the benefit of hindsight. Because trading that receives scrutiny will be evaluated after the fact and with the benefit of hindsight, questions concerning the materiality of particular information should be resolved in favor of materiality, and trading should be avoided.

4. When is information “nonpublic”?

Information that has not been disclosed to the public is generally considered to be nonpublic information. One common misperception is that material information loses its “nonpublic” status as soon as a press release is issued disclosing the information. In fact, information is considered to be available to the public only when it has been released broadly to the marketplace (such as by a press release issued by the Company or made in an appropriate disclosure filing with the SEC) and the investing public has had time to absorb the information fully.

5. When do the trading window periods begin and end?

The trading window periods will generally open at the end of the second full trading day following the day Sequans Communications has publicly released quarterly financial results for the first, second and third fiscal quarters and annual financial results for the entire fiscal year. For example, if Sequans Communications announced results during the business day on Thursday, the trading window will begin at the end of market trading on Monday. Each of the periods ends on the earlier of (i) the 10th calendar day of the third month of Sequans Communications’ quarter, or (ii) such other date as Sequans Communications may specify. You will be notified of the exact dates for a given quarter by email.

6. Are there any exceptions?

Unfortunately, the SEC and the U.S. courts do not recognize any exceptions to the insider trading rules, even the need to raise immediate cash for personal emergencies such as medical expenses. The policies do not, however, apply to exercises of outstanding options (but do apply to any sales of any ADSs representing shares so purchased or to a cashless exercise of outstanding options through a broker, as this entails selling a portion of the underlying shares of ADSs to cover the costs of the exercise) or to any transactions in which the employee has no control over the timing (such as any exchange of shares pursuant to a merger). The policies also do not apply to any private transactions where there is no real transfer of ownership, such as the transfer of securities into trusts, or any gift transactions. In addition, the policies regarding trading window periods and pre-clearance do not apply to transactions made pursuant to a pre-approved Trading Plan, which is discussed in further detail below, or made in connection with the payment of the exercise price of any stock option or satisfaction of any tax obligation, withholding obligation or any other required deduction that arises in connection with any equity award granted by the Company.






7. Are trades during the trading window periods presumptively OK?

No. Any individual who is actually aware of material non-public information should never trade until the public disclosure is made, even during the trading window periods, unless the trades are made pursuant to a Trading Plan. From time to time we may declare a special “blackout period” and prohibit trading due to material non-public information developments. Such “blackout periods,” however, would not apply to pre-approved Trading Plans.

That is why we have the additional pre-clearance requirement for members of the Board of Directors, executive officers and designated employees, who are most likely to be in possession of any material non-public information.
8. Do I need permission to trade in Sequans Communications securities?

Yes, if you are a member of the Board of Directors, and executive officers or a designated employee (see Appendix A), as these individuals are subject to the additional pre-clearance policy. Because not every member of the Board of Directors or officer will be aware at all times of any material non-public information, the pre-clearance procedure is needed to ensure that no trades are inadvertently made by those persons prior to public disclosure of this material information. In addition, when requesting pre-clearance, we ask that you notify us of the proposed date of the trade and the number of shares or ADSs to be traded, and to make sure that you make the request at least two business days prior to the date that you propose to trade.

9. What can I tell my family members and friends?

You are responsible for ensuring that family members who reside with you (including a spouse, a child, a child away at college, stepchildren, grandchildren, parents, stepparents, grandparents, siblings and in-laws), anyone else who lives in your household, and any family members who do not live in your household but whose transactions in the Company’s securities are directed by you or are subject to your influence or control, such as parents, children or siblings who consult with you before they trade in the Company’s securities, comply with these policies. You are responsible for the transactions of these other persons and therefore should make them aware of the need to confer with you before they trade in the Company’s securities. The SEC and the U.S. courts often view people in the same household as a “unit” and impose penalties accordingly. In addition, any person who possesses material nonpublic information about the Company is an “insider” for so long as the information is not publicly known and must not pass that information on to others intentionally or unintentionally (“tipping”).

You should also be aware that trading in securities by anyone who received any material nonpublic information (including information in the form of a recommendation that they buy or sell securities, even if the exact item is not disclosed) from you, including your relatives, friends, doctor, lawyer or accountant, can result in liability for you, for them and for the Company. This is true whether you told them in the hopes they could trade and make some money, whether you were telling stories over a cocktail, or whether you thought they were under an obligation of confidence to you. It does not matter if you benefit personally from their trading. The U.S. courts are continually broadening this type of liability, resulting in substantial penalties. The SEC, the stock exchanges and FINRA (the Financial Industry Regulatory Authority) use sophisticated electronic surveillance techniques to uncover insider trading, and the SEC has imposed large



penalties even when the disclosing person did not profit from the trading. You should exercise extreme discretion in making any disclosures.

Questions and Answers About 10b5-1 Trading Plans

1. What is an approved 10b5-1 trading plan?

A 10b5-1 trading plan is a contract, instruction or written plan for the purchase or sale of Sequans Communications securities that meets the requirements of SEC Rule 10b5-1 and is approved by our Chief Financial Officer or Chief Executive Officer. An “approved Rule 10b5-1 trading plan” is a plan that has been approved by the Company in writing as being in compliance with the Insider Trading Compliance Program (a “Trading Plan”).

2. What are Sequans Communications’ requirements for 10b5-1 trading plans?

Sequans Communications imposes some requirements on Trading Plans. These limitations are as follows:

The Trading Plan must be in writing and signed by the person adopting the Trading Plan.

The Trading Plan must be established at a time when you do not possess material non-public information about the Company.

The Chief Financial Officer or Chief Executive Officer must approve that the Trading Plan is in compliance with the Insider Trading Compliance Program.

Amendment or modification to the Trading Plan is permissible so long as the amendment or modification is approved by the Chief Financial Officer or Chief Executive Officer; provided, however, any such amendment or modification may not become effective until thirty (30) days has elapsed from the time the amendment or modification to the plan was submitted to our Chief Financial Officer or Chief Executive Officer for approval.

The first trade made pursuant to the Trading Plan may take place no less than thirty (30) days after adoption of the plan, or any amendment or modification to the plan.

The Trading Plan must specify a fixed number of ADSs or shares to be purchased or sold, or specify or set a formula for the amount of ADSs or shares to be purchased or sold, the dates on which the ADSs or shares are to be purchased or sold, and the prices (which can be the market price) at which the ADSs or shares are to be purchased or sold.

Alternatively, a Trading Plan can be adopted that completely delegates to another independent person who is free of any inside information (e.g., a stockbroker) complete discretion, without any influence whatsoever by the person adopting the plan, over the authority as to how, when and whether to sell or purchase ADSs shares.




Trades made under the Trading Plan must be executed by a stockbroker other than the stockbroker that executes trades in other securities for the person adopting the Trading Plan, and the person adopting the Trading Plan acknowledges that, during the term of the Trading Plan, he or she may not confer with the stockbroker executing trades under the Trading Plan regarding Sequans Communications or its securities.

3. What actions are necessary to adopt a plan?

You must provide the proposed 10b5-1 trading plan to the Chief Financial Officer or Chief Executive Officer for confirmation that the proposed plan meets the requirements described in this Statement. It must meet the requirements described in this Statement. Once you obtain Sequans Communications’ approval, you must sign and deliver the Trading Plan to your stockbroker. The Trading Plan must also be filed with the Chief Financial Officer or Chief Executive Officer of Sequans Communications.

Sequans Communications will not review Trading Plans for compliance with Rule 10b5-1, but only for compliance with its internal requirements. You remain individually responsible for compliance with all applicable laws, rules and regulations on insider trading and remain subject to disciplinary action for any violations, regardless of whether a Trading Plan has been adopted.

Sequans Communications strongly recommends that you consult with outside experts before adopting a Trading Plan.

4. I am subject to the trading window period and it is currently closed. May I adopt a Trading Plan while the window is closed?

Trading Plans must be established at a time when you are not in possession of material non-public information. Although there is no specific prohibition on adopting a Trading Plan during a closed trading window, you should carefully consider whether you are in possession of material non-public information. In addition, the first trading under the plan may not occur until 30 days after its adoption.

5. Can I trade outside the Trading Plan?

Yes. You may sell or purchase Sequans Communications securities outside the Trading Plan if such trades are pre-cleared and made during the open window periods and otherwise made in accordance with the Company’s trading policy and applicable law. However, trades outside of the Trading Plan will not have the benefit of a trading plan affirmative defense and must not hedge trades made under the Trading Plan. Furthermore, making trades outside of the plan, especially multiple trades, may suggest that you are trading on material nonpublic information and may weaken the defense for ADSs or shares sold under an established Trading Plan.







6. Will my Trading Plan be publicly disclosed?

It is not currently required that your Trading Plan be publicly disclosed when adopted but the SEC has considered proposed rules to require disclosure of such arrangements. Furthermore, the Company may choose to disclose certain information about your plan and trades in its reports filed with the SEC or otherwise if it feels such disclosure is appropriate for investors.

7. Can I terminate the Trading Plan?

Yes. You may terminate your Trading Plan at any time so long as you promptly provide written notice to the Chief Financial Officer or Chief Executive Officer of Sequans Communications. Note that if you terminate the plan, Sequans Communications will not approve a new Trading Plan for ninety (90) days post termination. You may also want to consider whether your Trading Plan should provide for automatic suspension or termination upon certain events (e.g., an insider’s death or bankruptcy, the announcement of a tender offer for Sequans Communications stock, or a merger).

If you choose to terminate your Trading Plan prior to its expiration date, we encourage you to consider not trading in the Company’s securities for at least ninety (90) days after termination, to help reduce any appearance that you terminated the Trading Plan and subsequently traded because you learned of material nonpublic information.

Questions and Answers About Speculative Transactions

1. What are “speculative transactions” and why shouldn’t I do them?

Certain speculative transactions are of concern not only because of insider trading considerations, but also because of the appearance created by the transaction and the potential repercussions that the transactions may have with investors, regulators and others. Speculative transactions include types of transactions that are commonly viewed as a form of “betting” against the Company or transactions that have the potential to create the wrong focus or send the wrong message. Directors, officers and employees are therefore prohibited from engaging in any short sales of the Company’s shares or ADSs (where you sell securities you do not currently own, in the hope that by the time you have to deliver the market price will have declined) because short sales have the potential to signal to the market that the seller lacks confidence in the Company’s prospects and may reduce the seller’s initiative to improve Company performance. Similarly, given the relatively short term of publicly-traded options, transactions in options may create the appearance that a director, officer or employee is trading based on material nonpublic information and focus a director’s, officer’s or other employee’s attention on short-term performance at the expense of the Company’s long-term objectives. Accordingly, transactions in put options, call options or other derivative securities on any exchange or in any other organized market are also prohibited by this policy.

In addition, hedging or monetization transactions are prohibited. These transactions can be accomplished through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. Such hedging transactions may permit a director, officer or employee to continue to own securities of the Company obtained through option or other equity awards or otherwise, but without the full risks and rewards of ownership. When this



occurs, the person may no longer have the same objectives as the Company’s other security holders.

The Company believes that speculative transactions in Sequans Communications securities such as these reflect badly on the Company.

Securities held in a margin account or pledged as collateral for loan may be sold without your consent by the broker if you fail to meet a margin call or by the lender in foreclosure if you default on the loan. Because a margin or foreclosure sale may occur at a time when you are aware of material nonpublic information or otherwise not permitted to trade in Company securities, you are prohibited from holding Company securities in a margin account or pledging securities as collateral for a loan. An exception to this prohibition may be granted where you wish to pledge securities as collateral for a loan (not including margin debt) and can clearly demonstrate the financial capacity to repay the loan without resort to the pledged securities. If you wish to pledge Company securities as collateral for a loan, you must submit a request for approval by our Chief Financial Officer at least two weeks prior to the proposed execution of documents evidencing the proposed pledge.

2. Am I supposed to hold any stock that I purchase for a particular period of time?
As a general rule, the Company encourages all employees to hold any securities that they purchase in the open market (i.e., not including shares purchased upon exercise of an employee stock option) for at least six months
.
Post-Termination Transactions

These policies continue to apply to transactions in the Company’s securities even after termination of service to the Company. If you are aware of material nonpublic information when you terminate employment or service, you may not trade in the Company’s securities until that information has become public or is no longer material.


Where to go for additional information

Your compliance with these policies is extremely important both for you and the Company. Any person who has any questions about specific transactions or trading plans may obtain additional information from our Chief Financial Officer. Note that the ultimate responsibility for adhering to these policies, however, rests with you. Use your best judgment and act with the Company’s best interests, as well as your own, in mind.

As with all other Sequans Communications policies, officers, directors and certain designated employees must exercise their best judgment and act with the best interests of Sequans Communications in mind.


As adopted on May 1, 2018







APPENDIX A

Name
Position/Department
Georges KARAM
Chairman, CEO
Wes CUMMINS
Director
Hubert DE PESQUIDOUX
Director
Yves MAITRE
Director
Maria MARCED
Director
Richard NOTTENBURG
Director
Dominique PITTELOUD
Director
Zvi SLONIMSKY
Director
Deborah CHOATE
CFO
Bertrand DEBRAY
BU-BBIOT
Louis CHUANG
BU-MIOT
Danny KEDAR
COO
Nick TALUJA
VP WW Sales & Support
VP Engineering
VP Marketing
VP Key Accounts & Carrier Mgt
Sales
[detailed list of restricted positions updated quarterly]
Customer support
BU-BBIOT
BU-MIOT
Engineering
Key Accounts & Carrier Mgt
Operations
Finance
Information Systems
Human Resource
Marketing Communications
Investor Relations
Executive Assistant
Office Assistant
Office Manager


EX-12.1 9 exhibit121ceosoxcertificat.htm EX-12.1 CEO SOX CERTIFICAT Document

Exhibit 12.1
Certification by the Chief Executive Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Dr. Georges Karam, certify that:
 
 1I have reviewed this Annual Report on Form 20-F of Sequans Communications S.A.;
 
 2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
 3Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
 
 4The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
 
 a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 c.Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 d.Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
 
 5The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
 
 a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
 
 b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.
 
 
Date: May 15, 2024


/s/ Dr. Georges Karam
Name: Dr. Georges Karam
Title: Chief Executive Officer

EX-12.2 10 exhibit122cfosoxcertificat.htm EX-12.2 CFO SOX CERTIFICATION - SECTION 302 - FY2022 Document


Exhibit 12.2
Certification by the Chief Financial Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Deborah Choate, certify that:
 
 1I have reviewed this Annual Report on Form 20-F of Sequans Communications S.A.;
 2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
 3Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
 
 4The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
 
 a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 c.Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 d.Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
 
 5The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
 
 a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
 
 b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: May 15, 2024



/s/ Deborah Choate
Name: Deborah Choate
Title: Chief Financial Officer

EX-13.1 11 exhibit131-ceosoxcertifica.htm EX-13.1 CEO SOX CERTIFICATION - SECTION 906 FY2022 Document


Exhibit 13.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Sequans Communications S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Georges Karam, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 
 (1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2024
 
By: /s/ Dr. Georges Karam
 
Name: Dr. Georges Karam
Title: Chief Executive Officer


EX-13.2 12 exhibit132cfosoxcertificat.htm EX-13.2 CFO SOX CERTIFICATION - SECTION 906 FY2022 Document


Exhibit 13.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Sequans Communications S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Deborah Choate, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 
 (1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 15, 2024
 
By: /s/ Deborah Choate
 
Name: Deborah Choate
Title: Chief Financial Officer


EX-15.1 13 exhibit151eyconsentfy2023.htm EX-15.1 AUDITORS CONSENT Document

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1)
Registration Statement (Form S-8 No. 333-187611) pertaining to the Stock Option Subscription Plan, BSA Subscription Plan and BSA (Warrants) Issuance Agreements dated June 26, 2012 of Sequans Communications S.A.,
(2)Registration Statement (Form S-8 No. 333-194903) pertaining to the Stock Option Subscription Plan and BSA (Warrants) Issuance Agreements dated June 25, 2013 of Sequans Communications S.A;
(3)
Registration Statement (Form S-8 No. 333-203539) pertaining to the Stock Option Subscription Plan 2014-1, BSA Subscription Plan 2014-1 and BSA (Warrants) Issuance Agreements dated June 26, 2014, of Sequans Communications S.A.,
(4)
Registration Statement (Form S-8 No. 333-211011) pertaining to the Stock Option Subscription Plan 2015-1 and BSA (Warrants) Issuance Agreements dated June 29, 2015, of Sequans Communications S.A.,
(5)
Registration Statement (Form S-8 No. 333-214444) pertaining to the Stock Options Subscription Plan 2016-1, Restricted Share Award Plan 2016-1, BSA (Warrants) Subscription Plan 2016-1, BSA (Warrants) Subscription Plan 2016-2 and BSA (Warrants) Issuance Agreements dated June 28, 2016, of Sequans Communications S.A.,
(6)
Registration Statement (Form S-8 No. 333-215911) pertaining to the Restricted Share Award Plan 2016-2 Agreement dated June 28, 2016, of Sequans Communications S.A.,
(7)
Registration Statement (Form S-8 No. 333-219430) pertaining to the Stock Option subscription Plan 2017-1, Restricted Share Aware Plan 2017-1, Restricted Share Aware Plan 2017-2, Restricted Share Aware Plan 2017-3, BSA (Warrants) Issuance Agreement 2017-1, BSA (Warrants) Issuance Agreement 2017-2 and BSA (Warrants) Issuance Agreements dated June 30, 2017, of Sequans Communications S.A.,
(8)
Registration Statement (Form S-8 No. 333-226458) pertaining to the Stock Option Subscription Plan 2018, Restricted Share Award Plan 2018-1, Restricted Share Award Plan 2018-2, BSA 2018-1 (Warrants) Issuance Agreement, BSA 2018-2 (Warrants) Issuance Agreement, BSA (Warrants) Issuance Agreement, dated June 29, 2018, and Restricted Share Award Plan 2018-4, of Sequans Communications S.A.,
(9)
Registration Statement (Form S-8 No. 333-233473) pertaining to the Stock Option Subscription Plan 2019, Restricted Share Award Plan 2019-1, Restricted Share Award Plan 2019-2, BSA 2019-1 (Warrants) Issuance Agreement, BSA 2019-2 (Warrants) Issuance Agreement, and BSA (Warrants) Issuance Agreement, Dated July 1, 2019, of Sequans Communications S.A.,
(10)
Registration Statement (Form S-8 No. 333-239968) pertaining to the Stock Option Subscription Plan 2020, Restricted Share Award Plan 2020-1, Restricted Share Award Plan 2020-2, BSA 2020-1 (Warrants) Issuance Agreement, BSA 2020-2 (Warrants) Issuance Agreement, and Stock Warrants Issuance Agreement, Dated June 29, 2020, of Sequans Communications S.A.,
(11)
Registration Statement (Form F-3 No. 333-255865) of Sequans Communications S.A.,
(12)
Registration Statement (Form S-8 No. 333-259914 ) pertaining to the Stock Option Subscription Plan 2021, Restricted Share Award Plan 2021-1, Restricted Share Award Plan 2021-2, Partner Warrants 2021-1 Issuance Agreement, Partner Warrants 2021-2 Issuance Agreement, Director Warrants Issuance Agreement Dated June 25, 2021, of Sequans Communications S.A.,
(13)Registration Statement (Form S-8 No. 333-266481) pertaining to Stock Option Subscription Plan 2022, Restricted Share Award Plan 2022-1, Restricted Share Award Plan 2022-2, Partner Warrants 2022-1 Issuance Agreement, Partner Warrants 2022-2 Issuance Agreement, Director Warrants Issuance Agreement, Dated June 24, 2022
(14)Registration Statement (Form F-3 No. 333-271884) pertaining to registering for resale 11,683,493 ADSs, representing 46,733,972 ordinary shares issued by Sequans Communications S.A, to the Selling Securityholders on April 13, 2023, pursuant to the Securities Purchase Agreement, and on January 11, 2022, pursuant to the Renesas Securities Purchase Agreement.
of our reports dated May 15, 2024, with respect to the consolidated financial statements of Sequans Communications S.A. and the effectiveness of internal control over financial reporting of Sequans Communications S.A. included in this Annual Report (Form 20-F) of Sequans Communications S.A. for the year ended December 31, 2023.

/s/ Ernst & Young Audit
Paris - La Défense, France

May 15, 2024









EX-97.1 14 exhibit971-compensationrec.htm EX-97.1 COMPENSATION RECOVERY POLICY Document

SEQUANS COMMUNICATIONS S.A.

COMPENSATION RECOVERY POLICY
(Adopted and approved on October 24, 2023)


1.Purpose

Sequans Communications S.A. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company has adopted this Compensation Recovery Policy (this “Policy”). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the ”Exchange Act”) and explains when the Company will be required to seek recovery of Incentive Compensation awarded or paid to a Covered Person. Please refer to Exhibit A attached hereto (the “Definitions Exhibit”) for the definitions of capitalized terms used throughout this Policy.

2. Miscalculation of Financial Reporting Measure Results

In the event of a Restatement, the Company will seek to recover, reasonably promptly, all Recoverable Incentive Compensation from a Covered Person. Such recovery, in the case of a Restatement, will be made without regard to any individual knowledge or responsibility related to the Restatement. Notwithstanding the foregoing, if the Company is required to undertake a Restatement, the Company will not be required to recover the Recoverable Incentive Compensation if the Compensation Committee determines it Impracticable to do so, after exercising a normal due process review of all the relevant facts and circumstances.

If such Recoverable Incentive Compensation was not awarded or paid on a formulaic basis, the Company will seek to recover the amount that the Compensation Committee determines in good faith should be recouped.

3. Other Actions

The Compensation Committee may, subject to applicable law, seek recovery in the manner it chooses, including by seeking reimbursement from the Covered Person of all or part of the compensation awarded or paid, by electing to withhold unpaid compensation, by set-off, or by rescinding or canceling unvested stock.

In the reasonable exercise of its business judgment under this Policy, the Compensation Committee may in its sole discretion determine whether and to what extent additional action is appropriate to address the circumstances surrounding a Restatement to minimize the likelihood of any recurrence and to impose such other discipline as it deems appropriate.






4. No Indemnification or Reimbursement


Notwithstanding the terms of any other policy, program, agreement or arrangement, in no event will the Company or any of its affiliates indemnify or reimburse a Covered Person for any loss under this Policy and in no event will the Company or any of its affiliates pay premiums on any insurance policy that would cover a Covered Person’s potential obligations with respect to Recoverable Incentive Compensation under this Policy.

5. Administration of Policy

The Compensation Committee will have full authority to administer this Policy. The Compensation Committee will, subject to the provisions of this Policy and Rule 10D-1 of the Exchange Act, and the Company’s applicable exchange listing standards, make such determinations and interpretations and take such actions in connection with this Policy as it deems necessary, appropriate or advisable. All determinations and interpretations made by the Compensation Committee will be final, binding and conclusive.

6. Other Claims and Rights

The remedies under this Policy are in addition to, and not in lieu of, any legal and equitable claims the Company or any of its affiliates may have or any actions that may be imposed by law enforcement agencies, regulators, administrative bodies, or other authorities. Further, the exercise by the Compensation Committee of any rights pursuant to this Policy will not impact any other rights that the Company or any of its affiliates may have with respect to any Covered Person subject to this Policy.

7. Acknowledgement by Covered Persons; Condition to Eligibility for Incentive Compensation

The Company will provide notice and seek acknowledgement of this Policy, in substantially the form included as Exhibit B attached hereto, from each Covered Person, provided that the failure to provide such notice or obtain such acknowledgement will have no impact on the applicability or enforceability of this Policy. After the Effective Date, the Company must be in receipt of a Covered Person's acknowledgement as a condition to such Covered Person’s eligibility to receive Incentive Compensation. All Incentive Compensation subject to this Policy will not be earned, even if already paid, until the Policy ceases to apply to such Incentive Compensation and any other vesting conditions applicable to such Incentive Compensation are satisfied.

8. Amendment; Termination

The Board or the Compensation Committee may amend or terminate this Policy at any time. The Policy shall automatically terminate if the Company is no longer listed on the New York Stock Exchange.




9. Effectiveness

Except as otherwise determined in writing by the Compensation Committee, this Policy will apply to any Incentive Compensation that is Received by a Covered Person on or after the Effective Date. This Policy will survive and continue notwithstanding any termination of a Covered Person’s employment with the Company and its affiliates.

10. Successors

This Policy shall be binding and enforceable against all Covered Persons and their successors, beneficiaries, heirs, executors, administrators, or other legal representatives.






































Exhibit A

SEQUANS COMMUNICATIONS S.A.

COMPENSATION RECOVERY POLICY

DEFINITIONS EXHIBIT

Applicable Period” means the three completed fiscal years of the Company immediately preceding the earlier of (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes (or reasonably should have concluded) that a Restatement is required or (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement. The “Applicable Period” also includes any transition period (that results from a change in the Company’s fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence.

Board” means the Board of Directors of the Company.

Compensation Committee” means the Company’s committee of independent directors responsible for executive compensation decisions, or in the absence of such a committee, a majority of the independent directors serving on the Board.

Covered Person” means any person who is, or was at any time, during the Applicable Period, an Executive Officer of the Company. For the avoidance of doubt, a Covered Person may include a former Executive Officer that left the Company, retired, or transitioned to an employee role (including after serving as an Executive Officer in an interim capacity) during the Applicable Period.

"Effective Date” means October 2, 2023, the effective date of the listing standards for recovery of erroneously awarded compensation adopted by NASDAQ and NYSE, and approved by the SEC.

Executive Officer” means the Company’s president, principal executive officer, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person (including an officer of the Company’s parent(s) or subsidiaries) who performs similar policy-making functions for the Company.

Financial Reporting Measure” means a measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements (including, but not limited to, “non-GAAP” financial measures, such as those appearing in the Company’s earnings releases or Management Discussion and



Analysis), and any measure that is derived wholly or in part from such measure. Stock price and total shareholder return (and any measures derived wholly or in part therefrom) shall be considered Financial Reporting Measures.

Impracticable.” The Compensation Committee may determine in good faith that recovery of Recoverable Incentive Compensation is “Impracticable” if: (i) pursuing such recovery would violate home country law of the jurisdiction of incorporation of the Company where that law was adopted prior to November 28, 2022 and the Company provides an opinion of home country counsel to that effect acceptable to the Company’s applicable listing exchange; (ii) the direct expense paid to a third party to assist in enforcing this Policy would exceed the Recoverable Incentive Compensation and the Company has (A) made a reasonable attempt to recover such amounts and (B) provided documentation of such attempts to recover to the Company’s applicable listing exchange; or (iii) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended.

Incentive Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive Compensation does not include any base salaries (except with respect to any salary increases earned wholly or in part based on the attainment of a Financial Reporting Measure performance goal); bonuses paid solely at the discretion of the Compensation Committee or Board that are not paid from a “bonus pool” that is determined by satisfying a Financial Reporting Measure performance goal; bonuses paid solely upon satisfying one or more subjective standards and/or completion of a specified employment period; non-equity incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures; and equity awards that vest solely based on the passage of time and/or attaining one or more non-Financial Reporting Measures.

Received.” Incentive Compensation is deemed “Received” in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period.

Recoverable Incentive Compensation” means the amount of any Incentive Compensation (calculated on a pre-tax basis) Received by a Covered Person during the Applicable Period that is in excess of the amount that otherwise would have been Received if the calculation were based on the Restatement. For the avoidance of doubt, Recoverable Incentive Compensation does not include any Incentive Compensation Received by a person (i) before such person began service in a position or capacity meeting the definition of an Executive Officer, (ii) who did not serve as an Executive Officer at any time during the performance period for that Incentive Compensation, or (iii) during any period the Company did not have a class of its securities listed on a national securities exchange or a national securities association. For Incentive Compensation based on (or derived from) stock price or total shareholder return where the amount of Recoverable Incentive Compensation is not subject to mathematical



recalculation directly from the information in the applicable Restatement, the amount will be determined by the Compensation Committee based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon which the Incentive Compensation was Received (in which case, the Company will maintain documentation of such determination of that reasonable estimate and provide such documentation to the Company’s applicable listing exchange).

Restatement” means an accounting restatement of any of the Company’s financial statements filed with the Securities and Exchange Commission under the Exchange Act, or the Securities Act of 1933, as amended, due to the Company’s material noncompliance with any financial reporting requirement under U.S. securities laws, regardless of whether the Company or Covered Person misconduct was the cause for such restatement. “Restatement” includes any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (commonly referred to as “Big R” restatements), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred to as “little r” restatements).
































Exhibit B

SEQUANS COMMUNICATIONS S.A.

COMPENSATION recovery POLICY

ACKNOWLEDGMENT


Acknowledgement will be done via email per the following template:

Dear [Name],

The Company has adopted the attached Compensation Recovery Policy in response to recent SEC rules. This policy outlines the Company's ability to recover incentive compensation in certain circumstances.

To be eligible to receive incentive compensation going forward, please review the policy and reply to this e-mail with the statement: "I acknowledge that I have read and understood, and agree to be subject to the terms of, the Sequans Communications S.A. Compensation Recovery Policy."

Thank you for your attention to this matter.

Sincerely,
[CFO or HR Director]



EX-101.SCH 15 sqns-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss) Statement link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss) Statement link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Financial Position link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Financial Position (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Changes in Equity (Deficit) Statement link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Statements of Cash Flow link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Corporate information link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of significant accounting and reporting policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Segment information link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Other revenues and expenses link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Income tax link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Earnings (loss) per share link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Property, plant and equipment link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Intangible assets link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Trade receivables link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Cash and cash equivalents link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Issued capital and reserves link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Share-based payment plans link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Interest-bearing loans and borrowings link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Lease liabilities link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Government grant advances and loans link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Provisions link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Other non-current liabilities link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Trade payables and other current liabilities link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Information about financial instruments link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Related party disclosures link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Events after the reporting date link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of significant accounting and reporting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of significant accounting and reporting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Segment information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Other revenues and expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Income tax (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Earnings (loss) per share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Property, plant and equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Intangible assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Trade receivables (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Cash and cash equivalents (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Issued capital and reserves (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Share-based payment plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Interest-bearing loans and borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Lease liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Government grant advances and loans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Provisions (Tables) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Other non-current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Trade payables and other current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Information about financial instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Related party disclosures (Tables) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Summary of significant accounting and reporting policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Summary of significant accounting and reporting policies - Schedule of Subsidiaries (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Summary of significant accounting and reporting policies - Schedule of Average and Closing Exchange Rate for the U.S. Dollar (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Summary of significant accounting and reporting policies - Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Summary of significant accounting and reporting policies - Schedule of Useful Lives Most Commonly Used (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Segment information (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Other revenues and expenses - Schedule of Financial Income and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Other revenues and expenses - Financial Income and Expenses (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Other revenues and expenses - Schedule of Cost of Revenue, Operating Expenses, and Employee Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Other revenues and expenses - Research and Development Expense and Tax Credit Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Income tax - Schedule of Major Components of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Income tax - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Income tax - Reconciliation of Income Taxes Computed at the French Statutory Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Income tax - Summary of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Income tax - Significant Components of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Earnings (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Property, plant and equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Intangible assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Trade receivables - Schedule of Non-Interest Bearing Trade Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Trade receivables - Schedule of Movements in the Provision for Impairment of Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Trade receivables - Aging Analysis of Trade Receivables That Were Not Impaired (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Cash and cash equivalents - Schedule of Cash and Cash Equivalents Held in U.S. dollar and Euros (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Issued capital and reserves - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Issued capital and reserves - Authorized capital, in number of shares (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Issued capital and reserves - Shares Issued and Fully Paid (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Issued capital and reserves - Capital Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Share-based payment plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Share-based payment plans - Breakdown of share-based payments expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Share-based payment plans - General employee stock option, founders warrant plans and restricted shares awards (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Share-based payment plans - Warrant plans for certain consultants considered equivalent to employees (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Share-based payment plans - Movements in number and WAEP (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Share-based payment plans - Movements in number and restricted shares awards (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - Share-based payment plans - Valuation assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - Interest-bearing loans and borrowings - Schedule of Interest-Bearing Loans and Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - Interest-bearing loans and borrowings - Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - Interest-bearing loans and borrowings - Venture Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - Interest-bearing loans and borrowings - Interest-Bearing Financing Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - Interest-bearing loans and borrowings - Unsecured related party loan (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - Lease liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954537 - Disclosure - Lease liabilities - Summary of movements in right-of-use assets and lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954538 - Disclosure - Government grant advances and loans - Schedule of Government Grant Advances and Loans (Details) link:presentationLink link:calculationLink link:definitionLink 9954539 - Disclosure - Government grant advances and loans - Government Grant Advances (Details) link:presentationLink link:calculationLink link:definitionLink 9954540 - Disclosure - Government grant advances and loans - Research Project Financing (Details) link:presentationLink link:calculationLink link:definitionLink 9954541 - Disclosure - Government grant advances and loans - Government Loans (Details) link:presentationLink link:calculationLink link:definitionLink 9954542 - Disclosure - Provisions - Reconciliation of Changes in Provisions (Details) link:presentationLink link:calculationLink link:definitionLink 9954543 - Disclosure - Provisions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954544 - Disclosure - Provisions - Schedule of Main Assumptions Used (Details) link:presentationLink link:calculationLink link:definitionLink 9954545 - Disclosure - Other non-current liabilities - Schedule of Other Non-Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954546 - Disclosure - Other non-current liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954547 - Disclosure - Trade payables and other current liabilities - Schedule of Trade Payables and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954548 - Disclosure - Trade payables and other current liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954549 - Disclosure - Information about financial instruments - Schedule of Financial Assets and Financial Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954550 - Disclosure - Information about financial instruments - Schedule of Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954551 - Disclosure - Information about financial instruments - Schedule of Present Fair Values of Derivative Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954552 - Disclosure - Information about financial instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954553 - Disclosure - Information about financial instruments - Summary of Customers Representing Company's Total Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954554 - Disclosure - Information about financial instruments - Schedule of Liquidity Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954555 - Disclosure - Information about financial instruments - Changes in Liabilities Arising from Financing Activities (Details) link:presentationLink link:calculationLink link:definitionLink 9954556 - Disclosure - Commitments and contingencies - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954557 - Disclosure - Commitments and contingencies - Bank Guarantee (Details) link:presentationLink link:calculationLink link:definitionLink 9954558 - Disclosure - Commitments and contingencies - Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954559 - Disclosure - Commitments and contingencies - Purchase Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954560 - Disclosure - Commitments and contingencies - Pledge of Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954561 - Disclosure - Related party disclosures - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954562 - Disclosure - Related party disclosures - Compensation of Key Management Personnel (Details) link:presentationLink link:calculationLink link:definitionLink 9954563 - Disclosure - Related party disclosures - Directors’ Interests In An Employee Share Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954564 - Disclosure - Events after the reporting date (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 16 sqns-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 17 sqns-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 18 sqns-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Net effect of dilutive stock options (in shares) Dilutive effect of share options on weighted average number of ordinary shares Cost: Gross carrying amount Gross carrying amount [member] Disclosure of defined benefit plans [table] Disclosure of defined benefit plans [table] license fee License fee [Member] License fee Standards issued but not yet effective New Accounting Standards Issued But Not Yet Effective, Policy [Policy Text Block] New Accounting Standards Issued But Not Yet Effective, Policy [Policy Text Block] Research tax credit Research And Development Tax Credit, Capitalised Research And Development Tax Credit, Capitalised Bank guarantee issued in favor of owners of new leased office space Exposure to credit risk on loan commitments and financial guarantee contracts Increase (Decrease) in government grant advances (1) Adjustments For Decrease (Increase) In Government Grant Advances Adjustments For Decrease (Increase) In Government Grant Advances Non-current liabilities: Non-current liabilities [abstract] Share-based payment expense for the year Share-based payment expense Key management personnel compensation, share-based payment Project [Domain] Project1 [Domain] [Domain] for Project [Axis] Reconciliation of Income Taxes Computed at the French Statutory Rate Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate [Table Text Block] Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate [Table Text Block] Warrants Warrant1 [Member] Warrant1 [Member] Legal proceedings contingent liability Legal proceedings contingent liability [member] Interest on supplier payable with extended payment terms Interest Expense On Noncurrent Payables To Trade Suppliers Interest Expense On Noncurrent Payables To Trade Suppliers Financial assets, category [member] Financial assets, category [member] Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Per Share Debt Instrument, Convertible, Conversion Price Per Share Current Provisions Current provisions Conversion of loans (in shares) Number Of Shares Issued Through Conversion Of Loan, Equity Number Of Shares Issued Through Conversion Of Loan, Equity Lynrock Lake Lynrock Lake [Member] Lynrock Lake Repayment of government loans Repayments of borrowings, classified as financing activities NIS denominated accounts Israel, New Shekels Wages and salaries Wages and salaries Non-deductible share-based payment expense Tax effect of expense not deductible in determining taxable profit (tax loss) Concentration Risk, Percentage Concentration Risk, Percentage Concentration Risk, Percentage Discount rate Actuarial assumption of discount rates Post- employment benefits Provisions For Employee Benefits, Netting [Member] Provisions For Employee Benefits [Member] Increase (decrease) through non-cash interest Increase (Decrease) Through Non-Cash Interest, Liabilities Arising From Financing Activities Increase (Decrease) Through Non-Cash Interest, Liabilities Arising From Financing Activities Trade receivables Current Trade Receivables, Gross Current Trade Receivables, Gross Trade payables Current trade payables Disclosure of financial liabilities [line items] Disclosure of financial liabilities [line items] Interest-Bearing Receivables Financing, Research Tax Credit Interest-Bearing Receivables Financing, Research Tax Credit [Member] Interest-Bearing Receivables Financing, Research Tax Credit Summary of Customers Representing Company's Total Revenue Disclosure of major customers [text block] Trade receivables Disclosure of trade and other receivables [text block] Conversion of convertible debt (in shares) Number Of Shares Issued Through Conversion Of Convertible Instruments, Equity Number Of Shares Issued Through Conversion Of Convertible Instruments, Equity 2019-2 notes Convertible Notes 2019-2 [Member] Convertible Notes 2019-2 [Member] Bond Issuance Agreement Bond Issuance Agreement [Member] Bond Issuance Agreement [Member] Customer [Axis] Customer [Axis] Research and Development Arrangement, Contract to Perform for Others1 [Line Items] Research and Development Arrangement, Contract to Perform for Others1 [Line Items] Research and Development Arrangement, Contract to Perform for Others1 [Line Items] Founders warrants and stock options Founders Warrants And Stock Options [Member] Founders Warrants And Stock Options [Member] Financial liabilities at fair value through profit or loss Financial liabilities at fair value through profit or loss, category [member] WAEP of units exercised during the year (in usd per unit) Weighted Average Exercise Price Of Share Options And Other Equity Instruments Exercised In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options And Other Equity Instruments Exercised In Share-Based Payment Arrangement Authorised capital (in shares) Number Of Shares Issued And Shares Reserved For Issue Number Of Shares Issued And Shares Reserved For Issue Cash, cash equivalents and deposits Cash, cash equivalents and short-term deposits Cash, Cash Equivalents And Deposit Cash, Cash Equivalents And Deposit Range [axis] Range [axis] International International [Member] International [Member] IFRS 16 IFRS 16 [Member] IFRS 16 [Member] Vesting1 [Axis] Vesting1 [Axis] Vesting1 [Axis] Past due status [member] Past due status [member] Total financial income Finance income Financial instruments, class [member] Financial instruments, class [member] Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Proceeds from issue of warrants and exercise of stock options/warrants granted under share-based payment plans, net of transaction costs Proceeds From Issue Of Warrants And Exercise Of Options Proceeds From Issue Of Warrants And Exercise Of Options Vesting quarterly over the remaining two years Share-based Compensation Award, Tranche Five [Member] Share-based Compensation Award, Tranche Five [Member] Analysis of income and expense [abstract] Analysis of income and expense [abstract] Venture debt Venture Debt [Member] Venture Debt [Member] Valuation techniques used in fair value measurement [axis] Valuation techniques used in fair value measurement [axis] Contingent liabilities [member] Contingent liabilities [member] Research tax credit receivable Current receivables from taxes other than income tax All Currencies [Domain] All Currencies [Domain] Proceeds from (repayment of) interest-bearing receivables financing, net Proceeds From Interest-Bearing Receivables Financing Proceeds From Interest-Bearing Receivables Financing Weighted average remaining contractual life Weighted Average Remaining Contractual Life Of Outstanding Share Options And Other Equity Instruments In Share-Based Payment Arrangement Weighted Average Remaining Contractual Life Of Outstanding Share Options And Other Equity Instruments In Share-Based Payment Arrangement Sequans Communications Finland Oy Sequans Communications Finland Oy [Member] Sequans Communications Finland Oy Share-based payment plans Disclosure of share-based payment arrangements [text block] Net foreign exchange difference Effect of exchange rate changes on cash and cash equivalents Components, net Current raw materials and current production supplies Special Transaction Bonus, Approved By Board Of Directors Special Transaction Bonus, Approved By Board Of Directors Special Transaction Bonus, Approved By Board Of Directors Disclosure of detailed information about property, plant and equipment [line items] Disclosure of detailed information about property, plant and equipment [line items] Interest-bearing receivables financing Interest-Bearing Receivables Financing Line Of Credit [Member] Interest-Bearing Receivables Financing Line Of Credit [Member] Trade payables and other current liabilities Disclosure of trade and other payables [text block] Government loans Current Government Loans Current Government Loans Total equity and liabilities Equity and liabilities Utilized amounts Utilisation, allowance account for credit losses of financial assets Vesting1 [Domain] Vesting1 [Domain] [Domain] for Vesting1 [Axis] GBP denominated accounts United Kingdom, Pounds Provision for risk Other provisions Income Statement Location [Domain] Income Statement Location 1 [Domain] [Domain] for Income Statement Location [Axis] New and amended standards and interpretations and Standards issued but not yet effective New Accounting Pronouncements, Policy1 [Policy Text Block] New Accounting Pronouncements, Policy1 [Policy Text Block] revenue from sales of other services revenue from sales of other services revenue from sales of other services Statement of compliance Statement of IFRS compliance [text block] Products and services [member] Products and services [member] Interest rate Trade Payables, Discount Rate Trade Payables, Discount Rate Local Phone Number Local Phone Number Debt instrument, interest rate Debt Instrument, Convertible, Interest Rate Debt Instrument, Convertible, Interest Rate Included in operating expenses (between gross profit and operating result): Operating Expense, Netting [Member] Operating Expense [Member] Disposals, Cost (Depreciation and impairment) Disposals, intangible assets other than goodwill Contract liabilities Current contract liabilities Temporary difference, unused tax losses and unused tax credits [member] Temporary difference, unused tax losses and unused tax credits [member] Increase (decrease) through changes in fair values, liabilities arising from financing activities Increase (decrease) through changes in fair values, liabilities arising from financing activities Maturity [axis] Maturity [axis] Assumed annual lapse rate of awards (%) Assumed Annual Lapse Rate, Share Options And Other Equity Instruments Granted Assumed Annual Lapse Rate, Share Options And Other Equity Instruments Granted Net trade receivables Accounts receivable Trade receivables Financial Instruments [Abstract] Financial Instruments [Abstract] Financial Instruments [Abstract] Impact of debt reimbursement Tax Effect Of Impact Of Debt Reimbursement Tax Effect Of Impact Of Debt Reimbursement Repayment of venture debt Repayment of venture debt Repayments of Venture Debt Repayments of Venture Debt Available borrowings, percentage of face value of accounts receivable Borrowings Available, Percentage Of Face Value Of Derecognised Assets Borrowings Available, Percentage Of Face Value Of Derecognised Assets Schedule of Major Components of Income Tax Expense Disclosure Of Major Components Of Tax Expense (Income) [Table Text Block] Disclosure Of Major Components Of Tax Expense (Income) [Table Text Block] Inventories Disclosure of inventories [text block] Weighted average fair value (in € per unit) Weighted Average Fair Value At Measurement Date, Share Options And Other Equity Instruments Granted Weighted Average Fair Value At Measurement Date, Share Options And Other Equity Instruments Granted Financial assets, class [member] Financial assets, class [member] Financial liabilities Description of accounting policy for financial liabilities [text block] Foreign exchange loss (gain) Adjustments for unrealised foreign exchange losses (gains) Percentage of revenue from project Research And Development Arrangement, Contract To Perform For Others, Royalty Percentage Research And Development Arrangement, Contract To Perform For Others, Royalty Percentage Sales and marketing Sales and marketing expense Strategic Partner, Amendment Contract Strategic Partner, Amendment Contract [Member] Strategic Partner, Amendment Contract Vested during the year Number of other equity instruments exercised or vested in share-based payment arrangement Total current liabilities Current liabilities Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16 Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16 Types of transfer [member] Types of transfer [member] Convertible debt Current debt instruments issued Impact of the extinguishment of the convertible debts after amendment Tax Effect Of Impact Of Extinguishment Of Convertible Debt Tax Effect Of Impact Of Extinguishment Of Convertible Debt Depreciation and impairment Depreciation And Impairment Expense Depreciation And Impairment Expense Document Accounting Standard Document Accounting Standard Inventory adjustments Inventory Adjustments [Member] Inventory Adjustments [Member] Geographical areas [axis] Geographical areas [axis] Condensed Financial Statements, Captions [Line Items] Condensed Financial Statements, Captions [Line Items] Net effect of conversion of convertible notes (in shares) Effect Of Conversion Of Convertible Notes Effect Of Conversion Of Convertible Notes ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Charge for the year Additional allowance recognised in profit or loss, allowance account for credit losses of financial assets Other comprehensive income (loss) Other comprehensive income [abstract] Research Tax Credit [Domain] Research Tax Credit [Domain] Research Tax Credit [Domain] Customer A Customer A [Member] Customer A [Member] Fair value of financial instruments Description of accounting policy for fair value measurement [text block] Interest on financing component of long term development services agreement (see Notes 18 and 19) Interest Expense on Financing of Long Term Services Agreement Interest Expense on Financing of Long Term Services Agreement Exercise price per ADS (in dollars per share) Investment Warrants, Exercise Price Per ADS Investment Warrants, Exercise Price Per ADS Research Tax Credit 2021 Research Tax Credit 2021 [Member] Research Tax Credit 2021 Security Purchase Agreement Security Purchase Agreement [Member] Security Purchase Agreement License Licenses License [Member] Cash flow hedges Derivative Liabilities [Member] Derivative Liabilities [Member] Decrease (Increase) in research tax credit receivable Adjustments For Decrease (Increase) In Current Receivables From Taxes Other Than Income Tax Adjustments For Decrease (Increase) In Current Receivables From Taxes Other Than Income Tax Post-employment medical benefits Post-employment medical defined benefit plans [member] Stock Options Stock Options [Member] Stock Options [Member] Government and other grants Income from government grants Total non-current assets Non-current assets Total non-current Non-current Financial Assets, At Fair Value Non-current Financial Assets, At Fair Value Excess sales amount threshold Research And Development Arrangement, Contract To Perform For Others, Excess Sales Threshold Research and Development Arrangement, Contract to Perform for Others, Excess Sales Threshold Derivative financial instruments and hedge accounting Description of accounting policy for derivative financial instruments and hedging [text block] Trade and other payables (current and non current) Trade payables Trade And Other Payables [Member] Trade And Other Payables [Member] Provisions on trade receivables At January 1, At year end Allowance account for credit losses of financial assets Disclosure of other provisions [line items] Disclosure of other provisions [line items] Counterparty Name [Domain] Counterparty Name [Domain] Expected volatility (%) Expected Volatility, Share Options And Other Equity Instruments Granted Expected Volatility, Share Options And Other Equity Instruments Granted Payments Payments of Lease Liabilities Payments of Lease Liabilities Intangible assets with indefinite useful life [member] Intangible assets with indefinite useful life [member] Cash flow hedge Cash flow hedges [member] Greater than 120 days Later than four months [member] Total compensation expense for key management personnel Key management personnel compensation Key management personnel compensation Wages and benefits Employee benefits expense Decrease (Increase) in inventories Adjustments for decrease (increase) in inventories Notional Amount Nominal amount of hedging instrument Disclosure of detailed information about borrowings [table] Disclosure of detailed information about borrowings [table] Security Exchange Name Security Exchange Name Cost of components Cost of merchandise sold Other components of equity Other equity interest Product revenue Product revenue Revenue from sale of goods Disclosure of analysis of other comprehensive income by item [line items] Disclosure of analysis of other comprehensive income by item [line items] Disclosure of subsidiaries [line items] Disclosure of subsidiaries [line items] Contract liabilities Contract liabilities Future Minimum Undiscounted Lease Payments Disclosure of maturity analysis of operating lease payments [text block] General and Administrative General and Administrative [Member] General and Administrative Increase (decrease) due to changes in accounting policy required by IFRSs [member] Increase (decrease) due to changes in accounting policy required by IFRSs [member] More than five years Later than five years [member] Maximum Maximum [Member] Turnover: depending on the seniority Actuarial Assumption Of Turnover Actuarial Assumption Of Turnover Other non-current financial assets Non-current financial assets available-for-sale Document Type Document Type Gross profit Gross profit Breakdown of share-based payments expenses on entity's profit or loss Explanation of effect of share-based payments on entity's profit or loss [text block] Segment information Disclosure of entity's operating segments [text block] Other capital reserves Other reserves Diluted per ADS (in dollars per share) American Deposit Shares Outstanding, Diluted American Deposit Shares Outstanding, Diluted Total financial expenses Finance costs Term of secured lease payments Exposure To Credit Risk On Loan Commitments And Financial Guarantee Contracts, Term Of Secured Payments Exposure To Credit Risk On Loan Commitments And Financial Guarantee Contracts, Term Of Secured Payments 4 to 5 years Later than four years and not later than five years [member] 3 to 4 years Later than three years and not later than four years [member] Provision for impairment Provision For Impairment Provision For Impairment Provision for impairment ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleassets ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleassets Forgivable Loan Research Project Financing - Forgivable Loan [Member] Research Project Financing - Forgivable Loan [Member] Upfront payment, borrowings Upfront Payment, Borrowings Upfront Payment, Borrowings Decrease in R&D expenses Increase (Decrease) In Research And Development Expenses Increase (Decrease) In Research And Development Expenses Property, plant and equipment Disclosure of property, plant and equipment [text block] Disclosure of detailed information about property, plant and equipment [table] Disclosure of detailed information about property, plant and equipment [table] Retirement age Actuarial assumption of retirement age Other provisions Miscellaneous other provisions [member] Schedule of Other Non-Current Liabilities Disclosure Of Other Non-Current Liabilities [Table Text Block] Disclosure Of Other Non-Current Liabilities [Table Text Block] Risks [member] Risks [member] Financial liabilities: Financial Instruments, Liabilities [Abstract] Financial Instruments, Liabilities [Abstract] Profit or loss [abstract] Profit or loss [abstract] Top of range Top of range [member] Top of range [member] Title of 12(b) Security Title of 12(b) Security Total value of investments Financial assets pledged as collateral Financial assets pledged as collateral for liabilities or contingent liabilities Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [table] Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [table] Other revenues and expenses Disclosure of other operating income (expense) [text block] Deferred revenue Current deferred income including current contract liabilities Interest on lease contracts (see Note 15) Interest expense on lease liabilities RSA Restricted Stock1 [Member] Restricted Stock1 [Member] Finished goods, at the lower of cost and net realizable value Current finished goods Convertible Notes Amended, Option Two Convertible Notes Amended, Option Two [Member] Convertible Notes Amended, Option Two [Member] Specified bank accounts Specified Bank Accounts [Member] Specified Bank Accounts [Member] Optional notice term Borrowings Maturity, Optional Term Borrowings Maturity, Optional Term Increase (decrease) through financing cash flows Increase (decrease) through financing cash flows, liabilities arising from financing activities 60-120 days Later Than Two Months And Not Later Than Four Months [Member] Later Than Two Months And Not Later Than Four Months [Member] Fair value Financial Instruments, Liabilities, Fair Value [Abstract] Financial Instruments, Liabilities, Fair Value [Abstract] 1 to 2 years Later than one year and not later than two years [member] Sale (Purchase) of financial assets Proceeds From (Purchases Of) Financial Assets, Classified As Investing Activities Proceeds From (Purchases Of) Financial Assets, Classified As Investing Activities Statistical Measurement [Axis] Statistical Measurement [Axis] Entity Interactive Data Current Entity Interactive Data Current Subscription price (in dollars per share) Debt Instrument, Convertible, Subscription Price Debt Instrument, Convertible, Subscription Price Government grant advances and loans Total non-current portion Non-current government grants Attributable to: Comprehensive income attributable to [abstract] Product Product [Member] Trade and other receivables Trade and other receivables Level 1 Level 1 of fair value hierarchy [member] Cost of revenue Cost Of Sales, Policy1 [Policy Text Block] Cost Of Sales, Policy1 [Policy Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer WAEP of units outstanding at January 1, (in usd per unit) WAEP of units outstanding at period end (in usd per unit) Weighted Average Exercise Price Of Share Options And Other Equity Instruments Outstanding In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options And Other Equity Instruments Outstanding In Share-Based Payment Arrangement Shareholders of the parent Profit (loss), attributable to owners of parent 30-60 days Later than one month and not later than two months [member] Disclosure of subsidiaries [table] Disclosure of subsidiaries [table] Summary of movement in number and WAEP of stock options Disclosure of number and weighted average exercise prices of share options [text block] Financial Assets Measured At Fair Value Through Other Comprehensive Income Financial Assets Measured At Fair Value Through Other Comprehensive Income [Member] Financial Assets Measured At Fair Value Through Other Comprehensive Income Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Counterparty Name [Axis] Counterparty Name [Axis] Real-estate Real Estate, Right-of-use Assets [Member] Real Estate, Right-of-use Assets [Member] Non-adjusting events after reporting period Non-adjusting events after reporting period [member] Average rate Average foreign exchange rate Related party disclosures Disclosure of related party [text block] Percentage of operating expenses Percentage Of Entity's Operating Expense Percentage Of Entity's Operating Expense Range of exercise prices (in usd per unit) Exercise Price Of Outstanding Share Options And Other Equity Instruments In Share-Based Payment Arrangement Exercise Price Of Outstanding Share Options And Other Equity Instruments In Share-Based Payment Arrangement Disclosure of right-of-use assets Disclosure of quantitative information about right-of-use assets [text block] Bank guarantee Financial guarantee contracts [member] Auditor Location Auditor Location Income tax Disclosure of income tax [text block] Board members fees to non-executive members Key Management Personnel Compensation, Board Of Director Fees Key Management Personnel Compensation, Board Of Director Fees Convertible debt Non-Current Portion Of Non-Current Convertible Borrowings Issued Non-Current Portion Of Non-Current Convertible Borrowings Issued Classes of financial instruments [axis] Classes of financial instruments [axis] Trade and other receivables Trade And Other Receivables [Member] Trade And Other Receivables [Member] Total equity (deficit) Beginning balance Ending balance Equity Equity Operating lease expense Minimum operating lease payments recognised as expense Change in fair value of convertible debt derivative Gains on change in fair value of derivatives Number Of Installments [Domain] Number Of Installments [Domain] Number Of Installments [Domain] Significant accounting judgments, estimates and assumptions Use Of Estimates, Policy1 [Policy Text Block] Use Of Estimates, Policy1 [Policy Text Block] Lead-Times Increased COVID-19 And Other Supply Chain Constraints Lead-Times Increased COVID-19 And Other Supply Chain Constraints [Member] Lead-Times Increased COVID-19 And Other Supply Chain Constraints Germany GERMANY Convertible Notes Amended, Option One Convertible Notes Amended, Option One [Member] Convertible Notes Amended, Option One [Member] Disclosure Of Cash And Cash Equivalents [Line Items] Disclosure Of Cash And Cash Equivalents [Line Items] [Line Items] for Disclosure Of Cash And Cash Equivalents [Table] Components of equity [axis] Components of equity [axis] B. Riley FBR, Inc B. Riley FBR, Inc [Member] B. Riley FBR, Inc Document Shell Company Report Document Shell Company Report Credit risk Credit risk [member] Operating expenses: Operating Expenses 1 [Abstract] Operating Expenses [Abstract] Audit Information [Abstract] Audit Information Title of Individual [Axis] Title of Individual [Axis] Diluted earnings (loss) per ADS (in dollars per share) American Deposits Shares, Diluted Earnings (Loss) per Share American Deposits Shares, Diluted Earnings (Loss) per Share Income Statement Location [Axis] Income Statement Location 1 [Axis] Income Statement Location [Axis] Level 3 Level 3 of fair value hierarchy [member] Assembly services, royalties and other Services And Royalty Expense Services And Royalty Expense Net other comprehensive income (loss) to be reclassified to profit or loss in subsequent years Other comprehensive income that will be reclassified to profit or loss, net of tax Cost of revenue Cost of sales After one year but not more than five years Later than one year and not later than five years [member] China CHINA U.S. dollar denominated accounts United States of America, Dollars Furniture and office equipment Furniture And Office Equipment [Member] Furniture And Office Equipment [Member] Costs of Public Offerings Description of accounting policy for issued capital [text block] Disclosure of Fair Value of Financial Instruments Disclosure of fair value of financial instruments [text block] Increase (decrease) in number of ADS issued Increase (decrease) in number of ADS issued Increase (decrease) in number of ADS issued Interest expense Interest expense Number of units outstanding at January 1, Number of units outstanding at period end Number Of Share Options And Other Equity Instruments Outstanding In Share-Based Payment Arrangement Number Of Share Options And Other Equity Instruments Outstanding In Share-Based Payment Arrangement Borrowings, Excluding Government Loans And Research Project Financing Borrowings, Excluding Government Loans And Research Project Financing [Member] Borrowings, Excluding Government Loans And Research Project Financing [Member] Lease liability Lease liabilities [member] Conversion ratio Debt Instrument, Convertible, Conversion Ratio2 Debt Instrument, Convertible, Conversion Ratio Capitalized development expenditures Purchases Of Capitalised Development Expenditures, Classified As Investing Activities Purchases Of Capitalised Development Expenditures, Classified As Investing Activities America JAPAN Provisions Disclosure of provisions [text block] Share Capital, Reserves And Other Equity Interest [Abstract] Share Capital, Reserves And Other Equity Interest [Abstract] Share Capital, Reserves And Other Equity Interest [Abstract] Net cash flows from financing activities Cash flows from (used in) financing activities Exercise price, premium percentage Debt Instrument, Convertible, Warrant, Exercise Price Percentage Debt Instrument, Convertible, Warrant, Exercise Price Percentage Interest on loans Interest expense on borrowings Schedule of Interest-Bearing Loans and Borrowings Disclosure of detailed information about borrowings [text block] Total financial assets Fair value Financial assets, at fair value Financial assets, at fair value Number of employees retired during the year Number Of Employees Retired During The Year Number Of Employees Retired During The Year Depreciation expense Depreciation, right-of-use assets Entering into significant commitments or contingent liabilities Entering into significant commitments or contingent liabilities [member] Issued capital and reserves Disclosure of share capital, reserves and other equity interest [text block] Other capital reserves Other reserves [member] Total non-current portion Non-current portion of non-current borrowings Intangible assets Fixed Assets [Member] Fixed Assets [Member] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type 1 [Axis] Deferred Revenue Arrangement Type [Axis] Purchase Commitment, Excluding Long-term Commitment1 [Table] Purchase Commitment, Excluding Long-term Commitment1 [Table] Purchase Commitment, Excluding Long-term Commitment1 [Table] Disclosure of finance lease and operating lease by lessee [line items] Disclosure of finance lease and operating lease by lessee [line items] Less than 30 days Current [member] Number of operating segments Number Of Operating Segments1 Number Of Operating Segments1 Schedule of Financial Liabilities Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities Explanatory [Table Text Block] Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities Explanatory [Table Text Block] Sale period Share-Based Compensation Arrangement By Share-Based Payment Award, Sale Period Share-Based Compensation Arrangement By Share-Based Payment Award, Sale Period Disclosure of financial assets that are either past due or impaired [line items] Disclosure of financial assets that are either past due or impaired [line items] LIBOR London Interbank Offered Rate (LIBOR) 1 [Member] London Interbank Offered Rate (LIBOR) 1 [Member] Disclosure of financial assets that are either past due or impaired [table] Disclosure of financial assets that are either past due or impaired [table] Expense By Nature [Table] Expense By Nature [Table] Expense By Nature [Table] Unsecured related party loan Current unsecured bank loans received and current portion of non-current unsecured bank loans received Classes of financial liabilities [axis] Classes of financial liabilities [axis] Expense from equity-settled share-based payment transactions Expense from equity-settled share-based payment transactions Schedule of Inventories Schedule Of Inventory, Current 1 [Table Text Block] Schedule Of Inventory, Current [Table Text Block] Financial liabilities, class [member] Financial liabilities, class [member] FRANCE FRANCE Computer equipment Computer equipment [member] Total other comprehensive income (loss) Other comprehensive income Convertible Notes 2015 Convertible Notes 2015 [Member] Convertible Notes 2015 Maximum amount payable Research And Development Arrangement, Contract To Perform For Others, Maximum Royalty Payable Research And Development Arrangement, Contract To Perform For Others, Maximum Royalty Payable Number Of Installments [Axis] Number Of Installments [Axis] Number Of Installments Transaction costs Transaction costs Share issue related cost Government grant advances and loans Government Grant Advances And Loans [Member] Government Grant Advances And Loans [Member] Other revenue Other revenue Lease liabilities Non-current lease liabilities Entity Emerging Growth Company Entity Emerging Growth Company Recognized revenues License and Services Agreement, Revenue License and Services Agreement, Revenue Research and development costs Research And Development Costs Research And Development Costs Impact of debt reimbursement Adjustments For Impact Of Debt Reimbursement Adjustments For Impact Of Debt Reimbursement First Installment First Installment [Member] First Installment Statement of financial position [abstract] Statement of financial position [abstract] Government loan - Interest Free Loan Government Loans - Interest Free Loan [Member] Government Loans - Interest Free Loan [Member] Disclosure of reconciliation of liabilities arising from financing activities [line items] Disclosure of reconciliation of liabilities arising from financing activities [line items] Non-current Miscellaneous non-current liabilities [abstract] Classes of share capital [axis] Classes of share capital [axis] Schedule of Total Revenue by Region Disclosure of geographical areas [text block] Disclosure of other provisions, contingent liabilities and contingent assets [Abstract] Disclosure of other provisions, contingent liabilities and contingent assets [Abstract] Disclosure of other provisions, contingent liabilities and contingent assets [Abstract] Basic earnings (loss) per ADS (in dollars per share) American Deposits Shares, Basic Earnings (Loss) per Share American Deposits Shares, Basic Earnings (Loss) per Share Reclassification Impairment loss recognised in profit or loss, property, plant and equipment Inventories Total net inventories Current inventories Provision for slow-moving or damaged inventory Current inventories Customer D Customer D [Member] Customer D [Member] Disclosure of detailed information about intangible assets [line items] Disclosure of detailed information about intangible assets [line items] Ranges [member] Ranges [member] Royalty accrual Royalty Accrual [Member] Royalty Accrual [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Award vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 2 Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 2 Capitalized development costs Capitalised development expenditure [member] Types of risks [axis] Types of risks [axis] Convertible Notes 2015 And 2018 - Nokomis Convertible Notes 2015 And 2018 - Nokomis [Member] Convertible Notes 2015 And 2018 - Nokomis Borrowings by name [axis] Borrowings by name [axis] Debt term Borrowings Maturity, Term Borrowings Maturity, Term Non-controlling interests Comprehensive income, attributable to non-controlling interests Minimum Minimum [Member] Disclosure of finance lease and operating lease by lessee [table] Disclosure of finance lease and operating lease by lessee [table] Interest-bearing loans and borrowings: Interest-Bearing Loans And Borrowings [Member] Interest-Bearing Loans And Borrowings [Member] Maintenance Revenue Nonsoftware Service, Support And Maintenance Arrangement 1 [Member] Nonsoftware Service, Support And Maintenance Arrangement [Member] Foreign exchange loss (gain) Foreign Exchange Gain (Loss) on Lease Liabilities Foreign Exchange Gain (Loss) on Lease Liabilities Research tax credit Research And Development Tax Credit Research And Development Tax Credit Aggregated time bands [member] Aggregated time bands [member] Business Contact Business Contact [Member] Research Tax Credit 2020 Research Tax Credit 2020 [Member] Research Tax Credit 2020 Disclosure of Financial Liabilities Disclosure of financial liabilities [text block] Hedging instruments [axis] Hedging instruments [axis] Total non-current Non-current financial assets Number of categories of authorized shares Number Of Categories Of Shares Authorised Number Of Categories Of Shares Authorised Equity (deficit): Equity [abstract] Depreciation and impairment: Accumulated depreciation, amortisation and impairment [member] Interest income Interest income Government Grants [Abstract] Government Grants [Abstract] Government Grants [Abstract] Deferred revenue, maintenance period Deferred Revenue Arrangement, Period Of Recognition Deferred Revenue Arrangement, Period Of Recognition Increase (Decrease) Through Conversion Of Loans, Equity Increase (Decrease) Through Conversion Of Loans, Equity Increase (Decrease) Through Conversion Of Loans, Equity Conversion price per ADS (in dollars per share) Debt Instrument, Convertible, Conversion Price Per ADS Debt Instrument, Convertible, Conversion Price Per ADS Disclosure of maturity analysis for non-derivative financial liabilities [table] Disclosure of maturity analysis for non-derivative financial liabilities [table] Machinery and equipment Machinery [member] Inventories Description of accounting policy for measuring inventories [text block] Research project, term Research And Development Arrangement, Contract To Perform For Others, Term Research And Development Arrangement, Contract To Perform For Others, Term Share-based payment arrangements [member] Share-based payment arrangements [member] Revenue Revenue Disclosure of other provisions [table] Disclosure of other provisions [table] Customer B Customer B [Member] Customer B [Member] Other Employees Other Employees [Member] Other Employees Research Tax Credit 2022 Research Tax Credit 2022 [Member] Research Tax Credit 2022 Share-Based Payment Arrangements [Abstract] Share-Based Payment Arrangements [Abstract] Share-Based Payment Arrangements [Abstract] Restricted share awards (RSA) Restricted Share Awards (RSA) [Member] Restricted Share Awards (RSA) [Member] Disclosure of geographical areas [line items] Disclosure of geographical areas [line items] Total current Current Financial Liabilities, At Fair Value Current Financial Liabilities, At Fair Value Retrospective application and retrospective restatement [axis] Retrospective application and retrospective restatement [axis] Number of awards granted, in ADS (in shares) Number Of Other Equity Instruments Granted In Share-Based Payment Arrangement, In ADS Number Of Other Equity Instruments Granted In Share-Based Payment Arrangement, In ADS Liabilities arising from financing activities beginning balance Liabilities arising from financing activities ending balance Liabilities arising from financing activities Document Transition Report Document Transition Report Issue of shares in connection with the ATM program (in shares) Number Of Share Issued, ATM Program Number Of Share Issued, ATM Program Award vesting percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Percentage Granting of shares Granting Of Shares [Member] Granting Of Shares [Member] Property, plant and equipment [member] Property, plant and equipment [member] Entity's total for related parties [member] Entity's total for related parties [member] Disclosure of major customers [line items] Disclosure of major customers [line items] Granted during the year Number of other equity instruments granted in share-based payment arrangement Deposits and other receivables Non-current loans and receivables Disclosure of detailed information about intangible assets [table] Disclosure of detailed information about intangible assets [table] Weighted average number of shares used for computing: Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract] Share premium Share premium [member] Unsecured Promissory Note Unsecured Promissory Note [Member] Unsecured Promissory Note Sell price multiple Sell price multiple (applied to exercise price) Selling Price Multiple, Share Options And Other Equity Instruments Granted Selling Price Multiple, Share Options And Other Equity Instruments Granted Korea KOREA, REPUBLIC OF Sequans Communications Ltd. Sequans Communications Ltd. [Member] Sequans Communications Ltd. [Member] Current income tax expense Current tax expense (income) Liquidity risk Liquidity risk [member] Types of hedges [axis] Types of hedges [axis] Other comprehensive income (loss) not to be reclassified to profit or loss in subsequent years : Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract] Convertible Notes Amended, Option Three Convertible Notes Amended, Option Three [Member] Convertible Notes Amended, Option Three [Member] Disclosure of credit risk exposure [line items] Disclosure of credit risk exposure [line items] Cash flow hedges Derivative Assets [Member] Derivative Assets [Member] Available-for-sale financial assets Financial assets available-for-sale, category [member] Entity Address, Country Entity Address, Country Royalty Agreement Terms Royalty Agreement Terms 1 [Member] Royalty Agreement Terms [Member] Diluted earnings (loss) per share (in dollars per share) Diluted earnings (loss) per share Decrease in weighted average share price (as a percent) Weighted Average Share Price of Share Options And Other Equity Instruments In Share-Based Payment Arrangement, Change As Percentage Weighted Average Share Price of Share Options And Other Equity Instruments In Share-Based Payment Arrangement, Change As Percentage Expense for defined contributions plans Post-employment benefit expense, defined contribution plans Classes of contingent liabilities [axis] Classes of contingent liabilities [axis] Financial liabilities considered in liquidity risk Non-derivative financial liabilities, undiscounted cash flows Arising (released) during the year Additional provisions, other provisions Schedule of Income and Share Data Used in Basic and Diluted Earnings (Loss) Per Share Computations Earnings per share [text block] Deferred income tax Description of accounting policy for deferred income tax [text block] Convertible debt Convertible Debt1 [Member] Convertible Debt1 Provision for credit notes to be issued Current refunds provision Professional fees expense Professional fees expense Disclosure of transactions between related parties [line items] Disclosure of transactions between related parties [line items] Percentage of bonus in event of dismissal Termination Indemnity Amount of Bonus, Percentage Termination Indemnity Amount of Bonus, Percentage Convertible Notes 2015 - Nokomis Convertible Notes 2015 - Nokomis [Member] Convertible Notes 2015 - Nokomis 2015 convertible notes Convertible Borrowings Issued - April 2015 [Member] Convertible Borrowings Issued - April 2015 [Member] Total non-current Non-Current Financial Liabilities, At Fair Value Non-Current Financial Liabilities, At Fair Value Accrued interest Borrowings, Accrued Interest Borrowings, Accrued Interest Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Gain (loss) on debt modification Gain (Loss) On Debt Modification Gain (Loss) On Debt Modification Exercise price (usd per share) Weighted average exercise price of other equity instruments granted in share-based payment arrangement Life used to compute amortization in the case of perpetual licenses Useful Lives Or Amortisation Rates, Intangible Assets Other Than Goodwill, Period Useful Lives Or Amortisation Rates, Intangible Assets Other Than Goodwill, Period Sequans Communications Israel (2009) Ltd. Sequans Communications Israel (2009) Ltd. [Member] Sequans Communications Israel (2009) Ltd. [Member] WAEP of units forfeited during the year (in usd per unit) Weighted Average Exercise Price Of Share Options And Other Equity Instruments Forfeited In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options And Other Equity Instruments Forfeited In Share-Based Payment Arrangement Customers [member] Customers [member] Exchange difference Increase (decrease) through net exchange differences, property, plant and equipment Earnings (loss) per share Description of accounting policy for earnings per share [text block] Customer F Customer F [Member] Customer F Other currencies denominated accounts Other Currencies [Member] Other Currencies [Member] Other financial assets Available-For-Sale Securities [Member] Available-For-Sale Securities [Member] Intangible assets Description of accounting policy for intangible assets other than goodwill [text block] Fixed Contractual Rate Fixed interest rate [member] Key management personnel Key management personnel of entity or parent [member] Document Period End Date Document Period End Date Increase (decrease) through change in nominal value Increase (Decrease) Through Change In Nominal Value Increase (Decrease) Through Change In Nominal Value Compensation of Key Management Personnel Disclosure of transactions between related parties [text block] Issue of equity, net proceeds Issue Of Equity, Net Proceeds Issue Of Equity, Net Proceeds Accumulated tax losses available for offset against future taxable profits Unused tax losses for which no deferred tax asset recognised Sell price multiple that had been used Selling Price Multiple, Share Options And Other Equity Instruments Granted, Option 1 Selling Price Multiple, Share Options And Other Equity Instruments Granted, Option 1 Percentage of total revenues Percentage of entity's revenue Percentage of entity's revenue Government loans Government loans Government Loans [Member] Government Loans [Member] Customer E Customer E [Member] Customer E [Member] Strategic Partner, Second Amendment Contract Strategic Partner, Second Amendment Contract [Member] Strategic Partner, Second Amendment Contract Disclosure of geographical areas [table] Disclosure of geographical areas [table] Research project financing Research project financing Research Project Financing [Member] Research Project Financing Property, plant and equipment Beginning balance Ending balance Property, plant and equipment Disclosure Of Cash And Cash Equivalents [Table] Disclosure Of Cash And Cash Equivalents [Table] Disclosure Of Cash And Cash Equivalents [Table] Issue of shares and warrants (in shares) Increase (decrease) in number of ordinary shares issued Convertible debts and venture debt - equity component Convertible Debt And Venture Debt, Equity [Member] Convertible Debt And Venture Debt, Equity [Member] Net increase (decrease) in cash and cash equivalents Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Tax credits Tax Effect Of Tax Credits Tax Effect Of Tax Credits Entity's total for subsidiaries [member] Entity's total for subsidiaries [member] Fixed and variable wages, social charges and benefits expensed in the year Key management personnel compensation, short-term employee benefits Types of contracts [axis] Types of contracts [axis] Expense By Nature [Line Items] Expense By Nature [Line Items] [Line Items] for Expense By Nature [Table] 2016 convertible notes Convertible Borrowings Issued - April 2016 [Member] Convertible Borrowings Issued - April 2016 [Member] Performance obligation Transaction price allocated to remaining performance obligations Entity's total for impairment of financial assets [member] Entity's total for impairment of financial assets [member] Convertible notes 2016 Convertible Notes 2016 [Member] Convertible Notes 2016 Government Grant Research Project Financing - Government Grant [Member] Research Project Financing - Government Grant [Member] Customer G Customer G [Member] Customer G Number of government loans Number Of Borrowings Number Of Borrowings Schedule of Cash and Cash Equivalents Schedule Of Cash And Cash Equivalents1 [Table Text Block] Schedule Of Cash And Cash Equivalents1 [Table Text Block] Non-current portion of other non-current borrowings Non-current portion of other non-current borrowings Total financial liabilities Fair value Financial liabilities, at fair value Purchase Commitment, Excluding Long-term Commitment1 [Domain] Purchase Commitment, Excluding Long-term Commitment1 [Domain] [Domain] for Purchase Commitment, Excluding Long-term Commitment1 [Axis] Plant and equipment Plant And Equipment [Member] Plant And Equipment [Member] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Statement of cash flows [abstract] Statement of cash flows [abstract] Sequans Communications Inc. Sequans Communications Inc. [Member] Sequans Communications Inc. [Member] Disclosure of contingent liabilities [table] Disclosure of contingent liabilities [table] Total comprehensive loss Comprehensive income Gain (loss) related to ineffective position of hedging instrument Gain (loss) on hedge ineffectiveness Cash and cash equivalents Cash and cash equivalents at January 1 Cash and cash equivalents at period end Cash and cash equivalents Loss transferred from other comprehensive income to the statement of operations Reclassification adjustments on cash flow hedges, net of tax Convertible debts and venture debt - liability Convertible Debt And Venture Debt, Liability [Member] Convertible Debt And Venture Debt, Liability [Member] Document Annual Report Document Annual Report Percentage Of Principal Amount Of The Note, Company Termination Fee Percentage Of Principal Amount Of The Note, Company Termination Fee Percentage Of Principal Amount Of The Note, Company Termination Fee Payments above limit Insurance Payment Minimum Insurance Payment Minimum Building and leasehold improvements Buildings And Leasehold Improvements [Member] Buildings And Leasehold Improvements [Member] Closing rate Closing foreign exchange rate Deferred Revenue Arrangement Type [Domain] Deferred Revenue Arrangement Type 1 [Domain] [Domain] for Deferred Revenue Arrangement Type [Axis] Convertible notes 2016 and 2019-1 Convertible Notes 2016 And 2019-1 [Member] Convertible Notes 2016 And 2019-1 Total non-current liabilities Non-current liabilities Fair value assumptions for determining value of the grants Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block] Cover [Abstract] Cover [Abstract] Loan commitments [member] Loan commitments [member] Purchase Commitment, Excluding Long-term Commitment1 [Axis] Purchase Commitment, Excluding Long-term Commitment1 [Axis] Purchase Commitment, Excluding Long-term Commitment1 [Axis] Cash and cash equivalents Description of accounting policy for determining components of cash and cash equivalents [text block] Basis per ADS (in dollars per share) ADS outstanding for basic and diluted earnings (loss) per ADS (in shares) American Deposit Shares Outstanding American Deposit Shares Outstanding Total assets Assets Convertible Note 2021 - Lynrock Lake Note Convertible Notes 2021 - Lynrock Lake Note [Member] Convertible Notes 2021 - Lynrock Lake Note Unutilised, allowance account for credit losses of financial assets [Abstract] Unutilised, allowance account for credit losses of financial assets Unutilised, allowance account for credit losses of financial assets Germany UNITED STATES revenue from sales of license revenue from sales of license revenue from sales of license Cumulative translation adjustments Reserve of exchange differences on translation [member] Development services Development Services [Member] Development Services [Member] Notional amount Total funding Government debt instruments Notional amount Sequans Communications Ltd. Pte. Sequans Communications Ltd. Pte. [Member] Sequans Communications Ltd. Pte. [Member] Foreign exchange gain Net foreign exchange gain Income tax expense (benefit) Weighted Average Ordinary Shares and Adjusted Weighted Average Ordinary Shares, Diluted [Abstract] Weighted Average Ordinary Shares and Adjusted Weighted Average Ordinary Shares, Diluted [Abstract] Financing activities: Cash flows from (used in) financing activities [abstract] Depreciation charge for the year Depreciation, property, plant and equipment Current borrowings Current borrowings Ordinary shares Issued capital [member] 2 to 3 years Later than two years and not later than three years [member] Functional currencies and translation of financial statements denominated in currencies other than the U.S. dollar Description of accounting policy for functional currency [text block] Entity Current Reporting Status Entity Current Reporting Status Taiwan TAIWAN Number of warrants authorized (in shares) Number of instruments granted in share-based payment arrangement Increase (decrease) through conversion of convertible instruments, equity Increase (decrease) through conversion of convertible instruments, equity 5G New Product Development 5G New Product Development [Member] 5G New Product Development Salary increase Actuarial assumption of expected rates of salary increases Accumulated deficit Accumulated deficit Retained earnings Supplier contract Non-cancelable purchase commitments with third-party manufacturer and suppliers for future deliveries of equipment and components Purchase Commitment1 [Member] Purchase Commitment1 [Member] Weighted average share price of options at exercise date (in usd per option) Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise Other Provisions, Contingent Liabilities And Contingent Assets Explanatory [Abstract] Other Provisions, Contingent Liabilities And Contingent Assets Explanatory [Abstract] Other Provisions, Contingent Liabilities And Contingent Assets Explanatory [Abstract] Other current liabilities and provisions Total other current liabilities Other current liabilities Basic (in shares) Weighted average number of shares outstanding for basic EPS (in shares) Weighted average number of ordinary shares used in calculating basic earnings per share Right of use Right-of-use assets [member] Deferred tax asset not recognized on losses (Loss available for offsetting against future taxable income) Unused tax losses [member] Value added tax Description of accounting policy for taxes other than income tax [text block] Convertible debt embedded derivative Non-current derivative financial liabilities Increase (Decrease) in provisions Adjustments for provisions Schedule of Main Assumptions Used Disclosure of defined benefit plans [text block] Exclusion from past due period of accounts receivable Exclusion From Borrowings, Past Due Period Exclusion From Borrowings, Past Due Period Disclosure of terms and conditions of share-based payment arrangement [line items] Disclosure of terms and conditions of share-based payment arrangement [line items] Interest received Interest received, classified as investing activities Increase (Decrease) in contract liabilities Adjustments for increase (decrease) in deferred income including contract liabilities Impact of exchange rate Unrealised foreign exchange gains (losses) [member] Shareholder Loan Agreement Shareholder Loan Agreement [Member] Shareholder Loan Agreement Increase (Decrease) in trade payables and other liabilities Adjustments for increase (decrease) in trade and other payables Current liabilities: Current liabilities [abstract] Financial expenses: Expenses by nature [abstract] Massive IoT Technology, IOT [Member] Technology, IOT [Member] Disclosure of transaction price allocated to remaining performance obligations [line items] Disclosure of transaction price allocated to remaining performance obligations [line items] Entity Voluntary Filers Entity Voluntary Filers Disclosure of material accounting policy information [text block] Disclosure of material accounting policy information [text block] Statistical Measurement [Domain] Statistical Measurement [Domain] Sales and Marketing Sales and Marketing [Member] Sales and Marketing Issue of shares in connection with the exercise of options and warrants (in shares) Number Of Share Options And Warrants Exercised In Share-based Payment Arrangement Number Of Share Options And Warrants Exercised In Share-based Payment Arrangement Repayment of convertible debt and accrued interest Repayment of convertible debt and accrued interest Repayment Of Convertible Debt And Accrued Expenses Repayment Of Convertible Debt And Accrued Expenses Share capital [member] Share capital [member] Increase (decrease) in other provisions Increase (decrease) in other provisions Increase (decrease) in other provisions Percentage of total cost of sales Percentage Of Entity's Cost Of Sales Percentage Of Entity's Cost Of Sales Commitments Commitments And Contingencies, Policy1 [Policy Text Block] Commitments And Contingencies, Policy1 [Policy Text Block] Deposits Deposits 1 [Member] Deposits [Member] Operating income (loss) Profit (loss) from operating activities Related Party [Abstract] Related Party [Abstract] Related Party [Abstract] Lease Contracts [Member] Lease Contracts [Member] Lease Contracts [Member] Total operating expenses Operating expense Customer C Customer C [Member] Customer C [Member] Intangible Assets [Abstract] Intangible Assets [Abstract] Intangible Assets [Abstract] Shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Number of shares outstanding Bpifrance Participations Bpifrance Participations [Member] Bpifrance Participations Income tax expense (benefit) Income tax expense (benefit) Tax expense (income) Other benefits Other short-term employee benefits Other, net Miscellaneous other operating expense WAEP of units granted during the year (in usd per unit) Weighted Average Exercise Price Of Share Options And Other Equity Instruments Granted In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options And Other Equity Instruments Granted In Share-Based Payment Arrangement Prepaid expenses Current prepayments Share capital of the Company (in excess of) Proportion of ownership interests held by non-controlling interests Geographical [Axis] Geographical [Axis] Previously stated Previously stated [member] Adjustments for increase (decrease) in derivative financial liabilities Adjustments for increase (decrease) in derivative financial liabilities Purchase Commitment, Excluding Long-term Commitment1 [Line Items] Purchase Commitment, Excluding Long-term Commitment1 [Line Items] [Line Items] for Purchase Commitment, Excluding Long-term Commitment1 [Table] Non-current assets: Non-current assets [abstract] Term of collaborative project Government Grant Advances, Term Of Project Government Grant Advances, Term Of Project Number of units forfeited during the year Number Of Share Options And Other Equity Instruments Forfeited In Share-Based Payment Arrangement Number Of Share Options And Other Equity Instruments Forfeited In Share-Based Payment Arrangement Development costs capitalized (*) Research And Development Costs Capitalized, Net Of Tax Credit Research And Development Costs Capitalized, Net Of Tax Credit Dividend yield (%) Expected Dividend As Percentage, Share Options And Other Equity Instruments Granted Expected Dividend As Percentage, Share Options And Other Equity Instruments Granted 2018 convertible notes Convertible Borrowings Issued - September 2018 [Member] Convertible Borrowings Issued - September 2018 [Member] Convertible debt amendments Convertible Debt Amendment, Net Convertible Debt Amendment, Net Interest rate types [member] Interest rate types [member] Provisions Non current Non-current provisions Disclosure Of Financial Assets And Liabilities [Table] Disclosure Of Financial Assets And Liabilities [Table] Disclosure Of Financial Assets And Liabilities [Table] Reduction in debt carrying value Debt Instrument, Increase (Decrease) For Period, Net 1 Debt Instrument, Increase (Decrease) For Period, Net Earnings (loss) per share Disclosure of earnings per share [text block] Issued capital Ordinary shares Issued capital Other receivables Other receivables BPI France Participation – Fonds Large Venture BPI France Participation [Member] BPI France Participation Disclosure of major customers [table] Disclosure of major customers [table] Period after termination date Research And Development Arrangement, Contract To Perform For Others, Period After Date Of Termination Research And Development Arrangement, Contract To Perform For Others, Period After Date Of Termination Increase (decrease) through exercise of warrants, equity Increase (decrease) through exercise of warrants, equity Continuing involvement in derecognised financial assets by type of transfer [axis] Continuing involvement in derecognised financial assets by type of transfer [axis] Classes of other provisions [axis] Classes of other provisions [axis] Net remaining contract liability License and Services Agreement, Contract Liability License and Services Agreement, Contract Liability Issue of shares in connection with the exercise of options and warrants, and vesting of restricted shares awards Increase (Decrease) Through Exercise Of Options And Warrants, Equity Increase (Decrease) Through Exercise Of Options And Warrants, Equity Disclosure of transactions between related parties [table] Disclosure of transactions between related parties [table] Entity Ex Transition Period Entity Ex Transition Period Income tax paid Income taxes paid, classified as operating activities Other provisions and accruals Other Provisions And Accruals [Member] Other Provisions And Accruals [Member] Contract liabilities Non-current contract liabilities Provision used, other provisions Released (used) during the year Provision used, other provisions Contract assets Current contract assets Shares Issued and Fully Paid Disclosure of classes of share capital [text block] Increase (decrease) in working capital Increase (decrease) in working capital Monthly over the remaining 36 months Vesting scenario 2 Share-Based Compensation Award, Tranche Two1 [Member] Share-Based Compensation Award, Tranche Two1 [Member] IT and office equipment Information Technology And Office Equipment [Member] Information Technology And Office Equipment [Member] Permanent differences and other Other tax effects for reconciliation between accounting profit and tax expense (income) Basic earnings (loss) per share (in dollars per share) Basic earnings (loss) per share WAEP of units expired during the year (in usd per unit) Weighted Average Exercise Price Of Share Options And Other Equity Instruments Expired In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options And Other Equity Instruments Expired In Share-Based Payment Arrangement Re-measurement gains (losses) on defined benefit plans Re-measurement gains (losses) on defined benefit plans Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans Contact Personnel Fax Number Contact Personnel Fax Number Change in fair value of convertible debt derivative Change in the fair value of convertible debt embedded derivative Expenses related to the change in fair value of the convertible debt embedded derivative Gains (losses) on change in fair value of derivatives Disclosure of Leases [Table] Disclosure of Leases [Table] Disclosure of Leases [Table] Options Option contract [member] Trade payables Payables Non-current trade payables Total current Current financial assets Intangible assets with indefinite useful life [axis] Intangible assets with indefinite useful life [axis] Discount rate Fair Value Inputs, Discount Rate1 Fair Value Inputs, Discount Rate1 Derivative financial liabilities Derivative financial liabilities Conversion of convertible debt, in ADS (in shares) Number Of ADS Issued Through Conversion Of Convertible Instruments, Equity Number Of ADS Issued Through Conversion Of Convertible Instruments, Equity From subsidiaries Subsidiaries [Member] Research Tax Credit [Axis] Research Tax Credit [Axis] Research Tax Credit Share-based payment expense Adjustments for share-based payments Long-term investments Long-Term Investments [Member] Long-Term Investments [Member] Disclosure of detailed information about financial instruments [abstract] Disclosure of detailed information about financial instruments [abstract] Research and development costs Description of accounting policy for research and development expense [text block] Number of projects Research And Development Arrangement, Contract To Perform For Others, Number Of Projects Research And Development Arrangement, Contract To Perform For Others, Number Of Projects Borrowings, accrued interest and conversion bonus Borrowings, Accrued Interest And Conversion Bonus Borrowings, Accrued Interest And Conversion Bonus Schedule of Movements in the Provision for Impairment of Receivables Reconciliation of Changes in Provisions Disclosure of other provisions [text block] Research Tax Credit 2023 Research Tax Credit 2023 [Member] Research Tax Credit 2023 Disclosure of transaction price allocated to remaining performance obligations [table] Disclosure of transaction price allocated to remaining performance obligations [table] Types of interest rates [axis] Types of interest rates [axis] Proceeds from convertible debt, net of transaction cost Proceeds From Convertible Borrowings Issued, Net Proceeds From Convertible Borrowings Issued, Net Reclassification Reclassifications, Property, Plant and Equipment Reclassifications, Property, Plant and Equipment Foreign exchange gain (loss), net Foreign exchange gains and losses related to hedges of euro Foreign exchange (gains) losses related to hedges of euro Foreign exchange gain (loss) Financial assets: Financial Instruments, Assets [Abstract] Financial Instruments, Assets [Abstract] Long-Term Research Project - October 2014 Long-Term Research Project - October 2014 [Member] Long-Term Research Project - October 2014 [Member] Debt instrument, ownership limit Debt Instrument, Ownership Limit Debt Instrument, Ownership Limit Unrecognized benefit of tax losses carryforward Tax effect of tax losses Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] Product and Service [Domain] Product and Service [Domain] Net effect of dilutive warrants (in shares) Dilutive effect of convertible instruments on weighted average number of ordinary shares Loss (gain) on disposal of property, plant and equipment Adjustments for gain (loss) on disposals, property, plant and equipment Share-based payment expenses Expense from share-based payment transactions with employees Current assets: Current assets [abstract] Other bank fees and financial charges Bank and similar charges Commitments and contingencies Disclosure of commitments and contingent liabilities [text block] Categories of related parties [axis] Categories of related parties [axis] Others Other current payables Revenue from development contracts where no related incremental costs were identified Revenue from rendering of information technology services Schedule of Research and Development Arrangement, Contract to Perform for Others Schedule Of Research And Development Arrangement Contract To Perform For Others1 [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others1 Statement of changes in equity [line items] Statement of changes in equity [line items] Number of collaborative projects Government Grant Advances, Number Of Collaborative Projects, Entered During Period Government Grant Advances, Number Of Collaborative Projects, Entered During Period Reasonably possible change in risk variable, percent Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent Classes of financial assets [axis] Classes of financial assets [axis] Number of installments Borrowings, Number Of Installments Borrowings, Number Of Installments Increase (decrease) through other changes Increase (decrease) through other changes, liabilities arising from financing activities ASSETS Assets [abstract] Entity File Number Entity File Number Investing activities: Cash flows from (used in) investing activities [abstract] Loss for the year Loss for the year Net losses Profit (Loss) Profit (loss) Par value per share Par value per share Par value per share Auditor Firm ID Auditor Firm ID Entity Shell Company Entity Shell Company SGP denominated accounts Singapore, Dollars Schedule of Present Fair Values of Derivative Financial Instruments Disclosure of detailed information about financial instruments [text block] Current income tax Description of accounting policy for income tax [text block] Market approach Market approach [member] Research And Development Arrangement, Contract To Perform For Others, Type [Domain] Research And Development Arrangement, Contract To Perform For Others, Type 1 [Domain] [Domain] for Research and Development Arrangement, Contract to Perform for Others, Type Convertible debt amendments (Note 14.1) Convertible Debt Amendment, Net Income Convertible Debt Amendment, Net Income Convertible debt amendments Adjustments For Convertible Debt Amendments Adjustments For Convertible Debt Amendments Project [Axis] Project1 [Axis] Project [Axis] Deferred revenue Non-current deferred income including non-current contract liabilities Statement of changes in equity [abstract] Statement of changes in equity [abstract] License and services revenue Other Revenue [Member] Other Revenue [Member] Termination indemnity amount (in months) Termination Indemnity Amount of Gross Annual Base Remuneration, Duration Termination Indemnity Amount of Gross Annual Base Remuneration, Duration Government loans Non-Current Government Loans Non-Current Government Loans Period of the maintenance Revenue From Software Maintenance And Support Services, Period Of Maintenance Revenue From Software Maintenance And Support Services, Period Of Maintenance Counterparties [axis] Counterparties [axis] Contact Personnel Name Contact Personnel Name Long-Term Research Project - January 2016 Long-Term Research Project - January 2016 [Member] Long-Term Research Project - January 2016 [Member] Relationship To Entity [Domain] Relationship To Entity [Domain] [Domain] for Title Of Individual [Axis] Factoring of receivables Factoring of receivables [member] Applicable tax rate Applicable tax rate Rest of world Europe, Middle East, And Africa [Member] Europe, Middle East, And Africa [Member] Risk–free interest rate (%) Risk Free Interest Rate, Share Options And Other Equity Instruments Granted Risk Free Interest Rate, Share Options And Other Equity Instruments Granted Document Registration Statement Document Registration Statement Entity Address, Address Line One Entity Address, Address Line One Pension costs Post-employment benefit expense in profit or loss, defined benefit plans License and services agreement upfront payment License and Services Agreement, Upfront Payment to be Received License and Services Agreement, Upfront Payment to be Received Assets [member] Assets [member] Schedule of Intangible Assets Disclosure of reconciliation of changes in intangible assets and goodwill [text block] Financial assets Description of accounting policy for financial assets [text block] Leasehold improvements Leasehold improvements [member] Forward contracts Forward contract [member] Directors Directors, Vice Presidents And Managers [Member] Directors, Vice Presidents And Managers Income Taxes [Abstract] Income Taxes [Abstract] Income Taxes [Abstract] Lease liabilities Current Current lease liabilities Share-based payments Increase (decrease) through share-based payment transactions, equity Disclosure of detailed information about borrowings [line items] Disclosure of detailed information about borrowings [line items] Conversion price premium percentage Debt Instrument, Convertible, Conversion Price, Premium Percentage Debt Instrument, Convertible, Conversion Price, Premium Percentage Total current Current financial liabilities Cash, cash equivalents and short-term investments Cash, Cash Equivalents And Short-Term Investments [Member] Cash, Cash Equivalents And Short-Term Investments [Member] Total minimum lease payments Minimum lease payments payable under non-cancellable operating lease Interest paid Interest paid, classified as financing activities Interest paid, classified as financing activities Trade payable term Trade Payable Term Trade Payable Term Share-based payment transactions Description of accounting policy for share-based payment transactions [text block] Executive Team Executive Team [Member] Executive Team Attributable to: Profit (loss), attributable to [abstract] Government loan, Covid-19 support plan Government Loan, Covid-19 Support Plan [Member] Government Loan, Covid-19 Support Plan Schedule of Research and Development Expense Disclosure Of Research And Development Expense Explanatory [Table Text Block] Disclosure Of Research And Development Expense Explanatory [Table Text Block] New IFRSs [axis] New IFRSs [axis] Operating activities: Cash flows from (used in) operating activities [abstract] Within one year Not later than one year [member] Affiliate of Nokomis Capital, L.L.C. Affiliated Entity 1 [Member] Affiliated Entity [Member] Leases Description of accounting policy for leases [text block] Assumed annual lapse rate of RSA (%) Assumed Annual Lapse Rate, Other Equity Instruments Granted Assumed Annual Lapse Rate, Other Equity Instruments Granted Later than one year Later than one year [member] Government loan - 5.24% Loan Government Loans - 5.24 Percent Loan [Member] Government Loans - 5.24 Percent Loan [Member] Debt instruments issued Debt instruments issued Issue of shares in connection with the public offering of March 2022 (Note 12) Increase (Decrease) Through Share Issued, ATM Program, Equity Increase (Decrease) Through Share Issued, ATM Program, Equity Trade payables Trade payables Total current assets Current assets Other comprehensive income (loss) to be reclassified to profit or loss in subsequent years : Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] Other Provisions, Contingent Liabilities and Contingent Assets [Abstract] Other Provisions, Contingent Liabilities and Contingent Assets [Abstract] Other Provisions, Contingent Liabilities and Contingent Assets [Abstract] Short-term deposits Current Deposit Assets Current Deposit Assets Other related parties [member] Other related parties [member] Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Disclosure of classes of share capital [table] Disclosure of classes of share capital [table] Classes of intangible assets other than goodwill [axis] Classes of intangible assets other than goodwill [axis] Other provisions [member] Other provisions [member] Social security costs and other payroll taxes Social security contributions Schedule of Liquidity Risk Disclosure of maturity analysis for non-derivative financial liabilities [text block] Carrying amount Financial Instruments, Assets, Carrying Amount [Abstract] Financial Instruments, Assets, Carrying Amount [Abstract] Classes of ordinary shares [axis] Classes of ordinary shares [axis] Carrying amount Financial Instruments, Liabilities, Carrying Amount [Abstract] Financial Instruments, Liabilities, Carrying Amount [Abstract] Warrants Warrants [member] Schedule of Government Grant Advances and Loans Disclosure Of Government Grant Advances And Loans, Explanatory [Table Text Block] Disclosure Of Government Grant Advances And Loans, Explanatory Unsecured related party loan Finance lease liability Finance lease liability Finance Lease Liabilities [Member] Finance Lease Liabilities [Member] Restricted share awards Restricted Shares [Member] Restricted Shares [Member] Development and other services Development And Other Services [Member] Development And Other Services [Member] Consultants considered equivalent to employees Consultants [Member] Consultants [Member] Borrowings, interest rate Interest rate Borrowings, interest rate Hedges [member] Hedges [member] Categories of financial assets [axis] Categories of financial assets [axis] Liabilities arising from financing activities [member] Liabilities arising from financing activities [member] Disclosure of detailed information about financial instruments [table] Disclosure of detailed information about financial instruments [table] Ordinary Shares And ADS Ordinary Shares And ADS [Member] Ordinary Shares And ADS Trade receivables and contract assets Trade receivables [member] Net other comprehensive income (loss) not to be reclassified to profit or loss in subsequent years Other comprehensive income that will not be reclassified to profit or loss, net of tax Customer [Domain] Customer [Domain] Disclosure of financial liabilities [table] Disclosure of financial liabilities [table] Research project financing Current Research Project Financing Current Research Project Financing Shareholders of the parent Comprehensive income, attributable to owners of parent Additions Additions on Lease Liabilities Additions on Lease Liabilities Quarterly over the remaining three years Vesting scenario 3 Share-Based Compensation Award, Tranche Three1 [Member] Share-Based Compensation Award, Tranche Three1 [Member] Research and Development Research and Development [Member] Research and Development Net effect of vesting of restricted stock (in shares) Effect Of Vesting Of Restricted Stock Effect Of Vesting Of Restricted Stock Issue of shares and warrants Issue of equity Disclosure of defined benefit plans [line items] Disclosure of defined benefit plans [line items] Interest-bearing loans and borrowings Disclosure of borrowings [text block] Deferred income tax expense (benefit) Deferred tax expense (income) B. Riley Asset Management LLC and Lynrock Lake B. Riley Asset Management LLC and Lynrock Lake [Member] B. Riley Asset Management LLC and Lynrock Lake Basis of consolidation Consolidation, Policy1 [Policy Text Block] Consolidation, Policy1 [Policy Text Block] Warrant, as a percentage of note value Debt Instrument, Convertible, Warrant, Percentage Of Note Value Debt Instrument, Convertible, Warrant, Percentage Of Note Value Second Security Purchase Agreement Second Security Purchase Agreement [Member] Second Security Purchase Agreement Property, plant and equipment Description of accounting policy for property, plant and equipment [text block] Disposals on Lease Liabilities Disposals on Lease Liabilities Disposals on Lease Liabilities Deferred tax liabilities Deferred tax liabilities Increase (decrease) in number of shares outstanding Increase (decrease) in number of shares outstanding Unsecured related party loan Unsecured Related Party Loan [Member] Unsecured Related Party Loan Proceeds from borrowings Proceeds from borrowings, classified as financing activities Disclosure of reconciliation of liabilities arising from financing activities [table] Disclosure of reconciliation of liabilities arising from financing activities [table] Borrowing, Retention Amount Borrowing, Retention Amount Borrowing, Retention Amount Cost of Revenue Cost of Revenue [Member] Cost of Revenue General and administrative Selling, general and administrative expense Types of share-based payment arrangements [axis] Types of share-based payment arrangements [axis] Service Sales [Member] Service Sales [Member] Service Sales [Member] Government grant advances Non-Current Government Grant Advances Non-Current Government Grant Advances Bottom of range Bottom of range [member] Bottom of range [member] Payment of lease liabilities Payments of lease liabilities, classified as financing activities Proceeds received from long-term projects Proceeds from government grants, classified as financing activities After the two year anniversary of grant Share-Based Compensation Award, Tranche Four [Member] Share-Based Compensation Award, Tranche Four [Member] Working capital adjustments: Adjustments For Working Capital [Abstract] Adjustments For Working Capital [Abstract] Increase (decrease) through effect of changes in foreign exchange rates Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities Litigation Case [Domain] Litigation Case [Domain] Entity Filer Category Entity Filer Category Ordinary shares [member] Ordinary shares [member] Currencies Other Than US Dollar Currencies Other Than US Dollar [Member] Currencies Other Than US Dollar Research project financing Non-Current Research Project Financing Non-Current Research Project Financing Impact of change in the corresponding risk variable on operating expenses Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Operating Expenses Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Operating Expenses Current Fiscal Year End Date Current Fiscal Year End Date Convertible debt Convertible Debt And Accrued Interest [Member] Convertible Debt And Accrued Interest [Member] Disclosure of credit risk exposure [table] Disclosure of credit risk exposure [table] Amount funded from government grant advances Government Grant Advances, Funding Commitment Amount Government Grant Advances, Funding Commitment Amount Repayment of convertible debt Repayment Of Convertible Debt Repayment Of Convertible Debt Address Type [Domain] Address Type [Domain] Accumulated deficit Retained earnings [member] Share premium Share premium Classes of property, plant and equipment [axis] Classes of property, plant and equipment [axis] Non-cash adjustment to reconcile profit (loss) before tax to net cash used in operating activities: Adjustments to reconcile profit (loss) [abstract] Products and services [axis] Products and services [axis] Class Action Lawsuit, Revenue Recognition Policy Class Action Lawsuit, Revenue Recognition Policy [Member] Class Action Lawsuit, Revenue Recognition Policy [Member] Rest of Asia Asia Pacific [Member] Convertible debt Convertible debt Convertible Borrowings Issued [Member] Convertible Borrowings Issued [Member] Losses on change in fair value of derivatives Losses on change in fair value of derivatives Weighted average share price (in € per share) Weighted Average Share Price, Share Options And Other Equity Instruments Granted Weighted Average Share Price, Share Options And Other Equity Instruments Granted Schedule of Financial Income and Expenses Disclosure Of Finance Income And Costs Explanatory [Table Text Block] Disclosure Of Finance Income And Costs Explanatory [Table Text Block] Decrease in total compensation (as a percent) Share-Based Compensation Arrangement By Share-Based Payment Award, Change In Compensation Cost, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Change In Compensation Cost, Percentage PIK interest rate Debt Instrument, Convertible, Payment-In-Kind Interest Rate Debt Instrument, Convertible, Payment-In-Kind Interest Rate Number of warrants issued Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights1 Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights1 Number of units expired during the year Number Of Share Options And Other Equity Instruments Expired In Share-Based Payment Arrangement Number Of Share Options And Other Equity Instruments Expired In Share-Based Payment Arrangement Net gain (loss) on cash flow hedge Net gain (loss) on cash flow hedge Other comprehensive income, net of tax, cash flow hedges Interest expenses on upfront payment License and Services Agreement, Interest Expense on Upfront Payment License and Services Agreement, Interest Expense on Upfront Payment Euro denominated accounts Euro Member Countries, Euro ABLE France ABLE France [Member] ABLE France Additions/Amortization Additions other than through business combinations, intangible assets other than goodwill Cash at banks Balances with banks Useful life Useful Lives Or Depreciation Rates, Property, Plant And Equipment, Period Useful Lives Or Depreciation Rates, Property, Plant And Equipment, Period After the first year anniversary of grant Vesting scenario 1 Share-Based Compensation Award, Tranche One1 [Member] Share-Based Compensation Award, Tranche One1 [Member] Convertible debt embedded derivative Embedded Derivative [Member] Embedded Derivative [Member] Proceeds from current borrowings Proceeds from current borrowings Convertible debt amendment, net expense Convertible Debt Amendment, Net Expense Convertible Debt Amendment, Net Expense Intangible assets other than goodwill [member] Intangible assets other than goodwill [member] Earnings per share [abstract] Earnings per share [abstract] American Depositary Shares, each representing four ordinary shares, nominal value €0.01 per share American Depositary Shares [Member] American Depositary Shares Development services agreements Development Services Agreements [Member] Development Services Agreements [Member] Income from short-term investments and term deposits and other finance revenue Investment income Provision To Serve Expected Demand For Customers And Projects Provision To Serve Expected Demand For Customers And Projects [Member] Provision To Serve Expected Demand For Customers And Projects Interest expense, net Adjustments for finance costs Levels of fair value hierarchy [axis] Levels of fair value hierarchy [axis] Disclosure of detailed information about financial instruments [line items] Disclosure of detailed information about financial instruments [line items] Tax expense (income) during the year recognized in Profit or Loss Deferred tax expense (income) recognised in profit or loss Purchase of intangible assets and property, plant and equipment Purchase Of Property, Plant And Equipment And Intangible Assets, Classified As Investing Activities Purchase Of Property, Plant And Equipment And Intangible Assets, Classified As Investing Activities Impairment of financial assets [axis] Impairment of financial assets [axis] Statement of changes in equity [table] Statement of changes in equity [table] Public and private equity offering proceeds, net of transaction costs paid Proceeds from issuing shares Condensed Income Statement [Table] Condensed Income Statement [Table] Major ordinary share transactions Major ordinary share transactions [member] Offering price Aggregate Offering Price Aggregate Offering Price Net cash flow used in operating activities Cash flows from (used in) operating activities Document Fiscal Period Focus Document Fiscal Period Focus Bridge loans from related party Increase (Decrease) Through Exercise Of Bridge Loans From Related Party, Equity Increase (Decrease) Through Exercise Of Bridge Loans From Related Party, Equity Reconciliation of changes in other provisions [abstract] Reconciliation of changes in other provisions [abstract] Schedule of Average and Closing Exchange Rate for the U.S. Dollar Disclosure Of Exchange Rate For Functional Currency [Table Text Block] Disclosure Of Exchange Rate For Functional Currency [Table Text Block] Revenue recognition Description of accounting policy for recognition of revenue [text block] City Area Code City Area Code Underwriters' over-allotment shares issued (in shares) Increase (Decrease) In Number Of Underwriters' Over-Allotment Shares Issued Increase (Decrease) In Number Of Underwriters' Over-Allotment Shares Issued Impaired additional trade receivables Impairment loss recognised in profit or loss, trade receivables Product and Service [Axis] Product and Service [Axis] Financial instruments at fair value through other comprehensive income Financial instruments at fair value through other comprehensive income Financial Liabilities Measured At Fair Value Through Other Comprehensive Income [Member] Financial Liabilities Measured At Fair Value Through Other Comprehensive Income [Member] Disclosure Of Financial Assets And Liabilities [Line Items] Disclosure Of Financial Assets And Liabilities [Line Items] [Line Items] for Disclosure Of Financial Assets And Liabilities [Table] Deferred tax liability At January 1st At December 31st Deferred tax liability (asset) Deferred tax liability (asset) Condensed Income Statements, Captions [Line Items] Condensed Income Statements, Captions [Line Items] Total non-current Non-current financial liabilities Adjustment to interest rate basis Borrowings, adjustment to interest rate basis Title Of Individual [Axis] Title Of Individual 1 [Axis] Title Of Individual [Axis] Amortization and impairment of property, plant and equipment Adjustments For Depreciation Expense And Impairment Loss (Reversal Of Impairment Loss) Recognized In Profit Or Loss, Property, Plant And Equipment Adjustments For Depreciation Expense And Impairment Loss (Reversal Of Impairment Loss) Recognized In Profit Or Loss, Property, Plant And Equipment 2019-1 notes Convertible Notes 2019-1 [Member] Convertible Notes 2019-1 [Member] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Foreign currency risk Currency risk [member] Interest rate used to value liability Significant unobservable input, entity's own equity instruments Convertible Notes 2018 - Nokomis Convertible Notes 2018 - Nokomis [Member] Convertible Notes 2018 - Nokomis Disclosure of non-adjusting events after reporting period [abstract] Development Of The 5G Development Of The 5G [Member] Development Of The 5G Schedule of Effect of Implementation of IFRIC Decision on IAS 19 Disclosure of initial application of standards or interpretations [text block] Convertible debt embedded derivative Current derivative financial liabilities Increase (decrease) through other changes, equity Increase (decrease) through other changes, equity Total Asia Asia [Member] Ordinary share price (usd per share) Share Price1 Price of a single share of a number of saleable stocks of a company. Research and development Total research and development expense Research and development expense Fee and commission expense Fee and commission expense Fair value assumptions for determining value of the grants Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block] Aging Analysis of Trade Receivables That Were Not Impaired Disclosure of financial assets that are either past due or impaired [text block] Inventories [Abstract] Inventories [Abstract] Inventories [Abstract] Financial liabilities, category [member] Financial liabilities, category [member] Financial income (expense): Financial Income (Expense) [Abstract] Financial Income (Expense) [Abstract] Repayment of interest-bearing research project financing Repayments of Interest-bearing Research Project Financing Repayments of Interest-bearing Research Project Financing Broadband IoT Technology, Broadband [Member] Technology, Broadband [Member] Interest-bearing financing of receivables Current borrowings and current portion of non-current borrowings Schedule of Financial Assets Disclosure of financial assets [text block] Borrowings by name [member] Borrowings by name [member] Exchange differences on translation of foreign operations Foreign currency translation Other comprehensive income, net of tax, exchange differences on translation of foreign operations Guaranteed return (in percentage) Guaranteed Return, Rate Guaranteed Return, Rate Currency [Axis] Currency [Axis] Entity Address, City or Town Entity Address, City or Town Decrease (Increase) in trade receivables and other receivables Adjustments for decrease (increase) in trade and other receivables Reconciliation of changes in intangible assets other than goodwill [abstract] Reconciliation of changes in intangible assets other than goodwill [abstract] Non-adjusting events after reporting period [axis] Non-adjusting events after reporting period [axis] Right-of-use assets Right-of-use assets at beginning of period Right-of-use assets at end of period Right-of-use assets Currently stated [member] Currently stated [member] Lease liabilities Lease liabilities at beginning of period Lease liabilities at end of period Lease liabilities Total financial liabilities Financial liabilities Revenue: Revenue [abstract] Derivative maturity period Derivative Financial Liabilities, Maturity, Term Derivative Financial Liabilities, Maturity, Term [Member] WAEP of units exercisable at period end (in usd per unit) Subscription price (eur per share) Weighted Average Exercise Price Of Share Options And Other Equity Instruments Exercisable In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options And Other Equity Instruments Exercisable In Share-Based Payment Arrangement RMB denominated accounts China, Yuan Renminbi 272 Capital Fund LP 272 Capital Fund LP [Member] 272 Capital Fund LP Share price per ADS (usd per share) Share Price Per ADS Share Price Per ADS Changes in tax rates Changes in tax rates or tax laws enacted or announced [member] Disclosure of maturity analysis for non-derivative financial liabilities [line items] Disclosure of maturity analysis for non-derivative financial liabilities [line items] Document Information [Table] Document Information [Table] Maximum percentage of ordinary shares provided to cover underwriter's over-allotment option Maximum Percentage Of Ordinary Shares Placed Within Offering Provided To Cover Underwriter's Over-allotment Option Maximum Percentage Of Ordinary Shares Placed Within Offering Provided To Cover Underwriter's Over-allotment Option License and development services agreement Deferred Income Classified as Non-current, Strategic Agreement Deferred Income Classified as Non-current, Strategic Agreement Past due status [axis] Past due status [axis] Increase (decrease) through non-cash impact of amendment Increase (Decrease) Through Non-Cash Impact Of Amendment, Liabilities Arising From Financing Activities Increase (Decrease) Through Non-Cash Impact Of Amendment, Liabilities Arising From Financing Activities Total current Current Financial Assets, At Fair Value Current Financial Assets, At Fair Value Current contract liabilities License and Services Agreement, Current Contract Liability License and Services Agreement, Current Contract Liability Additions Additions other than through business combinations, property, plant and equipment Level 2 Level 2 of fair value hierarchy [member] Investments revenue License and Services Agreement, Investments Revenue License and Services Agreement, Investments Revenue Liabilities arising from financing activities [axis] Liabilities arising from financing activities [axis] Provisions Description of accounting policy for provisions [text block] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research And Development Arrangement, Contract To Perform For Others, Type 1 [Axis] Research And Development Arrangement, Contract To Perform For Others, Type [Axis] Released (unused) during the year Unused provision reversed, other provisions Deferred tax effect, equity Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature1 Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature1 Title of Individual [Domain] Title of Individual [Domain] Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Lease liabilities Disclosure of leases [text block] Current Other current liabilities: Miscellaneous current liabilities [abstract] Convertible debt embedded derivative Convertible Borrowings embedded derivative [Member] Convertible Borrowings embedded derivative Summary of movement in number and WAEP of founder warrants, warrants and restricted shares awards Disclosure of number and weighted average exercise prices of other equity instruments [text block] Rental charges Rent Expense on Leases Rent Expense on Leases Subclassifications of assets, liabilities and equities [abstract] Subclassifications of assets, liabilities and equities [abstract] Corporate Information And Statement Of IFRS Compliance [Abstract] Corporate information and statement of IFRS compliance [abstract] Licenses Licences and franchises [member] Schedule of Cost of Revenue and Operating Expenses Disclosure Of Cost Of Sales, Operating Expenses, And Employee Benefits Explanatory [Table Text Block] Disclosure Of Cost Of Sales, Operating Expenses, And Employee Benefits Explanatory [Table Text Block] Document Information [Line Items] Document Information [Line Items] % equity interest Proportion of ownership interest in subsidiary Bad debt expense Adjustments for Bad Debt Expense Adjustments for Bad Debt Expense Schedule of Trade Payables and Other Current Liabilities Disclosure Of Trade And Other Current Payables Explanatory [Table Text Block] Disclosure Of Trade And Other Current Payables Explanatory [Table Text Block] Schedule of Non-Interest Bearing Trade Receivables Schedule of Accounts, Notes, Loans and Financing Receivable 1 [Table Text Block] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Reduction of issued capital Reduction of issued capital Reduction of issued capital Contingent liabilities related to joint ventures Contingent liabilities related to joint ventures [member] Board Of Directors [Member] Board Of Directors [Member] Board Of Directors [Member] Additions Additions to right-of-use assets At France’s statutory income tax rate of 26.5% in 2021 and 25% in 2022 and in 2023 Tax expense (income) at applicable tax rate Employees and social debts Short-term employee benefits accruals Amortization of intangible assets Amortisation expense France 2023, 4G eRedCap Project France 2023, 4G eRedCap Project [Member] France 2023, 4G eRedCap Project Subsidiaries [axis] Subsidiaries [axis] Number of units granted during the year Number Of Share Options And Other Equity Instruments Granted In Share-Based Payment Arrangement Number Of Share Options And Other Equity Instruments Granted In Share-Based Payment Arrangement Withholding tax Withholding Tax Withholding Tax Entity Registrant Name Entity Registrant Name 5G New Product Development, Team Of Engineers 5G New Product Development, Team Of Engineers [Member] 5G New Product Development, Team Of Engineers IT and office equipment IT and Office Equipment, Right-of-use Assets [Member] IT and Office Equipment, Right-of-use Assets [Member] Corporate information Disclosure Of Nature Of Business, Explanatory [Text Block] Disclosure Of Nature Of Business, Explanatory [Text Block] Repayment of convertible debt, accrued interest Repayment Of Convertible Debt, Accrued Interest Repayment Of Convertible Debt, Accrued Interest Temporary difference, unused tax losses and unused tax credits [axis] Temporary difference, unused tax losses and unused tax credits [axis] Auditor Name Auditor Name Decrease in borrowings Increase in borrowings Increase (Decrease) Borrowings Increase (Decrease) Borrowings Disclosure of analysis of other comprehensive income by item [table] Disclosure of analysis of other comprehensive income by item [table] Deposits and other receivables Loans And Other Receivables [Member] Loans And Other Receivables [Member] Notice term Borrowings, Notice Term Borrowings, Notice Term Counterparties [member] Counterparties [member] Financial expense Financial Expense [Member] Financial Expense [Member] Entity Central Index Key Entity Central Index Key EQUITY (DEFICIT) AND LIABILITIES Equity and liabilities [abstract] Disclosure of contingent liabilities [line items] Disclosure of contingent liabilities [line items] Receivables from taxes other than income tax Receivables from taxes other than income tax Disclosure of classes of share capital [line items] Disclosure of classes of share capital [line items] Financial instruments at fair value through other comprehensive income Financial assets at fair value through other comprehensive income, category [member] Schedule of Useful Lives Most Commonly Used Schedule of Property, Plant and Equipment Disclosure of detailed information about property, plant and equipment [text block] Tax expense during the year recognised in OCI Income tax relating to components of other comprehensive income Financial income and expense Description of accounting policy for finance income and costs [text block] Cash equivalents Cash equivalents Exercise price (in dollars per share) Investment Warrants, Exercise Price1 Investment Warrants, Exercise Price1 Amortization of capitalized development costs Capitalized Research And Development Costs, Amortization Capitalized Research And Development Costs, Amortization Significant Components of Deferred Tax Assets and Liabilities Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Purchase commitments Purchase Commitment, Remaining Minimum Amount Committed1 Purchase Commitment, Remaining Minimum Amount Committed1 Foreign exchange loss Net foreign exchange loss Geographical areas [member] Geographical areas [member] Entity [Domain] Entity [Domain] Trade receivables Accounts receivable Current trade receivables Hedging instruments [member] Hedging instruments [member] Equity [member] Equity [member] Shares issued (in shares) Ordinary shares (in shares) Number of shares issued Amendment Flag Amendment Flag Disposals ifrs-full_DisposalsToRightofuseAssets ifrs-full_DisposalsToRightofuseAssets Included in cost of revenue: Cost Of Sales 1 [Member] Cost Of Sales [Member] Legal Entity [Axis] Legal Entity [Axis] Disclosure of Leases [Line Items] Disclosure of Leases [Line Items] [Line Items] for Disclosure of Leases [Table] Amount of guarantee secured, percentage Guarantee Secured by Collateral, Percent Guarantee Secured by Collateral, Percent Sequans Communications SAS Sequans Communications SAS [Member] Sequans Communications SAS Information about financial instruments Disclosure of financial instruments [text block] Effect of foreign exchange Increase (decrease) through net exchange differences, deferred tax liability (asset) Impact of debt reimbursement Other finance income Other finance income (cost) Revenue Risk [Member] Revenue Risk [Member] Revenue Risk [Member] Proceeds from interest-bearing research project financing Proceeds From Borrowings Of Research Project Financing Issued Proceeds From Borrowings Of Research Project Financing Issued Amortization and impairment of intangible assets Adjustments For Amortisation And Impairment Loss (Reversal Of Impairment Loss) Recognized In Profit Or Loss, Intangible Assets Adjustments For Amortisation And Impairment Loss (Reversal Of Impairment Loss) Recognized In Profit Or Loss, Intangible Assets Non-current contract liabilities License and Services Agreement, Non-current Contract Liability License and Services Agreement, Non-current Contract Liability Current interest payable Current interest payable Loans and finance leases related to convertible debts issued and government loans granted Loans And Finance Leases Related To Convertible Debts Issued And Government Loans Granted [Member] Loans And Finance Leases Related To Convertible Debts Issued And Government Loans Granted [Member] Amortization disposals amortization disposal Right of use Assets amortization disposal Right of use Assets Intangible assets Disclosure of intangible assets [text block] Valuation techniques [member] Valuation techniques [member] Accrued interest Non-current interest payable Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income, Excluding Reserve Of Exchange Differences On Translation [Member] Accumulated Other Comprehensive Income, Excluding Reserve Of Exchange Differences On Translation [Member] Outstanding at January 1, Outstanding at period end Number of other equity instruments outstanding in share-based payment arrangement Carrying amount [member] Carrying amount [member] Government grants, loans and research tax credits Description Of Accounting Policy For Government Grants, Loans And Research Tax Credits [Policy Text Block] Description Of Accounting Policy For Government Grants, Loans And Research Tax Credits [Policy Text Block] Accrued interest Non-Current Interest Payable, Research Project Financing Non-Current Interest Payable, Research Project Financing Decrease (Increase) of short-term deposit Proceeds From (Purchase Of) Short-term Deposits Proceeds From (Purchase Of) Short-term Deposits Schedule of Subsidiaries Disclosure of subsidiaries [text block] Other current liabilities Other Financial Liabilities [Member] Other Financial Liabilities [Member] Number of units exercisable at period end Number Of Share Options And Other Equity Instruments Exercisable In Share-Based Payment Arrangement Number Of Share Options And Other Equity Instruments Exercisable In Share-Based Payment Arrangement Disposals Disposals, property, plant and equipment Disposals, property, plant and equipment Fair value of convertible note Borrowings Renesas Electronics Corporation Renesas Electronics Corporation [Member] Renesas Electronics Corporation Cash and cash equivalents Disclosure of cash and cash equivalents [text block] Strategic Partner Strategic Partner [Member] Strategic Partner License and development services agreements (See Note 19) Deferred Income Classified as Current, Strategic Agreement Deferred Income Classified as Current, Strategic Agreement Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of terms and conditions of share-based payment arrangement [table] Forfeited during the year Number of other equity instruments forfeited in share-based payment arrangement Classes of assets [axis] Classes of assets [axis] Other Other intangible assets [member] Foreign currency transactions Description of accounting policy for foreign currency translation [text block] Government grant advances Current Government Grant Advances Current Government Grant Advances Other non-current liabilities Disclosure of other non-current liabilities [text block] Operating segments [Abstract] Operating segments [Abstract] Operating segments [Abstract] Number of banks Number Of Banks For Which Cash And Cash Equivalents Are Held Number Of Banks For Which Cash And Cash Equivalents Are Held New IFRSs [member] New IFRSs [member] Loss before income taxes Loss before income taxes Profit (loss) before tax Types of contracts [member] Types of contracts [member] Property, plant and equipment [abstract] Property, plant and equipment [abstract] Additional fee to be paid at end of term Venture Debt, Additional Fee Rate Venture Debt, Additional Fee Rate Government grant advances and loans Disclosure of government grants [text block] Net cash flow used in investments activities Cash flows from (used in) investing activities Remeasurement of non-monetary accounts Remeasurement Of Non-Monetary Accounts [Member] Remeasurement Of Non-Monetary Accounts [Member] Neither past due nor Impaired Financial assets neither past due nor impaired [member] Intangible assets Beginning balance Ending balance Intangible assets other than goodwill Strategic Partner, Second Amendment Contract, 5G Chipset China Strategic Partner, Second Amendment Contract, 5G Chipset China [Member] Strategic Partner, Second Amendment Contract, 5G Chipset China Number of units exercised during the year Number Of Share Options And Other Equity Instruments Exercised Or Vested In Share-Based Payment Arrangement Number Of Share Options And Other Equity Instruments Exercised Or Vested In Share-Based Payment Arrangement Exchange difference Increase (decrease) through net exchange differences, intangible assets other than goodwill All levels of fair value hierarchy [member] All levels of fair value hierarchy [member] Statement of comprehensive income [abstract] Statement of comprehensive income [abstract] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Major customers [axis] Major customers [axis] Total Total financial assets Financial assets Fair value Financial Instruments, Assets, Fair Value [Abstract] Financial Instruments, Assets, Fair Value [Abstract] Total, beginning of period Total, end of period Provisions Past due but not impaired Financial assets past due but not impaired [member] Condensed Financial Statements [Table] Condensed Financial Statements [Table] Events after the reporting date Disclosure of events after reporting period [text block] Government grant advances and loans Total current portion Current government grants Categories of financial liabilities [axis] Categories of financial liabilities [axis] Diluted (in shares) Weighted average number of shares outstanding for diluted EPS (in shares) Weighted average number of ordinary shares used in calculating diluted earnings per share EX-101.PRE 19 sqns-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 20 logosequans2017.jpg begin 644 logosequans2017.jpg MB5!.1PT*&@H -24A$4@ 2( !." 8 "$_QLC 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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sqns-20231231_g1.jpg begin 644 sqns-20231231_g1.jpg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end GRAPHIC 22 sqns-20231231_g2.jpg begin 644 sqns-20231231_g2.jpg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sqns-20231231_g3.jpg begin 644 sqns-20231231_g3.jpg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sqns-20231231_g4.jpg begin 644 sqns-20231231_g4.jpg M_]C_X 02D9)1@ ! 0$ > !X #_VP!# (! 0(! 0(" @(" @(" P4# P,# M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_ MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# S_P 1" &2 U<# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]_*XSXP?& M2S^%6EKE1P'Z_J.ONK@6MN\C>-[W4'< MM$SF. '^"->%']?J377@Z"JS][9&E.',SLK;]JWQ1%J0F=K&2'=DP>3A<>@/ MWOUKW7X8?$VQ^*'A\7EK^[FC.R>!CEH6_J/0_P#ZJ^./.KM_V?\ QZ_@OXBV MF7(M=086TR]CG[I_!L?@37HXK!P<+P5FC6=-6T/K6BD1]Z CH>:6O#.8**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH X_X\:^?#OPNU:=3MYEA1G[6DJJV?\ P/Z_X.BV>DY4^VA]U^ M9_X2#PAI]Y_S M\0(_Y@&MBN*_9\F,WPET8G_GV0?^.BNUKY62M)H\][A1114@%%%% !1110 4 M44QYUCZD4 /HJE M:OJ*^8];_;OT:RSBY3_OJL2?_@H/I*(<7*_]]5NLOK/H>?/BK+HNSJ(^M3,V>/\ CX7_ +ZH_LJO MV#_7;+?YS[?^UQ_WJ7[4G]X5\/K_ ,%&+1A_Q\+_ -]4X?\ !1:T/_+=/^^J M7]E5^P_]=*V?\ SW'X&G#_ (*)6F/]>/SH M_LJOV'_KIEO\Y]M_:D_O"C[4G]X5\3?\/$;3'^O_ /'J%_X*(6;'_CX'_?5' M]EU^P?ZZ9;_.?;/VI/[PH^U)_>%?% _X*&VF?^/@?]]4[_AX79G_ )>!_P!] M4?V77[#_ -<\N_G/M7[0GK1]H3UKXM_X>$VG_/M'VA/6OB\?\%![0G_ %Z_]]4H_P""@MH?^6Z_]]4? MV97[!_KCEW\Y]G_:$]:/M">M?&2_\% K0_\ +=?^^J4?\% ;3_GN/SH_LROV M'_KCE_\ .?9GVA/6C[0GK7QJO[?UHW_+8?\ ?5*/V_+,_P#+8?G1_9E;L'^N M&7_SGV3]H3UH^T)ZU\;_ /#?5IC_ %P_[ZIP_;XLR/\ 7C_OJC^S*W8?^M^7 M_P Y]C?:$]:/M">M?'8_;VM,?ZX?]]4X?MYVI'^M_6E_9M;L'^M^7_S'V%]H M3UH^T)ZU\??\-YVO_/4?]]4O_#>%KC_6K_WU1_9M;L/_ %NP'\Q]@_:$_O"C M[0G]X5\@?\-WVO\ SW'_ 'U2K^W?:Y_UP_[ZH_LVMV'_ *VX#^8^OOM"?WA1 M]H3^\*^0Q^W9:D_Z\?G3A^W3:G_EL/SI?V=6[#_ULP'\Q]=?:$_O"C[0G]X5 M\C_\-SVO_/9?^^J!^W/:_P#/8?\ ?5']G5NP?ZV8#^8^N/M"?WA1]H3^\*^2 M4_;EM6_Y;#\Z=_PW):_\]1^=']G5NP_]:\!_,?6GVA/[PH^T)_>%?)J_MP6S M?\MA^=/7]MRV(_UP_.C^SZO8?^M6!_F/J_[0G]X4?:$_O"OE1?VU;9O^6OZT M]?VT;9A_K1^=+^SZO8?^M&!_F/JC[0G]X4?:$_O"OEH?MGVW_/5?SIZ_ME6Y M_P"6J_G2^H5>Q7^L^"_F/J+ST_O#\Z7S5_O"OF!?VQ;=A_K1^=/3]L&V8_ZW M]:/J-7L/_67!?S'TYYJ^HH\U?45\S)^U[;G_ ):_K4B?M=0-_P M/UI?4:O8 MK_63!_S'TKYJ^HH\U?45\W+^UM W_+4?G3U_:QM_^>OZT?4JG8?^L6#_ )CZ M.\U?44>:OJ*^=!^U=;X_UH_.GI^U=;$?ZW_QZE]2J=BEQ!A']H^B/-7U%'FK MZBOGI/VJK=_^6O\ X]3Q^U-;_P#/7]:/J=3L/^WL)_,?07FKZBCS5]17@ _: MAMS_ ,M?UJ1/VG8&_P"6GZTOJ=0K^W<+W/>_-7U%'FKZBO!U_::@/_+0?G3U M_:7MV/\ K!^='U2IV'_;>&[GNOFKZBCS5]17AR_M(V[?\M!^=/'[1X3_'^M'U:8_P"UJ'<]AWCU%&\>HKR!?CQ MQ^_^M2)\M[QZBC>/45Y0/C;$?XQ^=/3XTQ$??I?5Y MC_M2AW/5-X]11O'J*\O3XS1'^*GCXQ1X^\/SI>PD/^TJ/<]-WCU%&ZO-E^+\ M;?Q#\Z>OQ:B;^*CV$BO[0H]ST;=1NKST?%2,G[PIX^*,9_BI>QD5]>I=SO\ M.:6N)M_B1$W\56H_B#"_\7ZTO92+6+IOJ=917/0>-H9/X_UJU%XK@D'WQ4\C M-%6@]F:]%48MESF M@!:*** "BBB@ HHHH \E_;';;\*)/^NT?_H8KY.\WZ5]7?MFMM^$DO\ UVC_ M /0Q7R/YU?093_!?K^B.N@_=/C7Q9K-]XA_:^CTW2]=UOQ)>Z7XHCCM8=)L) M+*UL':>.ZNAJ%U*R07'DV<4L4<,1D."S[1)C'VIYOTKYI^(>GZCXF^+<$=Q\ M+KR]\7V'B2UFTWQ5%8VT=K;Z2MS$[DWBRI,,0>:K1'+-)QL:,U]&>=79@TU0 M2_K:/?7RUO9IJ]DK:M_O9/\ K=_UI9-6=E=W^W/V_C-^VQI7A"&54N4W+GHU?'OQ MJ_X*1S74LT=M<=R!AJ]3"Y36K=#XS.>.,!@4TY79^A'C+]I71_#B/NNH^/\ M:KQ+XC?\%!]+T8.([E,C_:K\Q_B;^VGJ6II--<:@+> ?>>278JY.!DGCJ:\M MG^-DWC(/);:E'>(&VLT,PD /H2":^APW#L4_?>I^89IXHXF<'4PL'R+2]M/O MV/T2^('_ 4Q.YQ#/],&O&/&7_!0O5-3=]EPXSZ-7Q[J?BMHYX4GF(:ZD\J( MOI0+AG')KV*64T(;(^ QO&V:5DI2DTGL>\:_^V)K>J.W^E2?] M]5S%_P#M&ZS?GFZD_P"^J\PB;(:I(>M=D<-3CLCY^IG&+J.\IL[2]^+^J7AY MN9/^^JK?\+)U I_Q\2?G7,5'J&I0Z1I\ESM24K(M59WW->+Q1=X!\U_SJ0>*KL?\M7_ M #K*B_U8IU3RILI59]S63Q3=;?\ 6O\ G4D?BN[Q_KG_ #K(3[M2)TILI/O4^CE5S3VD^YK1^)KLI_K7_.GQ^);DY_>R?G69%_JQ3H_P"*ILBE4GW- M6+Q+);H?\ +5_SK,AZ4^ERHM5)WW-0>)+HH/WK_G3T\37)7_6O M^=9B_P"J%.3I1RHT]I+N:R^)+KC]Z_YU(OB2Y _UK_G66G:I*CE5BE4GW-0> M)+HX_>O^=2?\))=$?ZU_SK+3M4E%D:*I+N:8\1W7_/5_^^JOB&Y!_UC?G6.M19%JI+N:7_ D-S_SU M;\ZC?G69#TJ2E9 M7+]I+N:L?B&YX_>-^=6$\0W./]8_YUDQ]%J=.E396-(U)=S8A\07'/[Q_P Z MLP^(+C;_ *QOSK(AZM5F'[E+E5SHC.7,EG Q2Y4SKH1J5)9NWK7C7C+XXI;%EC?]:\WU[XO7.H2'$A_.M(T+GW.4\(8K$)2GHCZ M2O?CNEL<>?\ ^/5G3?M$;3Q.?SKYB?Q;7/YU?U:)]OA^" M*,5[[/IJ#]H@D_Z\_P#?56X?VA23_KC^#5\SVVHRC^(U?M]0D_O&CZO$[?\ M4_"GTI#\?V8?ZT_]]5-7[>_<_P 1J?JT2EPCACZ* M@^.Y_P">I_.KEO\ '0EO]:?SKYXMK^3^]6A;7S_WC4?5XE_ZIX8^@H?C<3_R MU/XFKD/QK+#_ %I_.O +:_?CYC5^VO7]32^K1'_JMAT>]0_&8L?]:?SJY#\8 M"W_+0_G7A-K>OG[QK2M[Q_[S5'U:(_\ 5C#H]OA^+Y8?ZP_G5JW^++'_ ):? MK7BMM=O_ 'C6A;7;_P!XTOJT2EPU01[-!\5&S_K#^=7(/B@2?]8?SKQVWNF' MO1_$TM_RTJS'\2VQ_K/UKRBWN6]:M1W+8ZFI>&B5 M_J_0/5(_B81_RT_6IH_B:1_RT/YUY4ER_P#>-2I0?]8?SJ=/BC_M_K7DD= MXV>M31WC<C^*V!_K/UJQ#\6<#[_ .M>/I=L>YJ6.[;'WC4O M"Q&LIIH]E@^,!3^/]:N0?&EXQ_K#^=>*1W3?WC4JW3X^\:AX2!HLM@CW.V^. M;I_RT/YU?M?C^R'F3]:\"6Z?/WC4J7<@;[QJ/J4&:QP26S/HBU_:(QU?]:O0 M?M#(2,O^M?-R7C@_>-2I?./XC4/ TS58>Q]0Z=\>H)NKBNBTCXM6M]C]X.?> MOD6WU:6/^-OSK5TSQ?M45G:/K<>I0AE.:T /_MJ-M^#\Q_Z;1?^AK7Q_P"?7U[^VXVWX,W'_7:+_P!&+7QK MYU?1Y1_!?K^B.JA\)\V^+?VHO&OAWXV6/AG[=X7.F:OKSV5K>"\=[A(4U*W2 M0/$MHR1A4*^G_/KY-\7C3]"_:!O9-&M]+U/5=<\1:?%J.G0 M^!-4BGFBCNHV+G4!+Y $7-PS[?+=HSE26S7U+YU=N$O["/,[OO\ )??_ %V- MI?Q96V_X<^\?V:SGX-:'_P!>L?\ Z"*[RN"_9G.?@MH/_7I'_P"@BN]KY*K\ M;]3@>X4R:40QEC3ZX?XR^/X_!WAV>5F"[5/>E"+D^5&%>M&E3=26R,/XT_'R MQ\ :=*TDZ*R@]Z_/G]J;_@H-)-//!9W)[CY6KA/VX/VMKG5];N;:"X;;N(X: MOB[Q%XJN-=NW>21FR<]:^YRK)(J*J5#^<>-O$2K.K+#85V1WOQ!_:%U3QA=2 M%[F0AB?XJX"XUF>_E8NY//K6?$K5]/"E&&B1^-5\75K2YJDKF/\0[@Q M>&W?S8X=ES;-YDHRD>)X^6Y' [\CZU5NM2.N1Z5$FKV]T)M0,4TNFN8@4\B1 MMAP[$'CJ"#T(P0#72Q_ZP_2I1UJ?9WE>_8]C 9S'#X>-%T[N,I23T^THKK%O M3EOI)7ZK0XV2V:\^Q6;W%WY<&NRP(_G,91']GD;;O.6_B(SG;RAJ^\Y8KET:7RIU1-SC:Y( Z\,><\%@2PU998=&36-2N;33S; M3@3F[:W\^9)0BAY58'.P$@$_,M M+V/F;5.)8RESJCRQ;DU9[-^T>CY=U[2.MK^XO*WGFLZK>G5[M&U*VLKB,Q#3 MWOM5DLB5\M&#F )LERY;=N[@KA<5)XWOH;B+7X[V^NH=1BG5+.T2X<*]OLC; M<(ONN"?-W.5.W:>1MR/0Z>GW:7L7;5FU#BJE3G3J1H6Y$EI*SNG!_P K23Y7 MS)*SYGW=YTZ-]32P??\ PIL7^K-.@^_^%;GR'0EAZU)5=;J.&>.-Y$628D1J M6 +X&3@=\#FI;6ZCOK9)H9$FBD4,CHP97!Z$$<$5+-N227,UI_7^3^XLQ?ZL M4ZFQ?ZL4ZDMQ(>GW:D3I5=;N(7 @\R/SBAD$>X;BH.-V.N,D<^]6$Z4C1)K< MD3[M2U$GW:EJ#0D'2E3[U(.E*GWJ&6MB0=:?3!UI](I%BG)UIM.3K2>QH/3[ MU/IB?>I]+J:$T7^K%.C_ (J;%_JQ3H_XJDM$L/2GTR'I3Z"T2+_JA3DZ4U?] M4*A9(G:I*C3M4E(M;$E*G6DI4ZT&B+"?>IXZTQ/O4\ M=:S*6Y)2KT-)2KT-!H/AZ5)4K59A^ MY5:'JU68?N4CIB3Q]15F#J*K1]15F#J*S-HEF+[E6H/N_A56+[E68?N?A63. MA%37=6&F6;,3C S7S_\ %KXJ/) MIK>C%/4_4> \MHUI^TGNBI=:W+?S$EB<^]92?$#0XM6^PR:WI*WWF"+[.UY& M)=YX"[-/[7\C^S?[5NOM'G8V;=J?KTQWSC'-56J MN#TZ)O[K?=ON?M$8*"2CWM^#_P CTVUZBM"WZUXKI?CW6_ ?AK3X]1F>6XU7 M1HETR*9%#B^&$\LG&26WQM\W]UJUM?U_Q+H^F^*+P:_(#X6@@D2%;2#;=N($ M>3S"4)VL<\)M(W'GH!G+%Q3>CT_X/GY7]&NX*I=+O_7]?)GL=M5^#J*\7^)O MQ2U/1'U:\TN[U5DT+R!,D,%FME&[[6\N=IF\YRP8RG><;65AD_,> )>+BKZ/3T^_V\U[96[%3+*RLA0((V4&/*[E)&[J< UV5EK^I^(O'7B+=XC_L"T M\-7EM;QVI@@:*Y1XTD+S%UWXSL_ZZ_D>C:M MXBT_PKIM30=7M=>TV&\L;FWO+2X M4/%/!()(Y5/0JPR"/<5Q'Q3\)MXNCT5+/5;+3-;T[4!J&F"[C$T5S+'&X9&C MW*S#8S9*D,OWATKE/#WQ-U7QEJ?AK2X;VT\&R:E>:K9Z@;!8+A;JYMY$)>V> M5"I+L7.61C@N""P#"'7M-PDO3S6FOWNUM]M[ESE9KM^NNGW?UH>\6U:%M7SE M9_&3Q7K2^'-'MYM6NY+N[U:!]1T>*P2\U!;*;RHRHNR+==P)9]H)^0[549QU M>C>*O&FL:KX3\,ZQ>7WA2]U*+4)YKY8K*2]O%MW185 Q-;I(\I#FEH_3YGN5IUK2MJ^?_#VDWM_^U%I5S_PF-Y?;?"7G M-):0V@@OE2Z167'EN0C'YFVN"&SM95^6K'PP\?>*Y/AQ\.?$.J>*+F^F\7:G M:V]Y"UG:PVT4;Q3X5-L8<,[+'DESEONA =M13Q*E;3=V_P#)W!?C_7<<[.5U MLK_^2J3_ #/HBVK0MJ^;]1^,'B;7_%=WIFE>(TM(7^(B^'%N(;6WG-O:?V9Y MLD2[E(WB8.0S;BK#!#*"A72/B'XX\/V\^I77C&YU2'0O'D/A8VLNFVD:ZC:R MW,4?F3LD8;SE%P,-%Y:?NAE#DFIIXJ,VE%/6WX\GG_T\C^/8*DU"]^E_PYO_ M )!_@?3\;B./:'X:^)&EKJ6MVFL>&;_P /I97'B*VTJXOK47UU M''+'*E@?L[)L^91\LF)#DCY2$\3&]DG_ ,&]K>OZ$N:3L_ZZ_B?5$?B+3SXA M_LG[=9_VI]G^U_8_.7[1Y.[;YOEYW;-W&[&,\9K23[M?.?CO6=:^%GQ+\0QI MK2]_;L2*8'R=/\ IDM"6X+37X$V!]( M8,GW%:\UY0C_ #-_^2J3_'ET\FF1[1.#FNEOQ<5^%]?--'7>&OVB?A_XN\5) MH>D^.O!VIZU(SQII]IK5M-=.R EU$2N6)4*Q(QQ@^E;.H?%7POH?C2R\-WOB M30;3Q%J"A[72I]0BCO;E3NP4A+;V'RMR ?NGTKYCC_LC_AV0_P#:7E_;L7_] M@X_X^/[6^W7'V+[/CYO/\[9MV\]>V:Z+QC-J7P*\0:IXY@F\,>,=#\2:OI%I MXKT2<+]OT_4D%O;(]K,"RNZL87^S2(&!7_+S>MKQO MH]%*32YNZ;]+?GIMWL^VOO\ 8_%?PO?>.;CPO!XDT&;Q+:Q^;/I$>H1-?PI@ M-N: -Y@&&4Y*]&'K6AX$\;:9\1O"MGK6CW!NM.O0QBD:)XF^5BK!D<*ZL&5@ M58 @@@BO /#+[V?3IX@HU70M1G6>25E<%DNHE M*3HS#RY(E8@EPI%=S^R/=#R?B+8PD&QTSQSJ<5KM8D*)#'/(H!)QB::7V]*T MH574LGO9M^37)=?^3K79K7K9*;Y96\[+T:E9_P#DOZ=-?8HZE3[M11U*GW:L MHE'6I4^]40ZU*GWJ"AXZU(.M1CK4@ZU##J31U,G:H8ZF3M4DD\3E:U=&UV6P MF4AB,5DQU-'U%0]1,]V^$OQ(:61(W?VZU[9I=X+NW##N,U\I?#!9?[43;G&: M^G?!N[^S4SUQ7AXZFHRT.2HE?MAV6D_&D^"Y- M'?6;M[];,2^'+^'57L QP)+Z %)K4#^+Y7"CDMCFO8O.KXVU[^Q[C]J>34+V MU\66_B*#Q B6\6A^'_[.M[A!>10I]IOH[-I;A3$[3,&N!&50J0,YK[ \_P!Z M[L))SH*7\645T_X)^@7[,9S\$O#_ /UYQ?\ H(KOZ\__ &8#GX'^ M'O\ KRB_] %>@5\A5^-^IYKW$;[M?.'[<'VO_A#+KR-WW#TKZ0KA_C+X C\8 M^'9XF4-N4]JUPM10J*3/*SG#2Q&$G3ANT?@%^T%]L_X3"Y\[=]\]:\XK[G_; M@_9)N=(UNYN8+=MNXGA:^+O$7A6XT*[=)(V7!QTK]2P6)A5IIQ/XOXARG$8/ M%RC574S8>M2P]6J*(8-2P]6KLZG@(QOB!:1W_AQH)5WQ37-M&Z_WE,\8(KF] M>O9M<\.&QG):30HR;PGG?*K>7$3_ +R[I/J%KO7MX[H[9$21!OM)!FS&#YN, ;O7 Z^E:C'>2V=K+=Q8"3O$K2)@DC#$9')/YTY] L;F\2YDLK22XCD\Q)6A4NC<# M<#C(/RKS_LCTJ/92[_U_70Z,)GV"I))T?LI/W8/9TVT[KWDW!N[U7-IMKS'B M>:UJ@T^&^8Z=,L4,,7V;R)C ML1_WID82 -NQE,8'3)S74#2[:=9]]O _GE6DW1@^85^Z3ZXP,>F*9>>&=-UB MZ6:[T^RNID&U9)H%=E Y !(SU-#I2YKI_P!:ET>(,(N6-2@FDNJYDGRTHWY; MQO?V;ZKXK[F'X]TW^U?&.B1?V?I^I?N+IO)O6Q'_ ,LN<['Y_#\:I>$[V]NH M/#>F6^H3VD(M+M+EDCC=F>"2.,!&<,-H)(!P^7G M9Y\*R;,]<9!QT'Y5/:Z7;6H@,=M!']FC,4.V,#RD.,JOH/E7@>@]*7LGS[TMS-OX@U"2RBU7[>P\S5OL+:9 MY9Y@7]YG=CVVTVP\:7;^+K(Q27US8ZC)=QHLD<"0OY2R']T M?.R&CVDOPL$U-K\6-F+]N#GVNIM= MQV%E'=.QD:98%$C,006+8SG#,,^C'UI>SG;<%G&7\L[T$VXR2]V.EU9+2S]U MZJ;]YZIK9KD_#]Y<:CKGA"\N-5^V/J4$MT8"D8$):W)(3: =HW;3NW'@'_"LW]J?:[.^B:":V$2;+=$@=MRE1ORIC ;+$$L>%X [/3?#6G:= M=O/;V%E!-(YD>2.!59FP1N) R3AFY_VCZU+I_AK3M(O&N+73[*VG=!$TL4"H M[(,84D#./E7CV'I2]E*]SJK<0X2I"5)4O=:T7+"V]5I;:6]HK26KY?/3BK;Q MYJD<.H%;B^*2Z!-JML]U%;+M9=NQXUC)(0[^DN3\HY/-:.K>)=5\(0ZD\EZV MILNC/J*"2%$6&1#@A0H!V?,.&+$!?O'-=-I_A#2;"&00:7IT(G5TD"6R+YBM MC<#@<@[5R.^!Z5>-C 9O,\F+S!&8@^P9V'G;GTX''M2C3EW_ *U_S7W$5<\P M#FN3#KEZKEBF^VJ3:\[-7[=#E] MY;+XH"&75VU9AI#/ND2)73,R<_NPHVG& M1QGKR>W:)TK.T;PUIV@)BQL+*R^]_J(%CZXST Z[5S_NCTK13I6D596/)S/& MPQ-2,J:TBK;*/5O:.BWZ$B?=J6HD^[4M(X"0=*5/O4@Z4J?>H9:V)!UI],'6 MGTBD6*E/H+1(O^J%.3I35_U0IR=*1?0F3M4E1IVJ2IZ%DB=JDJ-.U24BUL24J= M:2E3K0:(L)]ZGCK3$^]3QUK,I;DE*O0TE*O0T&@^'I4E1P]*DJ>I9/'T6ITZ M5!'T6ITZ5/0N):AZM5F'[E5H>K59A^Y2.F)/'U%68.HJM'U%68.HK,VB68ON M5:@^Z/I56+[E6H/NCZ5DSH1!JNEC4;9E(SD8KPSXM?"9I)7DC3WX%?0,7)JO MJF@1:I'AE!SZBKA)Q9]'D>;]I-G'YN_P#O;\9S[YKZQ\7?!2&_+LB#\J\Y\0_!&>T#X_$VNZ+=3.GE:/<-=+$8MWF2;"J'=GC;N)ZMG_A&M.NTN4EL+*1+XJURKP*1<%>J$E%?(^8*22 >A)JS<^ M"-%UG7;;5+O2-+NM3L\"WNYK2-YX,$D;'(W+@DG@]ZTK;1)O[A_*KUOHTH_@ M/Y4FHA[2GU94UKPMIGC'3?L>KZ=8:I:%@_D7END\>X9P=K C(JCK/P:T?Q)J M>B>?9:8VCZ/;3VHTJ2Q1[:59/+VC8?E4(8P0-I[=,5U-MHTW]W]*OVVCR_W3 M^59RA"6Z*=6F^IDW7P[\/ZWX[TBUV^38SV4;#I[Z="UK"_/S+&5V@_,W('\1]:W+;1I M1CY#5^VTB7^X:'&#W6Y'M(=S-;X>Z!J5SID3RZ( -.>2RC9M/P !Y)( M_=_=7[N.@]*TW\ Z%J/A3^P;C1=)GT/8L?\ 9TEG&UIM4[E'E$;, @$#'! J M_:Z5+G[AK1M]*E_N5#4=4^H>T@M4S,T;X=>'](AMX[30M&M8[29+F!8;*-!# M*D7DI(H"\,L0" CD*-HXXK5B\$Z-+!)&VD:8T*NVVF2_W:T+;39/[M&E_Z\O\E]R#VD-OZ_K4?+9PZC926]Q%'/!. MACEBD4,DBD8*L#P01P0:H^%_A!X3\)Z#-I>E^%_#NFZ9BEWPK9 W-ZFH=!^"O@WPWI#Z?IWA+PS86$ MQB,EM;:7!%"YBD,L>450#LD)=>/E8DC!.:Z2WL']/TJU'I\F/NFI:C>Y+G%[ MF9?^#])UF]FN+S2].NKBYLVT^:6:V1WEMF.6@8D9,9/)0\'TK'^*'P>L/B/X M(U'38&71-1NM+FTJTU6SA"W6GQ2;^(&1H%G?,9Y%V (V5V!I.#OX[[6_AJNJ?%C0/%EO="UN])M+ MK3KB,P[Q>VTVQ]F=PV,LL4;!OFXWC'S9'5KI\F>A_*I4TV3CY?TI)12273;Y MWO\ F_O,U[-)I=?TM;\D<9X8_9[\ ^#?%(UO2/ _A#2M:4NPU"ST:V@N@7!# MGS%0-E@3GGG)S6I-\(O"E]X[A\4S>&/#TWB: !8M7?386OXP%*@+.5\P?*2. M#T)%=+'IDF?N_I4T>FOQ\M3:*22Z;>0W./WG-:+\(?"GA_QI>>)-/\,>';'Q M'?AA<#TJ/X)_#'_A4G@2/2WO$U*]FN[K4;^] M6#R!=W-Q.\\LFS:/Z_,; M'4J?=IZ:=)_X(^0_E4.:1#G%&5# M&6-:^BZ#+?3J I_*NI\/?"^2=@67]*]$\)?#1+5T)3I[5RU<3&*T.:IBHK1% M+X5> 3;RQNR\]>E>VZ1:BUME7VK*\.>'ULHUPN,5OHNP5XE>KSNYBFY:L=11 M17.4>*?MXML^!5X?^FT/_HU:^'/M'^<5]N_\% 9?)_9_OF])H/\ T]?3Y+_ ?K^B.[#?">$ZM^S]XMUS]J ^)KJVN(O#MGJD=U:1:=XKNX3< %29 M;J-]RL NO$OBS5/C%/)I\WCZ]U*W\1I;K);3 M6_\ PC,>G+.HFCD7=Q(L'F [AYWF@;?EVU]$_P!I>]=^$4?8KEV\_-)_\#U3 M6R-O^7LGUO\ DVOT_)[W/TE_9;.?@7X<_P"O&'_T 5Z#7G?[*;;_ (!^&3ZZ M? ?_ !P5Z)7QM7XWZGF2W"F31":,J:?168CROXT_ .Q\?Z=*LD",S ]J_/G] MJ;_@GS)#///9VQ[GY5K]664.,&L+Q+X#L_$,#++$C9'<5Z>"S*I0>C/D.(>$ M<)F<'SK4_GT^(/[/6J>#[J0/;2 *3_#7 7&C3V,K!T(Y]*_<[XS?L3Z5XNAE M9+9-S9Z+7Q[\:O\ @FY-:RS26UOW)&%K[#!Y]3J*T]&?@>?>&>,PLG*@KH_- M?QG>2Z=X?G,3-'-.T=M&Z]4:1UC##W&[/X56\1^/(_#^J&SC^P>;#")G^V7P MML@DA54E3N/RG/0#C)YKZ%^.O[$^OV.@7T5K:,US&%FMP1@-)&P= 3VRR@9[ M9KS+Q+\#=3M;_P"U(VHZ7<2(J2^4(VWA3Q7J*OSN]-]OU/ M!PN7T,+1A',*=_>G=7:Z0Y;N*H.Y8U(SCYSZ5%/XMOY+C7)HI]MK%I]Q-9KL4X:(A/,SC)RX?@Y& # MWKJ=8^''VH78N#<[KNU2UD<$*P"%B'&!P^7)STR!@56?P#;?8F@_?)&;!M.P MI'$9QD]/O<=?TIN%1JR?*0EE8QX2,E0"N3@X.W!YK03P!%/%<"ZO;^\:2T>R1I3&#!&^-VT M*BC)PO)!^Z*DM_#$FBB6^CGO-5O[>U>&T2X,2ASY4M?LV?)&VMN9^Y;7XNNCX4U5]<\,V%W( LMQ M;H\@'0,0-V/QS6FGW:S_ SI)T'P[8V1;>UK;I$[C^-@H!/XG)_&M!/NUT*] ME<^1S!TGBJKH?!S2MZ7=OP)HO]6:=!]_\*;%_JS3H/O_ (4'+T)8>M25'#UJ M2I9:W)HO]6*=38O]6*=26Y2'I]VI$Z5&GW:D3I2+B2)]VI:B3[M2U!J2#I2I M]ZD'2E3[U#+6Q(.M/I@ZT^D4BQ3DZTVG)UI/8T'I]ZGTQ/O4^EU-":+_ %8I MT?\ %38O]6*='_%4EHEAZ4^F0]*?06B1?]4*AI*5>AH- M!\/2I*CAZ5)4]2R>/HM3ITJ"/HM3ITJ>A<2U#U:K,/W*K0]6JS#]RD=,2>/J M*LP=15:/J*LP=169M$LQ?+K5J+DC_/I56+K M5J'J/\^E)F\21H5?J*CN?#\%XOS(/RJ;-2F[2%>34ZW.NE*:?NF#=?#6UNN? M+7\JIO\ !VUE_@'Y5TK^)+>W'+C\ZC'CBTB_Y:+GZT7ET/=PV,QZ7N-F!!\& M;?/^K'Y5:B^#EN#]P?E6S!X_M,_?7\ZLQ>/+0G[Z_G4\TST5C.K4C[Z_G5J'QQ:[?OK^=+FF;1QN9>9DV_PFM_[@_* MKD'PI@!^X*T[?QM;8^^M6H?&=J3]]?SJ>:9JL9F/F9D'PM@&/D%6X?A?"!]P M5HP^,;8X^8?G5J'QA;;?O#\ZARF:K&9AYF=%\,H1_"/RJW%\-HA_!^E7X_%U MLW\0_.K47BRW_O+^=1S3-8XO'^91B^',('W1^56H/A[$/X:O)XIM\?>7\ZLP M>*+<_P 0J7*9JL5CO,J6_@&('[HJU!X%B!^[^E6X/$L!/4?G5F#Q'#G[PJ'* M9LL5C?,K)X(B7^&K,7@F,CH*M)XABQ]X59C\10XZ_K4\TS58G&>94B\#1XZ5 M,G@2(CH*NP^(X'YU.GB2#'WA^=0Y3-(XC&>94C\"Q'^&IXO D/]T5=B\2 M0X^\*L1>)(?[PJ'.H;1Q&+\RC%X!BW=*G3P#%Z?I5Z+Q+!G[PJ=/$EOG[P_. MIYIFJKXKS*:?#Z$#[OZ5-%\/HB/NC\JOIXEMR/O"IXO$\ [C\ZCFF:QK8DHP M_#R$_P 'Z58C^''YU/-4-E6Q!03X7\ZMP^(H';[P_.H7 M]I>]?H)_P4LE\C]F#5F])K;_ -*(Z_-C^U3ZU]3DB_( W &5C)'3D_4?\ :I]: M]#"M2I+E5K:6[62_X;Y&O_+R2\_OU?\ PY^L/[)#;_V>?"A]=,MS_P"0UKTB MO,OV/'\S]FWP>?72;8_^0EKTVOBJOQOU/,ENPHHHK,04444 -DB64?,,UEZK MX0M-50AXD.?45K44TVMB90C)6DCROQE^S5H_B-'W6L?/^S7B7Q&_X)\:7K(< MQVR9/^S7V#3'@63J!752QM6G\+/%QO#N!Q*_>01^9/Q _P""9QW.88/I@5XQ MXR_X)Z:IICOLMW./1:_9.YT*WNA\T:GZBLC4OAGIVH@[H(SGVKU*.?5H[GQF M.\,MZ4[?Z++C_ ':Y6^_9WUFP?FUD_P"^:_\SBV3\%K$G_X)\:2R'%LO_?-=4>(:74\ M:IX4XM/W6?D"_@N]MQ@PO^5-C\)W8;_4R?E7ZNZO_P $Y;":3Y;=?^^:H?\ M#MRSS_J!_P!\UJL^HG#+PRS!.R/RUB\*W>?]3)^5/_X1:[/_ "Q?\J_4@?\ M!-ZS!_U _P"^:4?\$X;,?\L%_P"^:?\ ;U$%X:9AV/R[B\+W> /*?\JD'A6[ M/_+)_P J_4-?^"<=F/\ E@O_ 'S3O^'%KK;_ *I_RJ2/PI=X_P!2_P"5?I\O_!.>T4?\>Z_]\TX?\$Z;0?\ +!/^ M^:/[=HE?\0US#L?F$/"]V/\ EB_Y5+_PB]WC_5-^5?IS_P .ZK/_ )X#\!3A M_P $[;3'^H'Y5/\ ;E$O_B&^8'YCKX8NL?ZI_P JX_[YH_MRB4O#C,.Q^9:^%KO=_JG_ "J3_A%;K_GD M_P"5?ID/^">5IG_CW'_?-._X=Z68_P"7&;K/^J?\J_2__AWM:?\ / ?]\T+_ ,$][4'_ % _[YI?VW1*7AUC M^Q^:B>%[K=_JF_*G_P#",77_ #R>OTJ'_!/BT!_U"_\ ?-*/^"?5H/\ E@O_ M 'S2_MNC'>/['YL1^&;L)_JG_ "I\?AJY&?W4GY5^DR_\$_;0?\L%_P"^ M:4?\$_K3_G@/RH_MJB4O#S''YN1>&KD?\LG_ "IX\-71_P"63_E7Z1+^P#:+ M_P L1_WS2C]@.S'_ "Q'Y4O[:I%+P]QW8_. >&[H(/W3_E3T\,W(7_5/^5?H M[_PP+:8_U(_[YIP_8'LP/]0/^^:/[:I%?\0^QQ^; M_P#?-.3PY<@_ZM_RK]$?^&$+7_GB/^^:5?V$+7/^I'_?-+^V:12X!QW8_/,> M'KD-_JV_*GKX>N2?]6WY5^A8_83M0?\ 4C\JN<']T_Y5^A/_##%K_SQ7_OF@?L,6O_ #Q'_?-']L4B M_P#4/&]C\^H?#ESC_5M^5/\ ^$;?E7Z")^PU:K_ ,L1^5._X8;M?^>0 M_*E_:](K_43&GY_Q^'KGC]VWY583P]@7&?N'\JL1:!< CY&_*ON8?L86W_/)?RIZ_ ML:VX_P"62_E4_P!JTS5<%8SL?#T6A7&W[A_*K,.B7 'W&_*OMQ?V.K=1_JA^ M5/3]CZV4_P"J_2H_M2D:K@S%GQ1%H=P/X&_*G36DEHN74C%?9&O?LO66AV32 MR(%"C/2ODS]I_P 8Z7X $T,3IO7(X-:T<9&J[1.W#<$8JI*S.%\1^.(M(0Y8 M<"O.O$_QR\LL$?\ 6O,_'OQ=DUB\D",<$G'-<=+J\EY)EF/YUZT*/5GWF5\# M4**3K:L],U#XRW-Q)Q(>OK5,_$N[G/\ K&_.N%MF+-5^W-:M_'UT?XVKC;:K\'44))O4U*GB2;'WC6,G6ID^[4\J#ZM2[&TGB2;/4U-'XEF_O&L0=:E3[U3 MRH/JU/L;D?B68'[QJ:/Q-/\ WC6"G6IH^@J>1"^KT^QNIXFGQ]YJFB\43A?O M-6''4L?05/LT3["'8W8_%$^/O-4R>*YP/O-^=8<=2I]VIY$/V4.QO)XKF!^] M^M3)XOG!^^?SK '6I4^]2]G$OV4.QT,/C*=3]\_G5F+QS<+CYS7,#K4@ZU#I MQ'[.)VEA\2KFW/WS^==)H7QFGMV7+G\Z\MC-3QN1BLI4(/H)P1]'>%/CBLVT M._ZUZ'H'CRWU11AQD^]?'EEJDELW#$8KKO"7Q$GTZ=,N;_#?XCKJT2JS#GWKT2WF$T8(KR:E-P=F<[5B2BBBLQ'SK_P % M09?)_90UIO2:U_\ 2F*OR_\ [2]Z_3C_ (*K2^3^R%KK>DUI_P"E45?E/_:7 MO7UF0_[N_7]$=^%^ \9ETY=%_:0U#4;35Q:OJ&JPQWEPFGZF8I&RFRU>Z$GD M;L$*$^X&;&T$[3]#?VE[U\IZSKL>H?M MHUH8+NTCUJ*ZO8_^$GNH+>VD$JR MC,+J(Y)=P5O*CWX;&<5]&?VE[UWX"WL=._Z+OYW_ .'N:K^+/^NY^S/[&#;_ M -F+P4?71[4_^05KU&O*OV)6W_LL>!3ZZ)9G_P @I7JM?$5OXDO5GF2W8444 M5F(**** "BBB@ HHHH **,TQIE3JPH ?15>34X8^KC\ZKS>);6'K(GYT[,ES MBMV7R@/8?E2>4OH*Q+CQ_86_6:/\ZKR?$[3HU_X^(_SJN278S>(I+>2.A-LA M_AI/LD?]VN/N/C3I4+X-S'_WT*C_ .%X:3_S]1_]]"G[*?8Q^NX=?:1VGV2/ M^[1]DC_NUQ?_ O#2?\ GZC_ .^A1_PO#2?^?J/_ +Z%/V4^P?7L/_,CM/LD M?]VC[)'_ ':XS_A=VD_\_4?_ 'U1_P +NTG_ )^H_P#OJCV4^P?7L/\ S([/ M[)'_ ':7[*G]T5Q?_"[M)_Y^H_\ OJE_X7;I/_/S%_WU1[*?8/KN'_F1V?V5 M/[HH^RI_=%<9_P +LTK_ )^8_P#OJE_X79I/_/S'_P!]4O93[!]=P_\ ,CLO MLJ?W11]E3^Z*XW_A=6E?\_"?G1_PNK2O^?A/SH]E/L/Z[A_YD=E]E3^Z*/LJ M?W17'#XU:4?^7A/SH_X71I7_ #\)_P!]"CV4^P?7E'V9/2N0_P"%RZ4? M^7B/_OH4?\+ETH?\O$?_ 'T*/93[!]E'V9/2N1_X7'I9_Y>$_[Z%' M_"XM+_Y[I_WT*/93[!]EZ?]]4?\+>TW_GNG_?5'LY]@^N4 M/YD=;]G3^Z*/LZ?W17)_\+>TS_GNGYBE'Q=TT_\ +=/S%'LY]A_6Z'\R.K^S MI_=%'V=/[HKE/^%NZ9_S\)^='_"W--_Y^$_.CV<^P?6Z'\R.K^SI_=%'V=/[ MHKE?^%MZ;_S\1_F*/^%M::?^6Z?F*/9S[#^MT/YD=5]G3^Z*/LZ?W17+?\+9 MT[_GNGYT?\+8T[_GNGYT>SGV#ZW1_F1U/V=/[HH^SI_=%Z?G2_ M\+6TX_\ +>/\Z/9S[!];H_S(ZC[.G]T4?9T_NBN7_P"%J:?_ ,]T_.E_X6G8 M'_ENGYBCV<^P?6J/\R.G^SI_=%'V=/[HKF?^%HV'_/>/\Z7_ (6A8'_EO'^8 MI>SD/ZU1[HZ7R$_NC\J#$H'W17-_\+/L#_RVC_.E_P"%FV!'^M3\Z.20?6J/ M\R//_P!JWQ%)H/@JZ>+(.P]*_%C]K'XB7NM^,;I9'?&\CG\:_:7X[7MAXT\+ MW$(D4ED(ZU^2G[9'P(DT[Q%4H^SRP1[S&3CYLJ=PW?W&%>CW.E26$Y5@1 M@URFK?""+7O"^LZ=+>.CZG?/J$%PD>&M)"!C'/S8QSR,@D<5[F+A6DKT>SZ] M=/QM>WF>H^EN_P"C_P" 4;KQY,-1\.Q:AXJ_X1VWOM#%Y)-_HJ>?/F/O-&PZ M,QVKBO1/AEJFH:UX*TZYU6(PW\L?[U3$8B<$@,4/*D@ X[9K$T3X;QVNH:?) M-.MS#9Z0=(DA:'Y9U)3+'DX!"XV\]>M7_#'PKTVPT73K74K73]:ETC*6=S>R,81FK-]E^4?UO_3, MK1?%E[:/=E]3O(@WC+[ H\I;C?$P7$/SL/+3W7D=AS73)\:[8ZY!:V^BZY=V M]QJ+:5'?1K;K;M.N[>/GE5\+M<9V8)4@9XS3B^$V_=_I_P![Q"NO?ZCTQ^Z^ M][?>_2N,\%Z-J.B^/([E-+O9KR76YY9+&ZT^_,=LLDKA[E;EI!9AA&2P*19( M.P$DDGFIRJP]G3EUM?[H)_\ MVWKM>ZJ(KC3TU%@K6UN[S%8HLLX?'W5!1"@+ $CG'4?"#XDZEX\U'7H;[1+K M3H]+U&:TBF9H=C*FW"-MF=O,^8DD )C&#GBJ$GPC^V: ]C_:&W?KRZYO\C.- MMR)_*QN_V=N[/?..U;W@+P/=^#O$.N3#4(+C3-8O'OTMS:%9[>5P@;][OPR? M*<#8",_>.*UP\:T>15-E&W3>T-_GS*_Z%/FYM-KW_&7_ -J=K;5H6U9]M6A; M5TFQ>MJT+:L^VK0MJ1!H6G6M*VK-M.M:5M4 :%M6A;5GVU:%M4@:,'05?MJH M0=!5^VJ22_;]*M1]!56WZ5:CZ"DQ$R=:F3[M0IUJ9/NU B4=:E3[U1#K4J?> MJ0)$ZU-'T%0IUJ:/H*D1/'4L?05%'4L?04$$\=2I]VHHZE3[M9@2CK4J?>J( M=:E3[U!0\=:D'6HQUJ0=:AAU)HZF3M4,=3)VJ22:.IXGV$&H(ZN6-DUU(H J M&([KX5:W+;Z@BY/45]*^%+IKC3XR?2O!OA'X&DDN4N:^@=!L?L5FJ^@KQ M,=*+EHDUG_Z5PU^1_P#:7O7ZT?\ !7US M'^Q)XE8=I;(_^3D-?CO_ &E[U]?P_P#[N_\ %^B._"_ >;ZG:7?B/X]C&MV> MN6^F7J7$VEV=ZEE/9)C WHJ!I@C%'8O,>./+^8 ^T?VE[U\Z7UZUM\8 T-EJ M\48U,C^TDO[Y;!"\BF2(QA-N]BH!Y\HDIKQ/XH?MM:1X7CD"W4>1_M5O2PU2H[11YF,S?"X57JR2/H>[URWLURSJ M/J:YS7?B]IFC(=]Q&,>]? /Q9_X*6!3*EM<>HX:OG/X@_M^:MKDKB.Z?!/\ M>KV)V!P]U3=V?J7XK_:ZT315;_2HLC_:KROQE_P4*TO30P2Y M3CT:ORP\2?M,ZSK+MFZEY_VC7):A\3=1U Y:X)6*]:Z%EM!=#RY<79E)WO.SZ$C_;2UHG_CZE_P"^J>O[ M:6M8_P"/F3_OJOGV%CZFG[J7U.CV&N(,=_.SZ#C_ &T-:/\ R\R?]]4__AL_ M6BO_ !\R?]]&O $/RCZ4NZE]2I=BEQ#C?YV?0(_;-UK;_P ?$G_?5/3]LS62 MO_'T_P"=?/RL<5(CG;U-+ZG2[%KB#'?SL]^'[9>L9_X^I?\ OJI?^&RM9"_\ M?,G_ 'W7@*,>*DW4OJE+L:+/\;_.SWS_ (;(UG_GYD_[ZIT?[8^LY_X^I/\ MOJO!=U*CO[7.KX_P"/F3_OJO#(F..IIVZE]4I= MBUGF,_G9[G_PUQJ_'^DR?]]4\?M;ZOM_X^7_ #KPTGY1]*>CG;U-+ZG2[%?V MYC/YV>Y_\-:ZL?\ EXD_[Z-/'[6>K8_X^)/^^J\.1OFJ3>?4U/U2EV+_ +;Q MG\[/ M[_G2C]JG52G_ !\/^=>+YQ3@WR4OJM/L4LZQ?\[/:H_VIM5(_P"/A_SIW_#4 MNJ?\_#_G7B\3<4[=2^JT[[%_VSB_YV>V1_M1ZIN_U[_G4T?[4&J1]:GZK3ML:1SG%_P [/:H_VG=3(_U\G_?53Q_M-:F5_P!>_P"=>+P' MY?QJU&?D%3]5IWV-XYQBOYV>QI^TMJ9;_7M^=3I^TGJ1_P"6[_G7CL/^T'?W$9!F?'?FO/_B9J0\;6[B5=Q(K.B-643<:(THQ=T=F'SO%T MY:'#> AE%8&M_"JUU '] MV.?:NN-:VA]]E?'E2-HUSY/33I('Y4]?2K4$+ ]#7O>I_ 9))"53OZ5F3? 9 MU/"_I6GM8GVM#B_!U%JSR:VC/I5^WC)(KTVW^!UB= M2XDP;^T>;VT1K0MHC7HT/P4D7^"KL/P7D ^X:7MHE+B/!_S'G=M&?\BM"VC- M>@6_P:EV_=/Y5=M_@](O\/Z5'M8E?ZQ83^8X&VB-:%M$:[R#X12#^&KEO\)G M7^&E[:(?V_A/YCA[6,UHVR5V=O\ "J1?X?S%7X?APO\QQML ME:%LE==#\,9$_A_2KMO\-G ^Z:GVT1_VYAOYCE;=,U?MD-=1;_#EO[M7;?X> M/Z?I4^VB/^VL-_,/X;/C[M2Z\0_M&CW.+1*D5?EKMXOAI(?X:G3X9/C[OZ5/MX%?7Z/E2K"V>E>@0?"YB?N_ MI5NW^%1)'RU+Q$"_K=-]3SJ*W9NU7;72I9R,*:]2TGX0+(1D?I78>'O@S I7 M [G4'&$;GVKTKP+\&W:5&D3\Q7JN@_#BUL4'[M?RK MI;/28[1?E4"O/K8YO2)G*K?8R/"OA&+1K=<(,UT*KM6A5VBEKSI2;=V8A111 M4@?-7_!672GU;]B/Q@L:[C#!'.?81S(Y/Y*:_$K^TO>OZ"?VH?A^GQ0^!GB7 M0I/N:II\]JQQT#H5)_6OYX-;AN/#VLW>GW:-#=V,SV\\;=4=&*L#]"#7UG#L MTZ]=/\&/!\WQ8^+/AWPW &=]9U"&U;;_"C,-[?0+N)^E>ZH0I M0TV1U-)-R/WO_8HTJ30_V6/ EI*NR2VT.SB9?0K @/\ *O5*Q?A]HZZ#X/L+ M55"+%"JA0.F!6U7YQ*7-)R/&"@G HK$\:>*HO#>ER2R,!M&>M))MV1,YJ$>: M6Q)XD\6VWA^U9Y)%7:,\FOFWX_\ [;FG>"8)DCN4W*#T:O%?VS?VXO[":YM; M:X^89'#5^=?Q;_:"U+QOJ4K-<.0Q/\5?499D;J>_4V/QGC'Q(AA&Z&%=V?3' MQY_X*%WNN2S);7+8.>C5\R>,_P!H+5O%$[E[F0AB?XJ\ZFU*2\;+L3]33(3E M?QK["A@:5)6BC\%S+B3&XV;E4FRO\1/B+JFF6L$ML$N'DG(=),Y9%CDD8+@_ M>(3 SQDU1UGQK+'KFEP69AF@NFB>:1@3B.5@L>W!ZM\Y!.1A#5V^TG^TKNRD MW[/L5QY^-N=_[MTQ[??S^%9VD?#]-*MTC6Y+>7>QW*$Q_=CC_P!7".>BC@'W M-7RU.9VV_P"&/1RW$Y3["F\7\<6[Z/WE)VU_PJTHVZZ&C_PE")JZVLMK>0++ MY@BGD51',4!+ #=N' 8C*C(4D9&,Q6_CB.30TOS97D<$YB%L6,6;HRD!-N'( M'4??VXS]:H:;\.SINO07PN+5I+:6>19#9_OYO,608EDW9?;O&,8X7&.A%BS\ M%SVT-\1+I6_4 JR1C3R+9@"Q9FB\SYG;=@MNY ''%3>J]U^1HZ.1QMRU.;2% M])K7F?,NMGRV;EJM^6-WI?F\326T]DCVUQ"US'/(;9HT>4^6!P&63:">AD? M!^@QQ0_:7?\ 73_,4HY+M*;=OY4U>\YK2]]5%PFKM[.+=]#3T?Q0-3OOLTME M>Z?.T7GQI/*8M#5FCV!K+3!:R M'D'E@[9''3 [5T(Z5I'FM[VYY>:K"*O;!.\+>:5_)2U[;MZWZ:*5/]33X>C4 MQ/\ 4T^'HU4>>MB6'I3Z9#TI]3T-$3I]P?2EI$^X/I2TD-$@Z4]/NTP=*>GW M:1HB5.U25&G:I*CH:$E.3K3:J1/OCZU&GWJD3[X^M(M;D].CIM M.CI&A(G6G4U.M.I=2R=/N#Z4L?\ JS]:1/N#Z4L?^K/UJ2T31=*=38NE.H+1 M*?N+]*I]062I]ZGCK3$^]3QUH-"2G1=:;3 MHNM!:)TZU(GWJC3K4B?>K,M#Z4?GX5 MF;Q+*?=JU%TJJGW:M1=*SZF\2>'K5N'[_P"'^-5(>M64<(?P_P :DWB3CK5E M>E8U[K\-D#N8<>]8.M?%>UL<_O%X]Z7*V>IAL#7K-*G$[L>7CG%/7R,<[:\7 MU/X\I'(0K]_6LR;X\NQX?]:?L9'TV&X4QTU>Q] P?9<'[O6IX?L^?X:^>K?X MZ2G^,_G5R#XX2G^,_C2]A(]"/"&-/H(?9L_PU;C^SX_A_"O (?C7(W\=78?C M1(1]\U/L)&L>$L8>\P?9\?PU9A\CMLKPFW^,LNW[Q_.KMO\ &&1OXOUJ?8R- M%PIC$>Y1^1G^&K47D8'W:\1@^+LA_BJY!\6G;^*I]A(U7"^+/:H_)_V*LQ^1 MG^&O&+?XJR-_%^9J_#\47/\ %^M9O#R-%PSBD>PQ^5QTJS#Y6/X:\AA^)TC_ M ,7ZU=M_B2Y'WJGZO(T7#>*/6H/+_P!FK$'E9[5Y5;_$9O[U7;?XAOZ_K4O# MR-5P[B3U%/*SVJS%Y6.-O2O,H?B [=ZLQ^/F(^]^M3]7D:K(,2>FQ^5CM4\? ME8_AKS*/X@L!]ZID^(+X^]6?U:1<W6O+D^(; _>J>/XB MOCK2^K2-%DE<]2A\KVJ>+RMX^[7ED7Q$<'[U3Q_$9_[QJ/JTC59/7/55\K'\ M-6(O*Q_#7E"?$E\=34\?Q)?'WJCZO(T64UCUB#RO]FK$7E_[->31?$QQ_%4R M?$UP/O?K4_5IFJRNL>N)Y/\ LU8A\C_9KR)/B>_]ZIHOB@X/WOUJ?JLS59;5 M/8+?R<\;*GC,0;^'\*\>C^*;@_?/YU,GQ4?(^8_G4?59FLXZ;K@8 9K6MKL3"O)M# M\>13[?G'YUV&A^)%FZ-G\:XITFC6%22TD=A15:QNQ.O6K-']?D\RZ9%RMI<'@D^BOP<_W ML^H%?M[7$?&GX':1\:/#<]AJ=M!.DR%&61 RL#V(/!%=F!QDL-5]I'YFE*HX M2NC^:S^TO>OT0_X(C_L=7WB/QZ/B/K=G)#:01F/2%D7&\-P\^/0CY5]0S'T- M?1>C?\$3?A[IGC==2_L.S(27S CO(\77/^J+%/PVXK[*^&?PRT_X8Z!%8V$* M1I&H7Y1CI7JYAG:K4O944U?>YO5Q/-'EB='%&(8@HZ 8IU%%?/'(-D;8A/M7 MS'^W'\5)?"/A2Y$;%3M-?3DB[T(]J^8_VX_A7+XN\*7)C4L=IKMP'+[9O,F0H>17ZIA^7D7+L?Q7F?M?K,O;;W)(>E20?<_&HX>E20?<_&M>IQ(S/ M%?BH^$[.*?[,UR))MCA7VE$".[,.#DA4/'?UJ36?%@TG6].LXXA<&]G)\6F][,W8/$UG<:K]C623S_FVYA=4-ID1G5F #* WWE) R/7FC!X)U"XURWFO)UE2&2X\R7 M[7*S3+)'*B[8B/+C*AU'&:9U=2HD987:.'<<+O<*53/\ M$<$'I4?BWQ%?^'/ M(>"QM+F":6*WW27;1.))'"#Y1&PVC(YSGKQQSD:SX ENM8U)Q"M[::I)YLJ/ MJMQ:!WLFKDMOXJ@M]-O&OW@MI],C\ MV]2-FD2%3EE(8JI;*@]!U!':FW'Q TG3;J:&:Y='A95F_<2%;?<%*F1@N$!# M#!8@=>?E.,;QCI+7WCC18HG15OT87R$G MV_V(6>H3);SR2.RRVZM;1!F4 $.=I. 2N".ISQ+J3O9?U_6AV87*,'JXOKSM+>RBKM[]->^--.T?4#;7$TBR(5$C+!(\<&XX7S'"E M$S_M$<'/2I-=\02V&H6]C9VRW=_=(\JI)+Y4<<:%0S.P5B.64#"DDGTR1SFI M?#B6?5=1*P+?6>J.))4DU>YL]HV+&R%(P4<$+G)P3D@\ 5N:]H=XNOVFJ:;] MF>XMX9+66&X=HTFB8JW#!6*L&0'[IR"1Z$%YVU,/JF60G2]G)RO%WYFE'FY4 MTO=?-%<^CYK::WM=EI_%RZ18V_\ :D+6MY.S(EO;*]XTFWJR!%WE<8))48R, MXXI9?'^DQ6MG*+EI1J"-);+#!)+),$(#@(JEMRYY7&1AL@;6Q1FTC6_[4LM6 M2/2Y+Z."6UFMFN)$B$3LC@K)L)+ QKGY #N/3 RN@>"KC2=3TZXDEAO< M;<@>9<2I+A!C[H(89.#T..323GL@6$RWV?M*LK2]ZZC)6NE/W5=2=M(>\VT^ M;3RT-$^(&D^(;F"*SNC*;F,R0MY,BQR@ %@KE0I89Y4'7=3R?:(S)!LLYF^T@8R(L)^\9=WS*F2N&R!M.*FD>![NQ_X1G?);G^QI+AY ML,?F$DI_#O@RZTJU\,I(\!.C6SPS[6/SDH%&WCD9'?%3S5#> M>%R:+DXSDUK;WET]IUY.O+#IIS=3;TSQ78:JUB(+@2'4(GF@ 1AO5"H;/'RD M%@"#@YSQP:@NOB)I%I#:N;F1_MWF"W2*VEDDF,;!7"HJEB03TQT!/0$UA:3X M'U;P[::1+:_V=]T2?1GN M)K61M/AO(YC'N =II4=2H/;"G.3QQUZU/--Z6*G@,K@W/VK<4Y65U=V]I;[+ MM>U/6VO,[?W=:W\9VNH7.DBUEAE@U>.26)V+JQ5%!X79C//(8J1[GBF:?\2= M'U"&26*XF:-$WJWV68"X&X+F+*_O&78+ M?+/L8Y(G8E=N1V!YSC\:;;^&/$J>#[;21+IL TZ."!7M[F6)[^.-E!!8(#;[ MD4@[-YRW!&.3FG?5&KP.5O2%3K;XDM.>:O\ "[^ZH:*V]]KVOZI\6=/T^SLK MB&*^NDNKW[$ZI93^9 P^]N3RRP8<84@%L\5I_P#"<6=K<:HUS+#!;Z4(FD- M+D7-O+;R0&0@(61U#!23PQ&.#SP<-@^*6C26[.)KS>LP@^SG3[@7)MTO=Z[OLK"Z6^MHYD$@25 ZB2-HW //* ML RGV(!%3UG^%[*ZTW0+*"^N?MEY# B3SXQYK@#+?B:T*UZG@5HQC4E&#NDW M9]_R_)$Z?<'TI8_]6?K2)]P?2EC_ -6?K4DHFBZ4ZFQ=*=06B4_<7Z4Y/NTT M_<7Z4Y/NTB^A,GWJ?3$^]3Z@LE3[U/'6F)]ZGCK0:$E.BZTVG1=:"T3IUJ1/ MO5&G6I$^]69:'TH^Y24H^Y0621=*?3(NE/J>I993[U3Q=1]:@3[U3Q=1]:E[ M&D2S!]S\:LQ_<%5H/N?C5F/[@I=3HB3IUJS#T_"JR=:LP]/PK,WB64^[5J+I M55/NU:C.%K/J;Q)1((U)-6QT?C7XVRW4SK&_?UKB;[QQDQZC),W+'KZU;@E8GJ:Y&R^(6EV?A_3+_4[_3](&IP) M-&MU=)'DLH8J"Q&[&16SJ?C31_#6/[1U;3=/R%(^TW219#9Q]XCKM./H?2KE M.*;3>QZD>3EO'8Z2VD/K5^WD.164LKM9L]N(YI-A:(,^U'..,L < ^H!^AKG M?"WC[Q)K/C.^TF70M$@&E& W"5^M1*I&,E%]?(&TD M>D6TIK0MI37*Z%\0] URWO);+7-'NXM-7?=O!>QR+:KRD?VO*NY+'[9']I<%=V1'G<1MYZ=.:M#XH^&;379M+E M\1:%%J=LK/-:/?Q">)57>Q9-VX +\Q)' YZ5#G%;L>AUMM*:T+:4UYSX!_:$ M\(>.?"8UFWU[2K:U#M'*+F]@1X&7>YAU*+5(9TN8I(S(9&53F)1C@L<,,D<"I]K!JZ9":=K=3N;60UHV MSUY9X[^.=C8?!O6?$_A34]"U_P#LLH@D@N5NK<.7C!5C&_7:^<9!Y%=3\8?B M/)\(_A=K'B.+3_[5ETN(2):>?Y'V@EU4+OVMM^]UP:SG6C%.3V2O\OZ0*S>A MW5LU:%LU>5^%/V@;?Q/<^!4M].=?^$R%VLHDFQ)I1@J M3S78Z=\7O"=WK6HZ;%XH\.RZCH\_V:\OVN/8ET7$?VS_K^FOO%>+5UL=-;N:M1N:Y7P]\5_"WB/Q7>:#I_B70+_ %S3 M@S7>G6^H0RW=J%8*QDB5BZX) .0,$CUKGO$O[1FCOK_ABP\,:YX:UV;5-:MK M&_CMKU+J2UMY[>:5),1OE2WEJ5+ @@G /6H=2/NV>[27S=E^(.R3;Z)W^2N> MHHW-2HW%9GA[Q-IOBF&>73-0LM1CMIY+69[6=9EBF0[7C8J3AU/!4\@]:XO7 M/C9=:;X_\96-M:VUQIO@;P\FJ7H;FJQS4J.DL-1U M[Q#:>'K_ $J6]#/I,L^&5RX3$@,31R+PNY95Y%7V^-_Q'3XR+X-'@;P2;QM+ M;6%G/C&Z$7V<3B'!_P")9GS,D';C&/XJ.>/,H]6[?^2J7_I+N9>TBX\RVT?W MOE7XJQ[3'(0:FCD/%>&>$?VQH]?\9_$O1+KP])I]UX#CNY[%FO0Z:_%;*/.9 M#L!C*,T2LI#8$R'G-=)X-^.5]X@\=>"(+FSMK71_'GA@ZO9A0[S6UW'Y,DD+ M29"LIBG!7Y%.87/.0%SIUH5$G!Z-)_)J37W\K7KH-RBG9[W:^YI/[N9?+4]5 MC>IHWX%01U+'T%:6$6$:I%;Y:BCJ5/NU $P;FI$;YJB'6I4^]042*Y!J59"" M*A'6I!UJ&'4L13$5;M[]XB.35*.ID[5+5R6;^E^*Y[-A\YX]Z[SP=\3FBD0, MU>51U;M+EH'!!KGJ4HR1C.C&1]6^!_&*:FJ_-^M=O ^],U\S_";Q:\5ZB%CU M%?17AR\^UV*-ZBO#Q5+DD;/:EU*W>?RQ/"9.FP.-WY5 M/7QFGQ;E23/G'@YZU[C^SQ\=U\;2_P!D7LV^[5=UN['+2 =5)[D#GZ ^E=-; M RA'F6IX^7<34<365&:Y6]O\CUNBBBN$^F"L3QIX5B\2:7)%(H.X8Z5MT$9% M--IW1,X*<>66Q^=G[9O[#O\ ;K7-U;6_S')X6OSK^+?[/NI>"-2E5K=P%)_A MK^A#Q)X2MO$%JR21JVX8Y%?-OQ__ &(].\;03/';)N8'HM?499GCI^Y4V/QG MC'PWABVZ^%5F?AS-ILEFV'4CZBF0C"_C7W'\>?\ @GI>Z'+,]M;-@9Z+7S)X MS_9]U;PO.X>VD 4G^&OL*&.I55>+/P7,N&\;@IN-2#/,;W4X]*B#R!F\R5(4 M51EF9V"C'Y\^P)I;+7[2]UFYL(YMUW9A6FCVD;0P!')&#U'3ID9J/QWX;%B$9_P!)BDMX M4./82*A)']PU;JM/3;_@';EN24*]%>UERSE&7+JDN;FA&,7?U=]K73O9.^]< M^-],M+:^E>Y(CTUUCN"(G.QF.T 8'S<\<9JUJ?B2RT33([NYG"6\I4(ZJ7W[ MAD8V@GIS]*Y7_A&9])M;VV2*:;;-IQ\P1G]^RS!I7''J68^F35>\\/WTVDW= MD]M.T&AQ-#8D(?\ 2/,;Y2N.OEQ?)_P)JCVDUI8]>GP[E4YQY:SY5)7UCK%P MAJM-&YSMULGJGRR;ZV7QS86E\UFXU#[2-QV+IUPVX*0"PPF"N2.1QR.>:M-X MNL+;4#;-+(71Q$[I!(\4;DC"M(%**>1P2.H]152YM97^(EK.(W,"Z?<(9 IV MAC+"0,],D _D:K^$M2;PY:MIMQ9Z@]T+N8AX[5VCN!),SB3S -B\/SN8$;3[ M9KGE?4\U9;@IT8U*492ERIN//&^LI1;^#1+E5UK\2=TD[]!I>JQZM',4#J8) MG@=6QD,IQV)ZC!'LPZ=*NCI6!X782:_XA9.8_MJ*2.A<6\6[_P!E'X5OCI5Q M=XIL\C'T(T:O+#9QB_\ P**E;Y7)4_U-/AZ-3$_U-/AZ-5'(MB6'I3Z9#TI] M3T-$3I]P?2EI$^X/I2TD-$@Z4]/NTP=*>GW:1HB5.U25&G:I*CH:$E.3K3:< MG6AE]!Z?>J1/OCZU&GWJD3[X^M(M;D].CIM.CI&A(G6G4U.M.I=2R=/N#Z4L M?^K/UI$^X/I2Q_ZL_6I+1-%TIU-BZ4Z@M$I^XOTIR?=II^XOTIR?=I%]"9/O M4^F)]ZGU!9*GWJ>.M,3[U/'6@T)*=%UIM.BZT%HG3K4B?>J-.M2)]ZLRT/I1 M]RDI1]R@LDBZ4^F1=*?4]2RRGWJGBZCZU GWJGBZCZU+V-(EF#[GXU9C^X*K M0?<_&K,?W!2ZG1$G3K5F'I^%5DZU9AZ?A69O$LI]VK4?*_A55/NU:BZ5GU-X MF#X\TQM0TN0+_=_I7RS\3/#$UEJT_T M1^X8;'4<1!2@_P"K6_4\^T7PYJWA6]AN&T-]:6YT&VTYHHYX0UK)&&WHWF,! MY;[ADH6^Y]T\5I>"?A==Z!/#'=P6]W]F\.)IBS_*09-SEHUS\VW!4= " /H. MUMXRK=.]7[<5G/"0E)M^?X\U_P#TIG5""C:W2WX6_P D8'PQ\&:IH_A?PZMW MJNIVLEAI\$%QIRBV>!G6,*P+>6SGG^[)CCBDU/X?:GKFH?$"--MJGB*PAMK* MX9Q@L(71B0"6 !8=1],UV%L*OVXY%75H1J1<9=;_ (JWZA"*@E;H>3VWPUUK M6?#>HQSV?BS^TH_#EUI=HE[)I*V9,D:@1(;?:Y&Y5VEP #G&<5W5I\/)X_' M/@*Y73H%LO#VF75O(1Y8%G(Z0*@55 M(]RKO+AMKG8 S_*IP!W]L*T+85E3PT::2BWI_P #1^6B*<$VWW_X/^;/'_"? MPQUZ;PKX*T:_\/2)_P (KXH:^N)I9[:2">'_ $MDGC D+<-)%PRJP)&!P2.B M\7^!/$XU?XA7NDZ9;73ZP-+^PB;R)/.$/^N,:R'8)4'*>: F\*3D UZ9;"M" MV%2L)%4_9IO>_G\*C^2^\7*KW^7Y_P"9X,WPB\:^(_#GQ)-Q9:W<7'B2VTU- M/&K7.G"[F,,C>8'%KM@3 QCDY4CYLY5?9/VA?"&H^//@MKFDZ3;_ &K4+Q(U MAB\Q4WD2HQ^9B . >IKIK0(-&_:OTO M6]*CC;P=>?;-1O")55M-OY;4P.RH2"5EQ&WR@X97)QGFM\ _@?XB\*:AX,TO MQ!%X\<>#II7@N8I="_L7?Y&+I?%'P_UW^U-,#7MJ(= M97[5,SB&02DH'MY77]\(\%QD$ U:\&_L\>*+/QIH6F75ND?AM4A\2ZC>+<(V MW6UM6MV14W;\&0QSA@-NZ,\@MBO>H!P*OVPK+ZI#EY7>VGX*WXVB_6,;=;EE M=/MI\K[?BUZ-WZ'@7PP^$/BJ33/A5X=OO"7]@M\,[AY[S73=VLMOJ>VWFMV% MJ(W,Y^TM*)7\Z.+&#NW-C*0?LM>(M4_9,^&'@F);SPKJ>EWLHHQY M=NUEY+7_ #>YQO[.VE:KX:^%]CHVL>'M.\.7>AEK!8=-*?8;J-#A;B!58LB2 M#YMDF'5BP.>&;AD\,WDOQ9^.^C0H\U]XHT2ROM/C9PHF#V+46M+9M0AA:WCNC$IF2)F5F0/C(4E5)&<$J/04J]'VT M>6;W33?756]+WL]AT_W=N3I:WW_Y:?F?,^O_ ++/B_3/%7P?U;1+*'RH#HP0>5=*=VUV0-+$VTL6!CP"%R/:3X&U0_M8Q>)?LO_$D7PD^F&Y\ MQ.+@WBR!-F=WW 3G&/?-=\O6I4'S57(E/G7\TI?.4>5_*VW^6ABJ,5'E7:*_ M\!=U_P '_/4^8/B9^RYXN\0_#;QY>Z-9PVWC2#Q9J6L^'A)<1A=1M+FW2"6! MF#819HC(,.5PZQDXQFNKT?PSJ%C\3?V?_#T]N(M0\*>'KN^U11(K&V"64%GL M)7((:6;L<'RR0>*]Y0L8]=?5%L;1=3F@6UDO!"OGO"K,RQE\;B@9F( M7. 6)[UA2H1IKECM[J?_ &Y%J/Z7Z::6NRIP4GS==?\ R:2D_P#@?C?I71=W0OC"C\6P/QK\ZM=^) M+ZOJ ?B_-X/\ M%5E?P38DM9ED7G@X.<'V/3\:\*_X3'_:%.B\9%9 =PZU[3PB:LT?GL<\E&2E M%ZH_8[P_K,/B+0[2_MVWP7D*31MZJP!'Z&KE>5?L5^*6\7_LU>%KIFW%;7R, M^T;M&/T6O5:^!JPY*DH=G8_I_ 8E8C#4\0OMQ3^]7"BBBLSK"HYK=)UPP!J2 MB@#F/$_PRL/$4166!&SZBO$_BA^Q+I'BB.0K:QY/^S7TG2,@<9C,HPN*5JL4S\R_C;_ ,$O[;6[6:/['OCWK* ,C#(P=2".AV]XN&13]17.:[\(=,UE#OMXSGVKVI!BELG/HM>S1XC@])'Y_CO":O#6B[GXX2^ M'KFW4@QL.?2HTL94ZJ:_3WQ9_P $T(I"YB@_\=KS[7?^":ES"[>7 ?\ OFO0 MAG5"74^5Q'A[F5)_#<_/RPT6/2HG6&+RQ)*\S\DEG=BS')]S^'0<"K0A8+TK M['US_@G7J5NQV6[_ /?-9%S_ ,$_]7ACS]F?C_9K=9C0:T9Y];A7-')RJ1;? M<^4T0^5TI\2D!N#7T3J'[$&M6SX^S2?]\U77]BO6AG_19?R-:?7J/ MM.1G@<*GT-/Q7OD?[%NM _\ 'K+_ -\T]?V+=:Q_Q[2?]\TOKE'N-]Q_L7:T/\ EVD_[YI__#&&M!?^/:3_ +Y-+Z[2[E+A[&_R,\$4 M'%2(AV]#^5>]#]C+6MO_ ![R?]\T]/V,]9"_\>K_ )4OKE+N6N'\=_(SP= > M*DQ7NH_8TUC/_'K+_P!\U+_PQKK)7_CVD_[XI?6Z7LG_ 'S2^N4GU*608VWP,\*13NZ5(BG<.#U] M*]U3]CK6-W_'M)_WS4B_L=ZSG_CV?_OFE]3\C2^N4NY?]A8W^1GAL:DGI3]I]#^5>Y)^R!K / M_'L_Y4\?L@:P1_Q[/^5+ZY2[E_V%C?Y&>(H/D'TI8U/EG@]:]P7]D'5\?\>T MGX"G+^R'K&/^/>7_ +YI?6Z7)Q*<=#3L5[\G_ 'S3 MU_9&U?'_ ![2?]\TOK=+N6LCQG\C/$B/E'TIZ*=O0_E7MG_#(^K\?Z-)_P!\ MT\?LD:OM_P"/9_RI?7*7 M/V3M5 _U$G_?-+ZU2[E_V)C/Y&>+(/FJ0#FO9_\ AE'5-_\ Q[O_ -\T_P#X M94U0$?N'_*E];I=RUDF,_D9XQUI\0YKV;_AE;5/^>+_E3D_97U0'_4M^5+ZW M3[EK)<7_ ",\=3[U2)]ZO8E_98U3=_J6_P"^:>G[+.I@_P"I?\JGZU2[EK)< M7_(SQW&:Q?\,MZG_P \7_*G#]EW4PG^H>E]:I]REDN+_D9X_$.*=BO8 MH_V7]3 _X]W_ "IW_#,&I?\ /!_RI?6J=]R_[&Q?\C/)$^]4\0Y'UKUF/]F+ M4MW^H;\JF3]F;4AC]R_Y5/UJG;.3XK^1GE,?6K,(P/PKU)/V;]1#?ZEORJ>/]G' M4?\ GB_Y5'UFGW-HY3BOY6>7IRM6HNE>FI^SGJ '^I;\JFC_ &=M0 _U+_E4 M?6(=S993BOY6>9Q"IFMEGX(SQ7ID?[/5^/\ EB_Y58A_9]OQ_P LG_*I^L0[ MF\,KQ2^RSQ#7/ -OJH.8QS[5Q?B+X%1S[BD?Z5]4)^S_ 'V?]4WY5(?V?;U^ ML+?E3^MQ74]W!5LRPWP7/B34O@5-#)\J'KZ50D^#]U"?]6WY5]U/^SA<2?\ M+N?RIG_#,,T@_P"/8_\ ?-7]?CW/K +@?P-6A!X#G'\+5].Q_ .5?^6!_*K,?P'E!_U)_* MI^OQ+7$.*_D/F:W\"SC^ U?MO!,W]TU](K\#)!_RQ/Y5-%\$'4?ZH_E4_7XE MK/\ $_RGSO;^"YA_"?RJ];>#9A_":^@8?@K(O_+$_E5B'X,NI_U/Z5/U]%K/ ML3_*>"0>$9A_!^E6H_"$N/NG\J]Y7X/./^67Z5,GPB8#_5?I4O'(M9YB/Y3P M9/!TO]TU*G@^;'W3^5>]Q_"1O^>6/PJ9/A,P_P"6?Z5/UY%K.J[^R>"IX-FS M]T_E4T?@R8_P'\J]Z3X4G_GE^E3Q_"O_ *9_I4_7D4LXK_RG@D?@R;/W3^53 M1^#)O[IKWN+X6[3_ *O]*GB^&'S?ZO\ 2H^O%_VK6['@:>"I\?=-3Q^"9\?= M-?04'PK##[GZ5;A^%*_W/TJ'CD:+,:S^R?/$?@><_P !_*ID\"SE?N-^5?2% MM\)XSCY!^57[7X2PXY05#S!&\<;6?0^9T\ 7!/W&_*K$7PZNF/\ JV_*OJ*U M^%%J.J"M&U^%]FG_ "S7\JAYD=$<15>Y\J0?#*[?_EFWY5:A^%5ZQ_U;?E7U M=#\/;./_ )9K^53IX(M$_P"6:_E6;S)FRJRZGR]I_P &[N7K&WY5U.@? F5V M7>A_*OH&'PO;P](U_*K4.E10]% _"L99A)[#=5GF?AKX)PV@4L@X]J[K1?"$ M&EH-J#(]JVEB"]J=7'.M*6YFY-C(X1$.*?1160@HHHH ^/O^"R.LMI/P#T3! MQYFN1*?^_%P?Z5^:W_"5>Y_.OT)_X+G:C_9_[/GAH_WO$,0_\EKFORX_X2'Z MU^B\-4.;!)^;/Y-\8,Q]CQ%*%_L1.^_X2KW/YTH\5<]3^=_\ 53\M_MCS/VB_X)>WW]H_L>>&I/5[L?\ DW-7T-7S'_P2*O?MW[$7A=_6 M2]_]+)Z^G*_)\Q5L757]Z7YL_N3A*?/D6"GWI4__ $A!1117&?0!1110 444 M4 %%%% !3&A5^JBGT4 5Y-+AEZH/RJM-X8M)NL2'\*T:,T[LEPB]T85QX L+ MCK!'^55Y/ACITB_\>\?Y5TA<#O2>8H[U7/+N9O#TGO%'&7'P6TJ9\FVC_P"^ M14?_ H_2?\ GUC_ .^17:FX0?Q"C[4G]X4_:S[F/U+#O[*.*_X4?I/_ #ZQ M_P#?(H_X4?I/_/K'_P!\BNU^U)_>%'VI/[PI^UGW#ZCA_P"5'%_\*1TG_GUC M_P"^:/\ A2.D_P#/K'_WS7:?:D_O"C[6@_BH]K/N'U'#_P J.+_X4CI/_/K' M_P!\TO\ PI+2?^?:+_OFNR^UQ_WJ/ME?\^T?_ M 'S2_P#"D])_Y]H_^^:['[7'_>H^UQ_WJ7M9]P^I8?\ E1QW_"E=*_Y]T_*C M_A2NE?\ /NGY5V/VN/\ O4?:X_[U'M9]Q_4L/_*CCQ\%=*'_ "[I^5'_ I? M2O\ GW3_ +Y%=A]KC_O4?:X_[U'M9]P^I8?^5'(?\*8TK_GW3_OFC_A3&E?\ M^Z?]\UU_VN/^]1]KC_O4>UGW#ZEA_P"5'(_\*:TH?\N\?_?(H_X4UI1_Y=X_ M^^177?:X_P"]1]KC_O4>UGW#ZG0_E1R/_"FM+_Y]T_[Y%+_PIO2_^?>/_OD5 MUOVN/^]0;R,?Q4>UGW#ZG0_E1R7_ IS2Q_R[I_WR*#\'M+'_+!/^^171W_B M*VL(R7D48]37GGQ"_:.T?PC Y>YC!4?WA5Q=26PU@J#VBCGZ/YBP7*Y''#5\S_$[_@I'>:A)((+@ MXYQAJ]*C@,1,WCE=)_91^@>O>(_">CYWFWX^E<1XA^.7A#3-WS0?\ :KTJ>3S^TS9931_E1^GU]^U%X4AE M./LY_*L+6?VN/#5O]WR/TK\S&^)VI3ODW$G_ 'U37\*;OC]\_ MYUI_9<.X_P"R\/\ RH_1U/VO/#[=H:>G[7&@'_GE7YTQ>*;O'^M?\ZLP^*+O M_GJ_YTO[+AW%_9>'_E/T27]K/06_YY5(O[5V@D?\LJ_/.'Q/=?\ /5_SJS%X MFNN/WK_G1_9< _LO#_RGZ#I^U5H1[15(O[4^A'M#7Y_0^);H_P#+5_SJU#XD MNL?ZU_SJ?[,AW'_9=#^5'WXG[46A'M%4B_M/Z$W:*O@F+Q)C=?6C^S8B_LVA_*?="?M*:*W:*I4_:1T0]HJ^'(?$5S_P ]&_.K4/B& MX_YZ-^=3_9L _LVA_*C[>7]HW1CVCJ5/VBM&(Z)7Q-#X@N/^>C_G5J'7[C'^ ML?\ .E_9L _LVA_*?::_M#:-_P!,ZE3]H31SV3]*^,8M>GS]]OSJS#KL^/\ M6-^=']FP%_9U'^4^R5^/VD$](ZE3X^:2>R5\>0Z[B?I4J_'32F[)7R-%K4__/1OSJU%K<__ #T;\Z/[ M/@']GT?Y3ZT7XX:4>RU(GQMTH]DKY0BUJ;^^U68M:F_OM2_LZ ?4*78^JA\: MM+/9:>/C9IG^S^=?+2:S-Q\[5(-9FS]]J7]GQ#ZA1['U(/C5I@_N4X?&K3!V M6OEW^V)A_&WYT_\ MB;^^WYU/]GQ']1I=CZA_P"%UZ;Z1_G3A\:].Q_!7S!_ M:TW]]OSIZZM-M^^WYTO[/@+ZE2['T\OQLT[T6G?\+LT_T6OF)-7FS]]J=_:\ MW]\TOJ$ ^I4^Q]._\+JT\]EIR_&K3\?P5\R+J\V/OFGIJ\VW[YI?4(!]3I]C MZ:'QJT__ &*EJ/XA7SNS*/OG\ZAY? /9(^K+/XR6LQYD7\ZV+'XDVEUC]XOYU\B6 MWB:XB_C;\ZT[#Q[=6^,2'\ZQEERZ$NBCZ^M/$\%R.''YU>BODE'!%?*NC_%Z MYML9D/YUV7ASXYMD;W_6N6>!DMC-TF>_*X:EK@?#?Q7M]149<9/O77Z?KD5Z M@*L#^-<K/XP\;XWXHF_[D/R M*Y\>:4-3%G_:5K]J:7R!%O\ F,F<;<>N>,5J>=[UYW DL7C3^TY!>36<*]VA5E--R/A,_R;#X*%"6'DWSQO+5 M.TM+QT2M:ZT>NJO;2_[8?\$:6W_L)>%O^NM]_P"EL]?5=?*/_!&%MW[!OA7_ M *[7W_I=/7U=7Y!FG^^UO\4OS9_G#V _Z\TO_2(A1117"?2A1110 44U MY!&.36?J7BBUTU"7D48]Z:3>Q,I*.K-*FM*J=37G/BS]H#2]!1MUQ'Q_M5Y! MX]_;CT[2@XCN$X]&KIIX2K/9'DXO/<'AU[\T?3EQK,%N.77\ZRM0^(=A8#YI MD'XU\&^./^"A1RPBG_)J\A\7_MV:EJ#/LG?_ +ZKTJ6259:L^2QOB)@:6D'< M_2W5?CYI.GD[KF/C_:KF]6_:MT:Q_P"7F/\ [ZK\L=?_ &L-8U%F/VF3_OJN M5U+]H#5KWK<7,?_?58EQ^WGI: M*<7"?]]5^6-[\5]2NP+4\3\4W[J/T MZUC_ (*$6-NYVSKQ_M5G'_@HE:?\]Q_WU7YEW/C&\G',K_G5?_A)[K_GJWYU MNLCH]3SY>)./;NF?IV?^"B=H!_KA^=)_P\5M/^>Z_BU?F(_B>[V_ZUJC/BF[ M7_EL_P"=/^PZ)G_Q$G']S]/C_P %%K0#_CX3_OJD_P"'B]H?^6Z_]]5^8+^* M[O;_ *YZC_X2J[_YZR?G3_L*B3_Q$G,.Y^H+?\%&+11_Q\+_ -]4'_@HS9C_ M )>%_.OR\?Q3=8_UK_G33XJNS_RU?\Z/["HB_P"(E9AW/U$;_@HW9J/]>O\ MWU36_P""CMGG_CX7_OJOR[?Q3=X_UK_G48=S]1_P#AY%9_\]Q_WU0?^"D=F/\ EN/^^J_+1O%5WD?OI/SI)?%= MV%_UTG7UI_V#1%_Q$S,.Y^I9_P""DMD#_KQ_WU2-_P %)++'^O'_ 'U7Y8_\ M)7=NW^ND_.FR^*;M5_UTGYT_[!H$_P#$3?]:_YTDGBR[X_?/^=+^P: O^(FYCW/U0/_!2BR'_ M "W'_?54M7_X*;6=G 3YZYQ_>K\NCXMO"/\ 72?G67KWBN[>+!E?\Z/[!H(] M#*N/\RQF)C03W/N[XO\ _!52YN8Y([2<^@PU?,/Q+_;8U[QK-)_I4N&S_%7@ M=WJ$MQ*=S$\^M$)R:UIX&C3^%'])Y/@JBHJ=:5VSJ=5^(>H:W*6EGD.[KDU0 M^VR3'YF)^IK/AKF-+^(CZ7#J#WJ7=\W]MRZ=:Q6T2E_NAE7MZ'DGOR<M68OZ5Q]Y\5;*PFN(5M;^YN8-172 MT@C$8:XF,0EPK.ZJ!M/\3+R"!DXRS6_B5J>E>)O#MG'X=U IJXF\Z)GMO.CV M*2 #Y^S(QN/)&T\<\5+KPM=>7XV_S0.:7]>=CO8NM68NU>;^)/BS]L\,:W-I M\6LZ='I4[6\FI?98)426.8(R*CR OGUQM /4,-M=)XH^),?@Z21Y]*UB:PM= MGVJ^BCC$%L&(&3O=7<#(),:OCZ@BA5X/7I_GU]//87,M?(ZZ+I5J'K7$>#-2 MN+KXI^+K=YYI+>V2Q,,;.2D6Z-RVT=!D@9QUI@^)A\.^+_%PU*:633]*^PI: M6\40:1I)E8>6@ RS.^T $]3V&:7MXI7?=K[K_P"1/,>B0U:B[5Q&G>*7^($] MWI"2>(/".KV'ESR1M':-.T+Y"NI(GB9"0P.#N!3G'>+]G^75]>\'6FLZKXAU M/5)+L31FWFAM8X8RLSH&7RH4;.%[L1R>.F&JR^OIOY[Z>HW'C#QS+;W4L4?A?1XXK>-7S&+AXWG:1D^Z2 (@,@X&['WC1X9^* M]S9:SIE#P8FM7K-$H EWIND^5<]"?E''/ K)8F#=GI_4OT@_O17-; M^O.*_.7X,]8BZU9AZUP.E_$G_A-[\:&]KXF\'ZCJ-I]LL9[B&U\R>)67>T?, MR!EW+N250P#CY>N,OX5:3KOC$^*(]2\9>(KJ'3]3N](CB$=G;[HQ&H5R\,"2 M"0%R0R.O('%)U]>6*;=F_N:5N][OL/G6C[NWX7_(]=_#7QK>Z] M\ +;5I9_EK\^A"E\.FLO^!_ MF>T0]*MP]:\A\0?':/Q%X+\0VL&G>(?#]^_ANZU;39KQ$A:ZA5"/-CV2,Z,K M-&=L@1QO4X]-WX:?&ZWUD6NFWVE>(M.O!HXU2![RV#MJ<";5>2)(W>7<"R_) M(BR'>ORY-+VT7)Q[?_;7^[E=QCWDMQ_:> MFZ[X<@BTB3789]3@C1;NR0@/*BQN[J5W)E)%1_G7Y:GV\.K_ *U_^1?W/L5= M;?UT_P U]Z/38NM6H>E>;P_M VMCX6O-8U;P[XIT*V@B@FMEO+:)WU'SFV1) M$(99 )&A>)=&O-$:T-QILT,$]V\5U,( M8IHQ!+(DBE]P(5RX*,-N=H8=6"W_ *\O7RW%S)ZK^O\ A^G?H>IP]:MPUXU= M?M=Z?HKZTM_X1\:V+>&6C?6A);VK+I=O(JLER[I<,KQD%CB(O(/+?<@P,]#X MH_:/TWPKJ^K0QZ-X@U:P\-K$VMZG8Q0&UT@.HD_>!Y4DDVQ$2,(4D*J1D9.* MGVT'K?\ K_+SVOH',CTZ+M5F+^E>3>+_ -JG2?!6K:Y"^A>)]0LO#'DR:OJ5 MI;PFSL(942192SRJSJ%?+"-7=0I)7!4M#IO[3-Y8?$_X@6&L^'-1M/#/@NSA MO3JL8MW$<1@DE=Y%6X:1@X3]V$BR!G>%J)8BG%7;[_A_PS^Y]AIXZTQ/O4\=:0$E.3I3:(,G&:^B/#UP9[)"?2O"Q-'DEH?7ZQ_P#!P<^S]F[PG_V,T/\ Z275?DCY]?IG M"W^X+U9_'7C5"_$TG_+[QK]N-M?Y74&3>(+#7=>?7!265N_CZ&Y-Q)=F.ZP!=02M'"Y_ABD_U8*]@ #N&"V:[+SZ]G"V M46CYOB^;JT\)+I[-67*XVVTU^+O>R6NA^W__ 1:;=^P3X4/_3:__P#2ZXKZ MQKY+_P""*C;OV!/"9_Z;7_\ Z77%?6E?E&9_[Y5_Q2_-G]B\&_\ (@P/_7FE M_P"D1"BBFRRB),FN$^D%9MHYK'U_QE:Z'"S22*,>]TLSRI;SGN.#7ROXY^.&I>*+ART[X)_O5P=]JTMX[%G)KZK" M9-3AK(_%LZ\0,5B&XT79'JOQ/_; O7MWN+J\DBA,B1[OF;YG<(HP,GEF _&O M+O&7QR>"2Z6YN9FF@LY+YHE!+-$GWB#TSD@8)[UR/Q.L;G4_!H?9HM N+-3/9RV[SS2'<%1)%5S M@(.<8^8 9.<>DH1@FHK^K/\ 4^=H.6,@JV(F[7DI:[64>7_P)MKSMILSN+/Q MY'KL\$:S2">YM5O%C93D1-@ D],Y/3-.>X9^IK@-'\,6NG^.M$N[G1B9Y=&C MB6Y&GF0Q7"[1\[A3Y;;. 6(X&,]JP](\)KX>^%'AN Z#%YEY'%_:;W&F2WK( MRQ.5\Z!"))<,=H#<1Y!P-HQOSVOI_5PJY+AIN].J];+9/?GO;WM;QZPS$BN>M?B-I-YJ_V))KCSOM#V@=[.9(3,N-W..*S/AAINMV MG@O2HS);6,=O).D]M<6#^:8Q<2!%3]Z/+'E[0N0^!CEAUQ--\-:C8W@O9AJ- MQ9+XDFE>P,( 17E81W";5#L%9EUK4JM6[@ MVHV=KN[2WBT[V5E=+762/2CTK(TWQ;;:HLQ2.Z'DWKV!_9M+6SBODW MI)=FON/0G.%JAX?UJ+Q'HEK?P+(L-Y$LJ"0 , 1D9P2,_C7 Z-9WD_Q.T^]_ MLO['(;N[2]9-,F5Q&4E\OS+IF*S*Q6,J%&%^506WA M2\_LZP75;-39C3Q%!'=:%/J/D2>;(9,+&RM$Q!C^8CD 8(VFO4_#]O):>'K" M*:XEO)8[>-7GEC,>Y1A\'>5"IS)R:2L[)7= MO>VDUL^S++_=IE/?[M,K<^9>PC]*93WZ4RGT($?I4<_W_P *D?I4<_W_ ,*0 M#*1_NTM(_P!VJZ$/'K*K#='-W>GE&J-(RAKH);8 M253N-/PW%<\J6I_1'"7BI3Y(T,85(36):?#ORKD2?;,_\3AM6QY7JA7R^OOG M=^E="ML5-2HNVN65%.2DUJO\T_S2/V3!9_@L9%]M MM06"^;5!J=N[VWF)$?)6%D9=P+ J#T93R/3F2T^%=W#:W,G]L(^IS:HFK)EZK"]_I&H/K5Z+RZ&H:3Y]N?W:+L$0E7@% 0220, Y(W&?3_A M+=:39:!]BU:*.[T.::56EM#);LDH(:)(Q("B*" @WG: !S760FK47/Y5/U>F MMEV[]+6_(KDB_P"NYS,_PH^U>!=9T3[?M_M>]FO/.\C/E>9-YNW;NYQTSD>N M.U9WC[]GO_A/M8U2X>_T[;J83;)=Z4+J[L=@ "P2F0"-"1DKMSEFP03D>@Q' MFK,1Z5+PM*22:V22]%L#C%WOU_K]3/\ #W@_^Q?%FLZK]H\S^UUMU\KR\>5Y M2,O7/.<^@Q[UG:_\'AXBOM>N?[1>VGU:2RN+9TA#?8IK7YHV()Q("V"5P.,C M/.1U<1XJU#UJY4825FNM_F3RJUC%\&^";O3/$E[K6K:A!J.JWD$5H&MK4VL$ M,*%F"JA>1B2SL2Q<]0 !CG3^&G@W_A /!UII/VC[7]F:5O-\OR]V^1WZ9/3= MCKVK1AJU%VIQIQC:W2_XN[_$.57N<9'X-G;XA>,;79+%:>+-,A=+I82T<4J( M\#ACTSM,3 $C(W8Z&IY/@#;:K:+;7M_+):GPQ_PC4JQ1>6[+E29E8D@'Y>%( M/U/2NVAJU#TK'ZO"VO\ 7Q?I)HJR;U_K9_FDSE_"/PUU2#Q58ZOX@UNVUB[T MFS>RLA:Z?]B11)L\R20&23>[>6@X*J,'"\\:GAGPS_PK+2O$MYYD^H_;[^YU MCRH+8F1=R+^Z55+%V^3C R2>E;T76K,/6FZ2M[NCLU?U=_S2&HQ5ETO?]/R. M2^$7@&YT3X%:?HEZ[17]U82&[9ER8II]TDG'&=K2,/PIOACX3>(K'X:R^%-1 M\0Z+=Z7_ &,VD0/;:++;SQ_NA$LC,UTZMA(=1M9TUN[T][7PY=>'UDM8]DRF8PD3H^[Y67R>!@_ M>ZC'/9P]*MP]:52A"?-S+??Y\W_R/^#_ -C] M?#USJD_V[PW9R:GX>N/#[+HWAQ=.C(EVXN)!YSM)(-ISEL'(QMP2W9>)_P!G MJT\;W=K]OOI&LH_#-UX;FACBVO*LY@)E5R2%*^3P-IY;KQSW,-6H>E1]7IVM M;^O>_P#DY??Y(2A%;?U\/_R*^[U/.M:^ VM?$7X<7_ASQ=XGLM7AFAMDM6MM M%6WC22%Q(LLT$-3TS;X#T>2_N;&<7'AW MPE_9;8MKE)RD@^TR>8&V #E=N2?FZ5ZQ%UJU#TH]A#FY[:_U_7X;"Y(VL+_V/ M;+Q!\0-4U^V@\!7LFM^0]TGB;PBNM/')'&(LPR>?"T:,JIE#N&X$C&2*]?AZ MU;AK-X>FW=K^OZ932:LSSWQ7^SFOBGPK\1-+CU1+)/'MLELI2SRNFA+5;<87 M>-X^7.,KC./>M*V^$6N^'_B;K_B'0_$&E6\7B*PM[>>TO]'>Z\N>WC=(I5=+ MB+Y/G&Z,@D[>'7/'=1'I5F(_RINE![_UO_FQ?_ $^ #?!W6M9 MOFN="C_M=84.G^']&.CZ7$8]V9OL_G39G?=AI-PRJ(,?+D^IQ=JK1?UJS%VJ MXI12BMD%DKV+"=JD'6HT[5(.M,.A)4E1U)4#[$E/3[M,IZ?=I$CDZT^F)UI] M0 \=*D3[M1CI4B?=H$/3I4B=*8@XIZ<"@3)(ZDCJ-!BI(Z1(].M2)UJ-.M2) MUJ6!(GWJ>.M,3[U/'6D!)3DZ4VG)TH*6X]/O4^F)]ZGT#'1TZFI3NM1T%V'C MI4@Z4P#BI%4D4B1Z?=J1/NTQ%.*ECB) XJ6 J=*D3I3X+!Y.@-:6G^&IKDCY M34MHASBMRA#"TC<"MK0O"LVHRC"'FNA\,_#QIG&]:]6\#^!K>T52RC/TKDJX ME16ASO$PV,SX6?#5K1DD=?S%>Q:=:_9;=1Z"H-(L8K>$!0!5^O$K57-W9#ES M!1116))^?/\ P<+-M_9K\)_]C/#_ .DEW7Y%^=[U^N/_ <.Y/[-'A+'_0T0 M_P#I)=U^0N&K])X8_P!Q7JS^1/&2*?$DO\$/R.0CO!=>-1:Q[)8H;X2R?\3" M0)$_F;QB,@!GW<[5R,]2*[CSO>N/EN)3XJC@@-Y]H%RKNCBWV"+=\[N<9[UT^&KV,-HGZGSG%3OM?966RMJU<_<(?\B'!?]>:?_I$0KD?BEXS3POH3N^Z M>E88>"G429Z6:5Y4<-*<=SXH_:Y_:5N-2U.X@AF.W)'!KY/U[Q'/K%R[R.26 M/K76_&K[3_PDUQYV[[YZUY^_WS]:_1,'0C""2/Y4SW,JV)Q,G48$YJ)^]25& M_>NM'A$5S>PV%OYD\L<,>Y5W2,%&6(51D]R2 /:-@5 M_=F1@NX;L=\"HY[.QZV#RBIB:4:L+V;FG97^&*EIW;N[+0[ZJ]>;?\)!JNCZ M)I5T;R]EAU(7FDVCREBTK-(38S,..2B8W=6WJ3R:O>#=1U/4M5GCC>2Y?PW: MMIY2YNG1+N?4TU53=OZ_K;[SHK\/5*=.55S5E?\&X M]=O>LO+F5SMI;R*.Y2!I8UFE5F2,L SA<;B!U(&1GZCUI:X[Q!XBCT+QKX=N M=U[QT+WQW:/87G35;2V _M9\S M02&(%DM57RVA82<2LV=QX/"BCVBO;S(PO#E?$G07D5V)/*ECE\IC&^Q@=C#JIQT(]**\MW_ /".^'_%46EW<_\ :,6J!+E) M=1F9[>V:1-TIR7*#8S'S0I( )YVTL&I7OS7'AI=ZC-RRAH2CL26&]60MEL&3&0%PM.JK^AS1X M;G5LJ,KN7PZ:/W8S2;OHWS)):W=]=K^BO]VHI*AT337T?0[6UDN);N2WB5'G ME8L\K PC]*93WZ4RG MT($?I4<_W_PJ1^E1S_?_ I ,I'^[2TC_=JNA#W(VZBFS_<_&G-U%-G^Y^-- M;$LC3[U$_P!S\:$^]1/]S\:9+W(J;)3J;)0(;39*=39*?4@:1FHIA\WX5+44 M_P!_\*:W!-IW1&8P33'3#5)39.32LF]3TL)G>,PSO2FT(G%2+/L-14QS\U1[ M),^QP/B9FE#1RN:,5X!4\>H!36.'(IC3D/4_5T?14?&+&I^\CI8]245-'K" M]:Y;[0WK49NV#=>]+ZNCM_XC1B/Y3M8M<0=Q4\?B"/\ O5P@OG'\5,_M%]QY M[^M'U9$_\1IQ'\IZ-%XDB'\531^*80?O"O,_[2?^\:9_:T@)^;]:7U5"_P"( MU8C^4]6C\6PC^,5/%XTA ^\*\B_M>3U-,77)@OWJ/JB%_P 1KQ'\I[3#XVAS M]X5;A\;0Y^\*\.CUZ8G[Q_.K<.NS9^\?SH^IH:\:L0_LGN$/C:#^\/SJU#XV M@/\ $/SKP^'7)O[Y_.KD&N2G^(U'U5&L?&7$/[)[?#XSA_O"K4/C.'^\*\4A MUN7^\?SJY!K4NW[Q[5#PR-H^,5=_9/:8?&4/]\5;@\8PX^]^M>+1:W+N^\?S MJ[;:W+C[QJ/JZ-5XO5W]D]FB\80D_>'YU;A\7PX^\*\:M]9EQ]X]*NQ:Q+_> M/7UJ/8&T?%FN_LGL<'B^$_Q"K<'BZ$_Q"O&[?69?[U7;?6)2O4_G4NCH:KQ6 MK/[)[%#XMBQ]^K_6O([?5Y<#DU=AU:0C[Q_.H]F:Q\3JSZ'K">*(B.OZU,OB6( MG[U>70:M)_>/>K<>IOCJ:CD-H^)=9]#TM?$41_B_6I4UZ-J\Z@U%SCDU_MBH:-EXAU7T.R355 MQUJ9=14CK7)17;8JW!=,:DUCQ_5?0ZA+U<=:ECO%-<_#,6-68)FSUJ&S5<=5 M'T-R.Y!J5)>*RH)3G\:N0/E:ALVCQM4?0OQMD5+&,U7MSD?_ %JLQH=0VCQ7-]#,73685)%I3$5NP6RGM5N"S7'2H]L;1XHF^ASD>CN3 M_P#6J5=$D;M^E=3#8H!TJY#8(1T]:GV[-8\23?0X]= D(Z5,GAR0]OTKMH=. M0G[HJS#IJ$]!4?6&;+B";Z'"Q^&)7/W35V'P?(ZCY:[JWTR/(^6K]MIZ*/NU MF\0S3^VYLX*U\#R-QM-:^G?#TL>17906: \"M"UA ["LGB)">:5)'.Z7\/XT MZK^E=#IOA2&WQ\H_*M"W3!_.KD?]:YYU9,CZS.6['Z=IR0C@5MZ?+Y&VLVTZ M5?M^@KFD:1DSIM'O]P%;*-N7-SAE'E? M*SY?BJK7Y,-[:#BG"ZNT[[:W279*S[7ZW?[#$\4:'-$R[MRFNNILL8E3!KDC)Q=T>_6I1J0<);,_+7]KG]F MJXTW4[B>&$[C>.?@?J7A>X<- M X /]VN#OM)ELW8,A%?1TYQEJC\IKX:I1ERS5BHGW:96'\2M6N=%\-Q_9I6M M9;N]MK(W 4'[,LLR1L_/&0&.,\9(ZU0UJW_X5QI1FT^:_N9[^>WL88[^]FN8 M4EDD$:R$N6< ;\D*0#C'!YH4MS:AESJTXR3]Z:UX9&I6EPNF7U_:?8I8)8XWMX98[BDM$THVFA7,,1BF23S+M7 M2)F&\-B,C><-M?.1\HVY9)O'6JZ.^JVMW_9]Q=Z=-8!9887CC:.YEV$;2['< MN&YW8.1QPE1URWBGQU?Z1-K4=M M#:2/8-8) )=RAS/+L;<1G\"!QZ'I6;K_ (LU33]#UZWOFLY[G36M&26U66U5 MTE<#&!(7!!#=+A$=W\P-M0#?P"ASMY*[N.='Q"U/6X]2M8;FU!ETF74+:X33KF%8@I4$* MTC+YP(D&V1-HXSCD"B=2._S^[4>%R;%\_/2DDXI-O7W>97ULM'RZ_@O>T/0G M^[44EV#>%EOIENGN;.>:22(2QY"Q(PRGF$.>>2V>>0%JCJ7Q$UK2?" M]EK,RZ7);:M:RS6\"1.)+5OL[W$>]BY$@VIM;"IRW2[O-:?^ 2>MNV[5^Z?[M,KE1XGUZUFNK>2#3[V[DTQK^TAMU:/:X;'E M,S,=_P!Y<-A,X/ S2'QG-%\/M;U$W4-S=:;!-)M6QDLVA98MZJ\4C,P/0\XR M",>IIU$D_(Y:F1XA+1IW:2M=[NW;17TN[7=[7.J?I3*YC3XFT/6_#&GI-)Y* MZ9.KKO.)67R,,?4\L6)-3N%;Q*UN8K2[,,KQBW)\M6WI@ M9YQN XHE4Y=/ZW2_4VHI;HN"0 :WH[N5OB-?0F20PI MIUNZQECM5C),"0.F2 /R%$9\UOZZ7.?%Y-.A*47*]DW]SM;U^]>;W->D?[M< MMX4L&\6VC:II)W'MC%SPD?LNJ:] M9C'E6]]YL8 ^Z)8TD8?]]LY_X%5QG=+S,,3ED:?M(J=Y4U[RMINHNSOKK)=. M_E?9;J*;/]S\:JH"$J&7 M_6&IJAE_UAH,QU0/]\_6IZ@?[Y^M-DH2F'K3Z8>M5T)$J(??;ZU+40^^WUH( M%J$?_*@<"U#U/XUI_&KEOUK(Z MZ9>@ZU=@^[^54H.M78/N_E6_*KUK]T5FSJB7(>E7 M8>OXU2AZ5=AZ_C69V0+4/6K\'W#]*H0]:OP?U4[;H*N0]JR>QU0+L'3\ZNIWJE!T_.KJ=ZR9U0V+=OT' MX5=M/O?C5*WZ#\*NVGWOQJ&=42];=1]*MQ]!52VZCZ5;CZ"L^IUP+L72K=OT MJI%TJW;]*S.J!>M_O5:AZU5M_O5:AZUF]CJ@7;;H/K5VU^[5*VZ#ZU=M?NUF M=4"[:]*M1=*JVO2K472H.N!=@Z?G5Z#H*HP=/SJ]!T%9G5 MP]!5N'K^-5(> M@JW#U_&LY'5 OVW4?2KD/2J=MU'TJY#TK&1T1+D72KL'3\ZI1=*NP=/SJ'L= M<"Y;_>JW!]X?6JEO]ZK<'WA]:@ZH%V'J*O0]/PJC#U%7H>GX5F=4"Q!U-7K? MK5&#J:O6_6LSK@78.OYU;C_K52#K^=78(BY_&LY'5 M6G2M.Q@,I6HM,TEI& M'%=+I.C>6!D5A)H]"E2;':/8;0*V47:N*9! (5J2N=NYZL(\JL%%%%(H^ O^ M#@-=_P"SGX4_[&6+_P!);JOR9\D5^M?_ 7Y3?\ L[>%?^QDB_\ 26ZK\H/( M]J_4.%%_L"]6?QIXVSMQ/)?W(?D<+#X-OY/&IO)D9+1+D/$L5]( 1G.^13D' MUV# ['-==Y(KEYXIW\3V4$M]&C)>O);S?VJ5\^,3[WB\GJ[ 9BP%/^ MNU]_Z77%?6%?*7_!&1=O[!_A8?\ 3:^_]+9Z^K:_(LT_WVM_BE^;/[4X,UX? MP+_Z6T]E>W,=W&(I3=7<]PX4'("O([,F#R-I&" >H%?N5XL_9_P!+UY&W M6\?/^S7D'CW]AS3M5#F.W3GT6O0?QH_/L=X?XN@FL'4:5[V3:U[^I^/P M^%5CI]E-;M:SR+/+'-*\]S+-+(T;!DS([%R%*C SCKQR:@U7P/8ZI#J,=S;> M8FJHL=T/,8>:JC '!XX],5^COCC_ ()ZG+&*#\EKR'Q?^PGJ6GL^R!_^^:]: MEF5":/B<9PWG-&7,Y2;[W?E_\BON79'Q_>^$K&]COUEM]PU-UEN?G8>:RA54 M]>.$7ICI4-_X/T[4VU SVV\ZI%'#PWJF[9C!^4C<2"N#G!SD"OH#Q!^RA MK&FEA]FD_P"^:Y/4O@)J]F<&VD_[YKKC7I21\_/#9E2ZR5O-]+?_ ",?_ 5V M1Y%:?#K2+&WN42VD;[6\4L[R7$LDDSQ-OC9G9BQ(/J>@ Z "I=1\(Z?JIO// MM]_V\1"?]XP\SRSE.AXP?3KWKT&]^%&I6H.;>3_OFJ$GP\U!?^6+_P#?-:W@ MSEG6S#FYY3G?O=WTM_\ (Q^Y=D<1=^!M,N]7>_DMV,\I5I5\YQ#,RC"L\0;8 M[ 8+*2-J\\#%?2?AUI&B3;X+:3=]F:S'FW,LP6 [28@'8@)\HP!P.<8R<]I M<^#KR F.,523X::+;I*@M9#%-'+%Y37,K1P MK)D.(T+%8L@D?(%X.!Q79OX8N]O^J:HSX6NV_P"6+_E3:@V3]>Q^K]I.[W]Y MZZM]^[;]6^YSEYX;M+N0R,DJR_9S:B2.9XW6,D$@%2".5'(YXZU6A\'6-OHU M[8HDIBU!66X:69YI)=R[#EW)8_* !D\ "NK?PI=[?]2]1_\ "*W?_/*3\J;Y M'N8_6,6H\BG*W:[MO?\ /4Y"+P@FH>'=,M]4_>7EA&JBXMII(75PFUF1U*NN MX9R,]\V2Q.2"C @[1@XQGOS5>Y^'VG/<))NU,2K$(O,74[E790S, S M"3+8+-C).,XZ5V+^%KO'^J?\JCD\+7C-_J7_ "I6@$?4+ MQ[@[.B( L<:]!_ BY]R>O6NG_P"$6NQ_RQ?\J'\*W>W_ %,GY52Y%JC.>,QD MH.E.3::2UN[)6=E?9:+;LC(;J*;/]S\:U6\*W>1^YD_*DE\*797_ %,G7TJU M)6.!TI]C'3[U$_W/QK4_X12[1O\ 4R?E39?"UVR_ZF3\J?,B72G?8R*;)6K_ M ,(I=Y_U3_E22>$[OC]R_P"5/F5Q>RGV,FFR5K?\(E>?\\9/RILOA.\&/W+_ M )4K8_X1&\_P">3_E4;^$; MS=_JG_*G&20O93[&54,O^L-;7_")7G_/%_RJ.3PA>%_]3)^5',C/V4^QEU _ MWS]:VO\ A%+P_P#+&3\JB;P?>%C^Y?\ *JYD2J,^QDTP]:V?^$0N_P#GD_Y5 M'_PB%X2?W+_E3YE8GV4^QDU$/OM]:VO^$0O/^>3_ )5'_P (?>;C^YD_*GS( MCV,^QE5"/N5M?\(C>_\ /"3\JB_X0^]"_P"ID_*CF0O93[&9!U-7(/O?E5F' MP?>;O]3)^57(?"%X&_U3_E1S(<*4^Q4AZG\:N6_6K$/A&\S_ *E^_:KEOX2O M ?\ 4O\ E6?,CKA2GV(8.M78/N_E4\/A.['_ "Q?\JN0^%;L+_J9/RK.4D=4 M*4^Q6B^]^57K7[HJ2+PK=Y_U3_E5VV\,78'^J?\ *LG)'5&E/L10]*NP]?QJ M6#PM=_\ /)_RJY#X8NO^>3]?2HYD=<*E16^GRC'RGI5R#3 MY,?=-8MG1&+)8NE78.GYU%;Z9*X^Z?RK0@T>8_PGO4-HZX08MO\ >JW!]X?6 MI+70)F_A-:5GX6F;^$UFY)'93I2?0K0]15Z 9'X5IZ?X*FD(^4UN:=\/Y#C* MUBZD4=]+"U'T.;MX&8]*U;'3)).U=;IO@#9C*UO6'A*.$#Y:PE62V/3HY?-[ MG(:9X:>3M70Z9X4V=1710:6D(Z"K"Q!16$JK9Z=+!QCN4K+24@'2KJ($7BG4 M5DW<[$DM$%%%%(84444 ?!G_ 7MC,O[/?A; S_Q4<7_ *2W-?E3]E;^[7ZT M?\%R+'[=\ _#8_NZ_$?_ "6N*_+W^P_8_E7Z=PK42P"7FS^-O&S"SJ<3RDOY M(?D<#'\.[**^DG"3;I;B.Z(:0LH=)?-& ?NC>22!C-;'V5O[M=-_8?L?RI1H M?/0_E7T49PBK1/R[$K&8FRKS#(N/#^! MB_\ GS2_](B%%%%<)]*%%9?B_P ;Z-\/M%DU+7=5T[1M/B(#W-[ _#RL-)MO$7B9P2-UG8&W@!]?,N3$K+[Q[_;-=-#!UZVM* M+:[]/OV./%YAAL*KXBHH^K/?:*^+/%'_ 5?U.#>NG>!M,@&/EEO=;9V!]XX MX,?^1*X77/\ @KIX]MY,V^B>"H5 QMDBN9B3ZY$J?EC\:]&'#^,ENDOFOTN? M,XGC_(J'Q5K^D9?Y'Z&TUH5?J*_,V_\ ^"Q_Q2LCQ8_#U_\ N$7@_P#;RL>\ M_P""V_Q5M6.-'^'C8_ZAEX/_ &[KI7"^,>SC]_\ P#R*GBSPU#XJS_\ )?Y M'Z@W&C07 Y1?RK*U#X=V%^/FA0_A7Y>WG_!=OXLVO3P]\.V_[<+P?^W556_X M+V_%I?\ F6?AW_X!7G_R36RX4S#I;[_^ <$_&+A!NTJ[_P#!<_\ Y$_2G5O@ M%I.HYS;1\_[-?_)-:QX;S*.S7W_\ ..?BAP34WJO_P %S_\ D3[D MUC]B32;S.+>/_OFL6X_8,TMU.+=/^^:^,G_X+_\ Q94?\BK\.O\ P$O/_DFH MF_X.!/BR/^93^'?_ ("7G_R36JR/-%U7W_\ ..7'G TW=U'_P""Y_\ R)]7 MZQ_P3WL;ASM@7G_9K./_ 3MM/\ G@/^^:^6W_X.!_BO_P!"C\.O_ 6\_P#D MBHV_X.#?BNI_Y%#X=?\ @+>?_)%:?V3FB^TOO_X!ROBS@:3O[1_^ 3_R/J<_ M\$[+0C_4C\J3_AW5:?\ /!?Q6OE5_P#@X4^*Z?\ ,G_#K_P&O/\ Y(I$_P"# MA;XKO_S)WPZ_\!KS_P"2*/[+S3^9??\ \ ?^M' __/Q_^ 2_R/JH_P#!.FT( M_P"/=/\ OFD_X=T6@_Y8+_WS7RT/^#@_XKG_ )E#X=?^ MY_\D4\?\'!'Q78 M?\BC\.__ %O/_DBC^RLT[K[_P#@$?ZT\"K>H_\ P"?^1]0M_P $Y[1A_P > MZ_\ ?-!_X)S69_Y=U_*OF)?^#@#XKD?\BE\._P#P%O/_ ))IZ_\ !?KXKM_S M*?P[_P# 2\_^2:?]DYKW7W_\ A\6Z_]\U\UC_@OI\5S_S*GP[_ / 2\_\ DFI!_P %[OBN1_R*OP[_ M / .\_\ DFG_ &1FO=??_P C_6_@);U'_X+G_\ (GT?XKD?\ (K_#O_P#O/\ Y)J>U_X+M_%:Y?!\-?#M M?^W*\/\ [R_X+(_$ZZ W:;\ M.X^,G_B4WAQ_Y.5F\MS-;R7WO_(ZJ?$? ]3X9O\ \ E_D>J'_@FU9$_Z@?\ M?-(W_!-NRQ_J!_WS7GMI_P %F/&EJ%^U:?X%N"#EA!I]XNX>G_'PX4^YS]*U M])_X+?:C:R$7WP^TR^&>##JS6F/?YHY,]^P_3E/+E^=CTH8W@UJ\Z MBC_BBU^AU)_X)M66?]0O_?-(W_!-FR/_ "P7_OFN:O\ _@N#=W;[+;X>6.F_ M]-9]6>]7_OF.)&_G5?\ X?$^+-9;=INE^!@JJ-T;Q74D@/J?WJ$?0K^-1]0S M;>5E_P!O+]+D2S'@M;54_2,O\CK#_P $U[+_ )X#_OFD_P"':UD?^6 _[YKS MZ^_X*^_$R!V*Z?\ #W;DD*=)O"0/3/VP9_(5EW?_ 6<^*%K_P PGX>-_P!P MN\'_ +=UI'+LS>TE]_\ P#BGGO!$/BF__ )?Y'JG_#M:R_Y]Q_WS2'_@FI8G M_EW'_?->-W/_ 6Y^*=OTT+X=M_W#KP?^W=9MS_P76^*L!X\-_#MO^W&\'_M MU6BRG-GLU]__ #DGQ7P#'XJC_\ !<__ )$]U/\ P33LO^??_)-5 M_9&;]U]__ ,_];O#_P#Y^O\ \%S_ /D3WW_AVA9?\^X_[YIK?\$T++/_ ![C M_OFO 3_P7N^*X'_(J_#O_P [S_Y)IA_X+Y_%<'_ )%7X=_^ EY_\DTO[)S; MNOO_ . 4N*^ /^?C_P#!<_\ Y$^@?^'9UG_S[K_WS33_ ,$S+(G_ (]Q_P!\ MU\^O_P %^/BNO_,J?#O_ ,!+S_Y)IC?\%_OBN#_R*?P[_P# 6\_^2:7]E9M_ M,OO_ . 4N*. 7_R\?_@$_P#Y$^A?^'95B/\ EV'_ 'S33_P3+LL_\>Z_]\U\ M\O\ \' 7Q77_ )E+X=_^ MY_\D4UO^#@CXK@?\BC\.__ %O/_DBE_9F:K[2 M^_\ X _]9> W_P O'_X!/_Y$^B/^'95C_P ^Z_E3?^'8]B2?]'7\J^=?^(@[ MXK_]"A\._P#P&O/_ )(IC?\ !PG\5Q_S)_P[_P# :\_^2*/[-S7^9??_ , I M<0\"?SO_ , G_D?1O_#L:Q_Y]U_*D/\ P3%L?^?=?^^:^?_)%']FYK_,OO_P" +_6#@3^= M_P#@$O\ (^B/^'8UE_SP'_?--_X=AV6/^/=?^^:^>U_X."_BNW_,H?#O_P ! MKS_Y(IX_X.!OBN3_ ,BC\.__ %O/_DBG_9N;?S+[_\ @$_ZQ?\ R33_ +,S;^9??_P"?]9> 5_R M\?\ X+G_ /(GT*O_ 3.LE/_ ![C_OFID_X)I6*_\NX_[YKYX7_@OK\5V'_( MJ?#O_P !+S_Y)IR_\%\?BNW_ #*OP[_\!+S_ .2:/[*S;NOO_P" /_6K@%?\ MO'_X+G_\B?14?_!-FR'_ "P'_?-2K_P3?LU_Y8#_ +YKYS'_ 7L^*Y/_(K? M#O\ \ [S_P"2:>O_ 7G^*Y'_(K_ [_ / .\_\ DFE_9&;=U]__ _UOX! M7_+U_P#@N?\ \B?1J_\ !..S!_U"_P#?-31_\$Z[1?\ E@/^^:^;XO\ @O%\ M5I&_Y%CX=C_MRO/_ ))K1M?^"X_Q4N.OA_X=K_W#[P_^W5)Y1FJW:^__ (!< M.,. I?#5?_@N?_R)]")_P3QM%_Y=Q_WS4J_\$][0?\L%_P"^:\'M/^"U7Q1N MO^8/\.U_[A=X?_;NM2V_X+%_$^XZZ?\ #Q?^X1>?_)E9/+,R6\E][_R.RGQ+ MP3+X9O\ \ E_D>T)_P $_+13_J%_*ID_8$M%_P"6(_[YKR.'_@L-X[M81]KL MOA^']18W2;OHOVDG]:NQ?\%LM:LW4R^#]"OTQ\P@GFM\GZR X'X&I_LO-6KQ ML_G_ )V/3I9IPC)JI^P9:+_RQ'_?-2+^PA:_\\1_WS7FT_P#P M7-9;?Y?A=!YA_P"IFR%]_P#CU&>W''UK)E_X+;ZU=A_+\+>'].+?ZL7/VF?9 M_O&/ /YK^%0LKS9[I?\ @47^38Y9SP;#_E^GZ*7^1[)'^PM:I_RQ'Y5*G[#E MJH_U(_*O#IO^"P_CV]M]UC9?#Q^>7%C=2CZ8%T,'\:S;O_@L;\3[8\:;\.V_ M[A-X/_;RG_968O=K[_\ @'-/B?@Z'Q3?_@$O\CZ(3]B2V'_+$?E4J_L56P_Y M9#\J^8+K_@M9\4K?_F#?#MO^X9>?_)=9UU_P7)^*EOG'A_X=MC_J'W@_]NJT M62YF]FOO_P" ?_ "33_L'-'U7W M_P# ,UX@\"_\_G_X+G_\B?:*?L>6Z_\ +(?E4J_LA6X_Y9#\J^)F_P""]_Q8 M3_F5OAU_X!WG_P DTUO^"^OQ87_F5?AU_P" =Y_\DTO[!S3NOO\ ^ :+Q!X' MZ5G_ ."Y_P#R)]OI^R- !_JQ^53)^R= /^60_*OA?_A_U\6/^A4^'7_@'>?_ M "33&_X+_P#Q87_F5/AU_P" EY_\DU/]@YGW7W_\ T7B#P3TJO\ \ G_ /(G MW@G[*EN#_J__ !VI4_97@7_EE^E? Y_X.!/BP#_R*?PZ_P# 2\_^2:8W_!P5 M\6%_YE+X=?\ @+>?_)%+^P8_*I4_9PA4?<'Y M5^=#_P#!PW\6%_YD_P"'7_@->?\ R10G_!PW\6&_YD_X=?\ @->?_)%3_8.8 M]X_?_P O_B('!__ #]?_@$_\C]'%_9WA'\ _*I4_9]B'_+,?E7YPC_@X4^+ M!'_(H?#K_P !KS_Y(IZ?\'"'Q8;_ )E'X=?^ MY_\D4?ZOYCW7W_ / '_P 1 M%X/7_+U_^ 3_ ,C](5^ D2_\L_TIZ? F)3]S]*_-X?\ !P9\62?^12^'?_@+ M>?\ R13Q_P '!'Q9(_Y%/X=?^ EY_P#)-'^KN8OK'[_^ '_$2>#E_P OG_X! M/_(_21/@C$O\'Z5+'\&(U_A'Y5^;*_\ !P)\66_YE3X=?^ EY_\ )-/7_@O] M\62/^15^'7_@'>?_ "31_JYF/>/W_P# #_B)W!R_Y?/_ , G_P#(GZ8VGPBA MC_AJ]%\+H%_A'Y5^8:?\%^_BTW_,K?#O_P [S_Y)IX_X+\?%HG_ )%CX=_^ M =Y_\DTO]6,P_N_?_P M>*W!T?^7S_\ G_\B?J/:_#R"(?<'Y5>M_!D$7\ MK\K5_P""^7Q:8?\ (L?#O_P#O/\ Y)I\7_!>SXM2'_D6OAV/^W*\_P#DFI_U M5S!]OO\ ^ :+Q?X/C_R_?_@N?_R)^KD&@10C[HJU'8QQ]J_*BV_X+J?%B?KH M'P\7_N'WA_\ ;JM*U_X+;?%6X_YA'P\7_N&7A_\ ;NLGPMCENU]__ .NGXN\ M*R^"L_\ P"?^1^I*QA>@IU?F-:?\%E_BG+_W";P_^WE;6E_\%?/B M3,F)M-\!2-GAETZ[C 'IC[2W\ZR?#6+76/W_ / .ZGXH\.STC5?_ (!+_(_1 M^BO@71O^"MGC&3R_M/ASPE-C[_ES7$._Z9W[?UKL_#W_ 5;NKO'V[P#; =" MUGX@\PM[[9+=,?3<<>IKGGD.,CT3_P"WE^K/4H<=9)5^&O\ >I?Y'V/17SYX M4_X*1^!M:_Y">F>+- ]7FT[[;&3[&T:9L>Y4>^*]4^'7Q\\&?%E_+\.^)=(U M2Y"[GM8[@+=1CU:%L2+^*BN*K@<125YP=N_3[]CZ#"YI@\3_ *L9>C5_N.O MHHHKD.X**** /CW_ (+':2=5^!6B8&1%K4;GZ>1./ZU^;/\ PC/^S^E?J_\ M\%*_"9\3?L^SN%W?8;J&?I_M;/\ V>OSH/A'G[OZ5]QP_B.7"\O9O]#^$,N/E_2O< M^LGYQ_8OD?HQ_P $OK+^S_V0?#L>,8>Z./K=2FOH>O(_V(/#)\*?LX>&[8C; MNM1-C'_/0F3_ -FKUROS3&2YL1.2ZM_F?U]P]1='*L-1>\:<%]T4@)P*^?/C MO^U[<6=US=[9FAN]:GC,T$,@X:.W0$"613D,Y/EHPQB0AU7I?VS?B) M=^#?AC;:9I\\MI?^*]0CT>.XB8K)!&RO),R$(?\ 3]1E,]PN3R$)^6)?]B-40=E%<3X@#2!BSLWU M-=WXC_UAKA=>^ZU?1T9.6Y^.9I.4FY2=V<+KB?.U<;KG4_C79ZY]]JXS7.I_ M&O5I'P.8G*:UUKE]6^^WTKJ-;ZUR^K??;Z5ZU'<^$Q^QSNI=/QK/DZ&M#4NG MXUGR=#7HQV/E*GQE>;K5>;K7I7[)_P#R=5\-?^QJTS_TJBK]!8O'/QD\0_MJ M>.M%^)NG7TW[/$%WJ?\ :4GB?1TM]&BT]!)Y+Q7,D:[F#^7LV.2E0;#)(%4%F;@ #DFO:_@M^S!IWQBL_%OBO5?%$'@;X:^%;A8KC6KJ MQEO96>9R(+>&!"&EE(Y(R HY)%'QN_99TWX8>$/#/CGP=XUM/B!X'UO4CI8U M!--ETVXLKV,+(T$UO(6*DJ!C/1#%4I58T9-IMI;/1O9-[)ZK1OJN MZ.%Y!C5AI8N*3@DW\4;N,7RN48WYY1NFN91MH]=';QSQ?X0U;P%XBN-)US2] M1T;5;/:)[*_MGM[B LH8;HW 96>5@#A$4$^YP!R17!>*_P!BSP9X@^&O MBG7?A?\ %VS^(=_X)M#J6L:5+X=N=(F%FK*KW%NTC,)E0ME@=A"C..0#Y]#, MZ^KLM'V9[F+X3Q<,;B*&%7-"E4G33WL88EF-PD:_/(61X\(/FR^#C!(UEC*,9N,G:R;=TTK1MS:VL[75['-2R M#'5:5.K2@I*RW;5KI+N].MPI\,YA7J.E149--+2I3:)M!?Q/HEH[27&E+>-9_;2$;8C2J"RKOV[M MO)4$ @G-?4?_ 44^(LGQ8_9;_9P\02:5HVA_;],UK9I^DVWV>RLT2\BC2.) M,G"A47J23R3UK>OB)4ZE.'+=3=K]O=E+Y_#_ ,'H>?@LJIXG!XK$NJE*C!3Y M;-N2]I3IO71)7J)K=NS5EN?)*=JG3[M??/P ^*WQ"B_8K^%&A?";XN_#OP?K M-FVK+JVCZKK>GV]_=2R7K-;*D4ZNV2N['W0=Z]S7/'FMSJHWS+:SA&[4NVOGZ=*MV!_>?A51.E M2+: MZ8=A[UBV4>.>]:EIU6N64VOAT/I*&)<5RTO=7EO\WO\ IY%Z%W9%'U_B_G[FB]F6>-60AE89!'>JLPY-5;:8PW;1?PR+O ]", _GD?K6T5U M.2I4;T9!?]/SK%O?O5M7_3\ZQ;W[U=E,^?Q?4J'I4,E3'I4,E:G'$@?[M0O] MZIG^[7>_LD_\G7?#3_L:M,_]*XJA[G=AZ?M*D8=VD>;R]ZA?K7ZLP^.OC+XA M_;7\=Z)\3M.OYOV=H+O4_P"TI/$^C);Z-%IZ"3R)(KF2-=S!_+V;').<]LCX M+^"?[+VG?&.T\7>+-5\40>!?AIX5N%AN-;NK&6]E9YG(@MX8$(:64CDC< HY M)%>'A M?N-)US2]1T75;,J M)[*_MGMKB LH8;HW 9QA7:WGMY"Q4E3N4AB&"D\#&?3OVV?@%K/[2_\ P59\:>%- M$>VMYKJ6VGN;RZ8I;:?;1Z=;O+/*P!PB*"?6.IN<4OA:FW>ZMRC&*BU)2]JJK33BVGK325F]6UNCXXJ&2OI#Q/^ MQ9X,U_X9^*==^%_Q=L_B'?\ @FT.I:QI^,_CEHW@_5?$#$6NEV>@W.L26B[S&#=NC(D!)&= MN7.TAC1]\>&/\ @GQXAU#]K[Q)\)M3UK2M+?P=!<:CK&LA7N+> MWL88EF-PD:_/(61X\(/FR^#C!(S/%'[-OA3Q+\0/"7ACX1_$&?XFZQXHO#8F M"7PY/HS63DJ$9C([AD8%B2#\HC8D#BBEC:,W%0=^9)JR=K.]FW:R3L[7L.MP M_CZ<)SJ04>23@TY14G.+2E&,6^:;3:ORIVN>/1?UJ8=:^GE_X)\^#O%&JZUX M5\%_&K2/%?Q+T*"XED\/KX>NK2VOI+96:XAM;QF*RNH1MOR*'QD'&37@7PI\ M0:#X5^(&G:CXGT%_$^B6CM)<:4MZUG]M(1MB-*H+*N_:6V\E00""WF'+1?&'CZ"?5_$/BJ9[**6V@,NR MVLH9KMA&NY 695.[(SWKG>9TS"6% MH5'.$:5.LY1@W)QJ0IR2C"]V[U(QU:TO)V2=OS_3I4D7]:]._; G^)\OQKNU M^+UO

-(+>**=I[2"!IXE!$;[H%$8"V['+'''F,7]:]+#U/:4U/37L M[KY/2Y\?F6%^K8F>'M)27_ &]&[L_*[)AUJ9.E0CK4R=*W/+D2P?>' MUK9L.M8T'WA]:UH)O)'^?K2FKZ(Z,#3E4J*$=V[&Q!?I9ID^O2D?Q)+.<(6V M^W _QK$@D:\?>W3/ ]*T(!AA]*Y922^$^II5E3]VC]_7_@?+7S+45Q*X/.WZ M5(@.S))/XU%!]S\*F7_5UA)MZLUYG+WI;C]F*4C"\$]*#UI3]W\*:(EL1RQ! MI Y'SCHPX8?0CFE_MBYM^&'T;_'\ZON.]17QSG\:ZH+4\C$RN94_WC]:ADJ:? M[Q^M0R5N>0MR"7^M125++_6HI*DZ($-0R5])_P#!)3/_ \'^'F.OFWF/_ & MXKZ!\*^.OBUX\^'/Q=A_:1T[41\-['0+R32[CQ5HR:?-#JN<6?V%FC21Y3AA MA,CIG&<'R,?F+P]1Q44[14M[-ZM62L[O3NKMI'WG#O"<,RPJQ$JLHN4Y05H< MT5:*ES3ES+DCKJ^65DFS\YCUJ31]#O?$^LVFG:;9W6H:A?2K!;6MM$TLUQ(Q M 5$102S$D #))KV?X+?LG:3XL^$DOQ \?\ CF#X=>#IM0;2M-N3I,VJ7>K7 M2KO=8H(V7]V@^](6 !XY-=GX _9G7X ?MG_ G4=)\2V/C/P=XRUZPOM"URUM MI+47:1WJ1R))#)\T4J-@,A)QN'.<@=#Q=+VGL;ZWML[7M>U]KVUM>]C@P_#V M,G1CB912@[/XH\RBY*/-R7Y^7F:2ER\MVM=3Y=US2;K0-4N;&^MKBRO;*5H+ MBWGC,&]'^"5]\0/AO\2;;XC^ M']"O8;#7$DT2?1[W2GG+"%S%(SAXG*XWAOO$#'7'+2S"FX0<]')1>S:7-HKO M97>BO:YWUN&L7&=9T5>%.4TKRBI-4[N346U*7*E>3BFEK?8\ E[T1=J^EOA- M^Q%\.OB;>>'_ ]-\>O#]IX^\4QQ?8=)M- NKZQCGF4&*WFO@RHDA)"L C!& MXR:YKX$_L57'Q$\6_$.#Q7XDL_!6@?"E7_X275?LCZDUO()S;K'%!&0TI:16 MYR% 7)/3-/&T5*2D[6UV?IIIKKVONNZ)AP]CYQIN$4^=V5I0=G:]I6E[FFOO M\NB?9GBJ?=J6+M7M.B?LE:/\7OC]HW@KX6>.X?&ECJ%FU[>ZU?:--HT.CQQ[ MVF:='9SM1%#;E)!WJ!SQ70>(_P!BWP9K_P -/%&N?"_XNV?Q#O\ P3:'4M8T MN7P[BO:[TT5T]79:/L9Q MX;Q]12=.,6E=:3@^9I*34/>]]I-74.9JZ3U:/GM/O5,GW:Z[X$?$+P_\+O&S MZSX@\(V?C86MLYT_3KZX>*R%WE?+DN%3YIHE 8F+*AS@$XR#[_\ \%;_ !)- MXO\ C'\-]7N([:&XU3X;Z+>2QV\0CAC>3SG(1!PJ@G@=ABM)XAPK0I\NDNO; M1O;KMY+;5ZVY*&54ZV7UL;[7WJ=O9>> M:\$_;=^/J_M-_M2^,/&, Q8:C>>58#9M/V:%5BA)'J40,?=C4PQ-;ZRJ$XK9 MNZ;=M;*ZY5OK;7[+-,9E&!CEG]HX>M-OG4%&5-1N^7FE9JI.ZA[M]%\JEL8,U;/K6]I_6L&SZUO:?U MKDJGLX/H;VE_>'U_PKHM*'-<[I?WA]?\*Z+2^M>?5/J\'N=)I YKJ-&3<@^M M=5/K<&=9H*E4&&8?0UTL&F1:U&BWMO;7RQGA?ZL5UVA]*\ZI)Q=XGUN!W/2?AE\:_&GPT\L:3K]U(TC,C:?-()$N5'WGMY M0 )4'?A77(W(N1GY-T1 \8R*W_['-Q;YAFFM)X7$UO<0-MEM)1]V5#V89^A! M((()!\K$TJ=7^(M>_7Y]_P _,_1LFSK$T;1D^:/9_H_Z1]O45PO[-_Q3F^,/ MP@TO6;M(X]1W365\L8Q&;FWF>WF*#J$,D3E0><$45\]4IRIS=.6Z=C]*IU(U M(*I'9JY>^-/@M/'WPZU/3)!Q=0/&"?X21P?P.#^%?G5JGP^ETO49[::-DE@D M:-U(Z$'!K]/Y8Q-&5/0C%?._[0'[/;7>MR:KI\&\R\S1J.6/]X>_K7HY;C/9 M-P>S/D.+#?A7-XL\46.G0JQDNIECSM^Z M.Y_ 9/X5ZI'\-I99_*6VE,F<;0IS^5>V?LY_ /\ X1J]_M6^A N2,1J>?*7O M^)KU*^8QZI;0+UN"@99(QGC<\ M3R*,\;F&:^?[C6K;Q%H4=[:2"6WN$#HP&./0@\@CH0>000:^X=3TZ/5+-X9! ME6&*^9OCS^RW>V>IW.K^&)H;*ZN6+W-O*A-I?-_>;;S')V\Q0K@< M5!+V51V[/]'^G]-?,Y_E$\2O;4/BZKO_ ,$^?_$?^L-<+KWW6KK/&NK3^%KK MR?$&GW>@RYV"2Y7-K(>VR<9C.>P)#>JBN2UMQ)$64@J1D$'@BOI:,6DGT/QO M-J52G)QJ)I^9P^N??:N,USJ?QKL]3^->K2/S_,3E-;ZUR^K??;Z M5U&MGFN7U8_.WTKUJ.Y\)C]CG=2Z?C6?)T-:&I=/QK/DZ&O1CL?*5/C.R_9E MU>U\/_M*_#Z^O[FWLK&R\2Z=/<7%Q((XH(UN8V9W8D!5 !)). !7TWH7[8MK M)_P4$\?>'/%OBD>(?@YX^U>_T6[2[U+[5I=M;S2,(+N$EC'&(VV$2+@!"QR. MH^*INM5YNM<.*P-/$2O4VY91_P# N77R:MHSZ?).)L5EE+V>&T?M(5+]^127 M*ULXR4G=/=:'VQ^R+\7U^$'PW^)_PAT#XD^"/"7BM/$::AH'B/5S:W6A:O%& M#%*AG>.:&/=&J.C$355U'^R?" M<%G)%8E%9!/++\14R_\ LZ"E&"4HQ2J345&4G*THII2:YFKO=64D['WC)^UG MX1^&'_!7GQWXG;Q'IW_"+^*--.BQ^(;'9J-K8O+86ZI<87>DJ)+&%8W^M)*"IA5;>R5XE*YR M[LFTXYS7PV_6J\OWZY/[&I*,([\L8PU2>D?79ZN_RTT/5CQWC'[>R%_!- MZ%AN= \337@.EW\XL[6-H'N$WQQHRF8%G#)E"C#YN/BR:FP]::RV*KNMS:M3 M6R^VT]^J5K)/1+0*W&%2K@J6#=.T82I2TE)*]*,HKE2:4'+FYI2CJY:^1^A/ MBO\ :%\"_ CXU_!#QGXCO_AQXB^)>DZQ<3^+]5\ *CV4^GRJ8TEF,(6&6['F M.Y\M02%P\??'OXJ>%M1UKQ%I/[3_P "5\*H)[K3WM+/3)=8D@?=Y4/V M..Q,XF*L%93@+\V6XK\X$[5.GW:S>34W%)N^ZU2:L^B3NE;IZN]S;_7[%0 MI96,!VEB996^5!QCZD#O7V!^U5\$=.UO]C[X3:/I_P 4?@YJ.I_"_2-7.J6M MKXQM99;IIK@3QI;*#F5RJXQ@?,0!7Q"G2IHOZ5Z6)PTJK@XRMRN^W6TH_E)G MRF6YO1PE'$4JM'G=:/(WS-6CSPJ=GKS4XZ]KH]_\"?L5Z1\1_"^AZQIWQG^$ MFGVM];1R:C;:[JYTN_TJ;&9(C ZDRA>BM&2'QT6K/_!0_P".'A_XV?&W3%\+ M7]SK.A^$/#]EX;M]5N(O+DU4VRMNN"#\V&9CC=Z9[U\_)VJ=/NU:PLG556#PU%0=3EYY7D[\NJLF[*[]Y[Z[66A83I4,4FV M\,3<;SOC/;/0C\>/R]ZF3I4@L5OEVMZ<&NWH>'@ZZI5?>5T]'Z/^M/,LVG%: M5IU6LF!9[' F0S1CHX^\/\:TK"ZCF*[7'T/!KEE9Z(^GI8"7EO]W^5 MS2M_NU:3H*JP'BK4?05B[K1FBBXZ26I/%_2A/O41'^51_:E$VP9D?^X@W-^0 MJ%J#UV%FZFJENGG7AF_@5=BGU]?Y#\JT$T>:].9AY'_VF/A[?W]U;V5C9>)=.GN+BXD$<4$:W,;,[LQ 5 M0 223@ 5Q3_=J%_O5#W.VA4Y)QFNCN?;>@_MC6LO_!0?X@>&_%WBD>(O@WX_ MU>_T6[2[U+[5I=K;S2,+>[A)8QQB-MA$BX"H6.1P1%^R#\85^#_PW^*'P@T# MXE>"/"7BN/Q&FHZ!XCU8WZS]:E&\N>K)>\[QC63C.":U2U M3BT_=DKK=W^I/VT/B_\ $'4/!.@>'?&?QD^&_CVWDU5=1_LGPG!9R16)12@G MEN;:VBCW$%AL#L<$$@<8],D_:T\(?##_ (*\^._%#>)-._X1?Q1IIT6/Q#8[ M-1M;%Y;"W5+C"[TE1)HPK#D?>R."*^"9>]1/TI_V93Y>5[6FG9*/Q\J>W5** MMN+_ %RQ:K*O&[DITIISE*;7LO:63K4E*-VFW";=XOW4 MO=M>+:;=[K[3^-_C&W^('_!5OQUXE\#?&'POX)O0L-SH'B::\!TN_G%G:QM M]PF^.-&4S LX9,H48?-QVGBO]H7P+\"/C5\$?&?B._\ AQXB^)>DZQM4E4WDXQDY*5U%MIRC:REO;>Y^CWC[X^?%7PMJ M.M>(M)_:@^!"^%5$UUI[VEGIDNL20/GRH?L<=B9Q,58*P. OS9;BO@GX=>"Y M?BGX^L='&JZ'HTNIRL#?:S>I8V,!P6)EE;Y4!QCZD#O7-Q?UJ8=:Z,%@(89- M0\E>R3TVO9:[_P# 6IY>?\2U[=E;[@_: MN^"&G:Y^QW\)M'T_XI?!K4M4^%^D:N=5M;7QC:RRW337 GC2V4',KE5QC ^8 M@"L;5=$T+]MS]E7X36%G\0?A_P"#?%/PUM+G0M3T_P 4ZQ_9<<\#2AX+B!W! M5_E&'"\Y[< 5\?)TJ1/NT1P$E&SGJIN:=MG+FOZI\[T*K\449U7)8=Z:]E!M]==+,^B?V__ (N:!X]U_P ^'/#VL)XGM_AUX3M/#MS MK:!O*U.XCW&0Q%P&:)/Q4L5-)7222V2C%1BM==(I*[U>Y,.M3)TJ$=:F3I72>+(E@^\/K5V MZW)$'49V')'J.]4H/O#ZUL6:AP0:FI?H=. JNG552.Z9%8D&)=IRIZ'UK0A^ M\/I51M%EMR7M^03DH>AJ6"ZV/B16C;I@BN-N+\CZZE@U5]_#_=U7^?Y_F7H/ MN?A4R_ZNH+=P4ZU.I_=UG)-;CE2G3]VHFGYDAZTI^[^%(>M*QPOX4T92V$;K M^-5[CK3S=K(V(]TQ!Y$8W8^O8?C2-IUQPJ.\& ?QK4>R6U3 '_UZS+_ *M^-=--ZGD8F-C)G^\?K4,E33_> M/UJ&2N@\=;D$O]:BDJ67^M125)T0/=?^"8?C'2/ '[W]REM;P;K.=5W2.0JY8@#)ZD#O7;?LN_M$1?&:7X@_"?XH^+XY_#'C2RN9 M=%U7Q#J/F0:#JD.Z2WF2:9ML2N 5.& ;Y!GG!^3JADKSL7@(5Y2E+=Q45Y6; M:DO--W^2/KLFXHQ&7T:="DKQC-S:N[34HJ,H22^RXII^K/N;]EC]H[5+[]CG M2_A]X/\ B7X ^''CCP;K5Y-.OBL69L-9LICO#0W-Q#+$)%D)&T$;EYR1BN6\ M8_'#Q-=_M??!&V^(7Q>\ ^.;7PMK]K>RW&@QVT&EZ"CW,+2!KF."&)\J@9B" MRIM//6OCT]:@DK%9="-?ZQI>]]E>]K:/=+^KVT/3EQCBIX*&"]ZT5&/QS47& M,N97@FHMZ)7M;2]N;4^V_P!F/]J'2?A[^TY^T-I%MXOT/PM/\1[R]'AWQ/>Q M1WFE074=]+) 9BR21^1(LA_>%65>#Z5A?M=_&3XIV'P'U71/%?QY^$/B[3]> MN(87T'PA#I]W/?+'()!))-:VB"%5(!&Z0,W(QUS\>3=*A?[MIV?ZZXN6&J8;5*3J-R@J)Q=++"]P)2Y*^;YBJ MB?.6&,GYI^$NO:K/^V#\7_$7@#XR^"_A[KHV$FG'3_#$.FWM_K22J5,*K;V2O$I7.7=DVG'.:^#D^[4L7:C^ MQZ;LY.^EG=)Z7;TO>UN9I;Z670)\>8KDG3A%P3?,N2_(I-NS MYG)W]ZQV7P5^$DGQI\9'1XO$'A+PTPMWN/MGB+58]-LSM(&SS7XWG/"]\'TK MZC_X*5_#+3?%.E^$/%&B_$7X5Z];^#_!.C^'KRQTSQ3;75_/UO5?DSYG!9K0P^"K86='F=56YN9 MJUFFM+=&K^>Q].?!/QQH7[.7["?C?7+/6](N/B)\4)QX8M;&"[1[W1]*7YKF M:1%.^/SB-@W8R A&:^;TZ5!'T%3ITK:E04*DZE[N37R25DO3KZMOJ>=C\REB M*%##J/+&E%I)=6VW*3\W>WHDNA)%_6IAUJ&+^M3#K76>)(F3I4UO]ZH4Z5-; M_>JEL8,U;/K6]I_6L&SZUO:>>:Y*I[.#Z&]I?WA]?\*Z+2^M<[I?WA]?\*Z+ M2SS7GU3ZO![G2:1UKJ=$^X/K7+:0:ZG1/N#ZUYU4^MP9UNA?ZL5UVA]*Y'0O M]6*W-,\76%O>_9$F:\O>HM+.)KJX/_;.,,WZ5Y]2$I?"KGUV BY-**/1M"^X M/K6[?:]_9%NL-O"U]J=Z3%8V49Q)=28Z#T4=68\*H)/ K%\$?#_QIXZ9([+2 MAH%JYYNM2 DGQZI;H?\ T8Z$?W6%?1_P)_9?LO 4QU"Y\^]U.X4+/>W;![B8 M==HP J)G^! JYYQGFO'Q%>E2^)W?9?J^GY^FY^E9/D.)JVE57)'SW^2_S.D_ M9:^&\OPL^$6GZ5/*)[D&2XN90,+-<32--,X'8-([D#L"**]#AA6",*HP!P!1 M7@5)RG-SEN]3]&IPC"*A'9:#ZBNK-+R/:XR*EHJ"C*7PC:K+NVUHV]NEM'M0 M8%244 %%%% !4=Q D\9$@!7WI[-M%96J:C(24B&YN_. OUH2N)M)79S'CCX6 M:-K]O*K1)F0$,N,JP/7(KYL^)'[$OA.ZDE;3K.*QF.>=*D>VY/4E(B$)_P!Y M37T]=Z2]Z?W[M-_L]$'X?XYKD_$GQ)\(^$]3DL-3\3^'=,O8@-]M=:C##+&" M 1E68$9!!Z=Z[\*ZT'^YD[^5SR\ #_P S=X1_\&UO_P#%4O[:S3N__ %_D-< <._] M L/OE_\ )'YAM_P3IUYO^6EY_P!^!_C3&_X)R:Z3_K+W_OP/\:_3[_A9'@#_ M *&[PE_X-;?_ .*H/Q'\ '_F;O"7_@UM_P#XNE_;69]W_P" +_Y$T7 7#W_0 M+#[Y?_)'Y>M_P3>UL_\ +6^_[\#_ !J-O^";.M,?]9J'_?A?\:_40_$7P!_T M-_A+_P &MO\ _%TA^(W@'_H;O"7_ (-;?_XNE_;.9_U!?Y%K@3A]?\PT/OE_ M\D?ER_\ P35UAO\ EKJ/_?A:1?\ @FGJZ_\ +;4?^_*U^HW_ L3P#_T-WA+ M_P &MO\ _%T?\+$\ C_F;O"7_@UM_P#XNE_;&9?U!?Y%?ZC9!_T#0^^7_P D M?EXO_!-C6?\ GKJ'_?A?\:D'_!-W6P/]9?\ _?@?XU^FUW\7_AKI\NR?QQX) MA?&=LFLVRDC\7I@^-OPN_P"A_P# G_@\M?\ XNJ_M?-'JK_^ +_Y$E\#VO_Q=+_PN[X7?]#]X$_\ ![:__%U7]K9KY_\ @"_^1,_]1.'? M^@:'WO\ ^2/S3'_!.O7Q_P M+O\ [\#_ !J0?\$[O$('W[O_ +\#_&OTI'QN M^%O_ $/_ ($_\'MK_P#%TO\ PO#X7?\ 0_\ @/\ \'MK_P#%T_[7S7S_ / % M_P#(D/@/AS_H&A]\O_DC\V%_X)Z>(@/OW/\ WX_^O4UM_P $^O$<;??N/_ ? M_P"RK](O^%X_"X?\S_X$_P#!Y:__ !=!^.OPMC_YJ!X$_P#![:__ !=/^V,U M\_\ P!?_ ")/^H/#E[_58??+_P"2/SNMOV O$@7F:3'^U:?_ &5.E_X)]ZY( M?^/@!O\ KS/_ ,77Z!W?Q_\ AJQVQ^// Y/J=P\%Z-K\F?$LW[#WBIU.V[0CVL6_^.5G7?["'BF0/_ *P/ <:Y:Y_$;_Y5H?\+]^%CKS\0/ 8_P"X]:__ M !=+^T\TCT?_ ( O_D3*7!W#\]70A][_ /DC\Y[G]@7Q.W6:0_2U_P#LJS[C M_@G[XD8_?G/_ &[_ /V5?I,WQX^%A'_)0O 7_@^M/_CE1M\=?A83_P E \!_ M^#VU_P#BZU6;YJMK_P#@"_\ D3DGP)PY+?#0^]__ "1^:Y_X)\>(S_'FM_P3S\1'^.Y_P"_'_UZ_2C_ (7G\+?^B@^ _P#P>VO_ ,72-\=/A8!S M\0/ ?_@]M?\ XNG_ &QFWG_X O\ Y$S7 7#?_0-#[W_\D?FJ?^"=WB$C[]W_ M -^!_C3#_P $Z]?)_P!9=_\ ?@?XU^E@^.?PL/\ S4#P%_X/;7_XND/QQ^%G M_10/ 7_@]M?_ (NE_;&:^?\ X O_ )$M<"<-_P#0-#[W_P#)'YI-_P $Y]>; M_EI>?]^!_C3&_P""/PL_Z'_P'_P"#VT_^+H/Q MQ^%F/^2@> __ >VG_Q=+^U\U\__ !?_(E+@;AS_H&A][_^2/S-;_@G!KC? M\M;W_OP/\:8W_!-W6S_RTO\ _OP/\:_3,_''X6?]%!\!_P#@]M/_ (Y2'XX_ M"S_HH'@/_P 'MI_\72_M?-//_P 7_R):X'X=_Z!X?>__DC\R_\ AVQK0_Y: MZA_WX7_&F-_P35U@_P#+74?^_*U^FW_"\?A;_P!% \!?^#VT_P#CE)_PN_X6 M_P#10/ ?_@]M?_CE+^ULT\__ !?_(E?ZD\/?] \/O?_ ,D?F0O_ 33U=?^ M6VH_]^5J1?\ @FQK(_Y:ZA_WX7_&OTS_ .%W_"P?\U \!_\ @]M?_CE+_P + MP^%H_P":@> O_![:_P#QRC^ULT\__ %_D/\ U*X>_P"@>'WO_P"2/S-7_@FU MK2_\M+__ +\+_C3A_P $WM;_ .>M]_WX'^-?I@/CC\+/^B@> _\ P>VG_P 7 M3A\VG_Q=5_:^:^?_@"_^1(_U&X<_P"@:'WO_P"2/S4'_!.K M7A_RTN_^_ _QIR_\$[/$ _CN_P#OP/\ &OTI_P"%X_"S_HH'@/\ \'MI_P#% MTH^.7PL'_-0/ 7_@]M?_ (NC^U\U\_\ P!?_ ")/^HO#G_0-#[W_ /)'YKC_ M ()W^(1_'=?]^!_C3U_X)Z>(@/OW/_?C_P"O7Z3?\+S^%G_10/ 7_@]M?_BZ M4?'/X6_]% \!_P#@]M?_ (NG_;&:^?\ X O_ )$C_4/AO_H&A][_ /DC\VT_ MX)[^(U/W[C_P'_\ KU>MOV ?$J_\M9OQMO\ [*OT7'QS^%O_ $4#P'_X/;7_ M .+J1?CO\*Q_S4'P'_X/K7_XND\XS7K?_P 7_R)4. ^&T],-#[W_P#)'YZ6 MO[!7BB/_ )>&'UM/_LZGD_8*\0RK^\G3\;$__'*^_KK]H3X7QH=OC_P*?]W7 M+4G_ -#JA-\=_AQ<'_DH/@2(>@UVT+?GOQ4/,LSENO\ R1?_ ")UPX0X?IZJ MA!?-_P#R1\!W7_!/_P 0!/O LC#H6UZU;'YO4@^-?PQ"_\C_X%_P#![:__ !=)8[,5HN9> MD4OT.V.3Y5!;;_ N?!!_8AULVX#0:OO[MA /R'/ZTZU_88U5@!XN_R:]:@?EOQ5FV^/OPVM?O>/_ D MJ^JZY:AA^'F8/^>*/[1S-;?^D+_(P?"F03^*A'_P)_\ R1\#7/[!?BAS_KW/ MTM#_ /%UGW/[ 7B5L_O9C]+;_P"RK]&H?V@/A;*HS\0? @SZZ[:__%TK_'?X M6'_FH/@+_P 'UK_\75+-LU6U_P#P!?\ R)A/@?AV6^'A][_^2/S7D_X)]>(R M?OW'_@/_ /7II_X)[^(F_CN?_ ?_ .O7Z3GXY_"W_HH'@/\ \'MK_P#%TG_" M\_A;_P!% \!_^#VU_P#BZO\ MG-?/_P!?_(G/_J%PU_T#0^]_P#R1^:K?\$\ M?$+?QW7_ 'X'^--;_@G=X@/\=W_WX'^-?I6?CG\+/^B@> O_ >VO_Q=)_PO M/X6?]% \!?\ @^M?_BZ7]L9KY_\ @"_^1+7 G#?_ $#0^]__ "1^:7_#NO7_ M /GI=_\ ?@?XTT_\$YM>/_+2\_[\#_&OTN_X7C\+/^B@> __ >VG_Q=)_PO M'X6?]#_X#_\ ![:?_%TO[7S7S_\ %_\B4N!>'/^@:'WO_Y(_,\_\$X]VG_ ,72_M?-//\ \ 7_ ,B6N!N'?^@>'WO_ .2/S+;_ ()M MZTW_ "TO_P#OPO\ C33_ ,$V-9Q_K=0_[\+_ (U^FI^./PL_Z*!X#_\ ![:? M_%TW_A>/PM/_ #4#P%_X/;7_ ..4O[6S3S_\ 7_R):X(X=_Z!X?>_P#Y(_,E MO^":>L-_RVU'_ORM"_\ !-/6%_Y;:C_WY6OTV_X7?\+/^B@> _\ P>VO_P < MH_X7?\+/^B@> _\ P>VO_P M+_RTO\ _OPO^-?IE_PO'X6_]% \!?\ @]M/_CE M^./PL_Z*!X#_ /![:?\ Q=/^ULT\_P#P!?\ R(O]2>'?^@>'WO\ ^2/S07_@ MF]K>?];??]^!_C3A_P $XM< _P!;>_\ ?D?XU^EX^./PL_Z*#X#_ /![:_\ MQ=*/CC\+/^B@^ __ >VG_QRG_:^:^?_ ( O_D2/]1^'?^@>'WO_ .2/S27_ M ()R:Z!_K+S_ +\#_&GC_@G5KP_Y:7?_ 'X'^-?I7_PO'X6?]#_X#_\ ![:? M_%T?\+Q^%G_10/ ?_@]M/_BZ?]KYKY_^ +_Y$G_47AS_ *!H?>__ )(_-9?^ M"=GB ?QW?_?@?XTX?\$[_$(_CNO^_ _QK]*!\VO\ \72_ M\+S^%G_10/ 7_@]M?_BZ?]L9KY_^ +_Y$C_43AO_ *!H?>__ )(_-E?^">GB M(#[]S_WX_P#KT^/_ ()[^(U/#W'_ (#_ /UZ_20?'/X6_P#10/ ?_@]M?_BZ M4?'/X6_]% \!_P#@]M?_ (NC^V,U\_\ P!?_ ")/^H7#?_0-#[W_ /)'YSV_ M[ 'B4?\ +68?]NW_ -E6C;?L%>*$_P"7AQ];3_[.OT*7X[?"S_HH/@+_ ,'U MI_\ %U*GQZ^%@_YJ%X"_\'UK_P#'*EYMFCWO_P" +_Y$Z*? _#L=L/#[W_\ M)'P#:?L+^*XR,70_&R/_ ,/?!7Q'U.2S\/>)_#.NWD49F>#3M2ANI$0$#<51B0,D#/ MN*PGFN8I#LBO:%"-_5__ "1\*Z/^Q1XJ4+OU!\YY\NP X]LR M&NX\-_L07LJK]KU'Q*#W$:V\:G_QQF_6OM^+PRH_Y9C\JLQ:"%_A'Y5P3SC$ MRWE^"_R/;PW#&6T?@P\?G=_FSYG\$?L0^%H2AU&V^VMT8:G%-.C@M+6TM;4'*Q6L2Q1#Z!0!73QZ-QTJ2+0%1MR!HV/\2': M?TKS:]>I5_B3;]7<^GPD*5!6ITE'T5CH-#\-Z=I48^S0QC'?%:H&!7,VGVJR MZ/YP]&X;\QQ^GXULZ=J7GC!R".H(P17&XV/3C-2V+U%&ET57 MM9]R?80['F9_9QTP_P#+*W_[]+_A36_9OTT_\LK?_OTM>G5^5OQL\?\ P+\> M_&#X^ZK\&/$W@C1/%?AKPCK^A>+K7P_JUNGBKQQ=O=V\VISS01O_ &A,FGPV MLZ1SD%LW4JP$)&"\?6)\_+?I)[[R;Z712PM-J]NJ6W=[+N^J76SV/ MT#_X9KTS_GE;_P#?I?\ "C_AFO3/^>5O_P!^E_PK\\OCG>_LXZ%^Q%^U#/X0 MUOX#_A5XY\1>,I8?%3>-8=(L=2O4\/:0\4^ZVU$([; M);R6QMP%DP8KBX*G*FMO:3K2?DFKM^=E>7G%GY5Z714>UGW+^K MT^QYJO[..DB5W^S6Q_NKY*X%1S_LZ6$BX%O9ISU6!17IU%'M9]Q^PAV/,I/V M<--DNL^7;A.,@0K1)^SQ8NI'V>R [8@7(_&O3:*/:S[A["'8\S3]G73XH% @ MM&/\1:!<_A2/^SIIXN=ZPVI7& IA7%>FT4>UGW#V,.Q\O>!_@_&/VO\ QC9+ M(+>-/#>BN5A4(#FZU4=!W^6O9'^#,8.%?Y.@SU/XUS'@RPGC_;-\97+0RBWE M\-:-$DI0['=;K52R@]"0'4D=MP]17LE84I.VO=_FSNQ].'M5;^6'_I$3SR/X M("-P?M#G'8G@U8?X-QM"/G4,@44N9A[*%K6//1\#U_Y^I?SJ*?X%"4X^U28[_-7H]%/G M9/L(=CS7_A0B@<7#X],T?\*%'_/R_P#WU7S;_P %G?%7P%F\%>'O!7Q4U/X= MZ1XZ\;V][8>#-6\7:A:V4'A$GREN=;AFNG6*&XM0T;QM&1.\@2.,@,[+YIIE M[\.=>_;?MKFWO] UG]HA/BQ:2V%\DJ2^(I?![:/&3*CK\W]CO9O*Q*_Z*9W) M_P"/DBE2JNI+E\[7Z?%&/X:K2!BSK]=?\$>/ M[)@_8P@MM$_X1>33K3Q%K")<>$3_ ,4E>,U[+(TFB <)INYRL:*6$961-\NW MS'JG)SCS+^6,OO46U\N:WG;;>RJX>G"7(UKS-?=S6^_EVZ=]K^N?\*(7_GYD M_.@? =?^?F3\Z])HHYV/ZO3['G'_ HA?^?J3\Z=;_ T6YP+F3;V&[I7HM%' M.Q_5X=CS\_!0'_EYE_[ZH_X4DO\ S]2_]]5Z!12YV'L(=CS_ /X4DO\ S]2_ M]]57U+X(C[#+B[FSM/(:O2*@U'_CQE_W31SL/J]/L?-G['WPD.J?#C52UW/\ MGB?7D'S>FKW@_I7K"?!!5<9N93SZUB?L:V$^G?#C5TN(98';Q1K\H61"I*/J M]XZ-@]F4@@]P0>]>NUG1G+V\W?:) F[.T' MM2I\%XA,\AE8\_*N>!7>45IS,Y/8P[' S_!A9U_UI4YZJ<4LOP3AENL^?((^ M,@&N]HHYF'L8=C@I?@VDBD;@!VQP1^-*GP8BBA50^X_Q%CR:[RBES,/91['! M2?!:);K>LC%<8"D\42_!6*=5S,R-GG9P"*^4O^"B?C?]GS5/VR/AIX1\2^(O MAOX4^-4%_HWB"V\3:_JMG8ZEX;TJUU#SEAL)+EU8RW\L4EH8+;EXYI'E!5$5 M_,_V:IOA.WQWT^[75-#T?XEV\'CM/CEJUIJC:7K>FZ<+I]LFL7D;QS6RI(EN M;2621#'$A:U985;_'_P"2I:^E[J7\MGN5*C%2Y;?R]/YK_C97BOM+ MMU^^V^#D8.%8;.@SU_.H(_@D(W!^T.V#G!/!K\X-.\:?!3QG^P+X-O;/Q=^S M!XJ^''P^^)OBJ.[\)^.O&MMI_A;5A/>ZLUC$TR07B&>.&5+F"%[:3S%(==I" M/7WQ_P $Z=#\1^&OV%_A78^+8+FUUZW\.VJW%M\FE]ZOK^EKKS1FZ<;I-;W_\E=G;^EZ=3L9/A!&T( 90QR&X MZ?2HX?@Q';P_ZUGQP%Q\$HI'REQ*N1R W -1_\*/7_ M )^I?^^J]#HI\[%["'8\]_X4BO\ S]3?]]4#X(K_ ,_4W_?5>A44]=8LQ_6OIBO(OVRK"?4? MAQI"6\,L[KXHT"4K&A8A$U>S=VP.RJ"2>P!/:LZTY>SEZ,[,MH4_K=*Z^U'\ MT:-A\"P]JC&ZD+,H))-2'X$*3_Q\O^=>@Z=_QXQ?[HJ>M>>1Q?5J?8\W/P'0 M?\O#_G2?\*'7'_'S)^=>DT4<[#ZM3['FW_"B% _X^9/SI?\ A1(/_+S)^=>D M44<\@^K4^QYQ_P *)'_/S)^= ^!(_P"?E_SKT>BCGD'U:GV/.!\"@C[A M)M?U6SL=2\-Z5:ZAYRPV$ERZL9;^6*2T,%MR\O\ 'Z\BD9=6@TI;E^-9:+]]LWI;BU63DPJ1:@P[Q4*M M>'.W_/\ =!)WOVO=2_EL]RWA8*2@EK[O_DU]/5VO%?:6NG7]"O\ A22_\_4O M_?5'_"DE_P"?J7_OJOS;^&^N?LS:YX0\-:Q?:S\%(/V:?%?Q(O\ 5=2\(1ZE MI5QX/\'2-H/DZ;;ZC%"[6=O) M*=+^.WCTH)IJ7JR"=-.$CBQ#"3]X/]$\C_6?/C&[YLUK>5G>]UR_)N-VGV:V M7>S>AG[*G=)+1W^=FU==UIOWNO,ZS_A2*_\ /U-_WU0?@@I_Y>IO^^J]"HJ. M=E?5X=C@+7X)QQ39:XD88/!-+:_!2.%RS7$C<' )XS7?44. MWB_UK.Y/)#;/S=H?PUK+[E.#@7.E9'ZBOIJO&_&=A/)^V;X-N5AE-O%X M:UF)Y0AV([76E%5)Z D(Q [[3Z&LJLG;YK\T=F I0]H[_P L_P#TB1U?_"FX M!*!N_=C'?G\34,7P72%FQ+NR>-QSBN_HK3F9Q^RCV.#/P3MVN _G/C;DJ&X) MI)?@TLJ$;POH5X(KO:*.9A[*/8\_M_@L+=\^<7XQASD5+>?!R.9=J2;1QR.# M7=T4^9A[*-K' M\%(WM57SY ZGJ#]X5%_P */7_GZE_.O0ZX[]H;Q'X/\(? MCQCJGQ"O+?3_ +I^C75QX@N)Y)$CBL5B8SEC'\^/+W<+\QS@ DXJ9U7"+DW MMWT7WCCAHSDHI&;_ ,*/7_GZE_[ZI?\ A2*_\_4W_?5?F[\-]<_9FUSPAX:U MB^UGX*0?LT^*_B1?ZKJ7A"/4M*N/!_@Z1M!\G3;?48H7:SMY+A[62\\F;$:7 M5RH ,RH[7;/QA\!;G1/V:_!GBS7_ -X/^,5G#HVNZ)XC\6:G;Z?K/ACPS:: MJ\VGP6;WSK-YU]#$EH8(OWCQS.TX(15?2+;G&#O=N">FJYHW=UWCKIUBF[JU MC)TJ?*Y+9)N_31V6O9[7_FT2>Y^BH^"*_P#/U-_WU3C\$E_Y^I?^^J^>?V5/ MB=\(K7_@J;\>/#7A#QOX1U3Q3J>A:+<:II\/B>/4M4DOX+S6!>QNK3/,#;"2 MWC,7"VZ&",+&@11]C4N9\JEW13P]-3E"VS_1/Y/4\^_X4DO_ #\R_P#?5*/@ MJ!_R\R_]]5Z!12YF/V$.QP/_ I8?\_4O_?5:&@?#,:).6\UGS_>-==11S,/ M8P,P:$!V%.71 .PK1HI/2KM%%V5R1*@T['I2G3^<\!AT M-6J*+L?*AL8(3FBG44AA1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% %:/2H8KYK@+^\;@FK-%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %(Z>8A!Z'BEHH KZ?IL6FH1$NT, :LT4 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% -%% !1110 4444 ?_V0$! end XML 26 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover Page
12 Months Ended
Dec. 31, 2023
shares
Document Information [Line Items]  
Document Type 20-F
Document Registration Statement false
Document Annual Report true
Document Period End Date Dec. 31, 2023
Current Fiscal Year End Date --12-31
Document Transition Report false
Document Shell Company Report false
Entity File Number 001-35135
Entity Registrant Name SEQUANS COMMUNICATIONS S.A.
Entity Address, Address Line One 15-55 Boulevard Charles de Gaulle
Entity Address, Postal Zip Code 92700
Entity Address, City or Town Colombes
Entity Address, Country FR
Entity Incorporation, State or Country Code I0
Title of 12(b) Security Ordinary shares, nominal value €0.01 per share
Trading Symbol SQNS
Security Exchange Name NYSE
Entity Common Stock, Shares Outstanding 246,262,004
Entity Well-known Seasoned Issuer No
Entity Voluntary Filers No
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Accelerated Filer
Entity Emerging Growth Company false
ICFR Auditor Attestation Flag true
Document Financial Statement Error Correction [Flag] false
Document Accounting Standard International Financial Reporting Standards
Entity Shell Company false
Amendment Flag false
Entity Central Index Key 0001383395
Document Fiscal Year Focus 2022
Document Fiscal Period Focus FY
American Depositary Shares, each representing four ordinary shares, nominal value €0.01 per share  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing four ordinary shares, nominal value €0.01 per share
Trading Symbol SQNS
Security Exchange Name NYSE
Business Contact  
Document Information [Line Items]  
Entity Address, Address Line One 15-55 Boulevard Charles de Gaulle
Entity Address, Postal Zip Code 92700
Entity Address, City or Town Colombes
Entity Address, Country FR
Contact Personnel Name Georges Karam
City Area Code +33
Local Phone Number 1 70 72 16 00
Contact Personnel Fax Number 1 70 72 16 09

XML 27 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Audit Information
12 Months Ended
Dec. 31, 2023
Audit Information [Abstract]  
Auditor Firm ID 1692
Auditor Name Ernst & Young Audit
Auditor Location Paris-La Défense, France
XML 28 R3.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:      
Product revenue $ 33,616,000 $ 60,551,000 $ 50,879,000
Cost of revenue 9,476,000 17,671,000 23,690,000
Gross profit 24,140,000 42,880,000 27,189,000
Operating expenses:      
Research and development 26,124,000 26,610,000 26,414,000
Sales and marketing 11,861,000 10,027,000 9,049,000
General and administrative 15,993,000 10,082,000 10,045,000
Total operating expenses 53,978,000 46,719,000 45,508,000
Operating income (loss) (29,838,000) (3,839,000) (18,319,000)
Financial income (expense):      
Interest expense (11,409,000) (10,925,000) (11,329,000)
Interest income 176,000 68,000 47,000
Impact of debt reimbursement 0 0 5,177,000
Convertible debt amendments 247,000 476,000 0
Change in fair value of convertible debt derivative 3,200,000 6,878,000 3,848,000
Foreign exchange gain (loss), net (692,000) 1,082,000 938,000
Loss before income taxes (38,316,000) (6,260,000) (19,638,000)
Income tax expense (benefit) 2,674,000 2,748,000 625,000
Loss for the year (40,990,000) (9,008,000) (20,263,000)
Attributable to:      
Shareholders of the parent $ (40,990,000) $ (9,008,000) $ (20,263,000)
Basic earnings (loss) per share (in dollars per share) $ (0.18) $ (0.05) $ (0.14)
Diluted earnings (loss) per share (in dollars per share) $ (0.18) $ (0.05) $ (0.14)
Weighted average number of shares used for computing:      
Basic (in shares) 225,183,996 184,587,104 146,691,784
Diluted (in shares) 225,183,996 184,587,104 146,691,784
Basic earnings (loss) per ADS (in dollars per share) $ (0.73) $ (0.20) $ (0.55)
Diluted earnings (loss) per ADS (in dollars per share) $ (0.73) $ (0.20) $ (0.55)
Income tax expense (benefit)      
Basis per ADS (in dollars per share) 56,295,999 46,146,776 36,672,946
Diluted per ADS (in dollars per share) 56,295,999 46,146,776 36,672,946
Product      
Revenue:      
Product revenue $ 8,060,000 $ 22,974,000 $ 30,410,000
License and services revenue      
Revenue:      
Product revenue $ 25,556,000 $ 37,577,000 $ 20,469,000
XML 29 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statements of Comprehensive Income (Loss) Statement - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of comprehensive income [abstract]      
Loss for the year $ (40,990) $ (9,008) $ (20,263)
Other comprehensive income (loss) to be reclassified to profit or loss in subsequent years :      
Net gain (loss) on cash flow hedge (76) 202 (129)
Exchange differences on translation of foreign operations 97 (638) 157
Net other comprehensive income (loss) to be reclassified to profit or loss in subsequent years 21 (436) 28
Other comprehensive income (loss) not to be reclassified to profit or loss in subsequent years :      
Re-measurement gains (losses) on defined benefit plans (46) 71 (33)
Net other comprehensive income (loss) not to be reclassified to profit or loss in subsequent years (46) 71 (33)
Total other comprehensive income (loss) (25) (365) (5)
Total comprehensive loss (41,015) (9,373) (20,268)
Attributable to:      
Shareholders of the parent (41,015) (9,373) (20,268)
Non-controlling interests $ 0 $ 0 $ 0
XML 30 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statements of Financial Position
€ in Thousands
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Non-current assets:      
Property, plant and equipment $ 6,815,000 $ 8,489,000 $ 8,010,000
Intangible assets 64,300,000 48,705,000 37,984,000
Deposits and other receivables 801,000 783,000 2,311,000
Other non-current financial assets 360,000 337,000 357,000
Total non-current assets 72,276,000 58,314,000 48,662,000
Current assets:      
Inventories 6,335,000 9,387,000 6,433,000
Trade receivables 8,115,000 8,494,000 13,622,000
Contract assets 497,000 176,000 789,000
Prepaid expenses 1,422,000 1,399,000 2,108,000
Other receivables 4,958,000 5,799,000 7,252,000
Research tax credit receivable 9,864,000 4,515,000 5,863,000
Short-term deposits 0 5,000,000 0
Cash and cash equivalents 5,705,000 5,671,000 4,835,000
Total current assets 36,896,000 40,441,000 40,902,000
Total assets 109,172,000 98,755,000 89,564,000
Equity (deficit):      
Issued capital 2,878,000 2,306,000 3,687,000
Share premium 14,568,000 2,418,000 298,389,000
Other capital reserves 70,261,000 62,870,000 57,198,000
Accumulated deficit (93,362,000) (65,099,000) (383,554,000)
Other components of equity (416,000) (391,000) (26,000)
Total equity (deficit) (6,071,000) 2,104,000 (24,306,000)
Non-current liabilities:      
Government grant advances and loans 3,256,000 6,235,000 9,354,000
Lease liabilities 1,645,000 2,278,000 3,373,000
Provisions 2,222,000 2,196,000 2,137,000
Trade payables 0 1,788,000 964,000
Deferred tax liabilities 264,000 258,000 138,000
Contract liabilities 0 404,000 2,706,000
Total non-current liabilities 7,387,000 59,817,000 65,126,000
Current liabilities:      
Trade payables 16,281,000 9,342,000 13,916,000
Convertible debt 52,278,000 0 0
Lease liabilities 1,471,000 1,291,000 1,247,000
Unsecured related party loan 8,922,000 0 0
Government grant advances and loans 4,606,000 4,159,000 6,206,000
Other current liabilities and provisions 8,899,000 8,355,000 9,180,000
Contract liabilities 5,852,000 5,964,000 8,677,000
Total current liabilities 107,856,000 36,834,000 48,744,000
Total equity and liabilities 109,172,000 98,755,000 89,564,000
Interest-bearing receivables financing      
Current liabilities:      
Interest-bearing financing of receivables 9,544,000 7,723,000 9,518,000
Convertible debt      
Non-current liabilities:      
Convertible debt 0 43,455,000 36,373,000
Convertible debt embedded derivative   3,203,000 10,081,000
Current liabilities:      
Interest-bearing financing of receivables 52,278,000 0 0
Convertible debt embedded derivative $ 3,000 $ 0 $ 0
XML 31 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statements of Financial Position (Parenthetical) - € / shares
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of financial position [abstract]      
Par value per share € 0.01 € 0.01 € 0.02
Shares issued (in shares) 246,262,004 193,426,478 151,419,322
Shares outstanding (in shares) 246,262,004 193,426,478 151,419,322
XML 32 R7.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statements of Changes in Equity (Deficit) Statement - USD ($)
$ in Thousands
Total
Ordinary shares
Share premium
Other capital reserves
Accumulated deficit
Cumulative translation adjustments
Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Dec. 31, 2020   133,934,090          
Beginning balance at Dec. 31, 2020 $ (36,806) $ 3,269 $ 276,560 $ 46,677 $ (363,291) $ (219) $ 198
Loss for the year (20,263)       (20,263)    
Re-measurement gains (losses) on defined benefit plans | Previously stated (33)           (33)
Re-measurement gains (losses) on defined benefit plans (33)            
Foreign currency translation 157         157  
Net gain (loss) on cash flow hedge (129)           (129)
Total comprehensive loss (20,268)       (20,263) 157 (162)
Issue of shares in connection with the exercise of options and warrants (in shares)   2,985,200          
Issue of shares in connection with the exercise of options and warrants, and vesting of restricted shares awards 138 $ 70 68        
Issue of shares and warrants 10,000            
Transaction costs (177)   (177)        
Share-based payments 5,135     5,135      
Conversion of convertible debt (in shares)   7,227,308          
Increase (decrease) through conversion of convertible instruments, equity $ 17,672 $ 175 (12,111) 5,386      
Ending balance (in shares) at Dec. 31, 2021 151,419,322 151,419,322          
Ending balance at Dec. 31, 2021 $ (24,306) $ 3,687 298,389 57,198 (383,554) (62) 36
Loss for the year (9,008)       (9,008)    
Re-measurement gains (losses) on defined benefit plans | Previously stated 71           71
Re-measurement gains (losses) on defined benefit plans 71            
Foreign currency translation (638)         (638)  
Net gain (loss) on cash flow hedge 202           202
Total comprehensive loss (9,373)       (9,008) (638) 273
Issue of shares in connection with the exercise of options and warrants (in shares)   3,441,468          
Issue of shares in connection with the exercise of options and warrants, and vesting of restricted shares awards 0 $ 48 (48)        
Transaction costs (2,170)   (2,170)        
Increase (decrease) through change in nominal value 0 $ (2,283) 2,283        
Reduction of issued capital 0   (327,463)   327,463    
Increase (decrease) through exercise of warrants, equity 195     195      
Share-based payments $ 5,477     5,477      
Ending balance (in shares) at Dec. 31, 2022 193,426,478 193,426,478          
Ending balance at Dec. 31, 2022 $ 2,104 $ 2,306 2,418 62,870 (65,099) (700) 309
Loss for the year (40,990)       (40,990)    
Re-measurement gains (losses) on defined benefit plans (46)           (46)
Foreign currency translation 97         97  
Net gain (loss) on cash flow hedge (76)           (76)
Total comprehensive loss (41,015)       (40,990) 97 (122)
Issue of shares in connection with the exercise of options and warrants (in shares)   5,520,010          
Issue of shares in connection with the exercise of options and warrants, and vesting of restricted shares awards 0 $ 60 (60)        
Transaction costs (551)   (551)        
Reduction of issued capital 0   (12,727)   12,727    
Increase (decrease) through exercise of warrants, equity 82     82      
Share-based payments 7,104     7,104      
Bridge loans from related party $ 205     205      
Ending balance (in shares) at Dec. 31, 2023 246,262,004 246,262,004          
Ending balance at Dec. 31, 2023 $ (6,071) $ 2,878 $ 14,568 $ 70,261 $ (93,362) $ (603) $ 187
XML 33 R8.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Statements of Cash Flow - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating activities:      
Loss before income taxes $ (38,316) $ (6,260) $ (19,638)
Non-cash adjustment to reconcile profit (loss) before tax to net cash used in operating activities:      
Amortization and impairment of property, plant and equipment 4,594 3,979 3,354
Amortization and impairment of intangible assets 7,348 8,036 7,199
Share-based payment expense 7,104 5,477 5,135
Increase (Decrease) in provisions (97) 207 461
Interest expense, net 11,233 10,857 11,285
Change in the fair value of convertible debt embedded derivative (3,200) (6,878) (3,848)
Impact of debt reimbursement 0 0 (5,177)
Convertible debt amendments (247) (476) 0
Foreign exchange loss (gain) 741 (394) (1,034)
Loss (gain) on disposal of property, plant and equipment 0 24 48
Bad debt expense 0 0 65
Working capital adjustments:      
Decrease (Increase) in trade receivables and other receivables (41) 6,660 1,366
Decrease (Increase) in inventories 3,052 (2,954) (208)
Decrease (Increase) in research tax credit receivable (3,204) (1,556) (3,682)
Increase (Decrease) in trade payables and other liabilities 7,252 (6,970) 4,693
Increase (Decrease) in contract liabilities (199) (6,171) (6,791)
Increase (Decrease) in government grant advances (1) (1,080) (2,456) (1,387)
Income tax paid (2,201) (2,964) (346)
Net cash flow used in operating activities (7,261) (1,839) (8,505)
Investing activities:      
Purchase of intangible assets and property, plant and equipment (5,457) (7,169) (9,544)
Capitalized development expenditures (24,115) (15,494) (19,375)
Sale (Purchase) of financial assets (41) 1,548 (1,694)
Decrease (Increase) of short-term deposit 5,000 (5,000) 10,900
Interest received 176 68 47
Net cash flow used in investments activities (24,437) (26,047) (19,666)
Financing activities:      
Public and private equity offering proceeds, net of transaction costs paid 25,450 30,111 9,852
Proceeds from issue of warrants and exercise of stock options/warrants granted under share-based payment plans, net of transaction costs 0 0 138
Proceeds from (repayment of) interest-bearing receivables financing, net 1,483 3,046 21
Proceeds from interest-bearing research project financing 545 0 0
Proceeds from borrowings 9,000 0 0
Proceeds from convertible debt, net of transaction cost 0 0 39,682
Repayment of venture debt 0 0 (7,869)
Repayment of government loans (1,126) (958) (469)
Repayment of convertible debt and accrued interest 0 0 (8,750)
Repayment of interest-bearing research project financing (939) (812) (804)
Payment of lease liabilities (1,321) (1,205) (1,063)
Interest paid (1,356) (1,467) (5,310)
Net cash flows from financing activities 31,736 28,715 25,428
Net increase (decrease) in cash and cash equivalents 38 829 (2,743)
Net foreign exchange difference (4) 7 4
Cash and cash equivalents at January 1 5,671 4,835 7,574
Cash and cash equivalents at period end $ 5,705 $ 5,671 $ 4,835
XML 34 R9.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Corporate information
12 Months Ended
Dec. 31, 2023
Corporate information and statement of IFRS compliance [abstract]  
Corporate information Corporate information
Sequans Communications S.A. (“Sequans”) is organized as a limited liability company (“société anonyme”) incorporated and domiciled in the Republic of France, with its principal place of business at 15-55 boulevard Charles de Gaulle, 92700 Colombes, France. Sequans, together with its subsidiaries (the “Company”), is a fabless designer, developer and provider of cellular semiconductor chips and modules for massive and broadband Internet of Things (IoT) markets. The Company’s semiconductor solutions incorporate baseband processor and radio frequency transceiver integrated circuits along with its proprietary signal processing techniques, algorithms and software stacks. For 5G/4G massive IoT applications, the Company provides a comprehensive product portfolio based on its Monarch LTE-M/NB-IoT and Calliope Cat 1 chip platforms, featuring low power consumption, a large set of integrated functionalities, and a global deployment capability. For 5G/4G broadband and critical IoT applications, the Company offers a product portfolio based on its Cassiopeia Cat 4/Cat 6 and planned Taurus 5G chip platforms, optimized for low-cost residential, enterprise, and industrial applications.
XML 35 R10.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of significant accounting and reporting policies
12 Months Ended
Dec. 31, 2023
Corporate information and statement of IFRS compliance [abstract]  
Disclosure of material accounting policy information [text block] Summary of significant accounting and reporting policiesBasis of preparation
The Consolidated Financial Statements are presented in U.S. dollars.
The Consolidated Financial Statements for the year ended December 31, 2023 have been prepared on a going concern assumption. During 2021, 2022 and 2023, we financed our operations primarily through proceeds from the issue of shares through public offerings and private placements (2021, $9.9 million; 2022, $30.1 million; 2023, $25.5 million), bridge loans ($9.0 million in 2023) and convertible notes (2021, $39.7 million). We experienced net losses of $20.3 million, $9.0 million and $41.0 million in 2021, 2022 and 2023, respectively. At December 31, 2023, our accumulated deficit was $93.4 million and we had negative working capital of $71.0 million. We expect to continue to incur significant expense related to the development of our 4G and 5G products and expansion of our business, including research and development and sales and administrative expenses. In addition, we will incur expense to meet our commitments to our customers under various purchase orders and contracts. The Company will be required to obtain additional financing, including through a combination of government research and development funding, strategic licensing and/or service agreements, or additional equity, debt offerings or bridge loans, to meet these cash flow needs.
The Company’s internal cash forecast which is built from sales forecasts by products and by customer, assumes a slightly increasing operating cost structure, ongoing and new government funding of research programs and ongoing and new strategic funding activities. The Company expects to be able to obtain additional funding through one or more possible license agreements, business partnerships or other similar arrangements; or from financing from institutional or strategic investors, from the capital markets, or a combination of the above. However, the Company cannot guarantee if or when any such transactions will occur or whether they will be on satisfactory terms. In addition, the Company's forecasts of cash proceeds from revenues could be adversely impacted if customers delay or reduce purchases.
The Company does not and cannot know if the current uncertainties in these geopolitical areas, which are unfolding in real-time, may escalate and result in broad economic and security conditions, which could result in material implications for the Company's business. In addition, the Company's insurance policies typically contain a war exclusion of some description and the Company does not know how its insurers are likely to respond in the event of a loss alleged to have been caused by geopolitical uncertainties.
While the Company has taken and will continue to take actions to obtain new funding, the above factors raise substantial doubt about the Company’s ability to continue as a going concern as there is no assurance that the Company will be successful in satisfying its future cash needs.
Statement of compliance
The Consolidated Financial Statements of the Company have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standard Board (“IASB”) and whose application is mandatory for the year ended December 31, 2023. Comparative figures are presented for December 31, 2021 and 2022.
The accounting policies are consistent with those of the same period of the previous financial year, except for the changes disclosed in Note 2.2 to the Consolidated Financial Statements.
The Consolidated Financial Statements of the Company as of and for the years ended December 31, 2021, 2022 and 2023 have been authorized for issue in accordance with a resolution of the board of directors on April 30, 2024.
Basis of consolidation
The Consolidated Financial Statements comprise the financial statements of Sequans Communications S.A., which is the ultimate parent of the group, and its subsidiaries as of and for the years ended December 31, 2023, 2022 and 2021:
NameCountry of
incorporation
Year of
incorporation
%
equity
interest
Sequans Communications Ltd.United Kingdom2005100 
Sequans Communications Inc.United States2008100 
Sequans Communications Ltd. Pte.Singapore2008100 
Sequans Communications Israel (2009) Ltd.Israel2009100 
Sequans Communications Finland OyFinland2020100 
Sequans Communications SASFrance2023100 
The financial statements of the subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. All intra-group balances, transactions, income and expenses and profits and losses resulting from intra-group transactions are eliminated in full. The subsidiaries have been fully consolidated from their date of incorporation.
Changes in accounting policy and disclosures
New and amended standards and interpretations
The accounting policies used in 2023 are consistent with those of the previous financial year, except for the following new and amended IFRS and IFRIC interpretations effective as of January 1, 2023:
Amendments to IAS 1: Classification of Liabilities as Current or Non-current: In January 2020, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The Company adopted the amendments effective for annual reporting periods beginning on or after January 1, 2022. Adoption of these amendments had no material impact on the Consolidated Financial Statements.
Amendments to IAS 1 and IFRS Practice Statement 2: Disclosure of Accounting Policies: In February 2021, the IASB issued amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements, in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their ‘significant’ accounting policies with a requirement to disclose their ‘material’ accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendments to IAS 1 are applicable for annual periods beginning on or after January 1 2023 with earlier application permitted. Since the amendments to the Practice Statement 2 provide non-mandatory guidance on the application of the definition of material to accounting policy information, an effective date for these amendments is not necessary. The amendments had no material impact on the Company.
Amendments to IAS 8: Definition of Accounting Estimates: In February 2021, the IASB issued amendments to IAS 8, in which it introduces a definition of ‘accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, they clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 and apply to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. Earlier application is permitted as long as this fact is disclosed. The amendments had no material impact on the Company.
Amendments to IAS 12: Deferred Tax related to Assets and Liabilities arising from a Single Transaction: In May 2021, the Board issued amendments to IAS 12, which narrow the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments should be applied to transactions that occur on or after the beginning of the earliest comparative period presented. In addition, at the beginning of the earliest comparative period presented, a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability should also be recognized for all deductible and taxable temporary differences associated with leases and decommissioning obligations. The amendments had no material impact on the Company.
Standards issued but not yet effective
Standards and interpretations issued but not yet effective up to the date of issue of the Company’s Consolidated Financial Statements are listed below. The Company intends to adopt these standards when they become effective:
Amendments to IFRS 16: Lease Liability in a Sale and Leaseback. In September 2022, the IASB issued amendments to IFRS 16 to specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction, to ensure the seller-lessee does not recognize any amount of the gain or loss that relates to the right of use it retains. The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and must applied retrospectively to sale and leaseback transactions entered into after the date of initial application of IFRS 16. Earlier application is permitted and that fact must be disclosed.The amendments are not expected to have a material impact on the Company’s financial statements.

Amendments to IAS 1: Classification of Liabilities as Current or Non-current. In January 2020 and October 2022, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify:
What is meant by a right to defer settlement
That a right to defer must exist at the end of the reporting period
That classification is unaffected by the likelihood that an entity will exercise its deferral right
That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification
In addition, a requirement has been introduced to require disclosure when a liability arising from a loan agreement is classified as non-current and the entity’s right to defer settlement is contingent on compliance with future covenants within twelve months.
The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and must be applied retrospectively. The Company is currently assessing the impact the amendments will have on current practice and whether existing loan agreements may require renegotiation.

Supplier Finance Arrangements - Amendments to IAS 7 and IFRS 7. In May 2023, the IASB issued amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures to clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity’s liabilities, cash flows and exposure to liquidity risk. The amendments will be effective for annual reporting periods beginning on or after 1 January 2024. Early adoption is permitted, but will need to be disclosed. The amendments are not expected to have a material impact on the Company’s financial statements.

COVID-19
Management has considered what effect the COVID-19 pandemic has on the amounts recognized in the financial statements. Management has identified potential risks related to the impact on the production of the Company's products, on the Company's ability to source components required for production and on the demand for the Company's products by customers impacted by the pandemic. In the year ended December 31, 2021, the primary impacts on operations of the COVID-19 pandemic were increased product demand in the broadband IoT business, increases in certain costs related to a temporary shortage of components, and delays in growth in product revenues in the massive IoT business due to the limits
placed on production capacity driven by the component shortages. During 2022 and 2023, the Company did not identify any direct impact of the pandemic on its business. As of December 31, 2023, the Company has not identified any impact on its assets and liabilities.

Russian invasion in Ukraine
While the Company's key engineering competencies are performed in-house, primarily in France, the United Kingdom, Israel and the United States, the Company outsources some application software development and testing activities to an independent third-party provider of engineering services. The Company works with a dedicated team of 48 software engineers based in Kyiv, Ukraine. If the Russian invasion of Ukraine is protracted or if Ukraine experiences further political instability, these engineers may be unable to work for a sustained period of time, which could adversely impact the research and development operations. The Company has developed a contingency plan if the engineers in Kyiv are unable to continue working on their projects for us for a sustained period of time, but if the contingency plan is not effective or sanctions are imposed that prevent the Company from conducting business in Ukraine, the Company could suffer delays in product introduction or delays in resolution of customer software bugs, which could have a negative impact on its revenues. During 2022 and 2023, the Ukraine team was able to work effectively and the Company did not identify any direct impact from the situation on its business. As of December 31, 2023, the Company has not identified any impact on its assets and liabilities.
accounting policies
Functional currencies and translation of financial statements denominated in currencies other than the U.S. dollar
The Consolidated Financial Statements are presented in U.S. dollars, which is also the functional currency of Sequans Communications S.A. The Company uses the U.S. dollar as its functional currency due to the high percentage of revenues, cost of revenue, capital expenditures and operating costs, other than those related to headcount and overhead, which are denominated in U.S. dollars. Each subsidiary determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency.
As at the reporting date, the assets and liabilities of each subsidiary are translated into the presentation currency of the Company (the U.S. dollar) at the rate of exchange in effect at the Statement of Financial Position date and their Statement of Operations is translated at the weighted average exchange rate for the reporting period. The exchange differences arising on the translation are taken directly to a separate component of equity (“Cumulative translation adjustments”).
Foreign currency transactions
Foreign currency transactions are initially recognized by Sequans Communications S.A. and each of its subsidiaries at their respective functional currency rates prevailing at the date of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency spot rate of exchange in effect at the reporting date. All differences are taken to the Consolidated Statement of Operations within financial income or expense. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the initial transactions.
The table below sets forth, for the periods and dates indicated, the average and closing exchange rate for the U.S. dollar (USD) to the euro (EUR), the U.K. pound sterling (GBP), the Singapore dollar (SGD) and the New Israeli shekel (NIS):
USD/EURUSD/GBPUSD/SGDUSD/NIS
December 31, 2021
Average rate1.1835 1.3761 0.7444 0.3097 
Closing rate1.1326 1.3479 0.7413 0.3221 
December 31, 2022
Average rate1.0539 1.2372 0.7255 0.2980 
Closing rate1.0666 1.2026 0.7459 0.2840 
December 31, 2023
Average rate1.0816 1.2435 0.7447 0.2716 
Closing rate1.1050 1.2714 0.7573 0.2763 
Earnings (loss) per ordinary share and per ADS
Basic earnings (loss) amounts per ordinary share and per ADS are computed using the weighted average number of shares outstanding during each period.
Diluted earnings per ordinary share and per ADS include the effects of dilutive options and warrants as if they had been exercised, unless the effect would be anti-dilutive.
Revenue recognition
The Company’s total revenue consists of product revenue and services and license revenue.
Revenue from contracts with customers is recognized when control of the goods or services is transferred to the customer at an amount that reflects the fair value of the consideration to which the Company is entitled, excluding sales taxes or duties.
The Company applies a five-step approach in determining the amount and timing of revenue to be recognized: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when the performance obligation is satisfied.
When a contract includes multiple promised goods and services, the Company evaluates each component to determine whether they represent separate performance obligations and determines the appropriate allocation of the contract consideration to each identified performance obligation based on estimated relative stand-alone selling prices.
If the consideration in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the goods or services to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved. Specifically, milestone payments in development services contracts represent variable consideration, the receipt of which is dependent upon the achievement of technical milestones.
The Company sometimes receives advance payments from customers for the provision of development services. The Company determines if there is a significant financing component for these contracts considering the length of time between the customers’ payment and the transfer of control of the goods and services. When a significant financing component has been identified, the transaction price for these contracts is discounted, using the rate that would be reflected in a separate financing transaction at contract inception. The Company applies the practical expedient for short-term advances received from customers. That is, the promised amount of consideration is not adjusted for the effects of a significant financing component if the period between the transfer of the promised good or service and the payment is one year or less.
Product revenue
Substantially all of the Company’s product revenue is derived from the sale of semiconductor solutions for 4G wireless applications.
Revenue from the sale of products is usually recognized at a point in time when the Company satisfies its performance obligation to the buyer, whether direct end customer, end customer's manufacturing partner or distributor. This occurs when there is no continuing managerial involvement to the degree usually associated with ownership nor effective control over the sale of products is retained, which is based on the specified Incoterms, but usually occurs on shipment of the goods. Sale of products to some distributors is recognized when the products are sold to the end-customer but these contracts are not significant. The Company is the principal in all product sales regardless of customer type. Products are not sold with a right of return but are covered by warranty. This is an assurance-type warranty. The Company does not accrue for a general warranty obligation as the Company has not historically incurred and does not expect material warranty costs. Although the products sold have embedded software, the Company believes that software is incidental to the products it sells.
License and services revenue
License and services revenue consists of revenues from the sale of licenses to use the Company’s technology solutions and any fees for the associated annual software maintenance and support services, as well as from the sale of technical support and development services. Development services include advanced technology development services for technology partners and software or product development and integration services for customers.
Revenue from the sale of licenses is recognized at a point in time when the Company satisfies its performance obligation which occurs when the software has been delivered to the customer (assuming no other significant obligations exist), as licenses provide the right to use the software as it exists when made available to the customer.
Revenue from the sale of software maintenance and support services is recognized over the period of the maintenance (generally one year). When the first year of maintenance is included in the software license price, an amount generally equal to the negotiated rate for one year of maintenance is deducted from the value of the license and recognized as revenue over the period of maintenance as described above. The difference between license and maintenance services invoiced and the amount recognized in revenue is recorded as deferred revenue.
Revenue from technical support and development services is generally recognized over time using the percentage-of-completion method. For each service contract, the Company determines whether the pattern of transfer of control meets one of the criteria for revenue recognition over time: (a) the customer simultaneously receives and consumes the benefits provided by the entity's performance as the entity performs (b) the Company's performance creates or enhances an asset (for example, work in progress) that the customer controls as the asset is created or enhanced or (c) the Company's performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. Generally, the support and development contracts meet one or more of these criteria, based on the facts and circumstances both within the contract and the nature of the services provided. Typically, the customers consume the services as they are provided through ongoing technical support or through an iterative development process. Certain contracts also include terms which allow the customer to have control over the asset as it is created or provide Sequans the right to payment for all work performed to date.
Due to revenue recognition over time, contract assets are created for services provided that Sequans does not yet have the right to invoice. Contract liabilities are created when milestones are billed in advance of being earned.
When a contract does not meet one of the criteria above, revenue is recognized at a point in time, when there is evidence of transfer of control, which typically occurs upon achievement of certain or all contract milestones. Percentage-of-completion is calculated based on the input method using estimated costs as a measure of performance completed.
The costs associated with these arrangements are recognized as incurred. Revenue from development contracts where no related direct costs were identified amounted to $214,000 for the year ended December 31, 2023 ($236,000 in 2022 and no direct cost in 2021).
Contract assets
A contract asset is the right to consideration in exchange for goods or services transferred to the customer. As described above, when the Company performs by transferring goods or services before the customer pays consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional. Where the Company has an unconditional right to payment, these are included in unbilled revenue until billing occurs and classified as trade receivables.
We have elected to use the practical expedient not to adjust the promised amount of consideration for the effects of a significant financing component when the period between when we transfer the promised good or service to our customers and when we expect the customers to pay for that good or service is one year or less.
We also have elected to use the practical expedient not to disclose information about our remaining performance obligations for contracts that have an original expected duration of one year or less.
We do not have any costs that meet the criteria for costs to obtain a contract or cost to fulfill a contract.
As of December 31, 2023, the transaction price allocated to the unsatisfied or partially unsatisfied performance obligations was $88,000 and is expected to be recognized in the 2024.
As of December 31, 2022, the transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) was $1,643,000 for which $1,276,000 was expected to be recognized in the next year and $367,000 in the years after, excluding the amounts related to the development service contract entered into in October 2019, described under note 19.
As of December 31, 2021, the transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) was $4,273,000 for which $4,017,000 was expected to be recognized in the next year and $256,000 in the year after, excluding the amounts related to the development service contract entered into in October 2019, described under note 19.
Contract liabilities
Contract liabilities represent amounts invoiced and/or cash received in advance related to services being performed. Contract liabilities include both upfront payments from license and development service agreements in excess of revenues recognized, as well as deferred revenue from advance payments for goods or maintenance services.
Revenue recognized in the current period from amounts included in deferred revenue at the beginning of the year was $190,000, $271,000 and $765,000 for 2023, 2022 and 2021, respectively (See Note 19 Other non-current liabilities and Note 18 trade payables and other current liabilities).
Cost of revenue
Cost of product revenue includes all direct and indirect costs incurred with the sale of products, including shipping and handling. Cost of services revenue includes direct costs incurred to support the obligations covered by development services contracts (mainly employees and subcontractors costs). Research and development costs associated with product development (including normal customer support which generates product improvement) are recorded in research and development expenses.

Research and development costs
Research costs are expensed as incurred. Development costs are recognized as an intangible asset if the Company can demonstrate:
the technical feasibility of completing the intangible asset so that it will be available for use or sale;
its intention to complete the asset and use or sell it;
its ability to use or sell the asset;
how the asset will generate future economic benefits;
the availability of adequate resources to complete the development and to use or sell the asset; and
the ability to measure reliably the expenditure during development.
Beginning in 2015, certain development costs incurred at the end of the product development cycle when the criteria for capitalization are met, became material as the Company began making its product available on more operator networks which require significant testing and qualification work in order to finalize the product for sale on that network. In 2021, the Company capitalized costs for the development of the chipsets for LTE NB-IoT (the Monarch 2). In 2021, 2022 and 2023, the Company also capitalized costs for the development for LTE Category 1 and the development of the 5G chipsets. The intangible assets are tested for impairment annually. (See Notes 4.4 and 8 to the Consolidated Financial Statements).
Research and development costs associated with product development (including normal customer support which generates product improvements) are recorded in operating expense. In some cases, the Company has negotiated agreements with customers and partners whereby the Company provides certain development services beyond its normal practices or planned product roadmap. Amounts received from these agreements are recorded in services revenue. Direct costs incurred by the Company as a result of the commitments in the agreements are recorded in cost of revenue. Other research and development costs related to the projects covered by the agreements, but which would have been incurred by the Company without the existence of such agreements are recorded in research and development expense.

Government grants, loans and research tax credits
The Company operates in certain jurisdictions which offer government grants or other incentives based on the qualifying research expense incurred or to be incurred in that jurisdiction. These incentives are recognized as the qualifying research expense is incurred if there is reasonable assurance that all related conditions will be complied with and the grant will be received. When the grant relates to an expense item, it is recognized as a reduction of the related expense over the period necessary to match the grant on a systematic basis to the costs that it is intended to compensate. Any cash received in advance of the expenses being incurred is recorded as a liability.
Some long-term research projects are also financed through low-interest forgivable loans. The present value of forgivable loans is calculated based on expected future payments discounted using the interest rate applied for standard loans with the same maturity. The difference between present value and amount received is accounted for as a grant.
Where loans or similar assistance provided by governments or related institutions are interest-free, the present value is calculated based on expected future payments discounted using the interest rate applied for standard loans with the same maturity. The difference between present value and amount received is accounted for as a grant.
The Company also benefits from research incentives in the form of tax credits which are detailed in Note 4.4 to the Consolidated Financial Statements. When the incentive is available only as a reduction of taxes owed, such incentive is accounted for as a reduction of tax expense; otherwise, it is accounted for as a government grant with the benefit recorded as a reduction of research and development costs, whether capitalized or expensed.
Financial income and expense
Financial income and expense include:
interest expense related to accounts receivable financing, the debt component of convertible debt, bridge loans, government loans, lease contracts, upfront payments, financing components of customer contracts and a supplier payable with extended payment terms;
other expenses paid to financial institutions for financing operations;
foreign exchange gains and losses;
change in fair value of financial assets and liabilities
impact of convertible debt amendments; and
impact of convertible debt reimbursement.
The Company reflects foreign exchange gains and losses related to hedges (through derivatives) of euro-based operating expenses in operating expenses.
Taxation
Current income tax
Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date.
Current income tax relating to items recognized directly in equity is recognized in equity.
Deferred income tax
Deferred income tax is provided using the liability method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.
Deferred income tax liabilities are recognized for all taxable temporary differences, except with respect to taxable temporary differences associated with investments in subsidiaries where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.
Deferred income tax assets are recognized for all deductible temporary differences, carry forwards of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forwards of unused tax credits and unused tax losses can be utilized.
The carrying amount of deferred income tax assets is reviewed at the reporting date and adjusted to the extent that it is probable that sufficient future taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.
Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the statement of financial position date.
Deferred income tax relating to items recognized directly in equity is recognized in equity.
Deferred income tax assets and deferred income tax liabilities are offset if a legally enforceable right of offset exists.
Value added tax
Revenue, expenses and assets are recognized net of the amount of value added tax except:
where the value added tax incurred on a purchase of assets or services is not recoverable from the tax authorities, in which case the value added tax is recognized as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
receivables and payables that are stated with the amount of value added tax included.
Value added tax recoverable consists of value added tax paid by the Company to vendors and suppliers located in the European Union, in the United Kingdom and in Israel, and recoverable from the tax authorities. Value added tax recoverable is collected on a monthly or quarterly basis.
Inventories
Inventories consist primarily of the cost of semiconductors, including wafer fabrication, assembly, testing and packaging; components; and modules purchased from subcontractors. Inventories are valued at the lower of cost (determined using the weighted average cost method) or net realizable value (estimated market value less estimated cost of completion and the estimated costs necessary to make the sale).
The Company writes down the carrying value of its inventories for estimated amounts related to the lower of cost or net realizable value, obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated net realizable value. The estimated net realizable value of the inventory is based on historical usage and assumptions about future demand, future product purchase commitments, estimated manufacturing yield levels and market conditions on a product-by-product basis. When the circumstances that previously caused inventories to be written down below cost no longer exist or when there is clear evidence of an increase in net realizable value because of changed economic circumstances, the amount of the write-down is reversed (i.e. the reversal is limited to the amount of the original write-down) so that the new carrying amount is the lower of the cost and the revised net realizable value.
Financial assets
Financial assets are classified, at initial recognition, as (1) measured at amortized cost, (2) fair value through other comprehensive income (OCI), or (3) fair value through profit or loss. The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and Sequans’ business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value.
Receivables
Trade receivables are measured at amortized cost. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take into account the risk of payment default throughout the lifetime of the receivables. Based on an analysis of historical credit losses, the Company has not applied any expected credit losses to its outstanding receivables as of the reporting date beyond specific provisions for doubtful accounts. The Company records an allowance for any specific account it considers as doubtful based on the particular circumstances of the account. The carrying amount of the receivable is thus reduced through the use of an allowance account, and the amount of the charge is recognized on the line “General and administrative expenses” in the Consolidated Statement of Operations. Subsequent recoveries, if any, of amounts previously provided for are credited against the same line in the Consolidated Statement of Operations. When a trade accounts receivable is uncollectible, it is written-off against the allowance account for trade accounts receivable.
Short-term investments
Short-term investments are financial instruments with an initial maturity of greater than 90 days, but less than one year, and are reported as current financial assets.
Deposits
Deposits are reported as non-current financial assets (loans and receivables) when their initial maturity is more than twelve months.
Cash and cash equivalents
Cash and cash equivalents in the Consolidated Statements of Financial Position includes cash at banks, term deposits and money market funds, which correspond to highly liquid investments readily convertible to known amounts of cash and subject to an insignificant risk of change in value.
Property, plant and equipment
Property, plant and equipment is stated at cost less accumulated depreciation and any accumulated impairment loss. Depreciation is computed using the straight-line method over the estimated useful lives of each component. The Company presents right-of-use of lease contracts in property, plant and equipment and right of use assets are depreciated on a straight-line basis over the lease term. The useful lives most commonly used are the following:
Machinery and equipment  3 to 5 years
Building and leasehold improvements  Lesser of 6 years or the life of the lease
Computer equipment  3 years
Furniture and office equipment  5 years
Impairment tests are performed whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If any indication exists, the Company estimates the asset’s recoverable amount, which is the higher of the fair value less cost to sell and the value in use. Where the carrying amount exceeds that recoverable amount, the asset is considered impaired and it is written down to its recoverable amount.
Depreciation expense is recorded in cost of revenue or operating expenses, based on the function of the underlying assets.
Intangible assets
Intangible assets, which primarily consist of purchased licenses for development or production technology and tools, as well as standard-related patent licenses and development costs meeting the criteria for capitalization, are stated at cost less accumulated amortization and any accumulated impairment loss. Amortization is computed using the straight-line method over the estimated useful life of each component. Acquired licenses are amortized over their contractual life or five years in the case of perpetual licenses. Capitalized development costs are generally amortized over periods ranging from 3 to 5 years, representing the expected life of the related technology.
Useful lives are reviewed on a regular basis and changes in estimates, when relevant, are accounted for on a prospective basis. The amortization expense is recorded in cost of revenue or operating expenses, based on the function of the underlying assets.
Impairment tests are performed whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If any indication exists, the Company estimates the asset’s recoverable amount, which is the higher of the fair value less cost to sell and the value in use. Where the carrying amount exceeds that recoverable amount, the asset is considered impaired and it is written down to its recoverable amount.
Costs of equity transactions
Incremental costs directly attributable to the equity transaction are recorded as a deduction from equity.
Provisions
Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event for which it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in operating income (loss) net of any reimbursement.
Provisions include the provision for pensions and post-employment benefits. Pension funds in favor of employees are maintained in France, the United Kingdom, Singapore, the United States, Finland and Israel, and they comply with the respective legislation in each country and are financially independent of the Company. The pension funds are generally financed by employer and employee contributions and are accounted for as defined contribution plans with the employer contributions recognized as expense as incurred. There are no actuarial liabilities in connection with these plans.
French law also requires payment of a lump sum retirement indemnity to employees based on years of service and annual compensation at retirement. Benefits do not vest prior to retirement. This defined benefit plan is self-funded by the Company. It is calculated as the present value of estimated future benefits to be paid, applying the projected unit credit method whereby each period of service is seen as giving rise to an additional unit of benefit entitlement, each unit being measured separately to build up the final obligation. Following the application of IAS 19 as revised, actuarial gains and losses are recognized in equity. The discount rate is based on iBoxx Corporates AA. Since January 1, 2021, the Company has applied the IFRS IC decision on IAS 19 - Employee benefits which revised the methods for calculating commitments for defined benefit plans. In accordance with the adoption elected, Sequans has applied the full retrospective transition method.
Share-based payment transactions
Employees (including senior executives and members of the board of directors) and certain service providers of the Company receive remuneration in the form of share-based payment transactions, whereby they render services as consideration for equity instruments (“equity-settled transactions”).
The cost of equity-settled transactions is measured by reference to the fair value at the date on which they are granted. The exercise price is based on closing market price on the date of grant.
The cost of equity-settled transactions is recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the beneficiary becomes fully entitled to the award (the “vesting date”). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest which includes assumptions on the number of awards to be forfeited due to the employees’ failing to fulfill the service condition, and forfeitures following the non-completion of performance conditions. The Consolidated Statement of Operations charge or credit for a period represents the movement in cumulative expense recognized as at the beginning and end of that period.
Financial liabilities
Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.
All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings, net of directly attributable transaction costs.
Non derivative financial liabilities are subsequently measured at amortized cost whereas derivative liabilities not designated as hedging instruments are recognized at fair value through profit or loss.
Convertible debt
The Company evaluates at initial recognition of a convertible debt the different components and features of the hybrid instruments and determines whether these elements are equity instruments or embedded derivatives which require bifurcation. In subsequent periods, the liability component is accounted for using the effective interest method, based on the expected maturity of the debt. The equity component is not remeasured, while embedded derivatives unless closely related to the host instruments, are recorded at fair value through the Consolidated Statement of Operations.
As described in Note 14.1 to the Consolidated Financial Statements, the Company issued debt with an option to convert into shares of the Company in April 2015, April 2016, October 2017 and September 2018. The convertible notes were amended several times to extend term of the notes and reduce conversion rates.
On March 20, 2020, the convertible notes issued in April 2015, April 2016, September 2018, May 2019 and August 2019 were amended to grant the Company three options to extend the term of each note, except for the August 2019 notes which have two options. Each option will give the Company the right to extend the term of such note by one year and consequently reset the conversion price to a 20% premium above the 20-day volume weighted average price (VWAP) if it is lower than the existing conversion price. On the first option exercise, the payment-in-kind interest (PIK) will stay at 7% but the holder will be granted a warrant for 10% of the value of the note with a three-year term, at an exercise price of 20% premium above 20-day VWAP. On the second option exercise, the PIK will be adjusted to 9.5%, the previous warrants granted on the first option exercise will be extended by one year and the holder will be granted an additional warrant for 15% of the value of the note with a three year term, at an exercise price of 20% premium above 20-day VWAP. On the third option exercise, the PIK will be adjusted to 13.5%, and the holder will be granted an additional warrant for 20% of the value of the note with a three year term, at an
exercise price of 20% premium above 20-day VWAP. If at any time, the holder converts a note prior to the date of April 2022, it will receive an extra year’s worth of PIK so as to incentivize early conversion. In consideration for entering into the amendments, the warrants that noteholder owns that were scheduled to expire April 2021 were extended to April 2024 upon the signing of the note amendments.
From an accounting perspective, the amendment of the convertible notes resulted in the extinguishment of the existing notes and issuance of five new notes, accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the notes in cash; and
An embedded derivative, which reflects the Company's call options to extend the term of each note, the conversion option of Nokomis and in certain cases a repricing to decrease the conversion price.
The change in the liability component before and after the amendment was recorded in the Consolidated Statement of Operations in “Convertible debt amendments”.
The fair value of the liability component on the amendment date represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 26.3% as the market rate of interest in order to value the liability components.

The embedded derivatives of the notes were valued using the Geometric Brownian Motion framework relying on Monte-Carlo simulations. On March 20, 2020, the initial fair value of the embedded derivative of the notes was recorded in Other Capital reserves in shareholders' equity. The change in fair value is remeasured and recorded in the Consolidated Statement of Operations as financial income or loss at each statement of financial position date.

On April 9, 2021, the Company issued a note with options to convert into shares of the Company, limited to such conversion resulting in the noteholder owning more than 10% of the Company's outstanding shares. The Company retains an option to call the convertible debt under certain circumstances after 12 months, either in full or in part. If a change of control occurs at any time prior to the payment of the note in full, the noteholder shall have the right, in its sole discretion, to require Sequans to convert or redeem all of the outstanding principal amount (including accrued interest and unpaid interest).
As described in Note 14.1, the note was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the bonds in cash; and
An embedded derivative, which reflects the value of the conversion option.
The initial fair value of the notes was split between these two components.
The fair value of the liability component on the issuance date represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 20.89% as the market rate of interest in order to value the liability components of the note on issuance. The embedded derivative of the note was valued using the Geometric Brownian Motion framework relying on Monte-Carlo simulations. The change in fair value is remeasured and recorded as financial income or loss at each statement of financial position date.
On August 15, 2022, the Company elected to exercise the first option of the amendment signed on March 20, 2020 to extend the maturity of the convertible note issued in August 2019 to August 16, 2023. On August 15, 2023, the Company elected to exercise the second option of the amendment to extend the maturity of the convertible note to April 16, 2024. This resulted in the extinguishment of the existing note and issuance of a new note for accounting purposes. Therefore, the fair value of the debt just prior to amendment was estimated in order to record a gain on extinguishment in the Consolidated Statement of Operations in “Convertible debt amendments. The amended debt was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the notes in cash; and
An embedded derivative, which reflects the value of the conversion option.
In early April 2024, both note holders agreed to stay repayment of the notes until April 26, 2024. In late April, the Company began discussions to extend the standstill agreements, which are still in process as of April 30, 2024.
Short-term debt secured by accounts receivables
As described in Note 14.3 to the Consolidated Financial Statements, the Company has a factoring agreement with a French financial institution. The Company transfers to the finance company all invoices issued to qualifying customers, and the customers are instructed to settle the invoices directly with the finance company. Because there is recourse to the Company for amounts that are overdue, the Company retains all receivables on its Consolidated Statement of Financial Position until they are paid and any amounts drawn on the line of credit are reflected in short-term debt. The Company pays a commission on the face value of the accounts receivable submitted, which is recorded in General and Administration expense, and pays interest on any draw-down of the resulting line of credit.
In February 2021, the Company entered into an agreement to finance the 2021 research tax credit as it is earned over the year. The Company transfers to the finance company research tax credit receivable on a quarterly basis. Because there is recourse to the Company for amount not paid by the French tax administration, the Company retains all receivables on its Consolidated Statement of Financial Position until the French tax administration reimburses the finance company. Amounts drawn on the line of credit are reflected in short-term debt and commissions in the Consolidated Statement of Operations as financial expense. In March 2022, the Company entered into another agreement to finance the 2022 research tax credit, and in March 2023, the Company agreed to finance the 2023 research tax credit.
Lease contracts
Except for leases related to low-value assets and short-term lease, lease contracts, as defined under IFRS 16 "Leases", are recorded in the Statement of Consolidated Financial Position, through the recognition of:
an asset representing a right-of-use of the asset leased during the lease term of the contract; and
a liability related to the payment obligation.
At the commencement date of the lease, the Company recognizes a lease liability measured at the present value of the remaining lease payments to be made over the lease term, discounted using the Company’s incremental borrowing rate. The liability increases by the accrued interest resulting from the initial discounting of the lease liability and decreases by the payments made.
Right-of-use assets are depreciated on a straight-line basis over the lease term and tested for impairment when required.
Derivative financial instruments and hedge accounting
The Company uses financial instruments, including derivatives such as foreign currency forward and options contracts, to reduce the foreign exchange risk on cash flows from firm and highly probable commitments denominated in euros. The effective portion of the gain or loss on the hedging instrument is recognized directly as other comprehensive income (loss) in the cash flow hedge reserve, while any ineffective portion is immediately accounted for in financial results in the Consolidated Statement of Operations. Amounts recognized as other comprehensive income (loss) are transferred to the Consolidated Statement of Operations when the hedged transaction affects profit or loss. If the forecasted transaction is no longer expected to occur, the cumulative gain or loss previously recognized in equity is transferred to the Consolidated Statement of Operations.
All derivative financial instruments are recorded at fair value. Changes in fair value are recorded in current earnings or other comprehensive income (loss), depending on whether the derivative is designated as a hedge, its effectiveness as a hedge, and the type of hedge transaction. Any change in the fair value of the derivatives deemed ineffective as a hedge is immediately recognized in earnings.
Commitments
Commitments comprise primarily purchase commitments with third-party manufacturers for future deliveries of equipment and components, which are described in Note 21 to the Consolidated Financial Statements.
Significant accounting judgments, estimates and assumptions
In the process of applying the Company’s accounting policies, management must make judgments and estimates involving assumptions. These judgments and estimates can have a significant effect on the amounts recognized in the financial statements and the Company reviews them on an ongoing basis taking into consideration past experience and other relevant factors. The evolution of the judgments and assumptions underlying estimates could cause a material adjustment to the carrying amounts of assets and liabilities as recognized in the financial statements. The most significant management judgments and assumptions in the preparation of these financial statements are:
Revenue recognition
The Company’s policy for revenue recognition, in instances where multiple deliverables are sold contemporaneously to the same counterparty, is in accordance with IFRS 15 Revenue from contracts with customers. The application of IFRS 15 to contracts with customers requires management to make certain judgments, the most significant of which are outlined below. These judgments are based on an analysis of the facts and circumstances surrounding the transactions on a contract-by-contract basis.
Determination of performance obligations within a contract
The Company applies judgment in determining whether a promised good or service is a performance obligation under the terms of the contract and whether multiple promised goods or services should be accounted for separately or together as a bundle.
Allocation of contract consideration to distinct performance obligations based on their relative stand-alone selling prices
Typically, contracts state the value of individual promised goods and services directly. However, in instances where the fair value is not observable, management applies judgment in determining the relative stand-alone selling price for goods and services.
Estimation of percentage-of-completion based on the input method
For service contracts that are recognized over time based on the percentage-of-completion, the Company sets up an initial budget at contract inception and tracks the progress to completion based on time and costs incurred by the employees directly working on each project. Management reviews the progress and performance of open contracts in order to determine the best estimate of estimated costs at completion on a quarterly basis and updates the revenue recognized as necessary.
Trade receivables
The Company records an allowance for any specific account it considers as doubtful based on the particular circumstances of the account. Additional allowances could be required if the Company receives information that the financial condition of its customers has deteriorated, resulting in an impairment of their ability to make payments, or there are indicators that amounts receivable will become uncollectible.
Inventories
As disclosed in Note 2.3 to the Consolidated Financial Statements, the Company writes down the carrying value of its inventory to the lower of cost or net realizable value. The estimated net realizable value of the inventory is based on historical usage and assumptions about future demand, future product purchase commitments, estimated manufacturing yield levels and market conditions on a product-by-product basis. Actual demand may differ from the forecast established by the Company, which may materially impact recorded inventory values and cost of revenue.
Share-based compensation
As disclosed in Note 13 to the Consolidated Financial Statements, the Company has various share-based compensation plans for employees and non-employees that may be affected, as to the expense recorded in the Consolidated Statements of Operations, by changes in valuation assumptions. Fair value of stock options is estimated by using the binomial model on the date of grant based on certain assumptions, including, among others expected volatility, the expected option term, the risk-free interest rate and the expected dividend payout rate. The fair value of the Company’s shares underlying stock option grants equals the closing price on the New York Stock Exchange on the date of grant.
Fair value of financial instruments
Fair value corresponds to the quoted price for listed financial assets and liabilities. The Company determined that the fair values of cash, trade receivables and trade payables approximate their carrying amounts largely due to the short-term maturities of these instruments.
Where no active market exists, the Company establishes fair value by using a valuation technique determined to be the most appropriate in the circumstances.
Regarding compound debt instruments, the fair value of debt component was determined at the date of issuance using a valuation model that requires judgment, including estimating the change in value of the Company at different dates and market yields applicable to the Company’s straight debt (without the conversion option). The assumptions used in calculating the value of the conversion option, the expected volatility of the Company’s underlying stock price which has experienced fluctuations, and the market discount rate, represent the Company’s best estimates based on management’s judgment and subjective future expectations. The fair value of debt component were supported by work performed by an independent valuation specialist engaged by the Company.
Research and Development Costs
Costs incurred internally in research and development activities are charged to expense until technological feasibility has been established for the project. Once technological feasibility is established, development costs are capitalized until the product is available for general release to customers. Judgment is required in determining when technological feasibility of a product is established. We have determined that technological feasibility for our software products is reached after all high-risk development issues have been resolved. Generally, this occurs when the preliminary design review has been done.
Leases
The application of IFRS 16 “Leases” requires the Company to make assumptions and estimates in order to determine the value of the right-of-use assets and lease liabilities, which mainly relates to the determination of the Company’s incremental borrowing rate.
XML 36 R11.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Segment information
12 Months Ended
Dec. 31, 2023
Operating segments [Abstract]  
Segment information Segment information and Disaggregated Revenue Disclosures
The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. All information required to be disclosed under IFRS 8 Operating Segments is shown in the Consolidated Financial Statements and these associated Notes.
Sales to external customers disclosed below are based on the geographical location of the customers to which the Company invoices. The following table sets forth the Company’s total revenue by region for the periods indicated.
Year ended December 31,
202120222023
(in thousands)
Asia :
  China (including Hong-Kong)$3,509 $24,018 $21,702 
  Taiwan14,668 1,066 29 
  Korea1,090 30 
  Rest of Asia898 2,202 62 
     Total Asia20,165 27,294 21,823 
Germany4,990 15,525 1,001 
United States of America22,565 16,749 8,666 
Rest of world 3,159 983 2,126 
Total revenue$50,879 $60,551 $33,616 
Of our total revenue, 96.2% is attributable to international sales for the year ended December 31, 2023 (99.8% for 2022 and 99.6% for 2021).
The Company categorizes its total revenue based on technology.
Year ended December 31,
202120222023
(in thousands)
Broadband IoT$23,699 $36,181 $21,842 
Massive IoT27,180 24,370 11,774 
Total revenue$50,879 $60,551 $33,616 
Additionally, the Company categorize its total revenue based on product, license and services revenue.
Year ended December 31,
202120222023
(in thousands)
Product$30,410 $22,974 $8,060 
License17,073 31,005 22,997 
Development and other services3,396 6,572 2,559 
Total revenue$50,879 $60,551 $33,616 
License revenue includes, in particular, license fees from agreements signed with strategic partners. See Note 19 to these Consolidated Financial Statements.
The substantial majority of the Company’s non-current assets are held by the parent company, Sequans Communications S.A. and located in France. See Note 20.3 to these Consolidated Financial Statements for information about major customers.
XML 37 R12.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Other revenues and expenses
12 Months Ended
Dec. 31, 2023
Analysis of income and expense [abstract]  
Other revenues and expenses Other income and expensesFinancial income and expenses
Financial income:
 Year ended December 31,
 202120222023
 (in thousands)
Income from short-term investments and term deposits and other finance revenue$47 $68 $177 
Impact of debt reimbursement (Notes 14.1 and 14.2)5,177 — — 
Convertible debt amendments (Note 14.1)— 476 247 
Change in fair value of convertible debt derivative (Note 14.1)
3,848 6,878 3,200 
Foreign exchange gain3,032 7,076 1,166 
Total financial income$12,104 $14,498 $4,790 
Financial expenses:
 Year ended December 31,
 202120222023
 (in thousands)
Interest on loans$7,462 $8,146 $9,584 
Interest on lease contracts (see Note 15)760 571 479 
Interest on financing component of long term development services agreement (see Notes 18 and 19)2,156 966 115 
Interest on supplier payable with extended payment terms173 222 286 
Other bank fees and financial charges778 1,020 946 
Foreign exchange loss2,094 5,994 1,858 
Total financial expenses$13,423 $16,919 $13,268 
For the year ended December 31, 2023, interest on loans included $9,566,000 related to convertible debt instruments issued in 2021 and 2019, the French government debt financing received in 2020 and bridge loans received in later 2023 (compared with $8,094,000 and $7,334,000 for the years ended December 31, 2022 and 2021, respectively which also included government loans granted in 2015 and convertible debt instruments issued in 2018, 2016 and 2015, and the venture debt issued in 2018 in the year ended December 31, 2021) (See Note 14.1 to the Consolidated Financial Statements).
The net foreign exchange loss of $692,000 for the year ended December 31, 2023 (2022: net foreign exchange gain of $1,082,000; 2021: net foreign exchange gain $938,000) arises primarily from euro-based monetary liabilities.
For the year ended December 31, 2023, a gain of $3,200,000 (2022 : gain of $6,878,000; 2021: gain of $3,848,000) was recognized, related to the change in fair value of the convertible debt embedded derivative (See Note 14.1 to the Consolidated Financial Statements).
For the year ended December 31, 2023, income of $247,000 (2022: gain of $476,000) was recognized related to the impact of the convertible debt amendment (see Note 14.1 to the Consolidated Financial Statements).
For the year ended December 31, 2021, a gain of $5,177,000 was recognized related to the impact of the convertible debts reimbursement (see Note 14.1 to the Consolidated Financial Statements) and of the prepayment in full of the venture debt (see Note 14.2 to the Consolidated Financial Statements).
Cost of revenue and operating expenses
The tables below present the cost of revenue and operating expenses by nature of expense:
  Year ended December 31,
 Note202120222023
  (in thousands)
Included in cost of revenue:
Cost of components$18,365 $13,102 $5,071 
Depreciation and impairment7517 428 395 
Amortization of intangible assets8162 148 118 
Wages and benefits2,306 2,497 2,059 
Share-based payment expense1358 160 131 
Assembly services, royalties and other2,282 1,336 1,702 
$23,690 $17,671 $9,476 
Year ended December 31,
 Note202120222023
  (in thousands)
Included in operating expenses (between gross profit and operating result):
Depreciation and impairment7$2,837 $3,551 $4,082 
Amortization of intangible assets87,037 7,888 7,346 
Wages and benefits36,684 33,195 36,014 
Share-based payment expense135,077 5,317 6,973 
Foreign exchange (gains) losses related to hedges of euro(73)207 (180)
Other, net(6,054)(3,439)(257)
$45,508 $46,719 $53,978 
Employee benefits expense
  Year ended December 31,
 Note202120222023
  (in thousands)
Wages and salaries$29,422 $27,115 $28,863 
Social security costs and other payroll taxes9,386 8,408 9,087 
Other benefits167 159 159 
Pension costs15 10 (36)
Share-based payment expenses135,135 5,477 7,104 
Total employee benefits expense$44,125 $41,169 $45,177 
The amount recognized as an expense for mandatory social tax contributions amounts to $1,465,000 for the year ended December 31, 2023 ($1,434,000 and $1,398,000 for the years ended December 31, 2021 and 2022, respectively).
Research and development expense and tax credit receivable
The research tax credit in France is deducted from corporate income taxes due; if taxes due are not sufficient to cover the full amount of the credit, the balance is received in cash three years later (one year later if the Company is below certain size criteria, which was the case for each of the years ended December 31, 2023, 2022 and 2021). Total research tax credit receivable as of December 31, 2023 is $9,714,000, ($5,006,000 relating to tax credits receivables for 2023, $4,460,000 for 2022, $137,000 for 2021 and $111,000 for 2020). Part of the amount was financed in 2023 and the remaining amount is expected to be recovered in 2024 and 2029 in cash (see Note 14.3 to the Consolidated Financial Statements).
The Company also has research tax credits available in the United Kingdom.
In the years ended December 31, 2021, 2022 and 2023, the Company capitalized costs related to the development of chipsets for 5G, and related to certification of various products. In the year ended December 31, 2021, the Company also capitalized costs related to the development of chipsets for LTE NB-IoT (Monarch N/Monarch 2).
The impact of the reduction of research and development expense due to government grants, research tax credit and development costs capitalized was as follows:
 Year ended December 31,
 202120222023
 (in thousands)
Research and development costs$52,200 $47,353 $53,018 
Research tax credit(6,328)(4,622)(5,374)
Government and other grants(3,621)(4,888)(1,834)
Development costs capitalized (*)(18,297)(13,808)(22,328)
Amortization of capitalized development costs2,460 2,575 2,642 
Total research and development expense$26,414 $26,610 $26,124 
(*) Reflecting reduction for research tax credits of $2,145,000, $1,924,000 and $1,587,000 for the years ended December 31, 2023, 2022 and 2021, respectively.
XML 38 R13.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income tax
12 Months Ended
Dec. 31, 2024
Income Taxes [Abstract]  
Income tax Income tax
The major components of income tax expense are:
 Year ended December 31,
 202120222023
 (in thousands)
Consolidated Statement of Operations
Current income tax expense$504 $2,609 $2,683 
Deferred income tax expense (benefit)121 139 (9)
Income tax expense (benefit)$625 $2,748 $2,674 
In the years ended December 31, 2023 and 2022, withholding taxes were retained from a license fee invoiced in China. This withholding was only recoverable the year of the invoicing. As the parent company was in a tax loss position, the amount of $1,875,000 in 2023 and $2,250,000 in 2022 was not recoverable and was recorded in Income tax expense.
A reconciliation of income taxes computed at the French statutory rate 25.00% for the years ended December 31, 2023 and 2022 (26.50% for the year ended December 31, 2021) to the income tax expense (benefit) is as follows:
 Year ended December 31,
 202120222023
 (in thousands)
Profit (loss) before income taxes$(19,638)$(6,260)$(38,316)
At France’s statutory income tax rate of 26.5% in 2021 and 25% in 2022 and in 2023(5,204)(1,565)(9,579)
Non-deductible share-based payment expense1,361 1,369 1,776 
Tax credits(1,677)(1,156)(1,344)
Impact of the extinguishment of the convertible debts after amendment— 119 62 
Impact of debt reimbursement1,372 — — 
Permanent differences and other168 503 (212)
Withholding tax— 2,250 2,055 
Unrecognized benefit of tax losses carryforward4,605 1,228 9,916 
Income tax expense (income)$625 $2,748 $2,674 

Significant components of the Company’s deferred tax assets and liabilities are as follows:
Consolidated Statement of Financial PositionEquityConsolidated Statement of Operations
December 31,December 31,Year ended December 31,
202120222023202120222023202120222023
(in thousands)(in thousands)(in thousands)
Government loan(135)(127)— — — (277)142 (135)
Intangible assets(28)(133)(120)— — — 21 (105)13 
Cash flow hedge(2)(3)— — — (4)(1)
Remeasurement of non-monetary accounts(171)(487)(3)— — — (899)(316)485 
Convertible debts and venture debt - liability— — — — — — (23)— — 
Other provisions and accruals (490)(495)(962)— — — (242)(4)(468)
From subsidiaries138 258 264 — — — 119 139 (9)
Deferred tax asset not recognized on losses (Loss available for offsetting against future taxable income)
826 1,111 1,210 — — — 1,426 284 100 
        Total$138 $258 $264 — $— $— $121 $139 $(9)
The changes in deferred tax assets and liabilities were as follows:
202120222023
(in thousands)
At January 1st$19 $138 $258 
Tax expense (income) during the year recognized in Profit or Loss121 139 (9)
Tax expense (income) during the year recognized in equity— — — 
Effect of foreign exchange(2)(19)15 
At December 31st$138 $258 $264 
As of December 31, 2023 the Company had accumulated tax losses which arose in France of $402,130,063 that are available for offset against future taxable profits of Sequans Communications S.A within a limit of one million euro per year, plus 50% of the profit exceeding this limit. Remaining unapplied losses would continue to be carried forward indefinitely.
Deferred tax assets were recognized in 2021, 2022 and 2023 only to the extent that deferred tax liabilities existed relating to the same taxable entity, which are expected to reverse in the same period as the asset or into which a tax loss may be carried forward.
XML 39 R14.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Earnings (loss) per share
12 Months Ended
Dec. 31, 2023
Earnings per share [abstract]  
Earnings (loss) per share Earnings (loss) per share
Basic earnings (loss) per share and American Deposit Shares (ADS) amounts are calculated by dividing net income (loss) for the year attributable to all shareholders of the Company by the weighted average number of all shares or ADS outstanding during the year.
Diluted earnings per share and ADS amounts are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of shares or ADS outstanding during the year plus the weighted average number of shares or ADS that would be issued on the exercise of all the dilutive stock options and warrants, and upon vesting of restricted stock awards as well as conversion of convertible debt. Dilution is defined as a reduction of earnings per share or ADS or an increase of loss per share or ADS. As the exercise of all outstanding stock options and warrants as well as vesting as restricted stock awards and conversion of convertible debt, would decrease loss per ordinary share or ADS, they are considered to be anti-dilutive and excluded from the calculation of loss per ordinary share or ADS.
Basic and diluted earnings (loss) per ADS presented below reflect the ADS ratio in which each ADS represents 4 ordinary shares.
The following reflects the income and share data used in the basic and diluted earnings (loss) per ordinary share and ADS computations:
 Year ended December 31,
 202120222023
 (in thousands, except share and per share data)
Profit (Loss)$(20,263)$(9,008)$(40,990)
Weighted average number of shares outstanding for basic EPS146,691,784 184,587,104 225,183,996 
Net effect of dilutive stock options— — — 
Net effect of dilutive warrants— — — 
Net effect of vesting of restricted stock— — — 
Net effect of conversion of convertible notes— — — 
Weighted average number of shares outstanding for diluted EPS146,691,784 184,587,104 225,183,996 
Basic earnings (loss) per share$(0.14)$(0.05)$(0.18)
Diluted earnings (loss) per share$(0.14)$(0.05)$(0.18)
ADS outstanding for basic and diluted earnings (loss) per ADS36,672,946 46,146,776 56,295,999 
Basic earnings (loss) per ADS$(0.55)$(0.20)$(0.73)
Diluted earnings (loss) per ADS$(0.55)$(0.20)$(0.73)
XML 40 R15.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Property, plant and equipment
12 Months Ended
Dec. 31, 2023
Property, plant and equipment [abstract]  
Property, plant and equipment Property, plant and equipment
Property, plant and equipment include:
Leasehold
improvements
Plant and
equipment
IT and office
equipment
Right of useTotal
 (in thousands)
Cost:
At January 1, 2021$1,340 $27,435 $4,006 7,013 $39,794 
Additions16 1,842 373 437 2,668 
Disposals(20)(415)(3)(756)(1,194)
Reclassification94 — (94)— — 
Exchange difference(20)60 — 47 
At December 31, 20211,437 28,842 4,342 6,694 41,315 
Additions15 3,891 222 458 4,586 
Disposals— (175)(54)(73)(302)
Exchange difference(35)(178)(123)— (336)
At December 31, 20221,417 32,380 4,387 7,079 45,263 
Additions75 1,812 220 767 2,874 
Disposals— (2)(3)(414)(419)
Exchange difference10 107 16 — 133 
At December 31, 2023$1,502 $34,297 $4,620 $7,432 $47,851 
Depreciation and impairment:
At January 1, 20211,233 23,323 3,694 2,357 30,607 
Depreciation charge for the year45 1,869 181 1,259 3,354 
Reclassification19 — (19)— — 
Disposals(12)(372)(3)(296)(683)
Exchange difference(15)41 — 27 
At December 31, 20211,286 24,805 3,894 3,320 33,305 
Depreciation charge for the year67 2,441 241 1,230 3,979 
Disposals— (153)(52)(73)(278)
Exchange difference(20)(122)(90)— (232)
At December 31, 20221,333 26,971 3,993 4,477 36,774 
Depreciation charge for the year41 2,421 198 1,223 3,883 
Impairment— 711 — — 711 
Disposals— (2)— (414)(416)
Exchange difference69 — 84 
At December 31, 2023$1,381 $30,170 $4,199 5,286 $41,036 
Net book value:
At January 1, 2021$107 $4,112 $312 4,656 $9,187 
At December 31, 2021151 4,037 448 3,374 8,010 
At December 31, 202284 5,409 394 2,602 8,489 
At December 31, 2023$121 $4,127 $421 2,146 $6,815 
Right-of-use assets as of December 31, 2023 relate to real-estate leases ($7,212,000, gross, $6,859,000, gross as of December 31, 2022 and $6,474,000, gross as of December 31, 2021) as well as IT and office equipment leases ($220,000, gross, $220,000, gross as of December 31, 2022 and 2021).
In the year ended December 31, 2023, the Company recognized an impairment loss of $707,000 related to a production equipment with the carrying amount is not recoverable.
XML 41 R16.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Intangible assets
12 Months Ended
Dec. 31, 2023
Intangible Assets [Abstract]  
Intangible assets Intangible assets
Intangible assets include:
 Capitalized development costsLicensesTotal
 (in thousands)
Cost:
At January 1, 2021$16,798 $29,391 $46,189 
Additions18,297 1,450 19,747 
Disposals— — — 
Exchange difference— 167 167 
At December 31, 202135,095 31,008 66,103 
Additions13,808 5,101 18,909 
Disposals— (2,441)(2,441)
Exchange difference— (234)(234)
At December 31, 202248,903 33,434 82,337 
Additions22,327 633 22,960 
Disposals— (2,121)(2,121)
Exchange difference— (7)(7)
At December 31, 2023$71,230 $31,939 $103,169 
Depreciation and impairment:
At January 1, 2021$3,250 $17,627 $20,877 
Amortization2,460 4,591 7,051 
Impairment— 148 148 
Exchange difference— 43 43 
At December 31, 20215,710 22,409 28,119 
Amortization2,575 5,458 8,033 
Impairment— 
Disposals— (2,441)(2,441)
Exchange difference— (82)(82)
At December 31, 20228,285 25,347 33,632 
Amortization2,640 4,708 7,348 
Disposals— (2,121)(2,121)
Exchange difference— 10 10 
At December 31, 2023$10,925 $27,944 $38,869 
Net book value:
At January 1, 2021$13,548 $11,764 $25,312 
At December 31, 202129,385 8,599 37,984 
At December 31, 202240,618 8,087 48,705 
At December 31, 2023$60,305 $3,995 $64,300 
XML 42 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Inventories
12 Months Ended
Dec. 31, 2022
Inventories [Abstract]  
Inventories Inventories
 At December 31,
 202120222023
 (in thousands)
Components$2,683 $6,641 $4,706 
Finished goods5,091 4,599 4,559 
Total inventories at cost$7,774 $11,240 $9,265 
Provision for slow-moving or damaged components$225 $606 $1,065 
Provision for slow-moving or damaged finished goods1,116 1,247 1,865 
Total provision for slow-moving or damaged inventory$1,341 $1,853 $2,930 
Components, net$2,458 $6,035 $3,641 
Finished goods, at the lower of cost and net realizable value3,975 3,352 2,694 
Total net inventories$6,433 $9,387 $6,335 
The provisions for slow-moving or damaged inventory are related to units either damaged or in excess of the units needed to serve the expected demand for identified customers and projects. In the year ended December 31, 2022, the Company recorded expense related to certain components whose lead-times increased during the COVID-19 and other supply chain constraints, that ultimately were not used in production and expired. This represented $340,000 of the 2022 provision. In the year ended December 31, 2023, the Company recorded an additional expense of $126,000 and some components were physically scrapped resulting in a provision reversal of $104,000. At December 31, 2023 the provision related to those components represented $362,000. The remaining amount of $2,568,000 in depreciation is related to finished goods and components in excess of the units needed to serve the expected demand for identified customers and projects.
XML 43 R18.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Trade receivables
12 Months Ended
Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]  
Trade receivables Trade receivables and contract assets
Trade receivables and contract assets are non-interest bearing. Trade receivables generally have 30-90 day payment terms.
 At December 31,
 202120222023
 (in thousands)
Trade receivables$16,876 $11,243 $10,803 
Contract assets789 176 497 
Provision for credit notes to be issued(465)(225)(164)
Provisions on trade receivables(2,789)(2,524)(2,524)
Net trade receivables$14,411 $8,670 $8,612 
In the years ended December 31, 2023, 2022 and 2021, the Company recorded credit notes primarily related to customer rebate programs and product returns. Such rebates are recorded as a reduction of revenue in the same period that the product is delivered.
The movements in the provision for impairment of receivables were as follows:
 December 31,
 202120222023
 (in thousands)
At January 1,$2,724 $2,789 $2,524 
Charge for the year65 — — 
Utilized amounts— (265)— 
Unutilized amounts— — — 
At year end$2,789 $2,524 $2,524 
In the year ended December 31, 2021, the Company recognized a provision for impairment of $65,000. In the years ended December 31, 2022 and 2023, no new trade receivables were impaired. Trade receivables impaired are related primarily to significantly aged receivables, which the Company no longer expects to collect although still subject to enforcement.
As at year end, the aging analysis of trade receivables and contract assets that were not impaired is as follows:
 TotalNeither past
due nor
Impaired
Past due but not impaired
   <30 days30-60 days60-120 days>120 days
 (in thousands)
At December 31, 2021$14,411 $13,587 $241 $— $— $583 
At December 31, 2022$8,670 $8,367 $209 $94 $— $— 
At December 31, 2023$8,612 $6,532 $1,919 $101 $$56 
Due to its historical experience, the Company does not assign credit risk rating grades to its trade receivables, but assesses credit risk at the customer level. Based on an analysis of historical credit losses, the Company has not applied any expected credit losses to its outstanding receivables as of the year end beyond specific provisions for doubtful accounts.
XML 44 R19.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cash and cash equivalents
12 Months Ended
Dec. 31, 2023
Subclassifications of assets, liabilities and equities [abstract]  
Cash and cash equivalents Cash, cash equivalents and short-term deposits
 At December 31,
 202120222023
 (in thousands)
Cash at banks$4,828 $5,664 $5,697 
Cash equivalents
Short-term deposits— 5,000 — 
Cash, cash equivalents and deposits$4,835 $10,671 $5,705 
Cash at banks earns no interest. Cash equivalents in money market funds and short-term deposits are invested for short-term periods depending on the immediate cash requirements of the Company, and earn interest at market rates for short-term investments. The fair value of cash, cash equivalents and short-term deposits is equal to book value. Most of the cash, cash equivalents and short-term deposits is held in U.S. dollar and euros as follows:
 At December 31,
 202120222023
 (in thousands)
U.S. dollar denominated accounts$2,869 $9,720 $5,250 
Euro denominated accounts1,564 466 91 
GBP denominated accounts143 19 319 
SGP denominated accounts47 23 13 
NIS denominated accounts160 428 
RMB denominated accounts35 10 
Other currencies denominated accounts17 12 21 
Cash, cash equivalents and short-term deposits$4,835 $10,671 $5,705 
XML 45 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-based payment plans
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangements [Abstract]  
Share-based payment plans Share-based payment plans
The expense recognized for employee and other services received during the year ended December 31, 2023 and arising from equity-settled share-based payment transactions was $7,104,000 (2021: $5,135,000; 2022: $5,477,000). Of this total, $111,000 in 2023 (2021: $76,000; 2022: $124,000), related to warrants plans for consultants considered equivalent to employees.
The breakdown is as follows:
Year ended December 31,
 202120222023
 (in thousands)
Cost of revenue$57 $159 $131 
Research and development$2,109 $1,758 $2,019 
Sales and marketing$970 $1,132 $1,397 
General and administrative$1,999 $2,428 $3,557 
Total$5,135 $5,477 $7,104 
Stock options, warrants and restricted share awards give the right to acquire ordinary shares. The exercise price for options and warrants is based on the closing market price on the effective date of grant. There is no exercise price for restricted share awards; the beneficiary receives title to the underlying ordinary shares with no cash payment at the end of the vesting period. In general, the contractual life of the stock options and warrants is ten years. There are no cash settlement alternatives, and the Company has not developed a practice of cash settlement.
There have been no cancellations or modifications to any of the plans during the years ended December 31, 2021, 2022 or 2023.
General employee stock option and restricted shares awards
All employees of the French parent company and its subsidiaries are entitled to a grant of stock options or restricted shares awards.
In general, vesting of the stock options occurs over four years, with 25% vesting after the first anniversary of grant and the remaining 75% vesting monthly over the remaining 36 months. Restricted shares awards (RSA) vest over four years, with either 25% vesting after the 1-year anniversary of the grant and the remaining 75% of the grant vesting quarterly over the remaining 3 years, or with 50% vesting after the 2-year anniversary of the grant and the remaining 50% vesting quarterly over the remaining 2 years. From time to time, vesting of founders' warrants, stock options and restricted shares may be linked to employee performance with different vesting periods. Vested restricted shares may be sold only beginning two years after the effective date of grant.
All expenses related to these plans have been recorded in the Consolidated Statement of Operations in the same line items as the related employees’ cash-based compensation.
Warrant plans for board members and consultants
The Company awards warrants to members of the board of directors following approval by the shareholders and to a limited number of consultants who have long-term relationships with the Company. Vesting may be over a one-year, two-year, three-year or four-year period, or may be immediate, depending on the nature of the service contract. All expenses related to these plans have been recorded in the Consolidated Statements of Operations in the same line items as the related service provider’s cash-based compensation.
Movements in the periods presented
The following table illustrates the number of shares (ADS equivalents are not presented) and weighted average exercise prices (WAEP) of, and movements in, stock options and warrants during the period:
 December 31,
 202120222023
 NumberWAEPNumberWAEPNumberWAEP
Outstanding at January 1,5,687,367 $3.41 5,233,437 $1.73 5,868,521 $1.51 
Granted during the year1,076,000 $1.55 1,110,288 $0.70 1,500,000 $0.54 
Forfeited during the year(139,722)$1.85 (85,400)$1.78 (111,887)$1.70 
Exercised during the year(1)
(94,008)$1.47 — $— — $— 
Expired during the year(1,296,200)$8.35 (389,804)$2.05 (444,820)$1.89 
Outstanding at period end5,233,437 $1.73 5,868,521 $1.51 6,811,814 $1.27 
Of which, warrants for consultants equivalent to employees203,000 $1.79 487,288 $1.29 724,288 $1.05 
Exercisable at period end3,977,831 $1.79 4,685,828 $1.70 5,420,965 $1.44 
Of which, warrants for consultants equivalent to employees165,667 $1.72 228,595 $1.73 438,739 $1.28 
(1)The weighted average share estimated fair value at the dates of exercise of these options was $1.78 in 2021.

The following table illustrates the number of, and movements in, restricted shares awards (RSA) based on the number of ordinary shares (ADS equivalents are not presented) during the period:
December 31,
202120222023
Outstanding at January 1,9,525,135 10,379,481 16,752,551 
Granted during the year4,426,496 10,550,820 2,640,460 
Forfeited during the year(628,186)(736,282)(686,092)
Vested during the year(2,943,964)(3,441,468)(5,601,570)
Outstanding at period end10,379,481 16,752,551 13,105,349 
Exercise prices are denominated in U.S. dollars. Euro-denominated exercise prices were converted to U.S. dollars at the historical exchange rate for purposes of presentation in this table.
The weighted average remaining contractual life of stock options and warrants outstanding as December 31, 2023 was 2.6 years (2022: 2.8 years; 2021: 3.0 years).
The range of exercise prices per share for stock options and warrants outstanding at December 31, 2023 was $0.54 - $3.31, $0.62 - $3.31 at December 31, 2022 and $0.89—$3.31 at December 2021.
The weighted average fair value of stock options and warrants granted during the year ended December 31, 2023 was $0.27 (2022: $0.34; 2021: $0.72). The weighted average fair value of the restricted shares awards granted during the year ended December 31, 2023 was $0.66 (2022: $0.91; 2021: $1.14). The fair value is measured at the grant date. The following table lists the inputs to the models used for determining the value of the grants made for the years ended December 31, 2021, 2022 and 2023:

 December 31,
 202120222023
Dividend yield (%)— — — 
Expected volatility (%)59 57 59 
Risk–free interest rate (%)— 
1.25 to 2.1
2.5
Assumed annual lapse rate of awards (%)
15 for all except 2 for warrants and a limited group of beneficiaries
20 for all except 2 for BSA and a limited group of beneficiaries20 for all except 2 for BSA and a limited group of beneficiaries
Sell price multiple (applied to exercise price)
Weighted average share price ($)1.22 0.89 0.86 
Model usedBinomialBinomialBinomial
For the years ended December 31, 2022 and 2021 the expected volatility assumption is based on the Company’s volatility since its initial public offering in 2011. For the year ended December 31, 2023, the 6-year volatility of the Company has been used.
Stock options and warrants can be exercised during a period after the vesting date until the plan terminates. In the pricing model, the assumption was made that plan participants will exercise before the end of the exercise period if the share price reaches a certain multiple of the exercise price.
If a sell-price multiple of 3 instead of 2 had been used (no impact on the restricted shares) and if the weighted average share price used in the pricing model had been decreased by 10%, share-based payment total compensation for stock options, warrants and restricted shares awards granted through December 31, 2023 would have decreased by approximately (7.51)% (2022: (9.40)%; 2021: (8.18)%).
The expected life of the stock options and warrants is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.
XML 46 R21.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Interest-bearing loans and borrowings
12 Months Ended
Aug. 15, 2023
Dec. 31, 2023
Dec. 31, 2021
Financial Instruments [Abstract]      
Interest-bearing loans and borrowings $0.8092 Interest-bearing loans and borrowings
At December 31,
Note202120222023
(in thousands)
Current
Convertible debt14.1 — — 52,278 
Convertible debt embedded derivative14.1 — — 
Unsecured related party loan14.2 — — 8,922 
Interest-bearing receivables financing14.3 9,518 7,723 9,544 
Total current portion$9,518 $7,723 $70,747 
Non-current
Convertible debt14.1 $36,373 $43,455 $— 
Convertible debt embedded derivative14.1 10,081 3,203 — 
Total non-current portion$46,454 $46,658 $— 
As of December 31, 2023, the Company had no drawn or undrawn committed borrowing or overdraft facilities in place.
Unsecured related party loan
On November 8, 2023, in connection with contemplated acquisition of the Company by Renesas Electronics Corporation ("Renesas") that was in process at the time (subsequently terminated in February 2024), the Company entered into a Security Purchase Agreement with Renesas Electronics America ("Renesas America") whereby Renesas America agreed to the issuance of an unsecured subordinated note (the “Note”) in an aggregate principal amount of $6.0 million, at a stated rate of interest of 9.5% per annum. The principal amount and any accrued interest on the Note is due on the earliest to occur of (i) the written demand by the holder of the Note for repayment after the successful consummation of the offer by Renesas Electronics Europe GmbH, incorporated as a limited liability company under the laws of Germany (Gesellschaft mit beschränkter Haftung—GmbH) and a direct wholly owned subsidiary of Renesas, to acquire all of the Company’s outstanding ordinary shares, nominal value €0.01 per share (“Ordinary Shares”), including Ordinary Shares represented by American Depositary Shares (“ADSs”) and Ordinary Shares issuable upon the exercise or conversion or exchange of any outstanding options, warrants, convertible securities, restricted share awards or rights to purchase, subscribe for, or be allocated Ordinary Shares of the Company, for $0.7575 per Ordinary Share and $3.03 per ADS (the “Tender Offer”), (ii) 90 days after the termination of the Tender Offer (other than by reason of successful completion thereof), (iii) 90 days after the termination of the Memorandum of Understanding (the "MoU), dated as of August 4, 2023, by and between Renesas and the Company, and (iv) the date a Company Termination Fee (as defined in the MoU) is payable under the MoU.
On December 27, 2023, the Company entered into a second Security Purchase Agreement with Renesas America whereby Renesas America agreed to the issuance of a Note in an aggregate principal amount of $3.0 million, at a stated rate of interest of 9.5% per annum.
Interest expense related to the Notes recorded during the year ended December 31, 2023 amounted to $127,000). No repayments of principal occurred during the year ended December 31, 2023.
On February 22, 2024, Renesas notified the Company that Renesas was terminating the MoU due its receipt of an adverse Japanese tax ruling on February 15, 2024 from the National Tax Agency of Japan.
On April 9, 2024, the Company secured a standstill agreements from Renesas. The agreement granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met. In late April, the Company began discussions to extend the standstill agreement, which are still in process as of April 30, 2024.
Interest-bearing financing of receivables
In June 2014, the Company entered into a factoring agreement with a French financial institution whereby a line of credit was made available equal to 90% of the face value of accounts receivable from product sales to qualifying customers, up to the amount covered by the Company's credit insurance per customer. In July 2017, the Company signed an amendment to the initial agreement to include limited financing of accounts receivable from service sales of $800,000. The Company transfers to the finance company all invoices issued to qualifying customers, and the customers are instructed to settle the invoices directly with the finance company. The Company pays a commission on the face value of the accounts receivable submitted and interest at SOFR 3 months USD +2% which represents approximately a rate of 1.81% on any draw-down of the resulting line of credit. In the event that the customer does not pay the invoice within 60 days of the due date, the receivable is excluded from the line of credit, and recovery becomes the Company’s responsibility. At December 31, 2023, $2,531,000 ($4,732,000 at December 31, 2022 and $5,651,000 at December 31, 2021) had been drawn on the line of credit and recorded as a current borrowing.
In February 2021, the Company entered into an agreement to finance the 2021 research tax credit receivable as it is earned over the year. At December 31, 2021, the amount financed was $3,867,000, recorded as current liabilities and does not include retention of $1,562,000, which was received in 2022 ($1,436,000) and in 2027 ($133,000). After the payment of the retention amount, the interest-bearing financing debt was netted with the research tax credit receivable. The effective interest rate of 6.20% includes expenses related to the financing.
In March 2022, the Company entered into a new agreement to finance the 2022 research tax credit as it is earned over the year. At December 31, 2022, the amount financed was $2,991,000, recorded as current liabilities and does not include retention of $1,249,000, which $360,000 was received in 2023, $780,000 in January 2024 and $109,000 is expected to be received in 2028. The effective interest rate of 5.33% includes expenses related to the financing.
In April 2023, the Company entered into a new agreement to finance the 2023 research tax credit as it is earned over the year. At December 31, 2023, the amount financed was $3,369,000, recorded as current liabilities and does not include retention of $1,531,000, which is expected to be received in 2024 ($1,409,000) and in 2029 ($122,000). The effective interest rate of 14.62% includes expenses related to the financing.
Convertible debt
On April 14, 2015, the Company entered into a convertible note agreement with Nokomis Capital, L.L.C., one of the Company’s shareholders, regarding the issuance and sale of a convertible note in the principal amount of $12 million (the “2015 note”), which note was convertible into the Company’s shares, nominal value €0.02 per share, at a conversion rate of 540.5405 shares for each $1,000 principal amount of the 2015 note, subject to certain adjustments, which equated to an initial conversion price of $1.85 per share. On October 30, 2017, the convertible note was amended to extend the term from April 14, 2018 to April 14, 2019. On September 27, 2018, the convertible note was further amended to extend the term by two years to April 14, 2021, and to decrease the conversion price from $1.85 to $1.70 per share. In addition, the Company issued to Nokomis, for a total subscription price of $1.00, warrants to acquire 1,800,000 shares at an exercise price of $1.70 per share. Such warrants are exercisable at any time and had an expiration date of April 14, 2021.
On April 27, 2016, the Company entered into a convertible note agreement with Nokomis Capital, L.L.C. and two other financial institutions (the “Holders”) regarding the issuance and sale of convertible notes in the aggregate principal amount of $7.16 million (the “2016 notes”), which are convertible into the Company’s shares. The initial conversion price of the 2016 notes was $2.7126 per share. On October 30, 2017, the convertible note agreement was amended to extend the term from April 27, 2019 to April 27, 2020. In addition, the conversion price was decreased from $2.71 to $2.25 per share.
On September 27, 2018, the Company entered into a convertible note agreement with Nokomis Capital, L.L.C. in the principal amount of $4.5 million (the "2018 notes") under which the convertible note matures in April 2021 and is subordinated to certain venture debt to be issued by the Company and is convertible, at the holder’s option, into the company’s shares at a conversion rate of $1.70 per share. On September 27, 2018, all of the convertible notes issued in 2015 and convertible notes with a principal amount of $6 million issued in 2016 were amended to allow the convertible notes to be subordinated to certain venture debt to be issued by the Company.
On October 26, 2018, the Company further amended the 2015 note, the 2016 note and the 2018 note with Nokomis to clarify the terms of the subordination of these convertible notes to the Company’s venture debt holder.
On May 7, 2019, the Company entered into a convertible note agreement with Nokomis Capital, L.L.C. in the principal amount of $3.0 million (the "2019-1 notes"). The convertible note matures in April 2021 and is convertible, at the holder’s option, into the Company’s shares at a conversion rate of $1.21 per share.
On August 16, 2019, the Company entered into a convertible note agreement with Nokomis Capital, L.L.C. in the principal amount of $5.0 million (the "2019-2 notes"). The convertible note matures in August 2022 and is convertible, at the holder’s option, into the Company’s shares at a conversion rate of $1.03 per share.
Effective February 11, 2020, the Company amended the terms of the convertible note issued April 27, 2016 to Nokomis Capital, L.L.C., to extend the maturity of the note to April 14, 2021. In addition, the conversion price was reduced from $2.25 to $1.225 per ordinary share.
Effective March 20, 2020, the convertible notes issued in April 2015, April 2016, September 2018, May 2019 and August 2019 were amended to grant the Company three options to extend the term of each note, except for the August 2019 which has two options. Each option will give the Company the right to extend the term of such note by one year and consequently reset the conversion price to a 20% premium above the 20-day volume weighted average price (VWAP) if it is lower than the existing conversion price. On the first option exercise, the payment-in-kind interest (PIK) will stay at 7% but the holder will be granted a warrant for 10% of the value of the note with a three year term, at an exercise price of 20% premium above 20-day VWAP. On the second option exercise, the PIK will be adjusted to 9.5%, the previous warrants granted on the first option exercise will be extended by one year and the holder will be granted an additional warrant for 15% of the value of the note with a three year term, at an exercise price of 20% premium above 20-day VWAP. On the third option exercise, the PIK will be adjusted to 13.5%, and the holder will be granted an additional warrant for 20% of the value of the note with a three year term, at an exercise price of 20% premium above 20-day VWAP. If at any time, the holder converts a note prior to the date of August 2023, it will receive an extra year’s worth of PIK as a bonus so as to incentivize conversion. In consideration for entering into the amendments, the warrants that Nokomis owns that were scheduled to expire April 2021 were extended to April 2024 upon the signing of the note amendments.
The 2015, 2016, 2018 and 2019 notes (together, “the Nokomis Notes”) are unsecured obligations of the Company. The Nokomis Notes issued in 2015, 2016, 2018 and in May 2019 matured on April 14, 2021, and the 2019-2 Nokomis Note will mature on August 16, 2022, except if the Company exercises its option to extend the term of the notes as provided in the March 20, 2020 amendments. The Company has considered that the options to extend the terms will be exercised and therefore, has included the Nokomis Notes in non-current liabilities on the statement of financial position at December 31, 2020 and 2021. The Nokomis Notes are not redeemable prior to maturity. The accreted principal amounts of the Nokomis Notes are convertible at any time or times on or after the issuance dates until maturity, in whole or in part, subject to certain adjustments for significant corporate events, including certain dilutive issuances, dividends, stock splits and other similar events. Interest accrues on the unconverted portion of the Nokomis Notes at the rate of 7% per year (unless the above options are exercised), and is paid in kind annually on the anniversaries of the issuance of the Nokomis Notes. The Nokomis Notes also provide for customary events of default which, if any of them occurs, would permit or require the principal of and accrued interest on the Nokomis Notes to become or to be declared due and payable.
In the event of a recapitalization, reorganization, reclassification, consolidation, merger, sale of all or substantially all of the Company’s assets or other transaction, which in each case results in the Company’s shareholders receiving stock, securities or assets with respect to or in exchange for their ADSs or ordinary shares, the holders shall elect, at their option, either (a) to require the Company to repurchase for cash the entire accreted principal amount of the Nokomis Notes or (b) to convert the Nokomis Notes in their entirety.
The Nokomis Notes contain customary ongoing covenants of the Company. In addition, the Nokomis Notes provide that the Company will not grant a consensual security interest or pledge its personal property assets to a third-party lender (with certain limited exceptions) during the time that the notes are outstanding. Any amendment or waiver of the terms of the Notes requires the affirmative consent of the holders.
On January 13, 2021, January 17, 2021 and February 12, 2021, Nokomis Capital, L.L.C, converted portions of the convertible note issued in 2015 with a total principal value of $7,750,000 plus accrued interest and conversion bonus of $4,536,438, into a total of 7,227,308 ordinary shares. The recalculated fair value of the embedded derivatives related to the note at the conversion dates was $6,534,000 and the change of the fair value amounted to a loss of $3,269,000. The difference between the capital increase, the liability component and the fair value of the embedded option has been recorded in Other Capital Reserves in shareholders’ equity for an amount of $5,386,000.
On April 9, 2021, the Company entered into a convertible note agreement with Lynrock Lake Master Fund LP in the principal amount of $40.0 million (the "Lynrock Lake Note"). The Lynrock Lake Note matures in April 2024 and is convertible, at the holder’s option, into the Company’s shares at a conversion rate of $1.915 per share (representing $7.66 per ADS), subject to a 9.9% ownership limit for Lynrock Lake. The Lynrock Lake Note earns interest annually at an interest rate of 5.0625% for cash payments or 6% for payment in kind accruals. The Company retains an option to call the Lynrock Lake Note under certain circumstances after 12 months, either in full or in part. If a change of control occurs at any time prior to the payment of the note in full, Lynrock Lake Master Fund LP shall have the right, in its sole discretion, to require the Company to convert or redeem all of the outstanding principal amount (including accrued interest and unpaid interest). In the event that the note is not converted and the Company does not repay the amount due on the maturity date, the interest rate automatically increases to 8% beginning April 10, 2024.
The Lynrock Lake Note was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the bonds in cash; and
An embedded derivative, which reflects the value of the conversion option.
The initial fair value of the notes was split between these two components.
The fair value of the liability component on the issuance date represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 20.89% as the market rate of interest in order to value the liability components of the note on issuance. The embedded derivative of the Lynrock Lake Note was valued using the Geometric Brownian Motion framework relying on Monte-Carlo simulations. On April 9, 2021, the initial fair value of the embedded derivative of the notes was calculated to be $12,713,000 The change in fair value is remeasured and recorded as financial income or loss at each Statement of Financial Position date.
On April 14, 2021, the Company repaid the remaining amount of the Nokomis Notes that were due on April 14 (Nokomis Notes issued in April 2015 and in September 2018) with accrued paid-in-kind interest of 7%. $6,378,104 was repaid for the April 2015 convertible note ($4,250,000 in principal and $2,128,000 as accrued interest) and $5,346,699 ($4,500,000 in principal and $847,000 as accrued interest) for the September 2018 convertible note. The recalculated fair value of the embedded derivatives at the repayment date was $4,645,000 and was recorded as financial income in the Consolidated Statement of Operations and the change of the fair value amounted to a loss of $934,000.
On August 15, 2022, the Nokomis Note issued in August 2019 arrived at maturity and the Company elected to exercise the first option of the amendment signed on March 20, 2020, to extend the maturity to August 16, 2023 in exchange for the issuance of 594,680 warrants (148,670 ADSs) to Nokomis at an exercise price of $1.03 per warrant ($4.12 per ADS). The expiration date of these warrants is August 15, 2025. In accordance with Article II of the amendment, the interest rate on the note increased to 9.5% per annum effective August 15, 2022. Conversion price of the debt is unchanged. This resulted in the extinguishment of the existing note and issuance of a new note for accounting purposes. The amended debt was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the notes in cash; and
An embedded derivative, which reflects the value of the conversion option.
The value of the liability component at the extension date was $6,125,000. The fair value of the new liability component represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 23.2% as the market rate of interest in order to value the liability components for an amount of $5,454,000. The change in the liability component before and after the extension and the fair value of the warrants granted was recorded for a gain of $476,000 in the Consolidated Statement of Operations in “Convertible debt amendments. The fair value of the embedded derivative of the note was calculated at the extinguishment date and the change in fair value of $343,000 was recorded as financial expenses in the Consolidated Statement of Operations.
On August 15, 2023, the Nokomis Note issued in August 2019 arrived at maturity and the Company elected to exercise the second option of the amendment signed on March 20, 2020, to extend the maturity to August 16, 2024 in exchange for the issuance of 1,244,820 warrants (311,205 ADSs) to Nokomis at an exercise price of $0.8092 per warrant ($3.2328 per ADS). The expiration date of these warrants is August 15, 2026. In accordance with Article II of the amendment, the interest rate on the note increased to 13.5% per annum effective August 15, 2023. Conversion price of the debt is unchanged. This resulted in the extinguishment of the existing note and issuance of a new note for accounting purposes. The amended debt was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the notes in cash; and
An embedded derivative, which reflects the value of the conversion option.
On April 9, 2024, the Company secured standstill agreements from both convertible debt holders. The agreements granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met. In late April, the Company began discussions to extend the standstill agreements, which are still in process as of April 30, 2024.
The value of the liability component at the extension date was $6,707,000. The fair value of the new liability component represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 21.9% as the market rate of interest in order to value the liability components for an amount of $6,378,000. The change in the liability component before and after the extension and the fair value of the warrants granted was recorded for a gain of $247,000 in the Consolidated Statement of Operations in “Convertible debt amendments. The fair value of the embedded derivative of the note was calculated at the extinguishment date and the change in fair value of $421,000 was recorded as financial expenses in the Consolidated Statement of Operations.
At December 31, 2023, the recalculated fair value of the remaining Nokomis Note and the Lynrock Lake Note embedded derivatives was a total of $3,000 ($3,203,000 and $10,081,000 at December 31, 2022 and 2021 respectively) and the change of the fair value of $3,200,000 for the year ended December 31, 2023 ($6,878,000 and $3,848,000 for the years ended December 31, 2022 and 2021, respectively) was recorded in the Consolidated Statement of Operations.
The conversion rates of the convertible notes outstanding as of December 31, 2023, are as follows:
Conversion rate per shareConversion rate per ADS
2019-2 Nokomis Note$0.8082 $3.23 
2021 Lynrock Lake Note$1.915 $7.66 
XML 47 R22.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Lease liabilities
12 Months Ended
Dec. 31, 2023
Subclassifications of assets, liabilities and equities [abstract]  
Lease liabilities ease liabilities
The Company recognized right-of-use of assets of $2,146,000 (included in property, plant and equipment in the Consolidated Statements of Financial Position). Identified lease contracts mainly relate to real-estate rental agreements and IT and office equipment leases. The lease liabilities were discounted at an incremental borrowing rate of 14.2%.
The table below presents the carrying amounts of right-of-use assets recognized and the movements during the period:
Real-estateIT and office equipmentTotal
(In thousands)
As at January 1, 20214,184 472 4,656 
Additions437 — 437 
Disposals(210)(547)(757)
Depreciation expense(1,151)(108)(1,259)
Amortization disposals114 183 297 
As at December 31, 2021$3,374 $— $3,374 
Additions458 — 458 
Disposals(73)— (73)
Depreciation expense(1,230)— (1,230)
Amortization disposals73 — 73 
As at December 31, 2022$2,602 $— $2,602 
Additions767 — 767 
Disposals(414)— (414)
Depreciation expense(1,223)— (1,223)
Amortization disposals414 — 414 
As at December 31, 2023$2,146 $— $2,146 
The table below present the carrying amounts of lease liabilities and the movements during the period:
Lease liabilitiesCurrentNon-current
(In thousands)
As at January 1, 2021$5,776 $1,014 $4,762 
Additions437 
Disposals(993)
Interests expense760 
Foreign exchange loss (gain)(297)
Payments(1,063)
As at December 31, 2021$4,620 $1,247 $3,373 
Additions458 
Disposals(577)
Interests expense571 
Foreign exchange loss (gain)(298)
Payments(1,205)
As at December 31, 2022$3,569 $1,291 $2,278 
Additions767 
Disposals(414)
Interests expense479 
Foreign exchange loss (gain)36 
Payments(1,321)
As at December 31, 2023$3,116 $1,471 $1,645 
The rental charges relating to short-term and low value leases remained classified as operating expenses in the Consolidated Statements of Operations and amounted to $1,559,000 for the year ended December 31, 2023 ($1,248,000 and $1,411,000 for the years ended December 31, 2022 and 2021, respectively).
XML 48 R23.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Government grant advances and loans
12 Months Ended
Dec. 31, 2023
Government Grants [Abstract]  
Government grant advances and loans Government grant advances and loans
  December 31,
 Note202120222023
  (in thousands)
Current
Government grant advances16.1$3,317 $968 $708 
Research project financing16.21,057 1,237 1,518 
Government loans16.21,832 1,954 1,727 
Accrued interest16.2— — 653 
Total current portion$6,206 $4,159 $4,606 
Non-current
Government grant advances16.1$2,048 $872 $328 
Research project financing16.22,248 1,567 259 
Government loans16.33,084 1,424 173 
Accrued interest16.21,974 2,372 2,496 
Total non-current portion$9,354 $6,235 $3,256 
Government grant advances
In 2023, the Company was named as a participant in one new collaborative projects with combined funding of €428,000 ($436,000 using the exchange rate of the grant dates) which is expected to be released to the Consolidated Statement of Operations over the lives of the projects, estimated to be approximately three years.

In 2022, the Company was named as a participant in four new collaborative projects with combined funding of €1,376,000 ($1,364,000 using the exchange rate of the grant dates). Three of them are expected to be released to the Consolidated Statement of Operations over the lives of the projects, estimated to be approximately three years, one was fully released in the year ended December 31, 2022.

In 2021, the Company was named as a participant in two new collaborative projects with combined funding of €6,326,000 ($7,650,000 using the exchange rate of the grant dates) which is expected to be released to the Consolidated Statement of Operations over the lives of the projects, estimated to be approximately three years for both projects.
Research project financing
In October 2014, Bpifrance, one of the Company’s shareholders as well as the financial agency of the French government, provided funding to the Company in the context of a long-term research project, estimated to be completed over a 3-year period. In December 2016, Bpifrance and the Company signed an amendment to extend the period from three to four years. The total funding amounted to €6,967,000 ($8,988,000 using the exchange rate of the funding dates) with a portion in the form of a grant (€2,957,000 or $3,815,000) and a portion in the form of a forgivable loan (€4,010,000 or $5,173,000). The funding was paid in three installments, the last of which was received in 2019 for €992,000 ($1,126,000 using the exchange rate of the payment date). The grant was recognized as a reduction of research and development expense when corresponding expense was incurred. The forgivable loan advance will be repaid from March 31, 2019 to December 31, 2024 of which €870,000 ($939,000) using the exchange rate of the payment dates) in principal and interests was paid in 2023 (€540,000, or $571,000 in 2022; €675,000, or $804,000, in 2021), and bears interests at a 1.53% fixed contractual rate. The difference between the amount of grant received and the present value amounted to a reduction of $115,000 in the debt carrying value, with such difference
being amortized over the contract period. If the sales of the product developed under this program are in excess of €350 million ($396 million using the exchange rate as of December 31, 2021) during a period of three years, then the Company shall pay for three consecutive years after the date of the termination of the reimbursment a bonus to Bpifrance of 1% of annual revenues generated by products issued from the project (up to a maximum of €350,000,000 or $386,750,000 over a period of ten years). The Company doesn’t expect to perform any repayment to BPI.
In January 2016, Bpifrance provided funding to the Company for a new long-term research project, completed in early 2020. The total of the funding amounted to €2,095,000 ($2,288,000 using the exchange rate of the grant date) comprising a portion in the form of a grant (€668,000 or $729,000) and a portion in the form of a forgivable loan (€1,427,000 or $1,558,000). The funding was paid in four installments, the last of which was received in February 2020 for €365,000 ($405,000 using the exchange rate of the funding date). The grant was recognized as a reduction of research and development expense when corresponding expense was incurred. The forgivable loan advance was to be repaid, except if the project is a commercial failure, from July 1, 2020 to July 1, 2024 and bears interests at a 1.17% fixed contractual rate. The difference between the amount of grant received and the present value of future payments discounted using interest rate applied for standard loans with similar maturity amounted to a reduction of $30,000 in the debt carrying value, with such difference being amortized over the contract period. In late 2020, the Company determined that there was not enough market interest for the radio frequency of the product development funded by this grant, and abandoned the project. A request for forgiveness of the debt was made and, in April 2021, Bpifrance forgave a large portion of the advance, effectively transforming the forgiven advance to a grant and resulting in a one-time benefit of €1,214,000 ($1,442,111 using the exchange rate of the period), recorded as a reduction of Research and Development expenses. The unforgiven portion of €213,000 ($241,000) was reimbursed in February 2022.
In 2022, the Company received funding for one project of €309,000 ($316,000 using the exchange rate of the funding date) as a grant and €473,000 ($507,000 using the exchange rate of the funding date) as a reimbursable loan. The payment was received in March 2023.
In 2023, Bpifrance provided funding to the Company for a new long-term research project of €428,000 ($473,000 using the exchange rate at the closing date) as a grant and €142,000 ($157,000 using the exchange rate at the closing date) as a forgivable loan. The funding is paid in four installments. The first installment was received in March 2023 and amounted to €36,000 ($38,000 using the exchange rate of the funding date).
The accrued interest of $712,000 was recorded as of December 31, 2023 ($579,000 as of December 2022 and $563,000 as of December 31, 2021) at an estimated market rate in a range from 2.3% to 20.9%. The market rate of interest applied in 2021 ranged from 1.80% to 2.30%.Government loans
In September 2015, the Company received two loans from Bpifrance for a total amount of €2,000,000 ($2,228,000 using the exchange rate of the grant date). One loan of €1,000,000 bears interest at 5.24% per year, paid quarterly; the second loan of €1,000,000 is interest-free. The interest-free loan has been revalued using the 5.24% interest rate payable on the other loan. Both loans have seven year terms with the principal being amortized on a quarterly basis beginning in June 2017 and March 2018. At December 31, 2023, both loans were fully reimbursed.
On April 30, 2020, the Company finalized €5 million of French government debt financing that was received in May 2020 as part of the French COVID-19 economic support plan. The French loan is unsecured. The original five years long repayment schedule agreed in May 2020 was then extended with only interest payable from August 2021 to May 2022. The repayments of principal started in August 2022 until May 2026. As of December 31, 2023, $1,727,000 has been classified as current and $2,610,000 as non-current.
XML 49 R24.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Provisions
12 Months Ended
Dec. 31, 2023
Other Provisions, Contingent Liabilities and Contingent Assets [Abstract]  
Provisions Provisions
Post-
employment
benefits
Other provisionsTotalCurrentNon current
 (in thousands)
At January 1, 2021$834 $809 $1,643 $89 $1,554 
Arising (released) during the year(28)850 822 — — 
Released (used) during the year— (90)(90)— — 
Released (unused) during the year— (238)(238)— — 
At December 31, 2021806 1,331 2,137 — 2,137 
Arising (released) during the year(101)428 327 — — 
Released (used) during the year— — — — — 
Released (unused) during the year— (191)(191)— — 
At December 31, 2022705 1,568 2,273 77 2,196 
Arising (released) during the year107 257 364 — — 
Released (used) during the year(48)(76)(124)— — 
Released (unused) during the year— (291)(291)— — 
At December 31, 2023$764 $1,458 $2,222 $— $2,222 
The provision for post-employment benefits is for the lump sum retirement indemnity required to be paid to French employees if they retire as a Company employee. The comprehensive income (loss) for 2023 includes $46,000 of actuarial loss (actuarial gain of $71,000 in 2022 and actuarial loss of $20,000 in 2021. One employee retired in 2023 and no employee retired in 2021 and 2022.
The main assumptions used in the calculation are the following:
202120222023
Discount rate0.98%3.75%3.20%
Salary increaseBetween 1.5% and 3.5%Between 1.5% and 3.5%Between 1.5% and 3.5%
Retirement age60-62 years60-62 years65-67 years
Turnover: depending on the seniorityDecrease by age from 2% for directors, Vice presidents and managers and from 10% for other employees. 0% for executive teamDecrease by age from 2% for directors, Vice presidents and managers and from 12% for other employees. 0% for executive teamDecrease by age from 2% for directors, Vice presidents and managers and from 20% for other employees. 0% for executive team
At December 31, 2021, 2022 and 2023, “Other provisions” include primarily estimated royalty payments assessed on sales of modules to holders of patents which may be deemed as essential under the requirements of the LTE standard. The royalty provision is based on management’s judgment, taking into consideration the published royalty rates, various legal decisions, articles, reports and industry discussions on the subject which were available, and is recorded in the cost of product revenue. The Company’s modules are considered as final products incorporating the full LTE function, and therefore may have royalties assessed on their sale; no royalties are accrued on the sales of chips as the full LTE functionality is not included in the chip and it is not current industry practice to license standard-essential patents at the component level.
XML 50 R25.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Other non-current liabilities
12 Months Ended
Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]  
Other non-current liabilities Other non-current liabilities
 At December 31,
 202120222023
 (in thousands)
Trade payables$964 $1,788 $— 
Deferred tax liabilities138 258 264 
Contract liabilities:
  License and development services agreement2,706 404 — 
  Deferred revenue— — — 
  Total contract liabilities 2,706 404 — 
At December 31, 2021 and 2022, trade payables included the non-current part of a supplier debt related to acquisition of certain intangible assets which is scheduled to be paid in 27 months.
At December 31, 2023, the Company recognized a net deferred tax liability of $264,000 ($258,000 and $138,000 at December 31, 2022 and 2021, respectively) related to origination and reversal of timing differences.
On October 24, 2019, the Company signed a multi-year, non-exclusive license and development services agreement with a strategic partner, a Fortune Global 500 company. The agreement provided for an upfront payment of $18 million, which was received in October 2019, and recorded as a contract liability upon receipt. The contract includes clauses that allow for termination in certain circumstances, or in some cases of a change in control of the Company, which could result in a refund of certain or all amounts received under the contract, depending on the circumstances. The Company determined that this agreement includes a financing component related to the upfront payment, whereas the deliverables under the contract were to be delivered over more than one year, which results in the recognition of interest expense over a portion of the term of the agreement. In the year ended December 31, 2023, no revenue was recognized as the strategic partner has suspended the project ($8,619,000 recognized in revenues in 2022 and $11,419,000 in 2021 as a result of development services performed), license revenue of $1,500,000 in the year end December 31, 2022 and interest expenses on the upfront payment of $810,000 in 2022 and $1,628,000 in 2021). There was no interest expenses in the year ended December 31, 2023. At December 31, 2022 and 2023, there was no net remaining contract liability presented on the Statement of Financial Position ($4,211,000 was presented at December 31, 2021, reflecting the expected net amount of revenue less interest expenses to be recognized in the year ended December 31, 2022).
In December 2020, the Company signed a 5G technology access and license agreement with another strategic partner for an amount of $4,500,000. The agreement provided for an upfront payment which was received in January 2021. The Company determined that this agreement includes a financing component related to the upfront payment, which will results in the recognition of interest expense over a portion of the term of the agreement. In the year ended December 31, 2023, the Company recognized revenues for an amount of $571,000 ($1,083,000 in 2022 and $3,008,000 in 2021) as a result of development services performed and interest expenses on the upfront payment of $14,000. At December 31, 2023, the net remaining contract liability of $245,000 was presented on the Statement of Financial Position as current contract liabilities (At December 31, 2022: $862,000 as current portion ;At December 31, 2021 : $1,853,000, $1,639,000 as current portion and $214,000 as non-current portion).
In December 2021, the Company signed two amendments with the second strategic partner to extend the 5G technology access and license agreement. The first amendment was signed to extend the agreement to a manufacturing license for the 5G chip for a total amount of $5,000,000 of which $3,000,000 in cash which was received in February 2022 and $2,000,000 in the form of investments in production and testing equipment that will then be made available to Sequans for its own use. In the year ended December 31, 2023, the Company recognized revenues for an amount of $296,000 ($2,983,000 in 2022 and $311,000 in 2021), as a result of development services performed and interest expenses on the upfront payment of $25,000. At December 31, 2023, no contract liability presented on the Statement of Financial Position remained ($271,000 net remaining contract liability presented as current contract liabilities and $1,189,000 at December 31, 2021).
The second amendment is related to a manufacturing license for Monarch 2 chips and NB-IoT in India, for a total amount of $4,500,000 which was received in February 2022. The Company determined that this amendment includes a financing component related to the upfront payment, which will results in the recognition of interest expense over a portion of the term of the agreement. In the year ended December 31, 2023, the Company recognized revenues for an amount of $2,536,000 as a result of development services performed ($1,507,000 in 2022: $800,000 as license fees and $707,000 as a result of development services performed) and no interest expenses on the upfront payment. At December 31, 2023, $8,000 contract liability presented on the Statement of Financial Position remained ($2,544,000 at December 31, 2022: $2,141,000 as current contract liabilities and $404,000 as non-current liabilities; $3,652,000 at December 31, 2021: $1,160,000 as current contract liabilities and $2,492,000 as non-current liabilities).
In August 2022, the Company signed a 5G license agreement with a strategic partner for an amount of up to $60,000,000, to be paid over three years, to manufacture and sell the 5G chipset in China and well as the right to create derivative products based on the licensed technology that may be sold in China if a minor derivative and worldwide if a major derivative. In the year ended December 31, 2023, the Company recognized license fee revenues for an amount of $18,750,000 ($20,000,000 in 2022). At December 31, 2023 and 2022, the net remaining contract liability of $2,500,000 was presented on the Statement of Financial Position as current contract liabilities.
XML 51 R26.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Trade payables and other current liabilities
12 Months Ended
Dec. 31, 2023
Subclassifications of assets, liabilities and equities [abstract]  
Trade payables and other current liabilities Trade payables, other current liabilities and current contract liabilities
 At December 31,
 202120222023
 (in thousands)
Trade payables$13,916 $9,342 $16,281 
Other current liabilities:
Employees and social debts7,987 7,497 7,383 
Provisions— 77 — 
Others1,193 781 1,516 
Total other current liabilities$9,180 $8,355 $8,899 
Contract liabilities:
License and development services agreements (See Note 19)8,201 5,774 5,485 
Deferred revenue476 190 367 
$8,677 $5,964 $5,852 
As of December 31, 2021,trade payables included the current portion of a supplier debt related to acquisition of certain intangible assets of $244,000. In the year ended December 31, 2021, the Company contracted a new supplier debt related to the acquisition of certain intangible assets. As of December 31, 2021, $279,000 remained of this liability ($184,000 as the non-current portion). In the year ended December 31, 2022, the Company contracted a new supplier debt related to the acquisition of certain intangible assets. As of December 31, 2022, $3,350,000 remained of this liability ($786,000 as the non-current portion). As of December 31, 2023, $1,587,000 remained as current portion. In January 2020, the Company entered into an agreement with a technology company based in Israel to transfer a team of engineers to the Company for the purpose of accelerating 5G new product development. The remaining amount to be paid in June 2024 for this agreement is $1,430,000. This amount has been discounted and as of December 31, 2023, $1,288,000 is included in current trade payables ($1,002,000 and $780,000 as of December 31, 2022 and 2021, respectively), and the Company records interest expense associated with this amount each reporting period.
Terms and conditions of the above financial liabilities:
Trade payables are non-interest bearing and are generally settled on 30-day terms.
Other current liabilities, primarily accrued compensation and related social charges, are non-interest bearing.
Certain upfront payments received from strategic partners are deemed to include a financing component, and as such, bear interest.
Deferred revenue is primarily related to maintenance services. At December 31, 2021, 2022 and 2023, deferred revenue totaled $476,000 (recognized in 2022), $190,000 (recognized in 2023) and $367,000 (expected to be recognized during 2024), respectively.
XML 52 R27.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Information about financial instruments
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Financial Instruments [Abstract]    
Information about financial instruments Information about financial instrumentsFinancial risk management objectives and policies
The Company’s principal financial liabilities comprise trade payables (current and non-current), lease liabilities, interest-bearing receivables financing, government loans, convertible debt and unsecured related party loan. The Company has various financial assets such as trade receivables, deposits and cash and cash equivalents, which arise directly from its operations, as well as from capital increases.
The main risks arising from the Company’s financial instruments are foreign currency risk, credit risk, interest rate risk and cash flow liquidity risk. The Board of Directors reviews and agrees policies for managing each of these risks which are summarized below.
Foreign currency risk
The Company faces the following foreign currency exposures:
Operating activities, when revenues or expenses are denominated in different currencies from the functional currency of the entity carrying out these transactions.
Government loans are denominated in euros, and lease liabilities are denominated in different currencies while the functional currency of the entity carrying out these transactions is the U.S. dollar.
Non-derivative monetary financial instruments that are denominated and settled in a currency different from the functional currency of the entity which holds them.
Nearly 100% of total revenues and approximately 80% of total cost of sales are denominated in U.S. dollars. However, as a result of significant headcount and related costs from operations in France, which are denominated and settled in euros (the “structural costs”), the Company has transactional currency exposures which can be affected significantly by movements in the US dollar/euro exchange rates. Approximately 57% of operating expense is denominated in euros. (See Note 20.2 regarding hedging arrangements). If there were a 10% increase or decrease in exchange rate of the U.S. dollar to the euro, as measured using the Company's 2023 weighted average exchange rate of one euro = $1.0816, the Company estimates the impact, in absolute terms, on operating expenses and on financial liabilities for the year ended December 31, 2023 would have been approximately $4.2 million.
Credit risk
It is the Company’s policy that all customers who wish to trade on credit terms are subject to credit verification procedures and as such are considered to have low credit risk at initial recognition. The Company has subscribed to a credit insurance policy which provides assistance in determining credit limits and collection, in addition to some coverage of uncollectible amounts. In addition, receivable balances are monitored on an ongoing basis. There is a rebuttable presumption in IFRS 9 that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due. The Company considers that credit risk has not increased significantly on its outstanding not impaired trade receivables since initial recognition. The Company considers events of default based on the specific facts and circumstances relevant to the outstanding amount.
The following table summarizes customers representing a significant portion of the Company’s total revenue:
CustomerCustomer Location% of total revenues for the year ended December 31,Trade receivables at December 31,
  202320222021202320222021
AChina56 %33 %— %3,411,000 3,375,000 — 
BJapan16 %11 %13 %18,000 — 7,736,000 
CGermanyLess than 10%24 %Less than 10%— 3,585,000 3,652,000 
DAmerica— %14 %23 %— — 1,800,000 
ETaiwanLess than 10%Less than 10%23 %26,000 — 545,000 
FChinaLess than 10%Less than 10%14 %945,000 169,500 203,000 
With respect to credit risk arising from the other financial assets, which comprise cash and cash equivalents, the Company’s exposure to credit risk arises from default of the counterparty, with a maximum exposure equal to the carrying amount of these instruments. Nearly all cash and cash equivalents are held in France at three large and international banks.
Vendor concentration risk
Access to foundry capacity is critical to the Company’s operations as a fabless semiconductor company. The Company depends on a sole independent foundry in Taiwan to manufacture its semiconductor wafers. The Company works with three vendors for manufacturing and testing chipsets and three vendors for assembling modules, but typically works with one dedicated vendor per product.
Liquidity risk
The Company monitors its risk of a shortage of funds using a cash flow planning tool. This tool considers the maturity of both its financial investments and financial assets (e.g. accounts receivables, other financial assets) and projected cash flows from operations.
The following table includes our contractual obligations, including interest, for existing financial liabilities as of the following dates:
Within 1
year
1 to 2
years
2 to 3
years
3 to 4
years
4 to 5
years
More
than 5
years
Total
 (in thousands)
At December 31, 2021
Research project financing$1,057 $1,042 $1,684 $— $— $— $3,783 
Interest-bearing receivables financing9,518 — — — — — 9,518 
Government loans1,240 1,573 1,483 1,452 714 — 6,462 
Convertible debt— — 54,623 — — — 54,623 
Lease liabilities1,238 1,043 965 1,052 322 — 4,620 
Trade payables13,916 171 1,477 — — — 15,564 
Other current liabilities9,180 — — — — — 9,180 
$36,149 $3,829 $60,232 $2,504 $1,036 $— $103,750 
At December 31, 2022
Research project financing$1,237 $1,683 $146 $221 $— $— $3,287 
Interest-bearing receivables financing7,723 — — — — — 7,723 
Government loans1,534 1,397 1,367 673 — — 4,971 
Convertible debt (1)
— 54,348 — — — — 54,348 
Lease liabilities1,291 930 1,025 323 — — 3,569 
Trade payables9,342 2,235 — — — — 11,577 
Other current liabilities8,278 — — — — — 8,278 
$29,405 $60,593 $2,538 $1,217 $— $— $93,753 
At December 31, 2023
Research project financing$2,057 $113 $165 $207 $— $— $2,542 
Interest-bearing receivables financing9,544 — — — — — 9,544 
Government loans1,791 1,414 695 — — — 3,900 
Convertible debt52,278 — — — — — 52,278 
Unsecured related party loan8,922 — — — — — 8,922 
Lease liabilities1,471 1,102 387 61 70 25 3,116 
Trade payables16,281 — — — — — 16,281 
Other current liabilities8,899 — — — — — 8,899 
$101,243 $2,629 $1,247 $268 $70 $25 $105,482 
(1) Based on the existing contractual terms as of December 31, 2021 and 2022 and assuming the Company's options to extend maturity dates are exercised.
The Company’s liquidity risk for the next 12 months is described in note 2.1. The term of agreements with strategic partners which gave rise the contract liability recorded in the amount of $5,486,000, $6,178,000 and $10,907,000 as of December 31, 2023, 2022 and 2021, respectively, are described under note 19.
Capital management
The primary objective of the Company’s capital management is to continue to execute according to its business plans and budgets in order to achieve profitability and positive cash flow, and to maximize shareholder value.
Changes in liabilities arising from financing activities, including government grants
(in thousands)January 1, 2021Cash flowsForeign exchange movementAccrued interest
Non-cash impact of amendment and conversion
Other(1)
December 31, 2021
Government grant advances and loans$15,070 592 (449)427 — (80)$15,560 
Convertible debt$26,074 27,957 — 6,193 (16,008)(12,713)$36,373 
Venture debt$8,276 (8,743)180 819 — (532)$— 
Lease liabilities$5,776 $(1,063)$(297)$760 — $(556)$4,620 
Interest-bearing financing of receivables$14,228 21 (337,000)282,000 — (4,676,000)$9,518 
Total$69,424 18,764 (903)8,481 (16,008)(18,557)$66,071 

(in thousands)January 1, 2022Cash flows
Foreign exchange movementAccrued interestNon-cash impact of amendment and conversion
Other(1)

December 31, 2022
Government grant advances and loans$15,560 406 (365)266 — (5,473)$10,394 
Convertible debt$36,373 — — 7,762 (671)(9)$43,455 
Lease liabilities$4,620 (1,205)(298)571 — (119)$3,569 
Interest-bearing financing of receivables$9,518 3,046 (1)254 — (5,094)$7,723 
Total$66,071 2,247 (664)8,853 (671)(10,695)$65,141 
(in thousands)January 1, 2023Cash flowsForeign exchange movementAccrued interestNon-cash impact of amendment and conversion
Other(1)
December 31, 2023
Government grant advances and loans$10,394 (466)182 225 (2,473)$7,862 
Convertible debt$43,455 9,152 (247)(82)$52,278 
Unsecured related party loan— 9,000 — 127 — (205)8,922 
Lease liabilities$3,569 (1,321)113 479 — 276 $3,116 
Interest-bearing financing of receivables$7,723 1,483 179 234 — (191)$9,428 
Total$65,141 8,696 474 10,217 (247)(2,675)$81,606 
(1) In 2021, 2022 and 2023, Other includes additions in lease liabilities, which are non-cash. In 2021, Other includes the liability component and the fair value of the embedded option of the convertible debts converted during the year. In 2021, Other includes the impact of the forgiveness of the government grant advance and of the netting of the interest-bearing financing debt with the Research tax credit receivable.
Financial assets and liabilities
 Carrying amountFair value
 December 31,December 31,
 202120222023202120222023
 (in thousands)
Financial assets:
Trade and other receivables
Trade receivables and contract assets$14,411 $8,670 $8,612 $14,411 $8,670 $8,612 
Deposits and other receivables
Deposits451 436 431 451 436 431 
Other financial assets
Long-term investments357 337 360 357 337 360 
Financial instruments at fair value through other comprehensive income
Cash flow hedges— 142 74 — 142 74 
Cash, cash equivalents and short-term investments4,835 10,671 5,705 4,835 10,671 5,705 
Total financial assets$20,054 $20,256 $15,182 $20,054 $20,256 $15,182 
Total current$19,246 $19,483 $14,391 $19,246 $19,483 $14,391 
Total non-current$808 $773 $791 $808 $773 $791 
Financial liabilities:
Lease liability4,620 3,569 3,116 4,620 3,569 3,116 
Interest-bearing loans and borrowings:
Interest-bearing receivables financing9,518 7,723 9,544 9,518 7,723 9,544 
Convertible debt36,373 43,455 52,278 36,493 42,636 52,111 
Unsecured related party loan— — 8,922 — — 8,922 
Government loans6,001 5,171 4,337 6,001 5,171 4,337 
Research project financing3,868 3,383 2,489 3,868 3,383 2,489 
Convertible debt embedded derivative10,081 3,203 10,081 3,203 
Trade and other payables (current and non current)14,880 11,130 16,281 14,880 11,130 16,281 
Financial instruments at fair value through other comprehensive income
Cash flow hedges50 — — 50 — — 
Total financial liabilities$85,391 $77,634 $96,970 $85,511 $76,815 $96,803 
Total current$27,631 $21,556 $92,484 $27,631 $21,556 $92,317 
Total non-current$57,760 $56,078 $4,486 $57,880 $55,259 $4,486 
The carrying values of current financial instruments (cash and cash equivalents, short-term investments, trade receivables and trade and other payables, and interest-bearing receivables financing) approximate their fair values, due to their short-term nature.
Long-term investments are primarily related to a bank guarantee secured by pledges of investments in money market funds issued in favor of the owners of leased office space to secure annual lease payments by the Company for its office space in Colombes.
Government loans received from the financial agency of the French government were recorded as financial instruments in compliance with IAS 20 Accounting for Government Grants and Disclosure of Government Assistance.
The use of different estimations, methodologies and assumptions could have a material effect on the estimated fair value amounts. The methodologies are as follows:
Cash, cash equivalents, short-term investments, accounts receivable, accounts payable, other receivable and accrued liabilities: due to the short-term nature of these balances, carrying amounts approximate fair value.
Long-term investments are composed of debt-based mutual funds with traded market prices. Their fair values amounted to $357,000, $337,000 and $360,000 at December 31, 2021, 2022 and 2023, respectively. The carrying amounts approximate fair value measured based on significant observable input (Level 2).
Foreign exchange forward and option contracts: the fair values of foreign exchange forward and option contracts were calculated using the market price that the Company would pay or receive to settle the related agreements, by reference to published exchange rates (Level 2).
At December 31, 2021 and 2022, fair value of the debt components of convertibles notes was calculated using the effective interest rate of the debt component of the convertible note issued in April 2021 and amounted to $36,493,000 and $42,636,000, respectively. At December 31, 2023, fair value of the debt components of convertibles notes was calculated using the effective interest rate of the unsecured related party loan issued in November 2023 and amounted to $52,111,000.
As described under Note 14.1, the fair value of the embedded derivative related to the convertible debt is recalculated at the end of each reporting period. The fair value measured is based on significant observable input (Level 3).
Interest-bearing receivable financing, government loans, research project financing and venture debt: carrying amounts approximate fair value.
Fair Value Hierarchy
The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:
Level 1: quoted (unadjusted) prices in active markets for identical assets or liabilities.
Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly.
Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

As at December 31, 2021, the Company held the following financial instruments carried at fair value on the statement of financial position:

Assets measured at fair value
At December 31,
 2021Level 1Level 2Level 3
 (in thousands)
Long-term investments$357 — $357 — 
Liabilities measured at fair value
At December 31,
 2021Level 1Level 2Level 3
 (in thousands)
Convertible debt embedded derivative$10,081 — $10,081 — 
Financial instruments at fair value through other comprehensive income:
Cash flow hedge50 50
As at December 31, 2022, the Company held the following financial instruments carried at fair value on the statement of financial position:
Assets measured at fair value
At December 31,
 2022Level 1Level 2Level 3
 (in thousands)
Long-term investments$337 — $337 — 
Financial instruments at fair value through other comprehensive income:
Cash flow hedge142 142 
Liabilities measured at fair value
At December 31,
 2022Level 1Level 2Level 3
 (in thousands)
Convertible debt embedded derivative$3,203 — $3,203 — 
As of December 31, 2023, the Company held the following financial instruments carried at fair value on the statement of financial position:
Assets measured at fair value
At December 31,
 2023Level 1Level 2Level 3
 (in thousands)
Long-term investments360 — 360 — 
Financial instruments at fair value through profit and loss:
Cash flow hedge74 — 74 — 
Liabilities measured at fair value
At December 31,
 2023Level 1Level 2Level 3
 (in thousands)
Convertible debt embedded derivative— — 
Financial instruments at fair value
The Company uses financial instruments, including derivatives such as foreign currency forward and options contracts, to reduce the foreign exchange risk on cash flows from firm and highly probable commitments denominated in euros.
The following tables present fair values of foreign currency derivative financial instruments at December 31, 2023, 2022 and 2021.
 At December 31, 2021
 Notional AmountFair value
 (in thousands)
Forward contracts (buy euros, sell U.S dollars)5,000 $(50)
Options (buy euros, sell U.S. dollars)— — 
Total5,000 $(50)
 At December 31, 2022
 Notional AmountFair value
 (in thousands)
Forward contracts (buy euros, sell U.S. dollars)3,000 $142 
Options (buy euros, sell U.S. dollars)— — 
Total3,000 $142 
At December 31, 2023
Notional AmountFair value
(in thousands)
Forward contracts (buy euros, sell U.S. dollars)2,000 $74 
Options (buy euros, sell U.S. dollars)— — 
Total2,000 $74 
The fair value of foreign currency related derivatives is included in the Consolidated Statement of Financial Position in "Other receivables" at December 31, 2022 and 2023 and in 'Other current liabilities" at December 31, 2021. The earnings impact of cash flow hedges relating to forecasted operating expense transactions is reported in operating expense. Realized and unrealized gains and losses on these instruments deemed effective for hedge accounting are deferred in accumulated other comprehensive income until the underlying transaction is recognized in earnings or the instruments are designated as hedges.
During the year ended December 31, 2023, the Company recorded a loss of $76,000 (gain of $202,000 and loss of $129,000 for the years ended December 31, 2022 and 2021, respectively) in other comprehensive income (loss) related to the effective portion of the change in fair value of its cash flow hedges. During the years ended December 31, 2021 and 2023, the amount reclassified from other comprehensive income to Consolidated Statement of Operations was gains of $53,000 and $139,000, respectively and loss of $143,000 during the year ended December 31, 2022.
There was no ineffective portion of hedging instruments in the years ended December 31, 2021, 2022 and 2023.
The derivatives have maturity dates of less than 12 months. Management believes counterparty risk on financial instruments is minimal since the Company deals with major banks and financial institutions.
At December 31, 2023, the Company holds $455,000 in currencies other than the U.S. dollar compared with $951,000 at December 31, 2022 and $1,966,000 at December 31, 2021 (See Note 11). The amount received from research tax credit in 2021, 2022 and 2023 denominated in euros. At December 31, 2023, the Company has loans denominated in euros for a principal amount of $12,957,000 ($10,817,000 and $13,525,000 at December 31, 2022 and 2021, respectively).
XML 53 R28.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and contingencies
12 Months Ended
Dec. 31, 2023
Other Provisions, Contingent Liabilities And Contingent Assets Explanatory [Abstract]  
Commitments and contingencies Commitments and contingencies
Contingencies
From time to time, the Company has been and may become involved in legal proceedings arising in the ordinary course of its business.
In 2022, the Company was sued in three lawsuits in the United States District Court for the district of Minnesota by a company called Bell Semiconductor, LLC (“Bell”), accusing the Company of infringing certain U.S. Patents by the Company's use of certain design tools. In Bell Semiconductor, LLC v. Sequans Communications, SA et al, Case No. 0-22-cv-02106 (DMN), filed August 26, 2022, Bell accused the Company of infringing U.S. Patent Nos. 7,149,989 and 7, 260,803. In Bell Semiconductor, LLC v. Sequans Communications, SA et al, Case No. 0-22-cv-02344 (DMN), filed September 23, 2022, Bell accused the Company of infringing U.S. Patent Nos. 6,436,807 and 7,007,259. In Bell Semiconductor, LLC v. Sequans Communications, SA et al, Case No. 0-22-cv-02660 (DMN), filed October 21, 2022, Bell accused the Company of infringing U.S. Patent Nos. 7,231,626 and 7,396,760. The Company filed motions to dismiss in each case. In August 2023, Bell entered into a settlement agreement with supplier of the design tools that Bell asserts infringe the Patents and the three lawsuits against the Company were dismissed. The supplier of the design tools indemnified the Company for all the costs to defend and/or settle the lawsuits. The lawsuits were dismissed in August 2023.
Management is not aware of any other legal proceedings that, if concluded unfavorably, would have a significant impact on the Company's financial position, operations or cash flows.
Bank guarantee
A bank guarantee was issued in favor of the owners of leased office space in France, in order to secure six months of lease payments, for an amount of $348,000 as of December 31, 2023 ($337,000 and $357,000 as of December 31, 2022 and 2021, respectively). This guarantee was secured by the pledge of certificates of deposit and mutual funds for 100% of the amount of the guarantee. The total value of investments secured to cover this bank guarantee was $360,000 at December 31, 2023 ($337,000 and $357,000 at December 31, 2022 and 2021).
Purchase commitments
As of December 31, 2023, the Company had $2.7 million of non-cancelable purchase commitments with its third-party manufacturer and suppliers for future deliveries of equipment and components, principally during 2024.
XML 54 R29.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related party disclosures
12 Months Ended
Dec. 31, 2023
Related Party [Abstract]  
Related party disclosures Related party disclosures
There is no single investor who has the ability to control the Board of Directors or the vote on shareholder resolutions.
As of December 31, 2023, B. Riley Asset Management LLC and Lynrock Lake owned 10% or more of the share capital of the Company. On April 12, 2023, 272 Capital Fund LP, an entity managed by B. Riley Asset Management LLC (“BRAM”) and affiliated with Wes Cummins, a director of the Company and the President of BRAM, purchased 1,310,221 ADSs in the offering. Lynrock Lake also purchased 3,930,663 ADSs. On September 26, 2023, 272 Capital Fund LP purchased 2,120,141 ADSs.
As of December 31, 2022, only B. Riley Asset Management LLC owned 10% or more of the share capital of the Company. On March 11, 2022, 272 Capital Fund LP, an entity managed by B. Riley Asset Management LLC (“BRAM”) and affiliated with Wes Cummins, a director of the Company and the President of BRAM, purchased 2,833,333 ADSs in the offering.
As of December 31, 2021, only Lynrock Lake owned 10% or more of the share capital of the Company. As of December 31, 2022, Lynrock Lake owned 9.8% of the share capital of the Company.
In April 2015, the Company completed the sale of a $12 million convertible note, in April 2016 the sale of a $6.0 million convertible note, in September 2018 the sale of a $4.5 million convertible note, in May 2019 the sale of a $3.0 million convertible note and in August 2019 the sale of a $5.0 million convertible note, all to an affiliate of Nokomis Capital, L.L.C., a beneficial owner of 9.9% of the share capital of the Company as of December 31, 2020. In 2017, the Company amended the terms of the notes issued in 2015 and 2016 and as part of the agreement, Wesley Cummins, a former (as of February 2020) representative of Nokomis Capital, L.L.C., became a board observer in November 2017, and on June 29, 2018, the shareholders approved Mr. Cummins' nomination to the board of directors. Since February 2020, Nokomis no longer has representation on the board of directors and as of December 31, 2022 has declared itself to be no longer an owner of any shares of the Company.
Effective March 20, 2020, the convertible notes issued in April 2015, April 2016, September 2018, May 2019 and August 2019 were amended to grant the Company three options to extend the term of each note, except for the August 2019 which has two options (See Note 14.1).
In December 2020, January 2021 and February 2021, Nokomis converted the April 2015, April 2016 and May 2019 notes (see Note 14.1 Convertible debt). In August 2022, the Company elected to exercise the option to extend the maturity of the August 2019 note to August 2023. In August 2023, the Company elected to exercise the option to extend the maturity of the August 2019 note to April 2024. As of December 31, 2023, the principal amount and accrued interest of the convertible notes held by an affiliate of Nokomis Capital, L.L.C amounts to $6.9 million.
On April 9, 2021, the Company completed the sale of a $40.0 million convertible note with Lynrock Lake Master Fund LP. As of December 31, 2023, the principal amount and accrued interest of the convertible note amounts to $45.4 million.
On February 2, 2021, the board of director approved a consultancy services agreement with ABLE France, a company owned by Yves Maitre, member of the board of directors, for services in business development. The agreement was executed effective March 1, 2021. During the year ended December 31, 2021, $116,000 was paid to Mr. Maitre under the contract. No services were provided and payments were made in the years ended December 31, 2022 and 2023.
At the annual shareholders meeting on June 24, 2022, the shareholders approved the nomination of Dr. Sailesh Chittipeddi, Executive Vice President and Head of IoT and Infrastructure business unit of Renesas to the Board of Directors. As of December 31, 2023, Renesas Electronics Corporation owned 3.20% of the share capital of the Company (4.08% as of December 31, 2022).
On August 4, 2023,the Company entered into a Memorandum of Understanding with Renesas providing that Renesas and the Company engaged in a series of transactions pursuant to which Renesas would seek to acquire (through an affiliate) all of the issued and outstanding ordinary shares of the Company. On February 22, 2024, Renesas notified the Company that Renesas was terminating the Memorandum of Understanding due its receipt of an adverse Japanese tax ruling on February 15, 2024 from the National Tax Agency of Japan. Obtaining a favorable Japanese tax ruling had been one of the closing conditions for the transaction.
On March 19, 2024, Dr. Sailesh Chittipeddi resigned from the Company's Board of Directors.
No other transactions have been entered into with these or any other related parties in 2021, 2022 and 2023, other than normal compensation (including share based payment arrangements) for and reimbursement of expenses incurred in their roles as Directors or employees of the Company.
Compensation of key management personnel
 Year ended December 31,
 202120222023
 (in thousands)
Fixed and variable wages, social charges and benefits expensed in the year$2,837 $2,574 $2,689 
Share-based payment expense for the year2,478 2,903 4,144 
Board members fees to non-executive members210 199 199 
Total compensation expense for key management personnel$5,525 $5,676 $7,032 
Key management personnel comprises the chief executive officer and all executive vice presidents reporting directly to him.
The employment agreement with the chief executive officer calls for the payment of a termination indemnity of an amount equal to eighteen months of his gross annual base remuneration and 150% of bonus in the event of his dismissal without cause by the Board of Directors of the Company, as well as vesting of the ordinary shares that would have been vested during the twelve months following the end of his term. In case the dismissal would occur during the three months before or the twelve months following a change of control, he would be entitled to all the unvested share awards at the date of dismissal.
On July 25, 2023, the board of directors approved a special transaction bonus to Dr. Karam in the amount of €1,000,000 conditional upon the closing the proposed acquisition of the Company by Renesas. The transaction bonus was never paid due of the termination of the proposed transaction by Renesas in February 2024. In addition, on August 15, 2023, the board of directors approved the payment by the Company of legal fees incurred by Dr. Karam in the connection with the negotiation
with Renesas of the conditions of his retention as Chief Executive Officer of the Company upon change of control. A total amount of $50,401 in such legal fees were paid during 2023.
For the year ended December 31, 2023, we estimate that approximately $23,000 of the amounts set aside or accrued to provide pension, retirement or similar benefits to our employees was attributable to our executive officers.
Directors’ interests in an employee share incentive plan
The Company granted warrants to certain members of the Board of Directors during the years ended December 31, 2021, 2022 and 2023:
- On June 25, 2021, the shareholders authorized the Board of Directors to grant to each of Messrs. de Pesquidoux, Maitre, Nottenburg, Pitteloud, Sharma, Slonimsky and Cummins warrants to purchase 140,000 ordinary shares. On June 29, 2021, the Board used this authorization to make such grants with an exercise price of $1.49 per ordinary share.
- On June 24, 2022, the shareholders authorized the Board of Directors to grant to each of Messrs. de Pesquidoux, Maitre, Nottenburg, Pitteloud, Slonimsky and Cummins warrants to purchase 140,000 ordinary shares. On June 24, 2022, the Board used this authorization to make such grants with an exercise price of $0.65 per ordinary share.
- On June 27, 2023, the shareholders authorized the Board of Directors to grant to Mrs Marced Martin and each of Messrs. de Pesquidoux, Maitre, Nottenburg, Pitteloud, Slonimsky and Cummins warrants to purchase 180,000 ordinary shares. On June 27, 2023, the Board used this authorization to make such grants with an exercise price of $0.54 per ordinary share.
The board members were required to subscribe to the warrants at a price of €0.00001 per warrant for the warrants granted in 2023 and €0.00000714 in 2021 and 2022.
Share-based payment expense incurred in connection with these transactions amounted to $292,000 in the year ended December 31, 2023 (2022: $495,000; 2021: $443,000).
XML 55 R30.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Events after the reporting date
Feb. 07, 2023
Disclosure of non-adjusting events after reporting period [abstract]  
Events after the reporting date Events after the reporting date
Subsequent events up to the date the consolidated financial statements were authorized for issue were as follows:
On February 22, 2024, Renesas notified us that Renesas was terminating the MoU due its receipt of an adverse Japanese tax ruling on February 15, 2024 from the National Tax Agency of Japan.
At the meeting of March 5, 2024, the Board of Directors granted to employees 10,060,288 restricted share awards, representing 2,515,072 ADS with vesting over four years.
On March 27, 2024, the Company received a commitment for financing of its 4G eRedCap project for a total of €10.9 million ($12.0 million at the closing period exchange rate) from the French government (operated for the state by Bpifrance) as part of the France 2030 initiative to support the development of technologies deemed to be strategically important to the national interest. An upfront payment of €2.7 million ($3.0 at the closing period exchange rate) was received in April; three milestone payments for the remaining amount are scheduled over the duration of the project.
On April 9, 2024, we secured standstill agreements from our three main debt holders. The agreements granted an initial standstill period until April 26, 2024 that may be further extended subject to certain milestones being met. In late April, the Company began discussions to extend the standstill agreements, which are still in process as of April 30, 2024. The goal of the standstills is to provide sufficient time for the Company to effectively negotiate and finalize a new strategic transaction, thereby securing a long-term solution that aligns with the interests of all stakeholders.
On April 22, 2024, we issued an Unsecured Promissory Note with a principal amount of $5,000,000 to 272 Capital Master Fund, Ltd. The transaction closed on April 24, 2024. The Note bears paid-in kind interest at a rate of 12.0% per annum, compounded annually, with a guaranteed return of 40.0%. The Note matures on the earlier of April 22, 2025, or one day prior to the earliest extended maturity date of the Company’s existing convertible debt held by Lynrock Lake and Nokomis and subordinated notes held by Renesas. The Note contains customary covenants and is subject to customary events of default.
At the meeting of April 30, 2024, the Board of Directors granted to employees 147,776 restricted share awards, representing 36,944 ADS with vesting over four years.
XML 56 R31.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of significant accounting and reporting policies (Policies)
12 Months Ended
Dec. 31, 2023
Corporate information and statement of IFRS compliance [abstract]  
Statement of compliance
Statement of compliance
The Consolidated Financial Statements of the Company have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standard Board (“IASB”) and whose application is mandatory for the year ended December 31, 2023. Comparative figures are presented for December 31, 2021 and 2022.
The accounting policies are consistent with those of the same period of the previous financial year, except for the changes disclosed in Note 2.2 to the Consolidated Financial Statements.
The Consolidated Financial Statements of the Company as of and for the years ended December 31, 2021, 2022 and 2023 have been authorized for issue in accordance with a resolution of the board of directors on April 30, 2024.
Basis of consolidation
Basis of consolidation
The Consolidated Financial Statements comprise the financial statements of Sequans Communications S.A., which is the ultimate parent of the group, and its subsidiaries as of and for the years ended December 31, 2023, 2022 and 2021:
NameCountry of
incorporation
Year of
incorporation
%
equity
interest
Sequans Communications Ltd.United Kingdom2005100 
Sequans Communications Inc.United States2008100 
Sequans Communications Ltd. Pte.Singapore2008100 
Sequans Communications Israel (2009) Ltd.Israel2009100 
Sequans Communications Finland OyFinland2020100 
Sequans Communications SASFrance2023100 
The financial statements of the subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. All intra-group balances, transactions, income and expenses and profits and losses resulting from intra-group transactions are eliminated in full. The subsidiaries have been fully consolidated from their date of incorporation.
New and amended standards and interpretations and Standards issued but not yet effective
New and amended standards and interpretations
The accounting policies used in 2023 are consistent with those of the previous financial year, except for the following new and amended IFRS and IFRIC interpretations effective as of January 1, 2023:
Amendments to IAS 1: Classification of Liabilities as Current or Non-current: In January 2020, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The Company adopted the amendments effective for annual reporting periods beginning on or after January 1, 2022. Adoption of these amendments had no material impact on the Consolidated Financial Statements.
Amendments to IAS 1 and IFRS Practice Statement 2: Disclosure of Accounting Policies: In February 2021, the IASB issued amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements, in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their ‘significant’ accounting policies with a requirement to disclose their ‘material’ accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendments to IAS 1 are applicable for annual periods beginning on or after January 1 2023 with earlier application permitted. Since the amendments to the Practice Statement 2 provide non-mandatory guidance on the application of the definition of material to accounting policy information, an effective date for these amendments is not necessary. The amendments had no material impact on the Company.
Amendments to IAS 8: Definition of Accounting Estimates: In February 2021, the IASB issued amendments to IAS 8, in which it introduces a definition of ‘accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, they clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 and apply to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. Earlier application is permitted as long as this fact is disclosed. The amendments had no material impact on the Company.
Amendments to IAS 12: Deferred Tax related to Assets and Liabilities arising from a Single Transaction: In May 2021, the Board issued amendments to IAS 12, which narrow the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments should be applied to transactions that occur on or after the beginning of the earliest comparative period presented. In addition, at the beginning of the earliest comparative period presented, a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability should also be recognized for all deductible and taxable temporary differences associated with leases and decommissioning obligations. The amendments had no material impact on the Company.
Standards issued but not yet effective
Standards issued but not yet effective
Standards and interpretations issued but not yet effective up to the date of issue of the Company’s Consolidated Financial Statements are listed below. The Company intends to adopt these standards when they become effective:
Amendments to IFRS 16: Lease Liability in a Sale and Leaseback. In September 2022, the IASB issued amendments to IFRS 16 to specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction, to ensure the seller-lessee does not recognize any amount of the gain or loss that relates to the right of use it retains. The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and must applied retrospectively to sale and leaseback transactions entered into after the date of initial application of IFRS 16. Earlier application is permitted and that fact must be disclosed.The amendments are not expected to have a material impact on the Company’s financial statements.

Amendments to IAS 1: Classification of Liabilities as Current or Non-current. In January 2020 and October 2022, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify:
What is meant by a right to defer settlement
That a right to defer must exist at the end of the reporting period
That classification is unaffected by the likelihood that an entity will exercise its deferral right
That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification
In addition, a requirement has been introduced to require disclosure when a liability arising from a loan agreement is classified as non-current and the entity’s right to defer settlement is contingent on compliance with future covenants within twelve months.
The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and must be applied retrospectively. The Company is currently assessing the impact the amendments will have on current practice and whether existing loan agreements may require renegotiation.

Supplier Finance Arrangements - Amendments to IAS 7 and IFRS 7. In May 2023, the IASB issued amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures to clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity’s liabilities, cash flows and exposure to liquidity risk. The amendments will be effective for annual reporting periods beginning on or after 1 January 2024. Early adoption is permitted, but will need to be disclosed. The amendments are not expected to have a material impact on the Company’s financial statements.

COVID-19
Management has considered what effect the COVID-19 pandemic has on the amounts recognized in the financial statements. Management has identified potential risks related to the impact on the production of the Company's products, on the Company's ability to source components required for production and on the demand for the Company's products by customers impacted by the pandemic. In the year ended December 31, 2021, the primary impacts on operations of the COVID-19 pandemic were increased product demand in the broadband IoT business, increases in certain costs related to a temporary shortage of components, and delays in growth in product revenues in the massive IoT business due to the limits
placed on production capacity driven by the component shortages. During 2022 and 2023, the Company did not identify any direct impact of the pandemic on its business. As of December 31, 2023, the Company has not identified any impact on its assets and liabilities.

Russian invasion in Ukraine
While the Company's key engineering competencies are performed in-house, primarily in France, the United Kingdom, Israel and the United States, the Company outsources some application software development and testing activities to an independent third-party provider of engineering services. The Company works with a dedicated team of 48 software engineers based in Kyiv, Ukraine. If the Russian invasion of Ukraine is protracted or if Ukraine experiences further political instability, these engineers may be unable to work for a sustained period of time, which could adversely impact the research and development operations. The Company has developed a contingency plan if the engineers in Kyiv are unable to continue working on their projects for us for a sustained period of time, but if the contingency plan is not effective or sanctions are imposed that prevent the Company from conducting business in Ukraine, the Company could suffer delays in product introduction or delays in resolution of customer software bugs, which could have a negative impact on its revenues. During 2022 and 2023, the Ukraine team was able to work effectively and the Company did not identify any direct impact from the situation on its business. As of December 31, 2023, the Company has not identified any impact on its assets and liabilities.
Functional currencies and translation of financial statements denominated in currencies other than the U.S. dollar
Functional currencies and translation of financial statements denominated in currencies other than the U.S. dollar
The Consolidated Financial Statements are presented in U.S. dollars, which is also the functional currency of Sequans Communications S.A. The Company uses the U.S. dollar as its functional currency due to the high percentage of revenues, cost of revenue, capital expenditures and operating costs, other than those related to headcount and overhead, which are denominated in U.S. dollars. Each subsidiary determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency.
As at the reporting date, the assets and liabilities of each subsidiary are translated into the presentation currency of the Company (the U.S. dollar) at the rate of exchange in effect at the Statement of Financial Position date and their Statement of Operations is translated at the weighted average exchange rate for the reporting period. The exchange differences arising on the translation are taken directly to a separate component of equity (“Cumulative translation adjustments”).
Foreign currency transactions
Foreign currency transactions
Foreign currency transactions are initially recognized by Sequans Communications S.A. and each of its subsidiaries at their respective functional currency rates prevailing at the date of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency spot rate of exchange in effect at the reporting date. All differences are taken to the Consolidated Statement of Operations within financial income or expense. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the initial transactions.
Earnings (loss) per share
Earnings (loss) per ordinary share and per ADS
Basic earnings (loss) amounts per ordinary share and per ADS are computed using the weighted average number of shares outstanding during each period.
Diluted earnings per ordinary share and per ADS include the effects of dilutive options and warrants as if they had been exercised, unless the effect would be anti-dilutive.
Revenue recognition
Revenue recognition
The Company’s total revenue consists of product revenue and services and license revenue.
Revenue from contracts with customers is recognized when control of the goods or services is transferred to the customer at an amount that reflects the fair value of the consideration to which the Company is entitled, excluding sales taxes or duties.
The Company applies a five-step approach in determining the amount and timing of revenue to be recognized: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when the performance obligation is satisfied.
When a contract includes multiple promised goods and services, the Company evaluates each component to determine whether they represent separate performance obligations and determines the appropriate allocation of the contract consideration to each identified performance obligation based on estimated relative stand-alone selling prices.
If the consideration in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the goods or services to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved. Specifically, milestone payments in development services contracts represent variable consideration, the receipt of which is dependent upon the achievement of technical milestones.
The Company sometimes receives advance payments from customers for the provision of development services. The Company determines if there is a significant financing component for these contracts considering the length of time between the customers’ payment and the transfer of control of the goods and services. When a significant financing component has been identified, the transaction price for these contracts is discounted, using the rate that would be reflected in a separate financing transaction at contract inception. The Company applies the practical expedient for short-term advances received from customers. That is, the promised amount of consideration is not adjusted for the effects of a significant financing component if the period between the transfer of the promised good or service and the payment is one year or less.
Product revenue
Substantially all of the Company’s product revenue is derived from the sale of semiconductor solutions for 4G wireless applications.
Revenue from the sale of products is usually recognized at a point in time when the Company satisfies its performance obligation to the buyer, whether direct end customer, end customer's manufacturing partner or distributor. This occurs when there is no continuing managerial involvement to the degree usually associated with ownership nor effective control over the sale of products is retained, which is based on the specified Incoterms, but usually occurs on shipment of the goods. Sale of products to some distributors is recognized when the products are sold to the end-customer but these contracts are not significant. The Company is the principal in all product sales regardless of customer type. Products are not sold with a right of return but are covered by warranty. This is an assurance-type warranty. The Company does not accrue for a general warranty obligation as the Company has not historically incurred and does not expect material warranty costs. Although the products sold have embedded software, the Company believes that software is incidental to the products it sells.
License and services revenue
License and services revenue consists of revenues from the sale of licenses to use the Company’s technology solutions and any fees for the associated annual software maintenance and support services, as well as from the sale of technical support and development services. Development services include advanced technology development services for technology partners and software or product development and integration services for customers.
Revenue from the sale of licenses is recognized at a point in time when the Company satisfies its performance obligation which occurs when the software has been delivered to the customer (assuming no other significant obligations exist), as licenses provide the right to use the software as it exists when made available to the customer.
Revenue from the sale of software maintenance and support services is recognized over the period of the maintenance (generally one year). When the first year of maintenance is included in the software license price, an amount generally equal to the negotiated rate for one year of maintenance is deducted from the value of the license and recognized as revenue over the period of maintenance as described above. The difference between license and maintenance services invoiced and the amount recognized in revenue is recorded as deferred revenue.
Revenue from technical support and development services is generally recognized over time using the percentage-of-completion method. For each service contract, the Company determines whether the pattern of transfer of control meets one of the criteria for revenue recognition over time: (a) the customer simultaneously receives and consumes the benefits provided by the entity's performance as the entity performs (b) the Company's performance creates or enhances an asset (for example, work in progress) that the customer controls as the asset is created or enhanced or (c) the Company's performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. Generally, the support and development contracts meet one or more of these criteria, based on the facts and circumstances both within the contract and the nature of the services provided. Typically, the customers consume the services as they are provided through ongoing technical support or through an iterative development process. Certain contracts also include terms which allow the customer to have control over the asset as it is created or provide Sequans the right to payment for all work performed to date.
Due to revenue recognition over time, contract assets are created for services provided that Sequans does not yet have the right to invoice. Contract liabilities are created when milestones are billed in advance of being earned.
When a contract does not meet one of the criteria above, revenue is recognized at a point in time, when there is evidence of transfer of control, which typically occurs upon achievement of certain or all contract milestones. Percentage-of-completion is calculated based on the input method using estimated costs as a measure of performance completed.
The costs associated with these arrangements are recognized as incurred. Revenue from development contracts where no related direct costs were identified amounted to $214,000 for the year ended December 31, 2023 ($236,000 in 2022 and no direct cost in 2021).
Revenue recognition
The Company’s policy for revenue recognition, in instances where multiple deliverables are sold contemporaneously to the same counterparty, is in accordance with IFRS 15 Revenue from contracts with customers. The application of IFRS 15 to contracts with customers requires management to make certain judgments, the most significant of which are outlined below. These judgments are based on an analysis of the facts and circumstances surrounding the transactions on a contract-by-contract basis.
Determination of performance obligations within a contract
The Company applies judgment in determining whether a promised good or service is a performance obligation under the terms of the contract and whether multiple promised goods or services should be accounted for separately or together as a bundle.
Allocation of contract consideration to distinct performance obligations based on their relative stand-alone selling prices
Typically, contracts state the value of individual promised goods and services directly. However, in instances where the fair value is not observable, management applies judgment in determining the relative stand-alone selling price for goods and services.
Estimation of percentage-of-completion based on the input method
For service contracts that are recognized over time based on the percentage-of-completion, the Company sets up an initial budget at contract inception and tracks the progress to completion based on time and costs incurred by the employees directly working on each project. Management reviews the progress and performance of open contracts in order to determine the best estimate of estimated costs at completion on a quarterly basis and updates the revenue recognized as necessary.
Cost of revenue
Cost of revenue
Cost of product revenue includes all direct and indirect costs incurred with the sale of products, including shipping and handling. Cost of services revenue includes direct costs incurred to support the obligations covered by development services contracts (mainly employees and subcontractors costs). Research and development costs associated with product development (including normal customer support which generates product improvement) are recorded in research and development expenses.
Research and development costs
Research and development costs
Research costs are expensed as incurred. Development costs are recognized as an intangible asset if the Company can demonstrate:
the technical feasibility of completing the intangible asset so that it will be available for use or sale;
its intention to complete the asset and use or sell it;
its ability to use or sell the asset;
how the asset will generate future economic benefits;
the availability of adequate resources to complete the development and to use or sell the asset; and
the ability to measure reliably the expenditure during development.
Beginning in 2015, certain development costs incurred at the end of the product development cycle when the criteria for capitalization are met, became material as the Company began making its product available on more operator networks which require significant testing and qualification work in order to finalize the product for sale on that network. In 2021, the Company capitalized costs for the development of the chipsets for LTE NB-IoT (the Monarch 2). In 2021, 2022 and 2023, the Company also capitalized costs for the development for LTE Category 1 and the development of the 5G chipsets. The intangible assets are tested for impairment annually. (See Notes 4.4 and 8 to the Consolidated Financial Statements).
Research and development costs associated with product development (including normal customer support which generates product improvements) are recorded in operating expense. In some cases, the Company has negotiated agreements with customers and partners whereby the Company provides certain development services beyond its normal practices or planned product roadmap. Amounts received from these agreements are recorded in services revenue. Direct costs incurred by the Company as a result of the commitments in the agreements are recorded in cost of revenue. Other research and development costs related to the projects covered by the agreements, but which would have been incurred by the Company without the existence of such agreements are recorded in research and development expense.
Government grants, loans and research tax credits
Government grants, loans and research tax credits
The Company operates in certain jurisdictions which offer government grants or other incentives based on the qualifying research expense incurred or to be incurred in that jurisdiction. These incentives are recognized as the qualifying research expense is incurred if there is reasonable assurance that all related conditions will be complied with and the grant will be received. When the grant relates to an expense item, it is recognized as a reduction of the related expense over the period necessary to match the grant on a systematic basis to the costs that it is intended to compensate. Any cash received in advance of the expenses being incurred is recorded as a liability.
Some long-term research projects are also financed through low-interest forgivable loans. The present value of forgivable loans is calculated based on expected future payments discounted using the interest rate applied for standard loans with the same maturity. The difference between present value and amount received is accounted for as a grant.
Where loans or similar assistance provided by governments or related institutions are interest-free, the present value is calculated based on expected future payments discounted using the interest rate applied for standard loans with the same maturity. The difference between present value and amount received is accounted for as a grant.
The Company also benefits from research incentives in the form of tax credits which are detailed in Note 4.4 to the Consolidated Financial Statements. When the incentive is available only as a reduction of taxes owed, such incentive is accounted for as a reduction of tax expense; otherwise, it is accounted for as a government grant with the benefit recorded as a reduction of research and development costs, whether capitalized or expensed.
Financial income and expense
Financial income and expense
Financial income and expense include:
interest expense related to accounts receivable financing, the debt component of convertible debt, bridge loans, government loans, lease contracts, upfront payments, financing components of customer contracts and a supplier payable with extended payment terms;
other expenses paid to financial institutions for financing operations;
foreign exchange gains and losses;
change in fair value of financial assets and liabilities
impact of convertible debt amendments; and
impact of convertible debt reimbursement.
The Company reflects foreign exchange gains and losses related to hedges (through derivatives) of euro-based operating expenses in operating expenses.
Current income tax
Current income tax
Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date.
Deferred income tax
Deferred income tax
Deferred income tax is provided using the liability method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.
Deferred income tax liabilities are recognized for all taxable temporary differences, except with respect to taxable temporary differences associated with investments in subsidiaries where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.
Deferred income tax assets are recognized for all deductible temporary differences, carry forwards of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forwards of unused tax credits and unused tax losses can be utilized.
The carrying amount of deferred income tax assets is reviewed at the reporting date and adjusted to the extent that it is probable that sufficient future taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.
Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the statement of financial position date.
Deferred income tax relating to items recognized directly in equity is recognized in equity.
Deferred income tax assets and deferred income tax liabilities are offset if a legally enforceable right of offset exists.
Value added tax
Value added tax
Revenue, expenses and assets are recognized net of the amount of value added tax except:
where the value added tax incurred on a purchase of assets or services is not recoverable from the tax authorities, in which case the value added tax is recognized as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
receivables and payables that are stated with the amount of value added tax included.
Value added tax recoverable consists of value added tax paid by the Company to vendors and suppliers located in the European Union, in the United Kingdom and in Israel, and recoverable from the tax authorities. Value added tax recoverable is collected on a monthly or quarterly basis.
Inventories nventories
Inventories consist primarily of the cost of semiconductors, including wafer fabrication, assembly, testing and packaging; components; and modules purchased from subcontractors. Inventories are valued at the lower of cost (determined using the weighted average cost method) or net realizable value (estimated market value less estimated cost of completion and the estimated costs necessary to make the sale).
The Company writes down the carrying value of its inventories for estimated amounts related to the lower of cost or net realizable value, obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated net realizable value. The estimated net realizable value of the inventory is based on historical usage and assumptions about future demand, future product purchase commitments, estimated manufacturing yield levels and market conditions on a product-by-product basis. When the circumstances that previously caused inventories to be written down below cost no longer exist or when there is clear evidence of an increase in net realizable value because of changed economic circumstances, the amount of the write-down is reversed (i.e. the reversal is limited to the amount of the original write-down) so that the new carrying amount is the lower of the cost and the revised net realizable value.
Inventories
As disclosed in Note 2.3 to the Consolidated Financial Statements, the Company writes down the carrying value of its inventory to the lower of cost or net realizable value. The estimated net realizable value of the inventory is based on historical usage and assumptions about future demand, future product purchase commitments, estimated manufacturing yield levels and market conditions on a product-by-product basis. Actual demand may differ from the forecast established by the Company, which may materially impact recorded inventory values and cost of revenue.
Financial assets
Financial assets
Financial assets are classified, at initial recognition, as (1) measured at amortized cost, (2) fair value through other comprehensive income (OCI), or (3) fair value through profit or loss. The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and Sequans’ business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value.
Receivables
Trade receivables are measured at amortized cost. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take into account the risk of payment default throughout the lifetime of the receivables. Based on an analysis of historical credit losses, the Company has not applied any expected credit losses to its outstanding receivables as of the reporting date beyond specific provisions for doubtful accounts. The Company records an allowance for any specific account it considers as doubtful based on the particular circumstances of the account. The carrying amount of the receivable is thus reduced through the use of an allowance account, and the amount of the charge is recognized on the line “General and administrative expenses” in the Consolidated Statement of Operations. Subsequent recoveries, if any, of amounts previously provided for are credited against the same line in the Consolidated Statement of Operations. When a trade accounts receivable is uncollectible, it is written-off against the allowance account for trade accounts receivable.
Short-term investments
Short-term investments are financial instruments with an initial maturity of greater than 90 days, but less than one year, and are reported as current financial assets.
Deposits
Deposits are reported as non-current financial assets (loans and receivables) when their initial maturity is more than twelve months.
Cash and cash equivalents
Cash and cash equivalents
Cash and cash equivalents in the Consolidated Statements of Financial Position includes cash at banks, term deposits and money market funds, which correspond to highly liquid investments readily convertible to known amounts of cash and subject to an insignificant risk of change in value.
Property, plant and equipment
Property, plant and equipment
Property, plant and equipment is stated at cost less accumulated depreciation and any accumulated impairment loss. Depreciation is computed using the straight-line method over the estimated useful lives of each component. The Company presents right-of-use of lease contracts in property, plant and equipment and right of use assets are depreciated on a straight-line basis over the lease term. The useful lives most commonly used are the following:
Machinery and equipment  3 to 5 years
Building and leasehold improvements  Lesser of 6 years or the life of the lease
Computer equipment  3 years
Furniture and office equipment  5 years
Impairment tests are performed whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If any indication exists, the Company estimates the asset’s recoverable amount, which is the higher of the fair value less cost to sell and the value in use. Where the carrying amount exceeds that recoverable amount, the asset is considered impaired and it is written down to its recoverable amount.
Depreciation expense is recorded in cost of revenue or operating expenses, based on the function of the underlying assets.
Intangible assets
Intangible assets
Intangible assets, which primarily consist of purchased licenses for development or production technology and tools, as well as standard-related patent licenses and development costs meeting the criteria for capitalization, are stated at cost less accumulated amortization and any accumulated impairment loss. Amortization is computed using the straight-line method over the estimated useful life of each component. Acquired licenses are amortized over their contractual life or five years in the case of perpetual licenses. Capitalized development costs are generally amortized over periods ranging from 3 to 5 years, representing the expected life of the related technology.
Useful lives are reviewed on a regular basis and changes in estimates, when relevant, are accounted for on a prospective basis. The amortization expense is recorded in cost of revenue or operating expenses, based on the function of the underlying assets.
Impairment tests are performed whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If any indication exists, the Company estimates the asset’s recoverable amount, which is the higher of the fair value less cost to sell and the value in use. Where the carrying amount exceeds that recoverable amount, the asset is considered impaired and it is written down to its recoverable amount.
Leases
Lease contracts
Except for leases related to low-value assets and short-term lease, lease contracts, as defined under IFRS 16 "Leases", are recorded in the Statement of Consolidated Financial Position, through the recognition of:
an asset representing a right-of-use of the asset leased during the lease term of the contract; and
a liability related to the payment obligation.
At the commencement date of the lease, the Company recognizes a lease liability measured at the present value of the remaining lease payments to be made over the lease term, discounted using the Company’s incremental borrowing rate. The liability increases by the accrued interest resulting from the initial discounting of the lease liability and decreases by the payments made.
Right-of-use assets are depreciated on a straight-line basis over the lease term and tested for impairment when required.
Costs of Public Offerings
Costs of equity transactions
Incremental costs directly attributable to the equity transaction are recorded as a deduction from equity.
Provisions
Provisions
Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event for which it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in operating income (loss) net of any reimbursement.
Provisions include the provision for pensions and post-employment benefits. Pension funds in favor of employees are maintained in France, the United Kingdom, Singapore, the United States, Finland and Israel, and they comply with the respective legislation in each country and are financially independent of the Company. The pension funds are generally financed by employer and employee contributions and are accounted for as defined contribution plans with the employer contributions recognized as expense as incurred. There are no actuarial liabilities in connection with these plans.
French law also requires payment of a lump sum retirement indemnity to employees based on years of service and annual compensation at retirement. Benefits do not vest prior to retirement. This defined benefit plan is self-funded by the Company. It is calculated as the present value of estimated future benefits to be paid, applying the projected unit credit method whereby each period of service is seen as giving rise to an additional unit of benefit entitlement, each unit being measured separately to build up the final obligation. Following the application of IAS 19 as revised, actuarial gains and losses are recognized in equity. The discount rate is based on iBoxx Corporates AA. Since January 1, 2021, the Company has applied the IFRS IC decision on IAS 19 - Employee benefits which revised the methods for calculating commitments for defined benefit plans. In accordance with the adoption elected, Sequans has applied the full retrospective transition method.
Share-based payment transactions
Share-based payment transactions
Employees (including senior executives and members of the board of directors) and certain service providers of the Company receive remuneration in the form of share-based payment transactions, whereby they render services as consideration for equity instruments (“equity-settled transactions”).
The cost of equity-settled transactions is measured by reference to the fair value at the date on which they are granted. The exercise price is based on closing market price on the date of grant.
The cost of equity-settled transactions is recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the beneficiary becomes fully entitled to the award (the “vesting date”). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest which includes assumptions on the number of awards to be forfeited due to the employees’ failing to fulfill the service condition, and forfeitures following the non-completion of performance conditions. The Consolidated Statement of Operations charge or credit for a period represents the movement in cumulative expense recognized as at the beginning and end of that period.
Share-based compensation
As disclosed in Note 13 to the Consolidated Financial Statements, the Company has various share-based compensation plans for employees and non-employees that may be affected, as to the expense recorded in the Consolidated Statements of Operations, by changes in valuation assumptions. Fair value of stock options is estimated by using the binomial model on the date of grant based on certain assumptions, including, among others expected volatility, the expected option term, the risk-free interest rate and the expected dividend payout rate. The fair value of the Company’s shares underlying stock option grants equals the closing price on the New York Stock Exchange on the date of grant.
Financial liabilities
Financial liabilities
Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.
All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings, net of directly attributable transaction costs.
Non derivative financial liabilities are subsequently measured at amortized cost whereas derivative liabilities not designated as hedging instruments are recognized at fair value through profit or loss.
Convertible debt
The Company evaluates at initial recognition of a convertible debt the different components and features of the hybrid instruments and determines whether these elements are equity instruments or embedded derivatives which require bifurcation. In subsequent periods, the liability component is accounted for using the effective interest method, based on the expected maturity of the debt. The equity component is not remeasured, while embedded derivatives unless closely related to the host instruments, are recorded at fair value through the Consolidated Statement of Operations.
As described in Note 14.1 to the Consolidated Financial Statements, the Company issued debt with an option to convert into shares of the Company in April 2015, April 2016, October 2017 and September 2018. The convertible notes were amended several times to extend term of the notes and reduce conversion rates.
On March 20, 2020, the convertible notes issued in April 2015, April 2016, September 2018, May 2019 and August 2019 were amended to grant the Company three options to extend the term of each note, except for the August 2019 notes which have two options. Each option will give the Company the right to extend the term of such note by one year and consequently reset the conversion price to a 20% premium above the 20-day volume weighted average price (VWAP) if it is lower than the existing conversion price. On the first option exercise, the payment-in-kind interest (PIK) will stay at 7% but the holder will be granted a warrant for 10% of the value of the note with a three-year term, at an exercise price of 20% premium above 20-day VWAP. On the second option exercise, the PIK will be adjusted to 9.5%, the previous warrants granted on the first option exercise will be extended by one year and the holder will be granted an additional warrant for 15% of the value of the note with a three year term, at an exercise price of 20% premium above 20-day VWAP. On the third option exercise, the PIK will be adjusted to 13.5%, and the holder will be granted an additional warrant for 20% of the value of the note with a three year term, at an
exercise price of 20% premium above 20-day VWAP. If at any time, the holder converts a note prior to the date of April 2022, it will receive an extra year’s worth of PIK so as to incentivize early conversion. In consideration for entering into the amendments, the warrants that noteholder owns that were scheduled to expire April 2021 were extended to April 2024 upon the signing of the note amendments.
From an accounting perspective, the amendment of the convertible notes resulted in the extinguishment of the existing notes and issuance of five new notes, accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the notes in cash; and
An embedded derivative, which reflects the Company's call options to extend the term of each note, the conversion option of Nokomis and in certain cases a repricing to decrease the conversion price.
The change in the liability component before and after the amendment was recorded in the Consolidated Statement of Operations in “Convertible debt amendments”.
The fair value of the liability component on the amendment date represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 26.3% as the market rate of interest in order to value the liability components.

The embedded derivatives of the notes were valued using the Geometric Brownian Motion framework relying on Monte-Carlo simulations. On March 20, 2020, the initial fair value of the embedded derivative of the notes was recorded in Other Capital reserves in shareholders' equity. The change in fair value is remeasured and recorded in the Consolidated Statement of Operations as financial income or loss at each statement of financial position date.

On April 9, 2021, the Company issued a note with options to convert into shares of the Company, limited to such conversion resulting in the noteholder owning more than 10% of the Company's outstanding shares. The Company retains an option to call the convertible debt under certain circumstances after 12 months, either in full or in part. If a change of control occurs at any time prior to the payment of the note in full, the noteholder shall have the right, in its sole discretion, to require Sequans to convert or redeem all of the outstanding principal amount (including accrued interest and unpaid interest).
As described in Note 14.1, the note was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the bonds in cash; and
An embedded derivative, which reflects the value of the conversion option.
The initial fair value of the notes was split between these two components.
The fair value of the liability component on the issuance date represented the fair value of a similar liability that does not have an associated equity conversion feature, calculated as the net present value of contractually determined future cash flows, discounted at the rate of interest applied by the market at the time of issue to instruments of comparable credit status and providing substantially the same cash flows, on the same terms, but without the conversion option. The Company used 20.89% as the market rate of interest in order to value the liability components of the note on issuance. The embedded derivative of the note was valued using the Geometric Brownian Motion framework relying on Monte-Carlo simulations. The change in fair value is remeasured and recorded as financial income or loss at each statement of financial position date.
On August 15, 2022, the Company elected to exercise the first option of the amendment signed on March 20, 2020 to extend the maturity of the convertible note issued in August 2019 to August 16, 2023. On August 15, 2023, the Company elected to exercise the second option of the amendment to extend the maturity of the convertible note to April 16, 2024. This resulted in the extinguishment of the existing note and issuance of a new note for accounting purposes. Therefore, the fair value of the debt just prior to amendment was estimated in order to record a gain on extinguishment in the Consolidated Statement of Operations in “Convertible debt amendments. The amended debt was accounted for as compound financial instruments with two components:
A liability component reflecting the Company’s contractual obligation to pay interest and redeem the notes in cash; and
An embedded derivative, which reflects the value of the conversion option.
In early April 2024, both note holders agreed to stay repayment of the notes until April 26, 2024. In late April, the Company began discussions to extend the standstill agreements, which are still in process as of April 30, 2024.
Short-term debt secured by accounts receivables
As described in Note 14.3 to the Consolidated Financial Statements, the Company has a factoring agreement with a French financial institution. The Company transfers to the finance company all invoices issued to qualifying customers, and the customers are instructed to settle the invoices directly with the finance company. Because there is recourse to the Company for amounts that are overdue, the Company retains all receivables on its Consolidated Statement of Financial Position until they are paid and any amounts drawn on the line of credit are reflected in short-term debt. The Company pays a commission on the face value of the accounts receivable submitted, which is recorded in General and Administration expense, and pays interest on any draw-down of the resulting line of credit.
In February 2021, the Company entered into an agreement to finance the 2021 research tax credit as it is earned over the year. The Company transfers to the finance company research tax credit receivable on a quarterly basis. Because there is recourse to the Company for amount not paid by the French tax administration, the Company retains all receivables on its Consolidated Statement of Financial Position until the French tax administration reimburses the finance company. Amounts drawn on the line of credit are reflected in short-term debt and commissions in the Consolidated Statement of Operations as financial expense. In March 2022, the Company entered into another agreement to finance the 2022 research tax credit, and in March 2023, the Company agreed to finance the 2023 research tax credit.
Derivative financial instruments and hedge accounting
Derivative financial instruments and hedge accounting
The Company uses financial instruments, including derivatives such as foreign currency forward and options contracts, to reduce the foreign exchange risk on cash flows from firm and highly probable commitments denominated in euros. The effective portion of the gain or loss on the hedging instrument is recognized directly as other comprehensive income (loss) in the cash flow hedge reserve, while any ineffective portion is immediately accounted for in financial results in the Consolidated Statement of Operations. Amounts recognized as other comprehensive income (loss) are transferred to the Consolidated Statement of Operations when the hedged transaction affects profit or loss. If the forecasted transaction is no longer expected to occur, the cumulative gain or loss previously recognized in equity is transferred to the Consolidated Statement of Operations.
All derivative financial instruments are recorded at fair value. Changes in fair value are recorded in current earnings or other comprehensive income (loss), depending on whether the derivative is designated as a hedge, its effectiveness as a hedge, and the type of hedge transaction. Any change in the fair value of the derivatives deemed ineffective as a hedge is immediately recognized in earnings.
Commitments
Commitments
Commitments comprise primarily purchase commitments with third-party manufacturers for future deliveries of equipment and components, which are described in Note 21 to the Consolidated Financial Statements.
Significant accounting judgments, estimates and assumptions
In the process of applying the Company’s accounting policies, management must make judgments and estimates involving assumptions. These judgments and estimates can have a significant effect on the amounts recognized in the financial statements and the Company reviews them on an ongoing basis taking into consideration past experience and other relevant factors. The evolution of the judgments and assumptions underlying estimates could cause a material adjustment to the carrying amounts of assets and liabilities as recognized in the financial statements. The most significant management judgments and assumptions in the preparation of these financial statements are:
Revenue recognition
The Company’s policy for revenue recognition, in instances where multiple deliverables are sold contemporaneously to the same counterparty, is in accordance with IFRS 15 Revenue from contracts with customers. The application of IFRS 15 to contracts with customers requires management to make certain judgments, the most significant of which are outlined below. These judgments are based on an analysis of the facts and circumstances surrounding the transactions on a contract-by-contract basis.
Determination of performance obligations within a contract
The Company applies judgment in determining whether a promised good or service is a performance obligation under the terms of the contract and whether multiple promised goods or services should be accounted for separately or together as a bundle.
Allocation of contract consideration to distinct performance obligations based on their relative stand-alone selling prices
Typically, contracts state the value of individual promised goods and services directly. However, in instances where the fair value is not observable, management applies judgment in determining the relative stand-alone selling price for goods and services.
Estimation of percentage-of-completion based on the input method
For service contracts that are recognized over time based on the percentage-of-completion, the Company sets up an initial budget at contract inception and tracks the progress to completion based on time and costs incurred by the employees directly working on each project. Management reviews the progress and performance of open contracts in order to determine the best estimate of estimated costs at completion on a quarterly basis and updates the revenue recognized as necessary.
Trade receivables
The Company records an allowance for any specific account it considers as doubtful based on the particular circumstances of the account. Additional allowances could be required if the Company receives information that the financial condition of its customers has deteriorated, resulting in an impairment of their ability to make payments, or there are indicators that amounts receivable will become uncollectible.
Inventories
As disclosed in Note 2.3 to the Consolidated Financial Statements, the Company writes down the carrying value of its inventory to the lower of cost or net realizable value. The estimated net realizable value of the inventory is based on historical usage and assumptions about future demand, future product purchase commitments, estimated manufacturing yield levels and market conditions on a product-by-product basis. Actual demand may differ from the forecast established by the Company, which may materially impact recorded inventory values and cost of revenue.
Share-based compensation
As disclosed in Note 13 to the Consolidated Financial Statements, the Company has various share-based compensation plans for employees and non-employees that may be affected, as to the expense recorded in the Consolidated Statements of Operations, by changes in valuation assumptions. Fair value of stock options is estimated by using the binomial model on the date of grant based on certain assumptions, including, among others expected volatility, the expected option term, the risk-free interest rate and the expected dividend payout rate. The fair value of the Company’s shares underlying stock option grants equals the closing price on the New York Stock Exchange on the date of grant.
Fair value of financial instruments
Fair value corresponds to the quoted price for listed financial assets and liabilities. The Company determined that the fair values of cash, trade receivables and trade payables approximate their carrying amounts largely due to the short-term maturities of these instruments.
Where no active market exists, the Company establishes fair value by using a valuation technique determined to be the most appropriate in the circumstances.
Regarding compound debt instruments, the fair value of debt component was determined at the date of issuance using a valuation model that requires judgment, including estimating the change in value of the Company at different dates and market yields applicable to the Company’s straight debt (without the conversion option). The assumptions used in calculating the value of the conversion option, the expected volatility of the Company’s underlying stock price which has experienced fluctuations, and the market discount rate, represent the Company’s best estimates based on management’s judgment and subjective future expectations. The fair value of debt component were supported by work performed by an independent valuation specialist engaged by the Company.
Research and Development Costs
Costs incurred internally in research and development activities are charged to expense until technological feasibility has been established for the project. Once technological feasibility is established, development costs are capitalized until the product is available for general release to customers. Judgment is required in determining when technological feasibility of a product is established. We have determined that technological feasibility for our software products is reached after all high-risk development issues have been resolved. Generally, this occurs when the preliminary design review has been done.
Leases
The application of IFRS 16 “Leases” requires the Company to make assumptions and estimates in order to determine the value of the right-of-use assets and lease liabilities, which mainly relates to the determination of the Company’s incremental borrowing rate.
Fair value of financial instruments
Fair value of financial instruments
Fair value corresponds to the quoted price for listed financial assets and liabilities. The Company determined that the fair values of cash, trade receivables and trade payables approximate their carrying amounts largely due to the short-term maturities of these instruments.
Where no active market exists, the Company establishes fair value by using a valuation technique determined to be the most appropriate in the circumstances.
Regarding compound debt instruments, the fair value of debt component was determined at the date of issuance using a valuation model that requires judgment, including estimating the change in value of the Company at different dates and market yields applicable to the Company’s straight debt (without the conversion option). The assumptions used in calculating the value of the conversion option, the expected volatility of the Company’s underlying stock price which has experienced fluctuations, and the market discount rate, represent the Company’s best estimates based on management’s judgment and subjective future expectations. The fair value of debt component were supported by work performed by an independent valuation specialist engaged by the Company.
Research and Development Costs
Costs incurred internally in research and development activities are charged to expense until technological feasibility has been established for the project. Once technological feasibility is established, development costs are capitalized until the product is available for general release to customers. Judgment is required in determining when technological feasibility of a product is established. We have determined that technological feasibility for our software products is reached after all high-risk development issues have been resolved. Generally, this occurs when the preliminary design review has been done.
Leases
The application of IFRS 16 “Leases” requires the Company to make assumptions and estimates in order to determine the value of the right-of-use assets and lease liabilities, which mainly relates to the determination of the Company’s incremental borrowing rate.
XML 57 R32.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of significant accounting and reporting policies (Tables)
12 Months Ended
Dec. 31, 2023
Corporate information and statement of IFRS compliance [abstract]  
Schedule of Subsidiaries
The Consolidated Financial Statements comprise the financial statements of Sequans Communications S.A., which is the ultimate parent of the group, and its subsidiaries as of and for the years ended December 31, 2023, 2022 and 2021:
NameCountry of
incorporation
Year of
incorporation
%
equity
interest
Sequans Communications Ltd.United Kingdom2005100 
Sequans Communications Inc.United States2008100 
Sequans Communications Ltd. Pte.Singapore2008100 
Sequans Communications Israel (2009) Ltd.Israel2009100 
Sequans Communications Finland OyFinland2020100 
Sequans Communications SASFrance2023100 
Schedule of Average and Closing Exchange Rate for the U.S. Dollar
The table below sets forth, for the periods and dates indicated, the average and closing exchange rate for the U.S. dollar (USD) to the euro (EUR), the U.K. pound sterling (GBP), the Singapore dollar (SGD) and the New Israeli shekel (NIS):
USD/EURUSD/GBPUSD/SGDUSD/NIS
December 31, 2021
Average rate1.1835 1.3761 0.7444 0.3097 
Closing rate1.1326 1.3479 0.7413 0.3221 
December 31, 2022
Average rate1.0539 1.2372 0.7255 0.2980 
Closing rate1.0666 1.2026 0.7459 0.2840 
December 31, 2023
Average rate1.0816 1.2435 0.7447 0.2716 
Closing rate1.1050 1.2714 0.7573 0.2763 
Schedule of Useful Lives Most Commonly Used The useful lives most commonly used are the following:
Machinery and equipment  3 to 5 years
Building and leasehold improvements  Lesser of 6 years or the life of the lease
Computer equipment  3 years
Furniture and office equipment  5 years
Property, plant and equipment include:
Leasehold
improvements
Plant and
equipment
IT and office
equipment
Right of useTotal
 (in thousands)
Cost:
At January 1, 2021$1,340 $27,435 $4,006 7,013 $39,794 
Additions16 1,842 373 437 2,668 
Disposals(20)(415)(3)(756)(1,194)
Reclassification94 — (94)— — 
Exchange difference(20)60 — 47 
At December 31, 20211,437 28,842 4,342 6,694 41,315 
Additions15 3,891 222 458 4,586 
Disposals— (175)(54)(73)(302)
Exchange difference(35)(178)(123)— (336)
At December 31, 20221,417 32,380 4,387 7,079 45,263 
Additions75 1,812 220 767 2,874 
Disposals— (2)(3)(414)(419)
Exchange difference10 107 16 — 133 
At December 31, 2023$1,502 $34,297 $4,620 $7,432 $47,851 
Depreciation and impairment:
At January 1, 20211,233 23,323 3,694 2,357 30,607 
Depreciation charge for the year45 1,869 181 1,259 3,354 
Reclassification19 — (19)— — 
Disposals(12)(372)(3)(296)(683)
Exchange difference(15)41 — 27 
At December 31, 20211,286 24,805 3,894 3,320 33,305 
Depreciation charge for the year67 2,441 241 1,230 3,979 
Disposals— (153)(52)(73)(278)
Exchange difference(20)(122)(90)— (232)
At December 31, 20221,333 26,971 3,993 4,477 36,774 
Depreciation charge for the year41 2,421 198 1,223 3,883 
Impairment— 711 — — 711 
Disposals— (2)— (414)(416)
Exchange difference69 — 84 
At December 31, 2023$1,381 $30,170 $4,199 5,286 $41,036 
Net book value:
At January 1, 2021$107 $4,112 $312 4,656 $9,187 
At December 31, 2021151 4,037 448 3,374 8,010 
At December 31, 202284 5,409 394 2,602 8,489 
At December 31, 2023$121 $4,127 $421 2,146 $6,815 
XML 58 R33.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Segment information (Tables)
12 Months Ended
Dec. 31, 2023
Operating segments [Abstract]  
Schedule of Total Revenue by Region The following table sets forth the Company’s total revenue by region for the periods indicated.
Year ended December 31,
202120222023
(in thousands)
Asia :
  China (including Hong-Kong)$3,509 $24,018 $21,702 
  Taiwan14,668 1,066 29 
  Korea1,090 30 
  Rest of Asia898 2,202 62 
     Total Asia20,165 27,294 21,823 
Germany4,990 15,525 1,001 
United States of America22,565 16,749 8,666 
Rest of world 3,159 983 2,126 
Total revenue$50,879 $60,551 $33,616 
Of our total revenue, 96.2% is attributable to international sales for the year ended December 31, 2023 (99.8% for 2022 and 99.6% for 2021).
The Company categorizes its total revenue based on technology.
Year ended December 31,
202120222023
(in thousands)
Broadband IoT$23,699 $36,181 $21,842 
Massive IoT27,180 24,370 11,774 
Total revenue$50,879 $60,551 $33,616 
Additionally, the Company categorize its total revenue based on product, license and services revenue.
Year ended December 31,
202120222023
(in thousands)
Product$30,410 $22,974 $8,060 
License17,073 31,005 22,997 
Development and other services3,396 6,572 2,559 
Total revenue$50,879 $60,551 $33,616 
XML 59 R34.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Other revenues and expenses (Tables)
12 Months Ended
Dec. 31, 2023
Analysis of income and expense [abstract]  
Schedule of Financial Income and Expenses
Financial income:
 Year ended December 31,
 202120222023
 (in thousands)
Income from short-term investments and term deposits and other finance revenue$47 $68 $177 
Impact of debt reimbursement (Notes 14.1 and 14.2)5,177 — — 
Convertible debt amendments (Note 14.1)— 476 247 
Change in fair value of convertible debt derivative (Note 14.1)
3,848 6,878 3,200 
Foreign exchange gain3,032 7,076 1,166 
Total financial income$12,104 $14,498 $4,790 
Financial expenses:
 Year ended December 31,
 202120222023
 (in thousands)
Interest on loans$7,462 $8,146 $9,584 
Interest on lease contracts (see Note 15)760 571 479 
Interest on financing component of long term development services agreement (see Notes 18 and 19)2,156 966 115 
Interest on supplier payable with extended payment terms173 222 286 
Other bank fees and financial charges778 1,020 946 
Foreign exchange loss2,094 5,994 1,858 
Total financial expenses$13,423 $16,919 $13,268 
Schedule of Cost of Revenue and Operating Expenses
The tables below present the cost of revenue and operating expenses by nature of expense:
  Year ended December 31,
 Note202120222023
  (in thousands)
Included in cost of revenue:
Cost of components$18,365 $13,102 $5,071 
Depreciation and impairment7517 428 395 
Amortization of intangible assets8162 148 118 
Wages and benefits2,306 2,497 2,059 
Share-based payment expense1358 160 131 
Assembly services, royalties and other2,282 1,336 1,702 
$23,690 $17,671 $9,476 
Year ended December 31,
 Note202120222023
  (in thousands)
Included in operating expenses (between gross profit and operating result):
Depreciation and impairment7$2,837 $3,551 $4,082 
Amortization of intangible assets87,037 7,888 7,346 
Wages and benefits36,684 33,195 36,014 
Share-based payment expense135,077 5,317 6,973 
Foreign exchange (gains) losses related to hedges of euro(73)207 (180)
Other, net(6,054)(3,439)(257)
$45,508 $46,719 $53,978 
  Year ended December 31,
 Note202120222023
  (in thousands)
Wages and salaries$29,422 $27,115 $28,863 
Social security costs and other payroll taxes9,386 8,408 9,087 
Other benefits167 159 159 
Pension costs15 10 (36)
Share-based payment expenses135,135 5,477 7,104 
Total employee benefits expense$44,125 $41,169 $45,177 
Schedule of Research and Development Expense
The impact of the reduction of research and development expense due to government grants, research tax credit and development costs capitalized was as follows:
 Year ended December 31,
 202120222023
 (in thousands)
Research and development costs$52,200 $47,353 $53,018 
Research tax credit(6,328)(4,622)(5,374)
Government and other grants(3,621)(4,888)(1,834)
Development costs capitalized (*)(18,297)(13,808)(22,328)
Amortization of capitalized development costs2,460 2,575 2,642 
Total research and development expense$26,414 $26,610 $26,124 
XML 60 R35.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income tax (Tables)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Taxes [Abstract]    
Schedule of Major Components of Income Tax Expense  
The major components of income tax expense are:
 Year ended December 31,
 202120222023
 (in thousands)
Consolidated Statement of Operations
Current income tax expense$504 $2,609 $2,683 
Deferred income tax expense (benefit)121 139 (9)
Income tax expense (benefit)$625 $2,748 $2,674 
Reconciliation of Income Taxes Computed at the French Statutory Rate
A reconciliation of income taxes computed at the French statutory rate 25.00% for the years ended December 31, 2023 and 2022 (26.50% for the year ended December 31, 2021) to the income tax expense (benefit) is as follows:
 Year ended December 31,
 202120222023
 (in thousands)
Profit (loss) before income taxes$(19,638)$(6,260)$(38,316)
At France’s statutory income tax rate of 26.5% in 2021 and 25% in 2022 and in 2023(5,204)(1,565)(9,579)
Non-deductible share-based payment expense1,361 1,369 1,776 
Tax credits(1,677)(1,156)(1,344)
Impact of the extinguishment of the convertible debts after amendment— 119 62 
Impact of debt reimbursement1,372 — — 
Permanent differences and other168 503 (212)
Withholding tax— 2,250 2,055 
Unrecognized benefit of tax losses carryforward4,605 1,228 9,916 
Income tax expense (income)$625 $2,748 $2,674 
 
Significant Components of Deferred Tax Assets and Liabilities  
Significant components of the Company’s deferred tax assets and liabilities are as follows:
Consolidated Statement of Financial PositionEquityConsolidated Statement of Operations
December 31,December 31,Year ended December 31,
202120222023202120222023202120222023
(in thousands)(in thousands)(in thousands)
Government loan(135)(127)— — — (277)142 (135)
Intangible assets(28)(133)(120)— — — 21 (105)13 
Cash flow hedge(2)(3)— — — (4)(1)
Remeasurement of non-monetary accounts(171)(487)(3)— — — (899)(316)485 
Convertible debts and venture debt - liability— — — — — — (23)— — 
Other provisions and accruals (490)(495)(962)— — — (242)(4)(468)
From subsidiaries138 258 264 — — — 119 139 (9)
Deferred tax asset not recognized on losses (Loss available for offsetting against future taxable income)
826 1,111 1,210 — — — 1,426 284 100 
        Total$138 $258 $264 — $— $— $121 $139 $(9)
The changes in deferred tax assets and liabilities were as follows:
202120222023
(in thousands)
At January 1st$19 $138 $258 
Tax expense (income) during the year recognized in Profit or Loss121 139 (9)
Tax expense (income) during the year recognized in equity— — — 
Effect of foreign exchange(2)(19)15 
At December 31st$138 $258 $264 
XML 61 R36.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Earnings (loss) per share (Tables)
12 Months Ended
Dec. 31, 2023
Earnings per share [abstract]  
Schedule of Income and Share Data Used in Basic and Diluted Earnings (Loss) Per Share Computations
The following reflects the income and share data used in the basic and diluted earnings (loss) per ordinary share and ADS computations:
 Year ended December 31,
 202120222023
 (in thousands, except share and per share data)
Profit (Loss)$(20,263)$(9,008)$(40,990)
Weighted average number of shares outstanding for basic EPS146,691,784 184,587,104 225,183,996 
Net effect of dilutive stock options— — — 
Net effect of dilutive warrants— — — 
Net effect of vesting of restricted stock— — — 
Net effect of conversion of convertible notes— — — 
Weighted average number of shares outstanding for diluted EPS146,691,784 184,587,104 225,183,996 
Basic earnings (loss) per share$(0.14)$(0.05)$(0.18)
Diluted earnings (loss) per share$(0.14)$(0.05)$(0.18)
ADS outstanding for basic and diluted earnings (loss) per ADS36,672,946 46,146,776 56,295,999 
Basic earnings (loss) per ADS$(0.55)$(0.20)$(0.73)
Diluted earnings (loss) per ADS$(0.55)$(0.20)$(0.73)
XML 62 R37.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Property, plant and equipment (Tables)
12 Months Ended
Dec. 31, 2023
Property, plant and equipment [abstract]  
Schedule of Property, Plant and Equipment The useful lives most commonly used are the following:
Machinery and equipment  3 to 5 years
Building and leasehold improvements  Lesser of 6 years or the life of the lease
Computer equipment  3 years
Furniture and office equipment  5 years
Property, plant and equipment include:
Leasehold
improvements
Plant and
equipment
IT and office
equipment
Right of useTotal
 (in thousands)
Cost:
At January 1, 2021$1,340 $27,435 $4,006 7,013 $39,794 
Additions16 1,842 373 437 2,668 
Disposals(20)(415)(3)(756)(1,194)
Reclassification94 — (94)— — 
Exchange difference(20)60 — 47 
At December 31, 20211,437 28,842 4,342 6,694 41,315 
Additions15 3,891 222 458 4,586 
Disposals— (175)(54)(73)(302)
Exchange difference(35)(178)(123)— (336)
At December 31, 20221,417 32,380 4,387 7,079 45,263 
Additions75 1,812 220 767 2,874 
Disposals— (2)(3)(414)(419)
Exchange difference10 107 16 — 133 
At December 31, 2023$1,502 $34,297 $4,620 $7,432 $47,851 
Depreciation and impairment:
At January 1, 20211,233 23,323 3,694 2,357 30,607 
Depreciation charge for the year45 1,869 181 1,259 3,354 
Reclassification19 — (19)— — 
Disposals(12)(372)(3)(296)(683)
Exchange difference(15)41 — 27 
At December 31, 20211,286 24,805 3,894 3,320 33,305 
Depreciation charge for the year67 2,441 241 1,230 3,979 
Disposals— (153)(52)(73)(278)
Exchange difference(20)(122)(90)— (232)
At December 31, 20221,333 26,971 3,993 4,477 36,774 
Depreciation charge for the year41 2,421 198 1,223 3,883 
Impairment— 711 — — 711 
Disposals— (2)— (414)(416)
Exchange difference69 — 84 
At December 31, 2023$1,381 $30,170 $4,199 5,286 $41,036 
Net book value:
At January 1, 2021$107 $4,112 $312 4,656 $9,187 
At December 31, 2021151 4,037 448 3,374 8,010 
At December 31, 202284 5,409 394 2,602 8,489 
At December 31, 2023$121 $4,127 $421 2,146 $6,815 
XML 63 R38.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Intangible assets (Tables)
12 Months Ended
Dec. 31, 2023
Intangible Assets [Abstract]  
Schedule of Intangible Assets
Intangible assets include:
 Capitalized development costsLicensesTotal
 (in thousands)
Cost:
At January 1, 2021$16,798 $29,391 $46,189 
Additions18,297 1,450 19,747 
Disposals— — — 
Exchange difference— 167 167 
At December 31, 202135,095 31,008 66,103 
Additions13,808 5,101 18,909 
Disposals— (2,441)(2,441)
Exchange difference— (234)(234)
At December 31, 202248,903 33,434 82,337 
Additions22,327 633 22,960 
Disposals— (2,121)(2,121)
Exchange difference— (7)(7)
At December 31, 2023$71,230 $31,939 $103,169 
Depreciation and impairment:
At January 1, 2021$3,250 $17,627 $20,877 
Amortization2,460 4,591 7,051 
Impairment— 148 148 
Exchange difference— 43 43 
At December 31, 20215,710 22,409 28,119 
Amortization2,575 5,458 8,033 
Impairment— 
Disposals— (2,441)(2,441)
Exchange difference— (82)(82)
At December 31, 20228,285 25,347 33,632 
Amortization2,640 4,708 7,348 
Disposals— (2,121)(2,121)
Exchange difference— 10 10 
At December 31, 2023$10,925 $27,944 $38,869 
Net book value:
At January 1, 2021$13,548 $11,764 $25,312 
At December 31, 202129,385 8,599 37,984 
At December 31, 202240,618 8,087 48,705 
At December 31, 2023$60,305 $3,995 $64,300 
XML 64 R39.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Inventories (Tables)
12 Months Ended
Dec. 31, 2023
Inventories [Abstract]  
Schedule of Inventories
 At December 31,
 202120222023
 (in thousands)
Components$2,683 $6,641 $4,706 
Finished goods5,091 4,599 4,559 
Total inventories at cost$7,774 $11,240 $9,265 
Provision for slow-moving or damaged components$225 $606 $1,065 
Provision for slow-moving or damaged finished goods1,116 1,247 1,865 
Total provision for slow-moving or damaged inventory$1,341 $1,853 $2,930 
Components, net$2,458 $6,035 $3,641 
Finished goods, at the lower of cost and net realizable value3,975 3,352 2,694 
Total net inventories$6,433 $9,387 $6,335 
XML 65 R40.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Trade receivables (Tables)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]    
Schedule of Non-Interest Bearing Trade Receivables
Trade receivables and contract assets are non-interest bearing. Trade receivables generally have 30-90 day payment terms.
 At December 31,
 202120222023
 (in thousands)
Trade receivables$16,876 $11,243 $10,803 
Contract assets789 176 497 
Provision for credit notes to be issued(465)(225)(164)
Provisions on trade receivables(2,789)(2,524)(2,524)
Net trade receivables$14,411 $8,670 $8,612 
 
Schedule of Movements in the Provision for Impairment of Receivables
Post-
employment
benefits
Other provisionsTotalCurrentNon current
 (in thousands)
At January 1, 2021$834 $809 $1,643 $89 $1,554 
Arising (released) during the year(28)850 822 — — 
Released (used) during the year— (90)(90)— — 
Released (unused) during the year— (238)(238)— — 
At December 31, 2021806 1,331 2,137 — 2,137 
Arising (released) during the year(101)428 327 — — 
Released (used) during the year— — — — — 
Released (unused) during the year— (191)(191)— — 
At December 31, 2022705 1,568 2,273 77 2,196 
Arising (released) during the year107 257 364 — — 
Released (used) during the year(48)(76)(124)— — 
Released (unused) during the year— (291)(291)— — 
At December 31, 2023$764 $1,458 $2,222 $— $2,222 
The movements in the provision for impairment of receivables were as follows:
 December 31,
 202120222023
 (in thousands)
At January 1,$2,724 $2,789 $2,524 
Charge for the year65 — — 
Utilized amounts— (265)— 
Unutilized amounts— — — 
At year end$2,789 $2,524 $2,524 
Aging Analysis of Trade Receivables That Were Not Impaired  
As at year end, the aging analysis of trade receivables and contract assets that were not impaired is as follows:
 TotalNeither past
due nor
Impaired
Past due but not impaired
   <30 days30-60 days60-120 days>120 days
 (in thousands)
At December 31, 2021$14,411 $13,587 $241 $— $— $583 
At December 31, 2022$8,670 $8,367 $209 $94 $— $— 
At December 31, 2023$8,612 $6,532 $1,919 $101 $$56 
XML 66 R41.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cash and cash equivalents (Tables)
12 Months Ended
Dec. 31, 2023
Subclassifications of assets, liabilities and equities [abstract]  
Schedule of Cash and Cash Equivalents
 At December 31,
 202120222023
 (in thousands)
Cash at banks$4,828 $5,664 $5,697 
Cash equivalents
Short-term deposits— 5,000 — 
Cash, cash equivalents and deposits$4,835 $10,671 $5,705 
Most of the cash, cash equivalents and short-term deposits is held in U.S. dollar and euros as follows:
 At December 31,
 202120222023
 (in thousands)
U.S. dollar denominated accounts$2,869 $9,720 $5,250 
Euro denominated accounts1,564 466 91 
GBP denominated accounts143 19 319 
SGP denominated accounts47 23 13 
NIS denominated accounts160 428 
RMB denominated accounts35 10 
Other currencies denominated accounts17 12 21 
Cash, cash equivalents and short-term deposits$4,835 $10,671 $5,705 
XML 67 R42.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Issued capital and reserves (Tables)
12 Months Ended
Dec. 31, 2023
Share Capital, Reserves And Other Equity Interest [Abstract]  
Shares Issued and Fully Paid
Shares issued and fully paid
 At December 31,
 202120222023
 SharesAmountSharesAmountSharesAmount
 (in thousands, except for share data)
Ordinary shares151,419,322 3,028 193,426,478 1,934 246,262,004 2,463 
Converted to U.S. dollars at historical exchange rates$3,687 $2,306 $2,878 
XML 68 R43.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-based payment plans (Tables)
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangements [Abstract]  
Breakdown of share-based payments expenses on entity's profit or loss
The breakdown is as follows:
Year ended December 31,
 202120222023
 (in thousands)
Cost of revenue$57 $159 $131 
Research and development$2,109 $1,758 $2,019 
Sales and marketing$970 $1,132 $1,397 
General and administrative$1,999 $2,428 $3,557 
Total$5,135 $5,477 $7,104 
Summary of movement in number and WAEP of stock options
The following table illustrates the number of shares (ADS equivalents are not presented) and weighted average exercise prices (WAEP) of, and movements in, stock options and warrants during the period:
 December 31,
 202120222023
 NumberWAEPNumberWAEPNumberWAEP
Outstanding at January 1,5,687,367 $3.41 5,233,437 $1.73 5,868,521 $1.51 
Granted during the year1,076,000 $1.55 1,110,288 $0.70 1,500,000 $0.54 
Forfeited during the year(139,722)$1.85 (85,400)$1.78 (111,887)$1.70 
Exercised during the year(1)
(94,008)$1.47 — $— — $— 
Expired during the year(1,296,200)$8.35 (389,804)$2.05 (444,820)$1.89 
Outstanding at period end5,233,437 $1.73 5,868,521 $1.51 6,811,814 $1.27 
Of which, warrants for consultants equivalent to employees203,000 $1.79 487,288 $1.29 724,288 $1.05 
Exercisable at period end3,977,831 $1.79 4,685,828 $1.70 5,420,965 $1.44 
Of which, warrants for consultants equivalent to employees165,667 $1.72 228,595 $1.73 438,739 $1.28 
(1)The weighted average share estimated fair value at the dates of exercise of these options was $1.78 in 2021.

The following table illustrates the number of, and movements in, restricted shares awards (RSA) based on the number of ordinary shares (ADS equivalents are not presented) during the period:
December 31,
202120222023
Outstanding at January 1,9,525,135 10,379,481 16,752,551 
Granted during the year4,426,496 10,550,820 2,640,460 
Forfeited during the year(628,186)(736,282)(686,092)
Vested during the year(2,943,964)(3,441,468)(5,601,570)
Outstanding at period end10,379,481 16,752,551 13,105,349 
Fair value assumptions for determining value of the grants The following table lists the inputs to the models used for determining the value of the grants made for the years ended December 31, 2021, 2022 and 2023:
 December 31,
 202120222023
Dividend yield (%)— — — 
Expected volatility (%)59 57 59 
Risk–free interest rate (%)— 
1.25 to 2.1
2.5
Assumed annual lapse rate of awards (%)
15 for all except 2 for warrants and a limited group of beneficiaries
20 for all except 2 for BSA and a limited group of beneficiaries20 for all except 2 for BSA and a limited group of beneficiaries
Sell price multiple (applied to exercise price)
Weighted average share price ($)1.22 0.89 0.86 
Model usedBinomialBinomialBinomial
Fair value assumptions for determining value of the grants The following table lists the inputs to the models used for determining the value of the grants made for the years ended December 31, 2021, 2022 and 2023:
 December 31,
 202120222023
Dividend yield (%)— — — 
Expected volatility (%)59 57 59 
Risk–free interest rate (%)— 
1.25 to 2.1
2.5
Assumed annual lapse rate of awards (%)
15 for all except 2 for warrants and a limited group of beneficiaries
20 for all except 2 for BSA and a limited group of beneficiaries20 for all except 2 for BSA and a limited group of beneficiaries
Sell price multiple (applied to exercise price)
Weighted average share price ($)1.22 0.89 0.86 
Model usedBinomialBinomialBinomial
XML 69 R44.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Interest-bearing loans and borrowings (Tables)
12 Months Ended
Dec. 31, 2023
Financial Instruments [Abstract]  
Schedule of Interest-Bearing Loans and Borrowings
At December 31,
Note202120222023
(in thousands)
Current
Convertible debt14.1 — — 52,278 
Convertible debt embedded derivative14.1 — — 
Unsecured related party loan14.2 — — 8,922 
Interest-bearing receivables financing14.3 9,518 7,723 9,544 
Total current portion$9,518 $7,723 $70,747 
Non-current
Convertible debt14.1 $36,373 $43,455 $— 
Convertible debt embedded derivative14.1 10,081 3,203 — 
Total non-current portion$46,454 $46,658 $— 
The conversion rates of the convertible notes outstanding as of December 31, 2023, are as follows:
Conversion rate per shareConversion rate per ADS
2019-2 Nokomis Note$0.8082 $3.23 
2021 Lynrock Lake Note$1.915 $7.66 
XML 70 R45.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Lease liabilities (Tables)
12 Months Ended
Dec. 31, 2023
Subclassifications of assets, liabilities and equities [abstract]  
Disclosure of right-of-use assets
The table below presents the carrying amounts of right-of-use assets recognized and the movements during the period:
Real-estateIT and office equipmentTotal
(In thousands)
As at January 1, 20214,184 472 4,656 
Additions437 — 437 
Disposals(210)(547)(757)
Depreciation expense(1,151)(108)(1,259)
Amortization disposals114 183 297 
As at December 31, 2021$3,374 $— $3,374 
Additions458 — 458 
Disposals(73)— (73)
Depreciation expense(1,230)— (1,230)
Amortization disposals73 — 73 
As at December 31, 2022$2,602 $— $2,602 
Additions767 — 767 
Disposals(414)— (414)
Depreciation expense(1,223)— (1,223)
Amortization disposals414 — 414 
As at December 31, 2023$2,146 $— $2,146 
The table below present the carrying amounts of lease liabilities and the movements during the period:
Lease liabilitiesCurrentNon-current
(In thousands)
As at January 1, 2021$5,776 $1,014 $4,762 
Additions437 
Disposals(993)
Interests expense760 
Foreign exchange loss (gain)(297)
Payments(1,063)
As at December 31, 2021$4,620 $1,247 $3,373 
Additions458 
Disposals(577)
Interests expense571 
Foreign exchange loss (gain)(298)
Payments(1,205)
As at December 31, 2022$3,569 $1,291 $2,278 
Additions767 
Disposals(414)
Interests expense479 
Foreign exchange loss (gain)36 
Payments(1,321)
As at December 31, 2023$3,116 $1,471 $1,645 
XML 71 R46.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Government grant advances and loans (Tables)
12 Months Ended
Dec. 31, 2023
Government Grants [Abstract]  
Schedule of Government Grant Advances and Loans
  December 31,
 Note202120222023
  (in thousands)
Current
Government grant advances16.1$3,317 $968 $708 
Research project financing16.21,057 1,237 1,518 
Government loans16.21,832 1,954 1,727 
Accrued interest16.2— — 653 
Total current portion$6,206 $4,159 $4,606 
Non-current
Government grant advances16.1$2,048 $872 $328 
Research project financing16.22,248 1,567 259 
Government loans16.33,084 1,424 173 
Accrued interest16.21,974 2,372 2,496 
Total non-current portion$9,354 $6,235 $3,256 
XML 72 R47.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Provisions (Tables)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Other Provisions, Contingent Liabilities and Contingent Assets [Abstract]    
Reconciliation of Changes in Provisions
Post-
employment
benefits
Other provisionsTotalCurrentNon current
 (in thousands)
At January 1, 2021$834 $809 $1,643 $89 $1,554 
Arising (released) during the year(28)850 822 — — 
Released (used) during the year— (90)(90)— — 
Released (unused) during the year— (238)(238)— — 
At December 31, 2021806 1,331 2,137 — 2,137 
Arising (released) during the year(101)428 327 — — 
Released (used) during the year— — — — — 
Released (unused) during the year— (191)(191)— — 
At December 31, 2022705 1,568 2,273 77 2,196 
Arising (released) during the year107 257 364 — — 
Released (used) during the year(48)(76)(124)— — 
Released (unused) during the year— (291)(291)— — 
At December 31, 2023$764 $1,458 $2,222 $— $2,222 
The movements in the provision for impairment of receivables were as follows:
 December 31,
 202120222023
 (in thousands)
At January 1,$2,724 $2,789 $2,524 
Charge for the year65 — — 
Utilized amounts— (265)— 
Unutilized amounts— — — 
At year end$2,789 $2,524 $2,524 
Schedule of Main Assumptions Used
The main assumptions used in the calculation are the following:
202120222023
Discount rate0.98%3.75%3.20%
Salary increaseBetween 1.5% and 3.5%Between 1.5% and 3.5%Between 1.5% and 3.5%
Retirement age60-62 years60-62 years65-67 years
Turnover: depending on the seniorityDecrease by age from 2% for directors, Vice presidents and managers and from 10% for other employees. 0% for executive teamDecrease by age from 2% for directors, Vice presidents and managers and from 12% for other employees. 0% for executive teamDecrease by age from 2% for directors, Vice presidents and managers and from 20% for other employees. 0% for executive team
 
XML 73 R48.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Other non-current liabilities (Tables)
12 Months Ended
Dec. 31, 2023
Subclassifications of assets, liabilities and equities [abstract]  
Schedule of Other Non-Current Liabilities Other non-current liabilities
 At December 31,
 202120222023
 (in thousands)
Trade payables$964 $1,788 $— 
Deferred tax liabilities138 258 264 
Contract liabilities:
  License and development services agreement2,706 404 — 
  Deferred revenue— — — 
  Total contract liabilities 2,706 404 — 
XML 74 R49.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Trade payables and other current liabilities (Tables)
12 Months Ended
Dec. 31, 2023
Subclassifications of assets, liabilities and equities [abstract]  
Schedule of Trade Payables and Other Current Liabilities
 At December 31,
 202120222023
 (in thousands)
Trade payables$13,916 $9,342 $16,281 
Other current liabilities:
Employees and social debts7,987 7,497 7,383 
Provisions— 77 — 
Others1,193 781 1,516 
Total other current liabilities$9,180 $8,355 $8,899 
Contract liabilities:
License and development services agreements (See Note 19)8,201 5,774 5,485 
Deferred revenue476 190 367 
$8,677 $5,964 $5,852 
XML 75 R50.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Information about financial instruments (Tables)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Financial Instruments [Abstract]    
Schedule of Financial Assets
 Carrying amountFair value
 December 31,December 31,
 202120222023202120222023
 (in thousands)
Financial assets:
Trade and other receivables
Trade receivables and contract assets$14,411 $8,670 $8,612 $14,411 $8,670 $8,612 
Deposits and other receivables
Deposits451 436 431 451 436 431 
Other financial assets
Long-term investments357 337 360 357 337 360 
Financial instruments at fair value through other comprehensive income
Cash flow hedges— 142 74 — 142 74 
Cash, cash equivalents and short-term investments4,835 10,671 5,705 4,835 10,671 5,705 
Total financial assets$20,054 $20,256 $15,182 $20,054 $20,256 $15,182 
Total current$19,246 $19,483 $14,391 $19,246 $19,483 $14,391 
Total non-current$808 $773 $791 $808 $773 $791 
Financial liabilities:
Lease liability4,620 3,569 3,116 4,620 3,569 3,116 
Interest-bearing loans and borrowings:
Interest-bearing receivables financing9,518 7,723 9,544 9,518 7,723 9,544 
Convertible debt36,373 43,455 52,278 36,493 42,636 52,111 
Unsecured related party loan— — 8,922 — — 8,922 
Government loans6,001 5,171 4,337 6,001 5,171 4,337 
Research project financing3,868 3,383 2,489 3,868 3,383 2,489 
Convertible debt embedded derivative10,081 3,203 10,081 3,203 
Trade and other payables (current and non current)14,880 11,130 16,281 14,880 11,130 16,281 
Financial instruments at fair value through other comprehensive income
Cash flow hedges50 — — 50 — — 
Total financial liabilities$85,391 $77,634 $96,970 $85,511 $76,815 $96,803 
Total current$27,631 $21,556 $92,484 $27,631 $21,556 $92,317 
Total non-current$57,760 $56,078 $4,486 $57,880 $55,259 $4,486 
 
Disclosure of Financial Liabilities
 Carrying amountFair value
 December 31,December 31,
 202120222023202120222023
 (in thousands)
Financial assets:
Trade and other receivables
Trade receivables and contract assets$14,411 $8,670 $8,612 $14,411 $8,670 $8,612 
Deposits and other receivables
Deposits451 436 431 451 436 431 
Other financial assets
Long-term investments357 337 360 357 337 360 
Financial instruments at fair value through other comprehensive income
Cash flow hedges— 142 74 — 142 74 
Cash, cash equivalents and short-term investments4,835 10,671 5,705 4,835 10,671 5,705 
Total financial assets$20,054 $20,256 $15,182 $20,054 $20,256 $15,182 
Total current$19,246 $19,483 $14,391 $19,246 $19,483 $14,391 
Total non-current$808 $773 $791 $808 $773 $791 
Financial liabilities:
Lease liability4,620 3,569 3,116 4,620 3,569 3,116 
Interest-bearing loans and borrowings:
Interest-bearing receivables financing9,518 7,723 9,544 9,518 7,723 9,544 
Convertible debt36,373 43,455 52,278 36,493 42,636 52,111 
Unsecured related party loan— — 8,922 — — 8,922 
Government loans6,001 5,171 4,337 6,001 5,171 4,337 
Research project financing3,868 3,383 2,489 3,868 3,383 2,489 
Convertible debt embedded derivative10,081 3,203 10,081 3,203 
Trade and other payables (current and non current)14,880 11,130 16,281 14,880 11,130 16,281 
Financial instruments at fair value through other comprehensive income
Cash flow hedges50 — — 50 — — 
Total financial liabilities$85,391 $77,634 $96,970 $85,511 $76,815 $96,803 
Total current$27,631 $21,556 $92,484 $27,631 $21,556 $92,317 
Total non-current$57,760 $56,078 $4,486 $57,880 $55,259 $4,486 
 
Disclosure of Fair Value of Financial Instruments  
As at December 31, 2021, the Company held the following financial instruments carried at fair value on the statement of financial position:

Assets measured at fair value
At December 31,
 2021Level 1Level 2Level 3
 (in thousands)
Long-term investments$357 — $357 — 
Liabilities measured at fair value
At December 31,
 2021Level 1Level 2Level 3
 (in thousands)
Convertible debt embedded derivative$10,081 — $10,081 — 
Financial instruments at fair value through other comprehensive income:
Cash flow hedge50 50
As at December 31, 2022, the Company held the following financial instruments carried at fair value on the statement of financial position:
Assets measured at fair value
At December 31,
 2022Level 1Level 2Level 3
 (in thousands)
Long-term investments$337 — $337 — 
Financial instruments at fair value through other comprehensive income:
Cash flow hedge142 142 
Liabilities measured at fair value
At December 31,
 2022Level 1Level 2Level 3
 (in thousands)
Convertible debt embedded derivative$3,203 — $3,203 — 
As of December 31, 2023, the Company held the following financial instruments carried at fair value on the statement of financial position:
Assets measured at fair value
At December 31,
 2023Level 1Level 2Level 3
 (in thousands)
Long-term investments360 — 360 — 
Financial instruments at fair value through profit and loss:
Cash flow hedge74 — 74 — 
Liabilities measured at fair value
At December 31,
 2023Level 1Level 2Level 3
 (in thousands)
Convertible debt embedded derivative— — 
Schedule of Present Fair Values of Derivative Financial Instruments
The following tables present fair values of foreign currency derivative financial instruments at December 31, 2023, 2022 and 2021.
 At December 31, 2021
 Notional AmountFair value
 (in thousands)
Forward contracts (buy euros, sell U.S dollars)5,000 $(50)
Options (buy euros, sell U.S. dollars)— — 
Total5,000 $(50)
 At December 31, 2022
 Notional AmountFair value
 (in thousands)
Forward contracts (buy euros, sell U.S. dollars)3,000 $142 
Options (buy euros, sell U.S. dollars)— — 
Total3,000 $142 
At December 31, 2023
Notional AmountFair value
(in thousands)
Forward contracts (buy euros, sell U.S. dollars)2,000 $74 
Options (buy euros, sell U.S. dollars)— — 
Total2,000 $74 
 
Summary of Customers Representing Company's Total Revenue
The following table summarizes customers representing a significant portion of the Company’s total revenue:
CustomerCustomer Location% of total revenues for the year ended December 31,Trade receivables at December 31,
  202320222021202320222021
AChina56 %33 %— %3,411,000 3,375,000 — 
BJapan16 %11 %13 %18,000 — 7,736,000 
CGermanyLess than 10%24 %Less than 10%— 3,585,000 3,652,000 
DAmerica— %14 %23 %— — 1,800,000 
ETaiwanLess than 10%Less than 10%23 %26,000 — 545,000 
FChinaLess than 10%Less than 10%14 %945,000 169,500 203,000 
 
Schedule of Liquidity Risk
Within 1
year
1 to 2
years
2 to 3
years
3 to 4
years
4 to 5
years
More
than 5
years
Total
 (in thousands)
At December 31, 2021
Research project financing$1,057 $1,042 $1,684 $— $— $— $3,783 
Interest-bearing receivables financing9,518 — — — — — 9,518 
Government loans1,240 1,573 1,483 1,452 714 — 6,462 
Convertible debt— — 54,623 — — — 54,623 
Lease liabilities1,238 1,043 965 1,052 322 — 4,620 
Trade payables13,916 171 1,477 — — — 15,564 
Other current liabilities9,180 — — — — — 9,180 
$36,149 $3,829 $60,232 $2,504 $1,036 $— $103,750 
At December 31, 2022
Research project financing$1,237 $1,683 $146 $221 $— $— $3,287 
Interest-bearing receivables financing7,723 — — — — — 7,723 
Government loans1,534 1,397 1,367 673 — — 4,971 
Convertible debt (1)
— 54,348 — — — — 54,348 
Lease liabilities1,291 930 1,025 323 — — 3,569 
Trade payables9,342 2,235 — — — — 11,577 
Other current liabilities8,278 — — — — — 8,278 
$29,405 $60,593 $2,538 $1,217 $— $— $93,753 
At December 31, 2023
Research project financing$2,057 $113 $165 $207 $— $— $2,542 
Interest-bearing receivables financing9,544 — — — — — 9,544 
Government loans1,791 1,414 695 — — — 3,900 
Convertible debt52,278 — — — — — 52,278 
Unsecured related party loan8,922 — — — — — 8,922 
Lease liabilities1,471 1,102 387 61 70 25 3,116 
Trade payables16,281 — — — — — 16,281 
Other current liabilities8,899 — — — — — 8,899 
$101,243 $2,629 $1,247 $268 $70 $25 $105,482 
 
Schedule of Financial Liabilities
(in thousands)January 1, 2021Cash flowsForeign exchange movementAccrued interest
Non-cash impact of amendment and conversion
Other(1)
December 31, 2021
Government grant advances and loans$15,070 592 (449)427 — (80)$15,560 
Convertible debt$26,074 27,957 — 6,193 (16,008)(12,713)$36,373 
Venture debt$8,276 (8,743)180 819 — (532)$— 
Lease liabilities$5,776 $(1,063)$(297)$760 — $(556)$4,620 
Interest-bearing financing of receivables$14,228 21 (337,000)282,000 — (4,676,000)$9,518 
Total$69,424 18,764 (903)8,481 (16,008)(18,557)$66,071 

(in thousands)January 1, 2022Cash flows
Foreign exchange movementAccrued interestNon-cash impact of amendment and conversion
Other(1)

December 31, 2022
Government grant advances and loans$15,560 406 (365)266 — (5,473)$10,394 
Convertible debt$36,373 — — 7,762 (671)(9)$43,455 
Lease liabilities$4,620 (1,205)(298)571 — (119)$3,569 
Interest-bearing financing of receivables$9,518 3,046 (1)254 — (5,094)$7,723 
Total$66,071 2,247 (664)8,853 (671)(10,695)$65,141 
(in thousands)January 1, 2023Cash flowsForeign exchange movementAccrued interestNon-cash impact of amendment and conversion
Other(1)
December 31, 2023
Government grant advances and loans$10,394 (466)182 225 (2,473)$7,862 
Convertible debt$43,455 9,152 (247)(82)$52,278 
Unsecured related party loan— 9,000 — 127 — (205)8,922 
Lease liabilities$3,569 (1,321)113 479 — 276 $3,116 
Interest-bearing financing of receivables$7,723 1,483 179 234 — (191)$9,428 
Total$65,141 8,696 474 10,217 (247)(2,675)$81,606 
(1) In 2021, 2022 and 2023, Other includes additions in lease liabilities, which are non-cash. In 2021, Other includes the liability component and the fair value of the embedded option of the convertible debts converted during the year. In 2021, Other includes the impact of the forgiveness of the government grant advance and of the netting of the interest-bearing financing debt with the Research tax credit receivable.
 
XML 76 R51.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related party disclosures (Tables)
12 Months Ended
Dec. 31, 2023
Related Party [Abstract]  
Compensation of Key Management Personnel
Compensation of key management personnel
 Year ended December 31,
 202120222023
 (in thousands)
Fixed and variable wages, social charges and benefits expensed in the year$2,837 $2,574 $2,689 
Share-based payment expense for the year2,478 2,903 4,144 
Board members fees to non-executive members210 199 199 
Total compensation expense for key management personnel$5,525 $5,676 $7,032 
XML 77 R52.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of significant accounting and reporting policies - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jan. 01, 2020
Disclosure of detailed information about intangible assets [line items]          
Public and private equity offering proceeds, net of transaction costs paid $ 25,450 $ 30,111 $ 9,852    
Proceeds from convertible debt, net of transaction cost 0 0 39,682    
Net losses 40,990 9,008 20,263    
Accumulated deficit 93,362 65,099 383,554    
Increase (decrease) in working capital 71,000        
Right-of-use assets 2,146 2,602 3,374 $ 4,656  
Lease liabilities 3,116 3,569 4,620   $ 5,776
Lease liabilities 1,645 2,278 3,373   4,762
Lease liabilities $ 1,471 1,291 1,247   $ 1,014
Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16 14.20%        
Equity $ 6,071 (2,104) 24,306 $ 36,806  
Period of the maintenance 1 year        
Revenue from development contracts where no related incremental costs were identified $ 214 236      
Performance obligation 88 1,643 4,273    
Contract liabilities 190 271 765    
Proceeds from current borrowings $ 9,000        
Licenses          
Disclosure of detailed information about intangible assets [line items]          
Life used to compute amortization in the case of perpetual licenses 5 years        
Bottom of range | Capitalized development costs          
Disclosure of detailed information about intangible assets [line items]          
Life used to compute amortization in the case of perpetual licenses 3 years        
Top of range | Capitalized development costs          
Disclosure of detailed information about intangible assets [line items]          
Life used to compute amortization in the case of perpetual licenses 5 years        
Within one year          
Disclosure of detailed information about intangible assets [line items]          
Performance obligation   1,276 4,017    
Later than one year          
Disclosure of detailed information about intangible assets [line items]          
Performance obligation   $ 367 $ 256    
IFRS 16          
Disclosure of detailed information about intangible assets [line items]          
Right-of-use assets $ 2,146        
XML 78 R53.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of significant accounting and reporting policies - Schedule of Subsidiaries (Details)
12 Months Ended
Dec. 31, 2023
Sequans Communications Ltd.  
Disclosure of subsidiaries [line items]  
% equity interest 100.00%
Sequans Communications Inc.  
Disclosure of subsidiaries [line items]  
% equity interest 100.00%
Sequans Communications Ltd. Pte.  
Disclosure of subsidiaries [line items]  
% equity interest 100.00%
Sequans Communications Israel (2009) Ltd.  
Disclosure of subsidiaries [line items]  
% equity interest 100.00%
Sequans Communications Finland Oy  
Disclosure of subsidiaries [line items]  
% equity interest 100.00%
Sequans Communications SAS  
Disclosure of subsidiaries [line items]  
% equity interest 100.00%
XML 79 R54.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of significant accounting and reporting policies - Schedule of Average and Closing Exchange Rate for the U.S. Dollar (Details)
12 Months Ended
Dec. 31, 2023
uSD_to_EUR
Dec. 31, 2023
uSD_to_GBP
uSD_to_EUR
Dec. 31, 2023
uSD_to_EUR
uSD_to_SGD
Dec. 31, 2023
uSD_to_NIS
uSD_to_EUR
Dec. 31, 2022
uSD_to_EUR
Dec. 31, 2022
uSD_to_EUR
uSD_to_GBP
Dec. 31, 2022
uSD_to_SGD
uSD_to_EUR
Dec. 31, 2022
uSD_to_EUR
uSD_to_NIS
Dec. 31, 2021
uSD_to_EUR
Dec. 31, 2021
uSD_to_GBP
uSD_to_EUR
Dec. 31, 2021
uSD_to_SGD
uSD_to_EUR
Dec. 31, 2021
uSD_to_NIS
uSD_to_EUR
Dec. 31, 2023
uSD_to_GBP
Dec. 31, 2023
uSD_to_SGD
Dec. 31, 2023
uSD_to_NIS
Dec. 31, 2022
uSD_to_GBP
Dec. 31, 2022
uSD_to_SGD
Dec. 31, 2022
uSD_to_NIS
Dec. 31, 2021
uSD_to_GBP
Dec. 31, 2021
uSD_to_SGD
Dec. 31, 2021
uSD_to_NIS
Corporate information and statement of IFRS compliance [abstract]                                          
Average rate 1.0816 1.2435 0.7447 0.2716 1.0539 1.2372 0.7255 0.2980 1.1835 1.3761 0.7444 0.3097                  
Closing rate 1.1050 1.1050 1.1050 1.1050 1.0666 1.0666 1.0666 1.0666 1.1326 1.1326 1.1326 1.1326 1.2714 0.7573 0.2763 1.2026 0.7459 0.2840 1.3479 0.7413 0.3221
XML 80 R55.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of significant accounting and reporting policies - Performance Obligation (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of transaction price allocated to remaining performance obligations [line items]      
Performance obligation $ 88 $ 1,643 $ 4,273
Within one year      
Disclosure of transaction price allocated to remaining performance obligations [line items]      
Performance obligation   1,276 4,017
Later than one year      
Disclosure of transaction price allocated to remaining performance obligations [line items]      
Performance obligation   $ 367 $ 256
XML 81 R56.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of significant accounting and reporting policies - Schedule of Useful Lives Most Commonly Used (Details)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Building and leasehold improvements    
Disclosure of detailed information about property, plant and equipment [line items]    
Useful life   6 years
Computer equipment    
Disclosure of detailed information about property, plant and equipment [line items]    
Useful life 3 years  
Furniture and office equipment    
Disclosure of detailed information about property, plant and equipment [line items]    
Useful life 5 years  
Bottom of range | Machinery and equipment    
Disclosure of detailed information about property, plant and equipment [line items]    
Useful life   3 years
Top of range | Machinery and equipment    
Disclosure of detailed information about property, plant and equipment [line items]    
Useful life   5 years
XML 82 R57.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Segment information (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Operating segments [Abstract]      
Number of operating segments | segment 1    
Disclosure of geographical areas [line items]      
Product revenue $ 33,616 $ 60,551 $ 50,879
Broadband IoT      
Disclosure of geographical areas [line items]      
Product revenue 21,842 36,181 23,699
Massive IoT      
Disclosure of geographical areas [line items]      
Product revenue 11,774 24,370 27,180
Product      
Disclosure of geographical areas [line items]      
Product revenue 8,060 22,974 30,410
Development and other services      
Disclosure of geographical areas [line items]      
revenue from sales of license 2,559 6,572 3,396
license fee      
Disclosure of geographical areas [line items]      
revenue from sales of other services 22,997 31,005 17,073
Total Asia      
Disclosure of geographical areas [line items]      
Product revenue 21,823 27,294 20,165
Taiwan      
Disclosure of geographical areas [line items]      
Product revenue 29 1,066 14,668
Korea      
Disclosure of geographical areas [line items]      
Product revenue 30 8 1,090
China      
Disclosure of geographical areas [line items]      
Product revenue 21,702 24,018 3,509
Rest of Asia      
Disclosure of geographical areas [line items]      
Product revenue 62 2,202 898
Germany      
Disclosure of geographical areas [line items]      
Product revenue 1,001 15,525 4,990
Germany      
Disclosure of geographical areas [line items]      
Product revenue 8,666 16,749 22,565
Rest of world      
Disclosure of geographical areas [line items]      
Product revenue $ 2,126 $ 983 $ 3,159
Revenue Risk [Member] | International      
Disclosure of geographical areas [line items]      
Concentration Risk, Percentage 96.20% 99.80% 9960.00%
XML 83 R58.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Other revenues and expenses - Schedule of Financial Income and Expenses (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:      
Income from short-term investments and term deposits and other finance revenue $ 177,000 $ 68,000 $ 47,000
Impact of debt reimbursement 0 0 5,177,000
Convertible debt amendments (Note 14.1) 247,000 476,000 0
Change in fair value of convertible debt derivative 3,200,000 6,878,000 3,848,000
Foreign exchange gain 1,166,000 7,076,000 3,032,000
Total financial income 4,790,000 14,498,000 12,104,000
Financial expenses:      
Interest on loans 9,584,000 8,146,000 7,462,000
Interest on lease contracts (see Note 15) 479,000 571,000 760,000
Interest on financing component of long term development services agreement (see Notes 18 and 19) 115,000 966,000 2,156,000
Interest on supplier payable with extended payment terms 286,000 222,000 173,000
Other bank fees and financial charges 946,000 1,020,000 778,000
Foreign exchange loss 1,858,000 5,994,000 2,094,000
Total financial expenses $ 13,268,000 $ 16,919,000 $ 13,423,000
XML 84 R59.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Other revenues and expenses - Financial Income and Expenses (Narrative) (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of detailed information about borrowings [line items]        
Interest on loans $ 9,584,000 $ 8,146,000 $ 7,462,000  
Foreign exchange gains and losses related to hedges of euro (692,000) 1,082,000 938,000  
Expenses related to the change in fair value of the convertible debt embedded derivative 3,200,000 6,878,000 3,848,000  
Impact of debt reimbursement 0 0 5,177,000  
Convertible debt amendments (Note 14.1) 247,000 476,000 0  
Receivables from taxes other than income tax 9,714,000      
Research Tax Credit 2021        
Disclosure of detailed information about borrowings [line items]        
Receivables from taxes other than income tax     137,000  
Research Tax Credit 2020        
Disclosure of detailed information about borrowings [line items]        
Receivables from taxes other than income tax       $ 111,000
Research Tax Credit 2022        
Disclosure of detailed information about borrowings [line items]        
Receivables from taxes other than income tax   4,460,000    
Research Tax Credit 2023        
Disclosure of detailed information about borrowings [line items]        
Receivables from taxes other than income tax 5,006,000      
Loans and finance leases related to convertible debts issued and government loans granted        
Disclosure of detailed information about borrowings [line items]        
Interest on loans $ 9,566,000 $ 8,094,000 $ 7,334,000  
XML 85 R60.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Other revenues and expenses - Schedule of Cost of Revenue, Operating Expenses, and Employee Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Expense By Nature [Line Items]      
Share-based payment expenses $ 7,104 $ 5,477 $ 5,135
Foreign exchange (gains) losses related to hedges of euro 692 (1,082) (938)
Wages and salaries 28,863 27,115 29,422
Social security costs and other payroll taxes 9,087 8,408 9,386
Other benefits 159 159 167
Pension costs (36) 10 15
Expense for defined contributions plans 1,465 1,398 1,434
Wages and benefits 45,177 41,169 44,125
Included in cost of revenue:      
Expense By Nature [Line Items]      
Cost of components 5,071 13,102 18,365
Depreciation and impairment 395 428 517
Amortization of intangible assets 118 148 162
Share-based payment expenses 131 160 58
Assembly services, royalties and other 1,702 1,336 2,282
Wages and benefits 2,059 2,497 2,306
Included in operating expenses (between gross profit and operating result):      
Expense By Nature [Line Items]      
Depreciation and impairment 4,082 3,551 2,837
Amortization of intangible assets 7,346 7,888 7,037
Share-based payment expenses 6,973 5,317 5,077
Foreign exchange (gains) losses related to hedges of euro (180) 207 (73)
Other, net (257) (3,439) (6,054)
Wages and benefits $ 36,014 $ 33,195 $ 36,684
XML 86 R61.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Other revenues and expenses - Research and Development Expense and Tax Credit Receivable (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Analysis of income and expense [abstract]      
Receivables from taxes other than income tax $ 9,714    
Research and development costs 53,018 $ 47,353 $ 52,200
Research tax credit (5,374) (4,622) (6,328)
Government and other grants (1,834) (4,888) (3,621)
Development costs capitalized (*) (22,328) (13,808) (18,297)
Amortization of capitalized development costs 2,642 2,575 2,460
Total research and development expense 26,124 26,610 26,414
Research tax credit $ (2,145) $ (1,924) $ (1,587)
XML 87 R62.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income tax - Schedule of Major Components of Income Tax Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Taxes [Abstract]      
Current income tax expense $ 2,683 $ 2,609 $ 504
Deferred income tax expense (benefit) (9) 139 121
Income tax expense (benefit) $ 2,674 $ 2,748 $ 625
XML 88 R63.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income tax - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Taxes [Abstract]        
Withholding tax $ 2,055,000 $ 2,250,000 $ 0  
Accumulated tax losses available for offset against future taxable profits 402,130,063      
Deferred tax liability $ 264,000 $ 258,000 $ 138,000 $ 19,000
Applicable tax rate 25.00%   26.50%  
XML 89 R64.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income tax - Reconciliation of Income Taxes Computed at the French Statutory Rate (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Taxes [Abstract]      
Applicable tax rate 25.00%   26.50%
Loss before income taxes $ (38,316) $ (6,260) $ (19,638)
At France’s statutory income tax rate of 26.5% in 2021 and 25% in 2022 and in 2023 (9,579) (1,565) (5,204)
Non-deductible share-based payment expense 1,776 1,369 1,361
Tax credits (1,344) (1,156) (1,677)
Impact of the extinguishment of the convertible debts after amendment 62 119  
Impact of debt reimbursement     1,372
Permanent differences and other (212) 503 168
Withholding tax 2,055 2,250 0
Unrecognized benefit of tax losses carryforward 9,916 1,228 4,605
Income tax expense (benefit) $ 2,674 $ 2,748 $ 625
XML 90 R65.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income tax - Summary of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Taxes [Abstract]      
At January 1st $ 258 $ 138 $ 19
Tax expense (income) during the year recognized in Profit or Loss (9) 139 121
Tax expense during the year recognised in OCI 0 0 0
Effect of foreign exchange 15 (19) (2)
At December 31st $ 264 $ 258 $ 138
XML 91 R66.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income tax - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]        
Deferred tax liability (asset) $ 264 $ 258 $ 138 $ 19
Deferred tax effect, equity 0 0 0  
Tax expense (income) during the year recognized in Profit or Loss (9) 139 121  
Government loans        
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]        
Deferred tax liability (asset) (127) 7 (135)  
Deferred tax effect, equity 0 0 0  
Tax expense (income) during the year recognized in Profit or Loss (135) 142 (277)  
Intangible assets        
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]        
Deferred tax liability (asset) (120) (133) (28)  
Deferred tax effect, equity 0 0 0  
Tax expense (income) during the year recognized in Profit or Loss 13 (105) 21  
Cash flow hedge        
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]        
Deferred tax liability (asset) 2 (3) (2)  
Deferred tax effect, equity 0 0 0  
Tax expense (income) during the year recognized in Profit or Loss 5 (1) (4)  
Remeasurement of non-monetary accounts        
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]        
Deferred tax liability (asset) (3) (487) (171)  
Deferred tax effect, equity 0 0 0  
Tax expense (income) during the year recognized in Profit or Loss 485 (316) (899)  
Convertible debts and venture debt - liability        
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]        
Deferred tax liability (asset) 0 0 0  
Deferred tax effect, equity 0 0 0  
Tax expense (income) during the year recognized in Profit or Loss 0 0 (23)  
Other provisions and accruals        
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]        
Deferred tax liability (asset) (962) (495) (490)  
Deferred tax effect, equity 0 0 0  
Tax expense (income) during the year recognized in Profit or Loss (468) (4) (242)  
From subsidiaries        
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]        
Deferred tax liability (asset) 264 258 138  
Deferred tax effect, equity 0 0 0  
Tax expense (income) during the year recognized in Profit or Loss (9) 139 119  
Deferred tax asset not recognized on losses (Loss available for offsetting against future taxable income)        
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]        
Deferred tax liability (asset) 1,210 1,111 826  
Deferred tax effect, equity 0 0 0  
Tax expense (income) during the year recognized in Profit or Loss $ 100 $ 284 $ 1,426  
XML 92 R67.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Earnings (loss) per share (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Earnings per share [abstract]      
Profit (Loss) $ (40,990) $ (9,008) $ (20,263)
Weighted average number of shares outstanding for basic EPS (in shares) 225,183,996 184,587,104 146,691,784
Net effect of dilutive stock options (in shares) 0 0 0
Net effect of dilutive warrants (in shares) 0 0 0
Net effect of vesting of restricted stock (in shares) 0 0 0
Net effect of conversion of convertible notes (in shares) 0 0 0
Weighted average number of shares outstanding for diluted EPS (in shares) 225,183,996 184,587,104 146,691,784
Basic earnings (loss) per share (in dollars per share) $ (0.18) $ (0.05) $ (0.14)
Diluted earnings (loss) per share (in dollars per share) $ (0.18) $ (0.05) $ (0.14)
ADS outstanding for basic and diluted earnings (loss) per ADS (in shares) 56,295,999 46,146,776 36,672,946
Basic earnings (loss) per ADS (in dollars per share) $ (0.73) $ (0.20) $ (0.55)
Diluted earnings (loss) per ADS (in dollars per share) $ (0.73) $ (0.20) $ (0.55)
XML 93 R68.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance $ (8,489,000) $ (8,010,000) $ (9,187,000)
Reclassification 707,000    
Ending balance (6,815,000) (8,489,000) (8,010,000)
Cost:      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance (45,263,000) (41,315,000) (39,794,000)
Additions 2,874,000 4,586,000 2,668,000
Disposals (419,000) (302,000) (1,194,000)
Reclassification     0
Exchange difference 133,000 (336,000) 47,000
Ending balance (47,851,000) (45,263,000) (41,315,000)
Depreciation and impairment:      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance 36,774,000 33,305,000 30,607,000
Disposals 416,000 278,000 683,000
Reclassification     0
Exchange difference 84,000 (232,000) 27,000
Depreciation charge for the year 3,883,000 3,979,000 3,354,000
Reclassification 711,000    
Ending balance 41,036,000 36,774,000 33,305,000
Leasehold improvements      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance (84,000) (151,000) (107,000)
Ending balance (121,000) (84,000) (151,000)
Leasehold improvements | Cost:      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance (1,417,000) (1,437,000) (1,340,000)
Additions 75,000 15,000 16,000
Disposals 0 0 (20,000)
Reclassification     94,000
Exchange difference 10,000 (35,000) 7,000
Ending balance (1,502,000) (1,417,000) (1,437,000)
Leasehold improvements | Depreciation and impairment:      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance 1,333,000 1,286,000 1,233,000
Disposals 0 0 12,000
Reclassification     (19,000)
Exchange difference 7,000 (20,000) 1,000
Depreciation charge for the year 41,000 67,000 45,000
Reclassification 0    
Ending balance 1,381,000 1,333,000 1,286,000
Plant and equipment      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance (5,409,000) (4,037,000) (4,112,000)
Ending balance (4,127,000) (5,409,000) (4,037,000)
Plant and equipment | Cost:      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance (32,380,000) (28,842,000) (27,435,000)
Additions 1,812,000 3,891,000 1,842,000
Disposals (2,000) (175,000) (415,000)
Reclassification     0
Exchange difference 107,000 (178,000) (20,000)
Ending balance (34,297,000) (32,380,000) (28,842,000)
Plant and equipment | Depreciation and impairment:      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance 26,971,000 24,805,000 23,323,000
Disposals 2,000 153,000 372,000
Reclassification     0
Exchange difference 69,000 (122,000) (15,000)
Depreciation charge for the year 2,421,000 2,441,000 1,869,000
Reclassification   711,000  
Ending balance 30,170,000 26,971,000 24,805,000
IT and office equipment      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance (394,000) (448,000) (312,000)
Ending balance (421,000) (394,000) (448,000)
IT and office equipment | Cost:      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance (4,387,000) (4,342,000) (4,006,000)
Additions 220,000 222,000 373,000
Disposals (3,000) (54,000) (3,000)
Reclassification     (94,000)
Exchange difference 16,000 (123,000) 60,000
Ending balance (4,620,000) (4,387,000) (4,342,000)
IT and office equipment | Depreciation and impairment:      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance 3,993,000 3,894,000 3,694,000
Disposals 0 52,000 3,000
Reclassification     19,000
Exchange difference 8,000 (90,000) 41,000
Depreciation charge for the year 198,000 241,000 181,000
Reclassification 0    
Ending balance 4,199,000 3,993,000 3,894,000
Right of use      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance (2,602,000) (3,374,000) (4,656,000)
Ending balance (2,146,000) (2,602,000) (3,374,000)
Right of use | Cost:      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance (7,079,000) (6,694,000) (7,013,000)
Additions 767,000 458,000 437,000
Disposals (414,000) (73,000) (756,000)
Reclassification     0
Exchange difference 0 0 0
Ending balance (7,432,000) (7,079,000) (6,694,000)
Right of use | Depreciation and impairment:      
Disclosure of detailed information about property, plant and equipment [line items]      
Beginning balance 4,477,000 3,320,000 2,357,000
Disposals 414,000 73,000 296,000
Reclassification     0
Exchange difference 0 0 0
Depreciation charge for the year 1,223,000 1,230,000 1,259,000
Reclassification 0    
Ending balance $ 5,286,000 $ 4,477,000 $ 3,320,000
XML 94 R69.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Property, plant and equipment - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]        
Right-of-use assets $ 2,146,000 $ 2,602,000 $ 3,374,000 $ 4,656,000
Reclassification 707,000      
Real-estate        
Disclosure of detailed information about property, plant and equipment [line items]        
Right-of-use assets 7,212,000 6,859,000 $ 6,474,000  
IT and office equipment        
Disclosure of detailed information about property, plant and equipment [line items]        
Right-of-use assets $ 220,000 $ 220,000    
XML 95 R70.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Intangible assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Reconciliation of changes in intangible assets other than goodwill [abstract]      
Beginning balance $ (48,705) $ (37,984) $ (25,312)
Ending balance (64,300) (48,705) (37,984)
Cost:      
Reconciliation of changes in intangible assets other than goodwill [abstract]      
Beginning balance (82,337) (66,103) (46,189)
Additions/Amortization 22,960 18,909 19,747
Disposals, Cost (Depreciation and impairment) (2,121) (2,441) 0
Exchange difference (7) (234) 167
Ending balance (103,169) (82,337) (66,103)
Depreciation and impairment:      
Reconciliation of changes in intangible assets other than goodwill [abstract]      
Beginning balance 33,632 28,119 20,877
Additions/Amortization 7,348 8,033 7,051
Provision for impairment   3 148
Disposals, Cost (Depreciation and impairment) 2,121 2,441  
Exchange difference 10 (82) 43
Ending balance 38,869 33,632 28,119
Capitalized development costs      
Reconciliation of changes in intangible assets other than goodwill [abstract]      
Beginning balance (40,618) (29,385) (13,548)
Ending balance (60,305) (40,618) (29,385)
Capitalized development costs | Development Of The 5G      
Reconciliation of changes in intangible assets other than goodwill [abstract]      
Beginning balance (25,500) (14,200)  
Ending balance (18,400) (25,500) (14,200)
Capitalized development costs | Cost:      
Reconciliation of changes in intangible assets other than goodwill [abstract]      
Beginning balance (48,903) (35,095) (16,798)
Additions/Amortization 22,327 13,808 18,297
Disposals, Cost (Depreciation and impairment) 0 0 0
Exchange difference 0 0 0
Ending balance (71,230) (48,903) (35,095)
Capitalized development costs | Depreciation and impairment:      
Reconciliation of changes in intangible assets other than goodwill [abstract]      
Beginning balance 8,285 5,710 3,250
Additions/Amortization 2,640 2,575 2,460
Provision for impairment   0 0
Disposals, Cost (Depreciation and impairment) 0 0  
Exchange difference 0 0 0
Ending balance 10,925 8,285 5,710
Licenses      
Reconciliation of changes in intangible assets other than goodwill [abstract]      
Beginning balance (8,087) (8,599) (11,764)
Ending balance (3,995) (8,087) (8,599)
Licenses | Cost:      
Reconciliation of changes in intangible assets other than goodwill [abstract]      
Beginning balance (33,434) (31,008) (29,391)
Additions/Amortization 633 5,101 1,450
Disposals, Cost (Depreciation and impairment) (2,121) (2,441) 0
Exchange difference (7) (234) 167
Ending balance (31,939) (33,434) (31,008)
Licenses | Depreciation and impairment:      
Reconciliation of changes in intangible assets other than goodwill [abstract]      
Beginning balance 25,347 22,409 17,627
Additions/Amortization 4,708 5,458 4,591
Provision for impairment   3 148
Disposals, Cost (Depreciation and impairment) 2,121 2,441  
Exchange difference 10 (82) 43
Ending balance $ 27,944 $ 25,347 $ 22,409
XML 96 R71.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Intangible assets - Narrative (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of detailed information about intangible assets [line items]        
Intangible assets $ 64,300 $ 48,705 $ 37,984 $ 25,312
Capitalized development costs        
Disclosure of detailed information about intangible assets [line items]        
Intangible assets 60,305 40,618 29,385 $ 13,548
Capitalized development costs | Development Of The 5G        
Disclosure of detailed information about intangible assets [line items]        
Intangible assets $ 18,400 $ 25,500 $ 14,200  
XML 97 R72.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]      
Components, net $ 3,641 $ 6,035 $ 2,458
Finished goods, at the lower of cost and net realizable value 2,694 3,352 3,975
Total net inventories 6,335 9,387 6,433
Gross carrying amount      
Disclosure of detailed information about property, plant and equipment [line items]      
Components, net 4,706 6,641 2,683
Finished goods, at the lower of cost and net realizable value 4,559 4,599 5,091
Total net inventories 9,265 11,240 7,774
Inventory adjustments      
Disclosure of detailed information about property, plant and equipment [line items]      
Components, net (1,065) (606) (225)
Finished goods, at the lower of cost and net realizable value (1,865) (1,247) (1,116)
Total net inventories (2,930) (1,853) $ (1,341)
Inventory adjustments | Lead-Times Increased COVID-19 And Other Supply Chain Constraints      
Disclosure of detailed information about property, plant and equipment [line items]      
Total net inventories (362) $ (340)  
Inventory adjustments | Provision To Serve Expected Demand For Customers And Projects      
Disclosure of detailed information about property, plant and equipment [line items]      
Total net inventories $ (2,568)    
XML 98 R73.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Inventories - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]      
Current inventories $ (6,335,000) $ (9,387,000) $ (6,433,000)
Provision used, other provisions 124,000 0 90,000
Lead-Times Increased COVID-19 And Other Supply Chain Constraints      
Disclosure of detailed information about property, plant and equipment [line items]      
Provision used, other provisions 126,000    
Increase (decrease) in other provisions 104,000    
Inventory adjustments      
Disclosure of detailed information about property, plant and equipment [line items]      
Current inventories 2,930,000 1,853,000 $ 1,341,000
Inventory adjustments | Lead-Times Increased COVID-19 And Other Supply Chain Constraints      
Disclosure of detailed information about property, plant and equipment [line items]      
Current inventories 362,000 $ 340,000  
Inventory adjustments | Provision To Serve Expected Demand For Customers And Projects      
Disclosure of detailed information about property, plant and equipment [line items]      
Current inventories $ 2,568,000    
XML 99 R74.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Trade receivables - Schedule of Non-Interest Bearing Trade Receivables (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]      
Trade receivables $ 10,803 $ 11,243 $ 16,876
Contract assets 497 176 789
Provision for credit notes to be issued (164) (225) (465)
Provisions on trade receivables (2,524) (2,524) (2,789)
Net trade receivables $ 8,612 $ 8,670 $ 14,411
XML 100 R75.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Trade receivables - Schedule of Movements in the Provision for Impairment of Receivables (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]      
At January 1, $ 2,524 $ 2,789  
At year end 2,524 2,524 $ 2,789
Impaired additional trade receivables     65
Trade receivables and contract assets      
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]      
At January 1, 2,524 2,789 2,724
Charge for the year 0 0 65
Utilized amounts 0 (265) 0
Unutilised, allowance account for credit losses of financial assets [Abstract]   0 0
At year end $ 2,524 $ 2,524 $ 2,789
XML 101 R76.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Trade receivables - Aging Analysis of Trade Receivables That Were Not Impaired (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Disclosure of financial assets that are either past due or impaired [line items]      
Total $ 20,054 $ 15,182 $ 20,256
Impaired additional trade receivables 65    
Trade receivables and contract assets      
Disclosure of financial assets that are either past due or impaired [line items]      
Total 14,411 8,612 8,670
Trade receivables and contract assets | Neither past due nor Impaired      
Disclosure of financial assets that are either past due or impaired [line items]      
Total 13,587 6,532 8,367
Trade receivables and contract assets | Past due but not impaired | Less than 30 days      
Disclosure of financial assets that are either past due or impaired [line items]      
Total 241 1,919 209
Trade receivables and contract assets | Past due but not impaired | 30-60 days      
Disclosure of financial assets that are either past due or impaired [line items]      
Total 0 101 94
Trade receivables and contract assets | Past due but not impaired | 60-120 days      
Disclosure of financial assets that are either past due or impaired [line items]      
Total 0 4 0
Trade receivables and contract assets | Past due but not impaired | Greater than 120 days      
Disclosure of financial assets that are either past due or impaired [line items]      
Total $ 583 $ 56 $ 0
XML 102 R77.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]      
Cash at banks $ 5,697 $ 5,664 $ 4,828
Cash equivalents 8 7 7
Short-term deposits 0 5,000 0
Cash, cash equivalents and deposits $ 5,705 $ 10,671 $ 4,835
XML 103 R78.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cash and cash equivalents - Schedule of Cash and Cash Equivalents Held in U.S. dollar and Euros (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure Of Cash And Cash Equivalents [Line Items]      
Cash, cash equivalents and short-term deposits $ 5,705 $ 10,671 $ 4,835
U.S. dollar denominated accounts      
Disclosure Of Cash And Cash Equivalents [Line Items]      
Cash, cash equivalents and short-term deposits 5,250 9,720 2,869
Euro denominated accounts      
Disclosure Of Cash And Cash Equivalents [Line Items]      
Cash, cash equivalents and short-term deposits 91 466 1,564
GBP denominated accounts      
Disclosure Of Cash And Cash Equivalents [Line Items]      
Cash, cash equivalents and short-term deposits 319 19 143
SGP denominated accounts      
Disclosure Of Cash And Cash Equivalents [Line Items]      
Cash, cash equivalents and short-term deposits 13 23 47
NIS denominated accounts      
Disclosure Of Cash And Cash Equivalents [Line Items]      
Cash, cash equivalents and short-term deposits 1 428 160
RMB denominated accounts      
Disclosure Of Cash And Cash Equivalents [Line Items]      
Cash, cash equivalents and short-term deposits 10 3 35
Other currencies denominated accounts      
Disclosure Of Cash And Cash Equivalents [Line Items]      
Cash, cash equivalents and short-term deposits $ 21 $ 12 $ 17
XML 104 R79.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Issued capital and reserves - Narratives (Details)
12 Months Ended
Jun. 27, 2023
USD ($)
Jun. 24, 2022
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2023
€ / shares
Sep. 26, 2023
$ / shares
Apr. 12, 2023
$ / shares
Dec. 31, 2022
€ / shares
Dec. 31, 2021
€ / shares
Disclosure of classes of share capital [line items]                  
Reduction of issued capital     $ 0 $ 0          
Par value per share | € / shares         € 0.01     € 0.01 € 0.02
Ordinary shares [member]                  
Disclosure of classes of share capital [line items]                  
Par value per share | $ / shares           $ 0.7075 $ 0.515    
Ordinary shares                  
Disclosure of classes of share capital [line items]                  
Reduction of issued capital   $ 2,283,000              
Share premium                  
Disclosure of classes of share capital [line items]                  
Reduction of issued capital $ (12,727,000) 325,180,000 12,727,000 327,463,000          
Accumulated deficit                  
Disclosure of classes of share capital [line items]                  
Reduction of issued capital $ 12,727,000 $ (327,463,000) $ (12,727,000) $ (327,463,000)          
XML 105 R80.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Issued capital and reserves - Authorized capital, in number of shares (Details)
Dec. 31, 2023
category
€ / shares
shares
Dec. 31, 2022
€ / shares
shares
Dec. 31, 2021
€ / shares
shares
Share Capital, Reserves And Other Equity Interest [Abstract]      
Authorised capital (in shares) | shares 421,418,563 361,639,977 244,254,014
Number of categories of authorized shares | category 1    
Par value per share | € / shares € 0.01 € 0.01 € 0.02
XML 106 R81.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Issued capital and reserves - Shares Issued and Fully Paid (Details)
€ / shares in Units, € in Thousands, $ in Thousands
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2023
EUR (€)
€ / shares
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2022
EUR (€)
€ / shares
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2021
EUR (€)
€ / shares
shares
Share Capital, Reserves And Other Equity Interest [Abstract]            
Ordinary shares (in shares) | shares 246,262,004 246,262,004 193,426,478 193,426,478 151,419,322 151,419,322
Ordinary shares $ 2,878 € 2,463 $ 2,306 € 1,934 $ 3,687 € 3,028
Par value per share | € / shares   € 0.01   € 0.01   € 0.02
XML 107 R82.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Issued capital and reserves - Capital Transactions (Details) - USD ($)
1 Months Ended 12 Months Ended
Sep. 26, 2023
Apr. 12, 2023
Mar. 11, 2022
Jan. 11, 2022
Apr. 09, 2021
Jan. 31, 2022
Feb. 12, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of analysis of other comprehensive income by item [line items]                    
Ordinary share price (usd per share)     $ 0.75 $ 1.175 $ 1.375          
Share price per ADS (usd per share) $ 2.06 $ 2.06 $ 3.00 $ 4.70 $ 5.50          
Issue of shares and warrants $ 5,999,999 $ 20,000,000 $ 23,000,001 $ 9,281,349 $ 9,999,996 $ 9,281,000       $ 10,000,000
Transaction costs               $ 551,000 $ 2,170,000 $ 177,000
Shares issued (in shares)               246,262,004 193,426,478 151,419,322
Increase (decrease) through conversion of convertible instruments, equity $ 6,000,000   $ 23,000,000             $ 17,672,000
Underwriters' over-allotment shares issued (in shares)     4,000,000              
Convertible notes 2016 and 2019-1                    
Disclosure of analysis of other comprehensive income by item [line items]                    
Notional amount             $ 7,750,000      
Borrowings, accrued interest and conversion bonus             $ 4,536,438      
Shares issued (in shares)             7,227,308      
Ordinary shares                    
Disclosure of analysis of other comprehensive income by item [line items]                    
Issue of shares and warrants (in shares) 8,480,564 38,834,952 30,666,668 7,899,020 7,272,724 7,899,020        
Issue of shares and warrants $ 89,046 $ 423,301 $ 674,813 $ 178,802 $ 172,698 $ 179,000        
Increase (decrease) through conversion of convertible instruments, equity     $ 675,000       $ 175,239     $ 175,000
Conversion of convertible debt (in shares)     30,666,668             7,227,308
Share premium                    
Disclosure of analysis of other comprehensive income by item [line items]                    
Issue of shares and warrants 5,910,953 19,576,699 $ 22,325,188 9,102,547 9,827,297 $ 9,102,000        
Transaction costs $ 100,000 $ 400,000 2,000,000 $ 100,000 $ 100,000     $ 551,000 $ 2,170,000 $ 177,000
Increase (decrease) through conversion of convertible instruments, equity     $ 22,325,000       $ 12,111,185     $ (12,111,000)
XML 108 R83.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-based payment plans - Narrative (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2023
€ / shares
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2022
€ / shares
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2021
€ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Expense from equity-settled share-based payment transactions | $ $ 7,104   $ 5,477   $ 5,135  
Award vesting period 10 years          
Weighted average remaining contractual life 2 years 7 months 6 days   2 years 9 months 18 days   3 years  
Weighted average fair value (in € per unit) | € / shares   € 0.27   € 0.34   € 0.72
Sell price multiple that had been used     3      
Sell price multiple 2   2   2  
Decrease in weighted average share price (as a percent) 10.00%          
Decrease in total compensation (as a percent) (7.51%)   (9.40%)   (8.18%)  
Weighted average share price of options at exercise date (in usd per option)         $ 1.78  
Bottom of range [member]            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Range of exercise prices (in usd per unit) $ 0.54   $ 0.62   0.89  
Top of range [member]            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Range of exercise prices (in usd per unit) $ 3.31   $ 3.31   $ 3.31  
Warrants | Consultants considered equivalent to employees            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Expense from equity-settled share-based payment transactions | $ $ 111   $ 124   $ 76  
Restricted share awards (RSA)            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Weighted average fair value (in € per unit) | € / shares   € 0.66   € 0.91   € 1.14
XML 109 R84.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-based payment plans - Breakdown of share-based payments expenses (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Expense from equity-settled share-based payment transactions $ 7,104 $ 5,477 $ 5,135
Cost of Revenue      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Expense from equity-settled share-based payment transactions 131 159 57
Research and Development      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Expense from equity-settled share-based payment transactions 2,019 1,758 2,109
Sales and Marketing      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Expense from equity-settled share-based payment transactions 1,397 1,132 970
General and Administrative      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Expense from equity-settled share-based payment transactions $ 3,557 $ 2,428 $ 1,999
XML 110 R85.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-based payment plans - General employee stock option, founders warrant plans and restricted shares awards (Details)
12 Months Ended
Dec. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 10 years
Founders warrants and stock options  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 4 years
Founders warrants and stock options | After the first year anniversary of grant  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting percentage 25.00%
Founders warrants and stock options | Monthly over the remaining 36 months  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 36 months
Award vesting percentage 75.00%
RSA  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 4 years
Sale period 2 years
RSA | After the first year anniversary of grant  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 1 year
Award vesting percentage 25.00%
RSA | Quarterly over the remaining three years  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 3 years
Award vesting percentage 75.00%
RSA | After the two year anniversary of grant  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 2 years
Award vesting percentage 50.00%
RSA | Vesting quarterly over the remaining two years  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 2 years
Award vesting percentage 50.00%
XML 111 R86.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-based payment plans - Warrant plans for certain consultants considered equivalent to employees (Details)
12 Months Ended
Dec. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 10 years
Vesting scenario 1 | Warrants | Consultants considered equivalent to employees  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 2 years
Vesting scenario 2 | Warrants | Consultants considered equivalent to employees  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 3 years
Vesting scenario 3 | Warrants | Consultants considered equivalent to employees  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Award vesting period 4 years
XML 112 R87.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-based payment plans - Movements in number and WAEP (Details) - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of units outstanding at January 1, 5,868,521 5,233,437 5,687,367
Number of units granted during the year 1,500,000 1,110,288 1,076,000
Number of units forfeited during the year (111,887) (85,400) (139,722)
Number of units exercised during the year 0 0 (94,008)
Number of units expired during the year (444,820) 389,804 (1,296,200)
Number of units outstanding at period end 6,811,814 5,868,521 5,233,437
Number of units exercisable at period end 5,420,965 4,685,828 3,977,831
WAEP of units outstanding at January 1, (in usd per unit) $ 1.51 $ 1.73 $ 3.41
WAEP of units granted during the year (in usd per unit) 0.54 0.70 1.55
WAEP of units forfeited during the year (in usd per unit) 1.70 1.78 1.85
WAEP of units exercised during the year (in usd per unit) 0 0 1.47
WAEP of units expired during the year (in usd per unit) 1.89 2.05 8.35
WAEP of units outstanding at period end (in usd per unit) 1.27 1.51 1.73
WAEP of units exercisable at period end (in usd per unit) 1.44 1.70 1.79
Weighted average share price of options at exercise date (in usd per option)     1.78
Bottom of range      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Range of exercise prices (in usd per unit) 0.54 0.62 0.89
Top of range      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Range of exercise prices (in usd per unit) $ 3.31 $ 3.31 $ 3.31
Warrants | Consultants considered equivalent to employees      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of units outstanding at January 1, 487,288 203,000  
Number of units outstanding at period end 724,288 487,288 203,000
Number of units exercisable at period end 438,739 228,595 165,667
WAEP of units outstanding at January 1, (in usd per unit) $ 1.29 $ 1.79  
WAEP of units outstanding at period end (in usd per unit) 1.05 1.29 $ 1.79
WAEP of units exercisable at period end (in usd per unit) $ 1.28 $ 1.73 $ 1.72
XML 113 R88.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-based payment plans - Movements in number and restricted shares awards (Details)
12 Months Ended
Dec. 31, 2023
shares
$ / shares
Dec. 31, 2022
shares
$ / shares
Dec. 31, 2021
shares
$ / shares
Bottom of range      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Range of exercise prices (in usd per unit) | $ / shares $ 0.54 $ 0.62 $ 0.89
Top of range      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Range of exercise prices (in usd per unit) | $ / shares $ 3.31 $ 3.31 $ 3.31
Restricted share awards (RSA)      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Outstanding at January 1, 16,752,551 10,379,481 9,525,135
Granted during the year 2,640,460 10,550,820 4,426,496
Forfeited during the year (686,092) (736,282) (628,186)
Vested during the year (5,601,570) (3,441,468) (2,943,964)
Outstanding at period end 13,105,349 16,752,551 10,379,481
XML 114 R89.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Share-based payment plans - Valuation assumptions (Details) - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Dividend yield (%) 0.00% 0.00% 0.00%
Expected volatility (%) 59.00% 57.00% 59.00%
Risk–free interest rate (%) 250.00%   0.00%
Assumed annual lapse rate of awards (%) 15.00% 12.00% 10.00%
Sell price multiple (applied to exercise price) 2 2 2
Weighted average share price (in € per share) $ 0.86 $ 0.89 $ 1.22
Minimum      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Risk–free interest rate (%)   125.00%  
Maximum      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Risk–free interest rate (%)   210.00%  
Warrants      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Assumed annual lapse rate of awards (%) 2.00% 2.00% 2.00%
XML 115 R90.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Interest-bearing loans and borrowings - Schedule of Interest-Bearing Loans and Borrowings (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Borrowings, Excluding Government Loans And Research Project Financing      
Disclosure of detailed information about borrowings [line items]      
Interest-bearing financing of receivables $ 70,747 $ 7,723 $ 9,518
Total non-current portion 0 46,658 46,454
Convertible debt      
Disclosure of detailed information about borrowings [line items]      
Interest-bearing financing of receivables 52,278 0 0
Convertible debt 0 43,455 36,373
Unsecured related party loan      
Disclosure of detailed information about borrowings [line items]      
Interest-bearing financing of receivables 8,922 0 0
Interest-bearing receivables financing      
Disclosure of detailed information about borrowings [line items]      
Interest-bearing financing of receivables 9,544 7,723 9,518
Convertible debt embedded derivative      
Disclosure of detailed information about borrowings [line items]      
Interest-bearing financing of receivables 3 0 0
Convertible debt $ 0 $ 3,203 $ 10,081
XML 116 R91.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Interest-bearing loans and borrowings - Convertible Debt (Details)
1 Months Ended 12 Months Ended
Sep. 26, 2023
USD ($)
Aug. 15, 2023
USD ($)
$ / shares
shares
Aug. 15, 2022
USD ($)
$ / shares
shares
Mar. 11, 2022
USD ($)
Apr. 14, 2021
USD ($)
Apr. 09, 2021
USD ($)
$ / shares
Sep. 27, 2018
USD ($)
$ / shares
shares
Apr. 14, 2015
USD ($)
$ / shares
Feb. 12, 2021
USD ($)
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Aug. 14, 2023
USD ($)
Aug. 14, 2022
USD ($)
Mar. 20, 2020
Feb. 11, 2020
$ / shares
Feb. 10, 2020
$ / shares
Aug. 16, 2019
USD ($)
$ / shares
May 07, 2019
USD ($)
$ / shares
Oct. 30, 2017
$ / shares
Apr. 27, 2016
USD ($)
$ / shares
Apr. 14, 2015
€ / shares
Disclosure of detailed information about borrowings [line items]                                            
Change in fair value of convertible debt derivative                   $ 3,200,000 $ 6,878,000 $ 3,848,000                    
Gain (loss) on debt modification   $ 247,000 $ 476,000                                      
Shares issued (in shares) | shares                   246,262,004 193,426,478 151,419,322                    
Increase (decrease) through conversion of convertible instruments, equity $ 6,000,000     $ 23,000,000               $ 17,672,000                    
Repayment of convertible debt and accrued interest                   $ 0 $ 0 8,750,000                    
2015 convertible notes                                            
Disclosure of detailed information about borrowings [line items]                                            
Notional amount               $ 12,000,000                            
Conversion price (in dollars per share) | (per share)             $ 1.70 $ 1.85                           € 0.02
Conversion ratio               0.5405405                            
2018 convertible notes                                            
Disclosure of detailed information about borrowings [line items]                                            
Notional amount             $ 4,500,000                              
Conversion price (in dollars per share) | $ / shares             $ 1.70                              
Subscription price (in dollars per share) | $ / shares             $ 1.00                              
Number of warrants issued | shares             1,800,000                              
Exercise price (in dollars per share) | $ / shares             $ 1.70                              
2018 convertible notes | Warrants                                            
Disclosure of detailed information about borrowings [line items]                                            
Number of warrants issued | shares   1,244,820 594,680                                      
Exercise price (in dollars per share) | $ / shares   $ 0.8092 $ 1.03                                      
2018 convertible notes | American Depositary Shares, each representing four ordinary shares, nominal value €0.01 per share                                            
Disclosure of detailed information about borrowings [line items]                                            
Number of warrants issued | shares   311,205 148,670                                      
Exercise price (in dollars per share) | $ / shares   $ 3.2328 $ 4.12                                      
2016 convertible notes                                            
Disclosure of detailed information about borrowings [line items]                                            
Notional amount             $ 6,000,000                           $ 7,160,000  
Conversion price (in dollars per share) | $ / shares                                       $ 2.25 $ 2.7126  
2019-1 notes                                            
Disclosure of detailed information about borrowings [line items]                                            
Notional amount                                     $ 3,000,000      
Conversion price (in dollars per share) | $ / shares                                     $ 1.21      
2019-2 notes                                            
Disclosure of detailed information about borrowings [line items]                                            
Notional amount   $ 6,378,000 $ 6,125,000                   $ 6,707,000 $ 5,454,000       $ 5,000,000        
Conversion price (in dollars per share) | $ / shares                   $ 0.8082               $ 1.03        
Conversion price per ADS (in dollars per share) | $ / shares                   $ 3.23                        
Convertible notes 2016                                            
Disclosure of detailed information about borrowings [line items]                                            
Conversion price (in dollars per share) | $ / shares                               $ 1.225 $ 2.25          
Convertible Notes Amended, Option One                                            
Disclosure of detailed information about borrowings [line items]                                            
Conversion price premium percentage                             20.00%              
PIK interest rate                             7.00%              
Warrant, as a percentage of note value                             10.00%              
Exercise price, premium percentage                             20.00%              
Convertible Notes Amended, Option Two                                            
Disclosure of detailed information about borrowings [line items]                                            
PIK interest rate                             9.50%              
Warrant, as a percentage of note value                             15.00%              
Exercise price, premium percentage                             20.00%              
Convertible Notes Amended, Option Three                                            
Disclosure of detailed information about borrowings [line items]                                            
PIK interest rate                             13.50%              
Warrant, as a percentage of note value                             20.00%              
Exercise price, premium percentage                             20.00%              
Convertible debt                                            
Disclosure of detailed information about borrowings [line items]                                            
Interest rate                   7.00%                        
Derivative financial liabilities                   $ 3,000 3,203,000 10,081,000                    
Convertible debt embedded derivative                     $ 3,203,000 10,081,000                    
Convertible notes 2016 and 2019-1                                            
Disclosure of detailed information about borrowings [line items]                                            
Notional amount                 $ 7,750,000                          
Shares issued (in shares) | shares                 7,227,308                          
Convertible Notes 2015                                            
Disclosure of detailed information about borrowings [line items]                                            
Notional amount                 $ 7,750,000                          
Convertible debt embedded derivative                 6,534,000                          
Accrued interest                 $ 4,536,438                          
Shares issued (in shares) | shares                 7,227,308                          
Losses on change in fair value of derivatives                 $ 3,269,000                          
Convertible Note 2021 - Lynrock Lake Note                                            
Disclosure of detailed information about borrowings [line items]                                            
Notional amount           $ 40,000,000       $ 45,400,000                        
Conversion price (in dollars per share) | $ / shares           $ 1.915       $ 1.915                        
PIK interest rate           6.00%                                
Losses on change in fair value of derivatives           $ 12,713,000                                
Conversion price per ADS (in dollars per share) | $ / shares           $ 7.66       $ 7.66                        
Debt instrument, ownership limit           9.90%                                
Debt instrument, interest rate           5.0625%                                
Convertible Notes 2015 And 2018 - Nokomis                                            
Disclosure of detailed information about borrowings [line items]                                            
PIK interest rate   13.50% 9.50%   7.00%                                  
Change in fair value of convertible debt derivative                   $ (934,000)                        
Convertible debt embedded derivative         $ 4,645,000                                  
Convertible Notes 2015 - Nokomis                                            
Disclosure of detailed information about borrowings [line items]                                            
Repayment of convertible debt and accrued interest         6,378,104                                  
Repayment of convertible debt         4,250,000                                  
Repayment of convertible debt, accrued interest         2,128,000                                  
Convertible Notes 2018 - Nokomis                                            
Disclosure of detailed information about borrowings [line items]                                            
Repayment of convertible debt and accrued interest         5,346,699                                  
Repayment of convertible debt         4,500,000                                  
Repayment of convertible debt, accrued interest         $ 847,000                                  
Market approach | 2019-2 notes                                            
Disclosure of detailed information about borrowings [line items]                                            
Interest rate used to value liability   0.219 0.232                                      
Market approach | Convertible Note 2021 - Lynrock Lake Note                                            
Disclosure of detailed information about borrowings [line items]                                            
Interest rate used to value liability         0.2089                                  
Other capital reserves                                            
Disclosure of detailed information about borrowings [line items]                                            
Increase (decrease) through conversion of convertible instruments, equity                     $ 5,386,000                    
Other capital reserves | 2019-2 notes                                            
Disclosure of detailed information about borrowings [line items]                                            
Increase (decrease) through conversion of convertible instruments, equity   $ 421,000                                        
Other capital reserves | Convertible notes 2016 and 2019-1                                            
Disclosure of detailed information about borrowings [line items]                                            
Increase (decrease) through conversion of convertible instruments, equity     $ 343,000                                      
Other capital reserves | Convertible Notes 2015                                            
Disclosure of detailed information about borrowings [line items]                                            
Increase (decrease) through conversion of convertible instruments, equity                   $ 5,386,000                        
XML 117 R92.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Interest-bearing loans and borrowings - Venture Debt (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of detailed information about borrowings [line items]      
Repayment of venture debt $ 0 $ 0 $ 7,869,000
Interest on loans 9,584,000 8,146,000 7,462,000
Interest paid, classified as financing activities 1,356,000 1,467,000 5,310,000
Other finance income $ 0 $ 0 $ 5,177,000
XML 118 R93.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Interest-bearing loans and borrowings - Interest-Bearing Financing Receivables (Details) - USD ($)
1 Months Ended 12 Months Ended
Jun. 30, 2014
Dec. 31, 2022
Dec. 31, 2023
Mar. 31, 2022
Dec. 31, 2021
Feb. 28, 2021
Jul. 31, 2017
Jul. 01, 2017
Disclosure of detailed information about borrowings [line items]                
Accounts receivable   $ 8,670,000 $ 8,612,000   $ 14,411,000      
Interest-bearing receivables financing                
Disclosure of detailed information about borrowings [line items]                
Adjustment to interest rate basis               1.81%
Current borrowings   4,732,000 $ 2,531,000   5,651,000      
Interest-bearing receivables financing | LIBOR                
Disclosure of detailed information about borrowings [line items]                
Adjustment to interest rate basis               2.00%
Interest-Bearing Receivables Financing, Research Tax Credit                
Disclosure of detailed information about borrowings [line items]                
Interest rate     14.62% 5.33%   6.20%    
Notional amount   2,991,000 $ 3,369,000   3,867,000      
Borrowing, Retention Amount   1,249,000 1,531,000   1,562,000      
Interest-Bearing Receivables Financing, Research Tax Credit | Within one year                
Disclosure of detailed information about borrowings [line items]                
Borrowing, Retention Amount   780,000 1,409,000   1,436,000      
Interest-Bearing Receivables Financing, Research Tax Credit | More than five years                
Disclosure of detailed information about borrowings [line items]                
Borrowing, Retention Amount   $ 109,000 $ 122,000   $ 133,000      
Factoring of receivables | Interest-bearing receivables financing                
Disclosure of detailed information about borrowings [line items]                
Available borrowings, percentage of face value of accounts receivable 90.00%              
Exclusion from past due period of accounts receivable   60 days            
Service Sales [Member] | Factoring of receivables | Interest-bearing receivables financing                
Disclosure of detailed information about borrowings [line items]                
Accounts receivable             $ 800,000  
XML 119 R94.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Interest-bearing loans and borrowings - Unsecured related party loan (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Nov. 08, 2023
USD ($)
$ / shares
Sep. 26, 2023
$ / shares
Apr. 12, 2023
$ / shares
Mar. 11, 2022
$ / shares
Jan. 11, 2022
$ / shares
Apr. 09, 2021
$ / shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2023
€ / shares
Dec. 27, 2023
USD ($)
Dec. 31, 2022
€ / shares
Dec. 31, 2021
€ / shares
Disclosure of detailed information about borrowings [line items]                          
Par value per share | € / shares                   € 0.01   € 0.01 € 0.02
Share price per ADS (usd per share)   $ 2.06 $ 2.06 $ 3.00 $ 4.70 $ 5.50              
Interest on loans | $             $ 9,584 $ 8,146 $ 7,462        
Ordinary shares [member]                          
Disclosure of detailed information about borrowings [line items]                          
Par value per share   $ 0.7075 $ 0.515                    
Security Purchase Agreement                          
Disclosure of detailed information about borrowings [line items]                          
Share price per ADS (usd per share) $ 3.03                        
Security Purchase Agreement | Ordinary shares [member]                          
Disclosure of detailed information about borrowings [line items]                          
Par value per share 0.7575                        
Security Purchase Agreement | Ordinary Shares And ADS                          
Disclosure of detailed information about borrowings [line items]                          
Par value per share $ 0.01                        
Unsecured related party loan                          
Disclosure of detailed information about borrowings [line items]                          
Interest on loans | $             $ 127            
Unsecured related party loan | Security Purchase Agreement                          
Disclosure of detailed information about borrowings [line items]                          
Notional amount | $ $ 6,000                        
Borrowings, interest rate 9.50%                        
Unsecured related party loan | Second Security Purchase Agreement                          
Disclosure of detailed information about borrowings [line items]                          
Notional amount | $                     $ 3,000    
Borrowings, interest rate                     9.50%    
XML 120 R95.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Lease liabilities - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jan. 01, 2020
Disclosure of Leases [Line Items]          
Right-of-use assets $ 2,146 $ 2,602 $ 3,374 $ 4,656  
Lease liabilities 3,116 3,569 4,620   $ 5,776
Lease liabilities 1,645 2,278 3,373   4,762
Lease liabilities $ 1,471 1,291 1,247   $ 1,014
Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16 14.20%        
Rental charges $ 1,559 $ 1,248 $ 1,411    
IFRS 16          
Disclosure of Leases [Line Items]          
Right-of-use assets $ 2,146        
XML 121 R96.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Lease liabilities - Summary of movements in right-of-use assets and lease liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jan. 01, 2020
Disclosure of Leases [Line Items]        
Right-of-use assets at beginning of period $ 2,602 $ 3,374 $ 4,656  
Additions 767 458 437  
Depreciation expense (1,223) (1,230) (1,259)  
Disposals (414) (73) (757)  
Amortization disposals (414) (73) (297)  
Right-of-use assets at end of period 2,146 2,602 3,374  
Lease liabilities at beginning of period 3,569 4,620    
Current 1,471 1,291 1,247 $ 1,014
Lease liabilities 1,645 2,278 3,373 $ 4,762
Additions 767 458 437  
Disposals on Lease Liabilities (414) (577) (993)  
Interest on lease contracts (see Note 15) 479 571 760  
Foreign exchange loss (gain) 36 (298) (297)  
Payments (1,321) (1,205) (1,063)  
Lease liabilities at end of period 3,116 3,569 4,620  
Real-estate        
Disclosure of Leases [Line Items]        
Right-of-use assets at beginning of period 2,602 3,374 4,184  
Additions 767 458 437  
Depreciation expense (1,223) (1,230) (1,151)  
Disposals (414) (73) (210)  
Amortization disposals (414) (73) (114)  
Right-of-use assets at end of period 2,146 2,602 3,374  
IT and office equipment        
Disclosure of Leases [Line Items]        
Right-of-use assets at beginning of period 0 0 472  
Additions 0 0 0  
Depreciation expense 0 0 (108)  
Disposals 0 0 (547)  
Amortization disposals 0 0 (183)  
Right-of-use assets at end of period $ 0 $ 0 $ 0  
XML 122 R97.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Government grant advances and loans - Schedule of Government Grant Advances and Loans (Details)
€ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
EUR (€)
Current            
Government grant advances $ 708   $ 968   $ 3,317  
Research project financing 1,518   1,237   1,057  
Government loans 1,727   1,954   1,832  
Current interest payable 653   0   0  
Total current portion 4,606   4,159   6,206  
Non-current            
Government grant advances 328   872   2,048  
Research project financing 259   1,567   2,248  
Government loans 173   1,424   3,084  
Accrued interest 2,496   2,372   1,974  
Total non-current portion 3,256   6,235   9,354  
Amount funded from government grant advances $ 436 € 428 $ 1,364 € 1,376 $ 7,650 € 6,326
XML 123 R98.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Government grant advances and loans - Government Grant Advances (Details)
€ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
EUR (€)
project
Dec. 31, 2023
USD ($)
project
Dec. 31, 2022
EUR (€)
project
Dec. 31, 2022
USD ($)
project
Dec. 31, 2021
EUR (€)
project
Dec. 31, 2021
USD ($)
project
Research and Development Arrangement, Contract to Perform for Others1 [Line Items]            
Number of collaborative projects 1 1 4 4 2 2
Amount funded from government grant advances € 428 $ 436 € 1,376 $ 1,364 € 6,326 $ 7,650
Government Grant            
Research and Development Arrangement, Contract to Perform for Others1 [Line Items]            
Proceeds received from long-term projects € 428 $ 473        
Bottom of range [member] | Research project financing            
Research and Development Arrangement, Contract to Perform for Others1 [Line Items]            
Borrowings, interest rate 2.30% 2.30%     1.80% 1.80%
Top of range [member]            
Research and Development Arrangement, Contract to Perform for Others1 [Line Items]            
Term of collaborative project 3 years 3 years 3 years 3 years 3 years 3 years
Top of range [member] | Research project financing            
Research and Development Arrangement, Contract to Perform for Others1 [Line Items]            
Borrowings, interest rate 20.90% 20.90%     2.30% 2.30%
XML 124 R99.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Government grant advances and loans - Research Project Financing (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2022
USD ($)
Feb. 28, 2022
EUR (€)
Feb. 29, 2020
USD ($)
Feb. 29, 2020
EUR (€)
Dec. 31, 2016
USD ($)
instalment
Jan. 31, 2016
USD ($)
instalment
Oct. 31, 2014
USD ($)
Oct. 31, 2014
EUR (€)
Dec. 31, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
EUR (€)
Dec. 30, 2022
USD ($)
Dec. 30, 2022
EUR (€)
Dec. 31, 2020
EUR (€)
Jan. 31, 2016
EUR (€)
Disclosure of detailed information about borrowings [line items]                                      
Repayment of government loans                   $ (1,126,000)   $ (958,000)   $ (469,000)          
Accrued interest                   712,000,000   579,000   563,000          
Disposals on Lease Liabilities                   (414,000)   (577,000)   $ (993,000)          
Government Grant                                      
Disclosure of detailed information about borrowings [line items]                                      
Proceeds received from long-term projects                   473,000 € 428,000                
Government Grant | First Installment                                      
Disclosure of detailed information about borrowings [line items]                                      
Proceeds received from long-term projects                   38,000 36,000                
Forgivable Loan                                      
Disclosure of detailed information about borrowings [line items]                                      
Proceeds received from long-term projects                   $ 157,000 142,000                
Long-Term Research Project - October 2014                                      
Disclosure of detailed information about borrowings [line items]                                      
Research project, term             3 years 3 years 3 years         4 years 4 years        
Number of installments | instalment         3                            
Reduction in debt carrying value         $ 115,000                            
Long-Term Research Project - October 2014 | Fixed Contractual Rate                                      
Disclosure of detailed information about borrowings [line items]                                      
Interest rate                   1.53%                  
Long-Term Research Project - October 2014 | Research project financing                                      
Disclosure of detailed information about borrowings [line items]                                      
Total funding                 $ 8,988,000                 € 6,967,000  
Long-Term Research Project - October 2014 | Government Grant                                      
Disclosure of detailed information about borrowings [line items]                                      
Total funding                 3,815,000                 2,957,000  
Long-Term Research Project - October 2014 | Forgivable Loan                                      
Disclosure of detailed information about borrowings [line items]                                      
Total funding                 $ 5,173,000                 € 4,010,000  
Proceeds received from long-term projects                           $ 1,126,000 € 992,000        
Repayment of government loans                   $ (939,000) € (870,000) $ (571,000) € (540,000) $ (804,000) € (675,000)        
Long-Term Research Project - January 2016                                      
Disclosure of detailed information about borrowings [line items]                                      
Number of installments | instalment           4                          
Reduction in debt carrying value           $ 30,000                          
Long-Term Research Project - January 2016 | Fixed Contractual Rate                                      
Disclosure of detailed information about borrowings [line items]                                      
Interest rate           1.17%                         1.17%
Long-Term Research Project - January 2016 | Research project financing                                      
Disclosure of detailed information about borrowings [line items]                                      
Total funding           $ 2,288,000                   $ 316,000 € 309,000   € 2,095,000
Long-Term Research Project - January 2016 | Government Grant                                      
Disclosure of detailed information about borrowings [line items]                                      
Total funding           729,000                   $ 507,000 € 473,000   668,000
Long-Term Research Project - January 2016 | Forgivable Loan                                      
Disclosure of detailed information about borrowings [line items]                                      
Total funding           $ 1,558,000                         € 1,427,000
Royalty Agreement Terms | Long-Term Research Project - October 2014                                      
Disclosure of detailed information about borrowings [line items]                                      
Research project, term             10 years 10 years           3 years 3 years        
Excess sales amount threshold                           $ 396,000,000 € 350,000,000        
Period after termination date                           3 years 3 years        
Percentage of revenue from project                           1.00% 1.00%        
Maximum amount payable             $ 386,750,000 € 350,000,000                      
Bottom of range | Research project financing                                      
Disclosure of detailed information about borrowings [line items]                                      
Interest rate                   2.30%       1.80%          
Top of range | Research project financing                                      
Disclosure of detailed information about borrowings [line items]                                      
Interest rate                   20.90%       2.30%          
Entering into significant commitments or contingent liabilities | Long-Term Research Project - January 2016 | Forgivable Loan                                      
Disclosure of detailed information about borrowings [line items]                                      
Proceeds received from long-term projects     $ 405,000 € 365,000                              
Government grant advances and loans | Long-Term Research Project - January 2016                                      
Disclosure of detailed information about borrowings [line items]                                      
Repayment of government loans $ (241,000) € (213,000)                                  
XML 125 R100.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Government grant advances and loans - Government Loans (Details)
1 Months Ended
Apr. 30, 2020
EUR (€)
Sep. 30, 2015
USD ($)
borrowing
Dec. 31, 2023
USD ($)
Sep. 30, 2015
EUR (€)
Government loans        
Disclosure of detailed information about borrowings [line items]        
Number of government loans | borrowing   2    
Government debt instruments   $ 2,228,000   € 2,000,000
Debt term   7 years    
Government loan - 5.24% Loan        
Disclosure of detailed information about borrowings [line items]        
Government debt instruments       € 1,000,000
Interest rate   5.24%   5.24%
Government loan - Interest Free Loan        
Disclosure of detailed information about borrowings [line items]        
Government debt instruments       € 1,000,000
Government loan, Covid-19 support plan        
Disclosure of detailed information about borrowings [line items]        
Government debt instruments € 5,000,000      
Debt term 5 years      
Current borrowings | $     $ 1,727,000  
Total non-current portion | $     $ 2,610,000  
XML 126 R101.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Provisions - Reconciliation of Changes in Provisions (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Reconciliation of changes in other provisions [abstract]        
Total, beginning of period $ 2,273 $ 2,137    
Arising (released) during the year 364 327 $ 822  
Released (used) during the year (124) 0 (90)  
Released (unused) during the year (291) (191) (238)  
Total, end of period 2,222 2,273 2,137  
Current 0 77 0  
Non current 2,222 2,196 2,137  
Previously stated        
Reconciliation of changes in other provisions [abstract]        
Total, beginning of period     1,643  
Current       $ 89
Non current       $ 1,554
Post- employment benefits        
Reconciliation of changes in other provisions [abstract]        
Total, beginning of period 705 806    
Arising (released) during the year 107 (101) (28)  
Released (used) during the year (48) 0 0  
Released (unused) during the year 0 0 0  
Total, end of period 764 705 806  
Post- employment benefits | Previously stated        
Reconciliation of changes in other provisions [abstract]        
Total, beginning of period     834  
Other provisions        
Reconciliation of changes in other provisions [abstract]        
Total, beginning of period 1,568 1,331    
Arising (released) during the year 257 428 850  
Released (used) during the year (76) 0 (90)  
Released (unused) during the year (291) (191) (238)  
Total, end of period $ 1,458 $ 1,568 1,331  
Other provisions | Previously stated        
Reconciliation of changes in other provisions [abstract]        
Total, beginning of period     $ 809  
XML 127 R102.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Provisions - Narrative (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
employee
Dec. 31, 2022
USD ($)
employee
Dec. 31, 2021
USD ($)
employee
Disclosure of other provisions [line items]      
Provision for slow-moving or damaged inventory $ (6,335) $ (9,387) $ (6,433)
Provision used, other provisions 124 0 90
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans $ 46 $ (71) $ 33
Number of employees retired during the year | employee 1 0 0
FRANCE | Increase (decrease) due to changes in accounting policy required by IFRSs [member]      
Disclosure of other provisions [line items]      
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans $ 46 $ (71) $ 20
XML 128 R103.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Provisions - Schedule of Main Assumptions Used (Details)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of defined benefit plans [line items]      
Discount rate 3.20% 3.75% 0.98%
Directors      
Disclosure of defined benefit plans [line items]      
Turnover: depending on the seniority 2.00% 2.00% 2.00%
Other Employees      
Disclosure of defined benefit plans [line items]      
Turnover: depending on the seniority 10.00% 10.00% 10.00%
Executive Team      
Disclosure of defined benefit plans [line items]      
Turnover: depending on the seniority 0.00% 0.00% 0.00%
Bottom of range [member]      
Disclosure of defined benefit plans [line items]      
Salary increase 1.50% 1.50% 1.50%
Retirement age 60 years 60 years 60 years
Top of range [member]      
Disclosure of defined benefit plans [line items]      
Salary increase 3.50% 3.50% 3.50%
Retirement age 62 years 62 years 62 years
XML 129 R104.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Other non-current liabilities - Schedule of Other Non-Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]      
Payables $ 0 $ 1,788 $ 964
Deferred tax liabilities 264 258 138
License and development services agreement 0 404 2,706
Deferred revenue 0 0 0
Contract liabilities $ 0 $ 404 $ 2,706
XML 130 R105.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Other non-current liabilities - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Aug. 01, 2022
Feb. 28, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Oct. 24, 2019
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Deferred tax liabilities     $ 264 $ 258 $ 138  
License and services agreement upfront payment           $ 18,000
Recognized revenues       8,619 11,419  
Interest expenses on upfront payment       810 $ 1,628  
Net remaining contract liability       $ 4,211    
Trade payable term       30 days    
5G New Product Development            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Trade payable term       27 months 27 months  
Strategic Partner            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Interest expenses on upfront payment     14      
Strategic Partner, Amendment Contract            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Interest expenses on upfront payment     25      
Other revenue     296 $ 2,983 $ 311  
Strategic Partner, Second Amendment Contract            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Recognized revenues     707      
License            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Recognized revenues     1,500      
License | Strategic Partner, Second Amendment Contract            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Recognized revenues     800      
Other revenue     1,507      
License | Strategic Partner, Second Amendment Contract, 5G Chipset China            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Recognized revenues     18,750 20,000    
Development services | Strategic Partner            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Recognized revenues         4,500  
Net remaining contract liability     245 862 1,853  
Other revenue     571 1,083 3,008  
Current contract liabilities         1,639  
Non-current contract liabilities         214  
Development services | Strategic Partner, Amendment Contract            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Recognized revenues   $ 3,000   5,000    
Net remaining contract liability     271 1,189    
Investments revenue   $ 2,000        
Development services | Strategic Partner, Second Amendment Contract            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Recognized revenues     4,500      
Net remaining contract liability     8 2,544 3,652  
Current contract liabilities       2,141 1,160  
Non-current contract liabilities       $ 404 $ 2,492  
Development services | Strategic Partner, Second Amendment Contract, 5G Chipset China            
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]            
Recognized revenues $ 60,000          
Current contract liabilities     $ 2,500      
XML 131 R106.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Trade payables and other current liabilities - Schedule of Trade Payables and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]      
Trade payables $ 16,281 $ 9,342 $ 13,916
Other current liabilities:      
Employees and social debts 7,383 7,497 7,987
Provisions 0 77 0
Others 1,516 781 1,193
Total other current liabilities 8,899 8,355 9,180
License and development services agreements (See Note 19) 5,485 5,774 8,201
Deferred revenue 367 190 476
Contract liabilities $ 5,852 $ 5,964 $ 8,677
XML 132 R107.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Trade payables and other current liabilities - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]      
Trade payable term   30 days  
Trade payables $ 16,281,000 $ 9,342,000 $ 13,916,000
Deferred revenue 367,000 190,000 476,000
Trade payables 0 $ 1,788,000 $ 964,000
5G New Product Development      
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]      
Trade payable term   27 months 27 months
Trade payables     $ 244,000
Additions/Amortization 1,587,000 $ 3,350,000  
Trade payables     279,000
Trade payables   786,000 184,000
5G New Product Development, Team Of Engineers      
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]      
Trade payables 1,430,000    
Trade payables 1,288,000 1,002,000 780,000
Development services agreements      
Purchase Commitment, Excluding Long-term Commitment1 [Line Items]      
Deferred revenue $ 367,000 $ 190,000 $ 476,000
XML 133 R108.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Information about financial instruments - Schedule of Financial Assets and Financial Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Carrying amount      
Total financial assets $ 15,182 $ 20,256 $ 20,054
Total current 14,391 19,483 19,246
Total non-current 791 773 808
Fair value      
Total financial assets 15,182 20,256 20,054
Total current 14,391 19,483 19,246
Total non-current 791 773 808
Carrying amount      
Total financial liabilities 96,970 77,634 85,391
Total current 92,484 21,556 27,631
Total non-current 4,486 56,078 57,760
Fair value      
Total financial liabilities 96,803 76,815 85,511
Total current 92,317 21,556 27,631
Total non-current 4,486 55,259 57,880
Convertible debt      
Carrying amount      
Total financial liabilities 0 3,203 10,081
Fair value      
Total financial liabilities 3 3,203 10,081
Cash, cash equivalents and short-term investments      
Carrying amount      
Total financial assets 5,705    
Fair value      
Total financial assets 5,705 10,671 4,835
Lease liability      
Carrying amount      
Total financial liabilities 3,116 3,569 4,620
Fair value      
Total financial liabilities 3,116 3,569 4,620
Interest-bearing loans and borrowings: | Interest-bearing receivables financing      
Carrying amount      
Total financial liabilities 9,544 7,723 9,518
Fair value      
Total financial liabilities 9,544 7,723 9,518
Interest-bearing loans and borrowings: | Convertible debt      
Carrying amount      
Total financial liabilities 52,278 43,455 36,373
Fair value      
Total financial liabilities 52,111 42,636 36,493
Interest-bearing loans and borrowings: | Venture debt      
Carrying amount      
Total financial liabilities 8,922 0 0
Fair value      
Total financial liabilities 8,922 0 0
Interest-bearing loans and borrowings: | Government loans      
Carrying amount      
Total financial liabilities 4,337 5,171 6,001
Fair value      
Total financial liabilities 4,337 5,171 6,001
Interest-bearing loans and borrowings: | Research project financing      
Carrying amount      
Total financial liabilities 2,489 3,383 3,868
Fair value      
Total financial liabilities 2,489 3,383 3,868
Trade and other payables (current and non current) | Trade and other payables (current and non current)      
Carrying amount      
Total financial liabilities 16,281 11,130 14,880
Fair value      
Total financial liabilities 16,281 11,130 14,880
Financial instruments at fair value through other comprehensive income | Cash flow hedges      
Carrying amount      
Total financial liabilities 0 0 50
Fair value      
Total financial liabilities 0 0 50
Trade and other receivables | Trade receivables and contract assets      
Carrying amount      
Total financial assets 8,612 8,670 14,411
Fair value      
Total financial assets 8,612 8,670 14,411
Deposits and other receivables | Deposits      
Carrying amount      
Total financial assets 431 436 451
Fair value      
Total financial assets 431 436 451
Other financial assets | Long-term investments      
Carrying amount      
Total financial assets 360 337 357
Fair value      
Total financial assets 360 337 357
Financial instruments at fair value through other comprehensive income | Cash flow hedges      
Carrying amount      
Total financial assets 74 142 0
Fair value      
Total financial assets $ 74 142 0
Cash, cash equivalents and short-term investments | Cash, cash equivalents and short-term investments      
Carrying amount      
Total financial assets   $ 10,671 $ 4,835
XML 134 R109.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Information about financial instruments - Schedule of Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value $ 15,182 $ 20,256 $ 20,054
Fair value 96,803 76,815 85,511
Cash flow hedges | Financial instruments at fair value through other comprehensive income      
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value   3,203 10,081
Financial Assets Measured At Fair Value Through Other Comprehensive Income | Cash flow hedges      
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value (74) (142)  
Level 1 | Cash flow hedges | Financial instruments at fair value through other comprehensive income      
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value 0   0
Level 2 | Cash flow hedges | Financial instruments at fair value through other comprehensive income      
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value 3 3,203 10,081
Level 2 | Cash flow hedges      
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value (74) (142)  
Level 3 | Cash flow hedges | Financial instruments at fair value through other comprehensive income      
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value 0   0
Available-for-sale financial assets | Long-term investments      
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value 360 337 357
Available-for-sale financial assets | Long-term investments | Level 1      
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value 0 0 0
Available-for-sale financial assets | Long-term investments | Level 2      
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value 360 337 357
Available-for-sale financial assets | Long-term investments | Level 3      
Disclosure Of Financial Assets And Liabilities [Line Items]      
Fair value $ 0 $ 0 $ 0
XML 135 R110.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Information about financial instruments - Schedule of Present Fair Values of Derivative Financial Instruments (Details)
€ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
EUR (€)
Dec. 31, 2022
USD ($)
EUR (€)
Dec. 31, 2021
USD ($)
EUR (€)
Disclosure of financial liabilities [line items]      
Fair value $ 96,803,000 $ 76,815,000 $ 85,511,000
Financial assets, at fair value (15,182,000) (20,256,000) (20,054,000)
Loss transferred from other comprehensive income to the statement of operations 139,000 143,000 53,000
Level 2 | Cash flow hedges      
Disclosure of financial liabilities [line items]      
Financial assets, at fair value 74,000 142,000  
Cash flow hedges | Financial Assets Measured At Fair Value Through Other Comprehensive Income      
Disclosure of financial liabilities [line items]      
Financial assets, at fair value 74,000 142,000  
Financial instruments at fair value through other comprehensive income | Cash flow hedges      
Disclosure of financial liabilities [line items]      
Fair value   3,203,000 10,081,000
Financial instruments at fair value through other comprehensive income | Cash flow hedges | Level 2      
Disclosure of financial liabilities [line items]      
Fair value $ 3,000 $ 3,203,000 $ 10,081,000
Cash flow hedge | Financial instruments at fair value through other comprehensive income      
Disclosure of financial liabilities [line items]      
Notional Amount | € 2,000 3,000 5,000
Fair value $ 74,000 $ 142,000 $ (50,000)
Cash flow hedge | Forward contracts | Financial instruments at fair value through other comprehensive income      
Disclosure of financial liabilities [line items]      
Notional Amount | € 2,000 3,000 5,000
Fair value $ 74,000 $ 142,000 $ (50,000)
Cash flow hedge | Options | Financial instruments at fair value through other comprehensive income      
Disclosure of financial liabilities [line items]      
Notional Amount | € 0 0 0
Fair value $ 0 $ 0 $ 0
XML 136 R111.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Information about financial instruments - Narrative (Details)
12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
uSD_to_EUR
Dec. 31, 2023
USD ($)
uSD_to_GBP
Dec. 31, 2023
USD ($)
uSD_to_SGD
Dec. 31, 2023
USD ($)
uSD_to_NIS
Dec. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
bank
Dec. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
uSD_to_EUR
Dec. 31, 2022
USD ($)
uSD_to_GBP
Dec. 31, 2022
USD ($)
uSD_to_SGD
Dec. 31, 2022
USD ($)
uSD_to_NIS
Dec. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
uSD_to_EUR
Dec. 31, 2021
USD ($)
uSD_to_GBP
Dec. 31, 2021
USD ($)
uSD_to_SGD
Dec. 31, 2021
USD ($)
uSD_to_NIS
Dec. 31, 2020
USD ($)
Disclosure of detailed information about financial instruments [line items]                                      
Net gain (loss) on cash flow hedge   $ 76,000             $ (202,000)         $ 129,000          
Loss transferred from other comprehensive income to the statement of operations   139,000             143,000         53,000          
Gain (loss) related to ineffective position of hedging instrument   0                                  
Derivative maturity period 12 months                                    
Cash and cash equivalents $ 5,705,000 5,705,000 $ 5,705,000 $ 5,705,000 $ 5,705,000 $ 5,705,000 $ 5,705,000 $ 5,705,000 5,671,000 $ 5,671,000 $ 5,671,000 $ 5,671,000 $ 5,671,000 4,835,000 $ 4,835,000 $ 4,835,000 $ 4,835,000 $ 4,835,000 $ 7,574,000
Fair value 15,182,000 15,182,000 $ 15,182,000 $ 15,182,000 $ 15,182,000 $ 15,182,000 15,182,000 15,182,000 20,256,000 $ 20,256,000 $ 20,256,000 $ 20,256,000 $ 20,256,000 20,054,000 $ 20,054,000 $ 20,054,000 $ 20,054,000 $ 20,054,000  
Average rate     1.0816 1.2435 0.7447 0.2716       1.0539 1.2372 0.7255 0.2980   1.1835 1.3761 0.7444 0.3097  
Contract liabilities 190,000 190,000 $ 190,000 $ 190,000 $ 190,000 $ 190,000 190,000 190,000 271,000 $ 271,000 $ 271,000 $ 271,000 $ 271,000 765,000 $ 765,000 $ 765,000 $ 765,000 $ 765,000  
Fair value 96,803,000 96,803,000 96,803,000 96,803,000 96,803,000 96,803,000 96,803,000 96,803,000 76,815,000 76,815,000 76,815,000 76,815,000 76,815,000 85,511,000 85,511,000 85,511,000 85,511,000 85,511,000  
Convertible debt | Interest-bearing loans and borrowings:                                      
Disclosure of detailed information about financial instruments [line items]                                      
Fair value 52,111,000 52,111,000 52,111,000 52,111,000 52,111,000 52,111,000 52,111,000 52,111,000 42,636,000 42,636,000 42,636,000 42,636,000 42,636,000 36,493,000 36,493,000 36,493,000 36,493,000 36,493,000  
Available-for-sale financial assets | Long-term investments                                      
Disclosure of detailed information about financial instruments [line items]                                      
Fair value 360,000 360,000 360,000 360,000 360,000 360,000 360,000 360,000 337,000 337,000 337,000 337,000 337,000 357,000 357,000 357,000 357,000 357,000  
Euro denominated accounts                                      
Disclosure of detailed information about financial instruments [line items]                                      
Notional amount 12,957,000 12,957,000 12,957,000 12,957,000 12,957,000 12,957,000 12,957,000 12,957,000 10,817,000 10,817,000 10,817,000 10,817,000 10,817,000 13,525,000 13,525,000 13,525,000 13,525,000 13,525,000  
Currencies Other Than US Dollar                                      
Disclosure of detailed information about financial instruments [line items]                                      
Cash and cash equivalents 455,000 455,000 455,000 455,000 455,000 455,000 $ 455,000 $ 455,000 951,000 951,000 951,000 951,000 951,000 1,966,000 1,966,000 1,966,000 1,966,000 1,966,000  
Foreign currency risk                                      
Disclosure of detailed information about financial instruments [line items]                                      
Reasonably possible change in risk variable, percent             10.00%                        
Average rate             1.0816                        
Impact of change in the corresponding risk variable on operating expenses   4,200,000                                  
Foreign currency risk | U.S. dollar denominated accounts                                      
Disclosure of detailed information about financial instruments [line items]                                      
Percentage of total revenues             100.00%                        
Percentage of total cost of sales             80.00%                        
Foreign currency risk | Euro denominated accounts                                      
Disclosure of detailed information about financial instruments [line items]                                      
Percentage of operating expenses             57.00%                        
Credit risk                                      
Disclosure of detailed information about financial instruments [line items]                                      
Number of banks | bank               3                      
Liquidity risk                                      
Disclosure of detailed information about financial instruments [line items]                                      
Contract liabilities $ 5,486,000 $ 5,486,000 $ 5,486,000 $ 5,486,000 $ 5,486,000 $ 5,486,000 $ 5,486,000 $ 5,486,000 $ 6,178,000 $ 6,178,000 $ 6,178,000 $ 6,178,000 $ 6,178,000 $ 10,907,000 $ 10,907,000 $ 10,907,000 $ 10,907,000 $ 10,907,000  
XML 137 R112.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Information about financial instruments - Summary of Customers Representing Company's Total Revenue (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of major customers [line items]      
Accounts receivable $ 8,115 $ 8,494 $ 13,622
Credit risk | Customer A | China      
Disclosure of major customers [line items]      
Percentage of entity's revenue 56.00% 33.00% 0.00%
Accounts receivable $ 3,411,000 $ 3,375,000 $ 0
Credit risk | Customer B | Germany      
Disclosure of major customers [line items]      
Percentage of entity's revenue 16.00% 11.00% 13.00%
Accounts receivable $ 18,000 $ 0 $ 7,736,000
Credit risk | Customer C | Germany      
Disclosure of major customers [line items]      
Percentage of entity's revenue 10.00% 24.00% 10.00%
Accounts receivable $ 0 $ 3,585,000 $ 3,652,000
Credit risk | Customer D | America      
Disclosure of major customers [line items]      
Percentage of entity's revenue 0.00% 14.00% 23.00%
Accounts receivable $ 0 $ 0 $ 1,800,000
Credit risk | Customer E | Taiwan      
Disclosure of major customers [line items]      
Percentage of entity's revenue 1000.00% 10.00% 23.00%
Accounts receivable $ 26,000 $ 0 $ 545,000
Credit risk | Customer F | China      
Disclosure of major customers [line items]      
Percentage of entity's revenue 1000.00% 10.00% 14.00%
Accounts receivable $ 945,000 $ 169,500 $ 203,000
XML 138 R113.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Information about financial instruments - Schedule of Liquidity Risk (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Fair value $ 96,803 $ 76,815 $ 85,511
Financial assets, at fair value (15,182) (20,256) (20,054)
Level 2 | Cash flow hedges      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial assets, at fair value 74 142  
Liquidity risk      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 105,482 93,753 103,750
Liquidity risk | Within one year      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 101,243 29,405 36,149
Liquidity risk | 1 to 2 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 2,629 60,593 3,829
Liquidity risk | 2 to 3 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 1,247 2,538 60,232
Liquidity risk | 3 to 4 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 268 1,217 2,504
Liquidity risk | 4 to 5 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 70 0 1,036
Liquidity risk | More than five years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 25 0 0
Research project financing | Liquidity risk      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 2,542 3,287 3,783
Research project financing | Liquidity risk | Within one year      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 2,057 1,237 1,057
Research project financing | Liquidity risk | 1 to 2 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 113 1,683 1,042
Research project financing | Liquidity risk | 2 to 3 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 165 146 1,684
Research project financing | Liquidity risk | 3 to 4 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 207 221 0
Research project financing | Liquidity risk | 4 to 5 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Research project financing | Liquidity risk | More than five years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Interest-bearing receivables financing | Liquidity risk      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 9,544 7,723 9,518
Interest-bearing receivables financing | Liquidity risk | Within one year      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 9,544 7,723 9,518
Interest-bearing receivables financing | Liquidity risk | 1 to 2 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Interest-bearing receivables financing | Liquidity risk | 2 to 3 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Interest-bearing receivables financing | Liquidity risk | 3 to 4 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Interest-bearing receivables financing | Liquidity risk | 4 to 5 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Interest-bearing receivables financing | Liquidity risk | More than five years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Government loans | Liquidity risk      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 3,900 4,971 6,462
Government loans | Liquidity risk | Within one year      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 1,791 1,534 1,240
Government loans | Liquidity risk | 1 to 2 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 1,414 1,397 1,573
Government loans | Liquidity risk | 2 to 3 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 695 1,367 1,483
Government loans | Liquidity risk | 3 to 4 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 673 1,452
Government loans | Liquidity risk | 4 to 5 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 714
Government loans | Liquidity risk | More than five years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Convertible debt | Liquidity risk      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 52,278 54,348 54,623
Convertible debt | Liquidity risk | Within one year      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 52,278 0 0
Convertible debt | Liquidity risk | 1 to 2 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 54,348 0
Convertible debt | Liquidity risk | 2 to 3 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 54,623
Convertible debt | Liquidity risk | 3 to 4 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Convertible debt | Liquidity risk | 4 to 5 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Convertible debt | Liquidity risk | More than five years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Lease liability      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Fair value 3,116 3,569 4,620
Lease liability | Liquidity risk      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 3,116 3,569 4,620
Lease liability | Liquidity risk | Within one year      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 1,471 1,291 1,238
Lease liability | Liquidity risk | 1 to 2 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 1,102 930 1,043
Lease liability | Liquidity risk | 2 to 3 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 387 1,025 965
Lease liability | Liquidity risk | 3 to 4 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 61 323 1,052
Lease liability | Liquidity risk | 4 to 5 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 70 0 322
Lease liability | Liquidity risk | More than five years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 25 0 0
Trade payables | Liquidity risk      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 16,281 11,577 15,564
Trade payables | Liquidity risk | Within one year      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 16,281 9,342 13,916
Trade payables | Liquidity risk | 1 to 2 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 2,235 171
Trade payables | Liquidity risk | 2 to 3 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 1,477
Trade payables | Liquidity risk | 3 to 4 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Trade payables | Liquidity risk | 4 to 5 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Trade payables | Liquidity risk | More than five years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Other current liabilities | Liquidity risk      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 8,899 8,278 9,180
Other current liabilities | Liquidity risk | Within one year      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 8,899 8,278 9,180
Other current liabilities | Liquidity risk | 1 to 2 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Other current liabilities | Liquidity risk | 2 to 3 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Other current liabilities | Liquidity risk | 3 to 4 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Other current liabilities | Liquidity risk | 4 to 5 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Other current liabilities | Liquidity risk | More than five years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0 0 0
Cash flow hedges | Financial instruments at fair value through other comprehensive income      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Fair value   3,203 10,081
Cash flow hedges | Financial instruments at fair value through other comprehensive income | Level 1      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Fair value 0   0
Cash flow hedges | Financial instruments at fair value through other comprehensive income | Level 2      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Fair value 3 3,203 10,081
Cash flow hedges | Financial instruments at fair value through other comprehensive income | Level 3      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Fair value 0   $ 0
Cash flow hedges | Financial Assets Measured At Fair Value Through Other Comprehensive Income      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial assets, at fair value 74 $ 142  
Unsecured related party loan | Liquidity risk      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 8,922    
Unsecured related party loan | Liquidity risk | Within one year      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 8,922    
Unsecured related party loan | Liquidity risk | 1 to 2 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0    
Unsecured related party loan | Liquidity risk | 2 to 3 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0    
Unsecured related party loan | Liquidity risk | 3 to 4 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0    
Unsecured related party loan | Liquidity risk | 4 to 5 years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk 0    
Unsecured related party loan | Liquidity risk | More than five years      
Disclosure of maturity analysis for non-derivative financial liabilities [line items]      
Financial liabilities considered in liquidity risk $ 0    
XML 139 R114.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Information about financial instruments - Changes in Liabilities Arising from Financing Activities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance $ 65,141 $ 66,071 $ 69,424
Increase (decrease) through financing cash flows 8,696 2,247 18,764
Increase (decrease) through effect of changes in foreign exchange rates 474 (664) (903)
Increase (decrease) through non-cash interest 10,217 8,853 8,481
Increase (decrease) through non-cash impact of amendment (247) (671) (16,008)
Increase (decrease) through other changes     (18,557)
Increase (decrease) through changes in fair values, liabilities arising from financing activities (2,675) (10,695)  
Liabilities arising from financing activities ending balance 81,606 65,141 66,071
Government grant advances and loans      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance 10,394 15,560 15,070
Increase (decrease) through financing cash flows (466) 406 592
Increase (decrease) through effect of changes in foreign exchange rates 182 (365) (449)
Increase (decrease) through non-cash interest 225 266 427
Increase (decrease) through non-cash impact of amendment 0 0
Increase (decrease) through other changes     (80)
Increase (decrease) through changes in fair values, liabilities arising from financing activities (2,473) (5,473)  
Liabilities arising from financing activities ending balance 7,862 10,394 15,560
Convertible debt      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance 43,455 36,373 26,074
Increase (decrease) through financing cash flows 0 27,957
Increase (decrease) through effect of changes in foreign exchange rates 0 0
Increase (decrease) through non-cash interest 9,152 7,762 6,193
Increase (decrease) through non-cash impact of amendment (247) (671) (16,008)
Increase (decrease) through other changes     (12,713)
Increase (decrease) through changes in fair values, liabilities arising from financing activities (82) (9)  
Liabilities arising from financing activities ending balance 52,278 43,455 36,373
Venture debt      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance     8,276
Increase (decrease) through financing cash flows     (8,743)
Increase (decrease) through effect of changes in foreign exchange rates     180
Increase (decrease) through non-cash interest     819
Increase (decrease) through non-cash impact of amendment     0
Increase (decrease) through other changes     (532)
Unsecured related party loan      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance 0    
Increase (decrease) through financing cash flows 9,000    
Increase (decrease) through effect of changes in foreign exchange rates 0    
Increase (decrease) through non-cash interest 127    
Increase (decrease) through non-cash impact of amendment 0    
Increase (decrease) through changes in fair values, liabilities arising from financing activities (205)    
Liabilities arising from financing activities ending balance 8,922 0  
Lease Contracts [Member]      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance 3,569 4,620 5,776
Increase (decrease) through financing cash flows (1,321) (1,205) (1,063)
Increase (decrease) through effect of changes in foreign exchange rates 113 (298) (297)
Increase (decrease) through non-cash interest 479 571 760
Increase (decrease) through non-cash impact of amendment 0 0 0
Increase (decrease) through other changes     (556)
Increase (decrease) through changes in fair values, liabilities arising from financing activities 276 (119)  
Liabilities arising from financing activities ending balance 3,116 3,569 4,620
Interest-bearing receivables financing      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance 7,723 9,518 14,228
Increase (decrease) through financing cash flows 1,483 3,046 21
Increase (decrease) through effect of changes in foreign exchange rates 179 (1) (337)
Increase (decrease) through non-cash interest 234 254 282
Increase (decrease) through non-cash impact of amendment 0 0 0
Increase (decrease) through other changes     (4,676)
Increase (decrease) through changes in fair values, liabilities arising from financing activities (191) (5,094)  
Liabilities arising from financing activities ending balance $ 9,428 7,723 9,518
Previously stated      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance   66,071  
Liabilities arising from financing activities ending balance     66,071
Previously stated | Government grant advances and loans      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance   15,560  
Liabilities arising from financing activities ending balance     15,560
Previously stated | Convertible debt      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance   36,373  
Liabilities arising from financing activities ending balance     36,373
Previously stated | Venture debt      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance   0  
Liabilities arising from financing activities ending balance     0
Previously stated | Interest-bearing receivables financing      
Disclosure of reconciliation of liabilities arising from financing activities [line items]      
Liabilities arising from financing activities beginning balance   $ 9,518  
Liabilities arising from financing activities ending balance     $ 9,518
XML 140 R115.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and contingencies - Contingencies (Details)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Lynrock Lake    
Disclosure of contingent liabilities [line items]    
Share capital of the Company (in excess of) 9.80% 10.00%
XML 141 R116.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and contingencies - Bank Guarantee (Details) - Bank guarantee - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of credit risk exposure [line items]      
Term of secured lease payments 6 months    
Bank guarantee issued in favor of owners of new leased office space $ 348 $ 337 $ 357
Amount of guarantee secured, percentage 100.00%    
Total value of investments $ 360 $ 337 $ 357
XML 142 R117.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and contingencies - Purchase Commitments (Details)
$ in Millions
Dec. 31, 2023
USD ($)
Non-cancelable purchase commitments with third-party manufacturer and suppliers for future deliveries of equipment and components  
Disclosure of contingent liabilities [line items]  
Purchase commitments $ 2.7
XML 143 R118.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related party disclosures - Narrative (Details) - USD ($)
12 Months Ended
Sep. 26, 2023
Apr. 12, 2023
Mar. 11, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Aug. 15, 2023
Aug. 14, 2023
Jul. 25, 2023
Sep. 30, 2022
Aug. 15, 2022
Aug. 14, 2022
Aug. 31, 2019
Aug. 16, 2019
May 31, 2019
May 07, 2019
Sep. 27, 2018
Apr. 30, 2016
Apr. 27, 2016
Apr. 30, 2015
Apr. 14, 2015
Disclosure of transactions between related parties [line items]                                          
Special Transaction Bonus, Approved By Board Of Directors                 $ 1,000,000                        
272 Capital Fund LP | American Depositary Shares, each representing four ordinary shares, nominal value €0.01 per share                                          
Disclosure of transactions between related parties [line items]                                          
Increase (decrease) in number of shares outstanding 2,120,141 1,310,221 2,833,333                                    
Lynrock Lake | American Depositary Shares, each representing four ordinary shares, nominal value €0.01 per share                                          
Disclosure of transactions between related parties [line items]                                          
Increase (decrease) in number of shares outstanding   3,930,663                                      
Renesas Electronics Corporation                                          
Disclosure of transactions between related parties [line items]                                          
Share capital of the Company (in excess of)       3.20% 4.08%                                
Lynrock Lake                                          
Disclosure of transactions between related parties [line items]                                          
Share capital of the Company (in excess of)         9.80% 10.00%                              
Key management personnel | ABLE France                                          
Disclosure of transactions between related parties [line items]                                          
Professional fees expense           $ 116,000                              
B. Riley Asset Management LLC and Lynrock Lake                                          
Disclosure of transactions between related parties [line items]                                          
Share capital of the Company (in excess of)       10.00%                                  
Other related parties [member]                                          
Disclosure of transactions between related parties [line items]                                          
Fee and commission expense       $ 50,401                                  
2015 convertible notes                                          
Disclosure of transactions between related parties [line items]                                          
Notional amount                                         $ 12,000,000
2015 convertible notes | Affiliate of Nokomis Capital, L.L.C.                                          
Disclosure of transactions between related parties [line items]                                          
Notional amount                   $ 4,500,000                   $ 12,000,000  
Fair value of convertible note       $ 6,900,000                                  
2016 convertible notes                                          
Disclosure of transactions between related parties [line items]                                          
Notional amount                                 $ 6,000,000   $ 7,160,000    
2016 convertible notes | Affiliate of Nokomis Capital, L.L.C.                                          
Disclosure of transactions between related parties [line items]                                          
Notional amount                                   $ 6,000,000      
2019-1 notes                                          
Disclosure of transactions between related parties [line items]                                          
Notional amount                               $ 3,000,000          
2019-1 notes | Affiliate of Nokomis Capital, L.L.C.                                          
Disclosure of transactions between related parties [line items]                                          
Notional amount                             $ 3,000,000            
2019-2 notes                                          
Disclosure of transactions between related parties [line items]                                          
Notional amount             $ 6,378,000 $ 6,707,000     $ 6,125,000 $ 5,454,000   $ 5,000,000              
2019-2 notes | Affiliate of Nokomis Capital, L.L.C.                                          
Disclosure of transactions between related parties [line items]                                          
Notional amount                         $ 5,000,000                
XML 144 R119.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related party disclosures - Compensation of Key Management Personnel (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of transactions between related parties [line items]      
Fixed and variable wages, social charges and benefits expensed in the year $ 2,689,000 $ 2,574,000 $ 2,837,000
Share-based payment expense for the year 4,144,000 2,903,000 2,478,000
Board members fees to non-executive members 199,000 199,000 210,000
Total compensation expense for key management personnel 7,032,000 $ 5,676,000 $ 5,525,000
Key management personnel      
Disclosure of transactions between related parties [line items]      
Total compensation expense for key management personnel $ 23,000    
XML 145 R120.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related party disclosures - Directors’ Interests In An Employee Share Incentive Plan (Details)
12 Months Ended
Jun. 27, 2023
shares
$ / shares
Jun. 24, 2022
shares
$ / shares
Jun. 25, 2021
shares
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2023
€ / shares
Dec. 31, 2022
€ / shares
Dec. 31, 2021
€ / shares
Disclosure of transactions between related parties [line items]                  
Key management personnel compensation       $ 7,032,000 $ 5,676,000 $ 5,525,000      
Subscription price (eur per share) | $ / shares       $ 1.44 $ 1.70 $ 1.79      
Share-based payment expense       $ 4,144,000 $ 2,903,000 $ 2,478,000      
Key management personnel                  
Disclosure of transactions between related parties [line items]                  
Termination indemnity amount (in months)       18 months          
Percentage of bonus in event of dismissal       150.00%     150.00%    
Key management personnel compensation       $ 23,000          
Warrants | Board Of Directors [Member]                  
Disclosure of transactions between related parties [line items]                  
Number of warrants authorized (in shares) | shares 180,000 140,000 140,000            
Exercise price (usd per share) | $ / shares $ 0.54 $ 0.65 $ 1.49            
Subscription price (eur per share) | € / shares             € 0.00001 € 0.00000714 € 0.00000714
Share-based payment expense       $ 292,000 $ 495,000 $ 443,000      
XML 146 R121.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Events after the reporting date (Details)
12 Months Ended
Apr. 30, 2024
shares
Mar. 05, 2024
shares
Dec. 31, 2023
Apr. 22, 2024
EUR (€)
Mar. 27, 2024
USD ($)
Mar. 27, 2024
EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Award vesting period     10 years      
Granting of shares | Restricted share awards            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Granted during the year 147,776 10,060,288        
Number of awards granted, in ADS (in shares)   2,515,072        
Award vesting period 4 years 4 years        
Granting of shares | Restricted share awards | American Depositary Shares, each representing four ordinary shares, nominal value €0.01 per share            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Granted during the year 36,944          
Entering into significant commitments or contingent liabilities | France 2023, 4G eRedCap Project | Loan commitments [member]            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Notional amount         $ 12,000,000 € 10,900,000
Upfront payment, borrowings         $ 3,000,000.0 € 2,700,000
Entering into significant commitments or contingent liabilities | Unsecured Promissory Note            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Debt instruments issued | €       € 5,000,000    
Borrowings, interest rate       12.00%    
Guaranteed return (in percentage)       40.00%    
XML 147 R9999.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Label Element Value
CHINA  
Withholding Tax sqns_WithholdingTax $ 1,875,000
EXCEL 148 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 150 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 152 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1014 526 1 false 246 0 false 17 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.sequans.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.sequans.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Statements of Operations Sheet http://www.sequans.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss) Statement Sheet http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement Consolidated Statements of Comprehensive Income (Loss) Statement Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Financial Position Sheet http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition Consolidated Statements of Financial Position Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Financial Position (Parenthetical) Sheet http://www.sequans.com/role/ConsolidatedStatementsofFinancialPositionParenthetical Consolidated Statements of Financial Position (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Changes in Equity (Deficit) Statement Sheet http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement Consolidated Statements of Changes in Equity (Deficit) Statement Statements 7 false false R8.htm 0000008 - Statement - Statements of Cash Flow Sheet http://www.sequans.com/role/StatementsofCashFlow Statements of Cash Flow Statements 8 false false R9.htm 0000009 - Disclosure - Corporate information Sheet http://www.sequans.com/role/Corporateinformation Corporate information Notes 9 false false R10.htm 0000010 - Disclosure - Summary of significant accounting and reporting policies Sheet http://www.sequans.com/role/Summaryofsignificantaccountingandreportingpolicies Summary of significant accounting and reporting policies Notes 10 false false R11.htm 0000011 - Disclosure - Segment information Sheet http://www.sequans.com/role/Segmentinformation Segment information Notes 11 false false R12.htm 0000012 - Disclosure - Other revenues and expenses Sheet http://www.sequans.com/role/Otherrevenuesandexpenses Other revenues and expenses Notes 12 false false R13.htm 0000013 - Disclosure - Income tax Sheet http://www.sequans.com/role/Incometax Income tax Notes 13 false false R14.htm 0000014 - Disclosure - Earnings (loss) per share Sheet http://www.sequans.com/role/Earningslosspershare Earnings (loss) per share Notes 14 false false R15.htm 0000015 - Disclosure - Property, plant and equipment Sheet http://www.sequans.com/role/Propertyplantandequipment Property, plant and equipment Notes 15 false false R16.htm 0000016 - Disclosure - Intangible assets Sheet http://www.sequans.com/role/Intangibleassets Intangible assets Notes 16 false false R17.htm 0000017 - Disclosure - Inventories Sheet http://www.sequans.com/role/Inventories Inventories Notes 17 false false R18.htm 0000018 - Disclosure - Trade receivables Sheet http://www.sequans.com/role/Tradereceivables Trade receivables Notes 18 false false R19.htm 0000019 - Disclosure - Cash and cash equivalents Sheet http://www.sequans.com/role/Cashandcashequivalents Cash and cash equivalents Notes 19 false false R20.htm 0000021 - Disclosure - Share-based payment plans Sheet http://www.sequans.com/role/Sharebasedpaymentplans Share-based payment plans Notes 20 false false R21.htm 0000022 - Disclosure - Interest-bearing loans and borrowings Sheet http://www.sequans.com/role/Interestbearingloansandborrowings Interest-bearing loans and borrowings Notes 21 false false R22.htm 0000023 - Disclosure - Lease liabilities Sheet http://www.sequans.com/role/Leaseliabilities Lease liabilities Notes 22 false false R23.htm 0000024 - Disclosure - Government grant advances and loans Sheet http://www.sequans.com/role/Governmentgrantadvancesandloans Government grant advances and loans Notes 23 false false R24.htm 0000025 - Disclosure - Provisions Sheet http://www.sequans.com/role/Provisions Provisions Notes 24 false false R25.htm 0000026 - Disclosure - Other non-current liabilities Sheet http://www.sequans.com/role/Othernoncurrentliabilities Other non-current liabilities Notes 25 false false R26.htm 0000027 - Disclosure - Trade payables and other current liabilities Sheet http://www.sequans.com/role/Tradepayablesandothercurrentliabilities Trade payables and other current liabilities Notes 26 false false R27.htm 0000028 - Disclosure - Information about financial instruments Sheet http://www.sequans.com/role/Informationaboutfinancialinstruments Information about financial instruments Notes 27 false false R28.htm 0000029 - Disclosure - Commitments and contingencies Sheet http://www.sequans.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 28 false false R29.htm 0000030 - Disclosure - Related party disclosures Sheet http://www.sequans.com/role/Relatedpartydisclosures Related party disclosures Notes 29 false false R30.htm 0000031 - Disclosure - Events after the reporting date Sheet http://www.sequans.com/role/Eventsafterthereportingdate Events after the reporting date Notes 30 false false R31.htm 9954471 - Disclosure - Summary of significant accounting and reporting policies (Policies) Sheet http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies Summary of significant accounting and reporting policies (Policies) Policies 31 false false R32.htm 9954472 - Disclosure - Summary of significant accounting and reporting policies (Tables) Sheet http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesTables Summary of significant accounting and reporting policies (Tables) Tables http://www.sequans.com/role/Summaryofsignificantaccountingandreportingpolicies 32 false false R33.htm 9954473 - Disclosure - Segment information (Tables) Sheet http://www.sequans.com/role/SegmentinformationTables Segment information (Tables) Tables http://www.sequans.com/role/Segmentinformation 33 false false R34.htm 9954474 - Disclosure - Other revenues and expenses (Tables) Sheet http://www.sequans.com/role/OtherrevenuesandexpensesTables Other revenues and expenses (Tables) Tables http://www.sequans.com/role/Otherrevenuesandexpenses 34 false false R35.htm 9954475 - Disclosure - Income tax (Tables) Sheet http://www.sequans.com/role/IncometaxTables Income tax (Tables) Tables http://www.sequans.com/role/Incometax 35 false false R36.htm 9954476 - Disclosure - Earnings (loss) per share (Tables) Sheet http://www.sequans.com/role/EarningslosspershareTables Earnings (loss) per share (Tables) Tables http://www.sequans.com/role/Earningslosspershare 36 false false R37.htm 9954477 - Disclosure - Property, plant and equipment (Tables) Sheet http://www.sequans.com/role/PropertyplantandequipmentTables Property, plant and equipment (Tables) Tables http://www.sequans.com/role/Propertyplantandequipment 37 false false R38.htm 9954478 - Disclosure - Intangible assets (Tables) Sheet http://www.sequans.com/role/IntangibleassetsTables Intangible assets (Tables) Tables http://www.sequans.com/role/Intangibleassets 38 false false R39.htm 9954479 - Disclosure - Inventories (Tables) Sheet http://www.sequans.com/role/InventoriesTables Inventories (Tables) Tables http://www.sequans.com/role/Inventories 39 false false R40.htm 9954480 - Disclosure - Trade receivables (Tables) Sheet http://www.sequans.com/role/TradereceivablesTables Trade receivables (Tables) Tables http://www.sequans.com/role/Tradereceivables 40 false false R41.htm 9954481 - Disclosure - Cash and cash equivalents (Tables) Sheet http://www.sequans.com/role/CashandcashequivalentsTables Cash and cash equivalents (Tables) Tables http://www.sequans.com/role/Cashandcashequivalents 41 false false R42.htm 9954482 - Disclosure - Issued capital and reserves (Tables) Sheet http://www.sequans.com/role/IssuedcapitalandreservesTables Issued capital and reserves (Tables) Tables 42 false false R43.htm 9954483 - Disclosure - Share-based payment plans (Tables) Sheet http://www.sequans.com/role/SharebasedpaymentplansTables Share-based payment plans (Tables) Tables http://www.sequans.com/role/Sharebasedpaymentplans 43 false false R44.htm 9954484 - Disclosure - Interest-bearing loans and borrowings (Tables) Sheet http://www.sequans.com/role/InterestbearingloansandborrowingsTables Interest-bearing loans and borrowings (Tables) Tables http://www.sequans.com/role/Interestbearingloansandborrowings 44 false false R45.htm 9954485 - Disclosure - Lease liabilities (Tables) Sheet http://www.sequans.com/role/LeaseliabilitiesTables Lease liabilities (Tables) Tables http://www.sequans.com/role/Leaseliabilities 45 false false R46.htm 9954486 - Disclosure - Government grant advances and loans (Tables) Sheet http://www.sequans.com/role/GovernmentgrantadvancesandloansTables Government grant advances and loans (Tables) Tables http://www.sequans.com/role/Governmentgrantadvancesandloans 46 false false R47.htm 9954487 - Disclosure - Provisions (Tables) Sheet http://www.sequans.com/role/ProvisionsTables Provisions (Tables) Tables http://www.sequans.com/role/Provisions 47 false false R48.htm 9954488 - Disclosure - Other non-current liabilities (Tables) Sheet http://www.sequans.com/role/OthernoncurrentliabilitiesTables Other non-current liabilities (Tables) Tables http://www.sequans.com/role/Othernoncurrentliabilities 48 false false R49.htm 9954489 - Disclosure - Trade payables and other current liabilities (Tables) Sheet http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesTables Trade payables and other current liabilities (Tables) Tables http://www.sequans.com/role/Tradepayablesandothercurrentliabilities 49 false false R50.htm 9954490 - Disclosure - Information about financial instruments (Tables) Sheet http://www.sequans.com/role/InformationaboutfinancialinstrumentsTables Information about financial instruments (Tables) Tables http://www.sequans.com/role/Informationaboutfinancialinstruments 50 false false R51.htm 9954492 - Disclosure - Related party disclosures (Tables) Sheet http://www.sequans.com/role/RelatedpartydisclosuresTables Related party disclosures (Tables) Tables http://www.sequans.com/role/Relatedpartydisclosures 51 false false R52.htm 9954493 - Disclosure - Summary of significant accounting and reporting policies - Narrative (Details) Sheet http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails Summary of significant accounting and reporting policies - Narrative (Details) Details http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesTables 52 false false R53.htm 9954494 - Disclosure - Summary of significant accounting and reporting policies - Schedule of Subsidiaries (Details) Sheet http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails Summary of significant accounting and reporting policies - Schedule of Subsidiaries (Details) Details 53 false false R54.htm 9954495 - Disclosure - Summary of significant accounting and reporting policies - Schedule of Average and Closing Exchange Rate for the U.S. Dollar (Details) Sheet http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofAverageandClosingExchangeRatefortheUSDollarDetails Summary of significant accounting and reporting policies - Schedule of Average and Closing Exchange Rate for the U.S. Dollar (Details) Details 54 false false R55.htm 9954496 - Disclosure - Summary of significant accounting and reporting policies - Performance Obligation (Details) Sheet http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPerformanceObligationDetails Summary of significant accounting and reporting policies - Performance Obligation (Details) Details 55 false false R56.htm 9954497 - Disclosure - Summary of significant accounting and reporting policies - Schedule of Useful Lives Most Commonly Used (Details) Sheet http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails Summary of significant accounting and reporting policies - Schedule of Useful Lives Most Commonly Used (Details) Details 56 false false R57.htm 9954498 - Disclosure - Segment information (Details) Sheet http://www.sequans.com/role/SegmentinformationDetails Segment information (Details) Details http://www.sequans.com/role/SegmentinformationTables 57 false false R58.htm 9954499 - Disclosure - Other revenues and expenses - Schedule of Financial Income and Expenses (Details) Sheet http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails Other revenues and expenses - Schedule of Financial Income and Expenses (Details) Details 58 false false R59.htm 9954500 - Disclosure - Other revenues and expenses - Financial Income and Expenses (Narrative) (Details) Sheet http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails Other revenues and expenses - Financial Income and Expenses (Narrative) (Details) Details 59 false false R60.htm 9954501 - Disclosure - Other revenues and expenses - Schedule of Cost of Revenue, Operating Expenses, and Employee Benefits (Details) Sheet http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails Other revenues and expenses - Schedule of Cost of Revenue, Operating Expenses, and Employee Benefits (Details) Details 60 false false R61.htm 9954502 - Disclosure - Other revenues and expenses - Research and Development Expense and Tax Credit Receivable (Details) Sheet http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails Other revenues and expenses - Research and Development Expense and Tax Credit Receivable (Details) Details 61 false false R62.htm 9954503 - Disclosure - Income tax - Schedule of Major Components of Income Tax Expense (Details) Sheet http://www.sequans.com/role/IncometaxScheduleofMajorComponentsofIncomeTaxExpenseDetails Income tax - Schedule of Major Components of Income Tax Expense (Details) Details 62 false false R63.htm 9954504 - Disclosure - Income tax - Narrative (Details) Sheet http://www.sequans.com/role/IncometaxNarrativeDetails Income tax - Narrative (Details) Details 63 false false R64.htm 9954505 - Disclosure - Income tax - Reconciliation of Income Taxes Computed at the French Statutory Rate (Details) Sheet http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails Income tax - Reconciliation of Income Taxes Computed at the French Statutory Rate (Details) Details 64 false false R65.htm 9954506 - Disclosure - Income tax - Summary of Deferred Tax Assets (Details) Sheet http://www.sequans.com/role/IncometaxSummaryofDeferredTaxAssetsDetails Income tax - Summary of Deferred Tax Assets (Details) Details 65 false false R66.htm 9954507 - Disclosure - Income tax - Significant Components of Deferred Tax Assets and Liabilities (Details) Sheet http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails Income tax - Significant Components of Deferred Tax Assets and Liabilities (Details) Details 66 false false R67.htm 9954508 - Disclosure - Earnings (loss) per share (Details) Sheet http://www.sequans.com/role/EarningslosspershareDetails Earnings (loss) per share (Details) Details http://www.sequans.com/role/EarningslosspershareTables 67 false false R68.htm 9954509 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) Sheet http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) Details 68 false false R69.htm 9954510 - Disclosure - Property, plant and equipment - Narrative (Details) Sheet http://www.sequans.com/role/PropertyplantandequipmentNarrativeDetails Property, plant and equipment - Narrative (Details) Details 69 false false R70.htm 9954511 - Disclosure - Intangible assets (Details) Sheet http://www.sequans.com/role/IntangibleassetsDetails Intangible assets (Details) Details http://www.sequans.com/role/IntangibleassetsTables 70 false false R71.htm 9954512 - Disclosure - Intangible assets - Narrative (Details) Sheet http://www.sequans.com/role/IntangibleassetsNarrativeDetails Intangible assets - Narrative (Details) Details 71 false false R72.htm 9954513 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails Inventories - Schedule of Inventories (Details) Details 72 false false R73.htm 9954514 - Disclosure - Inventories - Narrative (Details) Sheet http://www.sequans.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 73 false false R74.htm 9954515 - Disclosure - Trade receivables - Schedule of Non-Interest Bearing Trade Receivables (Details) Sheet http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails Trade receivables - Schedule of Non-Interest Bearing Trade Receivables (Details) Details 74 false false R75.htm 9954516 - Disclosure - Trade receivables - Schedule of Movements in the Provision for Impairment of Receivables (Details) Sheet http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails Trade receivables - Schedule of Movements in the Provision for Impairment of Receivables (Details) Details 75 false false R76.htm 9954517 - Disclosure - Trade receivables - Aging Analysis of Trade Receivables That Were Not Impaired (Details) Sheet http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails Trade receivables - Aging Analysis of Trade Receivables That Were Not Impaired (Details) Details 76 false false R77.htm 9954518 - Disclosure - Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details) Sheet http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details) Details 77 false false R78.htm 9954519 - Disclosure - Cash and cash equivalents - Schedule of Cash and Cash Equivalents Held in U.S. dollar and Euros (Details) Sheet http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails Cash and cash equivalents - Schedule of Cash and Cash Equivalents Held in U.S. dollar and Euros (Details) Details 78 false false R79.htm 9954520 - Disclosure - Issued capital and reserves - Narratives (Details) Sheet http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails Issued capital and reserves - Narratives (Details) Details 79 false false R80.htm 9954521 - Disclosure - Issued capital and reserves - Authorized capital, in number of shares (Details) Sheet http://www.sequans.com/role/IssuedcapitalandreservesAuthorizedcapitalinnumberofsharesDetails Issued capital and reserves - Authorized capital, in number of shares (Details) Details 80 false false R81.htm 9954522 - Disclosure - Issued capital and reserves - Shares Issued and Fully Paid (Details) Sheet http://www.sequans.com/role/IssuedcapitalandreservesSharesIssuedandFullyPaidDetails Issued capital and reserves - Shares Issued and Fully Paid (Details) Details 81 false false R82.htm 9954523 - Disclosure - Issued capital and reserves - Capital Transactions (Details) Sheet http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails Issued capital and reserves - Capital Transactions (Details) Details 82 false false R83.htm 9954524 - Disclosure - Share-based payment plans - Narrative (Details) Sheet http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails Share-based payment plans - Narrative (Details) Details 83 false false R84.htm 9954525 - Disclosure - Share-based payment plans - Breakdown of share-based payments expenses (Details) Sheet http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails Share-based payment plans - Breakdown of share-based payments expenses (Details) Details 84 false false R85.htm 9954526 - Disclosure - Share-based payment plans - General employee stock option, founders warrant plans and restricted shares awards (Details) Sheet http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails Share-based payment plans - General employee stock option, founders warrant plans and restricted shares awards (Details) Details 85 false false R86.htm 9954527 - Disclosure - Share-based payment plans - Warrant plans for certain consultants considered equivalent to employees (Details) Sheet http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails Share-based payment plans - Warrant plans for certain consultants considered equivalent to employees (Details) Details 86 false false R87.htm 9954528 - Disclosure - Share-based payment plans - Movements in number and WAEP (Details) Sheet http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails Share-based payment plans - Movements in number and WAEP (Details) Details 87 false false R88.htm 9954529 - Disclosure - Share-based payment plans - Movements in number and restricted shares awards (Details) Sheet http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails Share-based payment plans - Movements in number and restricted shares awards (Details) Details 88 false false R89.htm 9954530 - Disclosure - Share-based payment plans - Valuation assumptions (Details) Sheet http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails Share-based payment plans - Valuation assumptions (Details) Details 89 false false R90.htm 9954531 - Disclosure - Interest-bearing loans and borrowings - Schedule of Interest-Bearing Loans and Borrowings (Details) Sheet http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails Interest-bearing loans and borrowings - Schedule of Interest-Bearing Loans and Borrowings (Details) Details 90 false false R91.htm 9954532 - Disclosure - Interest-bearing loans and borrowings - Convertible Debt (Details) Sheet http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails Interest-bearing loans and borrowings - Convertible Debt (Details) Details 91 false false R92.htm 9954533 - Disclosure - Interest-bearing loans and borrowings - Venture Debt (Details) Sheet http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails Interest-bearing loans and borrowings - Venture Debt (Details) Details 92 false false R93.htm 9954534 - Disclosure - Interest-bearing loans and borrowings - Interest-Bearing Financing Receivables (Details) Sheet http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails Interest-bearing loans and borrowings - Interest-Bearing Financing Receivables (Details) Details 93 false false R94.htm 9954535 - Disclosure - Interest-bearing loans and borrowings - Unsecured related party loan (Details) Sheet http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails Interest-bearing loans and borrowings - Unsecured related party loan (Details) Details 94 false false R95.htm 9954536 - Disclosure - Lease liabilities - Narrative (Details) Sheet http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails Lease liabilities - Narrative (Details) Details 95 false false R96.htm 9954537 - Disclosure - Lease liabilities - Summary of movements in right-of-use assets and lease liabilities (Details) Sheet http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails Lease liabilities - Summary of movements in right-of-use assets and lease liabilities (Details) Details 96 false false R97.htm 9954538 - Disclosure - Government grant advances and loans - Schedule of Government Grant Advances and Loans (Details) Sheet http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails Government grant advances and loans - Schedule of Government Grant Advances and Loans (Details) Details 97 false false R98.htm 9954539 - Disclosure - Government grant advances and loans - Government Grant Advances (Details) Sheet http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails Government grant advances and loans - Government Grant Advances (Details) Details 98 false false R99.htm 9954540 - Disclosure - Government grant advances and loans - Research Project Financing (Details) Sheet http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails Government grant advances and loans - Research Project Financing (Details) Details 99 false false R100.htm 9954541 - Disclosure - Government grant advances and loans - Government Loans (Details) Sheet http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails Government grant advances and loans - Government Loans (Details) Details 100 false false R101.htm 9954542 - Disclosure - Provisions - Reconciliation of Changes in Provisions (Details) Sheet http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails Provisions - Reconciliation of Changes in Provisions (Details) Details 101 false false R102.htm 9954543 - Disclosure - Provisions - Narrative (Details) Sheet http://www.sequans.com/role/ProvisionsNarrativeDetails Provisions - Narrative (Details) Details 102 false false R103.htm 9954544 - Disclosure - Provisions - Schedule of Main Assumptions Used (Details) Sheet http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails Provisions - Schedule of Main Assumptions Used (Details) Details 103 false false R104.htm 9954545 - Disclosure - Other non-current liabilities - Schedule of Other Non-Current Liabilities (Details) Sheet http://www.sequans.com/role/OthernoncurrentliabilitiesScheduleofOtherNonCurrentLiabilitiesDetails Other non-current liabilities - Schedule of Other Non-Current Liabilities (Details) Details 104 false false R105.htm 9954546 - Disclosure - Other non-current liabilities - Narrative (Details) Sheet http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails Other non-current liabilities - Narrative (Details) Details 105 false false R106.htm 9954547 - Disclosure - Trade payables and other current liabilities - Schedule of Trade Payables and Other Current Liabilities (Details) Sheet http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails Trade payables and other current liabilities - Schedule of Trade Payables and Other Current Liabilities (Details) Details 106 false false R107.htm 9954548 - Disclosure - Trade payables and other current liabilities - Narrative (Details) Sheet http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails Trade payables and other current liabilities - Narrative (Details) Details 107 false false R108.htm 9954549 - Disclosure - Information about financial instruments - Schedule of Financial Assets and Financial Liabilities (Details) Sheet http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails Information about financial instruments - Schedule of Financial Assets and Financial Liabilities (Details) Details 108 false false R109.htm 9954550 - Disclosure - Information about financial instruments - Schedule of Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails Information about financial instruments - Schedule of Assets and Liabilities Measured at Fair Value (Details) Details 109 false false R110.htm 9954551 - Disclosure - Information about financial instruments - Schedule of Present Fair Values of Derivative Financial Instruments (Details) Sheet http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails Information about financial instruments - Schedule of Present Fair Values of Derivative Financial Instruments (Details) Details 110 false false R111.htm 9954552 - Disclosure - Information about financial instruments - Narrative (Details) Sheet http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails Information about financial instruments - Narrative (Details) Details 111 false false R112.htm 9954553 - Disclosure - Information about financial instruments - Summary of Customers Representing Company's Total Revenue (Details) Sheet http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails Information about financial instruments - Summary of Customers Representing Company's Total Revenue (Details) Details 112 false false R113.htm 9954554 - Disclosure - Information about financial instruments - Schedule of Liquidity Risk (Details) Sheet http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails Information about financial instruments - Schedule of Liquidity Risk (Details) Details 113 false false R114.htm 9954555 - Disclosure - Information about financial instruments - Changes in Liabilities Arising from Financing Activities (Details) Sheet http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails Information about financial instruments - Changes in Liabilities Arising from Financing Activities (Details) Details 114 false false R115.htm 9954556 - Disclosure - Commitments and contingencies - Contingencies (Details) Sheet http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails Commitments and contingencies - Contingencies (Details) Details 115 false false R116.htm 9954557 - Disclosure - Commitments and contingencies - Bank Guarantee (Details) Sheet http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails Commitments and contingencies - Bank Guarantee (Details) Details 116 false false R117.htm 9954559 - Disclosure - Commitments and contingencies - Purchase Commitments (Details) Sheet http://www.sequans.com/role/CommitmentsandcontingenciesPurchaseCommitmentsDetails Commitments and contingencies - Purchase Commitments (Details) Details 117 false false R118.htm 9954561 - Disclosure - Related party disclosures - Narrative (Details) Sheet http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails Related party disclosures - Narrative (Details) Details 118 false false R119.htm 9954562 - Disclosure - Related party disclosures - Compensation of Key Management Personnel (Details) Sheet http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails Related party disclosures - Compensation of Key Management Personnel (Details) Details 119 false false R120.htm 9954563 - Disclosure - Related party disclosures - Directors??? Interests In An Employee Share Incentive Plan (Details) Sheet http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails Related party disclosures - Directors??? Interests In An Employee Share Incentive Plan (Details) Details 120 false false R121.htm 9954564 - Disclosure - Events after the reporting date (Details) Sheet http://www.sequans.com/role/EventsafterthereportingdateDetails Events after the reporting date (Details) Details http://www.sequans.com/role/Eventsafterthereportingdate 121 false false R9999.htm Uncategorized Items - sqns-20231231.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - sqns-20231231.htm Cover 122 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 45 fact(s) appearing in ix:hidden were eligible for transformation: ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases, ifrs-full:ActuarialAssumptionOfRetirementAge2019, sqns:ActuarialAssumptionOfTurnover, sqns:AssumedAnnualLapseRateShareOptionsAndOtherEquityInstrumentsGranted, sqns:BorrowingsMaturityTerm, sqns:DebtInstrumentConvertibleConversionRatio2, sqns:ResearchAndDevelopmentArrangementContractToPerformForOthersPeriodAfterDateOfTermination, sqns:ResearchAndDevelopmentArrangementContractToPerformForOthersTerm, sqns:RevenueFromSoftwareMaintenanceAndSupportServicesPeriodOfMaintenance, sqns:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2, sqns:ShareBasedCompensationArrangementByShareBasedPaymentAwardSalePeriod, sqns:UsefulLivesOrAmortisationRatesIntangibleAssetsOtherThanGoodwillPeriod, sqns:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod - sqns-20231231.htm 4 sqns-20231231.htm sqns-20231231.xsd sqns-20231231_cal.xml sqns-20231231_def.xml sqns-20231231_lab.xml sqns-20231231_pre.xml sqns-20231231_g1.jpg sqns-20231231_g2.jpg sqns-20231231_g3.jpg sqns-20231231_g4.jpg http://xbrl.sec.gov/dei/2023 https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full true true JSON 155 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sqns-20231231.htm": { "nsprefix": "sqns", "nsuri": "http://www.sequans.com/20231231", "dts": { "inline": { "local": [ "sqns-20231231.htm" ] }, "schema": { "local": [ "sqns-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "sqns-20231231_cal.xml" ] }, "definitionLink": { "local": [ "sqns-20231231_def.xml" ] }, "labelLink": { "local": [ "sqns-20231231_lab.xml" ] }, "presentationLink": { "local": [ "sqns-20231231_pre.xml" ] } }, "keyStandard": 334, "keyCustom": 192, "axisStandard": 47, "axisCustom": 9, "memberStandard": 75, "memberCustom": 140, "hidden": { "total": 49, "http://xbrl.sec.gov/dei/2023": 4, "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 12, "http://www.sequans.com/20231231": 33 }, "contextCount": 1014, "entityCount": 1, "segmentCount": 246, "elementCount": 1044, "unitCount": 17, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 2049, "http://xbrl.sec.gov/dei/2023": 47 }, "report": { "R1": { "role": "http://www.sequans.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.sequans.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "longName": "0000003 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromSaleOfGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:CostOfSales", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R4": { "role": "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement", "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss) Statement", "shortName": "Consolidated Statements of Comprehensive Income (Loss) Statement", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R5": { "role": "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "longName": "0000005 - Statement - Consolidated Statements of Financial Position", "shortName": "Consolidated Statements of Financial Position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:NoncurrentLoansAndReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R6": { "role": "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPositionParenthetical", "longName": "0000006 - Statement - Consolidated Statements of Financial Position (Parenthetical)", "shortName": "Consolidated Statements of Financial Position (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ParValuePerShare", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ifrs-full:ParValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "longName": "0000007 - Statement - Consolidated Statements of Changes in Equity (Deficit) Statement", "shortName": "Consolidated Statements of Changes in Equity (Deficit) Statement", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-22", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-22", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.sequans.com/role/StatementsofCashFlow", "longName": "0000008 - Statement - Statements of Cash Flow", "shortName": "Statements of Cash Flow", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:AdjustmentsForDepreciationExpenseAndImpairmentLossReversalOfImpairmentLossRecognizedInProfitOrLossPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R9": { "role": "http://www.sequans.com/role/Corporateinformation", "longName": "0000009 - Disclosure - Corporate information", "shortName": "Corporate information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfNatureOfBusinessExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfNatureOfBusinessExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.sequans.com/role/Summaryofsignificantaccountingandreportingpolicies", "longName": "0000010 - Disclosure - Summary of significant accounting and reporting policies", "shortName": "Summary of significant accounting and reporting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.sequans.com/role/Segmentinformation", "longName": "0000011 - Disclosure - Segment information", "shortName": "Segment information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.sequans.com/role/Otherrevenuesandexpenses", "longName": "0000012 - Disclosure - Other revenues and expenses", "shortName": "Other revenues and expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.sequans.com/role/Incometax", "longName": "0000013 - Disclosure - Income tax", "shortName": "Income tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-157", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.sequans.com/role/Earningslosspershare", "longName": "0000014 - Disclosure - Earnings (loss) per share", "shortName": "Earnings (loss) per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.sequans.com/role/Propertyplantandequipment", "longName": "0000015 - Disclosure - Property, plant and equipment", "shortName": "Property, plant and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.sequans.com/role/Intangibleassets", "longName": "0000016 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.sequans.com/role/Inventories", "longName": "0000017 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-13", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.sequans.com/role/Tradereceivables", "longName": "0000018 - Disclosure - Trade receivables", "shortName": "Trade receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-12", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.sequans.com/role/Cashandcashequivalents", "longName": "0000019 - Disclosure - Cash and cash equivalents", "shortName": "Cash and cash equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.sequans.com/role/Sharebasedpaymentplans", "longName": "0000021 - Disclosure - Share-based payment plans", "shortName": "Share-based payment plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-13", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.sequans.com/role/Interestbearingloansandborrowings", "longName": "0000022 - Disclosure - Interest-bearing loans and borrowings", "shortName": "Interest-bearing loans and borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-489", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-489", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.sequans.com/role/Leaseliabilities", "longName": "0000023 - Disclosure - Lease liabilities", "shortName": "Lease liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.sequans.com/role/Governmentgrantadvancesandloans", "longName": "0000024 - Disclosure - Government grant advances and loans", "shortName": "Government grant advances and loans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.sequans.com/role/Provisions", "longName": "0000025 - Disclosure - Provisions", "shortName": "Provisions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.sequans.com/role/Othernoncurrentliabilities", "longName": "0000026 - Disclosure - Other non-current liabilities", "shortName": "Other non-current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-13", "name": "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.sequans.com/role/Tradepayablesandothercurrentliabilities", "longName": "0000027 - Disclosure - Trade payables and other current liabilities", "shortName": "Trade payables and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.sequans.com/role/Informationaboutfinancialinstruments", "longName": "0000028 - Disclosure - Information about financial instruments", "shortName": "Information about financial instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.sequans.com/role/Commitmentsandcontingencies", "longName": "0000029 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.sequans.com/role/Relatedpartydisclosures", "longName": "0000030 - Disclosure - Related party disclosures", "shortName": "Related party disclosures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.sequans.com/role/Eventsafterthereportingdate", "longName": "0000031 - Disclosure - Events after the reporting date", "shortName": "Events after the reporting date", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1009", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1009", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies", "longName": "9954471 - Disclosure - Summary of significant accounting and reporting policies (Policies)", "shortName": "Summary of significant accounting and reporting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesTables", "longName": "9954472 - Disclosure - Summary of significant accounting and reporting policies (Tables)", "shortName": "Summary of significant accounting and reporting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "sqns:ConsolidationPolicy1PolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "sqns:ConsolidationPolicy1PolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.sequans.com/role/SegmentinformationTables", "longName": "9954473 - Disclosure - Segment information (Tables)", "shortName": "Segment information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.sequans.com/role/OtherrevenuesandexpensesTables", "longName": "9954474 - Disclosure - Other revenues and expenses (Tables)", "shortName": "Other revenues and expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfFinanceIncomeAndCostsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfFinanceIncomeAndCostsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.sequans.com/role/IncometaxTables", "longName": "9954475 - Disclosure - Income tax (Tables)", "shortName": "Income tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfMajorComponentsOfTaxExpenseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfMajorComponentsOfTaxExpenseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.sequans.com/role/EarningslosspershareTables", "longName": "9954476 - Disclosure - Earnings (loss) per share (Tables)", "shortName": "Earnings (loss) per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.sequans.com/role/PropertyplantandequipmentTables", "longName": "9954477 - Disclosure - Property, plant and equipment (Tables)", "shortName": "Property, plant and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://www.sequans.com/role/IntangibleassetsTables", "longName": "9954478 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.sequans.com/role/InventoriesTables", "longName": "9954479 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "sqns:ScheduleOfInventoryCurrent1TableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:ScheduleOfInventoryCurrent1TableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.sequans.com/role/TradereceivablesTables", "longName": "9954480 - Disclosure - Trade receivables (Tables)", "shortName": "Trade receivables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "sqns:ScheduleofAccountsNotesLoansandFinancingReceivable1TableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:ScheduleofAccountsNotesLoansandFinancingReceivable1TableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.sequans.com/role/CashandcashequivalentsTables", "longName": "9954481 - Disclosure - Cash and cash equivalents (Tables)", "shortName": "Cash and cash equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "sqns:ScheduleOfCashAndCashEquivalents1TableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:ScheduleOfCashAndCashEquivalents1TableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.sequans.com/role/IssuedcapitalandreservesTables", "longName": "9954482 - Disclosure - Issued capital and reserves (Tables)", "shortName": "Issued capital and reserves (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.sequans.com/role/SharebasedpaymentplansTables", "longName": "9954483 - Disclosure - Share-based payment plans (Tables)", "shortName": "Share-based payment plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.sequans.com/role/InterestbearingloansandborrowingsTables", "longName": "9954484 - Disclosure - Interest-bearing loans and borrowings (Tables)", "shortName": "Interest-bearing loans and borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.sequans.com/role/LeaseliabilitiesTables", "longName": "9954485 - Disclosure - Lease liabilities (Tables)", "shortName": "Lease liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.sequans.com/role/GovernmentgrantadvancesandloansTables", "longName": "9954486 - Disclosure - Government grant advances and loans (Tables)", "shortName": "Government grant advances and loans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfGovernmentGrantAdvancesAndLoansExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfGovernmentGrantAdvancesAndLoansExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.sequans.com/role/ProvisionsTables", "longName": "9954487 - Disclosure - Provisions (Tables)", "shortName": "Provisions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R48": { "role": "http://www.sequans.com/role/OthernoncurrentliabilitiesTables", "longName": "9954488 - Disclosure - Other non-current liabilities (Tables)", "shortName": "Other non-current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfOtherNonCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfOtherNonCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesTables", "longName": "9954489 - Disclosure - Trade payables and other current liabilities (Tables)", "shortName": "Trade payables and other current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfTradeAndOtherCurrentPayablesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:DisclosureOfTradeAndOtherCurrentPayablesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.sequans.com/role/InformationaboutfinancialinstrumentsTables", "longName": "9954490 - Disclosure - Information about financial instruments (Tables)", "shortName": "Information about financial instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.sequans.com/role/RelatedpartydisclosuresTables", "longName": "9954492 - Disclosure - Related party disclosures (Tables)", "shortName": "Related party disclosures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails", "longName": "9954493 - Disclosure - Summary of significant accounting and reporting policies - Narrative (Details)", "shortName": "Summary of significant accounting and reporting policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:IncreaseDecreaseInWorkingCapital", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ifrs-full:IncreaseDecreaseInWorkingCapital", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R53": { "role": "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails", "longName": "9954494 - Disclosure - Summary of significant accounting and reporting policies - Schedule of Subsidiaries (Details)", "shortName": "Summary of significant accounting and reporting policies - Schedule of Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-84", "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "sqns:ConsolidationPolicy1PolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-84", "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "sqns:ConsolidationPolicy1PolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofAverageandClosingExchangeRatefortheUSDollarDetails", "longName": "9954495 - Disclosure - Summary of significant accounting and reporting policies - Schedule of Average and Closing Exchange Rate for the U.S. Dollar (Details)", "shortName": "Summary of significant accounting and reporting policies - Schedule of Average and Closing Exchange Rate for the U.S. Dollar (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "usd_to_eur", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:DisclosureOfExchangeRateForFunctionalCurrencyTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:ClosingForeignExchangeRate", "unitRef": "usd_to_gbp", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:DisclosureOfExchangeRateForFunctionalCurrencyTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R55": { "role": "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPerformanceObligationDetails", "longName": "9954496 - Disclosure - Summary of significant accounting and reporting policies - Performance Obligation (Details)", "shortName": "Summary of significant accounting and reporting policies - Performance Obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails", "longName": "9954497 - Disclosure - Summary of significant accounting and reporting policies - Schedule of Useful Lives Most Commonly Used (Details)", "shortName": "Summary of significant accounting and reporting policies - Schedule of Useful Lives Most Commonly Used (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-94", "name": "sqns:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-94", "name": "sqns:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.sequans.com/role/SegmentinformationDetails", "longName": "9954498 - Disclosure - Segment information (Details)", "shortName": "Segment information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "sqns:NumberOfOperatingSegments1", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:NumberOfOperatingSegments1", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails", "longName": "9954499 - Disclosure - Other revenues and expenses - Schedule of Financial Income and Expenses (Details)", "shortName": "Other revenues and expenses - Schedule of Financial Income and Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InvestmentIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "sqns:DisclosureOfFinanceIncomeAndCostsExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:InvestmentIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "sqns:DisclosureOfFinanceIncomeAndCostsExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails", "longName": "9954500 - Disclosure - Other revenues and expenses - Financial Income and Expenses (Narrative) (Details)", "shortName": "Other revenues and expenses - Financial Income and Expenses (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestExpenseOnBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "sqns:DisclosureOfFinanceIncomeAndCostsExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-155", "name": "ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R60": { "role": "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails", "longName": "9954501 - Disclosure - Other revenues and expenses - Schedule of Cost of Revenue, Operating Expenses, and Employee Benefits (Details)", "shortName": "Other revenues and expenses - Schedule of Cost of Revenue, Operating Expenses, and Employee Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails", "longName": "9954502 - Disclosure - Other revenues and expenses - Research and Development Expense and Tax Credit Receivable (Details)", "shortName": "Other revenues and expenses - Research and Development Expense and Tax Credit Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:ResearchAndDevelopmentCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:DisclosureOfResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R62": { "role": "http://www.sequans.com/role/IncometaxScheduleofMajorComponentsofIncomeTaxExpenseDetails", "longName": "9954503 - Disclosure - Income tax - Schedule of Major Components of Income Tax Expense (Details)", "shortName": "Income tax - Schedule of Major Components of Income Tax Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:DisclosureOfMajorComponentsOfTaxExpenseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:DisclosureOfMajorComponentsOfTaxExpenseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.sequans.com/role/IncometaxNarrativeDetails", "longName": "9954504 - Disclosure - Income tax - Narrative (Details)", "shortName": "Income tax - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "sqns:WithholdingTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R64": { "role": "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails", "longName": "9954505 - Disclosure - Income tax - Reconciliation of Income Taxes Computed at the French Statutory Rate (Details)", "shortName": "Income tax - Reconciliation of Income Taxes Computed at the French Statutory Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "sqns:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:TaxExpenseIncomeAtApplicableTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R65": { "role": "http://www.sequans.com/role/IncometaxSummaryofDeferredTaxAssetsDetails", "longName": "9954506 - Disclosure - Income tax - Summary of Deferred Tax Assets (Details)", "shortName": "Income tax - Summary of Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-15", "name": "ifrs-full:DeferredTaxLiabilityAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R66": { "role": "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails", "longName": "9954507 - Disclosure - Income tax - Significant Components of Deferred Tax Assets and Liabilities (Details)", "shortName": "Income tax - Significant Components of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DeferredTaxLiabilityAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R67": { "role": "http://www.sequans.com/role/EarningslosspershareDetails", "longName": "9954508 - Disclosure - Earnings (loss) per share (Details)", "shortName": "Earnings (loss) per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:EarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R68": { "role": "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "longName": "9954509 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)", "shortName": "Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-15", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-28", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R69": { "role": "http://www.sequans.com/role/PropertyplantandequipmentNarrativeDetails", "longName": "9954510 - Disclosure - Property, plant and equipment - Narrative (Details)", "shortName": "Property, plant and equipment - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:RightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-292", "name": "ifrs-full:RightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R70": { "role": "http://www.sequans.com/role/IntangibleassetsDetails", "longName": "9954511 - Disclosure - Intangible assets (Details)", "shortName": "Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-15", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-210", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R71": { "role": "http://www.sequans.com/role/IntangibleassetsNarrativeDetails", "longName": "9954512 - Disclosure - Intangible assets - Narrative (Details)", "shortName": "Intangible assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": null }, "R72": { "role": "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails", "longName": "9954513 - Disclosure - Inventories - Schedule of Inventories (Details)", "shortName": "Inventories - Schedule of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:ScheduleOfInventoryCurrent1TableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:ScheduleOfInventoryCurrent1TableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.sequans.com/role/InventoriesNarrativeDetails", "longName": "9954514 - Disclosure - Inventories - Narrative (Details)", "shortName": "Inventories - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:Inventories", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:ScheduleOfInventoryCurrent1TableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-340", "name": "ifrs-full:ProvisionUsedOtherProvisions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R74": { "role": "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails", "longName": "9954515 - Disclosure - Trade receivables - Schedule of Non-Interest Bearing Trade Receivables (Details)", "shortName": "Trade receivables - Schedule of Non-Interest Bearing Trade Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-4", "name": "sqns:CurrentTradeReceivablesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:ScheduleofAccountsNotesLoansandFinancingReceivable1TableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "sqns:CurrentTradeReceivablesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:ScheduleofAccountsNotesLoansandFinancingReceivable1TableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails", "longName": "9954516 - Disclosure - Trade receivables - Schedule of Movements in the Provision for Impairment of Receivables (Details)", "shortName": "Trade receivables - Schedule of Movements in the Provision for Impairment of Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-15", "name": "ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:ScheduleofAccountsNotesLoansandFinancingReceivable1TableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-343", "name": "ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R76": { "role": "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails", "longName": "9954517 - Disclosure - Trade receivables - Aging Analysis of Trade Receivables That Were Not Impaired (Details)", "shortName": "Trade receivables - Aging Analysis of Trade Receivables That Were Not Impaired (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-14", "name": "ifrs-full:FinancialAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-344", "name": "ifrs-full:FinancialAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R77": { "role": "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails", "longName": "9954518 - Disclosure - Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details)", "shortName": "Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:BalancesWithBanks", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:ScheduleOfCashAndCashEquivalents1TableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:BalancesWithBanks", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:ScheduleOfCashAndCashEquivalents1TableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails", "longName": "9954519 - Disclosure - Cash and cash equivalents - Schedule of Cash and Cash Equivalents Held in U.S. dollar and Euros (Details)", "shortName": "Cash and cash equivalents - Schedule of Cash and Cash Equivalents Held in U.S. dollar and Euros (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-4", "name": "sqns:CashCashEquivalentsAndDeposit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-367", "name": "sqns:CashCashEquivalentsAndDeposit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R79": { "role": "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails", "longName": "9954520 - Disclosure - Issued capital and reserves - Narratives (Details)", "shortName": "Issued capital and reserves - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ReductionOfIssuedCapital", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-386", "name": "ifrs-full:ReductionOfIssuedCapital", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R80": { "role": "http://www.sequans.com/role/IssuedcapitalandreservesAuthorizedcapitalinnumberofsharesDetails", "longName": "9954521 - Disclosure - Issued capital and reserves - Authorized capital, in number of shares (Details)", "shortName": "Issued capital and reserves - Authorized capital, in number of shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-4", "name": "sqns:NumberOfSharesIssuedAndSharesReservedForIssue", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "sqns:NumberOfSharesIssuedAndSharesReservedForIssue", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.sequans.com/role/IssuedcapitalandreservesSharesIssuedandFullyPaidDetails", "longName": "9954522 - Disclosure - Issued capital and reserves - Shares Issued and Fully Paid (Details)", "shortName": "Issued capital and reserves - Shares Issued and Fully Paid (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:IssuedCapital", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R82": { "role": "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "longName": "9954523 - Disclosure - Issued capital and reserves - Capital Transactions (Details)", "shortName": "Issued capital and reserves - Capital Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-58", "name": "sqns:SharePrice1", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-58", "name": "sqns:SharePrice1", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "longName": "9954524 - Disclosure - Share-based payment plans - Narrative (Details)", "shortName": "Share-based payment plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:WeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAndOtherEquityInstrumentsInShareBasedPaymentArrangement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R84": { "role": "http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails", "longName": "9954525 - Disclosure - Share-based payment plans - Breakdown of share-based payments expenses (Details)", "shortName": "Share-based payment plans - Breakdown of share-based payments expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-405", "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R85": { "role": "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "longName": "9954526 - Disclosure - Share-based payment plans - General employee stock option, founders warrant plans and restricted shares awards (Details)", "shortName": "Share-based payment plans - General employee stock option, founders warrant plans and restricted shares awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-415", "name": "sqns:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-415", "name": "sqns:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails", "longName": "9954527 - Disclosure - Share-based payment plans - Warrant plans for certain consultants considered equivalent to employees (Details)", "shortName": "Share-based payment plans - Warrant plans for certain consultants considered equivalent to employees (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": null, "uniqueAnchor": null }, "R87": { "role": "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "longName": "9954528 - Disclosure - Share-based payment plans - Movements in number and WAEP (Details)", "shortName": "Share-based payment plans - Movements in number and WAEP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-15", "name": "sqns:NumberOfShareOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-28", "name": "sqns:NumberOfShareOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R88": { "role": "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "longName": "9954529 - Disclosure - Share-based payment plans - Movements in number and restricted shares awards (Details)", "shortName": "Share-based payment plans - Movements in number and restricted shares awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-436", "name": "sqns:ExercisePriceOfOutstandingShareOptionsAndOtherEquityInstrumentsInShareBasedPaymentArrangement", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-429", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R89": { "role": "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails", "longName": "9954530 - Disclosure - Share-based payment plans - Valuation assumptions (Details)", "shortName": "Share-based payment plans - Valuation assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-1", "name": "sqns:ExpectedDividendAsPercentageShareOptionsAndOtherEquityInstrumentsGranted", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:ExpectedDividendAsPercentageShareOptionsAndOtherEquityInstrumentsGranted", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails", "longName": "9954531 - Disclosure - Interest-bearing loans and borrowings - Schedule of Interest-Bearing Loans and Borrowings (Details)", "shortName": "Interest-bearing loans and borrowings - Schedule of Interest-Bearing Loans and Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-452", "name": "ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-452", "name": "ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "longName": "9954532 - Disclosure - Interest-bearing loans and borrowings - Convertible Debt (Details)", "shortName": "Interest-bearing loans and borrowings - Convertible Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-496", "name": "sqns:GainLossOnDebtModification", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R92": { "role": "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "longName": "9954533 - Disclosure - Interest-bearing loans and borrowings - Venture Debt (Details)", "shortName": "Interest-bearing loans and borrowings - Venture Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-1", "name": "sqns:RepaymentsofVentureDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": null }, "R93": { "role": "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "longName": "9954534 - Disclosure - Interest-bearing loans and borrowings - Interest-Bearing Financing Receivables (Details)", "shortName": "Interest-bearing loans and borrowings - Interest-Bearing Financing Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-15", "name": "ifrs-full:TradeReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:ScheduleofAccountsNotesLoansandFinancingReceivable1TableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-510", "name": "ifrs-full:BorrowingsAdjustmentToInterestRateBasis", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R94": { "role": "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "longName": "9954535 - Disclosure - Interest-bearing loans and borrowings - Unsecured related party loan (Details)", "shortName": "Interest-bearing loans and borrowings - Unsecured related party loan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ParValuePerShare", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ifrs-full:ParValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-504", "name": "sqns:SharePricePerADS", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R95": { "role": "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "longName": "9954536 - Disclosure - Lease liabilities - Narrative (Details)", "shortName": "Lease liabilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:RightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:RentExpenseonLeases", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R96": { "role": "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails", "longName": "9954537 - Disclosure - Lease liabilities - Summary of movements in right-of-use assets and lease liabilities (Details)", "shortName": "Lease liabilities - Summary of movements in right-of-use assets and lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-15", "name": "ifrs-full:RightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdditionsToRightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R97": { "role": "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails", "longName": "9954538 - Disclosure - Government grant advances and loans - Schedule of Government Grant Advances and Loans (Details)", "shortName": "Government grant advances and loans - Schedule of Government Grant Advances and Loans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-4", "name": "sqns:CurrentGovernmentGrantAdvances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "sqns:DisclosureOfGovernmentGrantAdvancesAndLoansExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "sqns:CurrentGovernmentGrantAdvances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "sqns:DisclosureOfGovernmentGrantAdvancesAndLoansExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "longName": "9954539 - Disclosure - Government grant advances and loans - Government Grant Advances (Details)", "shortName": "Government grant advances and loans - Government Grant Advances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-1", "name": "sqns:GovernmentGrantAdvancesNumberOfCollaborativeProjectsEnteredDuringPeriod", "unitRef": "project", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": null }, "R99": { "role": "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "longName": "9954540 - Disclosure - Government grant advances and loans - Research Project Financing (Details)", "shortName": "Government grant advances and loans - Research Project Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "sqns:NonCurrentInterestPayableResearchProjectFinancing", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R100": { "role": "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "longName": "9954541 - Disclosure - Government grant advances and loans - Government Loans (Details)", "shortName": "Government grant advances and loans - Government Loans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-568", "name": "sqns:NumberOfBorrowings", "unitRef": "borrowing", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-568", "name": "sqns:NumberOfBorrowings", "unitRef": "borrowing", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R101": { "role": "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails", "longName": "9954542 - Disclosure - Provisions - Reconciliation of Changes in Provisions (Details)", "shortName": "Provisions - Reconciliation of Changes in Provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-15", "name": "ifrs-full:Provisions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdditionalProvisionsOtherProvisions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R102": { "role": "http://www.sequans.com/role/ProvisionsNarrativeDetails", "longName": "9954543 - Disclosure - Provisions - Narrative (Details)", "shortName": "Provisions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:Inventories", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:ScheduleOfInventoryCurrent1TableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sqns:NumberOfEmployeesRetiredDuringTheYear", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R103": { "role": "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails", "longName": "9954544 - Disclosure - Provisions - Schedule of Main Assumptions Used (Details)", "shortName": "Provisions - Schedule of Main Assumptions Used (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.sequans.com/role/OthernoncurrentliabilitiesScheduleofOtherNonCurrentLiabilitiesDetails", "longName": "9954545 - Disclosure - Other non-current liabilities - Schedule of Other Non-Current Liabilities (Details)", "shortName": "Other non-current liabilities - Schedule of Other Non-Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:NoncurrentPayablesToTradeSuppliers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "sqns:DeferredIncomeClassifiedasNoncurrentStrategicAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R105": { "role": "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails", "longName": "9954546 - Disclosure - Other non-current liabilities - Narrative (Details)", "shortName": "Other non-current liabilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DeferredTaxLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-619", "name": "sqns:LicenseandServicesAgreementUpfrontPaymenttobeReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R106": { "role": "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails", "longName": "9954547 - Disclosure - Trade payables and other current liabilities - Schedule of Trade Payables and Other Current Liabilities (Details)", "shortName": "Trade payables and other current liabilities - Schedule of Trade Payables and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:DisclosureOfTradeAndOtherCurrentPayablesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sqns:DisclosureOfTradeAndOtherCurrentPayablesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R107": { "role": "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails", "longName": "9954548 - Disclosure - Trade payables and other current liabilities - Narrative (Details)", "shortName": "Trade payables and other current liabilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-13", "name": "sqns:TradePayableTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-608", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R108": { "role": "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "longName": "9954549 - Disclosure - Information about financial instruments - Schedule of Financial Assets and Financial Liabilities (Details)", "shortName": "Information about financial instruments - Schedule of Financial Assets and Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:FinancialAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentFinancialAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R109": { "role": "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "longName": "9954550 - Disclosure - Information about financial instruments - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "shortName": "Information about financial instruments - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-703", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R110": { "role": "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails", "longName": "9954551 - Disclosure - Information about financial instruments - Schedule of Present Fair Values of Derivative Financial Instruments (Details)", "shortName": "Information about financial instruments - Schedule of Present Fair Values of Derivative Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-719", "name": "ifrs-full:NominalAmountOfHedgingInstrument", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R111": { "role": "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "longName": "9954552 - Disclosure - Information about financial instruments - Narrative (Details)", "shortName": "Information about financial instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:GainLossOnHedgeIneffectiveness", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R112": { "role": "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails", "longName": "9954553 - Disclosure - Information about financial instruments - Summary of Customers Representing Company's Total Revenue (Details)", "shortName": "Information about financial instruments - Summary of Customers Representing Company's Total Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-726", "name": "ifrs-full:PercentageOfEntitysRevenue", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R113": { "role": "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "longName": "9954554 - Disclosure - Information about financial instruments - Schedule of Liquidity Risk (Details)", "shortName": "Information about financial instruments - Schedule of Liquidity Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-937", "name": "ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R114": { "role": "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "longName": "9954555 - Disclosure - Information about financial instruments - Changes in Liabilities Arising from Financing Activities (Details)", "shortName": "Information about financial instruments - Changes in Liabilities Arising from Financing Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-15", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "sqns:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-28", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "sqns:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R115": { "role": "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails", "longName": "9954556 - Disclosure - Commitments and contingencies - Contingencies (Details)", "shortName": "Commitments and contingencies - Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-985", "name": "ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": null }, "R116": { "role": "http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails", "longName": "9954557 - Disclosure - Commitments and contingencies - Bank Guarantee (Details)", "shortName": "Commitments and contingencies - Bank Guarantee (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-976", "name": "sqns:ExposureToCreditRiskOnLoanCommitmentsAndFinancialGuaranteeContractsTermOfSecuredPayments", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-976", "name": "sqns:ExposureToCreditRiskOnLoanCommitmentsAndFinancialGuaranteeContractsTermOfSecuredPayments", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R117": { "role": "http://www.sequans.com/role/CommitmentsandcontingenciesPurchaseCommitmentsDetails", "longName": "9954559 - Disclosure - Commitments and contingencies - Purchase Commitments (Details)", "shortName": "Commitments and contingencies - Purchase Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-980", "name": "sqns:PurchaseCommitmentRemainingMinimumAmountCommitted1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-980", "name": "sqns:PurchaseCommitmentRemainingMinimumAmountCommitted1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R118": { "role": "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails", "longName": "9954561 - Disclosure - Related party disclosures - Narrative (Details)", "shortName": "Related party disclosures - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-998", "name": "sqns:SpecialTransactionBonusApprovedByBoardOfDirectors", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-998", "name": "sqns:SpecialTransactionBonusApprovedByBoardOfDirectors", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R119": { "role": "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails", "longName": "9954562 - Disclosure - Related party disclosures - Compensation of Key Management Personnel (Details)", "shortName": "Related party disclosures - Compensation of Key Management Personnel (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R120": { "role": "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails", "longName": "9954563 - Disclosure - Related party disclosures - Directors\u2019 Interests In An Employee Share Incentive Plan (Details)", "shortName": "Related party disclosures - Directors\u2019 Interests In An Employee Share Incentive Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "sqns:TerminationIndemnityAmountofGrossAnnualBaseRemunerationDuration", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "unique": true } }, "R121": { "role": "http://www.sequans.com/role/EventsafterthereportingdateDetails", "longName": "9954564 - Disclosure - Events after the reporting date (Details)", "shortName": "Events after the reporting date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "c-1013", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1013", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true, "unique": true } }, "R9999": { "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "longName": "Uncategorized Items - sqns-20231231.htm", "shortName": "Uncategorized Items - sqns-20231231.htm", "isDefault": "false", "groupType": "", "subGroupType": "", "menuCat": "Cover", "order": "122", "firstAnchor": { "contextRef": "c-104", "name": "sqns:WithholdingTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sqns-20231231.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "sqns_A272CapitalFundLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "A272CapitalFundLPMember", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "272 Capital Fund LP", "label": "272 Capital Fund LP [Member]", "documentation": "272 Capital Fund LP" } } }, "auth_ref": [] }, "sqns_A5GNewProductDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "A5GNewProductDevelopmentMember", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5G New Product Development", "label": "5G New Product Development [Member]", "documentation": "5G New Product Development" } } }, "auth_ref": [] }, "sqns_A5GNewProductDevelopmentTeamOfEngineersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "A5GNewProductDevelopmentTeamOfEngineersMember", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5G New Product Development, Team Of Engineers", "label": "5G New Product Development, Team Of Engineers [Member]", "documentation": "5G New Product Development, Team Of Engineers" } } }, "auth_ref": [] }, "sqns_ABLEFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ABLEFranceMember", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ABLE France", "label": "ABLE France [Member]", "documentation": "ABLE France" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and impairment:", "label": "Accumulated depreciation, amortisation and impairment [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r61", "r70", "r108", "r119", "r122" ] }, "sqns_AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AccumulatedOtherComprehensiveIncomeExcludingReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income, Excluding Reserve Of Exchange Differences On Translation [Member]", "documentation": "Accumulated Other Comprehensive Income, Excluding Reserve Of Exchange Differences On Translation [Member]" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Actuarial assumption of discount rates" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r343" ] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salary increase", "label": "Actuarial assumption of expected rates of salary increases" } }, "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r343" ] }, "ifrs-full_ActuarialAssumptionOfRetirementAge2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfRetirementAge2019", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement age", "label": "Actuarial assumption of retirement age" } }, "en": { "role": { "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r343" ] }, "sqns_ActuarialAssumptionOfTurnover": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ActuarialAssumptionOfTurnover", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Turnover: depending on the seniority", "label": "Actuarial Assumption Of Turnover", "documentation": "Actuarial Assumption Of Turnover" } } }, "auth_ref": [] }, "ifrs-full_AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets", "presentation": [ "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charge for the year", "label": "Additional allowance recognised in profit or loss, allowance account for credit losses of financial assets" } }, "en": { "role": { "documentation": "The amount of additional allowance for credit losses of financial assets recognised in profit or loss. [Refer: Allowance account for credit losses of financial assets]" } } }, "auth_ref": [ "r365" ] }, "ifrs-full_AdditionalProvisionsOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionalProvisionsOtherProvisions", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arising (released) during the year", "label": "Additional provisions, other provisions" } }, "en": { "role": { "documentation": "The amount of additional other provisions made. [Refer: Other provisions]" } } }, "auth_ref": [ "r102" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions/Amortization", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r109" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r62" ] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions to right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r174" ] }, "sqns_AdditionsonLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AdditionsonLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions on Lease Liabilities", "documentation": "Additions on Lease Liabilities" } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustedWeightedAverageShares", "calculation": { "http://www.sequans.com/role/EarningslosspershareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average number of shares outstanding for diluted EPS (in shares)", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r97" ] }, "sqns_AdjustmentsForAmortisationAndImpairmentLossReversalOfImpairmentLossRecognizedInProfitOrLossIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AdjustmentsForAmortisationAndImpairmentLossReversalOfImpairmentLossRecognizedInProfitOrLossIntangibleAssets", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization and impairment of intangible assets", "label": "Adjustments For Amortisation And Impairment Loss (Reversal Of Impairment Loss) Recognized In Profit Or Loss, Intangible Assets", "documentation": "Adjustments For Amortisation And Impairment Loss (Reversal Of Impairment Loss) Recognized In Profit Or Loss, Intangible Assets" } } }, "auth_ref": [] }, "sqns_AdjustmentsForConvertibleDebtAmendments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AdjustmentsForConvertibleDebtAmendments", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt amendments", "label": "Adjustments For Convertible Debt Amendments", "documentation": "Adjustments For Convertible Debt Amendments" } } }, "auth_ref": [] }, "sqns_AdjustmentsForDecreaseIncreaseInCurrentReceivablesFromTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AdjustmentsForDecreaseIncreaseInCurrentReceivablesFromTaxesOtherThanIncomeTax", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (Increase) in research tax credit receivable", "label": "Adjustments For Decrease (Increase) In Current Receivables From Taxes Other Than Income Tax", "documentation": "Adjustments For Decrease (Increase) In Current Receivables From Taxes Other Than Income Tax" } } }, "auth_ref": [] }, "sqns_AdjustmentsForDecreaseIncreaseInGovernmentGrantAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AdjustmentsForDecreaseIncreaseInGovernmentGrantAdvances", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in government grant advances (1)", "label": "Adjustments For Decrease (Increase) In Government Grant Advances", "documentation": "Adjustments For Decrease (Increase) In Government Grant Advances" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (Increase) in inventories", "label": "Adjustments for decrease (increase) in inventories" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } } }, "auth_ref": [ "r355" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (Increase) in trade receivables and other receivables", "label": "Adjustments for decrease (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r358" ] }, "sqns_AdjustmentsForDepreciationExpenseAndImpairmentLossReversalOfImpairmentLossRecognizedInProfitOrLossPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AdjustmentsForDepreciationExpenseAndImpairmentLossReversalOfImpairmentLossRecognizedInProfitOrLossPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization and impairment of property, plant and equipment", "label": "Adjustments For Depreciation Expense And Impairment Loss (Reversal Of Impairment Loss) Recognized In Profit Or Loss, Property, Plant And Equipment", "documentation": "Adjustments For Depreciation Expense And Impairment Loss (Reversal Of Impairment Loss) Recognized In Profit Or Loss, Property, Plant And Equipment" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFinanceCosts", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Adjustments for finance costs" } }, "en": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss (gain) on disposal of property, plant and equipment", "label": "Adjustments for gain (loss) on disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]" } } }, "auth_ref": [ "r358" ] }, "sqns_AdjustmentsForImpactOfDebtReimbursement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AdjustmentsForImpactOfDebtReimbursement", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of debt reimbursement", "label": "Adjustments For Impact Of Debt Reimbursement", "documentation": "Adjustments For Impact Of Debt Reimbursement" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in contract liabilities", "label": "Adjustments for increase (decrease) in deferred income including contract liabilities" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r355" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for increase (decrease) in derivative financial liabilities", "label": "Adjustments for increase (decrease) in derivative financial liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in derivative financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial liabilities; Profit (loss)]" } } }, "auth_ref": [ "r358" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in trade payables and other liabilities", "label": "Adjustments for increase (decrease) in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r358" ] }, "ifrs-full_AdjustmentsForProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForProvisions", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in provisions", "label": "Adjustments for provisions" } }, "en": { "role": { "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]" } } }, "auth_ref": [ "r356" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash adjustment to reconcile profit (loss) before tax to net cash used in operating activities:", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment expense", "label": "Adjustments for share-based payments" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r356" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange loss (gain)", "label": "Adjustments for unrealised foreign exchange losses (gains)" } }, "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r290", "r356" ] }, "sqns_AdjustmentsForWorkingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AdjustmentsForWorkingCapitalAbstract", "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Working capital adjustments:", "label": "Adjustments For Working Capital [Abstract]", "documentation": "Adjustments For Working Capital [Abstract]" } } }, "auth_ref": [] }, "sqns_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature1", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred tax effect, equity", "label": "Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature1", "documentation": "Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature1" } } }, "auth_ref": [] }, "sqns_AdjustmentsforBadDebtExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AdjustmentsforBadDebtExpense", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Bad debt expense", "label": "Adjustments for Bad Debt Expense", "documentation": "Adjustments for Bad Debt Expense" } } }, "auth_ref": [] }, "sqns_AffiliatedEntity1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AffiliatedEntity1Member", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Affiliate of Nokomis Capital, L.L.C.", "label": "Affiliated Entity 1 [Member]", "documentation": "Affiliated Entity [Member]" } } }, "auth_ref": [] }, "sqns_AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AggregateOfferingPrice", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering price", "label": "Aggregate Offering Price", "documentation": "Aggregate Offering Price" } } }, "auth_ref": [] }, "ifrs-full_AggregatedTimeBandsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedTimeBandsMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesOperatingLeasesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregated time bands [member]", "label": "Aggregated time bands [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r24", "r168", "r177", "r178", "r182", "r183", "r185", "r191", "r208", "r277", "r308", "r311" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AllLevelsOfFairValueHierarchyMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All levels of fair value hierarchy [member]", "label": "All levels of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r73", "r160" ] }, "ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AllowanceAccountForCreditLossesOfFinancialAssets", "crdr": "credit", "calculation": { "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails": { "parentTag": "ifrs-full_TradeReceivables", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails", "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Provisions on trade receivables", "periodStartLabel": "At January 1,", "periodEndLabel": "At year end", "label": "Allowance account for credit losses of financial assets" } }, "en": { "role": { "documentation": "The amount of an allowance account used to record impairments to financial assets due to credit losses. [Refer: Financial assets]" } } }, "auth_ref": [ "r255" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "sqns_AmericanDepositSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AmericanDepositSharesOutstanding", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis per ADS (in dollars per share)", "terseLabel": "ADS outstanding for basic and diluted earnings (loss) per ADS (in shares)", "label": "American Deposit Shares Outstanding", "documentation": "American Deposit Shares Outstanding" } } }, "auth_ref": [] }, "sqns_AmericanDepositSharesOutstandingDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AmericanDepositSharesOutstandingDiluted", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted per ADS (in dollars per share)", "label": "American Deposit Shares Outstanding, Diluted", "documentation": "American Deposit Shares Outstanding, Diluted" } } }, "auth_ref": [] }, "sqns_AmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AmericanDepositarySharesMember", "presentation": [ "http://www.sequans.com/role/CoverPage", "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Depositary Shares, each representing four ordinary shares, nominal value \u20ac0.01\u00a0per share", "label": "American Depositary Shares [Member]", "documentation": "American Depositary Shares" } } }, "auth_ref": [] }, "sqns_AmericanDepositsSharesBasicEarningsLossperShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AmericanDepositsSharesBasicEarningsLossperShare", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings (loss) per ADS (in dollars per share)", "label": "American Deposits Shares, Basic Earnings (Loss) per Share", "documentation": "American Deposits Shares, Basic Earnings (Loss) per Share" } } }, "auth_ref": [] }, "sqns_AmericanDepositsSharesDilutedEarningsLossperShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AmericanDepositsSharesDilutedEarningsLossperShare", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings (loss) per ADS (in dollars per share)", "label": "American Deposits Shares, Diluted Earnings (Loss) per Share", "documentation": "American Deposits Shares, Diluted Earnings (Loss) per Share" } } }, "auth_ref": [] }, "ifrs-full_AmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmortisationExpense", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortisation expense" } }, "en": { "role": { "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives." } } }, "auth_ref": [ "r330" ] }, "sqns_AmortizationDisposalRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AmortizationDisposalRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization disposals", "label": "amortization disposal Right of use Assets", "documentation": "amortization disposal Right of use Assets" } } }, "auth_ref": [] }, "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AnalysisOfIncomeAndExpenseAbstract", "lang": { "en-us": { "role": { "terseLabel": "Analysis of income and expense [abstract]", "label": "Analysis of income and expense [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.sequans.com/role/IncometaxNarrativeDetails", "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable tax rate", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r55" ] }, "srt_AsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaMember", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Asia", "label": "Asia [Member]" } } }, "auth_ref": [] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rest of Asia", "label": "Asia Pacific [Member]" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r20", "r159", "r160", "r162", "r243", "r246" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "sqns_AssumedAnnualLapseRateOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AssumedAnnualLapseRateOtherEquityInstrumentsGranted", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed annual lapse rate of RSA (%)", "label": "Assumed Annual Lapse Rate, Other Equity Instruments Granted", "documentation": "Assumed Annual Lapse Rate, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "sqns_AssumedAnnualLapseRateShareOptionsAndOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AssumedAnnualLapseRateShareOptionsAndOtherEquityInstrumentsGranted", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed annual lapse rate of awards (%)", "label": "Assumed Annual Lapse Rate, Share Options And Other Equity Instruments Granted", "documentation": "Assumed Annual Lapse Rate, Share Options And Other Equity Instruments Granted" } } }, "auth_ref": [] }, "sqns_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.sequans.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r320", "r321", "r322" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.sequans.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r320", "r321", "r322" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.sequans.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r320", "r321", "r322" ] }, "sqns_AvailableForSaleSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "AvailableForSaleSecuritiesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial assets", "label": "Available-For-Sale Securities [Member]", "documentation": "Available-For-Sale Securities [Member]" } } }, "auth_ref": [] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofAverageandClosingExchangeRatefortheUSDollarDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average rate", "label": "Average foreign exchange rate" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r330" ] }, "sqns_B.RileyAssetManagementLLCAndLynrockLakeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "B.RileyAssetManagementLLCAndLynrockLakeMember", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B. Riley Asset Management LLC and Lynrock Lake", "label": "B. Riley Asset Management LLC and Lynrock Lake [Member]", "documentation": "B. Riley Asset Management LLC and Lynrock Lake" } } }, "auth_ref": [] }, "sqns_BPIFranceParticipationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BPIFranceParticipationMember", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BPI France Participation \u2013 Fonds Large Venture", "label": "BPI France Participation [Member]", "documentation": "BPI France Participation" } } }, "auth_ref": [] }, "sqns_BRileyFBRIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BRileyFBRIncMember", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B. Riley FBR, Inc", "label": "B. Riley FBR, Inc [Member]", "documentation": "B. Riley FBR, Inc" } } }, "auth_ref": [] }, "ifrs-full_BalancesWithBanks": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BalancesWithBanks", "crdr": "debit", "calculation": { "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails": { "parentTag": "sqns_CashCashEquivalentsAndDeposit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash at banks", "label": "Balances with banks" } }, "en": { "role": { "documentation": "The amount of cash balances held at banks." } } }, "auth_ref": [ "r360" ] }, "ifrs-full_BankAndSimilarCharges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BankAndSimilarCharges", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other bank fees and financial charges", "label": "Bank and similar charges" } }, "en": { "role": { "documentation": "The amount of bank and similar charges recognised by the entity as an expense." } } }, "auth_ref": [ "r330" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings (loss) per share (in dollars per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r95", "r96" ] }, "sqns_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BoardOfDirectorsMember", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board Of Directors [Member]", "label": "Board Of Directors [Member]", "documentation": "Board Of Directors [Member]" } } }, "auth_ref": [] }, "sqns_BondIssuanceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BondIssuanceAgreementMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bond Issuance Agreement", "label": "Bond Issuance Agreement [Member]", "documentation": "Bond Issuance Agreement [Member]" } } }, "auth_ref": [] }, "sqns_BorrowingRetentionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BorrowingRetentionAmount", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, Retention Amount", "label": "Borrowing, Retention Amount", "documentation": "Borrowing, Retention Amount" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of convertible note", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r334" ] }, "sqns_BorrowingsAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BorrowingsAccruedInterest", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Borrowings, Accrued Interest", "documentation": "Borrowings, Accrued Interest" } } }, "auth_ref": [] }, "sqns_BorrowingsAccruedInterestAndConversionBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BorrowingsAccruedInterestAndConversionBonus", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, accrued interest and conversion bonus", "label": "Borrowings, Accrued Interest And Conversion Bonus", "documentation": "Borrowings, Accrued Interest And Conversion Bonus" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsAdjustmentToInterestRateBasis", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to interest rate basis", "label": "Borrowings, adjustment to interest rate basis" } }, "en": { "role": { "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r363" ] }, "sqns_BorrowingsAvailablePercentageOfFaceValueOfDerecognisedAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BorrowingsAvailablePercentageOfFaceValueOfDerecognisedAssets", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available borrowings, percentage of face value of accounts receivable", "label": "Borrowings Available, Percentage Of Face Value Of Derecognised Assets", "documentation": "Borrowings Available, Percentage Of Face Value Of Derecognised Assets" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [axis]", "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r363" ] }, "ifrs-full_BorrowingsByNameMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [member]", "label": "Borrowings by name [member]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r363" ] }, "sqns_BorrowingsExcludingGovernmentLoansAndResearchProjectFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BorrowingsExcludingGovernmentLoansAndResearchProjectFinancingMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, Excluding Government Loans And Research Project Financing", "label": "Borrowings, Excluding Government Loans And Research Project Financing [Member]", "documentation": "Borrowings, Excluding Government Loans And Research Project Financing [Member]" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, interest rate", "verboseLabel": "Interest rate", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r363" ] }, "sqns_BorrowingsMaturityOptionalTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BorrowingsMaturityOptionalTerm", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Optional notice term", "label": "Borrowings Maturity, Optional Term", "documentation": "Borrowings Maturity, Optional Term" } } }, "auth_ref": [] }, "sqns_BorrowingsMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BorrowingsMaturityTerm", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt term", "label": "Borrowings Maturity, Term", "documentation": "Borrowings Maturity, Term" } } }, "auth_ref": [] }, "sqns_BorrowingsNoticeTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BorrowingsNoticeTerm", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notice term", "label": "Borrowings, Notice Term", "documentation": "Borrowings, Notice Term" } } }, "auth_ref": [] }, "sqns_BorrowingsNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BorrowingsNumberOfInstallments", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of installments", "label": "Borrowings, Number Of Installments", "documentation": "Borrowings, Number Of Installments" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of range", "verboseLabel": "Bottom of range [member]", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r164", "r185", "r196", "r294", "r295", "r363" ] }, "sqns_BpifranceParticipationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BpifranceParticipationsMember", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bpifrance Participations", "label": "Bpifrance Participations [Member]", "documentation": "Bpifrance Participations" } } }, "auth_ref": [] }, "sqns_BuildingsAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "BuildingsAndLeaseholdImprovementsMember", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and leasehold improvements", "label": "Buildings And Leasehold Improvements [Member]", "documentation": "Buildings And Leasehold Improvements [Member]" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r321", "r322" ] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CN", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "China", "label": "CHINA" } } }, "auth_ref": [] }, "currency_CNY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CNY", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RMB denominated accounts", "label": "China, Yuan Renminbi" } } }, "auth_ref": [] }, "ifrs-full_CapitalisedDevelopmentExpenditureMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalisedDevelopmentExpenditureMember", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/IntangibleassetsNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized development costs", "label": "Capitalised development expenditure [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets arising from development expenditure capitalised before the start of commercial production or use. An intangible asset shall only be recognised if the entity can demonstrate all of the following: (a) the technical feasibility of completing the intangible asset so that it will be available for use or sale; (b) its intention to complete the intangible asset and use or sell it; (c) its ability to use or sell the intangible asset; (d) how the intangible asset will generate probable future economic benefits. Among other things, the entity can demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset; (e) the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and (f) its ability to measure reliably the expenditure attributable to the intangible asset during its development." } } }, "auth_ref": [ "r353" ] }, "sqns_CapitalizedResearchAndDevelopmentCostsAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CapitalizedResearchAndDevelopmentCostsAmortization", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of capitalized development costs", "label": "Capitalized Research And Development Costs, Amortization", "documentation": "Capitalized Research And Development Costs, Amortization" } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r61", "r67", "r108", "r112", "r118", "r119", "r120", "r121", "r122", "r203", "r221", "r222" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount [member]", "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r67", "r112", "r118", "r120", "r121", "r203", "r221", "r222" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at January\u00a01", "periodEndLabel": "Cash and cash equivalents at period end", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r17", "r132", "r154" ] }, "sqns_CashCashEquivalentsAndDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CashCashEquivalentsAndDeposit", "crdr": "debit", "calculation": { "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails", "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, cash equivalents and deposits", "terseLabel": "Cash, cash equivalents and short-term deposits", "label": "Cash, Cash Equivalents And Deposit", "documentation": "Cash, Cash Equivalents And Deposit" } } }, "auth_ref": [] }, "sqns_CashCashEquivalentsAndShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CashCashEquivalentsAndShortTermInvestmentsMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash, cash equivalents and short-term investments", "label": "Cash, Cash Equivalents And Short-Term Investments [Member]", "documentation": "Cash, Cash Equivalents And Short-Term Investments [Member]" } } }, "auth_ref": [] }, "ifrs-full_CashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashEquivalents", "crdr": "debit", "calculation": { "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails": { "parentTag": "sqns_CashCashEquivalentsAndDeposit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash equivalents" } }, "en": { "role": { "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value." } } }, "auth_ref": [ "r360" ] }, "ifrs-full_CashFlowHedgesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowHedgesMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedge", "label": "Cash flow hedges [member]" } }, "en": { "role": { "documentation": "This member stands for hedges of the exposure to variability in cash flows that (a) are attributable to a particular risk associated with a recognised asset or liability (such as all or some future interest payments on variable rate debt) or a highly probable forecast transaction; and (b) could affect profit or loss. [Refer: Hedges [member]]" } } }, "auth_ref": [ "r117", "r210", "r211", "r214" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows from financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r123", "r134" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities:", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flow used in investments activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r123", "r134" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities:", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flow used in operating activities", "label": "Cash flows from (used in) operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r123", "r134" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities:", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [axis]", "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r234" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities [axis]", "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r234" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails", "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of related parties [axis]", "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r87" ] }, "ifrs-full_ChangesInOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ChangesInOtherProvisions", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (decrease) in other provisions", "terseLabel": "Increase (decrease) in other provisions", "label": "Increase (decrease) in other provisions" } }, "en": { "role": { "documentation": "The increase (decrease) in other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r105" ] }, "ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in tax rates", "label": "Changes in tax rates or tax laws enacted or announced [member]" } }, "en": { "role": { "documentation": "This member stands for changes in tax rates or tax laws enacted or announced." } } }, "auth_ref": [ "r271" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "sqns_ClassActionLawsuitRevenueRecognitionPolicyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ClassActionLawsuitRevenueRecognitionPolicyMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class Action Lawsuit, Revenue Recognition Policy", "label": "Class Action Lawsuit, Revenue Recognition Policy [Member]", "documentation": "Class Action Lawsuit, Revenue Recognition Policy [Member]" } } }, "auth_ref": [] }, "sqns_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants issued", "label": "Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights1", "documentation": "Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights1" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of assets [axis]", "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r99", "r100", "r163", "r176" ] }, "ifrs-full_ClassesOfAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfAssetsMember", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets [member]", "label": "Assets [member]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r99", "r163", "r176" ] }, "ifrs-full_ClassesOfContingentLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfContingentLiabilitiesAxis", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails", "http://www.sequans.com/role/CommitmentsandcontingenciesPledgeofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of contingent liabilities [axis]", "label": "Classes of contingent liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r106", "r202" ] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails", "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [axis]", "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r192", "r229", "r230", "r253", "r254" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails", "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [axis]", "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r221", "r223", "r225", "r226" ] }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialInstrumentsMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails", "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments, class [member]", "label": "Financial instruments, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r221", "r223", "r225", "r226" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [axis]", "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r229", "r230", "r253", "r254" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/IntangibleassetsNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [axis]", "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r113" ] }, "ifrs-full_ClassesOfOrdinarySharesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfOrdinarySharesAxis", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of ordinary shares [axis]", "label": "Classes of ordinary shares [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentNarrativeDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r68" ] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails", "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of other provisions [axis]", "label": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [axis]", "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ClassesOfShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalMember", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital [member]", "label": "Share capital [member]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofAverageandClosingExchangeRatefortheUSDollarDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Closing rate", "label": "Closing foreign exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r330" ] }, "sqns_CommitmentsAndContingenciesPolicy1PolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CommitmentsAndContingenciesPolicy1PolicyTextBlock", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments", "label": "Commitments And Contingencies, Policy1 [Policy Text Block]", "documentation": "Commitments And Contingencies, Policy1 [Policy Text Block]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) to be reclassified to profit or loss in subsequent years :", "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) not to be reclassified to profit or loss in subsequent years :", "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement_1": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r2", "r38", "r142", "r144", "r151", "r292" ] }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Attributable to:", "label": "Comprehensive income attributable to [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Comprehensive income, attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } } }, "auth_ref": [ "r2", "r40" ] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders of the parent", "label": "Comprehensive income, attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r2", "r41" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r341" ] }, "sqns_ConcentrationRiskPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConcentrationRiskPercentage", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk, Percentage", "label": "Concentration Risk, Percentage", "documentation": "Concentration Risk, Percentage" } } }, "auth_ref": [] }, "srt_CondensedFinancialStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedFinancialStatementsCaptionsLineItems", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Financial Statements, Captions [Line Items]", "label": "Condensed Financial Statements, Captions [Line Items]" } } }, "auth_ref": [] }, "srt_CondensedIncomeStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedIncomeStatementTable", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Income Statement [Table]", "label": "Condensed Income Statement [Table]" } } }, "auth_ref": [] }, "srt_CondensedIncomeStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedIncomeStatementsCaptionsLineItems", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Income Statements, Captions [Line Items]", "label": "Condensed Income Statements, Captions [Line Items]" } } }, "auth_ref": [] }, "sqns_ConsolidationPolicy1PolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConsolidationPolicy1PolicyTextBlock", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of consolidation", "label": "Consolidation, Policy1 [Policy Text Block]", "documentation": "Consolidation, Policy1 [Policy Text Block]" } } }, "auth_ref": [] }, "sqns_ConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConsultantsMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consultants considered equivalent to employees", "label": "Consultants [Member]", "documentation": "Consultants [Member]" } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelFaxNumber", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Fax Number", "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r321" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_ContingentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContingentLiabilitiesMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails", "http://www.sequans.com/role/CommitmentsandcontingenciesPledgeofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liabilities [member]", "label": "Contingent liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used." } } }, "auth_ref": [ "r107", "r202" ] }, "ifrs-full_ContingentLiabilitiesOfJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContingentLiabilitiesOfJointVentureMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesPledgeofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liabilities related to joint ventures", "label": "Contingent liabilities related to joint ventures [member]" } }, "en": { "role": { "documentation": "This member stands for contingent liabilities that are related to joint ventures. [Refer: Contingent liabilities [member]; Joint ventures [member]]" } } }, "auth_ref": [ "r281" ] }, "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfTransferAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfTransferAxis", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing involvement in derecognised financial assets by type of transfer [axis]", "label": "Continuing involvement in derecognised financial assets by type of transfer [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r309" ] }, "ifrs-full_ContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContractLiabilities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract liabilities" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } } }, "auth_ref": [ "r165", "r166" ] }, "sqns_ConvertibleBorrowingsEmbeddedDerivativeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleBorrowingsEmbeddedDerivativeMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt embedded derivative", "label": "Convertible Borrowings embedded derivative [Member]", "documentation": "Convertible Borrowings embedded derivative" } } }, "auth_ref": [] }, "sqns_ConvertibleBorrowingsIssuedApril2015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleBorrowingsIssuedApril2015Member", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2015 convertible notes", "label": "Convertible Borrowings Issued - April 2015 [Member]", "documentation": "Convertible Borrowings Issued - April 2015 [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleBorrowingsIssuedApril2016Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleBorrowingsIssuedApril2016Member", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016 convertible notes", "label": "Convertible Borrowings Issued - April 2016 [Member]", "documentation": "Convertible Borrowings Issued - April 2016 [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleBorrowingsIssuedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleBorrowingsIssuedMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt", "netLabel": "Convertible debt", "label": "Convertible Borrowings Issued [Member]", "documentation": "Convertible Borrowings Issued [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleBorrowingsIssuedSeptember2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleBorrowingsIssuedSeptember2018Member", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2018 convertible notes", "label": "Convertible Borrowings Issued - September 2018 [Member]", "documentation": "Convertible Borrowings Issued - September 2018 [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleDebt1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleDebt1Member", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt", "label": "Convertible Debt1 [Member]", "documentation": "Convertible Debt1" } } }, "auth_ref": [] }, "sqns_ConvertibleDebtAmendmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleDebtAmendmentNet", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Convertible debt amendments", "label": "Convertible Debt Amendment, Net", "documentation": "Convertible Debt Amendment, Net" } } }, "auth_ref": [] }, "sqns_ConvertibleDebtAmendmentNetExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleDebtAmendmentNetExpense", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt amendment, net expense", "label": "Convertible Debt Amendment, Net Expense", "documentation": "Convertible Debt Amendment, Net Expense" } } }, "auth_ref": [] }, "sqns_ConvertibleDebtAmendmentNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleDebtAmendmentNetIncome", "crdr": "credit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt amendments (Note 14.1)", "label": "Convertible Debt Amendment, Net Income", "documentation": "Convertible Debt Amendment, Net Income" } } }, "auth_ref": [] }, "sqns_ConvertibleDebtAndAccruedInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleDebtAndAccruedInterestMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt", "label": "Convertible Debt And Accrued Interest [Member]", "documentation": "Convertible Debt And Accrued Interest [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleDebtAndVentureDebtEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleDebtAndVentureDebtEquityMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debts and venture debt - equity component", "label": "Convertible Debt And Venture Debt, Equity [Member]", "documentation": "Convertible Debt And Venture Debt, Equity [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleDebtAndVentureDebtLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleDebtAndVentureDebtLiabilityMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debts and venture debt - liability", "label": "Convertible Debt And Venture Debt, Liability [Member]", "documentation": "Convertible Debt And Venture Debt, Liability [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleNotes2015And2018NokomisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotes2015And2018NokomisMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes 2015 And 2018 - Nokomis", "label": "Convertible Notes 2015 And 2018 - Nokomis [Member]", "documentation": "Convertible Notes 2015 And 2018 - Nokomis" } } }, "auth_ref": [] }, "sqns_ConvertibleNotes2015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotes2015Member", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes 2015", "label": "Convertible Notes 2015 [Member]", "documentation": "Convertible Notes 2015" } } }, "auth_ref": [] }, "sqns_ConvertibleNotes2015NokomisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotes2015NokomisMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes 2015 - Nokomis", "label": "Convertible Notes 2015 - Nokomis [Member]", "documentation": "Convertible Notes 2015 - Nokomis" } } }, "auth_ref": [] }, "sqns_ConvertibleNotes2016And20191Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotes2016And20191Member", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes 2016 and 2019-1", "label": "Convertible Notes 2016 And 2019-1 [Member]", "documentation": "Convertible Notes 2016 And 2019-1" } } }, "auth_ref": [] }, "sqns_ConvertibleNotes2016Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotes2016Member", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes 2016", "label": "Convertible Notes 2016 [Member]", "documentation": "Convertible Notes 2016" } } }, "auth_ref": [] }, "sqns_ConvertibleNotes2018NokomisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotes2018NokomisMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes 2018 - Nokomis", "label": "Convertible Notes 2018 - Nokomis [Member]", "documentation": "Convertible Notes 2018 - Nokomis" } } }, "auth_ref": [] }, "sqns_ConvertibleNotes20191Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotes20191Member", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019-1 notes", "label": "Convertible Notes 2019-1 [Member]", "documentation": "Convertible Notes 2019-1 [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleNotes20192Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotes20192Member", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019-2 notes", "label": "Convertible Notes 2019-2 [Member]", "documentation": "Convertible Notes 2019-2 [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleNotes2021LynrockLakeNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotes2021LynrockLakeNoteMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Note 2021 - Lynrock Lake Note", "label": "Convertible Notes 2021 - Lynrock Lake Note [Member]", "documentation": "Convertible Notes 2021 - Lynrock Lake Note" } } }, "auth_ref": [] }, "sqns_ConvertibleNotesAmendedOptionOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotesAmendedOptionOneMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes Amended, Option One", "label": "Convertible Notes Amended, Option One [Member]", "documentation": "Convertible Notes Amended, Option One [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleNotesAmendedOptionThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotesAmendedOptionThreeMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes Amended, Option Three", "label": "Convertible Notes Amended, Option Three [Member]", "documentation": "Convertible Notes Amended, Option Three [Member]" } } }, "auth_ref": [] }, "sqns_ConvertibleNotesAmendedOptionTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ConvertibleNotesAmendedOptionTwoMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes Amended, Option Two", "label": "Convertible Notes Amended, Option Two [Member]", "documentation": "Convertible Notes Amended, Option Two [Member]" } } }, "auth_ref": [] }, "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract", "lang": { "en-us": { "role": { "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]", "label": "Corporate information and statement of IFRS compliance [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CostOfMerchandiseSold": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CostOfMerchandiseSold", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cost of components", "label": "Cost of merchandise sold" } }, "en": { "role": { "documentation": "The amount of merchandise that was sold during the period and recognised as an expense." } } }, "auth_ref": [ "r338" ] }, "sqns_CostOfRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CostOfRevenueMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Revenue", "label": "Cost of Revenue [Member]", "documentation": "Cost of Revenue" } } }, "auth_ref": [] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of sales" } }, "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } } }, "auth_ref": [ "r0", "r49" ] }, "sqns_CostOfSales1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CostOfSales1Member", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Included in cost of revenue:", "label": "Cost Of Sales 1 [Member]", "documentation": "Cost Of Sales [Member]" } } }, "auth_ref": [] }, "sqns_CostOfSalesPolicy1PolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CostOfSalesPolicy1PolicyTextBlock", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost Of Sales, Policy1 [Policy Text Block]", "documentation": "Cost Of Sales, Policy1 [Policy Text Block]" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [axis]", "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r235" ] }, "ifrs-full_CounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesMember", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [member]", "label": "Counterparties [member]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r235" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CreditRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CreditRiskMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit risk", "label": "Credit risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r186", "r187", "r188", "r305" ] }, "sqns_CurrenciesOtherThanUSDollarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CurrenciesOtherThanUSDollarMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currencies Other Than US Dollar", "label": "Currencies Other Than US Dollar [Member]", "documentation": "Currencies Other Than US Dollar" } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency risk", "label": "Currency risk [member]" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r186", "r187", "r188", "r189", "r237" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r25", "r147", "r292" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest-bearing financing of receivables", "label": "Current borrowings and current portion of non-current borrowings" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_CurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentContractAssets", "crdr": "debit", "calculation": { "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails": { "parentTag": "ifrs-full_TradeReceivables", "weight": 1.0, "order": 2.0 }, "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract assets", "label": "Current contract assets" } }, "en": { "role": { "documentation": "The amount of current contract assets. [Refer: Contract assets]" } } }, "auth_ref": [ "r165" ] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r165" ] }, "ifrs-full_CurrentDebtInstrumentsIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentDebtInstrumentsIssued", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt", "label": "Current debt instruments issued" } }, "en": { "role": { "documentation": "The amount of current debt instruments issued. [Refer: Debt instruments issued]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentDeferredIncomeIncludingCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Current deferred income including current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r334", "r336" ] }, "sqns_CurrentDepositAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CurrentDepositAssets", "crdr": "debit", "calculation": { "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails": { "parentTag": "sqns_CashCashEquivalentsAndDeposit", "weight": 1.0, "order": 3.0 }, "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails", "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term deposits", "label": "Current Deposit Assets", "documentation": "Current Deposit Assets" } } }, "auth_ref": [] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt embedded derivative", "label": "Current derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_CurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total current", "label": "Current financial assets" } }, "en": { "role": { "documentation": "The amount of current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r216" ] }, "sqns_CurrentFinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CurrentFinancialAssetsAtFairValue", "crdr": "debit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialAssetsAtFairValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total current", "label": "Current Financial Assets, At Fair Value", "documentation": "Current Financial Assets, At Fair Value" } } }, "auth_ref": [] }, "ifrs-full_CurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total current", "label": "Current financial liabilities" } }, "en": { "role": { "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r216" ] }, "sqns_CurrentFinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CurrentFinancialLiabilitiesAtFairValue", "crdr": "credit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilitiesAtFairValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total current", "label": "Current Financial Liabilities, At Fair Value", "documentation": "Current Financial Liabilities, At Fair Value" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "sqns_CurrentGovernmentGrantAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CurrentGovernmentGrantAdvances", "crdr": "credit", "calculation": { "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails": { "parentTag": "ifrs-full_CurrentGovernmentGrants", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grant advances", "label": "Current Government Grant Advances", "documentation": "Current Government Grant Advances" } } }, "auth_ref": [] }, "ifrs-full_CurrentGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentGovernmentGrants", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 }, "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grant advances and loans", "totalLabel": "Total current portion", "label": "Current government grants" } }, "en": { "role": { "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r334" ] }, "sqns_CurrentGovernmentLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CurrentGovernmentLoans", "crdr": "credit", "calculation": { "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails": { "parentTag": "ifrs-full_CurrentGovernmentGrants", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government loans", "label": "Current Government Loans", "documentation": "Current Government Loans" } } }, "auth_ref": [] }, "ifrs-full_CurrentInterestPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentInterestPayable", "crdr": "credit", "calculation": { "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails": { "parentTag": "ifrs-full_CurrentGovernmentGrants", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current interest payable", "label": "Current interest payable" } }, "en": { "role": { "documentation": "The amount of current interest payable. [Refer: Interest payable]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "verboseLabel": "Current", "label": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r171" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r26", "r149", "r292" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentMember", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less than 30\u00a0days", "label": "Current [member]" } }, "en": { "role": { "documentation": "This member stands for a current time band." } } }, "auth_ref": [ "r306", "r312" ] }, "ifrs-full_CurrentPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPrepayments", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Current prepayments" } }, "en": { "role": { "documentation": "The amount of current prepayments. [Refer: Prepayments]" } } }, "auth_ref": [ "r265" ] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails": { "parentTag": "ifrs-full_Provisions", "weight": 1.0, "order": 1.0 }, "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current", "terseLabel": "Provisions", "label": "Current provisions" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r18" ] }, "ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentRawMaterialsAndCurrentProductionSupplies", "crdr": "debit", "calculation": { "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components, net", "label": "Current raw materials and current production supplies" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]" } } }, "auth_ref": [ "r346" ] }, "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit receivable", "label": "Current receivables from taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_CurrentRefundsProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentRefundsProvision", "crdr": "credit", "calculation": { "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails": { "parentTag": "ifrs-full_TradeReceivables", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Provision for credit notes to be issued", "label": "Current refunds provision" } }, "en": { "role": { "documentation": "The amount of current provision for refunds. [Refer: Refunds provision]" } } }, "auth_ref": [ "r280", "r282" ] }, "sqns_CurrentResearchProjectFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CurrentResearchProjectFinancing", "crdr": "credit", "calculation": { "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails": { "parentTag": "ifrs-full_CurrentGovernmentGrants", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research project financing", "label": "Current Research Project Financing", "documentation": "Current Research Project Financing" } } }, "auth_ref": [] }, "ifrs-full_CurrentTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.sequans.com/role/IncometaxScheduleofMajorComponentsofIncomeTaxExpenseDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/IncometaxScheduleofMajorComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current income tax expense", "label": "Current tax expense (income)" } }, "en": { "role": { "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } } }, "auth_ref": [ "r273" ] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "verboseLabel": "Accounts receivable", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r263", "r265" ] }, "sqns_CurrentTradeReceivablesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CurrentTradeReceivablesGross", "crdr": "debit", "calculation": { "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails": { "parentTag": "ifrs-full_TradeReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Current Trade Receivables, Gross", "documentation": "Current Trade Receivables, Gross" } } }, "auth_ref": [] }, "ifrs-full_CurrentUnsecuredBankLoansReceivedAndCurrentPortionOfNoncurrentUnsecuredBankLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentUnsecuredBankLoansReceivedAndCurrentPortionOfNoncurrentUnsecuredBankLoansReceived", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured related party loan", "label": "Current unsecured bank loans received and current portion of non-current unsecured bank loans received" } }, "en": { "role": { "documentation": "The amount of current unsecured bank loans received and the current portion of non-current unsecured bank loans received. [Refer: Unsecured bank loans received]" } } }, "auth_ref": [ "r330" ] }, "sqns_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CustomerAMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer A", "label": "Customer A [Member]", "documentation": "Customer A [Member]" } } }, "auth_ref": [] }, "sqns_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CustomerBMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer B", "label": "Customer B [Member]", "documentation": "Customer B [Member]" } } }, "auth_ref": [] }, "sqns_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CustomerCMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer C", "label": "Customer C [Member]", "documentation": "Customer C [Member]" } } }, "auth_ref": [] }, "sqns_CustomerDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CustomerDMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer D", "label": "Customer D [Member]", "documentation": "Customer D [Member]" } } }, "auth_ref": [] }, "sqns_CustomerEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CustomerEMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer E", "label": "Customer E [Member]", "documentation": "Customer E [Member]" } } }, "auth_ref": [] }, "sqns_CustomerFMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CustomerFMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer F", "label": "Customer F [Member]", "documentation": "Customer F" } } }, "auth_ref": [] }, "sqns_CustomerGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "CustomerGMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer G", "label": "Customer G [Member]", "documentation": "Customer G" } } }, "auth_ref": [] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "DE", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Germany", "label": "GERMANY" } } }, "auth_ref": [] }, "sqns_DebtInstrumentConvertibleConversionPricePerADS": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentConvertibleConversionPricePerADS", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price per ADS (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price Per ADS", "documentation": "Debt Instrument, Convertible, Conversion Price Per ADS" } } }, "auth_ref": [] }, "sqns_DebtInstrumentConvertibleConversionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentConvertibleConversionPricePerShare", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price Per Share", "documentation": "Debt Instrument, Convertible, Conversion Price Per Share" } } }, "auth_ref": [] }, "sqns_DebtInstrumentConvertibleConversionPricePremiumPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentConvertibleConversionPricePremiumPercentage", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price premium percentage", "label": "Debt Instrument, Convertible, Conversion Price, Premium Percentage", "documentation": "Debt Instrument, Convertible, Conversion Price, Premium Percentage" } } }, "auth_ref": [] }, "sqns_DebtInstrumentConvertibleConversionRatio2": { "xbrltype": "pureItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentConvertibleConversionRatio2", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion ratio", "label": "Debt Instrument, Convertible, Conversion Ratio2", "documentation": "Debt Instrument, Convertible, Conversion Ratio" } } }, "auth_ref": [] }, "sqns_DebtInstrumentConvertibleInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentConvertibleInterestRate", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate", "label": "Debt Instrument, Convertible, Interest Rate", "documentation": "Debt Instrument, Convertible, Interest Rate" } } }, "auth_ref": [] }, "sqns_DebtInstrumentConvertiblePaymentInKindInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentConvertiblePaymentInKindInterestRate", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PIK interest rate", "label": "Debt Instrument, Convertible, Payment-In-Kind Interest Rate", "documentation": "Debt Instrument, Convertible, Payment-In-Kind Interest Rate" } } }, "auth_ref": [] }, "sqns_DebtInstrumentConvertibleSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentConvertibleSubscriptionPrice", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription price (in dollars per share)", "label": "Debt Instrument, Convertible, Subscription Price", "documentation": "Debt Instrument, Convertible, Subscription Price" } } }, "auth_ref": [] }, "sqns_DebtInstrumentConvertibleWarrantExercisePricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentConvertibleWarrantExercisePricePercentage", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price, premium percentage", "label": "Debt Instrument, Convertible, Warrant, Exercise Price Percentage", "documentation": "Debt Instrument, Convertible, Warrant, Exercise Price Percentage" } } }, "auth_ref": [] }, "sqns_DebtInstrumentConvertibleWarrantPercentageOfNoteValue": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentConvertibleWarrantPercentageOfNoteValue", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant, as a percentage of note value", "label": "Debt Instrument, Convertible, Warrant, Percentage Of Note Value", "documentation": "Debt Instrument, Convertible, Warrant, Percentage Of Note Value" } } }, "auth_ref": [] }, "sqns_DebtInstrumentIncreaseDecreaseForPeriodNet1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet1", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reduction in debt carrying value", "label": "Debt Instrument, Increase (Decrease) For Period, Net 1", "documentation": "Debt Instrument, Increase (Decrease) For Period, Net" } } }, "auth_ref": [] }, "sqns_DebtInstrumentOwnershipLimit": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DebtInstrumentOwnershipLimit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, ownership limit", "label": "Debt Instrument, Ownership Limit", "documentation": "Debt Instrument, Ownership Limit" } } }, "auth_ref": [] }, "ifrs-full_DebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DebtSecurities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instruments issued", "label": "Debt instruments issued" } }, "en": { "role": { "documentation": "The amount of instruments issued by the entity that represent indebtedness." } } }, "auth_ref": [ "r334" ] }, "sqns_DeferredIncomeClassifiedasCurrentStrategicAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DeferredIncomeClassifiedasCurrentStrategicAgreement", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License and development services agreements (See Note 19)", "label": "Deferred Income Classified as Current, Strategic Agreement", "documentation": "Deferred Income Classified as Current, Strategic Agreement" } } }, "auth_ref": [] }, "sqns_DeferredIncomeClassifiedasNoncurrentStrategicAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DeferredIncomeClassifiedasNoncurrentStrategicAgreement", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesScheduleofOtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License and development services agreement", "label": "Deferred Income Classified as Non-current, Strategic Agreement", "documentation": "Deferred Income Classified as Non-current, Strategic Agreement" } } }, "auth_ref": [] }, "sqns_DeferredRevenueArrangementPeriodOfRecognition": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DeferredRevenueArrangementPeriodOfRecognition", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, maintenance period", "label": "Deferred Revenue Arrangement, Period Of Recognition", "documentation": "Deferred Revenue Arrangement, Period Of Recognition" } } }, "auth_ref": [] }, "sqns_DeferredRevenueArrangementType1Axis": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DeferredRevenueArrangementType1Axis", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue Arrangement Type [Axis]", "label": "Deferred Revenue Arrangement Type 1 [Axis]", "documentation": "Deferred Revenue Arrangement Type [Axis]" } } }, "auth_ref": [] }, "sqns_DeferredRevenueArrangementType1Domain": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DeferredRevenueArrangementType1Domain", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue Arrangement Type [Domain]", "label": "Deferred Revenue Arrangement Type 1 [Domain]", "documentation": "[Domain] for Deferred Revenue Arrangement Type [Axis]" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.sequans.com/role/IncometaxScheduleofMajorComponentsofIncomeTaxExpenseDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/IncometaxScheduleofMajorComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax expense (benefit)", "label": "Deferred tax expense (income)" } }, "en": { "role": { "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r58" ] }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails", "http://www.sequans.com/role/IncometaxSummaryofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expense (income) during the year recognized in Profit or Loss", "label": "Deferred tax expense (income) recognised in profit or loss" } }, "en": { "role": { "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]" } } }, "auth_ref": [ "r58" ] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails", "http://www.sequans.com/role/OthernoncurrentliabilitiesScheduleofOtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred tax liabilities" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r19", "r21", "r57" ] }, "ifrs-full_DeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/IncometaxNarrativeDetails", "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails", "http://www.sequans.com/role/IncometaxSummaryofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax liability", "periodStartLabel": "At January 1st", "periodEndLabel": "At December 31st", "terseLabel": "Deferred tax liability (asset)", "label": "Deferred tax liability (asset)" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r57" ] }, "sqns_Deposits1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "Deposits1Member", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits", "label": "Deposits 1 [Member]", "documentation": "Deposits [Member]" } } }, "auth_ref": [] }, "sqns_DepreciationAndImpairmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DepreciationAndImpairmentExpense", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and impairment", "label": "Depreciation And Impairment Expense", "documentation": "Depreciation And Impairment Expense" } } }, "auth_ref": [] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation charge for the year", "label": "Depreciation, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } } }, "auth_ref": [ "r65", "r69" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation expense", "label": "Depreciation, right-of-use assets" } }, "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } } }, "auth_ref": [ "r172" ] }, "sqns_DerivativeAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DerivativeAssetsMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges", "label": "Derivative Assets [Member]", "documentation": "Derivative Assets [Member]" } } }, "auth_ref": [] }, "ifrs-full_DerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DerivativeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative financial liabilities", "label": "Derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r334" ] }, "sqns_DerivativeFinancialLiabilitiesMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DerivativeFinancialLiabilitiesMaturityTerm", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative maturity period", "label": "Derivative Financial Liabilities, Maturity, Term", "documentation": "Derivative Financial Liabilities, Maturity, Term [Member]" } } }, "auth_ref": [] }, "sqns_DerivativeLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DerivativeLiabilitiesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges", "label": "Derivative Liabilities [Member]", "documentation": "Derivative Liabilities [Member]" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax", "label": "Description of accounting policy for deferred income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative financial instruments and hedge accounting", "label": "Description of accounting policy for derivative financial instruments and hedging [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for derivative financial instruments and hedging. [Refer: Financial instruments, class [member]; Derivatives [member]]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings (loss) per share", "label": "Description of accounting policy for earnings per share [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for earnings per share." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial instruments", "label": "Description of accounting policy for fair value measurement [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income and expense", "label": "Description of accounting policy for finance income and costs [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets", "label": "Description of accounting policy for financial assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Description of accounting policy for financial liabilities [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency transactions", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Functional currencies and translation of financial statements denominated in currencies other than the U.S. dollar", "label": "Description of accounting policy for functional currency [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the currency of the primary economic environment in which the entity operates." } } }, "auth_ref": [ "r331" ] }, "sqns_DescriptionOfAccountingPolicyForGovernmentGrantsLoansAndResearchTaxCreditsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DescriptionOfAccountingPolicyForGovernmentGrantsLoansAndResearchTaxCreditsPolicyTextBlock", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Government grants, loans and research tax credits", "label": "Description Of Accounting Policy For Government Grants, Loans And Research Tax Credits [Policy Text Block]", "documentation": "Description Of Accounting Policy For Government Grants, Loans And Research Tax Credits [Policy Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Current income tax", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Description of accounting policy for intangible assets other than goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Costs of Public Offerings", "label": "Description of accounting policy for issued capital [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Description of accounting policy for measuring inventories [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r75" ] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Description of accounting policy for property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Description of accounting policy for provisions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Description of accounting policy for recognition of revenue [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development costs", "label": "Description of accounting policy for research and development expense [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment transactions", "label": "Description of accounting policy for share-based payment transactions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Value added tax", "label": "Description of accounting policy for taxes other than income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r133" ] }, "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effect of Implementation of IFRIC Decision on IAS 19", "label": "Disclosure of initial application of standards or interpretations [text block]" } }, "en": { "role": { "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r137" ] }, "sqns_DevelopmentAndOtherServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DevelopmentAndOtherServicesMember", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development and other services", "label": "Development And Other Services [Member]", "documentation": "Development And Other Services [Member]" } } }, "auth_ref": [] }, "sqns_DevelopmentOfThe5GMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DevelopmentOfThe5GMember", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development Of The 5G", "label": "Development Of The 5G [Member]", "documentation": "Development Of The 5G" } } }, "auth_ref": [] }, "sqns_DevelopmentServicesAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DevelopmentServicesAgreementsMember", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development services agreements", "label": "Development Services Agreements [Member]", "documentation": "Development Services Agreements [Member]" } } }, "auth_ref": [] }, "sqns_DevelopmentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DevelopmentServicesMember", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development services", "label": "Development Services [Member]", "documentation": "Development Services [Member]" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings (loss) per share (in dollars per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r95", "r96" ] }, "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares", "calculation": { "http://www.sequans.com/role/EarningslosspershareDetails": { "parentTag": "ifrs-full_AdjustedWeightedAverageShares", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net effect of dilutive warrants (in shares)", "label": "Dilutive effect of convertible instruments on weighted average number of ordinary shares" } }, "en": { "role": { "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed conversion of the entity's convertible instruments." } } }, "auth_ref": [ "r350" ] }, "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "calculation": { "http://www.sequans.com/role/EarningslosspershareDetails": { "parentTag": "ifrs-full_AdjustedWeightedAverageShares", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net effect of dilutive stock options (in shares)", "label": "Dilutive effect of share options on weighted average number of ordinary shares" } }, "en": { "role": { "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options." } } }, "auth_ref": [ "r350" ] }, "sqns_DirectorsVicePresidentsAndManagersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DirectorsVicePresidentsAndManagersMember", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Directors", "label": "Directors, Vice Presidents And Managers [Member]", "documentation": "Directors, Vice Presidents And Managers" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of analysis of other comprehensive income by item [line items]", "label": "Disclosure of analysis of other comprehensive income by item [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of analysis of other comprehensive income by item [table]", "label": "Disclosure of analysis of other comprehensive income by item [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the analysis of other comprehensive income by item." } } }, "auth_ref": [ "r9" ] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://www.sequans.com/role/Interestbearingloansandborrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Interest-bearing loans and borrowings", "label": "Disclosure of borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.sequans.com/role/Cashandcashequivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Disclosure of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r328" ] }, "sqns_DisclosureOfCashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfCashAndCashEquivalentsLineItems", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Cash And Cash Equivalents [Line Items]", "label": "Disclosure Of Cash And Cash Equivalents [Line Items]", "documentation": "[Line Items] for Disclosure Of Cash And Cash Equivalents [Table]" } } }, "auth_ref": [] }, "sqns_DisclosureOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfCashAndCashEquivalentsTable", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Cash And Cash Equivalents [Table]", "label": "Disclosure Of Cash And Cash Equivalents [Table]", "documentation": "Disclosure Of Cash And Cash Equivalents [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Issued and Fully Paid", "label": "Disclosure of classes of share capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [line items]", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://www.sequans.com/role/Commitmentsandcontingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Disclosure of commitments and contingent liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesLineItems", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails", "http://www.sequans.com/role/CommitmentsandcontingenciesPledgeofAssetsDetails", "http://www.sequans.com/role/CommitmentsandcontingenciesPurchaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [line items]", "label": "Disclosure of contingent liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesTable", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails", "http://www.sequans.com/role/CommitmentsandcontingenciesPledgeofAssetsDetails", "http://www.sequans.com/role/CommitmentsandcontingenciesPurchaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [table]", "label": "Disclosure of contingent liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } } }, "auth_ref": [ "r106" ] }, "sqns_DisclosureOfCostOfSalesOperatingExpensesAndEmployeeBenefitsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfCostOfSalesOperatingExpensesAndEmployeeBenefitsExplanatoryTableTextBlock", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cost of Revenue and Operating Expenses", "label": "Disclosure Of Cost Of Sales, Operating Expenses, And Employee Benefits Explanatory [Table Text Block]", "documentation": "Disclosure Of Cost Of Sales, Operating Expenses, And Employee Benefits Explanatory [Table Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCreditRiskExposureLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCreditRiskExposureLineItems", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of credit risk exposure [line items]", "label": "Disclosure of credit risk exposure [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCreditRiskExposureTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCreditRiskExposureTable", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of credit risk exposure [table]", "label": "Disclosure of credit risk exposure [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the credit risk exposure." } } }, "auth_ref": [ "r225" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "presentation": [ "http://www.sequans.com/role/ProvisionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Main Assumptions Used", "label": "Disclosure of defined benefit plans [text block]" } }, "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r72" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [line items]", "label": "Disclosure of defined benefit plans [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [table]", "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r72" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Interest-Bearing Loans and Borrowings", "label": "Disclosure of detailed information about borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r363" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [line items]", "label": "Disclosure of detailed information about borrowings [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [table]", "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r363" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Present Fair Values of Derivative Financial Instruments", "label": "Disclosure of detailed information about financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r217", "r223", "r231" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentTables", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Useful Lives Most Commonly Used", "verboseLabel": "Schedule of Property, Plant and Equipment", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r68" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.sequans.com/role/Earningslosspershare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings (loss) per share", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r98" ] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://www.sequans.com/role/Segmentinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment information", "label": "Disclosure of entity's operating segments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r252" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.sequans.com/role/Eventsafterthereportingdate" ], "lang": { "en-us": { "role": { "terseLabel": "Events after the reporting date", "label": "Disclosure of events after reporting period [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r51" ] }, "sqns_DisclosureOfExchangeRateForFunctionalCurrencyTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfExchangeRateForFunctionalCurrencyTableTextBlock", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Average and Closing Exchange Rate for the U.S. Dollar", "label": "Disclosure Of Exchange Rate For Functional Currency [Table Text Block]", "documentation": "Disclosure Of Exchange Rate For Functional Currency [Table Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Fair Value of Financial Instruments", "label": "Disclosure of fair value of financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } } }, "auth_ref": [ "r328" ] }, "sqns_DisclosureOfFinanceIncomeAndCostsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfFinanceIncomeAndCostsExplanatoryTableTextBlock", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Income and Expenses", "label": "Disclosure Of Finance Income And Costs Explanatory [Table Text Block]", "documentation": "Disclosure Of Finance Income And Costs Explanatory [Table Text Block]" } } }, "auth_ref": [] }, "sqns_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of finance lease and operating lease by lessee [line items]", "label": "Disclosure of finance lease and operating lease by lessee [line items]" } } }, "auth_ref": [] }, "sqns_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of finance lease and operating lease by lessee [table]", "label": "Disclosure of finance lease and operating lease by lessee [table]" } } }, "auth_ref": [] }, "sqns_DisclosureOfFinancialAssetsAndLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfFinancialAssetsAndLiabilitiesLineItems", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Assets And Liabilities [Line Items]", "label": "Disclosure Of Financial Assets And Liabilities [Line Items]", "documentation": "[Line Items] for Disclosure Of Financial Assets And Liabilities [Table]" } } }, "auth_ref": [] }, "sqns_DisclosureOfFinancialAssetsAndLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfFinancialAssetsAndLiabilitiesTable", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Assets And Liabilities [Table]", "label": "Disclosure Of Financial Assets And Liabilities [Table]", "documentation": "Disclosure Of Financial Assets And Liabilities [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsExplanatory", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets", "label": "Disclosure of financial assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r231" ] }, "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory", "presentation": [ "http://www.sequans.com/role/TradereceivablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Aging Analysis of Trade Receivables That Were Not Impaired", "label": "Disclosure of financial assets that are either past due or impaired [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial assets that are either past due or impaired. [Refer: Financial assets]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets that are either past due or impaired [line items]", "label": "Disclosure of financial assets that are either past due or impaired [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets that are either past due or impaired [table]", "label": "Disclosure of financial assets that are either past due or impaired [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets that are either past due or impaired." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [abstract]", "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.sequans.com/role/Informationaboutfinancialinstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Information about financial instruments", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r238" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [line items]", "label": "Disclosure of detailed information about financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [table]", "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r217", "r223", "r231" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Financial Liabilities", "label": "Disclosure of financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r231" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [line items]", "label": "Disclosure of financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesTable", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [table]", "label": "Disclosure of financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } } }, "auth_ref": [ "r231" ] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://www.sequans.com/role/SegmentinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Revenue by Region", "label": "Disclosure of geographical areas [text block]" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_DisclosureOfGeographicalAreasLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeographicalAreasLineItems", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of geographical areas [line items]", "label": "Disclosure of geographical areas [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeographicalAreasTable", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of geographical areas [table]", "label": "Disclosure of geographical areas [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to geographical areas." } } }, "auth_ref": [ "r250" ] }, "sqns_DisclosureOfGovernmentGrantAdvancesAndLoansExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfGovernmentGrantAdvancesAndLoansExplanatoryTableTextBlock", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Government Grant Advances and Loans", "label": "Disclosure Of Government Grant Advances And Loans, Explanatory [Table Text Block]", "documentation": "Disclosure Of Government Grant Advances And Loans, Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGovernmentGrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGovernmentGrantsExplanatory", "presentation": [ "http://www.sequans.com/role/Governmentgrantadvancesandloans" ], "lang": { "en-us": { "role": { "terseLabel": "Government grant advances and loans", "label": "Disclosure of government grants [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for government grants." } } }, "auth_ref": [ "r78" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.sequans.com/role/Incometax" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r60" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value assumptions for determining value of the grants", "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r199" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value assumptions for determining value of the grants", "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r198" ] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.sequans.com/role/Intangibleassets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r116" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/IntangibleassetsNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [line items]", "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/IntangibleassetsNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [table]", "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r113" ] }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInventoriesExplanatory", "presentation": [ "http://www.sequans.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Disclosure of inventories [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for inventories." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://www.sequans.com/role/Leaseliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Disclosure of leases [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r180", "r181" ] }, "sqns_DisclosureOfMajorComponentsOfTaxExpenseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfMajorComponentsOfTaxExpenseIncomeTableTextBlock", "presentation": [ "http://www.sequans.com/role/IncometaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Major Components of Income Tax Expense", "label": "Disclosure Of Major Components Of Tax Expense (Income) [Table Text Block]", "documentation": "Disclosure Of Major Components Of Tax Expense (Income) [Table Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMajorCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMajorCustomersLineItems", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of major customers [line items]", "label": "Disclosure of major customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMajorCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMajorCustomersTable", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of major customers [table]", "label": "Disclosure of major customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the entity's major customers." } } }, "auth_ref": [ "r251" ] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.sequans.com/role/Summaryofsignificantaccountingandreportingpolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of material accounting policy information [text block]", "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r10" ] }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities [table]", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities." } } }, "auth_ref": [ "r227" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Future Minimum Undiscounted Lease Payments", "label": "Disclosure of maturity analysis of operating lease payments [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r178" ] }, "sqns_DisclosureOfNatureOfBusinessExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfNatureOfBusinessExplanatoryTextBlock", "presentation": [ "http://www.sequans.com/role/Corporateinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate information", "label": "Disclosure Of Nature Of Business, Explanatory [Text Block]", "documentation": "Disclosure Of Nature Of Business, Explanatory [Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of movement in number and WAEP of founder warrants, warrants and restricted shares awards", "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r361" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of movement in number and WAEP of stock options", "label": "Disclosure of number and weighted average exercise prices of share options [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r194" ] }, "sqns_DisclosureOfOtherNonCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfOtherNonCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Non-Current Liabilities", "label": "Disclosure Of Other Non-Current Liabilities [Table Text Block]", "documentation": "Disclosure Of Other Non-Current Liabilities [Table Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherNoncurrentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherNoncurrentLiabilitiesExplanatory", "presentation": [ "http://www.sequans.com/role/Othernoncurrentliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Disclosure of other non-current liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of other non-current liabilities. [Refer: Other non-current liabilities]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory", "presentation": [ "http://www.sequans.com/role/Otherrevenuesandexpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenues and expenses", "label": "Disclosure of other operating income (expense) [text block]" } }, "en": { "role": { "documentation": "The disclosure of other operating income or expense. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_DisclosureOfOtherProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherProvisionsExplanatory", "presentation": [ "http://www.sequans.com/role/ProvisionsTables", "http://www.sequans.com/role/TradereceivablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Movements in the Provision for Impairment of Receivables", "verboseLabel": "Reconciliation of Changes in Provisions", "label": "Disclosure of other provisions [text block]" } }, "en": { "role": { "documentation": "The disclosure of other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r105" ] }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherProvisionsLineItems", "presentation": [ "http://www.sequans.com/role/ProvisionsNarrativeDetails", "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other provisions [line items]", "label": "Disclosure of other provisions [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherProvisionsTable", "presentation": [ "http://www.sequans.com/role/ProvisionsNarrativeDetails", "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other provisions [table]", "label": "Disclosure of other provisions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.sequans.com/role/Propertyplantandequipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r71" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails", "http://www.sequans.com/role/PropertyplantandequipmentNarrativeDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]", "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails", "http://www.sequans.com/role/PropertyplantandequipmentNarrativeDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]", "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r68" ] }, "ifrs-full_DisclosureOfProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfProvisionsExplanatory", "presentation": [ "http://www.sequans.com/role/Provisions" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Disclosure of provisions [text block]" } }, "en": { "role": { "documentation": "The disclosure of provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of right-of-use assets", "label": "Disclosure of quantitative information about right-of-use assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r176" ] }, "sqns_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "presentation": [ "http://www.sequans.com/role/IncometaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Income Taxes Computed at the French Statutory Rate", "label": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate [Table Text Block]", "documentation": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate [Table Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://www.sequans.com/role/IntangibleassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsLineItems", "presentation": [ "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]", "label": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable", "presentation": [ "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [table]", "label": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of changes in the loss allowance and explanation of changes in the gross carrying amount for financial instruments." } } }, "auth_ref": [ "r221", "r222" ] }, "sqns_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatoryTableTextBlock", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Liabilities", "label": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities Explanatory [Table Text Block]", "documentation": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities Explanatory [Table Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [line items]", "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [table]", "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } } }, "auth_ref": [ "r289" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.sequans.com/role/Relatedpartydisclosures" ], "lang": { "en-us": { "role": { "terseLabel": "Related party disclosures", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r88" ] }, "sqns_DisclosureOfResearchAndDevelopmentExpenseExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Research and Development Expense", "label": "Disclosure Of Research And Development Expense Explanatory [Table Text Block]", "documentation": "Disclosure Of Research And Development Expense Explanatory [Table Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSegmentsMajorCustomersExplanatory", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Customers Representing Company's Total Revenue", "label": "Disclosure of major customers [text block]" } }, "en": { "role": { "documentation": "The disclosure of major customers." } } }, "auth_ref": [ "r251" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.sequans.com/role/Issuedcapitalandreserves" ], "lang": { "en-us": { "role": { "terseLabel": "Issued capital and reserves", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r35" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://www.sequans.com/role/Sharebasedpaymentplans" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment plans", "label": "Disclosure of share-based payment arrangements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r193" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Subsidiaries", "label": "Disclosure of subsidiaries [text block]" } }, "en": { "role": { "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r92", "r94", "r158" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of subsidiaries [line items]", "label": "Disclosure of subsidiaries [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of subsidiaries [table]", "label": "Disclosure of subsidiaries [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } } }, "auth_ref": [ "r92", "r94", "r158" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "presentation": [ "http://www.sequans.com/role/IncometaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Components of Deferred Tax Assets and Liabilities", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]" } }, "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } } }, "auth_ref": [ "r59" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r59" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails", "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails", "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]", "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r197" ] }, "sqns_DisclosureOfTradeAndOtherCurrentPayablesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureOfTradeAndOtherCurrentPayablesExplanatoryTableTextBlock", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Trade Payables and Other Current Liabilities", "label": "Disclosure Of Trade And Other Current Payables Explanatory [Table Text Block]", "documentation": "Disclosure Of Trade And Other Current Payables Explanatory [Table Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.sequans.com/role/Tradepayablesandothercurrentliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and other current liabilities", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.sequans.com/role/Tradereceivables" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transaction price allocated to remaining performance obligations [line items]", "label": "Disclosure of transaction price allocated to remaining performance obligations [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transaction price allocated to remaining performance obligations [table]", "label": "Disclosure of transaction price allocated to remaining performance obligations [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the transaction price allocated to the remaining performance obligations in contracts with customers." } } }, "auth_ref": [ "r168" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation of Key Management Personnel", "label": "Disclosure of transactions between related parties [text block]" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r84" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [line items]", "label": "Disclosure of transactions between related parties [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [table]", "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r87" ] }, "sqns_DisclosureofLeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureofLeasesLineItems", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Leases [Line Items]", "label": "Disclosure of Leases [Line Items]", "documentation": "[Line Items] for Disclosure of Leases [Table]" } } }, "auth_ref": [] }, "sqns_DisclosureofLeasesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureofLeasesTable", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Leases [Table]", "label": "Disclosure of Leases [Table]", "documentation": "Disclosure of Leases [Table]" } } }, "auth_ref": [] }, "sqns_DisclosureofotherprovisionscontingentliabilitiesandcontingentassetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisclosureofotherprovisionscontingentliabilitiesandcontingentassetsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other provisions, contingent liabilities and contingent assets [Abstract]", "label": "Disclosure of other provisions, contingent liabilities and contingent assets [Abstract]", "documentation": "Disclosure of other provisions, contingent liabilities and contingent assets [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposals, Cost (Depreciation and impairment)", "label": "Disposals, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r110" ] }, "sqns_DisposalsOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "DisposalsOnLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposals on Lease Liabilities", "label": "Disposals on Lease Liabilities", "documentation": "Disposals on Lease Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesAuthorizedcapitalinnumberofsharesDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposals", "terseLabel": "Disposals, property, plant and equipment", "label": "Disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r63" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r321" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r320", "r321", "r322" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r320", "r321", "r322", "r324" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r316" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r321" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r323" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "EUR", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro denominated accounts", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings per share [abstract]", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.sequans.com/role/EarningslosspershareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income and Share Data Used in Basic and Diluted Earnings (Loss) Per Share Computations", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r95" ] }, "sqns_EffectOfConversionOfConvertibleNotes": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "EffectOfConversionOfConvertibleNotes", "presentation": [ "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net effect of conversion of convertible notes (in shares)", "label": "Effect Of Conversion Of Convertible Notes", "documentation": "Effect Of Conversion Of Convertible Notes" } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Net foreign exchange difference", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r125", "r126" ] }, "sqns_EffectOfVestingOfRestrictedStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "EffectOfVestingOfRestrictedStock", "presentation": [ "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net effect of vesting of restricted stock (in shares)", "label": "Effect Of Vesting Of Restricted Stock", "documentation": "Effect Of Vesting Of Restricted Stock" } } }, "auth_ref": [] }, "sqns_EmbeddedDerivativeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "EmbeddedDerivativeMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt embedded derivative", "label": "Embedded Derivative [Member]", "documentation": "Embedded Derivative [Member]" } } }, "auth_ref": [] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Wages and benefits", "label": "Employee benefits expense" } }, "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r1", "r49", "r260" ] }, "ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entering into significant commitments or contingent liabilities", "label": "Entering into significant commitments or contingent liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for entering into significant commitments or contingent liabilities. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r272" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r318" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r318" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r327" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r318" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r325" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r318" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r318" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r326" ] }, "ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForImpairmentOfFinancialAssetsMember", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for impairment of financial assets [member]", "label": "Entity's total for impairment of financial assets [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Impairment of financial assets' axis if no other member is used." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails", "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for related parties [member]", "label": "Entity's total for related parties [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r87" ] }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForSubsidiariesMember", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for subsidiaries [member]", "label": "Entity's total for subsidiaries [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r92", "r94", "r158" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity (deficit)", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "negatedTerseLabel": "Equity", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r20", "r30", "r141", "r143", "r159", "r160", "r162" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Equity (deficit):", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity and liabilities", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r20" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY (DEFICIT) AND LIABILITIES", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity [member]", "label": "Equity [member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r8" ] }, "sqns_EuropeMiddleEastAndAfricaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "EuropeMiddleEastAndAfricaMember", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rest of world", "label": "Europe, Middle East, And Africa [Member]", "documentation": "Europe, Middle East, And Africa [Member]" } } }, "auth_ref": [] }, "sqns_ExclusionFromBorrowingsPastDuePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ExclusionFromBorrowingsPastDuePeriod", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exclusion from past due period of accounts receivable", "label": "Exclusion From Borrowings, Past Due Period", "documentation": "Exclusion From Borrowings, Past Due Period" } } }, "auth_ref": [] }, "sqns_ExecutiveTeamMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ExecutiveTeamMember", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Team", "label": "Executive Team [Member]", "documentation": "Executive Team" } } }, "auth_ref": [] }, "sqns_ExercisePriceOfOutstandingShareOptionsAndOtherEquityInstrumentsInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ExercisePriceOfOutstandingShareOptionsAndOtherEquityInstrumentsInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range of exercise prices (in usd per unit)", "label": "Exercise Price Of Outstanding Share Options And Other Equity Instruments In Share-Based Payment Arrangement", "documentation": "Exercise Price Of Outstanding Share Options And Other Equity Instruments In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_ExpectedDividendAsPercentageShareOptionsAndOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ExpectedDividendAsPercentageShareOptionsAndOtherEquityInstrumentsGranted", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield (%)", "label": "Expected Dividend As Percentage, Share Options And Other Equity Instruments Granted", "documentation": "Expected Dividend As Percentage, Share Options And Other Equity Instruments Granted" } } }, "auth_ref": [] }, "sqns_ExpectedVolatilityShareOptionsAndOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ExpectedVolatilityShareOptionsAndOtherEquityInstrumentsGranted", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (%)", "label": "Expected Volatility, Share Options And Other Equity Instruments Granted", "documentation": "Expected Volatility, Share Options And Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_ExpenseByNatureAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseByNatureAbstract", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial expenses:", "label": "Expenses by nature [abstract]" } } }, "auth_ref": [] }, "sqns_ExpenseByNatureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ExpenseByNatureLineItems", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense By Nature [Line Items]", "label": "Expense By Nature [Line Items]", "documentation": "[Line Items] for Expense By Nature [Table]" } } }, "auth_ref": [] }, "sqns_ExpenseByNatureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ExpenseByNatureTable", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense By Nature [Table]", "label": "Expense By Nature [Table]", "documentation": "Expense By Nature [Table]" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense from equity-settled share-based payment transactions", "label": "Expense from equity-settled share-based payment transactions" } }, "en": { "role": { "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r201" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment expenses", "label": "Expense from share-based payment transactions with employees" } }, "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Breakdown of share-based payments expenses on entity's profit or loss", "label": "Explanation of effect of share-based payments on entity's profit or loss [text block]" } }, "en": { "role": { "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)." } } }, "auth_ref": [ "r200" ] }, "ifrs-full_ExposureToCreditRiskOnLoanCommitmentsAndFinancialGuaranteeContracts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExposureToCreditRiskOnLoanCommitmentsAndFinancialGuaranteeContracts", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank guarantee issued in favor of owners of new leased office space", "label": "Exposure to credit risk on loan commitments and financial guarantee contracts" } }, "en": { "role": { "documentation": "The amount of the exposure to credit risk on loan commitments and financial guarantee contracts. [Refer: Loan commitments [member]; Financial guarantee contracts [member]; Credit risk [member]]" } } }, "auth_ref": [ "r221", "r222", "r225" ] }, "sqns_ExposureToCreditRiskOnLoanCommitmentsAndFinancialGuaranteeContractsTermOfSecuredPayments": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ExposureToCreditRiskOnLoanCommitmentsAndFinancialGuaranteeContractsTermOfSecuredPayments", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of secured lease payments", "label": "Exposure To Credit Risk On Loan Commitments And Financial Guarantee Contracts, Term Of Secured Payments", "documentation": "Exposure To Credit Risk On Loan Commitments And Financial Guarantee Contracts, Term Of Secured Payments" } } }, "auth_ref": [] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "FR", "presentation": [ "http://www.sequans.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FRANCE", "label": "FRANCE" } } }, "auth_ref": [] }, "ifrs-full_FactoringOfReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FactoringOfReceivablesMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Factoring of receivables", "label": "Factoring of receivables [member]" } }, "en": { "role": { "documentation": "This member stands for transactions in which an entity transfers its receivables to another party (the factor)." } } }, "auth_ref": [ "r309" ] }, "sqns_FairValueInputsDiscountRate1": { "xbrltype": "pureItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FairValueInputsDiscountRate1", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Discount rate", "label": "Fair Value Inputs, Discount Rate1", "documentation": "Fair Value Inputs, Discount Rate1" } } }, "auth_ref": [] }, "ifrs-full_FeeAndCommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FeeAndCommissionExpense", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fee and commission expense", "label": "Fee and commission expense" } }, "en": { "role": { "documentation": "The amount of expense relating to fees and commissions." } } }, "auth_ref": [ "r338" ] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial expenses", "label": "Finance costs" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r43" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial income", "label": "Finance income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r338" ] }, "sqns_FinanceLeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinanceLeaseLiabilitiesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured related party loan", "netLabel": "Finance lease liability", "verboseLabel": "Finance lease liability", "label": "Finance Lease Liabilities [Member]", "documentation": "Finance Lease Liabilities [Member]" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "totalLabel": "Total financial assets", "label": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } } }, "auth_ref": [ "r216", "r221", "r222", "r225", "r306" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial assets", "terseLabel": "Fair value", "negatedTerseLabel": "Financial assets, at fair value", "label": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r216" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments at fair value through other comprehensive income", "label": "Financial assets at fair value through other comprehensive income, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through other comprehensive income category. [Refer: Financial assets at fair value through other comprehensive income]" } } }, "auth_ref": [ "r233" ] }, "ifrs-full_FinancialAssetsAvailableforsaleCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAvailableforsaleCategoryMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale financial assets", "label": "Financial assets available-for-sale, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets available-for-sale category. [Refer: Financial assets available-for-sale]" } } }, "auth_ref": [ "r259" ] }, "ifrs-full_FinancialAssetsCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsCategoryMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets, category [member]", "label": "Financial assets, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r234" ] }, "sqns_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets Measured At Fair Value Through Other Comprehensive Income", "label": "Financial Assets Measured At Fair Value Through Other Comprehensive Income [Member]", "documentation": "Financial Assets Measured At Fair Value Through Other Comprehensive Income" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails", "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets, class [member]", "label": "Financial assets, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r192", "r229", "r230", "r253", "r254" ] }, "ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsNeitherPastDueNorImpairedMember", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Neither\u00a0past due nor Impaired", "label": "Financial assets neither past due nor impaired [member]" } }, "en": { "role": { "documentation": "This member stands for financial assets that are neither past due nor impaired. A financial asset is past due when a counterparty has failed to make a payment when contractually due. [Refer: Financial assets]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_FinancialAssetsPastDueButNotImpairedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsPastDueButNotImpairedMember", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Past due but not impaired", "label": "Financial assets past due but not impaired [member]" } }, "en": { "role": { "documentation": "This member stands for financial assets that are past due but not impaired. A financial asset is past due when a counterparty has failed to make a payment when contractually due. [Refer: Financial assets]" } } }, "auth_ref": [ "r256" ] }, "ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails", "http://www.sequans.com/role/CommitmentsandcontingenciesPledgeofAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total value of investments", "terseLabel": "Financial assets pledged as collateral", "label": "Financial assets pledged as collateral for liabilities or contingent liabilities" } }, "en": { "role": { "documentation": "The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]" } } }, "auth_ref": [ "r205" ] }, "sqns_FinancialExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialExpenseMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial expense", "label": "Financial Expense [Member]", "documentation": "Financial Expense [Member]" } } }, "auth_ref": [] }, "ifrs-full_FinancialGuaranteeContractsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialGuaranteeContractsMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank guarantee", "label": "Financial guarantee contracts [member]" } }, "en": { "role": { "documentation": "This member stands for contracts that require the issuer to make specified payments to reimburse the holder for a loss it incurs because a specified debtor fails to make payment when due in accordance with the original or modified terms of a debt instrument." } } }, "auth_ref": [ "r225", "r236" ] }, "sqns_FinancialIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialIncomeExpenseAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income (expense):", "label": "Financial Income (Expense) [Abstract]", "documentation": "Financial Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "sqns_FinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Abstract]", "label": "Financial Instruments [Abstract]", "documentation": "Financial Instruments [Abstract]" } } }, "auth_ref": [] }, "sqns_FinancialInstrumentsAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialInstrumentsAssetsAbstract", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets:", "label": "Financial Instruments, Assets [Abstract]", "documentation": "Financial Instruments, Assets [Abstract]" } } }, "auth_ref": [] }, "sqns_FinancialInstrumentsAssetsCarryingAmountAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialInstrumentsAssetsCarryingAmountAbstract", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount", "label": "Financial Instruments, Assets, Carrying Amount [Abstract]", "documentation": "Financial Instruments, Assets, Carrying Amount [Abstract]" } } }, "auth_ref": [] }, "sqns_FinancialInstrumentsAssetsFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialInstrumentsAssetsFairValueAbstract", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Financial Instruments, Assets, Fair Value [Abstract]", "documentation": "Financial Instruments, Assets, Fair Value [Abstract]" } } }, "auth_ref": [] }, "sqns_FinancialInstrumentsLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialInstrumentsLiabilitiesAbstract", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities:", "label": "Financial Instruments, Liabilities [Abstract]", "documentation": "Financial Instruments, Liabilities [Abstract]" } } }, "auth_ref": [] }, "sqns_FinancialInstrumentsLiabilitiesCarryingAmountAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialInstrumentsLiabilitiesCarryingAmountAbstract", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount", "label": "Financial Instruments, Liabilities, Carrying Amount [Abstract]", "documentation": "Financial Instruments, Liabilities, Carrying Amount [Abstract]" } } }, "auth_ref": [] }, "sqns_FinancialInstrumentsLiabilitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialInstrumentsLiabilitiesFairValueAbstract", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Financial Instruments, Liabilities, Fair Value [Abstract]", "documentation": "Financial Instruments, Liabilities, Fair Value [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial liabilities", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r216" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial liabilities", "terseLabel": "Fair\u00a0value", "label": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r216" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities at fair value through profit or loss", "label": "Financial liabilities at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r232" ] }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesCategoryMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities, category [member]", "label": "Financial liabilities, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r234" ] }, "sqns_FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments at fair value through other comprehensive income", "verboseLabel": "Financial instruments at fair value through other comprehensive income", "label": "Financial Liabilities Measured At Fair Value Through Other Comprehensive Income [Member]", "documentation": "Financial Liabilities Measured At Fair Value Through Other Comprehensive Income [Member]" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities, class [member]", "label": "Financial liabilities, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r229", "r230", "r253", "r254" ] }, "ifrs-full_FinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinishedGoods", "crdr": "debit", "calculation": { "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods, at the lower of cost and net realizable value", "label": "Current finished goods" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } } }, "auth_ref": [ "r266", "r346" ] }, "sqns_FirstInstallmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FirstInstallmentMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Installment", "label": "First Installment [Member]", "documentation": "First Installment" } } }, "auth_ref": [] }, "sqns_FixedAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FixedAssetsMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Fixed Assets [Member]", "documentation": "Fixed Assets [Member]" } } }, "auth_ref": [] }, "ifrs-full_FixedInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FixedInterestRateMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Contractual Rate", "label": "Fixed interest rate [member]" } }, "en": { "role": { "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r362" ] }, "sqns_ForeignExchangeGainLossonLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ForeignExchangeGainLossonLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange loss (gain)", "label": "Foreign Exchange Gain (Loss) on Lease Liabilities", "documentation": "Foreign Exchange Gain (Loss) on Lease Liabilities" } } }, "auth_ref": [] }, "ifrs-full_ForwardContractMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForwardContractMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward contracts", "label": "Forward contract [member]" } }, "en": { "role": { "documentation": "This member stands for a contract between two parties for the purchase or sale of an underlying asset at a specified future date for a settlement price determined in advance." } } }, "auth_ref": [ "r330" ] }, "sqns_FoundersWarrantsAndStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FoundersWarrantsAndStockOptionsMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Founders warrants and stock options", "label": "Founders Warrants And Stock Options [Member]", "documentation": "Founders Warrants And Stock Options [Member]" } } }, "auth_ref": [] }, "sqns_France20234GERedCapProjectMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "France20234GERedCapProjectMember", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "France 2023, 4G eRedCap Project", "label": "France 2023, 4G eRedCap Project [Member]", "documentation": "France 2023, 4G eRedCap Project" } } }, "auth_ref": [] }, "sqns_FurnitureAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "FurnitureAndOfficeEquipmentMember", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and office equipment", "label": "Furniture And Office Equipment [Member]", "documentation": "Furniture And Office Equipment [Member]" } } }, "auth_ref": [] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "GBP", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GBP denominated accounts", "label": "United Kingdom, Pounds" } } }, "auth_ref": [] }, "sqns_GainLossOnDebtModification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GainLossOnDebtModification", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on debt modification", "label": "Gain (Loss) On Debt Modification", "documentation": "Gain (Loss) On Debt Modification" } } }, "auth_ref": [] }, "ifrs-full_GainLossOnHedgeIneffectiveness": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainLossOnHedgeIneffectiveness", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) related to ineffective position of hedging instrument", "label": "Gain (loss) on hedge ineffectiveness" } }, "en": { "role": { "documentation": "The gain (loss) on hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item." } } }, "auth_ref": [ "r212" ] }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 5.0 }, "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails", "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of convertible debt derivative", "negatedTerseLabel": "Change in the fair value of convertible debt embedded derivative", "verboseLabel": "Expenses related to the change in fair value of the convertible debt embedded derivative", "label": "Gains (losses) on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r338" ] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange gain (loss), net", "verboseLabel": "Foreign exchange gains and losses related to hedges of euro", "negatedLabel": "Foreign exchange (gains) losses related to hedges of euro", "label": "Foreign exchange gain (loss)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } } }, "auth_ref": [ "r12", "r79" ] }, "ifrs-full_GainsOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of convertible debt derivative", "label": "Gains on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r338" ] }, "sqns_GeneralAndAdministrativeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GeneralAndAdministrativeMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative", "label": "General and Administrative [Member]", "documentation": "General and Administrative" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [axis]", "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r250", "r275", "r297", "r302" ] }, "ifrs-full_GeographicalAreasMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [member]", "label": "Geographical areas [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r250", "r275", "r297", "r302" ] }, "sqns_GovernmentGrantAdvancesAndLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GovernmentGrantAdvancesAndLoansMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grant advances and loans", "label": "Government Grant Advances And Loans [Member]", "documentation": "Government Grant Advances And Loans [Member]" } } }, "auth_ref": [] }, "sqns_GovernmentGrantAdvancesFundingCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GovernmentGrantAdvancesFundingCommitmentAmount", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount funded from government grant advances", "label": "Government Grant Advances, Funding Commitment Amount", "documentation": "Government Grant Advances, Funding Commitment Amount" } } }, "auth_ref": [] }, "sqns_GovernmentGrantAdvancesNumberOfCollaborativeProjectsEnteredDuringPeriod": { "xbrltype": "integerItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GovernmentGrantAdvancesNumberOfCollaborativeProjectsEnteredDuringPeriod", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of collaborative projects", "label": "Government Grant Advances, Number Of Collaborative Projects, Entered During Period", "documentation": "Government Grant Advances, Number Of Collaborative Projects, Entered During Period" } } }, "auth_ref": [] }, "sqns_GovernmentGrantAdvancesTermOfProject": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GovernmentGrantAdvancesTermOfProject", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of collaborative project", "label": "Government Grant Advances, Term Of Project", "documentation": "Government Grant Advances, Term Of Project" } } }, "auth_ref": [] }, "sqns_GovernmentGrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GovernmentGrantsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Government Grants [Abstract]", "label": "Government Grants [Abstract]", "documentation": "Government Grants [Abstract]" } } }, "auth_ref": [] }, "sqns_GovernmentLoanCovid19SupportPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GovernmentLoanCovid19SupportPlanMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government loan, Covid-19 support plan", "label": "Government Loan, Covid-19 Support Plan [Member]", "documentation": "Government Loan, Covid-19 Support Plan" } } }, "auth_ref": [] }, "sqns_GovernmentLoans5.24PercentLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GovernmentLoans5.24PercentLoanMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government loan - 5.24% Loan", "label": "Government Loans - 5.24 Percent Loan [Member]", "documentation": "Government Loans - 5.24 Percent Loan [Member]" } } }, "auth_ref": [] }, "sqns_GovernmentLoansInterestFreeLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GovernmentLoansInterestFreeLoanMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government loan - Interest Free Loan", "label": "Government Loans - Interest Free Loan [Member]", "documentation": "Government Loans - Interest Free Loan [Member]" } } }, "auth_ref": [] }, "sqns_GovernmentLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GovernmentLoansMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government loans", "verboseLabel": "Government loans", "label": "Government Loans [Member]", "documentation": "Government Loans [Member]" } } }, "auth_ref": [] }, "sqns_GrantingOfSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GrantingOfSharesMember", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granting of shares", "label": "Granting Of Shares [Member]", "documentation": "Granting Of Shares [Member]" } } }, "auth_ref": [] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost:", "netLabel": "Gross carrying amount", "label": "Gross carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r61", "r108", "r119", "r122", "r203", "r222", "r225", "r306" ] }, "ifrs-full_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross profit" } }, "en": { "role": { "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]" } } }, "auth_ref": [ "r261" ] }, "sqns_GuaranteeSecuredbyCollateralPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GuaranteeSecuredbyCollateralPercent", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesBankGuaranteeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of guarantee secured, percentage", "label": "Guarantee Secured by Collateral, Percent", "documentation": "Guarantee Secured by Collateral, Percent" } } }, "auth_ref": [] }, "sqns_GuaranteedReturnRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "GuaranteedReturnRate", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guaranteed return (in percentage)", "label": "Guaranteed Return, Rate", "documentation": "Guaranteed Return, Rate" } } }, "auth_ref": [] }, "ifrs-full_HedgingInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "HedgingInstrumentsAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging instruments [axis]", "label": "Hedging instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r207", "r210" ] }, "ifrs-full_HedgingInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "HedgingInstrumentsMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging instruments [member]", "label": "Hedging instruments [member]" } }, "en": { "role": { "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used." } } }, "auth_ref": [ "r207", "r210" ] }, "sqns_IFRS16Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IFRS16Member", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IFRS 16", "label": "IFRS 16 [Member]", "documentation": "IFRS 16 [Member]" } } }, "auth_ref": [] }, "currency_ILS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "ILS", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NIS denominated accounts", "label": "Israel, New Shekels" } } }, "auth_ref": [] }, "sqns_ITandOfficeEquipmentRightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ITandOfficeEquipmentRightofuseAssetsMember", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails", "http://www.sequans.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IT and office equipment", "label": "IT and Office Equipment, Right-of-use Assets [Member]", "documentation": "IT and Office Equipment, Right-of-use Assets [Member]" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r320", "r321", "r322" ] }, "sqns_IfrsFull_DisposalsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IfrsFull_DisposalsToRightofuseAssets", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposals", "label": "ifrs-full_DisposalsToRightofuseAssets", "documentation": "ifrs-full_DisposalsToRightofuseAssets" } } }, "auth_ref": [] }, "sqns_IfrsFull_ImpairmentLossRecognisedInProfitOrLossIntangibleassets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IfrsFull_ImpairmentLossRecognisedInProfitOrLossIntangibleassets", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for impairment", "label": "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleassets", "documentation": "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleassets" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentNarrativeDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Impairment loss recognised in profit or loss, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]" } } }, "auth_ref": [ "r48", "r64" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossTradeReceivables", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails", "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impaired additional trade receivables", "label": "Impairment loss recognised in profit or loss, trade receivables" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Trade receivables]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_ImpairmentOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentOfFinancialAssetsAxis", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of financial assets [axis]", "label": "Impairment of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Profit or loss [abstract]", "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "sqns_IncomeStatementLocation1Axis": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncomeStatementLocation1Axis", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails", "http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location 1 [Axis]", "documentation": "Income Statement Location [Axis]" } } }, "auth_ref": [] }, "sqns_IncomeStatementLocation1Domain": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncomeStatementLocation1Domain", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails", "http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location 1 [Domain]", "documentation": "[Domain] for Income Statement Location [Axis]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://www.sequans.com/role/IncometaxScheduleofMajorComponentsofIncomeTaxExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails", "http://www.sequans.com/role/IncometaxScheduleofMajorComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "totalLabel": "Income tax expense (benefit)", "label": "Tax expense (income)" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r44", "r52", "r54", "r55", "r90", "r157", "r242" ] }, "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome", "presentation": [ "http://www.sequans.com/role/IncometaxSummaryofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expense during the year recognised in OCI", "label": "Income tax relating to components of other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r45", "r53" ] }, "sqns_IncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncomeTaxesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Abstract]", "label": "Income Taxes [Abstract]", "documentation": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax paid", "label": "Income taxes paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } } }, "auth_ref": [ "r359" ] }, "sqns_IncreaseDecreaseBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseBorrowings", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in borrowings", "terseLabel": "Increase in borrowings", "label": "Increase (Decrease) Borrowings", "documentation": "Increase (Decrease) Borrowings" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ProvisionsNarrativeDetails", "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) due to changes in accounting policy required by IFRSs [member]", "label": "Increase (decrease) due to changes in accounting policy required by IFRSs [member]" } }, "en": { "role": { "documentation": "This member stands for the financial effect of changes in accounting policy required by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r135", "r136" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r132" ] }, "sqns_IncreaseDecreaseInNumberOfADSIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseInNumberOfADSIssued", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in number of ADS issued", "label": "Increase (decrease) in number of ADS issued", "documentation": "Increase (decrease) in number of ADS issued" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of shares and warrants (in shares)", "label": "Increase (decrease) in number of ordinary shares issued" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in number of shares outstanding", "label": "Increase (decrease) in number of shares outstanding" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r32" ] }, "sqns_IncreaseDecreaseInNumberOfUnderwritersOverAllotmentSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseInNumberOfUnderwritersOverAllotmentSharesIssued", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriters' over-allotment shares issued (in shares)", "label": "Increase (Decrease) In Number Of Underwriters' Over-Allotment Shares Issued", "documentation": "Increase (Decrease) In Number Of Underwriters' Over-Allotment Shares Issued" } } }, "auth_ref": [] }, "sqns_IncreaseDecreaseInResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseInResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in R&D expenses", "label": "Increase (Decrease) In Research And Development Expenses", "documentation": "Increase (Decrease) In Research And Development Expenses" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in working capital", "label": "Increase (decrease) in working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r358" ] }, "sqns_IncreaseDecreaseThroughChangeInNominalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseThroughChangeInNominalValue", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through change in nominal value", "label": "Increase (Decrease) Through Change In Nominal Value", "documentation": "Increase (Decrease) Through Change In Nominal Value" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through changes in fair values, liabilities arising from financing activities", "label": "Increase (decrease) through changes in fair values, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r130" ] }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through conversion of convertible instruments, equity", "label": "Increase (decrease) through conversion of convertible instruments, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } } }, "auth_ref": [ "r329" ] }, "sqns_IncreaseDecreaseThroughConversionOfLoansEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseThroughConversionOfLoansEquity", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) Through Conversion Of Loans, Equity", "label": "Increase (Decrease) Through Conversion Of Loans, Equity", "documentation": "Increase (Decrease) Through Conversion Of Loans, Equity" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through effect of changes in foreign exchange rates", "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r129" ] }, "sqns_IncreaseDecreaseThroughExerciseOfBridgeLoansFromRelatedPartyEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseThroughExerciseOfBridgeLoansFromRelatedPartyEquity", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Bridge loans from related party", "label": "Increase (Decrease) Through Exercise Of Bridge Loans From Related Party, Equity", "documentation": "Increase (Decrease) Through Exercise Of Bridge Loans From Related Party, Equity" } } }, "auth_ref": [] }, "sqns_IncreaseDecreaseThroughExerciseOfOptionsAndWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseThroughExerciseOfOptionsAndWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of shares in connection with the exercise of options and warrants, and vesting of restricted shares awards", "label": "Increase (Decrease) Through Exercise Of Options And Warrants, Equity", "documentation": "Increase (Decrease) Through Exercise Of Options And Warrants, Equity" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through exercise of warrants, equity", "label": "Increase (decrease) through exercise of warrants, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r329" ] }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through financing cash flows", "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } } }, "auth_ref": [ "r128" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/IncometaxSummaryofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange", "label": "Increase (decrease) through net exchange differences, deferred tax liability (asset)" } }, "en": { "role": { "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Deferred tax liability (asset)]" } } }, "auth_ref": [ "r340" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange difference", "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r111" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange difference", "label": "Increase (decrease) through net exchange differences, property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r66" ] }, "sqns_IncreaseDecreaseThroughNonCashImpactOfAmendmentLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseThroughNonCashImpactOfAmendmentLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through non-cash impact of amendment", "label": "Increase (Decrease) Through Non-Cash Impact Of Amendment, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Non-Cash Impact Of Amendment, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "sqns_IncreaseDecreaseThroughNonCashInterestLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseThroughNonCashInterestLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through non-cash interest", "label": "Increase (Decrease) Through Non-Cash Interest, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Non-Cash Interest, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through other changes", "label": "Increase (decrease) through other changes, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r131" ] }, "sqns_IncreaseDecreaseThroughShareIssuedATMProgramEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IncreaseDecreaseThroughShareIssuedATMProgramEquity", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of shares in connection with the public offering of March 2022 (Note 12)", "label": "Increase (Decrease) Through Share Issued, ATM Program, Equity", "documentation": "Increase (Decrease) Through Share Issued, ATM Program, Equity" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r6" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through other changes, equity", "label": "Increase (decrease) through other changes, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } } }, "auth_ref": [ "r7" ] }, "sqns_InformationTechnologyAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InformationTechnologyAndOfficeEquipmentMember", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IT\u00a0and\u00a0office equipment", "label": "Information Technology And Office Equipment [Member]", "documentation": "Information Technology And Office Equipment [Member]" } } }, "auth_ref": [] }, "sqns_InsurancePaymentMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InsurancePaymentMinimum", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments above limit", "label": "Insurance Payment Minimum", "documentation": "Insurance Payment Minimum" } } }, "auth_ref": [] }, "sqns_IntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IntangibleAssetsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets [Abstract]", "label": "Intangible Assets [Abstract]", "documentation": "Intangible Assets [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "negatedPeriodStartLabel": "Beginning balance", "negatedPeriodEndLabel": "Ending balance", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r14", "r112" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillMember", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/IntangibleassetsNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets other than goodwill [member]", "label": "Intangible assets other than goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r113", "r279", "r299" ] }, "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsWithIndefiniteUsefulLifeAxis", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets with indefinite useful life [axis]", "label": "Intangible assets with indefinite useful life [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r114" ] }, "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsWithIndefiniteUsefulLifeMember", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets with indefinite useful life [member]", "label": "Intangible assets with indefinite useful life [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets with an indefinite useful life. It also represents the standard value for the 'Intangible assets with indefinite useful life' axis if no other member is used. [Refer: Intangible assets with indefinite useful life]" } } }, "auth_ref": [ "r114" ] }, "sqns_InterestBearingLoansAndBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InterestBearingLoansAndBorrowingsMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest-bearing loans and borrowings:", "label": "Interest-Bearing Loans And Borrowings [Member]", "documentation": "Interest-Bearing Loans And Borrowings [Member]" } } }, "auth_ref": [] }, "sqns_InterestBearingReceivablesFinancingLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InterestBearingReceivablesFinancingLineOfCreditMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest-bearing receivables financing", "label": "Interest-Bearing Receivables Financing Line Of Credit [Member]", "documentation": "Interest-Bearing Receivables Financing Line Of Credit [Member]" } } }, "auth_ref": [] }, "sqns_InterestBearingReceivablesFinancingResearchTaxCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InterestBearingReceivablesFinancingResearchTaxCreditMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest-Bearing Receivables Financing, Research Tax Credit", "label": "Interest-Bearing Receivables Financing, Research Tax Credit [Member]", "documentation": "Interest-Bearing Receivables Financing, Research Tax Credit" } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r156", "r241", "r247" ] }, "ifrs-full_InterestExpenseOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnBorrowings", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on loans", "label": "Interest expense on borrowings" } }, "en": { "role": { "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease contracts (see Note 15)", "label": "Interest expense on lease liabilities" } }, "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r173" ] }, "sqns_InterestExpenseOnNoncurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InterestExpenseOnNoncurrentPayablesToTradeSuppliers", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on supplier payable with extended payment terms", "label": "Interest Expense On Noncurrent Payables To Trade Suppliers", "documentation": "Interest Expense On Noncurrent Payables To Trade Suppliers" } } }, "auth_ref": [] }, "sqns_InterestExpenseonFinancingofLongTermServicesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InterestExpenseonFinancingofLongTermServicesAgreement", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on financing component of long term development services agreement (see Notes 18 and 19)", "label": "Interest Expense on Financing of Long Term Services Agreement", "documentation": "Interest Expense on Financing of Long Term Services Agreement" } } }, "auth_ref": [] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid", "terseLabel": "Interest paid, classified as financing activities", "label": "Interest paid, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r127" ] }, "ifrs-full_InterestRateTypesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestRateTypesMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate types [member]", "label": "Interest rate types [member]" } }, "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r362" ] }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestReceivedClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Interest received, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } } }, "auth_ref": [ "r127" ] }, "sqns_InternationalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InternationalMember", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "International [Member]", "documentation": "International [Member]" } } }, "auth_ref": [] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 8.0 }, "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails", "http://www.sequans.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total net inventories", "negatedTerseLabel": "Current inventories", "negatedLabel": "Provision for slow-moving or damaged inventory", "label": "Current inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r15", "r76", "r263" ] }, "sqns_InventoriesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InventoriesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventories [Abstract]", "label": "Inventories [Abstract]", "documentation": "Inventories [Abstract]" } } }, "auth_ref": [] }, "sqns_InventoryAdjustmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InventoryAdjustmentsMember", "presentation": [ "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory adjustments", "label": "Inventory Adjustments [Member]", "documentation": "Inventory Adjustments [Member]" } } }, "auth_ref": [] }, "ifrs-full_InvestmentIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentIncome", "crdr": "credit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income from short-term investments and term deposits and other finance revenue", "label": "Investment income" } }, "en": { "role": { "documentation": "The amount of investment income, such as interest and dividends." } } }, "auth_ref": [ "r89", "r338" ] }, "sqns_InvestmentWarrantsExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InvestmentWarrantsExercisePrice1", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in dollars per share)", "label": "Investment Warrants, Exercise Price1", "documentation": "Investment Warrants, Exercise Price1" } } }, "auth_ref": [] }, "sqns_InvestmentWarrantsExercisePricePerADS": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "InvestmentWarrantsExercisePricePerADS", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per ADS (in dollars per share)", "label": "Investment Warrants, Exercise Price Per ADS", "documentation": "Investment Warrants, Exercise Price Per ADS" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of shares and warrants", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r6" ] }, "sqns_IssueOfEquityNetProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "IssueOfEquityNetProceeds", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of equity, net proceeds", "label": "Issue Of Equity, Net Proceeds", "documentation": "Issue Of Equity, Net Proceeds" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/IssuedcapitalandreservesSharesIssuedandFullyPaidDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued capital", "verboseLabel": "Ordinary shares", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r267" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r8" ] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "JP", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "America", "label": "JAPAN" } } }, "auth_ref": [] }, "country_KR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "KR", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Korea", "label": "KOREA, REPUBLIC OF" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total compensation expense for key management personnel", "terseLabel": "Key management personnel compensation", "label": "Key management personnel compensation" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r83" ] }, "sqns_KeyManagementPersonnelCompensationBoardOfDirectorFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "KeyManagementPersonnelCompensationBoardOfDirectorFees", "crdr": "debit", "calculation": { "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board members fees to non-executive members", "label": "Key Management Personnel Compensation, Board Of Director Fees", "documentation": "Key Management Personnel Compensation, Board Of Director Fees" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment expense for the year", "verboseLabel": "Share-based payment expense", "label": "Key management personnel compensation, share-based payment" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r82" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed and variable wages, social charges and benefits expensed in the year", "label": "Key management personnel compensation, short-term employee benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r81" ] }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelOfEntityOrParentMember", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresCompensationofKeyManagementPersonnelDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel", "label": "Key management personnel of entity or parent [member]" } }, "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } } }, "auth_ref": [ "r85" ] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesOperatingLeasesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "More than five years", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r177", "r178", "r191", "r308", "r310", "r313" ] }, "ifrs-full_LaterThanFourMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFourMonthsMember", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Greater than 120\u00a0days", "label": "Later than four months [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than four months." } } }, "auth_ref": [ "r330" ] }, "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "4 to 5 years", "label": "Later than four years and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than four years and not later than five years." } } }, "auth_ref": [ "r177", "r178", "r191", "r308", "r313", "r330" ] }, "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "30-60\u00a0days", "label": "Later than one month and not later than two months [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one month and not later than two months." } } }, "auth_ref": [ "r306", "r312", "r330" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After one year but not more than five years", "label": "Later than one year and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than five years." } } }, "auth_ref": [ "r307", "r313" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "1 to 2 years", "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r177", "r178", "r191", "r308", "r313", "r330" ] }, "ifrs-full_LaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearMember", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Later than one year", "label": "Later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year." } } }, "auth_ref": [ "r23" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "3 to 4 years", "label": "Later than three years and not later than four years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } } }, "auth_ref": [ "r177", "r178", "r191", "r308", "r313", "r330" ] }, "sqns_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LaterThanTwoMonthsAndNotLaterThanFourMonthsMember", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "60-120\u00a0days", "label": "Later Than Two Months And Not Later Than Four Months [Member]", "documentation": "Later Than Two Months And Not Later Than Four Months [Member]" } } }, "auth_ref": [] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2 to 3 years", "label": "Later than two years and not later than three years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } } }, "auth_ref": [ "r177", "r178", "r191", "r308", "r313", "r330" ] }, "sqns_LeadTimesIncreasedCOVID19AndOtherSupplyChainConstraintsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LeadTimesIncreasedCOVID19AndOtherSupplyChainConstraintsMember", "presentation": [ "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lead-Times Increased COVID-19 And Other Supply Chain Constraints", "label": "Lead-Times Increased COVID-19 And Other Supply Chain Constraints [Member]", "documentation": "Lead-Times Increased COVID-19 And Other Supply Chain Constraints" } } }, "auth_ref": [] }, "sqns_LeaseContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LeaseContractsMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contracts [Member]", "label": "Lease Contracts [Member]", "documentation": "Lease Contracts [Member]" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "periodStartLabel": "Lease liabilities at beginning of period", "periodEndLabel": "Lease liabilities at end of period", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r171" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Lease liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r288", "r291" ] }, "ifrs-full_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold improvements [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } } }, "auth_ref": [ "r341" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ifrs-full_LegalProceedingsContingentLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LegalProceedingsContingentLiabilityMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal proceedings contingent liability", "label": "Legal proceedings contingent liability [member]" } }, "en": { "role": { "documentation": "This member stands for a contingent liability for legal proceedings. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r281" ] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r73", "r160" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a02", "label": "Level 2 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r160" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a03", "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r160" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Levels of fair value hierarchy [axis]", "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r73", "r160" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Liabilities arising from financing activities beginning balance", "periodEndLabel": "Liabilities arising from financing activities ending balance", "label": "Liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [axis]", "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r289" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [member]", "label": "Liabilities arising from financing activities [member]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_LicencesAndFranchisesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LicencesAndFranchisesMember", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses", "label": "Licences and franchises [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity and the right to operate a business using the name, merchandise, services, methodologies, promotional support, marketing and supplies granted by another entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r283" ] }, "sqns_LicenseAndServicesAgreementInvestmentsRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LicenseAndServicesAgreementInvestmentsRevenue", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments revenue", "label": "License and Services Agreement, Investments Revenue", "documentation": "License and Services Agreement, Investments Revenue" } } }, "auth_ref": [] }, "sqns_LicenseFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LicenseFeeMember", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "license fee", "label": "License fee [Member]", "documentation": "License fee" } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseMember", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails", "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License", "verboseLabel": "Licenses", "label": "License [Member]" } } }, "auth_ref": [] }, "sqns_LicenseandServicesAgreementContractLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LicenseandServicesAgreementContractLiability", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net remaining contract liability", "label": "License and Services Agreement, Contract Liability", "documentation": "License and Services Agreement, Contract Liability" } } }, "auth_ref": [] }, "sqns_LicenseandServicesAgreementCurrentContractLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LicenseandServicesAgreementCurrentContractLiability", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current contract liabilities", "label": "License and Services Agreement, Current Contract Liability", "documentation": "License and Services Agreement, Current Contract Liability" } } }, "auth_ref": [] }, "sqns_LicenseandServicesAgreementInterestExpenseonUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LicenseandServicesAgreementInterestExpenseonUpfrontPayment", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expenses on upfront payment", "label": "License and Services Agreement, Interest Expense on Upfront Payment", "documentation": "License and Services Agreement, Interest Expense on Upfront Payment" } } }, "auth_ref": [] }, "sqns_LicenseandServicesAgreementNoncurrentContractLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LicenseandServicesAgreementNoncurrentContractLiability", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current contract liabilities", "label": "License and Services Agreement, Non-current Contract Liability", "documentation": "License and Services Agreement, Non-current Contract Liability" } } }, "auth_ref": [] }, "sqns_LicenseandServicesAgreementRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LicenseandServicesAgreementRevenue", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized revenues", "label": "License and Services Agreement, Revenue", "documentation": "License and Services Agreement, Revenue" } } }, "auth_ref": [] }, "sqns_LicenseandServicesAgreementUpfrontPaymenttobeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LicenseandServicesAgreementUpfrontPaymenttobeReceived", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License and services agreement upfront payment", "label": "License and Services Agreement, Upfront Payment to be Received", "documentation": "License and Services Agreement, Upfront Payment to be Received" } } }, "auth_ref": [] }, "ifrs-full_LiquidityRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiquidityRiskMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity risk", "label": "Liquidity risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r186", "r187", "r188", "r305" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "ifrs-full_LoanCommitmentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LoanCommitmentsMember", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan commitments [member]", "label": "Loan commitments [member]" } }, "en": { "role": { "documentation": "This member stands for firm commitments to provide credit under pre-specified terms and conditions." } } }, "auth_ref": [ "r225", "r236" ] }, "sqns_LoansAndFinanceLeasesRelatedToConvertibleDebtsIssuedAndGovernmentLoansGrantedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LoansAndFinanceLeasesRelatedToConvertibleDebtsIssuedAndGovernmentLoansGrantedMember", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans and finance leases related to convertible debts issued and government loans granted", "label": "Loans And Finance Leases Related To Convertible Debts Issued And Government Loans Granted [Member]", "documentation": "Loans And Finance Leases Related To Convertible Debts Issued And Government Loans Granted [Member]" } } }, "auth_ref": [] }, "sqns_LoansAndOtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LoansAndOtherReceivablesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits and other receivables", "label": "Loans And Other Receivables [Member]", "documentation": "Loans And Other Receivables [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "sqns_LondonInterbankOfferedRateLIBOR1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LondonInterbankOfferedRateLIBOR1Member", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIBOR", "label": "London Interbank Offered Rate (LIBOR) 1 [Member]", "documentation": "London Interbank Offered Rate (LIBOR) 1 [Member]" } } }, "auth_ref": [] }, "sqns_LongTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LongTermInvestmentsMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Long-Term Investments [Member]", "documentation": "Long-Term Investments [Member]" } } }, "auth_ref": [] }, "sqns_LongTermResearchProjectJanuary2016Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LongTermResearchProjectJanuary2016Member", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Research Project - January 2016", "label": "Long-Term Research Project - January 2016 [Member]", "documentation": "Long-Term Research Project - January 2016 [Member]" } } }, "auth_ref": [] }, "sqns_LongTermResearchProjectOctober2014Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LongTermResearchProjectOctober2014Member", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Research Project - October 2014", "label": "Long-Term Research Project - October 2014 [Member]", "documentation": "Long-Term Research Project - October 2014 [Member]" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total non-current portion", "label": "Non-current portion of non-current borrowings" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_LossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LossesOnChangeInFairValueOfDerivatives", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Losses on change in fair value of derivatives", "label": "Losses on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r338" ] }, "sqns_LynrockLakeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "LynrockLakeMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lynrock Lake", "label": "Lynrock Lake [Member]", "documentation": "Lynrock Lake" } } }, "auth_ref": [] }, "ifrs-full_MachineryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MachineryMember", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing long-lived, depreciable machinery used in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r274" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [] }, "ifrs-full_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorCustomersAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major customers [axis]", "label": "Major customers [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r251" ] }, "ifrs-full_MajorCustomersMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorCustomersMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customers [member]", "label": "Customers [member]" } }, "en": { "role": { "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used." } } }, "auth_ref": [ "r251" ] }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorOrdinaryShareTransactionsMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major ordinary share transactions", "label": "Major ordinary share transactions [member]" } }, "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r270" ] }, "ifrs-full_MarketApproachMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MarketApproachMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market approach", "label": "Market approach [member]" } }, "en": { "role": { "documentation": "This member stands for a valuation technique that uses prices and other relevant information generated by market transactions involving identical or comparable (ie similar) assets, liabilities or a group of assets and liabilities, such as a business." } } }, "auth_ref": [ "r293" ] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Liquidity Risk", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r227" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesOperatingLeasesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r24", "r168", "r177", "r178", "r182", "r183", "r185", "r191", "r208", "r228", "r277", "r308" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [] }, "sqns_MaximumPercentageOfOrdinarySharesPlacedWithinOfferingProvidedToCoverUnderwritersOverAllotmentOption": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "MaximumPercentageOfOrdinarySharesPlacedWithinOfferingProvidedToCoverUnderwritersOverAllotmentOption", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage of ordinary shares provided to cover underwriter's over-allotment option", "label": "Maximum Percentage Of Ordinary Shares Placed Within Offering Provided To Cover Underwriter's Over-allotment Option", "documentation": "Maximum Percentage Of Ordinary Shares Placed Within Offering Provided To Cover Underwriter's Over-allotment Option" } } }, "auth_ref": [] }, "sqns_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total minimum lease payments", "label": "Minimum lease payments payable under non-cancellable operating lease" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [] }, "sqns_MinimumOperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "MinimumOperatingLeasePayments", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Minimum operating lease payments recognised as expense" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MiscellaneousCurrentLiabilitiesAbstract", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current", "terseLabel": "Other current liabilities:", "label": "Miscellaneous current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousNoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MiscellaneousNoncurrentLiabilitiesAbstract", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current", "label": "Miscellaneous non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MiscellaneousOtherOperatingExpense", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Miscellaneous other operating expense" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_MiscellaneousOtherProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MiscellaneousOtherProvisionsMember", "presentation": [ "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other provisions", "label": "Miscellaneous other provisions [member]" } }, "en": { "role": { "documentation": "This member stands for miscellaneous other provisions. [Refer: Other provisions [member]]" } } }, "auth_ref": [ "r105" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [] }, "ifrs-full_NetForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange gain", "label": "Net foreign exchange gain" } }, "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r333", "r349" ] }, "ifrs-full_NetForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange loss", "label": "Net foreign exchange loss" } }, "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r333", "r349" ] }, "sqns_NewAccountingPronouncementsPolicy1PolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NewAccountingPronouncementsPolicy1PolicyTextBlock", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New and amended standards and interpretations and Standards issued but not yet effective", "label": "New Accounting Pronouncements, Policy1 [Policy Text Block]", "documentation": "New Accounting Pronouncements, Policy1 [Policy Text Block]" } } }, "auth_ref": [] }, "sqns_NewAccountingStandardsIssuedButNotYetEffectivePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NewAccountingStandardsIssuedButNotYetEffectivePolicyPolicyTextBlock", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Standards issued but not yet effective", "label": "New Accounting Standards Issued But Not Yet Effective, Policy [Policy Text Block]", "documentation": "New Accounting Standards Issued But Not Yet Effective, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "ifrs-full_NewIFRSsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NewIFRSsAxis", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New IFRSs [axis]", "label": "New IFRSs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r139" ] }, "ifrs-full_NewIFRSsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NewIFRSsMember", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New IFRSs [member]", "label": "New IFRSs [member]" } }, "en": { "role": { "documentation": "This member stands for IFRSs that have been issued but are not yet effective. It also represents the standard value for the 'New IFRSs' axis if no other member is used. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r139" ] }, "ifrs-full_NominalAmountOfHedgingInstrument": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NominalAmountOfHedgingInstrument", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "netLabel": "Notional\u00a0Amount", "label": "Nominal amount of hedging instrument" } }, "en": { "role": { "documentation": "The nominal amount of a hedging instrument. [Refer: Hedging instruments [member]]" } } }, "auth_ref": [ "r208", "r209" ] }, "sqns_NonCurrentFinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NonCurrentFinancialLiabilitiesAtFairValue", "crdr": "credit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilitiesAtFairValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total non-current", "label": "Non-Current Financial Liabilities, At Fair Value", "documentation": "Non-Current Financial Liabilities, At Fair Value" } } }, "auth_ref": [] }, "sqns_NonCurrentGovernmentGrantAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NonCurrentGovernmentGrantAdvances", "crdr": "credit", "calculation": { "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails": { "parentTag": "ifrs-full_NoncurrentGovernmentGrants", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grant advances", "label": "Non-Current Government Grant Advances", "documentation": "Non-Current Government Grant Advances" } } }, "auth_ref": [] }, "sqns_NonCurrentGovernmentLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NonCurrentGovernmentLoans", "crdr": "credit", "calculation": { "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails": { "parentTag": "ifrs-full_NoncurrentGovernmentGrants", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government loans", "label": "Non-Current Government Loans", "documentation": "Non-Current Government Loans" } } }, "auth_ref": [] }, "sqns_NonCurrentInterestPayableResearchProjectFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NonCurrentInterestPayableResearchProjectFinancing", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Non-Current Interest Payable, Research Project Financing", "documentation": "Non-Current Interest Payable, Research Project Financing" } } }, "auth_ref": [] }, "sqns_NonCurrentPortionOfNonCurrentConvertibleBorrowingsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NonCurrentPortionOfNonCurrentConvertibleBorrowingsIssued", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt", "label": "Non-Current Portion Of Non-Current Convertible Borrowings Issued", "documentation": "Non-Current Portion Of Non-Current Convertible Borrowings Issued" } } }, "auth_ref": [] }, "sqns_NonCurrentResearchProjectFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NonCurrentResearchProjectFinancing", "crdr": "credit", "calculation": { "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails": { "parentTag": "ifrs-full_NoncurrentGovernmentGrants", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research project financing", "label": "Non-Current Research Project Financing", "documentation": "Non-Current Research Project Financing" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [axis]", "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r50" ] }, "ifrs-full_NonadjustingEventsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsMember", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period", "label": "Non-adjusting events after reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r50" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r25", "r148", "r292" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets:", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/OthernoncurrentliabilitiesScheduleofOtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r165" ] }, "ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesScheduleofOtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Non-current deferred income including non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current deferred income including non-current contract liabilities. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r334", "r336" ] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPositionParenthetical", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt embedded derivative", "label": "Non-current derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_NoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total non-current", "label": "Non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r216" ] }, "sqns_NoncurrentFinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NoncurrentFinancialAssetsAtFairValue", "crdr": "debit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialAssetsAtFairValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total non-current", "label": "Non-current Financial Assets, At Fair Value", "documentation": "Non-current Financial Assets, At Fair Value" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentFinancialAssetsAvailableforsale": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentFinancialAssetsAvailableforsale", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current financial assets", "label": "Non-current financial assets available-for-sale" } }, "en": { "role": { "documentation": "The amount of non-current financial assets available-for-sale. [Refer: Financial assets available-for-sale; Non-current financial assets]" } } }, "auth_ref": [ "r259" ] }, "ifrs-full_NoncurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total non-current", "label": "Non-current financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r216" ] }, "ifrs-full_NoncurrentGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentGovernmentGrants", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 7.0 }, "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grant advances and loans", "totalLabel": "Total non-current portion", "label": "Non-current government grants" } }, "en": { "role": { "documentation": "The amount of non-current government grants recognised on the statement of financial position as deferred income. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_NoncurrentInterestPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentInterestPayable", "crdr": "credit", "calculation": { "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails": { "parentTag": "ifrs-full_NoncurrentGovernmentGrants", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansScheduleofGovernmentGrantAdvancesandLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Non-current interest payable" } }, "en": { "role": { "documentation": "The amount of non-current interest payable. [Refer: Interest payable]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Non-current lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r171" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r26", "r150", "r292" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities:", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLoansAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLoansAndReceivables", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits and other receivables", "label": "Non-current loans and receivables" } }, "en": { "role": { "documentation": "The amount of non-current loans and receivables. [Refer: Loans and receivables]" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_NoncurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/OthernoncurrentliabilitiesScheduleofOtherNonCurrentLiabilitiesDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "netLabel": "Payables", "label": "Non-current trade payables" } }, "en": { "role": { "documentation": "The non-current amount of payment due to suppliers for goods and services used in the entity's business. [Refer: Trade payables]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPortionOfOtherNoncurrentBorrowings", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsScheduleofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current portion of other non-current borrowings", "label": "Non-current portion of other non-current borrowings" } }, "en": { "role": { "documentation": "The non-current portion of non-current other borrowings. [Refer: Other borrowings]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_NoncurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentProvisions", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails": { "parentTag": "ifrs-full_Provisions", "weight": 1.0, "order": 2.0 }, "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "verboseLabel": "Non current", "label": "Non-current provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r18" ] }, "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities considered in liquidity risk", "label": "Non-derivative financial liabilities, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities." } } }, "auth_ref": [ "r227" ] }, "sqns_NonsoftwareServiceSupportAndMaintenanceArrangement1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NonsoftwareServiceSupportAndMaintenanceArrangement1Member", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maintenance Revenue", "label": "Nonsoftware Service, Support And Maintenance Arrangement 1 [Member]", "documentation": "Nonsoftware Service, Support And Maintenance Arrangement [Member]" } } }, "auth_ref": [] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesOperatingLeasesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Within one year", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r22", "r177", "r178", "r191", "r308", "r313" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "totalLabel": "Total funding", "verboseLabel": "Government debt instruments", "label": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r330" ] }, "sqns_NumberOfADSIssuedThroughConversionOfConvertibleInstrumentsEquity": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfADSIssuedThroughConversionOfConvertibleInstrumentsEquity", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of convertible debt, in ADS (in shares)", "label": "Number Of ADS Issued Through Conversion Of Convertible Instruments, Equity", "documentation": "Number Of ADS Issued Through Conversion Of Convertible Instruments, Equity" } } }, "auth_ref": [] }, "sqns_NumberOfBanksForWhichCashAndCashEquivalentsAreHeld": { "xbrltype": "integerItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfBanksForWhichCashAndCashEquivalentsAreHeld", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of banks", "label": "Number Of Banks For Which Cash And Cash Equivalents Are Held", "documentation": "Number Of Banks For Which Cash And Cash Equivalents Are Held" } } }, "auth_ref": [] }, "sqns_NumberOfBorrowings": { "xbrltype": "integerItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfBorrowings", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of government loans", "label": "Number Of Borrowings", "documentation": "Number Of Borrowings" } } }, "auth_ref": [] }, "sqns_NumberOfCategoriesOfSharesAuthorised": { "xbrltype": "integerItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfCategoriesOfSharesAuthorised", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesAuthorizedcapitalinnumberofsharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of categories of authorized shares", "label": "Number Of Categories Of Shares Authorised", "documentation": "Number Of Categories Of Shares Authorised" } } }, "auth_ref": [] }, "sqns_NumberOfEmployeesRetiredDuringTheYear": { "xbrltype": "integerItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfEmployeesRetiredDuringTheYear", "presentation": [ "http://www.sequans.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees retired during the year", "label": "Number Of Employees Retired During The Year", "documentation": "Number Of Employees Retired During The Year" } } }, "auth_ref": [] }, "sqns_NumberOfInstallmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfInstallmentsAxis", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Installments [Axis]", "label": "Number Of Installments [Axis]", "documentation": "Number Of Installments" } } }, "auth_ref": [] }, "sqns_NumberOfInstallmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfInstallmentsDomain", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Installments [Domain]", "label": "Number Of Installments [Domain]", "documentation": "Number Of Installments [Domain]" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of warrants authorized (in shares)", "label": "Number of instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of instruments granted in share-based payment arrangement." } } }, "auth_ref": [ "r303", "r304" ] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted during the year", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r199", "r361" ] }, "sqns_NumberOfOperatingSegments1": { "xbrltype": "integerItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfOperatingSegments1", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number Of Operating Segments1", "documentation": "Number Of Operating Segments1" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested during the year", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r361" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited during the year", "label": "Number of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r361" ] }, "sqns_NumberOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangementInADS": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangementInADS", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of awards granted, in ADS (in shares)", "label": "Number Of Other Equity Instruments Granted In Share-Based Payment Arrangement, In ADS", "documentation": "Number Of Other Equity Instruments Granted In Share-Based Payment Arrangement, In ADS" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at January\u00a01,", "periodEndLabel": "Outstanding at period end", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r361" ] }, "sqns_NumberOfShareIssuedATMProgram": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfShareIssuedATMProgram", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of shares in connection with the ATM program (in shares)", "label": "Number Of Share Issued, ATM Program", "documentation": "Number Of Share Issued, ATM Program" } } }, "auth_ref": [] }, "sqns_NumberOfShareOptionsAndOtherEquityInstrumentsExercisableInShareBasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfShareOptionsAndOtherEquityInstrumentsExercisableInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of units exercisable at period end", "label": "Number Of Share Options And Other Equity Instruments Exercisable In Share-Based Payment Arrangement", "documentation": "Number Of Share Options And Other Equity Instruments Exercisable In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_NumberOfShareOptionsAndOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfShareOptionsAndOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of units exercised during the year", "label": "Number Of Share Options And Other Equity Instruments Exercised Or Vested In Share-Based Payment Arrangement", "documentation": "Number Of Share Options And Other Equity Instruments Exercised Or Vested In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_NumberOfShareOptionsAndOtherEquityInstrumentsExpiredInShareBasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfShareOptionsAndOtherEquityInstrumentsExpiredInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of units expired during the year", "label": "Number Of Share Options And Other Equity Instruments Expired In Share-Based Payment Arrangement", "documentation": "Number Of Share Options And Other Equity Instruments Expired In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_NumberOfShareOptionsAndOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfShareOptionsAndOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of units forfeited during the year", "label": "Number Of Share Options And Other Equity Instruments Forfeited In Share-Based Payment Arrangement", "documentation": "Number Of Share Options And Other Equity Instruments Forfeited In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_NumberOfShareOptionsAndOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfShareOptionsAndOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of units granted during the year", "label": "Number Of Share Options And Other Equity Instruments Granted In Share-Based Payment Arrangement", "documentation": "Number Of Share Options And Other Equity Instruments Granted In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_NumberOfShareOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfShareOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of units outstanding at January\u00a01,", "periodEndLabel": "Number of units outstanding at period end", "label": "Number Of Share Options And Other Equity Instruments Outstanding In Share-Based Payment Arrangement", "documentation": "Number Of Share Options And Other Equity Instruments Outstanding In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_NumberOfShareOptionsAndWarrantsExercisedInSharebasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfShareOptionsAndWarrantsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of shares in connection with the exercise of options and warrants (in shares)", "label": "Number Of Share Options And Warrants Exercised In Share-based Payment Arrangement", "documentation": "Number Of Share Options And Warrants Exercised In Share-based Payment Arrangement" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPositionParenthetical", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "http://www.sequans.com/role/IssuedcapitalandreservesSharesIssuedandFullyPaidDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "verboseLabel": "Ordinary shares (in shares)", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r329" ] }, "sqns_NumberOfSharesIssuedAndSharesReservedForIssue": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfSharesIssuedAndSharesReservedForIssue", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesAuthorizedcapitalinnumberofsharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorised capital (in shares)", "label": "Number Of Shares Issued And Shares Reserved For Issue", "documentation": "Number Of Shares Issued And Shares Reserved For Issue" } } }, "auth_ref": [] }, "sqns_NumberOfSharesIssuedThroughConversionOfConvertibleInstrumentsEquity": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfSharesIssuedThroughConversionOfConvertibleInstrumentsEquity", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of convertible debt (in shares)", "label": "Number Of Shares Issued Through Conversion Of Convertible Instruments, Equity", "documentation": "Number Of Shares Issued Through Conversion Of Convertible Instruments, Equity" } } }, "auth_ref": [] }, "sqns_NumberOfSharesIssuedThroughConversionOfLoanEquity": { "xbrltype": "sharesItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "NumberOfSharesIssuedThroughConversionOfLoanEquity", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of loans (in shares)", "label": "Number Of Shares Issued Through Conversion Of Loan, Equity", "documentation": "Number Of Shares Issued Through Conversion Of Loan, Equity" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPositionParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r32" ] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating expense" } }, "en": { "role": { "documentation": "The amount of all operating expenses." } } }, "auth_ref": [ "r338" ] }, "sqns_OperatingExpenseNettingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OperatingExpenseNettingMember", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Included in operating expenses (between gross profit and operating result):", "label": "Operating Expense, Netting [Member]", "documentation": "Operating Expense [Member]" } } }, "auth_ref": [] }, "sqns_OperatingExpenses1Abstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OperatingExpenses1Abstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses 1 [Abstract]", "documentation": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "sqns_OperatingsegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OperatingsegmentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Operating segments [Abstract]", "label": "Operating segments [Abstract]", "documentation": "Operating segments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_OptionContractMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OptionContractMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Option contract [member]" } }, "en": { "role": { "documentation": "This member stands for a derivative financial instrument that gives the holder the right, but not the obligation, to purchase or sell an underlying asset for a specified price determined in advance. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r330" ] }, "sqns_OrdinarySharesAndADSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OrdinarySharesAndADSMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares And ADS", "label": "Ordinary Shares And ADS [Member]", "documentation": "Ordinary Shares And ADS" } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.sequans.com/role/CoverPage", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares [member]", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r95", "r337" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement_1": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 }, "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "label": "Other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r5", "r37", "r46", "r153" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxCashFlowHedges", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) on cash flow hedge", "negatedTerseLabel": "Net gain (loss) on cash flow hedge", "label": "Other comprehensive income, net of tax, cash flow hedges" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]" } } }, "auth_ref": [ "r27", "r46" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange differences on translation of foreign operations", "verboseLabel": "Foreign currency translation", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r27", "r46" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement", "http://www.sequans.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Re-measurement gains (losses) on defined benefit plans", "verboseLabel": "Re-measurement gains (losses) on defined benefit plans", "negatedTerseLabel": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r27", "r46", "r342" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Net other comprehensive income (loss) to be reclassified to profit or loss in subsequent years", "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r268", "r269" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Net other comprehensive income (loss) not to be reclassified to profit or loss in subsequent years", "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r268", "r269" ] }, "sqns_OtherCurrenciesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OtherCurrenciesMember", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other currencies denominated accounts", "label": "Other Currencies [Member]", "documentation": "Other Currencies [Member]" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities and provisions", "totalLabel": "Total other current liabilities", "label": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Others", "label": "Other current payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r334" ] }, "sqns_OtherEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OtherEmployeesMember", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Employees", "label": "Other Employees [Member]", "documentation": "Other Employees" } } }, "auth_ref": [] }, "ifrs-full_OtherEquityInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherEquityInterest", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Other components of equity", "label": "Other equity interest" } }, "en": { "role": { "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r267" ] }, "ifrs-full_OtherFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 }, "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of debt reimbursement", "verboseLabel": "Other finance income", "label": "Other finance income (cost)" } }, "en": { "role": { "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]" } } }, "auth_ref": [ "r338" ] }, "sqns_OtherFinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OtherFinancialLiabilitiesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Financial Liabilities [Member]", "documentation": "Other Financial Liabilities [Member]" } } }, "auth_ref": [] }, "ifrs-full_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other intangible assets [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r353" ] }, "ifrs-full_OtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherProvisions", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for risk", "label": "Other provisions" } }, "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r29", "r101" ] }, "sqns_OtherProvisionsAndAccrualsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OtherProvisionsAndAccrualsMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other provisions and accruals", "label": "Other Provisions And Accruals [Member]", "documentation": "Other Provisions And Accruals [Member]" } } }, "auth_ref": [] }, "sqns_OtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatoryAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatoryAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Provisions, Contingent Liabilities And Contingent Assets Explanatory [Abstract]", "label": "Other Provisions, Contingent Liabilities And Contingent Assets Explanatory [Abstract]", "documentation": "Other Provisions, Contingent Liabilities And Contingent Assets Explanatory [Abstract]" } } }, "auth_ref": [] }, "sqns_OtherProvisionsContingentLiabilitiesandContingentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OtherProvisionsContingentLiabilitiesandContingentAssetsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Provisions, Contingent Liabilities and Contingent Assets [Abstract]", "label": "Other Provisions, Contingent Liabilities and Contingent Assets [Abstract]", "documentation": "Other Provisions, Contingent Liabilities and Contingent Assets [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_OtherProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherProvisionsMember", "presentation": [ "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails", "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other provisions [member]", "label": "Other provisions [member]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r105" ] }, "ifrs-full_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other receivables" } }, "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r265" ] }, "ifrs-full_OtherRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherRelatedPartiesMember", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other related parties [member]", "label": "Other related parties [member]" } }, "en": { "role": { "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r86" ] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Other capital reserves", "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r267" ] }, "ifrs-full_OtherReservesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherReservesMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other capital reserves", "label": "Other reserves [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]" } } }, "auth_ref": [ "r8", "r34" ] }, "ifrs-full_OtherRevenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherRevenue", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "label": "Other revenue" } }, "en": { "role": { "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]" } } }, "auth_ref": [ "r330" ] }, "sqns_OtherRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "OtherRevenueMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "License and services revenue", "label": "Other Revenue [Member]", "documentation": "Other Revenue [Member]" } } }, "auth_ref": [] }, "ifrs-full_OtherShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other benefits", "label": "Other short-term employee benefits" } }, "en": { "role": { "documentation": "The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Permanent differences and other", "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r54" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPositionParenthetical", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/IssuedcapitalandreservesAuthorizedcapitalinnumberofsharesDetails", "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails", "http://www.sequans.com/role/IssuedcapitalandreservesSharesIssuedandFullyPaidDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Par value per share", "terseLabel": "Par value per share", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r31" ] }, "ifrs-full_PastDueStatusAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PastDueStatusAxis", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Past due status [axis]", "label": "Past due status [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r306" ] }, "ifrs-full_PastDueStatusMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PastDueStatusMember", "presentation": [ "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Past due status [member]", "label": "Past due status [member]" } }, "en": { "role": { "documentation": "This member stands for all past-due statuses. It also represents the standard value for the 'Past due status' axis if no other member is used." } } }, "auth_ref": [ "r306" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of lease liabilities", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r287" ] }, "sqns_PaymentsofLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PaymentsofLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments", "label": "Payments of Lease Liabilities", "documentation": "Payments of Lease Liabilities" } } }, "auth_ref": [] }, "sqns_PercentageOfEntitysCostOfSales": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PercentageOfEntitysCostOfSales", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of total cost of sales", "label": "Percentage Of Entity's Cost Of Sales", "documentation": "Percentage Of Entity's Cost Of Sales" } } }, "auth_ref": [] }, "sqns_PercentageOfEntitysOperatingExpense": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PercentageOfEntitysOperatingExpense", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of operating expenses", "label": "Percentage Of Entity's Operating Expense", "documentation": "Percentage Of Entity's Operating Expense" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfEntitysRevenue": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PercentageOfEntitysRevenue", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of total revenues", "verboseLabel": "Percentage of entity's revenue", "label": "Percentage of entity's revenue" } }, "en": { "role": { "documentation": "The percentage of the entity's revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r364" ] }, "sqns_PercentageOfPrincipalAmountOfTheNoteCompanyTerminationFee": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PercentageOfPrincipalAmountOfTheNoteCompanyTerminationFee", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage Of Principal Amount Of The Note, Company Termination Fee", "label": "Percentage Of Principal Amount Of The Note, Company Termination Fee", "documentation": "Percentage Of Principal Amount Of The Note, Company Termination Fee" } } }, "auth_ref": [] }, "sqns_PlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PlantAndEquipmentMember", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plant and equipment", "label": "Plant And Equipment [Member]", "documentation": "Plant And Equipment [Member]" } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension costs", "label": "Post-employment benefit expense in profit or loss, defined benefit plans" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]" } } }, "auth_ref": [ "r342", "r344" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense for defined contributions plans", "label": "Post-employment benefit expense, defined contribution plans" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } } }, "auth_ref": [ "r74" ] }, "ifrs-full_PostemploymentMedicalDefinedBenefitPlansMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PostemploymentMedicalDefinedBenefitPlansMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Post-employment medical benefits", "label": "Post-employment medical defined benefit plans [member]" } }, "en": { "role": { "documentation": "This member stands for post-employment medical defined benefit plans. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r276" ] }, "ifrs-full_PreviouslyStatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PreviouslyStatedMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Previously stated", "label": "Previously stated [member]" } }, "en": { "role": { "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)." } } }, "auth_ref": [ "r3", "r135", "r138", "r140" ] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowings", "label": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r285" ] }, "sqns_ProceedsFromBorrowingsOfResearchProjectFinancingIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ProceedsFromBorrowingsOfResearchProjectFinancingIssued", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from interest-bearing research project financing", "label": "Proceeds From Borrowings Of Research Project Financing Issued", "documentation": "Proceeds From Borrowings Of Research Project Financing Issued" } } }, "auth_ref": [] }, "sqns_ProceedsFromConvertibleBorrowingsIssuedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ProceedsFromConvertibleBorrowingsIssuedNet", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from convertible debt, net of transaction cost", "label": "Proceeds From Convertible Borrowings Issued, Net", "documentation": "Proceeds From Convertible Borrowings Issued, Net" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromCurrentBorrowings", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from current borrowings", "label": "Proceeds from current borrowings" } }, "en": { "role": { "documentation": "The cash inflow from current borrowings obtained. [Refer: Current borrowings]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds received from long-term projects", "label": "Proceeds from government grants, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r347" ] }, "sqns_ProceedsFromInterestBearingReceivablesFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ProceedsFromInterestBearingReceivablesFinancing", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from (repayment of) interest-bearing receivables financing, net", "label": "Proceeds From Interest-Bearing Receivables Financing", "documentation": "Proceeds From Interest-Bearing Receivables Financing" } } }, "auth_ref": [] }, "sqns_ProceedsFromIssueOfWarrantsAndExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ProceedsFromIssueOfWarrantsAndExerciseOfOptions", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issue of warrants and exercise of stock options/warrants granted under share-based payment plans, net of transaction costs", "label": "Proceeds From Issue Of Warrants And Exercise Of Options", "documentation": "Proceeds From Issue Of Warrants And Exercise Of Options" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public and private equity offering proceeds, net of transaction costs paid", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r284" ] }, "sqns_ProceedsFromPurchaseOfShorttermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ProceedsFromPurchaseOfShorttermDeposits", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (Increase) of short-term deposit", "label": "Proceeds From (Purchase Of) Short-term Deposits", "documentation": "Proceeds From (Purchase Of) Short-term Deposits" } } }, "auth_ref": [] }, "sqns_ProceedsFromPurchasesOfFinancialAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ProceedsFromPurchasesOfFinancialAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Sale (Purchase) of financial assets", "label": "Proceeds From (Purchases Of) Financial Assets, Classified As Investing Activities", "documentation": "Proceeds From (Purchases Of) Financial Assets, Classified As Investing Activities" } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product", "label": "Product [Member]" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails", "http://www.sequans.com/role/SegmentinformationDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and services [axis]", "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r248", "r296" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProductsAndServicesMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails", "http://www.sequans.com/role/SegmentinformationDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and services [member]", "label": "Products and services [member]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r248", "r296" ] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional fees expense", "label": "Professional fees expense" } }, "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } } }, "auth_ref": [ "r330" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement_1": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ConsolidatedStatementsofComprehensiveIncomeLossStatement", "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/EarningslosspershareDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss for the year", "verboseLabel": "Loss for the year", "negatedLabel": "Net losses", "netLabel": "Profit (Loss)", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r4", "r36", "r124", "r142", "r144", "r243", "r245", "r292", "r300" ] }, "ifrs-full_ProfitLossAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Attributable to:", "label": "Profit (loss), attributable to [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders of the parent", "label": "Profit (loss), attributable to owners of parent" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r39" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails", "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "terseLabel": "Loss before income taxes", "label": "Profit (loss) before tax" } }, "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r204", "r260", "r261", "r314", "r315" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "label": "Profit (loss) from operating activities" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r278", "r338" ] }, "sqns_Project1Axis": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "Project1Axis", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Project [Axis]", "label": "Project1 [Axis]", "documentation": "Project [Axis]" } } }, "auth_ref": [] }, "sqns_Project1Domain": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "Project1Domain", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Project [Domain]", "label": "Project1 [Domain]", "documentation": "[Domain] for Project [Axis]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "negatedPeriodStartLabel": "Beginning balance", "negatedPeriodEndLabel": "Ending balance", "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r13", "r67" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment [abstract]", "label": "Property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentNarrativeDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment [member]", "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r68", "r279", "r299" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "% equity interest", "label": "Proportion of ownership interest in subsidiary" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r91", "r93", "r146" ] }, "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails", "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital of the Company (in excess of)", "label": "Proportion of ownership interests held by non-controlling interests" } }, "en": { "role": { "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]" } } }, "auth_ref": [ "r145" ] }, "sqns_ProvisionForImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ProvisionForImpairment", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for impairment", "label": "Provision For Impairment", "documentation": "Provision For Impairment" } } }, "auth_ref": [] }, "sqns_ProvisionToServeExpectedDemandForCustomersAndProjectsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ProvisionToServeExpectedDemandForCustomersAndProjectsMember", "presentation": [ "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision To Serve Expected Demand For Customers And Projects", "label": "Provision To Serve Expected Demand For Customers And Projects [Member]", "documentation": "Provision To Serve Expected Demand For Customers And Projects" } } }, "auth_ref": [] }, "ifrs-full_ProvisionUsedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProvisionUsedOtherProvisions", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/InventoriesNarrativeDetails", "http://www.sequans.com/role/ProvisionsNarrativeDetails", "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision used, other provisions", "negatedTerseLabel": "Released (used) during the year", "label": "Provision used, other provisions" } }, "en": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r103" ] }, "ifrs-full_Provisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Provisions", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Total, beginning of period", "periodEndLabel": "Total, end of period", "label": "Provisions" } }, "en": { "role": { "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits." } } }, "auth_ref": [ "r18" ] }, "sqns_ProvisionsForEmployeeBenefitsNettingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ProvisionsForEmployeeBenefitsNettingMember", "presentation": [ "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Post- employment benefits", "label": "Provisions For Employee Benefits, Netting [Member]", "documentation": "Provisions For Employee Benefits [Member]" } } }, "auth_ref": [] }, "sqns_PurchaseCommitment1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PurchaseCommitment1Member", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesPurchaseCommitmentsDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier contract", "verboseLabel": "Non-cancelable purchase commitments with third-party manufacturer and suppliers for future deliveries of equipment and components", "label": "Purchase Commitment1 [Member]", "documentation": "Purchase Commitment1 [Member]" } } }, "auth_ref": [] }, "sqns_PurchaseCommitmentExcludingLongtermCommitment1Axis": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PurchaseCommitmentExcludingLongtermCommitment1Axis", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesPurchaseCommitmentsDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-term Commitment1 [Axis]", "label": "Purchase Commitment, Excluding Long-term Commitment1 [Axis]", "documentation": "Purchase Commitment, Excluding Long-term Commitment1 [Axis]" } } }, "auth_ref": [] }, "sqns_PurchaseCommitmentExcludingLongtermCommitment1Domain": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PurchaseCommitmentExcludingLongtermCommitment1Domain", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesPurchaseCommitmentsDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-term Commitment1 [Domain]", "label": "Purchase Commitment, Excluding Long-term Commitment1 [Domain]", "documentation": "[Domain] for Purchase Commitment, Excluding Long-term Commitment1 [Axis]" } } }, "auth_ref": [] }, "sqns_PurchaseCommitmentExcludingLongtermCommitment1LineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PurchaseCommitmentExcludingLongtermCommitment1LineItems", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-term Commitment1 [Line Items]", "label": "Purchase Commitment, Excluding Long-term Commitment1 [Line Items]", "documentation": "[Line Items] for Purchase Commitment, Excluding Long-term Commitment1 [Table]" } } }, "auth_ref": [] }, "sqns_PurchaseCommitmentExcludingLongtermCommitment1Table": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PurchaseCommitmentExcludingLongtermCommitment1Table", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-term Commitment1 [Table]", "label": "Purchase Commitment, Excluding Long-term Commitment1 [Table]", "documentation": "Purchase Commitment, Excluding Long-term Commitment1 [Table]" } } }, "auth_ref": [] }, "sqns_PurchaseCommitmentRemainingMinimumAmountCommitted1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted1", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesPurchaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchase commitments", "label": "Purchase Commitment, Remaining Minimum Amount Committed1", "documentation": "Purchase Commitment, Remaining Minimum Amount Committed1" } } }, "auth_ref": [] }, "sqns_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of intangible assets and property, plant and equipment", "label": "Purchase Of Property, Plant And Equipment And Intangible Assets, Classified As Investing Activities", "documentation": "Purchase Of Property, Plant And Equipment And Intangible Assets, Classified As Investing Activities" } } }, "auth_ref": [] }, "sqns_PurchasesOfCapitalisedDevelopmentExpendituresClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "PurchasesOfCapitalisedDevelopmentExpendituresClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capitalized development expenditures", "label": "Purchases Of Capitalised Development Expenditures, Classified As Investing Activities", "documentation": "Purchases Of Capitalised Development Expenditures, Classified As Investing Activities" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r164", "r185", "r196", "r294", "r295", "r363" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangesMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ranges [member]", "label": "Ranges [member]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r164", "r185", "r196", "r294", "r295", "r363" ] }, "sqns_RealEstateRightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RealEstateRightofuseAssetsMember", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails", "http://www.sequans.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real-estate", "label": "Real Estate, Right-of-use Assets [Member]", "documentation": "Real Estate, Right-of-use Assets [Member]" } } }, "auth_ref": [] }, "ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReceivablesFromTaxesOtherThanIncomeTax", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails", "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables from taxes other than income tax", "label": "Receivables from taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity." } } }, "auth_ref": [ "r335" ] }, "ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss transferred from other comprehensive income to the statement of operations", "label": "Reclassification adjustments on cash flow hedges, net of tax" } }, "en": { "role": { "documentation": "The amount of reclassification adjustments related to cash flow hedges, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Cash flow hedges [member]; Other comprehensive income]" } } }, "auth_ref": [ "r47", "r213", "r215" ] }, "sqns_ReclassificationsPropertyPlantandEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ReclassificationsPropertyPlantandEquipment", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification", "label": "Reclassifications, Property, Plant and Equipment", "documentation": "Reclassifications, Property, Plant and Equipment" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://www.sequans.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in intangible assets other than goodwill [abstract]", "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfChangesInOtherProvisionsAbstract", "presentation": [ "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in other provisions [abstract]", "label": "Reconciliation of changes in other provisions [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReductionOfIssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReductionOfIssuedCapital", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction of issued capital", "negatedTerseLabel": "Reduction of issued capital", "label": "Reduction of issued capital" } }, "en": { "role": { "documentation": "The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r329" ] }, "sqns_RelatedPartyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RelatedPartyAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party [Abstract]", "label": "Related Party [Abstract]", "documentation": "Related Party [Abstract]" } } }, "auth_ref": [] }, "sqns_RelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RelationshipToEntityDomain", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Relationship To Entity [Domain]", "label": "Relationship To Entity [Domain]", "documentation": "[Domain] for Title Of Individual [Axis]" } } }, "auth_ref": [] }, "sqns_RemeasurementOfNonMonetaryAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RemeasurementOfNonMonetaryAccountsMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement of non-monetary accounts", "label": "Remeasurement Of Non-Monetary Accounts [Member]", "documentation": "Remeasurement Of Non-Monetary Accounts [Member]" } } }, "auth_ref": [] }, "sqns_RenesasElectronicsCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RenesasElectronicsCorporationMember", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renesas Electronics Corporation", "label": "Renesas Electronics Corporation [Member]", "documentation": "Renesas Electronics Corporation" } } }, "auth_ref": [] }, "sqns_RentExpenseonLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RentExpenseonLeases", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rental charges", "label": "Rent Expense on Leases", "documentation": "Rent Expense on Leases" } } }, "auth_ref": [] }, "sqns_RepaymentOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RepaymentOfConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of convertible debt", "label": "Repayment Of Convertible Debt", "documentation": "Repayment Of Convertible Debt" } } }, "auth_ref": [] }, "sqns_RepaymentOfConvertibleDebtAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RepaymentOfConvertibleDebtAccruedInterest", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of convertible debt, accrued interest", "label": "Repayment Of Convertible Debt, Accrued Interest", "documentation": "Repayment Of Convertible Debt, Accrued Interest" } } }, "auth_ref": [] }, "sqns_RepaymentOfConvertibleDebtAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RepaymentOfConvertibleDebtAndAccruedExpenses", "crdr": "credit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of convertible debt and accrued interest", "terseLabel": "Repayment of convertible debt and accrued interest", "label": "Repayment Of Convertible Debt And Accrued Expenses", "documentation": "Repayment Of Convertible Debt And Accrued Expenses" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of government loans", "label": "Repayments of borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r286" ] }, "sqns_RepaymentsofInterestbearingResearchProjectFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RepaymentsofInterestbearingResearchProjectFinancing", "crdr": "credit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of interest-bearing research project financing", "label": "Repayments of Interest-bearing Research Project Financing", "documentation": "Repayments of Interest-bearing Research Project Financing" } } }, "auth_ref": [] }, "sqns_RepaymentsofVentureDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RepaymentsofVentureDebt", "crdr": "credit", "calculation": { "http://www.sequans.com/role/StatementsofCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails", "http://www.sequans.com/role/StatementsofCashFlow" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of venture debt", "terseLabel": "Repayment of venture debt", "label": "Repayments of Venture Debt", "documentation": "Repayments of Venture Debt" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentArrangementContractToPerformForOthersExcessSalesThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersExcessSalesThreshold", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess sales amount threshold", "label": "Research And Development Arrangement, Contract To Perform For Others, Excess Sales Threshold", "documentation": "Research and Development Arrangement, Contract to Perform for Others, Excess Sales Threshold" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumRoyaltyPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumRoyaltyPayable", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount payable", "label": "Research And Development Arrangement, Contract To Perform For Others, Maximum Royalty Payable", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Maximum Royalty Payable" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProjects": { "xbrltype": "integerItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProjects", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of projects", "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Projects", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Projects" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentArrangementContractToPerformForOthersPeriodAfterDateOfTermination": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPeriodAfterDateOfTermination", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period after termination date", "label": "Research And Development Arrangement, Contract To Perform For Others, Period After Date Of Termination", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Period After Date Of Termination" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPercentage", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of revenue from project", "label": "Research And Development Arrangement, Contract To Perform For Others, Royalty Percentage", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Royalty Percentage" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentArrangementContractToPerformForOthersTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTerm", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research project, term", "label": "Research And Development Arrangement, Contract To Perform For Others, Term", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Term" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentArrangementContractToPerformForOthersType1Axis": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersType1Axis", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "label": "Research And Development Arrangement, Contract To Perform For Others, Type 1 [Axis]", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Type [Axis]" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentArrangementContractToPerformForOthersType1Domain": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersType1Domain", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research And Development Arrangement, Contract To Perform For Others, Type [Domain]", "label": "Research And Development Arrangement, Contract To Perform For Others, Type 1 [Domain]", "documentation": "[Domain] for Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentCosts", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development costs", "label": "Research And Development Costs", "documentation": "Research And Development Costs" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentCostsCapitalizedNetOfTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentCostsCapitalizedNetOfTaxCredit", "crdr": "credit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Development costs capitalized (*)", "label": "Research And Development Costs Capitalized, Net Of Tax Credit", "documentation": "Research And Development Costs Capitalized, Net Of Tax Credit" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 }, "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "totalLabel": "Total research and development expense", "label": "Research and development expense" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r115" ] }, "sqns_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development [Member]", "documentation": "Research and Development" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentTaxCredit", "crdr": "credit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Research tax credit", "label": "Research And Development Tax Credit", "documentation": "Research And Development Tax Credit" } } }, "auth_ref": [] }, "sqns_ResearchAndDevelopmentTaxCreditCapitalised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchAndDevelopmentTaxCreditCapitalised", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research tax credit", "label": "Research And Development Tax Credit, Capitalised", "documentation": "Research And Development Tax Credit, Capitalised" } } }, "auth_ref": [] }, "sqns_ResearchProjectFinancingForgivableLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchProjectFinancingForgivableLoanMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forgivable Loan", "label": "Research Project Financing - Forgivable Loan [Member]", "documentation": "Research Project Financing - Forgivable Loan [Member]" } } }, "auth_ref": [] }, "sqns_ResearchProjectFinancingGovernmentGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchProjectFinancingGovernmentGrantMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government Grant", "label": "Research Project Financing - Government Grant [Member]", "documentation": "Research Project Financing - Government Grant [Member]" } } }, "auth_ref": [] }, "sqns_ResearchProjectFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchProjectFinancingMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research project financing", "verboseLabel": "Research project financing", "label": "Research Project Financing [Member]", "documentation": "Research Project Financing" } } }, "auth_ref": [] }, "sqns_ResearchTaxCredit2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchTaxCredit2020Member", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit 2020", "label": "Research Tax Credit 2020 [Member]", "documentation": "Research Tax Credit 2020" } } }, "auth_ref": [] }, "sqns_ResearchTaxCredit2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchTaxCredit2021Member", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit 2021", "label": "Research Tax Credit 2021 [Member]", "documentation": "Research Tax Credit 2021" } } }, "auth_ref": [] }, "sqns_ResearchTaxCredit2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchTaxCredit2022Member", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit 2022", "label": "Research Tax Credit 2022 [Member]", "documentation": "Research Tax Credit 2022" } } }, "auth_ref": [] }, "sqns_ResearchTaxCredit2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchTaxCredit2023Member", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit 2023", "label": "Research Tax Credit 2023 [Member]", "documentation": "Research Tax Credit 2023" } } }, "auth_ref": [] }, "sqns_ResearchTaxCreditAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchTaxCreditAxis", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit [Axis]", "label": "Research Tax Credit [Axis]", "documentation": "Research Tax Credit" } } }, "auth_ref": [] }, "sqns_ResearchTaxCreditDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchTaxCreditDomain", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesFinancialIncomeandExpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit [Domain]", "label": "Research Tax Credit [Domain]", "documentation": "Research Tax Credit [Domain]" } } }, "auth_ref": [] }, "sqns_ResearchandDevelopmentArrangementContracttoPerformforOthers1LineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ResearchandDevelopmentArrangementContracttoPerformforOthers1LineItems", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others1 [Line Items]", "label": "Research and Development Arrangement, Contract to Perform for Others1 [Line Items]", "documentation": "Research and Development Arrangement, Contract to Perform for Others1 [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative translation adjustments", "label": "Reserve of exchange differences on translation [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r80", "r262" ] }, "ifrs-full_RestatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RestatedMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/ProvisionsNarrativeDetails", "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currently stated [member]", "label": "Currently stated [member]" } }, "en": { "role": { "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used." } } }, "auth_ref": [ "r3", "r135", "r138", "r140", "r184", "r332" ] }, "sqns_RestrictedShareAwardsRSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RestrictedShareAwardsRSAMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted share awards (RSA)", "label": "Restricted Share Awards (RSA) [Member]", "documentation": "Restricted Share Awards (RSA) [Member]" } } }, "auth_ref": [] }, "sqns_RestrictedSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RestrictedSharesMember", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted share awards", "label": "Restricted Shares [Member]", "documentation": "Restricted Shares [Member]" } } }, "auth_ref": [] }, "sqns_RestrictedStock1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RestrictedStock1Member", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSA", "label": "Restricted Stock1 [Member]", "documentation": "Restricted Stock1 [Member]" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "label": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r267", "r269" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r8", "r262" ] }, "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails", "http://www.sequans.com/role/ProvisionsNarrativeDetails", "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retrospective application and retrospective restatement [axis]", "label": "Retrospective application and retrospective restatement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r3", "r135", "r138", "r140" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Revenue", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r42", "r152", "r204", "r239", "r244", "r248", "r249", "r251", "r260", "r261", "r292" ] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue:", "label": "Revenue [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromGovernmentGrants", "crdr": "credit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesResearchandDevelopmentExpenseandTaxCreditReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Government and other grants", "label": "Income from government grants" } }, "en": { "role": { "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]" } } }, "auth_ref": [ "r348" ] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r155", "r240", "r247", "r330" ] }, "ifrs-full_RevenueFromRenderingOfInformationTechnologyServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromRenderingOfInformationTechnologyServices", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from development contracts where no related incremental costs were identified", "label": "Revenue from rendering of information technology services" } }, "en": { "role": { "documentation": "The amount of revenue arising from the rendering of information technology services. [Refer: Revenue]" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_RevenueFromSaleOfGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromSaleOfGoods", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Product revenue", "terseLabel": "Product revenue", "label": "Revenue from sale of goods" } }, "en": { "role": { "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]" } } }, "auth_ref": [ "r330" ] }, "sqns_RevenueFromSalesOfLicense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RevenueFromSalesOfLicense", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "revenue from sales of license", "label": "revenue from sales of license", "documentation": "revenue from sales of license" } } }, "auth_ref": [] }, "sqns_RevenueFromSalesOfOtherServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RevenueFromSalesOfOtherServices", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "revenue from sales of other services", "label": "revenue from sales of other services", "documentation": "revenue from sales of other services" } } }, "auth_ref": [] }, "sqns_RevenueFromSoftwareMaintenanceAndSupportServicesPeriodOfMaintenance": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RevenueFromSoftwareMaintenanceAndSupportServicesPeriodOfMaintenance", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of the maintenance", "label": "Revenue From Software Maintenance And Support Services, Period Of Maintenance", "documentation": "Revenue From Software Maintenance And Support Services, Period Of Maintenance" } } }, "auth_ref": [] }, "sqns_RevenueRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RevenueRiskMember", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Risk [Member]", "label": "Revenue Risk [Member]", "documentation": "Revenue Risk [Member]" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "http://www.sequans.com/role/LeaseliabilitiesSummaryofmovementsinrightofuseassetsandleaseliabilitiesDetails", "http://www.sequans.com/role/PropertyplantandequipmentNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "periodStartLabel": "Right-of-use assets at beginning of period", "periodEndLabel": "Right-of-use assets at end of period", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r170", "r175" ] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://www.sequans.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use", "label": "Right-of-use assets [member]" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r169" ] }, "sqns_RiskFreeInterestRateShareOptionsAndOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RiskFreeInterestRateShareOptionsAndOtherEquityInstrumentsGranted", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk\u2013free interest rate (%)", "label": "Risk Free Interest Rate, Share Options And Other Equity Instruments Granted", "documentation": "Risk Free Interest Rate, Share Options And Other Equity Instruments Granted" } } }, "auth_ref": [] }, "sqns_RoyaltyAccrualMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RoyaltyAccrualMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty accrual", "label": "Royalty Accrual [Member]", "documentation": "Royalty Accrual [Member]" } } }, "auth_ref": [] }, "sqns_RoyaltyAgreementTerms1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "RoyaltyAgreementTerms1Member", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Agreement Terms", "label": "Royalty Agreement Terms 1 [Member]", "documentation": "Royalty Agreement Terms [Member]" } } }, "auth_ref": [] }, "currency_SGD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "SGD", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SGP denominated accounts", "label": "Singapore, Dollars" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Sales and marketing expense" } }, "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } } }, "auth_ref": [ "r338" ] }, "sqns_SalesAndMarketingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SalesAndMarketingMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansBreakdownofsharebasedpaymentsexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and Marketing", "label": "Sales and Marketing [Member]", "documentation": "Sales and Marketing" } } }, "auth_ref": [] }, "sqns_ScheduleOfCashAndCashEquivalents1TableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ScheduleOfCashAndCashEquivalents1TableTextBlock", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Schedule Of Cash And Cash Equivalents1 [Table Text Block]", "documentation": "Schedule Of Cash And Cash Equivalents1 [Table Text Block]" } } }, "auth_ref": [] }, "srt_ScheduleOfCondensedFinancialStatementsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfCondensedFinancialStatementsTable", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Financial Statements [Table]", "label": "Condensed Financial Statements [Table]" } } }, "auth_ref": [] }, "sqns_ScheduleOfInventoryCurrent1TableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ScheduleOfInventoryCurrent1TableTextBlock", "presentation": [ "http://www.sequans.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule Of Inventory, Current 1 [Table Text Block]", "documentation": "Schedule Of Inventory, Current [Table Text Block]" } } }, "auth_ref": [] }, "sqns_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthers1Table": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthers1Table", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others", "label": "Schedule Of Research And Development Arrangement Contract To Perform For Others1 [Table]", "documentation": "Schedule Of Research And Development Arrangement Contract To Perform For Others1" } } }, "auth_ref": [] }, "sqns_ScheduleofAccountsNotesLoansandFinancingReceivable1TableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ScheduleofAccountsNotesLoansandFinancingReceivable1TableTextBlock", "presentation": [ "http://www.sequans.com/role/TradereceivablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Non-Interest Bearing Trade Receivables", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable 1 [Table Text Block]", "documentation": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]" } } }, "auth_ref": [] }, "sqns_SecondSecurityPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SecondSecurityPurchaseAgreementMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Security Purchase Agreement", "label": "Second Security Purchase Agreement [Member]", "documentation": "Second Security Purchase Agreement" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r317" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r319" ] }, "sqns_SecurityPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SecurityPurchaseAgreementMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security Purchase Agreement", "label": "Security Purchase Agreement [Member]", "documentation": "Security Purchase Agreement" } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.sequans.com/role/ProvisionsNarrativeDetails", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "Selling, general and administrative expense" } }, "en": { "role": { "documentation": "The amount of expense relating to selling, general and administrative activities of the entity." } } }, "auth_ref": [ "r338" ] }, "sqns_SellingPriceMultipleShareOptionsAndOtherEquityInstrumentsGranted": { "xbrltype": "pureItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SellingPriceMultipleShareOptionsAndOtherEquityInstrumentsGranted", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Sell price multiple", "terseLabel": "Sell price multiple (applied to exercise price)", "label": "Selling Price Multiple, Share Options And Other Equity Instruments Granted", "documentation": "Selling Price Multiple, Share Options And Other Equity Instruments Granted" } } }, "auth_ref": [] }, "sqns_SellingPriceMultipleShareOptionsAndOtherEquityInstrumentsGrantedOption1": { "xbrltype": "pureItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SellingPriceMultipleShareOptionsAndOtherEquityInstrumentsGrantedOption1", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sell price multiple that had been used", "label": "Selling Price Multiple, Share Options And Other Equity Instruments Granted, Option 1", "documentation": "Selling Price Multiple, Share Options And Other Equity Instruments Granted, Option 1" } } }, "auth_ref": [] }, "sqns_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnOperatingExpenses", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of change in the corresponding risk variable on operating expenses", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Operating Expenses", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Operating Expenses" } } }, "auth_ref": [] }, "sqns_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reasonably possible change in risk variable, percent", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent" } } }, "auth_ref": [] }, "sqns_SequansCommunicationsFinlandOyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SequansCommunicationsFinlandOyMember", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sequans Communications Finland Oy", "label": "Sequans Communications Finland Oy [Member]", "documentation": "Sequans Communications Finland Oy" } } }, "auth_ref": [] }, "sqns_SequansCommunicationsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SequansCommunicationsInc.Member", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sequans Communications Inc.", "label": "Sequans Communications Inc. [Member]", "documentation": "Sequans Communications Inc. [Member]" } } }, "auth_ref": [] }, "sqns_SequansCommunicationsIsrael2009Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SequansCommunicationsIsrael2009Ltd.Member", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sequans Communications Israel (2009) Ltd.", "label": "Sequans Communications Israel (2009) Ltd. [Member]", "documentation": "Sequans Communications Israel (2009) Ltd. [Member]" } } }, "auth_ref": [] }, "sqns_SequansCommunicationsLtd.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SequansCommunicationsLtd.Member", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sequans Communications Ltd.", "label": "Sequans Communications Ltd. [Member]", "documentation": "Sequans Communications Ltd. [Member]" } } }, "auth_ref": [] }, "sqns_SequansCommunicationsLtd.Pte.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SequansCommunicationsLtd.Pte.Member", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sequans Communications Ltd. Pte.", "label": "Sequans Communications Ltd. Pte. [Member]", "documentation": "Sequans Communications Ltd. Pte. [Member]" } } }, "auth_ref": [] }, "sqns_SequansCommunicationsSASMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SequansCommunicationsSASMember", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sequans Communications SAS", "label": "Sequans Communications SAS [Member]", "documentation": "Sequans Communications SAS" } } }, "auth_ref": [] }, "sqns_ServiceSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ServiceSalesMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service Sales [Member]", "label": "Service Sales [Member]", "documentation": "Service Sales [Member]" } } }, "auth_ref": [] }, "sqns_ServicesAndRoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ServicesAndRoyaltyExpense", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assembly services, royalties and other", "label": "Services And Royalty Expense", "documentation": "Services And Royalty Expense" } } }, "auth_ref": [] }, "sqns_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 2", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 2" } } }, "auth_ref": [] }, "sqns_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting percentage", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Percentage" } } }, "auth_ref": [] }, "sqns_ShareBasedCompensationArrangementByShareBasedPaymentAwardChangeInCompensationCostPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardChangeInCompensationCostPercentage", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in total compensation (as a percent)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Change In Compensation Cost, Percentage", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Change In Compensation Cost, Percentage" } } }, "auth_ref": [] }, "sqns_ShareBasedCompensationArrangementByShareBasedPaymentAwardSalePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSalePeriod", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Sale Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Sale Period" } } }, "auth_ref": [] }, "sqns_ShareBasedCompensationAwardTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareBasedCompensationAwardTrancheFourMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After the two year anniversary of grant", "label": "Share-Based Compensation Award, Tranche Four [Member]", "documentation": "Share-Based Compensation Award, Tranche Four [Member]" } } }, "auth_ref": [] }, "sqns_ShareBasedCompensationAwardTrancheOne1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareBasedCompensationAwardTrancheOne1Member", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After the first year anniversary of grant", "verboseLabel": "Vesting scenario 1", "label": "Share-Based Compensation Award, Tranche One1 [Member]", "documentation": "Share-Based Compensation Award, Tranche One1 [Member]" } } }, "auth_ref": [] }, "sqns_ShareBasedCompensationAwardTrancheThree1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareBasedCompensationAwardTrancheThree1Member", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly over the remaining three years", "verboseLabel": "Vesting scenario 3", "label": "Share-Based Compensation Award, Tranche Three1 [Member]", "documentation": "Share-Based Compensation Award, Tranche Three1 [Member]" } } }, "auth_ref": [] }, "sqns_ShareBasedCompensationAwardTrancheTwo1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareBasedCompensationAwardTrancheTwo1Member", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly over the remaining 36 months", "verboseLabel": "Vesting scenario 2", "label": "Share-Based Compensation Award, Tranche Two1 [Member]", "documentation": "Share-Based Compensation Award, Tranche Two1 [Member]" } } }, "auth_ref": [] }, "sqns_ShareBasedPaymentArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareBasedPaymentArrangementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangements [Abstract]", "label": "Share-Based Payment Arrangements [Abstract]", "documentation": "Share-Based Payment Arrangements [Abstract]" } } }, "auth_ref": [] }, "sqns_ShareCapitalReservesAndOtherEquityInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareCapitalReservesAndOtherEquityInterestAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share Capital, Reserves And Other Equity Interest [Abstract]", "label": "Share Capital, Reserves And Other Equity Interest [Abstract]", "documentation": "Share Capital, Reserves And Other Equity Interest [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transaction costs", "terseLabel": "Transaction costs", "label": "Share issue related cost" } }, "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } } }, "auth_ref": [ "r329" ] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r267" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails", "http://www.sequans.com/role/IssuedcapitalandreservesNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r8" ] }, "sqns_SharePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SharePrice1", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary share price (usd per share)", "label": "Share Price1", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "sqns_SharePricePerADS": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SharePricePerADS", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails", "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price per ADS (usd per share)", "label": "Share Price Per ADS", "documentation": "Share Price Per ADS" } } }, "auth_ref": [] }, "sqns_SharebasedCompensationAwardTrancheFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SharebasedCompensationAwardTrancheFiveMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting quarterly over the remaining two years", "label": "Share-based Compensation Award, Tranche Five [Member]", "documentation": "Share-based Compensation Award, Tranche Five [Member]" } } }, "auth_ref": [] }, "ifrs-full_SharebasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharebasedPaymentArrangementsMember", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails", "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangements [member]", "label": "Share-based payment arrangements [member]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r197" ] }, "sqns_ShareholderLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "ShareholderLoanAgreementMember", "presentation": [ "http://www.sequans.com/role/IssuedcapitalandreservesCapitalTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholder Loan Agreement", "label": "Shareholder Loan Agreement [Member]", "documentation": "Shareholder Loan Agreement" } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermBorrowings", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current borrowings", "label": "Current borrowings" } }, "en": { "role": { "documentation": "The amount of current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_ShorttermEmployeeBenefitsAccruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermEmployeeBenefitsAccruals", "crdr": "credit", "calculation": { "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees and social debts", "label": "Short-term employee benefits accruals" } }, "en": { "role": { "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiaries [axis]", "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r92", "r94", "r158" ] }, "ifrs-full_SignificantUnobservableInputEntitysOwnEquityInstruments": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantUnobservableInputEntitysOwnEquityInstruments", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate used to value liability", "label": "Significant unobservable input, entity's own equity instruments" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of entity's own equity instruments." } } }, "auth_ref": [ "r161" ] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Social security costs and other payroll taxes", "label": "Social security contributions" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r345" ] }, "sqns_SpecialTransactionBonusApprovedByBoardOfDirectors": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SpecialTransactionBonusApprovedByBoardOfDirectors", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Special Transaction Bonus, Approved By Board Of Directors", "label": "Special Transaction Bonus, Approved By Board Of Directors", "documentation": "Special Transaction Bonus, Approved By Board Of Directors" } } }, "auth_ref": [] }, "sqns_SpecifiedBankAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "SpecifiedBankAccountsMember", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesPledgeofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specified bank accounts", "label": "Specified Bank Accounts [Member]", "documentation": "Specified Bank Accounts [Member]" } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.sequans.com/role/ProvisionsNarrativeDetails", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of cash flows [abstract]", "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [abstract]", "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [line items]", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofChangesinEquityDeficitStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of comprehensive income [abstract]", "label": "Statement of comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of financial position [abstract]", "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfIFRSCompliance": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfIFRSCompliance", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of compliance", "label": "Statement of IFRS compliance [text block]" } }, "en": { "role": { "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs." } } }, "auth_ref": [ "r11" ] }, "sqns_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "StockOptionsMember", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Stock Options [Member]", "documentation": "Stock Options [Member]" } } }, "auth_ref": [] }, "sqns_StrategicPartnerAmendmentContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "StrategicPartnerAmendmentContractMember", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic Partner, Amendment Contract", "label": "Strategic Partner, Amendment Contract [Member]", "documentation": "Strategic Partner, Amendment Contract" } } }, "auth_ref": [] }, "sqns_StrategicPartnerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "StrategicPartnerMember", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic Partner", "label": "Strategic Partner [Member]", "documentation": "Strategic Partner" } } }, "auth_ref": [] }, "sqns_StrategicPartnerSecondAmendmentContract5GChipsetChinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "StrategicPartnerSecondAmendmentContract5GChipsetChinaMember", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic Partner, Second Amendment Contract, 5G Chipset China", "label": "Strategic Partner, Second Amendment Contract, 5G Chipset China [Member]", "documentation": "Strategic Partner, Second Amendment Contract, 5G Chipset China" } } }, "auth_ref": [] }, "sqns_StrategicPartnerSecondAmendmentContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "StrategicPartnerSecondAmendmentContractMember", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic Partner, Second Amendment Contract", "label": "Strategic Partner, Second Amendment Contract [Member]", "documentation": "Strategic Partner, Second Amendment Contract" } } }, "auth_ref": [] }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subclassifications of assets, liabilities and equities [abstract]", "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "auth_ref": [] }, "srt_SubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SubsidiariesMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "From subsidiaries", "label": "Subsidiaries [Member]" } } }, "auth_ref": [] }, "country_TW": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "TW", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taiwan", "label": "TAIWAN" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "crdr": "debit", "calculation": { "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible share-based payment expense", "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } } }, "auth_ref": [ "r54" ] }, "sqns_TaxEffectOfImpactOfDebtReimbursement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TaxEffectOfImpactOfDebtReimbursement", "crdr": "debit", "calculation": { "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of debt reimbursement", "label": "Tax Effect Of Impact Of Debt Reimbursement", "documentation": "Tax Effect Of Impact Of Debt Reimbursement" } } }, "auth_ref": [] }, "sqns_TaxEffectOfImpactOfExtinguishmentOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TaxEffectOfImpactOfExtinguishmentOfConvertibleDebt", "crdr": "debit", "calculation": { "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of the extinguishment of the convertible debts after amendment", "label": "Tax Effect Of Impact Of Extinguishment Of Convertible Debt", "documentation": "Tax Effect Of Impact Of Extinguishment Of Convertible Debt" } } }, "auth_ref": [] }, "sqns_TaxEffectOfTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TaxEffectOfTaxCredits", "crdr": "credit", "calculation": { "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax credits", "label": "Tax Effect Of Tax Credits", "documentation": "Tax Effect Of Tax Credits" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfTaxLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfTaxLosses", "crdr": "debit", "calculation": { "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized benefit of tax losses carryforward", "label": "Tax effect of tax losses" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]" } } }, "auth_ref": [ "r54" ] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "calculation": { "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "At France\u2019s statutory income tax rate of 26.5% in 2021 and 25% in 2022 and in 2023", "label": "Tax expense (income) at applicable tax rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r54" ] }, "sqns_TechnologyBroadbandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TechnologyBroadbandMember", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Broadband IoT", "label": "Technology, Broadband [Member]", "documentation": "Technology, Broadband [Member]" } } }, "auth_ref": [] }, "sqns_TechnologyIOTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TechnologyIOTMember", "presentation": [ "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Massive IoT", "label": "Technology, IOT [Member]", "documentation": "Technology, IOT [Member]" } } }, "auth_ref": [] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]", "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r59" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]", "label": "Temporary difference, unused tax losses and unused tax credits [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r59" ] }, "sqns_TerminationIndemnityAmountofBonusPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TerminationIndemnityAmountofBonusPercentage", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of bonus in event of dismissal", "label": "Termination Indemnity Amount of Bonus, Percentage", "documentation": "Termination Indemnity Amount of Bonus, Percentage" } } }, "auth_ref": [] }, "sqns_TerminationIndemnityAmountofGrossAnnualBaseRemunerationDuration": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TerminationIndemnityAmountofGrossAnnualBaseRemunerationDuration", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination indemnity amount (in months)", "label": "Termination Indemnity Amount of Gross Annual Base Remuneration, Duration", "documentation": "Termination Indemnity Amount of Gross Annual Base Remuneration, Duration" } } }, "auth_ref": [] }, "sqns_TitleOfIndividual1Axis": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TitleOfIndividual1Axis", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title Of Individual [Axis]", "label": "Title Of Individual 1 [Axis]", "documentation": "Title Of Individual [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentGrantAdvancesDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansGovernmentLoansDetails", "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/ProvisionsScheduleofMainAssumptionsUsedDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of range", "verboseLabel": "Top of range [member]", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r164", "r185", "r196", "r294", "r295", "r363" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradePayablesandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r264", "r336" ] }, "sqns_TradeAndOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TradeAndOtherPayablesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables (current and non current)", "verboseLabel": "Trade payables", "label": "Trade And Other Payables [Member]", "documentation": "Trade And Other Payables [Member]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherPayablesToTradeSuppliers", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Trade payables" } }, "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } } }, "auth_ref": [ "r336" ] }, "ifrs-full_TradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherReceivables", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/CommitmentsandcontingenciesContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other receivables", "label": "Trade and other receivables" } }, "en": { "role": { "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]" } } }, "auth_ref": [ "r16", "r28" ] }, "sqns_TradeAndOtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TradeAndOtherReceivablesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other receivables", "label": "Trade And Other Receivables [Member]", "documentation": "Trade And Other Receivables [Member]" } } }, "auth_ref": [] }, "sqns_TradePayableTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TradePayableTerm", "presentation": [ "http://www.sequans.com/role/OthernoncurrentliabilitiesNarrativeDetails", "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payable term", "label": "Trade Payable Term", "documentation": "Trade Payable Term" } } }, "auth_ref": [] }, "sqns_TradePayablesDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "TradePayablesDiscountRate", "presentation": [ "http://www.sequans.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Trade Payables, Discount Rate", "documentation": "Trade Payables, Discount Rate" } } }, "auth_ref": [] }, "ifrs-full_TradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeReceivables", "crdr": "debit", "calculation": { "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/TradereceivablesScheduleofNonInterestBearingTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net trade receivables", "terseLabel": "Accounts receivable", "label": "Trade receivables" } }, "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } } }, "auth_ref": [ "r265" ] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/TradereceivablesAgingAnalysisofTradeReceivablesThatWereNotImpairedDetails", "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and contract assets", "label": "Trade receivables [member]" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r220", "r224", "r306", "r330" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.sequans.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligation", "label": "Transaction price allocated to remaining performance obligations" } }, "en": { "role": { "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]" } } }, "auth_ref": [ "r167" ] }, "ifrs-full_TypesOfContractsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfContractsAxis", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [axis]", "label": "Types of contracts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r298", "r301" ] }, "ifrs-full_TypesOfContractsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfContractsMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [member]", "label": "Types of contracts [member]" } }, "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } } }, "auth_ref": [ "r298", "r301" ] }, "ifrs-full_TypesOfHedgesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfHedgesAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of hedges [axis]", "label": "Types of hedges [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r210", "r211", "r214" ] }, "ifrs-full_TypesOfHedgesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfHedgesMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofPresentFairValuesofDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedges [member]", "label": "Hedges [member]" } }, "en": { "role": { "documentation": "This member stands for all types of hedges. It also represents the standard value for the 'Types of hedges' axis if no other member is used." } } }, "auth_ref": [ "r210", "r211", "r214" ] }, "ifrs-full_TypesOfInterestRatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfInterestRatesAxis", "presentation": [ "http://www.sequans.com/role/GovernmentgrantadvancesandloansResearchProjectFinancingDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of interest rates [axis]", "label": "Types of interest rates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r362" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [axis]", "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r186", "r187", "r188", "r190", "r206", "r218", "r219" ] }, "ifrs-full_TypesOfRisksMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risks [member]", "label": "Risks [member]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r186", "r187", "r188", "r190", "r206", "r218", "r219" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails", "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [axis]", "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r197" ] }, "ifrs-full_TypesOfTransferMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfTransferMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsInterestBearingFinancingReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of transfer [member]", "label": "Types of transfer [member]" } }, "en": { "role": { "documentation": "This member stands for all types of transfers of financial instruments. It also represents the standard value for the 'Continuing involvement in derecognised financial assets by type of transfer' axis if no other member is used." } } }, "auth_ref": [ "r309" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsSummaryofCustomersRepresentingCompanysTotalRevenueDetails", "http://www.sequans.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Germany", "label": "UNITED STATES" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "USD", "presentation": [ "http://www.sequans.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsHeldinUSdollarandEurosDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. dollar denominated accounts", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "ifrs-full_UnrealisedForeignExchangeGainsLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnrealisedForeignExchangeGainsLossesMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of exchange rate", "label": "Unrealised foreign exchange gains (losses) [member]" } }, "en": { "role": { "documentation": "This member stands for gains (losses) resulting from changes in foreign exchange rates which have not yet been realised." } } }, "auth_ref": [ "r339" ] }, "sqns_UnsecuredPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "UnsecuredPromissoryNoteMember", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured Promissory Note", "label": "Unsecured Promissory Note [Member]", "documentation": "Unsecured Promissory Note" } } }, "auth_ref": [] }, "sqns_UnsecuredRelatedPartyLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "UnsecuredRelatedPartyLoanMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsUnsecuredrelatedpartyloanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured related party loan", "label": "Unsecured Related Party Loan [Member]", "documentation": "Unsecured Related Party Loan" } } }, "auth_ref": [] }, "ifrs-full_UnusedProvisionReversedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedProvisionReversedOtherProvisions", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/ProvisionsReconciliationofChangesinProvisionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Released (unused) during the year", "label": "Unused provision reversed, other provisions" } }, "en": { "role": { "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r104" ] }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "presentation": [ "http://www.sequans.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated tax losses available for offset against future taxable profits", "label": "Unused tax losses for which no deferred tax asset recognised" } }, "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } } }, "auth_ref": [ "r56" ] }, "ifrs-full_UnusedTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedTaxLossesMember", "presentation": [ "http://www.sequans.com/role/IncometaxSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset not recognized on losses (Loss available for offsetting against future taxable income)", "label": "Unused tax losses [member]" } }, "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r59" ] }, "sqns_UnutilisedAllowanceAccountForCreditLossesOfFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "UnutilisedAllowanceAccountForCreditLossesOfFinancialAssets", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unutilised, allowance account for credit losses of financial assets [Abstract]", "label": "Unutilised, allowance account for credit losses of financial assets", "documentation": "Unutilised, allowance account for credit losses of financial assets" } } }, "auth_ref": [] }, "sqns_UpfrontPaymentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "UpfrontPaymentBorrowings", "crdr": "credit", "presentation": [ "http://www.sequans.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment, borrowings", "label": "Upfront Payment, Borrowings", "documentation": "Upfront Payment, Borrowings" } } }, "auth_ref": [] }, "sqns_UseOfEstimatesPolicy1PolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "UseOfEstimatesPolicy1PolicyTextBlock", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant accounting judgments, estimates and assumptions", "label": "Use Of Estimates, Policy1 [Policy Text Block]", "documentation": "Use Of Estimates, Policy1 [Policy Text Block]" } } }, "auth_ref": [] }, "sqns_UsefulLivesOrAmortisationRatesIntangibleAssetsOtherThanGoodwillPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "UsefulLivesOrAmortisationRatesIntangibleAssetsOtherThanGoodwillPeriod", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Life used to compute amortization in the case of perpetual licenses", "label": "Useful Lives Or Amortisation Rates, Intangible Assets Other Than Goodwill, Period", "documentation": "Useful Lives Or Amortisation Rates, Intangible Assets Other Than Goodwill, Period" } } }, "auth_ref": [] }, "sqns_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod", "presentation": [ "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesScheduleofUsefulLivesMostCommonlyUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life", "label": "Useful Lives Or Depreciation Rates, Property, Plant And Equipment, Period", "documentation": "Useful Lives Or Depreciation Rates, Property, Plant And Equipment, Period" } } }, "auth_ref": [] }, "ifrs-full_UtilisationAllowanceAccountForCreditLossesOfFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UtilisationAllowanceAccountForCreditLossesOfFinancialAssets", "crdr": "debit", "presentation": [ "http://www.sequans.com/role/TradereceivablesScheduleofMovementsintheProvisionforImpairmentofReceivablesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Utilized amounts", "label": "Utilisation, allowance account for credit losses of financial assets" } }, "en": { "role": { "documentation": "The decrease in an allowance account for credit losses of financial assets resulting from the utilisation of the allowance. [Refer: Allowance account for credit losses of financial assets]" } } }, "auth_ref": [ "r365" ] }, "ifrs-full_ValuationTechniquesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ValuationTechniquesMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation techniques [member]", "label": "Valuation techniques [member]" } }, "en": { "role": { "documentation": "This member stands for valuation techniques used by the entity to measure fair value. It also represents the standard value for the 'Valuation techniques used in fair value measurement' axis if no other member is used. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r161" ] }, "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ValuationTechniquesUsedInFairValueMeasurementAxis", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation techniques used in fair value measurement [axis]", "label": "Valuation techniques used in fair value measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r161" ] }, "sqns_VentureDebtAdditionalFeeRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "VentureDebtAdditionalFeeRate", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional fee to be paid at end of term", "label": "Venture Debt, Additional Fee Rate", "documentation": "Venture Debt, Additional Fee Rate" } } }, "auth_ref": [] }, "sqns_VentureDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "VentureDebtMember", "presentation": [ "http://www.sequans.com/role/InformationaboutfinancialinstrumentsChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetails", "http://www.sequans.com/role/InformationaboutfinancialinstrumentsScheduleofLiquidityRiskDetails", "http://www.sequans.com/role/InterestbearingloansandborrowingsVentureDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Venture debt", "label": "Venture Debt [Member]", "documentation": "Venture Debt [Member]" } } }, "auth_ref": [] }, "sqns_Vesting1Axis": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "Vesting1Axis", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting1 [Axis]", "label": "Vesting1 [Axis]", "documentation": "Vesting1 [Axis]" } } }, "auth_ref": [] }, "sqns_Vesting1Domain": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "Vesting1Domain", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansGeneralemployeestockoptionfounderswarrantplansandrestrictedsharesawardsDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting1 [Domain]", "label": "Vesting1 [Domain]", "documentation": "[Domain] for Vesting1 [Axis]" } } }, "auth_ref": [] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/OtherrevenuesandexpensesScheduleofCostofRevenueOperatingExpensesandEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wages and salaries", "label": "Wages and salaries" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r345" ] }, "sqns_Warrant1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "Warrant1Member", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails", "http://www.sequans.com/role/SharebasedpaymentplansWarrantplansforcertainconsultantsconsideredequivalenttoemployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant1 [Member]", "documentation": "Warrant1 [Member]" } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://www.sequans.com/role/InterestbearingloansandborrowingsConvertibleDebtDetails", "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails", "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for a class of antidilutive instrument representing warrants." } } }, "auth_ref": [ "r351" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price (usd per share)", "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r361" ] }, "sqns_WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsExercisableInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsExercisableInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/RelatedpartydisclosuresDirectorsInterestsInAnEmployeeShareIncentivePlanDetails", "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WAEP of units exercisable at period end (in usd per unit)", "verboseLabel": "Subscription price (eur per share)", "label": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Exercisable In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Exercisable In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WAEP of units exercised during the year (in usd per unit)", "label": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Exercised In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Exercised In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsExpiredInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsExpiredInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WAEP of units expired during the year (in usd per unit)", "label": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Expired In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Expired In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WAEP of units forfeited during the year (in usd per unit)", "label": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Forfeited In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Forfeited In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WAEP of units granted during the year (in usd per unit)", "label": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Granted In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Granted In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "WAEP of units outstanding at January 1, (in usd per unit)", "periodEndLabel": "WAEP of units outstanding at period end (in usd per unit)", "label": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Outstanding In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Share Options And Other Equity Instruments Outstanding In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansMovementsinnumberandWAEPDetails", "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average share price of options at exercise date (in usd per option)", "label": "Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise" } }, "en": { "role": { "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]" } } }, "auth_ref": [ "r195" ] }, "sqns_WeightedAverageFairValueAtMeasurementDateShareOptionsAndOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsAndOtherEquityInstrumentsGranted", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value (in \u20ac per unit)", "label": "Weighted Average Fair Value At Measurement Date, Share Options And Other Equity Instruments Granted", "documentation": "Weighted Average Fair Value At Measurement Date, Share Options And Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16", "presentation": [ "http://www.sequans.com/role/LeaseliabilitiesNarrativeDetails", "http://www.sequans.com/role/SummaryofsignificantaccountingandreportingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16", "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16" } }, "en": { "role": { "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment." } } }, "auth_ref": [ "r179" ] }, "sqns_WeightedAverageOrdinarySharesandAdjustedWeightedAverageOrdinarySharesDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageOrdinarySharesandAdjustedWeightedAverageOrdinarySharesDilutedAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "label": "Weighted Average Ordinary Shares and Adjusted Weighted Average Ordinary Shares, Diluted [Abstract]", "documentation": "Weighted Average Ordinary Shares and Adjusted Weighted Average Ordinary Shares, Diluted [Abstract]" } } }, "auth_ref": [] }, "sqns_WeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAndOtherEquityInstrumentsInShareBasedPaymentArrangement": { "xbrltype": "durationItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAndOtherEquityInstrumentsInShareBasedPaymentArrangement", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life", "label": "Weighted Average Remaining Contractual Life Of Outstanding Share Options And Other Equity Instruments In Share-Based Payment Arrangement", "documentation": "Weighted Average Remaining Contractual Life Of Outstanding Share Options And Other Equity Instruments In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "sqns_WeightedAverageSharePriceShareOptionsAndOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageSharePriceShareOptionsAndOtherEquityInstrumentsGranted", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansValuationassumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average share price (in \u20ac per share)", "label": "Weighted Average Share Price, Share Options And Other Equity Instruments Granted", "documentation": "Weighted Average Share Price, Share Options And Other Equity Instruments Granted" } } }, "auth_ref": [] }, "sqns_WeightedAverageSharePriceofShareOptionsAndOtherEquityInstrumentsInShareBasedPaymentArrangementChangeAsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WeightedAverageSharePriceofShareOptionsAndOtherEquityInstrumentsInShareBasedPaymentArrangementChangeAsPercentage", "presentation": [ "http://www.sequans.com/role/SharebasedpaymentplansNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in weighted average share price (as a percent)", "label": "Weighted Average Share Price of Share Options And Other Equity Instruments In Share-Based Payment Arrangement, Change As Percentage", "documentation": "Weighted Average Share Price of Share Options And Other Equity Instruments In Share-Based Payment Arrangement, Change As Percentage" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageShares", "calculation": { "http://www.sequans.com/role/EarningslosspershareDetails": { "parentTag": "ifrs-full_AdjustedWeightedAverageShares", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations", "http://www.sequans.com/role/EarningslosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average number of shares outstanding for basic EPS (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r97" ] }, "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract", "presentation": [ "http://www.sequans.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used for computing:", "label": "Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]" } } }, "auth_ref": [] }, "sqns_WithholdingTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sequans.com/20231231", "localname": "WithholdingTax", "crdr": "debit", "calculation": { "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sequans.com/role/IncometaxNarrativeDetails", "http://www.sequans.com/role/IncometaxReconciliationofIncomeTaxesComputedattheFrenchStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding tax", "label": "Withholding Tax", "documentation": "Withholding Tax" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2023-03-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_b&doctype=Standard", "URIDate": "2023-03-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2023-03-23" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106A&doctype=Standard", "URIDate": "2023-03-23" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2023-03-23" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2023-03-23" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2023-03-23" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2023-03-23" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2023-03-23" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2023-03-23" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2023-03-23" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard", "URIDate": "2023-03-23" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2023-03-23" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_b&doctype=Standard", "URIDate": "2023-03-23" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard", "URIDate": "2023-03-23" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard", "URIDate": "2023-03-23" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2023-03-23" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2023-03-23" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2023-03-23" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2023-03-23" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2023-03-23" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2023-03-23" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2023-03-23" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2023-03-23" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "90", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_90&doctype=Standard", "URIDate": "2023-03-23" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2023-03-23" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "92", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_92&doctype=Standard", "URIDate": "2023-03-23" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard", "URIDate": "2023-03-23" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard", "URIDate": "2023-03-23" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard", "URIDate": "2023-03-23" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2023-03-23" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "ab", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_ab&doctype=Standard", "URIDate": "2023-03-23" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2023-03-23" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2023-03-23" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2023-03-23" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_v&doctype=Standard", "URIDate": "2023-03-23" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2023-03-23" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard", "URIDate": "2023-03-23" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2023-03-23" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2023-03-23" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2023-03-23" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138&doctype=Standard", "URIDate": "2023-03-23" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard", "URIDate": "2023-03-23" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2023-03-23" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2023-03-23" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI", "URIDate": "2023-03-23" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS20_g39-39_TI", "URIDate": "2023-03-23" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2023-03-23" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard", "URIDate": "2023-03-23" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2023-03-23" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_g&doctype=Standard", "URIDate": "2023-03-23" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard", "URIDate": "2023-03-23" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2023-03-23" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard", "URIDate": "2023-03-23" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2023-03-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2023-03-23" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_b&doctype=Standard", "URIDate": "2023-03-23" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_c&doctype=Standard", "URIDate": "2023-03-23" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_d&doctype=Standard", "URIDate": "2023-03-23" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard", "URIDate": "2023-03-23" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86&doctype=Standard", "URIDate": "2023-03-23" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_88&doctype=Standard", "URIDate": "2023-03-23" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2023-03-23" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2023-03-23" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2023-03-23" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "39", "IssueDate": "2023-01-01", "Paragraph": "86", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2023-en-r&anchor=para_86_b&doctype=Standard", "URIDate": "2023-03-23" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard", "URIDate": "2023-03-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2023-03-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2023-03-23" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_d&doctype=Standard", "URIDate": "2023-03-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_e&doctype=Standard", "URIDate": "2023-03-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_46&doctype=Standard", "URIDate": "2023-03-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2023-03-23" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard", "URIDate": "2023-03-23" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_g&doctype=Standard", "URIDate": "2023-03-23" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "29", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2023-03-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "49", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2023-03-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_c&doctype=Standard", "URIDate": "2023-03-23" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2023-03-23" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2023-03-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2023-03-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2023-03-23" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2023-03-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard", "URIDate": "2023-03-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard", "URIDate": "2023-03-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2023-03-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "120", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_a&doctype=Standard", "URIDate": "2023-03-23" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2023-03-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2023-03-23" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2023-03-23" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2023-03-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard", "URIDate": "2023-03-23" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard", "URIDate": "2023-03-23" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "C12", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C", "URIDate": "2023-03-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2023-03-23" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2023-03-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard", "URIDate": "2023-03-23" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2023-03-23" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard", "URIDate": "2023-03-23" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard", "URIDate": "2023-03-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard", "URIDate": "2023-03-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2023-03-23" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2023-03-23" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2023-03-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard", "URIDate": "2023-03-23" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2023-03-23" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2023-03-23" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2023-03-23" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2023-03-23" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_a&doctype=Standard", "URIDate": "2023-03-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2023-03-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "23A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23A&doctype=Standard", "URIDate": "2023-03-23" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "24A", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24A_d&doctype=Standard", "URIDate": "2023-03-23" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "24A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24A&doctype=Standard", "URIDate": "2023-03-23" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "24B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24B&doctype=Standard", "URIDate": "2023-03-23" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "24C", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24C_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "24C", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24C_b_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "24C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24C&doctype=Standard", "URIDate": "2023-03-23" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "24E", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24E_a&doctype=Standard", "URIDate": "2023-03-23" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2023-03-23" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2023-03-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2023-03-23" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2023-03-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard", "URIDate": "2023-03-23" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2023-03-23" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2023-03-23" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2023-03-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard", "URIDate": "2023-03-23" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2023-03-23" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_h&doctype=Standard", "URIDate": "2023-03-23" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard", "URIDate": "2023-03-23" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B8E", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B8E&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2023-03-23" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2023-03-23" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2023-03-23" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2023-03-23" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2023-03-23" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2023-03-23" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2023-03-23" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2023-03-23" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2023-03-23" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2023-03-23" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2023-03-23" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2023-03-23" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2023-03-23" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b", "URIDate": "2023-03-23" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b", "URIDate": "2023-03-23" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b", "URIDate": "2023-03-23" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b", "URIDate": "2023-03-23" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_d&doctype=Standard&book=b", "URIDate": "2023-03-23" }, "r260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23" }, "r261": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r262": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r263": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard", "URIDate": "2023-03-23" }, "r264": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard", "URIDate": "2023-03-23" }, "r265": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r266": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard", "URIDate": "2023-03-23" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r268": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2023-03-23" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2023-03-23" }, "r271": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_h&doctype=Standard", "URIDate": "2023-03-23" }, "r272": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_i&doctype=Standard", "URIDate": "2023-03-23" }, "r273": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2023-03-23" }, "r274": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_c&doctype=Standard", "URIDate": "2023-03-23" }, "r275": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2023-03-23" }, "r276": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_b&doctype=Standard", "URIDate": "2023-03-23" }, "r277": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2023-03-23" }, "r278": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r279": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r280": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "87", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_87&doctype=Standard", "URIDate": "2023-03-23" }, "r281": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_88&doctype=Standard", "URIDate": "2023-03-23" }, "r282": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Section": "Example 4 Refunds policy", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex4_TI", "URIDate": "2023-03-23" }, "r283": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_d&doctype=Standard", "URIDate": "2023-03-23" }, "r284": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r285": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2023-03-23" }, "r286": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2023-03-23" }, "r287": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r288": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2023-03-23" }, "r289": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2023-03-23" }, "r290": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2023-03-23" }, "r291": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2023-03-23" }, "r292": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r293": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "62", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_62&doctype=Standard", "URIDate": "2023-03-23" }, "r294": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r295": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r296": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r297": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r298": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r299": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r300": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r301": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "96", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2023-03-23" }, "r302": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2023-03-23" }, "r303": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2023-03-23" }, "r304": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "IG23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_IG23&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r305": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r306": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2023-03-23" }, "r307": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r308": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r309": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B33&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r310": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r311": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r312": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG20D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r313": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r314": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r315": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2023-03-23" }, "r329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_20_d&doctype=Standard", "URIDate": "2023-03-23" }, "r333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard", "URIDate": "2023-03-23" }, "r337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard", "URIDate": "2023-03-23" }, "r339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2023-03-23" }, "r340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81&doctype=Standard", "URIDate": "2023-03-23" }, "r341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2023-03-23" }, "r343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_144&doctype=Standard", "URIDate": "2023-03-23" }, "r344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_5&doctype=Standard", "URIDate": "2023-03-23" }, "r345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard", "URIDate": "2023-03-23" }, "r346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2023-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2023-03-23" }, "r349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2023-03-23" }, "r352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard", "URIDate": "2023-03-23" }, "r354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2023-03-23" }, "r356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23" }, "r357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2023-03-23" }, "r358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard", "URIDate": "2023-03-23" }, "r363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b", "URIDate": "2023-03-23" } } } ZIP 156 0001383395-24-000034-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001383395-24-000034-xbrl.zip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

M_0NTZVAHNU,1M'DG"*;^5333-5F^\"]%H?'HO$.*+4[8C,TEPTND-L"?LU6R MZ-M,@^3B\>NW:,S^_:(I5R8I^9UB\)_XA^]_FM@\>_D?4$L#!!0 ( ME MKUB_38;$V]\$ *"B/0 1 US\J&&' A93T]OWGGOVI*4T5IUOYN<,_R M;<=[^.WOO?[IY>7?__?)O_WZ?QP<_-?GNROCS+>B,?="XU1P%G+;>'+"D1&. MN/&[+[X[C\RX=5DX],7XX"#^V:D_F0KG810:]5J]F5Z6?BN.&W7+;,)7!P/> MZ!PT3?OH8&!V.P>#=FO8JID#FS6'^P_'?'@TK+%FZZ#1;=4/FD=F\Z#3Z-8. M!HU!FS=YG75;[7W[N,ZX6:_;G4'3[#2MP9!UV]9P6..=09L-VS53/G<4PCO# M>WO!<2#"W_9&83@Y_O1IR(+!H2\>/L&'GV!$C;WD(IL[LXM^#(1[&'#K\,%_ M_ 1?+%SH#$5P,(Q<-[X\2*_'S^6=0_;#]_SQ5/[JH-8XJ#<^S7Z4WL5UO.^S MYST]/1W*>^#/Z[5:XQ-^/6 !3R^W_,@+Q73U"),O%T;YX]D#GAKR]F:WV_TD MOYV]T(^7!F+"P#VXE",L9G<.G%7WA6&;G_[KZU7?&O$Q.W"\(&2>-7N!X"\O M6/A9P/^*F!<<6OY8#MR$_R07OSQL%.IL'#!.>TEFR4#:G^(OYV\8KG[%^=M] M"@6,!C'-0M 2'%+M !KUC,W.8 97WJ)6 *OW<=L'=0Z![.7.[8B(4#[7I)E M\NV",*/@X(&QR7,0)U\L2AYNY[P"K67).('?K)M'K_TBOD+^X-AE8#3VN'?P MK;]W\NN(,_ODUS$/F8$_/P"A.H^_[9WZ7@@&Y.!^.H'G6/%?O^V%_$?X2_&H[CT803EW^VY[M!!.7 M38\]W^,P .?',5[(1?Q/Q[:Y)_\)WU^#%1..%3__1WC'A[_M60<@"(^-\4[< M.>Z!G;/1UEVX[&'/<.S?]H9@G_9.ALP-^*^?%FZTP7W//7B-Z2G<6##WTK/Y MCW_RZ>S^];V3&JA+H], 0_?^AZ1V^L()+.;^P9FX@$^"V6,:>RR<7?[SO 2CVXSO^R+V(7PA_W/>'X1,3_"MS$"X(T9YG]Z/)Q!=A MGXM'Q^)!/(:;8>:B="QM4-636Y/,:!J;CZ;;7AC.MX##DG'E//+@1O3&\& G MD%;E#E;EX-(#-7YP!B[O!0$/@QM8H,7]B'E??-]^")-U#K9@@O!)!Q);Q=_V$DMZ;$=B"J"=C; % M(VQL)KY:;:L#!(1MJ*\UGA>-!USL+0\95CP; MAC4&"_C;7GUA^( TN*G=\[R(N5=L$G <=W\$BG(SP9L',&H)1!QZ.+V$M49( M$Q)\@741?,D] TT)W.^@GHZZ4S_:.S%KZ;#3<6X\[L;6Q]V!<=<_/.ZM#[L+ MPVY]>-BMVK8'WJC!@O;Q<6]]PL'WRV/<6]?+1OV5<:^SGLH!?(8PQC[UQQ/N MQ:M73\ C'S@^_?-T?LDMF^)'/5AU;?E?_^)!"!%J;/MFHX)YP(7,K&VVDD&H MF,_0^C!+BRNKV6JT8$3U#0>$'GOA<]5HOV=DS6V,#(S^;6/3D;6V,3(PZ[?- MET:VKKZV:@OV\6AAX&=\$,YU$**E1UCVT96+_QG$#H'CUV=J69N-[ZB-X<-A MJUG#_VRFGO"+)8A\7OI!V)+CG M8CP;4U?JY(;2;#67O>^\!E-_38 O#*95T,Q@L+?QS.0WF!C=O6'(Q1DL"3=# M')WC247)#++QGD$6)+[FT3OL>ZN]:-\_^T+X3Z#>P5<61@+6O,6'=- P'GU8 MR;L+3N?,;L[HON.>%49,.,R52[1O#7G*KV]S6B#&:RV7$K6V-N)[7'+>W->)&7G-\M*T1-_.: MX\ZV1MQZ?8Y?<%7F*^T;0[KCH2.D@>P]\'K-[+X9YL.8P'JU:YOY3O/5MH@! M@,7-!]7.9U#-7 >5"P';KK7>/:B,<3@>.C^X?? _7/BK!PN6_=__ MUJF;]5\^/N+V5D;R) #> MP)!U!\?A=()#=L83%[/0\K.1P!=<2 4?_@CLO4_Q\^8/29X9^)&0?\ET]S%. MFQQ]@'Q/L)=^/@:_+A+\)/XK_O+73XO?I7_C/9[=+X(Q+-\LR8[X,^Y_?=MVI6;C%I\71O_;6 M/!)YO/7YMSN5WCI1W]6/G< _-T7.?X?^?\-4/KNCU/RH?X;?OS%'+]WV83!Y M];9?/M^^Y[;!PW/5R=ZV_V5C]<&?>]OJRO]%M _Z ?NKJ>R9?;G1# M"V++!U],5]\Q_7:C6ZX2_)J*\>Q>$^'_"3'PZM$E7VYT0UE0Y+X\A_/O-[KM M(&7P5M]U]O5F$PEKCC_E?/4]TV\W&R?SOK\P1/AFG5LE2WP,G@-S=C,NBXC2 MO\#DP-]#APM#+JA\927:Z>4_%XN+EG\\&\'BW2>2)T[_ H&)$/GBD[B&T83_ MI+^;?S<;ICV_U*P?-,SY(^)OTK_3AWQ:>._5TU O>AJ2MXD5//[3AH?]F+B. MY81?.=IOPW;@6UDVFRGKZMDVK!H!#Y)_8)5;[P>:);SFX3/&- M?OVT\OZSJ9@-0PWA-*@)9TY'G+H,17,SO!$VK-LBS@ &L7QB-UD2"\P[XQ,_ M<,+9)9645). -8DK3L,5;Y9^\YXW:Q'&8+S&.PC#.^YB#?TM2-M)83B_\I]\ M^I5Y+$Z0@9L<^)['W9MA;&AN!/P,OJ@D,MMTY72=JRKH%RD'R1K+Y*2]TI:,K.F M14/4F)F%1[D5$$TY]LPL//)6Q'H4'N0JHJK$0D@SOQ#2+#R&W.S5ZCF^&N'P M:EZ;^7EZS<8\8UTSI=#SJRZ#(.)V_L:V(% 1#J (SGR>F"<<(A&<^1RY.)-P M$/3*S%_".P@>A)\Y$W#!';>X\\A #L&%@[MYX;,KQ^,WPU/!;:> \+48"U0G M'/Z2/'.&:9GKC7>/C:17VYW6Y(A>(Z/ MCA\%[K2/E[S%Z.R80:. /\+A^?;QIZ@,E0[J=US_%&0'M(G=3,1*TQ$%?!8N_9!\%&0]RE*?,L1#N"J@=#*<@GE3 MFJ/97D8NQP*!)F'.I6R+5=",$V892C="!4VYXJ3 %C-R>?>2Y*,TI[)%WKTD\2C-OY!5'[@T)_DHS=1059_\Q$-A MVSV%>5":"]FR&6D?%L'P]MN'-#6\>VV9USID'5[51IY3KG24>A6JS3RG'4%RP)(9!X* M$H>",:Y*R82"I*9TY+OE*HV2>LPK&/VJI%@41*R3Z.K*3NF@?YO<;CGR.5(Z MZ-\BMUN2>)0F"+:L/DV8]_7DLW#IA^2C-)VP7?4I0SSD&KR7- ]*DP%;-B/= M@WI[3?ED+_V0?!1D!\HR(V6(IW :0)%Y4##6+B>#5Y*WJ'2@O+T,7H[-IH^4 MCF^WEL'+<<8[2D>LV\O@Y3GE2D>A6\W@Y3GK2L>6-')!>8I#P32V2HF&@J1& M./+M.P\>W,2"=[OT8#D(\0[!I=>/!H%C.TPX"\<2]OE?$0@.%*^B@B.<,\]+XVY#7E'A$8[P<]&Z0##NUFNU;G4-)V$2 M( \17CB>RSS[9EI-Z1'F$_*07K_7KZ3/HW M'O^#,Z%*85Z7,"/QTG0K.]>$>0@JT,ZQ,UB7,,] MIYSC5A=N#494' @YOA MK?#AG<+I+;@]8<^SD>"9X.V6I8#$3@2"F%U0S966,#&PKLRD?W01"<\!?>+P M_<<$1)@9F@KOTP)@\X$'=/?@@#"1CBI;MB^_;3X[K/C-](#=D1T&( M%X)YUL@)*II=[A+F!MXOOR3?#%*SS_@C=WVI@.<_)C!54CO?D.4&@[Q#0GWY M^9_],/3'-T/Y935Q0YB04!%R\Q5FI9$S*:5)@ MU@@3+72!L35K418J"/-!&P4%GR/'Q40\^I-7G 5\Y+OVY7@B_$?91;>:K4?, M&CF.*1#A<3_M7?R%^P^"34:.Q1)'P/(C+Q33X]/KPD11SED]9HT<_U2^*,K2 M"G+T5/FB*,<=-6OD6*^4,%#D>J7Q1E&6@R%%"Y8NB+ -%CF594Q3_ MO*N<@2+'790OBI(,E$F.+2A?%"49*)-KE3*,ENJQ>#;E4I9%DRU<#R52D5-EVHA^9;$49;-4BTLWY(XRC)6JH;F M9^>5,U2JAN8%BJ(L(Z5J:%Z@*$HR4'550_-O_:H9J+IJH?D61%&2@:JK%H]O M011E&2CE@G L(#F/L,KDJV/;+C]G =:9](8"+JIF$%A7+B8O4TAE&37E(O4R MA526N2,7OV?*%Z<3+*"[Q''CS]:/[D.("YAOH0G]S%7M!NX M62?'&NPR",HRU^3XBET&05F.%3FF9 Z"6^';D15BC72?BT?'6N@[<<^MD>>[ M_L/TL_"9/6">74T1-<@Q*'1%5)(I;9!C5NB*J"27IT&.<=E<1)0X M&(K"*->* JG++-&CG-95SBRHT+ +WC1>Q7+LFF$B18BDBG+H!%F/XA( MIBQK1IB2>%TRF>80V.<'VTJD5U74O"E+')0GJI+L75-9 J$\495D )N$B83/ MOA#^$S8M^#R]9F.>79=\YLG66(['/(O+C@;!'9>'$=S[I[[WR$6(77?.^" , MXA. X/(O/GSNX4#D#;X(!I-14?ZA29A_J(ADRS*OA,F+BDBV)!^G28[Y2-)2 M>)C++'EUY<=-M\V,<$_](+P9]IG+ [.BLB%'?!"435D6D1SU05 V9?DAY,B/ M=65S ^\)'WH/LOMBP*]YB']5U+R18T)HBZDL2T>.!:$MII*,7HLP Y*4.LDS M6@?@@]NW;"H)#R&PD2/^,UCN\_@[PR\+[Q)8DNUK$29!"$NK)!/8(DQL$)96 M69:0'%F1%'8&G EK=,]^G IN.^%"T>?2=S@E^4NGF(-)S19-#F'3":\7.N$Y M'F-DMF@2 YM.> 'A9S&'ZY@MFM'^IA->*W3":WE.>.$A_*:+67/]Q:R9YV)& M+DC.N!Y\//$%$]/YT=K?O A<$,#/?LD1F$V];G$LZMC#.#^X'9]1IHSKUR87>:LGCUS=/G*!N7KRR-7E(Y=Z5T0>)-R]"G,-VQ-> M6:Y>A4F)[0FO)#?OJ)KL1?:,V6!TX?I/_^#V0Q$;&PIR]XZJR6"4(I<\W;ZC M:A(3I<@E3_?OJ)I\P_;D0L$-/*HFYU"2$$MR!X^J2524),2RW,(*LQMW,&H6 M1$)6J-T,KWWOJ^]QF-AISY*=F!7R$BM,>I0LIER=Q@K3&R6+*59J>:W @-F9;D<':JR:LD^UX7MOO#Q?^"(8",\:\KAPT< M%UY8&:>S4TVJA8JH\G0\.]4D5*B(*D_GLU--VJ1449%P0"O,I)"0:UE.:(6I M%Q)R+HPGIT* M.6Y>O59-IF-^DZ5?J.+OU6O5Y#C*$4R.CA_<30N&H@=8KU63?=BB8 BX@O5: M-7F'LJ18CD]8KU63K2A+BF4YAX0YCE.7X<3?#&^%#R\53F]=)D^ ._\K"/\Q[NS\AN V&1 38NIX#[TQUK?V+"L:1_*@I#,^$=QR M9'=]^%*$3A#_V\.1,$?(P7KV%P%06KK+TBNLN*30Y3G'CJ3U&F&"AJ;L"M & MF%(8T?:VM4S'(TO2UQE$..&IH^EI= MV6GZ>@?!1&&;:T/3U[OC&Y, G*:OM=TC $--7VO0;1UTFK[>$4%K^GH'D5=0 M;Z^&IJ]WQT4O"D.:OM;6J1AD:?I:XR@''#4U?:VN[#1]30M,F]ZU4*3EV::F MN>-T=-,T=)ZZU MLTX*C9H"UQ:3.D8UF:X120J1K1VGY34*) HTP:]AN95&/BU-\.N8H5" :8)? MV[428*<)?@VRPD&F"?Z*"E83_!II]+KTM#3!KYUU.FC4!+^VF-0QJ@E^C4A2 MB&QK@E^CH-[6!+^&Y59:';4UP:]CAD(!I@E^;==*@)TF^#7("@>9)O@K*EA- M\&NDT>MCU-8$OW;6Z:!1$_S:8E+'J";X-2))(?)($_P:!?4C3?!K6&ZE&=21 M)OAUS% HP#3!K^U:";#3!+\&6>$@TP1_106[\P3_QV219[ND(\JL-ET?+E<1 M:"J7J&!VF;^D(X8.9=).@>4BS\UWG0I09XIOVN]0YI146RYR%4P%N)B2EHM< MQ5 I;F+[RT6>I5P=RB$\W>4B5Q%4(-@FLUSD*I@*1-XE+1>YBJ$"T7>9RT6> MQ&"G @&WX@G%;@6";3++1:Z"J4#D7=)RD:L8JA)]WW'FGL-$A%Q=650@X"Y3 M%GFZ4=T*1-UERB)/!J1;E:C[\IX]6[#5M5:5"<3+EDJN=DN%*/S2@Q=\< 9N M,KLWX8B+^Q'SOOB^_>2X[K)[=-(V:3@]HQ&T7<3J7 MH-&XO,#F6.C0,'5Z0(/HPR#2C#]]@)'J4))COKUAZG2 1EBQ"-.Y HV^#0.& MDI+OIDXD:#@2@J/.,FBH;K1NYYGC-W4*0B.L6(3I_(1&WX9+<4D)?U,G+S0< M"<%19S8T5#=:M_.L*ZCKM(=&6+$(TSD1C;X-E^*2B@SJ.H&BX4@(CCK;HJ&Z MT;J=9RU#72=0-,**19C.B9#.]M=W-FM 2 ::5R>=]ZCO+)E,2 ::027- #5V MEF,D) /-PI'VA1L[2ST1DH'F6SX6#2^/[769V\;P?7'?[T63B3D]'S/%.X:>A@'^\*9D=AE6>YJ"I M F>U15B]0S(42BB:*M!>VCJHMN@T56#K5L)J]N&]W^?BD6.D9DFACIEG7_CB M%(3AC[D(0()P\9_PK0;5=D"E OUXX7C, SFY<0R^3 ?<"V;S.VYQYY%!H%[L MY.>99V^J0.91FOP\8^:F"M08I=SSYB"6OK[F#C($MRP(SR)^[8OX M5MQ6QB-L$>9MWB^71""?H_#:#]>4R08#2V[?#UD8/1O*:20$?W-S0/D*0@B# MA$D>-3%X!A%/E44J8-5()I3'I_@R) M2PB]\".A(;HI1 ES:RI!=(4AU7A\#QYWCVZL<-B1)Q?:(LR%JFFI=B/LR!6# MA%E>-3&HPXX"4$J8X58)I3KL* ZBA*E]E2"ZRV%'GGALZVQ'A<*.//-@;9WM MT&%'V1C4V0X==M!'JO[M3@7%)T2K^$3E6 MK)0IS5/QC\C12:],Z9?/MPHH_A$Y=J24*BIO27!5?I>BIN"G-5?%5BIXNK_HJ*+Y*T5-Q4YJKXJL4/14WI7DJ M?D>EZ.GT^@\%%+^C4O14W)3FJ?@=E:*GXJ8T5\57('J224;9JRSYW%%HDTA' M@5AJZQ._"JX&9[_%<'@EO.MET$0<3MI M+Y[_G"]WB6D?U)NS^[S:)6;AT@_U'NF0B]HV$5!_Q 2_%7SL1..*RH=<"+B) M?.YXR!R/V^=,>([WL(5.2Z7(B%Q,252'&G+2C]:1S]*E'Y)/EUR 2EB'RI(1 MN8AW17F65)7$'5@6TXVP'8^)J;RF: >MUCVHMW-QT+KDPF+2\]X$WSB?>2<7 M.Q-VC"&F7K-]XL*E'S-(AJDP$N1B9J'=3EGP*#[$WG0@3[62MN\Y$+%WZ ML8D@',I^]H7PG]!]^SR]9N/L^6"GOO?(18AGBEW[(0_J-;/=\VSXGZY9,%-9 MJ^>VG"D=IFYS.9-]F\W&FLJ1%=#'E$/'J)3ETZR1BU&E<;IW0I?CD8RV\^C8 M$7/-1&GX<%6$H" MG:&;-7)1L49%Z3WXFS5R,;M&1>G]_ILUU$!)[634%EZF7R"PBE+<\@Q'!2%4Y8+1*Z"8%WAW/& ,V%ARXW, M&> 5M6_DN!?24BK+T)%C:4A+J2R+1XZJ65=*?>9R[-_RE8GO/'2\AVH:.Y,F M5T-00"79.9,F;4)00"69.),F@[&&@+YPCPOF@HAZ]MCQ'#SS.G0>*QJVFLIR M"B7)J2R#IRR]4)*!\JR1'5E4+E.U!13(NP9ITF MIZP%G7.KLF:='/VK!5U$R[1FG1QMG$>DC+^0BV]PU^\5*HM:CK)H5)*3W9XL M\ESI&I6D.[D,F]/ZFV0,@1#824 MI*S5GS G4*Z2E"20)F%BH'0E*2FV:1(F",I5DK($0HXEP-,U,J+ /[\ZGC/> M3F_0$LP4N7!_E038CPI+@'#F/6/@?UAN9,._OOA@_3U\R)7//-QMFK:CNA7^ MG]P*8U$5TJVE(%/4(APK*RF0MIIQ^NGS8].*/2_-[![4P(G-:=+5C+]737J]Z$GO')BYG'7; M;*L95Z^8]$*M2[TFSS7+Q\*WE0^7MSGG^5 4;>7#8SGG/?BYS>VXJ=^-5VQZ M#>:_<5#/"?/*A\;/Y__^R5=G_I4/B5?,/S8K4$<"RL>WJ=4OE)#+\PC>9EOY M>+; .7]>#KG](U[;A(/=MX_@O0E'7&#V1CR^F816%ADE;;DXJDH(7C>OII[P MK>]7[+O\K&CKF3T\_D/6\Z@J ?FF(MA@'/]B;B2[*-US:^0Y?T4\^!9P^]*[ M8([ +^%9+(B$W#BX;#_B$VUZDXGPF34J'A392O=?^=W_L%%WEF*/&5(-]0 D4-O7/-64^^6]JROS2CVE* M-5B*0E6$A)RJP69LPZ*1\.4)4Q^G+@N"6<>'4S9Q0N8N.VKIH2K;CO%**\?! MK6&= [.5S^I'F(5Y1?Q2&+TQO*G%O#,^\0/X3DSEA1H)[T,"9;I'&X(7=XEF M ?#Z+M&%2S^T:'0($T#::M"%355(JZT&NWD:^4Y5Z*&"ZWCRG?3*<#QO3OH& M3U:%G%<\ICT?"+M[N[0&QL\616B*U?UJTRQSE;4+Z=)+YP,*O'="-,8 MY9F6?"DV59TMPA0',5N37UNQ+N%J$6IUYL6(H%4CS&.0ZRJVT$6IM79E[/*E M'S%4K1IA,N$5@7WS8 3@GMIWW(5WMV]AMJ;8'S&_=2PYV N@$0IF+1SBU<=G MPUS=1L(:L8#W'@27GG+1>FK"$I6/GA(F PJ8^$W<5P79*^.U E3(#2L[%+(L##U;VQZR%[ZL95837JB])78]^S2 MUN-Z3@WD6C7"-3,%"#^'J+Z$?4FM&F'"![7#\2(0TZ7WZ+N/$O^7WAD7H"(/ MGA-P.VD4#NL:+'4A2!,5ZV9X+Y@7#+E87NTN0-=\ 3>\&=YQBSN/#,*C[63J M+F':884-/W.& \@\?M;L_,KQ8.RG@#VGX 7!;![4VNNA+;YTWMCS8V@CS"'= M"M^.T!2C\16/CL47K;+\J,]RQ8M&>#$+F7ET4#O*C0 BS,$E?D0Z]7_'3#O^\T0$ ,K&UQU=?GYYNZM6LR*XJ*6#RY,-8G!RHJ#,.VG[7QA M?G,Y!WBV3,)LX\=DEQ[%<\]^%&\!\CR]JF42I@*_LE#&\\MZ?.V'5P!"<3]B MV,SV#YAZ*DJL,! (LX/;E4D.")W!\\)YE/A4YF3-EJDF_TA0-VOU@WH^S+VI M)BU(3B8YGBS8,@F3@'KAW"80"/-S>N'<(@X(4UYJZ6:MD9=,ZI6EF[8KDSQK M ^N$.2>]<&X3")H.4G;AS!4'A"FH:_YT>7'7S^:'\.^"3[#*=78)\SJS:KN8 MO\],\AUG[CF\='Q^::,WH()^-B[D0N!)7YNA?\GMT)S M<1O)PST7XS07E%QR8X7^0/:7;!:^7:$EIF MQ3\F(7+1,5D)E<2P-LG%PX5):(/E^Y6<_-+C9XEX93)53<*!^#OF_8O_R(6' M3_J"[< _B@%*]J$H )"C 115^0M?/,3U.,4TH"A*_N0(!DI*M^#8MG':UW-L MVWDNRN0H!:VA=#TX[NF2:?_@ M_,"C#>97*,/HMG:'4UOOR>GM>Z!)_)&[OF3L>WCVU(/L$Y(V";SW;[D8^F(, MID'VFP\0*=D1W_E3YH;36:] ''U0](&+)7DEK=UA_G8"1V5Q_"UR_&21+&'> M(/X/YD5,3#$\+7(%,K%986XKD.8G=QP JO.3ZT^ZVC%*4?)7G9\L5.F6^,EU MG;ME"7UL45:=GU120S<8RK7O,?O/* CA&>>/,(5!;QCB"5@37^!GMU+:RU'K M.0:LL@EBZ/>=!P]D83%T3,=C)T1!!#''&!& 4%Q71FN9H5PX(@@SWU44)^28PU(]L/G#[S#) MM!P??O;#T!_?#.67RB2HV^380YNT"5-K]&2\ M)27.5<#D>+2U!#SWS+; 4^&IZMTULS?RTIQ.^6NKR5,5+IL,I;PTW1]2A2,U M2:*EZ6X=UINW7%C)W^K,OIH,S=+LIUF<"\&+S^7G.OUJDBV+TW_J/SJVV>U' M$\QWW+J%[_6J-7.;?S69D^W/_W+".2N!-Q+.S;P6YB,UZ8M2E27/R/.(,+5P MQT/A!Q.(.IQ'WIO@#U@(U_0\>^$K"%&PJ8^L+5X*(VX%?W3\*'"G?;S$SB]J MF76[@<#HT<%OL]SC_,,+7YR/)ZX_Y?PS]_C0"8-K'H8J[9X_(LQ.O"B&3$]_ M)["X"TK) 0BRNGQ^;8Y1[-;!2@@@A*F-G98+84:"HOVDL(GHB#!34:RQ551@ M'<).X39$G)Z0T)@A!D3BDI64&/Q M#F'BA)S>%"4#%8D)*NM-2?5J'<)< 3F](2$P32)0(.H[FA?WO&_(D=P^_-4'N'ZX8IN M$1[WTY%]X?Z#8),1O(,;CU(^6TR/+^ZJ9E^[A(D+#2I%@\0N829&@TI1IKM+ MF"JJ4*%XES#!4Y5:[2YA]J9D*.=)T'0)$S1E0CG7.29,J%1H#UZ7, U2E6UP M77(Y./*MB3[_P:T(Z;5[SL;J6 YR@22=><[5<) +)NG,2M\.[*D*]?GXM&Q>#:IWFM]N>9/R3694QW4,27D@DQZ4T\@A=4VR<6C M].14T"I@DHM&Z4T]@=*!MDDN>P^.QU6B$$QRD:U*DLC5=I$+ M?5621)Z.EDDO-I;$)1]R(;A]!S/L13QS&MGRF6,9&4$ I 84XJDXNWD6!?&5_^N(T"D)_#&Y?QA+T0P&O M^N!8MS ]'A=Y%+2NEOY+AK^:-J=.+IS>;1B490W(Q?*[#8.2^.!G-C[] M%"92,*NBJ?LZN1(+C8ME7)1P6FR[09+X(BNEDGSLAMILV([8V(;:9-6VI502 MI=@@R27M]DI84 #;(,D7:5$7$-$VU&:A^AS>Q]YT^K@JL/*YAP9)ODH+O# 'KJDV$;4; L\S4]$DR6D1#LY> M@%CKR^G(F00\A/_Q6/',6F=]ECI[Z8>6_R9)9BT/W[EZ$"G)0VPJ1.OM.D1* MXN>;F@Y4 BL%A11-H85!&O$F._=,P*&-1($^]W#/ MQ?C2>^1!*+\M4O3/\-=[9(Z+B+OP19^Y'.+$2#BAHU 4T"+'*&H8E+$0D&,- M-0S*6!3(,8/K2F!^W?+7X05SQ+^8&_'[D?"CAY'T%D[]\43P$3[FD5]ZEC_F MI\CY^6):AO<@P'.19X[),:NS>BA+)6J\E++,*,LY:KR4LAZI34Z>LF"$_W_^ M5P3S[_+X$)+^R!?A%AV5U9C(;6R$5B.U.4R-ENVN14K1GJ3%DJ?);RM%29(6 M2YZVM5T!NI"(6/(T8FVEZ+LKAPT<5U(BRU[U%9Z5G?E>'<50BCFC(H%<=4 I MTHJ*!')=LY6B@58O#I?P1@+L_V?.A.,]9+*)R0^]ARO'XS?#4\'M])'%N.#/ M(+)J@&GN\[,OA/\$'RAD,I5B@31"G_'!SOD6 M>2X@1TK1;1H*12X82O%^&@I%+A!*$9"KH?#%!]?!PT^E('8-#KDN$A5@0W<< M#KDN%!5@.W<<#KDN%A5@,^]X '*P1K?"_Y-;X8S"W#5I<9'_.M*I &&YT+SAEDT+W[R[&A3O&0:=A:-3 7IR9X&0YTK1J0 YN;- MR'5I4(J:7"V!55]_Y2R(!+?7WW)5)'((;+7*=1E1BL34H*&QY"A%=6K0T%B> M*!.B\1Y=YQW[@-/N#T-?!,S=RF[?%0V1-FV!06@!HDR,[AHL-GC^%3;GQ<>G MEO(?,-G(]DR?[V^ *\U55ZH#4LHLK09I7B"MJPU2PI3QAH)HO$,06F54 &E7 M*?YZ=>@P=\'7W[7W4726&,00 H]2G+<&C_8H7X:R4JR]AK+V.U^&<@7R#@5# M60'W5SL8"&7*V1 =M&P"BSSS'5W*^8Y=@T65/,I<0:KS*[L TNW[BKF"E'"V M1P$GK*E.=F 7B;1

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�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�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�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�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ŧ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